<SEC-DOCUMENT>0001178879-22-000014.txt : 20220804
<SEC-HEADER>0001178879-22-000014.hdr.sgml : 20220804
<ACCEPTANCE-DATETIME>20220804160835
ACCESSION NUMBER:		0001178879-22-000014
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		56
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220804
DATE AS OF CHANGE:		20220804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMICUS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001178879
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				200422823
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33497
		FILM NUMBER:		221136574

	BUSINESS ADDRESS:	
		STREET 1:		3675 MARKET STREET
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
		BUSINESS PHONE:		(215) 921-7600

	MAIL ADDRESS:	
		STREET 1:		3675 MARKET STREET
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMICUS THERAPEUTICS INC
		DATE OF NAME CHANGE:	20020729
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>fold-20220630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:3889360d-46b3-4f4f-a1c0-074f51e18b3e,g:d5204adc-c100-4730-97cf-6188f145481c,d:c325ed1a45484718a7ea1ead2bcfd471--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:fold="http://www.amicustherapeutics.com/20220630" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>fold-20220630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80L2ZyYWc6NWRlNGY0MTA0NzNhNDRlZmE4NWNhOTUyYjhiOGE3NTIvdGFibGU6ZTE3MzdmZWRiMzQ5NDc3YmE1ZjI5ODhmYjM0Y2E1N2IvdGFibGVyYW5nZTplMTczN2ZlZGIzNDk0NzdiYTVmMjk4OGZiMzRjYTU3Yl8zLTEtMS0xLTI1OTg5_ac139126-e727-4aac-8987-07eb7af37df5">0001178879</ix:nonNumeric><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80L2ZyYWc6NWRlNGY0MTA0NzNhNDRlZmE4NWNhOTUyYjhiOGE3NTIvdGFibGU6ZTE3MzdmZWRiMzQ5NDc3YmE1ZjI5ODhmYjM0Y2E1N2IvdGFibGVyYW5nZTplMTczN2ZlZGIzNDk0NzdiYTVmMjk4OGZiMzRjYTU3Yl80LTEtMS0xLTI1OTg5_869f4241-cf48-4043-b18f-72af83c1e04b">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80L2ZyYWc6NWRlNGY0MTA0NzNhNDRlZmE4NWNhOTUyYjhiOGE3NTIvdGFibGU6ZTE3MzdmZWRiMzQ5NDc3YmE1ZjI5ODhmYjM0Y2E1N2IvdGFibGVyYW5nZTplMTczN2ZlZGIzNDk0NzdiYTVmMjk4OGZiMzRjYTU3Yl81LTEtMS0xLTI1OTg5_d7e30d1f-fbc6-4b4d-b17f-369e0282a733">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80L2ZyYWc6NWRlNGY0MTA0NzNhNDRlZmE4NWNhOTUyYjhiOGE3NTIvdGFibGU6ZTE3MzdmZWRiMzQ5NDc3YmE1ZjI5ODhmYjM0Y2E1N2IvdGFibGVyYW5nZTplMTczN2ZlZGIzNDk0NzdiYTVmMjk4OGZiMzRjYTU3Yl82LTEtMS0xLTI1OTg5_3077f6ce-e31a-48f6-a3f1-c660a39f1c80">2022</ix:nonNumeric><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80L2ZyYWc6NWRlNGY0MTA0NzNhNDRlZmE4NWNhOTUyYjhiOGE3NTIvdGFibGU6ZTE3MzdmZWRiMzQ5NDc3YmE1ZjI5ODhmYjM0Y2E1N2IvdGFibGVyYW5nZTplMTczN2ZlZGIzNDk0NzdiYTVmMjk4OGZiMzRjYTU3Yl83LTEtMS0xLTI1OTg5_eb5491c8-e8fc-496d-95ec-72de79bf5583">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i6d38f6fadc98426f9e4074b1ab54e9d6_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfNTM5Mg_89960747-9384-4345-bf43-26f7a60be61c">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="fold-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1072316a8ef24e96928b3d944127fe65_I20220727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i11f13f2826434e75ba7e1100f8e58792_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ib23d91f5ea064297be63d22df3cfdee1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="cadPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9dcaac3e3f74257b9b5319bd5cd7e11_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8964c1432633472c8bc58ddf38701965_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d81a1ce547341fdbad1b2485e2b8dab_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i457540a06a0e4f12a8a6760a2e662d69_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97d51d17e9f74441bbd0bd417ab532ee_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90601765a2f2418a9abfd28bd624e1fb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib83568c208d34901bc8f2b3277a492eb_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b3bca726f0d46f2b136309217acf4e2_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6104ef486d1344d9b4a6249c99ecaa75_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id89ea44d86214f11955f8524c82ca59d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cc23a72515148e9bdb594c0ffdc44d9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6af221862afe4ec8a95c4bd66bc29a83_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66313300b8924ac38edbed17cd4621e8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a67d85fc2bc4508827b7d6504191b86_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d7fceb860b04c3284049f567598615f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20369be16fb64d618f19ff7c879c5f74_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i847ea7f79a9d45378381e71e73b6c2d6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8850617c24a64a82b3ac49102d519aac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b04ea28407641b98ad9d006e7f294a1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f89399acbed48f4948a667624d93858_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9b3ff93c685496a8f7db03682c9a6bc_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9145f98a12fd40a6a178726d7e2acfd7_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b08ba7dfa164bffb946e42d5c6b0353_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id499f57d04ef46548abf1e291e9d5885_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03bf3913256a4b41be32f6db37aa316c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6de8ae1734aa4d599eb85d75fd49b941_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i625ab03e96af4d8683f3acb33151056f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6afdfc73ba542e78bfc05da8ba789e6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib385a6b7137c45958b92a30dddce1f19_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0236634b4cb14481acb0fb30723e7beb_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaf9ecdf3e9d41aaaf315396d42a9e6e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0feda6c19ba4dde88c6ff31d463c64d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a489e0cac5148b098047e20f7b16d2c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id197126c4925481fbd6568b6714249d7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1575283eac554820897a66659337bdf4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia655833ddbb14af0823e080a718286f3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia265d46e7fdb4a6cbfc035ff181f41b7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdd0bea669974aef88283f7ce9684c7f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15ca856684364a728cfb2cacad448766_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3250897ae664ba78fc2758e4d197424_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0726224b301248d2932ff84f9938870f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebfefb1a4b464d5ba21ad742a3619573_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic229e029b81044fdbb354018535e5d3b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17008df080294bb0bf1240acd6c19c15_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5f30d05cafe48b79410089e00859443_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44b8bffb160d45dda13b5e2b78abce7f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i649bebfff85c4aeb81fb81bfe49eeb22_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03ca42e2698e4878b362989f4df7933e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69530f8676834a24b6824dd3090f275c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie01bcbab6a39452c8f207bbd1040e82e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d38f6fadc98426f9e4074b1ab54e9d6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1ae6aeddaf442cba31cc61b672cf523_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4608585deb7447ecabc5d85a3a731ff7_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia22486482e60492c860155dbff44d0c1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9888231cb6e4488995457f5adf3be783_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe98a5affced4afd82274d759802ef32_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5aab62a215e24c70a98a8fa127a0c93e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4736f08b10ec45f5a5791466daa3734d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc644fbd473b4779827e095e604e1fa1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2058a237abf345d3a1df9a3c8c9c52b2_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33bee7e70d4f41ae98aea43eaf262df5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fold:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i313bc2d8be6b49deab3982d26fd646fd_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a5beaca54dc4603a5614a45876a29e0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie925c891e72c47cea99fa4b411e16d37_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2786cde9d4554d08836966e040d3dd88_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee2998a9354d4afca4c7ca59fa536817_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18a1d906c5a545e698385837607d8ddb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b99930e76ff4d129e26d8c1981c9dee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fold:ShortTermCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifae0d641d44e4d74bd462bf49ef538ec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b41065183b64de594c948fc62b3fd96_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia21576db6b004494a12be3e92fdd6c66_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b96f9892c1f46b79e86ebc2d8e82423_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7817625b346c448d9777f5897c0b43fb_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:SeniorSecuredTermLoanDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11f9f50188a747e78f96bbbe4336d3aa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:SeniorSecuredTermLoanDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7db5d4a26355471cb3592c15bd783d1c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i4699991b02604e23976f7eb8d6c9a55f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d570dfe70e7454f85640ff0afc44736_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3501524d91e94a18bfac0415f9e68531_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c027874ad0b4c14b107e9e7d4d2a4b3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ccbe1db3305487c82f9fcfe73e288b9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i245ad67e6079446eae628bd054c5451c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45525b12c16f4e50b69bac633525c7c7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e34834a2be94b8e8074f10f13edbcb6_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabd36bef22694ce9b71e55b1717ed5db_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i613cc31dd21945f18cc9aca69ab98da3_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b06cd373bbe47dcbce2f3dabed11f52_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie40dbd39b0544892a3797b1b64ad108e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1217c1798fd34a71be289e7051cd1b47_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4c83b69fa62485e98e97922a5e49b57_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i659ab50b47154e78b47ef9e839307808_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9f84953690247a48cc8d3be225dedce_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ddfa60f46e544df947c8b0ff919e9db_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cce6f2cd8d64779a3cb98b16bc6010c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaa7d76b8bf74f59b0911c381d40613e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i667b2117b7d6414692a884314d59ed80_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc49c8cd141a4141b4d1b6b88a3c8ee3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddabb7fdfb774233b59ea3d5ebb33de8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i582299724ae3474088b179e8999bf21b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2f84ce5d8994d548056b41c664b19c0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56ccbb8636664d06a097e18deeca55d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7023ba5f3b3416e833c03c3b04dfd39_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccc9fcd06a114cdc9b7fd7bcc33f41ce_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:ATB200PompeProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">fold:ProbabilityWeightedDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0df4cd98b90b48bbac276b1d955f92ae_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:ATB200PompeProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b66abc5705c43f5b528d365e1c87cb4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:ATB200PompeProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">fold:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieeee7b9e37734d74a6b642a88110192e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:ATB200PompeProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">fold:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62b5a7d4e59f4a0cb528290f1c8d251f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia41bb3d6e6b341469638797bd696c267_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3206f3ebb21741d5af011059960d7b2d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67808a739f5e477b8929ea199cdf1917_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9642de7b1214086a13a7ba1bbf1e23a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6d84939f6a24c2dbbebe6fd3cbbd1ff_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i391211c299184c4890fc3d8186f647fa_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_1"></div><div style="min-height:40.5pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGV4dHJlZ2lvbjphODg5NDY2OTAyNDg0M2U1OTliMjA3YmRkZWE2ZDFjNF8yMDkz_a65a0cb0-001a-4fab-b659-595ce3e98cb5">10-Q</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGV4dHJlZ2lvbjphODg5NDY2OTAyNDg0M2U1OTliMjA3YmRkZWE2ZDFjNF8yMDk0_9a973e94-c954-4289-bb6d-bef1128ec928">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGV4dHJlZ2lvbjphODg5NDY2OTAyNDg0M2U1OTliMjA3YmRkZWE2ZDFjNF8yMzE_12b1946a-90e5-4ea1-9e66-d459240d215b">June 30, 2022</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">        </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGV4dHJlZ2lvbjphODg5NDY2OTAyNDg0M2U1OTliMjA3YmRkZWE2ZDFjNF8yMDk1_4d2e4c87-3de2-4d67-ae39-c834382fcf53">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGV4dHJlZ2lvbjphODg5NDY2OTAyNDg0M2U1OTliMjA3YmRkZWE2ZDFjNF8yMDk2_2fae5ac1-e5e8-48e9-a75a-645e01fb3401">001-33497</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGV4dHJlZ2lvbjphODg5NDY2OTAyNDg0M2U1OTliMjA3YmRkZWE2ZDFjNF8yMDk3_92347a33-aa68-4009-b45e-9735121d1db9">Amicus Therapeutics,&#160;Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.001%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGFibGU6NzAxYTRmYmM0ODYyNGM5YmIzZjg0NDM1Yjg0YTJjMGUvdGFibGVyYW5nZTo3MDFhNGZiYzQ4NjI0YzliYjNmODQ0MzViODRhMmMwZV8wLTAtMS0xLTI1OTg5_9c15498e-18dc-41bc-8db4-67bb020f79c0">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGFibGU6NzAxYTRmYmM0ODYyNGM5YmIzZjg0NDM1Yjg0YTJjMGUvdGFibGVyYW5nZTo3MDFhNGZiYzQ4NjI0YzliYjNmODQ0MzViODRhMmMwZV8wLTQtMS0xLTI1OTg5_27c9e1f0-b597-47df-ae40-860b1ee64a2d">71-0869350</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identification Number)</span></td></tr><tr style="height:3pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGFibGU6NzAxYTRmYmM0ODYyNGM5YmIzZjg0NDM1Yjg0YTJjMGUvdGFibGVyYW5nZTo3MDFhNGZiYzQ4NjI0YzliYjNmODQ0MzViODRhMmMwZV80LTAtMS0xLTI1OTg5_13b6633c-74d8-41db-b74b-5cee127d53ec">3675 Market Street,</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGFibGU6NzAxYTRmYmM0ODYyNGM5YmIzZjg0NDM1Yjg0YTJjMGUvdGFibGVyYW5nZTo3MDFhNGZiYzQ4NjI0YzliYjNmODQ0MzViODRhMmMwZV80LTEtMS0xLTI1OTg5_912aed5f-60b4-4688-bc3a-890475cff3e3">Philadelphia,</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGFibGU6NzAxYTRmYmM0ODYyNGM5YmIzZjg0NDM1Yjg0YTJjMGUvdGFibGVyYW5nZTo3MDFhNGZiYzQ4NjI0YzliYjNmODQ0MzViODRhMmMwZV80LTItMS0xLTI1OTg5_a2042b9a-43a8-4beb-b40d-06a2693ae4f0">PA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGFibGU6NzAxYTRmYmM0ODYyNGM5YmIzZjg0NDM1Yjg0YTJjMGUvdGFibGVyYW5nZTo3MDFhNGZiYzQ4NjI0YzliYjNmODQ0MzViODRhMmMwZV80LTQtMS0xLTI1OTg5_dcd5d1a6-7f36-4e51-bde2-b65079006dc6">19104</ix:nonNumeric></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr><tr style="height:5pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGFibGU6NzAxYTRmYmM0ODYyNGM5YmIzZjg0NDM1Yjg0YTJjMGUvdGFibGVyYW5nZTo3MDFhNGZiYzQ4NjI0YzliYjNmODQ0MzViODRhMmMwZV83LTAtMS0xLTI1OTg5_410445ca-4fd2-4d69-b3a9-f38e3fb3cbb4">(215)</ix:nonNumeric></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGFibGU6NzAxYTRmYmM0ODYyNGM5YmIzZjg0NDM1Yjg0YTJjMGUvdGFibGVyYW5nZTo3MDFhNGZiYzQ4NjI0YzliYjNmODQ0MzViODRhMmMwZV83LTMtMS0xLTI1OTg5_712878e7-364a-483a-a1e9-75c9269b3b35">921-7600</ix:nonNumeric></span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Registrant's Telephone Number,&#160;Including Area Code)</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGFibGU6ZmY4ZjAyZWI2ZmEzNDI0OWIzMjRjODkzZjI5ZmRlZDUvdGFibGVyYW5nZTpmZjhmMDJlYjZmYTM0MjQ5YjMyNGM4OTNmMjlmZGVkNV8xLTAtMS0xLTI1OTg5_7217b401-80cd-4746-876f-2ef287fbb305">Common Stock, par value $0.01 per share</ix:nonNumeric></span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGFibGU6ZmY4ZjAyZWI2ZmEzNDI0OWIzMjRjODkzZjI5ZmRlZDUvdGFibGVyYW5nZTpmZjhmMDJlYjZmYTM0MjQ5YjMyNGM4OTNmMjlmZGVkNV8xLTEtMS0xLTI1OTg5_76c60299-e6bc-40c4-8158-3169a4b7dc25">FOLD</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGFibGU6ZmY4ZjAyZWI2ZmEzNDI0OWIzMjRjODkzZjI5ZmRlZDUvdGFibGVyYW5nZTpmZjhmMDJlYjZmYTM0MjQ5YjMyNGM4OTNmMjlmZGVkNV8xLTItMS0xLTI1OTg5_1bfae59e-fbd9-4462-8d05-7bf1e9b7fe67">NASDAQ Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160; <ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGV4dHJlZ2lvbjphODg5NDY2OTAyNDg0M2U1OTliMjA3YmRkZWE2ZDFjNF8yMDk4_0d9373fe-573d-4ddd-ba0c-ced272e1d199">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160; <ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGV4dHJlZ2lvbjphODg5NDY2OTAyNDg0M2U1OTliMjA3YmRkZWE2ZDFjNF8yMDkx_faef37fa-4ade-4788-a19d-0e402e496780">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:28.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.001%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.216%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.399%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGFibGU6ODJjZjVlZTQxNzI2NDliNTg2MDJkNzcyMTQ2ODQzYmQvdGFibGVyYW5nZTo4MmNmNWVlNDE3MjY0OWI1ODYwMmQ3NzIxNDY4NDNiZF8wLTAtMS0xLTI1OTg5_fe6ab060-c586-46f5-b5ff-910eba69a129">Large accelerated filer</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGFibGU6ODJjZjVlZTQxNzI2NDliNTg2MDJkNzcyMTQ2ODQzYmQvdGFibGVyYW5nZTo4MmNmNWVlNDE3MjY0OWI1ODYwMmQ3NzIxNDY4NDNiZF8xLTQtMS0xLTI1OTg5_7b32643b-8c57-44c5-8a35-9592198e2f2a">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGFibGU6ODJjZjVlZTQxNzI2NDliNTg2MDJkNzcyMTQ2ODQzYmQvdGFibGVyYW5nZTo4MmNmNWVlNDE3MjY0OWI1ODYwMmQ3NzIxNDY4NDNiZF8yLTQtMS0xLTI1OTg5_f72f3c25-0440-4811-bb5b-89d75edd8db1">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. &#9744;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes <ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGV4dHJlZ2lvbjphODg5NDY2OTAyNDg0M2U1OTliMjA3YmRkZWE2ZDFjNF8yMDky_1a25afd8-beaf-4f96-ad05-bad323938996">&#9744;</ix:nonNumeric> No &#9746;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares outstanding of the registrant's common stock, $0.01 par value per share, as of July&#160;27, 2022 was <ix:nonFraction unitRef="shares" contextRef="i1072316a8ef24e96928b3d944127fe65_I20220727" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGV4dHJlZ2lvbjphODg5NDY2OTAyNDg0M2U1OTliMjA3YmRkZWE2ZDFjNF80OTQ3ODAyMzI3MTEz_dc1109f2-7f24-4645-8247-20801c4ccae8">280,498,461</ix:nonFraction> shares.</span></div><div style="margin-top:6pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMICUS THERAPEUTICS,&#160;INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form&#160;10-Q for the Quarterly Period Ended June 30, 2022 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_13">PART&#160;I.&#160;&#160;&#160;&#160;&#160;FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_13">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="12" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_16">Consolidated Financial Statements and Notes (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_16">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_19">Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_19">June</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_19"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_19">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_19">, 2022 and December 31, 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_19">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_22">Consolidated Statements of Operations for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_22">Three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_22">Six</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_22"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_22">June</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_22"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_22">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_22">, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_22">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_25">Consolidated Statements of Comprehensive Loss for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_25">Three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_25">Six</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_25"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_25">June</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_25"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_25">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_25">, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_25">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_28">Consolidated Statements of Changes in Stockholders' Equity for the</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_28"> Three and</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_28"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_28">Six</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_28"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_28">June 30</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_28">, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_28">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_31">Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_31">Six </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_31">Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_31">June</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_31"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_31">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_31">, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_31">8</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_34">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_34">9</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_61">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_61">20</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_73">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_73">29</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_76">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_76">29</a></span></div></td></tr><tr style="height:3pt"><td colspan="12" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_79">PART&#160;II.&#160;&#160;&#160;&#160;&#160;OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_79">29</a></span></div></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_82">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_82">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_85">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_85">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_88">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_88">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_91">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_91">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_94">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_94">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_97">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_97">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_100">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_100">31</a></span></div></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_103">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic325ed1a45484718a7ea1ead2bcfd471_103">32</a></span></div></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have filed applications to register certain trademarks in the United States and abroad, including AMICUS THERAPEUTICS and design, AMICUS ASSIST and design, CHART and design, AT THE FOREFRONT OF THERAPIES FOR RARE AND ORPHAN DISEASES, HEALING BEYOND DISEASE, OUR GOOD STUFF, and Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and design. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form&#160;10-Q contains forward-looking statements that involve risks, uncertainties, and assumptions. Forward-looking statements are all statements, other than statements of historical facts, that discuss our current expectation and projections relating to our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans, and objectives of management. These statements may be preceded by, followed by or include the words "aim," "anticipate," "believe," "can," "could," "estimate," "expect," "forecast," "intend," "likely," "may," "outlook," "plan," "potential," "predict," "project," "seek," "should," "will," "would," the negatives or plurals thereof, and other words and terms of similar meaning, although not all forward-looking statements contain these identifying words.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that our assumptions made in connection with the forward-looking statements are reasonable, we cannot assure you that the assumptions and expectations will prove to be correct. You should understand that the following important factors could affect our future results and could cause those results or other outcomes to differ materially from those expressed or implied in our forward-looking statements: </span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of our clinical trials of our drug candidates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing drug supply for our commercial, clinical and preclinical studies, including the cost of manufacturing Pompe Enzyme Replacement Therapy ("ERT" or "ATB200" or "cipaglucosidase alfa");</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the future results of preclinical research and subsequent clinical trials for pipeline candidates we may identify from time to time, including our ability to obtain regulatory approvals and commercialize these therapies and obtain market acceptance for such therapies;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing, and outcome of regulatory review of our product candidates, including AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any changes in regulatory standards relating to the review of our product candidates, including AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and development requirements of other product candidates that we pursue;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of commercialization activities, including product marketing, sales, and distribution;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the emergence of competing technologies and other adverse market developments;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully commercialize Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (also referred to as "migalastat HCl") and, if our regulatory applications are approved, AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manufacture or supply sufficient clinical or commercial products, including Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain reimbursement for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and, if our regulatory applications are approved, AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to satisfy post-marketing commitments or requirements for continued regulatory approval of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and, if approved and applicable, AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain market acceptance of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and, if our regulatory applications are approved, AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing, and prosecuting patent applications and maintaining, enforcing, and defending intellectual property-related claims, including Hatch-Waxman litigation;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of litigation that has been or may be brought against us or of litigation that we are pursuing or may pursue against others;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or invest in businesses, products, and technologies;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully integrate our acquired products and technologies into our business, or successfully divest or license existing products and technologies from our business, including the possibility that the expected benefits of the transactions will not be fully realized by us or may take longer to realize than expected;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish licensing agreements, collaborations, partnerships or other similar arrangements and to obtain milestone, royalty, or other payments from any such collaborators;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our business could be adversely impacted by the effects of the novel coronavirus ("COVID-19") outbreak, including due to actions by us, governments, our customers, our suppliers, or other third parties to control the spread of COVID-19, or by other health epidemics or pandemics;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with, and our ability to comply with, emerging environmental, social and governance standards;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to accurately forecast revenue, operating expenditures, or other metrics impacting profitability;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in foreign currency exchange rates; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting standards.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of these risks and uncertainties, we may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in Part&#160;I Item 1A &#8212; Risk Factors of the Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2021, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make.&#160;Those factors and the other risk factors described herein are not necessarily all of the important factors that could cause actual results or developments to differ materially from those expressed in any of our forward-looking statements. Other unknown or unpredictable factors also could harm our results. Our forward-looking statements do not reflect the potential impact of any future collaborations, alliances, business combinations, partnerships, strategic out-licensing of certain assets, the acquisition of preclinical-stage, clinical-stage, marketed products or platform technologies or other investments we may make. Consequently, there can be no assurance that actual results or developments anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, us. Given these uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Quarterly Report on Form&#160;10-Q in conjunction with our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (including the documents incorporated by reference therein) completely and with the understanding that our actual future results may be materially different from what we expect. These forward-looking statements speak only as of the date of this report. We undertake no obligation, and specifically decline any obligation, to publicly update or revise any forward-looking statements, even if experience or future developments make it clear that projected results expressed or implied in such statements will not be realized, except as may be required by law.&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I.&#160;&#160;&#160;&#160;FINANCIAL INFORMATION</span></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_16"></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;CONSOLIDATED FINANCIAL STATEMENTS AND NOTES (UNAUDITED)</span></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_19"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMy0xLTEtMS0yNTk4OQ_3d39c0a5-be35-4ee1-8b97-3d4a2d11681e">235,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMy0zLTEtMS0yNTk4OQ_ad7b7f57-be44-4e59-822a-000f0787254a">245,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments in marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfNC0xLTEtMS0yNTk4OQ_258fa5b7-3c50-46e7-a008-2dd9bf633203">151,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfNC0zLTEtMS0yNTk4OQ_1f4a3c2d-9ccd-43bd-bd65-a02456e798e7">237,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfNS0xLTEtMS0yNTk4OQ_74ed57b6-a7d0-4475-ba1f-90cb1a87d90c">52,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfNS0zLTEtMS0yNTk4OQ_6dca14b8-e662-454a-88ff-e1e64922c4bf">52,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfNi0xLTEtMS0yNTk4OQ_0b452e72-87d4-4261-b3fc-4af8dcf3dbb6">20,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfNi0zLTEtMS0yNTk4OQ_acb2b81b-a283-4a08-8181-60caa5dd151b">26,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfNy0xLTEtMS0yNTk4OQ_7d61250a-4267-414c-bdaa-3e3caa3c10ca">37,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfNy0zLTEtMS0yNTk4OQ_b22e3e5b-635e-4518-864f-24b2494da985">34,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfOC0xLTEtMS0yNTk4OQ_2ddaf7b9-4ef1-4ef0-8eb6-7e84e545b697">497,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfOC0zLTEtMS0yNTk4OQ_85c593f5-6b02-4be6-9af6-5903168ce19e">596,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfOS0xLTEtMS0yNTk4OQ_6c24f3b8-77d4-4c31-8b70-abe8a18fdcd2">30,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfOS0zLTEtMS0yNTk4OQ_e56b31c7-fe46-4e53-aee4-ad0ce5cdcf7f">20,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, less accumulated depreciation of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTAtMC0xLTEtMjU5ODkvdGV4dHJlZ2lvbjplY2NmMWRiNDU1NjA0NTAwOTYxMTU2MTllYTM1ZTI3MF82MQ_5dfb700d-823e-4a07-8a90-ea5d666ac6a6">22,188</ix:nonFraction> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">and $<ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTAtMC0xLTEtMjU5ODkvdGV4dHJlZ2lvbjplY2NmMWRiNDU1NjA0NTAwOTYxMTU2MTllYTM1ZTI3MF82OA_44793374-325c-40b0-a308-c399ccabb461">19,882</ix:nonFraction> at June 30, 2022 and December 31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTAtMS0xLTEtMjU5ODk_37ecef22-21cc-42c5-9e89-b23f2e1641e5">33,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTAtMy0xLTEtMjU5ODk_2024c6ef-ebbd-489c-bb0b-941361d0896f">42,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research&#160;&amp; development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTEtMS0xLTEtMjU5ODk_cef3a118-40b6-48a2-9600-edd82d2a8b3b">23,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTEtMy0xLTEtMjU5ODk_65e4595b-0d34-42ed-8b6b-80594ca156e9">23,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTItMS0xLTEtMjU5ODk_7fd91603-5a7d-4c76-9fe1-df9925ad8b66">197,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTItMy0xLTEtMjU5ODk_824e2e0e-a89c-45a7-9ed7-8508533b5dc9">197,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTMtMS0xLTEtMjU5ODk_166a06ad-0cbb-4696-a42c-bcd36cc95798">18,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTMtMy0xLTEtMjU5ODk_926ea2fa-03ff-4f4a-ae5d-2fcb3441ddd2">24,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTQtMS0xLTEtMjU5ODk_6a2706e8-8788-463b-ab07-391711676330">800,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTQtMy0xLTEtMjU5ODk_ed9469d6-11e6-4a2a-8578-ba7e421ed582">905,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTctMS0xLTEtMjU5ODk_e73272f7-0662-471c-94c8-144a59bf7dfa">23,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTctMy0xLTEtMjU5ODk_1fe36aaa-0077-49db-9281-a4396492c858">21,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTgtMS0xLTEtMjU5ODk_6de94bdd-3457-4515-8d26-3ac785951bb4">114,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTgtMy0xLTEtMjU5ODk_dda57382-8f26-4182-8e73-68329c2c59cd">98,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTktMS0xLTEtMjU5ODk_a3d83ae5-fe38-4242-bcb3-ba8e33a24068">19,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTktMy0xLTEtMjU5ODk_b37d4cad-b3f1-4190-8048-c182af727ff9">18,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjAtMS0xLTEtMjU5ODk_8e53d308-589c-49b3-b37a-17c71045e357">7,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjAtMy0xLTEtMjU5ODk_168fb924-01e3-4052-bf7a-eb124b7d97e8">7,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjEtMS0xLTEtMjU5ODk_71195d34-5984-4d0f-bdd1-5c6bd6d6ee9d">164,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjEtMy0xLTEtMjU5ODk_d6c90a61-a862-4b64-842c-686d2e9da2fd">145,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjItMS0xLTEtMjU5ODk_f4f29919-5cad-4c31-ae9d-e283c64ad656">390,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjItMy0xLTEtMjU5ODk_78f7f0e5-0ad0-48f5-afde-a39cfc964f2b">389,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjMtMS0xLTEtMjU5ODk_07407a55-c286-40ea-9a5b-73e659d797ea">52,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjMtMy0xLTEtMjU5ODk_528175fe-1fc9-4cdf-b935-373ca133fbf1">43,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred reimbursements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjQtMS0xLTEtMjU5ODk_57d2179a-3574-4a9c-bbee-b6f029cd3f43">5,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjQtMy0xLTEtMjU5ODk_fd5aae21-fb54-468a-915e-8be64b22c49c">5,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjUtMS0xLTEtMjU5ODk_eddd6341-cf2c-40b1-8899-0acf676b6157">4,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjUtMy0xLTEtMjU5ODk_53bc09c6-02c2-4b57-9fb1-e86bb8322f53">4,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjYtMS0xLTEtMjU5ODk_f41e8bb0-839b-445b-a204-794f926a2330">8,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjYtMy0xLTEtMjU5ODk_7a9a4a08-0084-4ceb-9e81-4d151c11b59f">8,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjctMS0xLTEtMjU5ODk_24dd2334-f680-492a-b7a3-4a6376426d64">627,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjctMy0xLTEtMjU5ODk_f1282bff-b535-4c5f-8a0b-d708724b4a97">597,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjgtMS0xLTEtMjU5ODk_0cc4b4ff-99e7-4549-a410-2162dbdb14cc"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjgtMy0xLTEtMjU5ODk_d6794b74-9533-4389-8bb0-bd56c666135b"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="cadPerShare" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzAtMC0xLTEtMjU5ODkvdGV4dHJlZ2lvbjplNGY1N2U5MjUyNTQ0NmFmYmI2Y2E3Yjc0ZmJmNjA0Yl8xOA_7005ba8a-6237-44a0-9486-a5a5d9cdf927"><ix:nonFraction unitRef="cadPerShare" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzAtMC0xLTEtMjU5ODkvdGV4dHJlZ2lvbjplNGY1N2U5MjUyNTQ0NmFmYmI2Y2E3Yjc0ZmJmNjA0Yl8xOA_dd3c2c2a-6193-4b8f-91a5-941f1d9eb382">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzAtMC0xLTEtMjU5ODkvdGV4dHJlZ2lvbjplNGY1N2U5MjUyNTQ0NmFmYmI2Y2E3Yjc0ZmJmNjA0Yl8zMg_ad75ab37-5928-4115-bc02-fe31b5f440ea"><ix:nonFraction unitRef="shares" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzAtMC0xLTEtMjU5ODkvdGV4dHJlZ2lvbjplNGY1N2U5MjUyNTQ0NmFmYmI2Y2E3Yjc0ZmJmNjA0Yl8zMg_d8ede20d-4490-4d5c-94c4-64418b47e638">500,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzAtMC0xLTEtMjU5ODkvdGV4dHJlZ2lvbjplNGY1N2U5MjUyNTQ0NmFmYmI2Y2E3Yjc0ZmJmNjA0Yl81NA_5f019ca4-4f80-4fbe-8d89-aea5ced4400d"><ix:nonFraction unitRef="shares" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzAtMC0xLTEtMjU5ODkvdGV4dHJlZ2lvbjplNGY1N2U5MjUyNTQ0NmFmYmI2Y2E3Yjc0ZmJmNjA0Yl81NA_a199fe21-13bb-4723-8f12-2044ff28ac9a">280,456,667</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzAtMC0xLTEtMjU5ODkvdGV4dHJlZ2lvbjplNGY1N2U5MjUyNTQ0NmFmYmI2Y2E3Yjc0ZmJmNjA0Yl82MQ_29a40d49-949f-4f42-bbeb-e682289237cd"><ix:nonFraction unitRef="shares" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzAtMC0xLTEtMjU5ODkvdGV4dHJlZ2lvbjplNGY1N2U5MjUyNTQ0NmFmYmI2Y2E3Yjc0ZmJmNjA0Yl82MQ_b110ea20-16db-495b-8524-15a679515396">278,912,800</ix:nonFraction></ix:nonFraction> shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzAtMS0xLTEtMjU5ODk_f2955ce6-d1d4-4204-aefe-68277e665aac">2,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzAtMy0xLTEtMjU5ODk_860b2b66-d91a-4dc2-9b9d-32e0556b9756">2,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzEtMS0xLTEtMjU5ODk_f8cdb9ff-9dad-4069-a2a0-5364d8063fa6">2,631,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzEtMy0xLTEtMjU5ODk_5edf81ae-7ab8-4785-a41e-a79443a0bd81">2,595,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive (loss) gain:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzMtMS0xLTEtMjU5ODk_b43b5ff2-e304-4c2c-ad3e-650c7807e65e">16,603</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzMtMy0xLTEtMjU5ODk_a40ed397-d48f-4db6-ab66-4a98370f9408">5,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzQtMS0xLTEtMjU5ODk_7dcc97e4-bfb7-4bab-b77a-f912eb6a1b15">637</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzQtMy0xLTEtMjU5ODk_c9d674e9-8699-426e-9239-3d4e52bc6834">270</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzUtMS0xLTEtMjU5ODk_0e1a0b79-c63a-48bc-980c-447c7ff287d3">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzUtMy0xLTEtMjU5ODk_4844e19a-f415-4616-a2da-a38d14662dca">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzYtMS0xLTEtMjU5ODk_6d3b78bb-7a60-4d0c-9404-0e244a2fd044">2,443,339</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzYtMy0xLTEtMjU5ODk_5251f6b5-acf3-45f0-96a6-15b4c5b801f5">2,295,922</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzctMS0xLTEtMjU5ODk_4e14c86a-36c9-4e03-85ee-632c0d914a25">173,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzctMy0xLTEtMjU5ODk_13b0314c-1da8-4c97-ba38-39776eb16f32">307,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Liabilities and Stockholders&#8217; Equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzgtMS0xLTEtMjU5ODk_6adb0450-9740-4737-954f-122ea1985acc">800,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzgtMy0xLTEtMjU5ODk_11e4faa3-106b-41ea-af65-8f56df5234f9">905,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.590%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMi0xLTEtMS0yNTk4OQ_db96c553-29ee-4a58-97ae-be9c51d675ea">80,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMi0zLTEtMS0yNTk4OQ_d986c2bd-6574-4900-ba01-a8e2fee02618">77,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMi00LTEtMS0yNjUxMQ_0d783240-b7bb-4a1b-a4dc-f907d4055cd3">159,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMi02LTEtMS0yNjUxMQ_489ea54e-1067-4f00-9f72-7ece8194ea2e">143,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMy0xLTEtMS0yNTk4OQ_95b3ddfa-be22-4247-b867-e0b1c8717354">8,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMy0zLTEtMS0yNTk4OQ_52d197c4-1e46-43bf-89bc-ca1d284f592b">8,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMy00LTEtMS0yNjUxMQ_c3aa7b99-2e75-4671-b065-d5b5d71a2b3d">15,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMy02LTEtMS0yNjUxMQ_bd4aa07b-a781-4efa-bc56-c6113825719f">14,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfNC0xLTEtMS0yNTk4OQ_fee09b4e-0733-481c-9502-4b24e168fc92">72,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfNC0zLTEtMS0yNTk4OQ_6f3d97e4-fb17-4b63-8556-5cbabba17672">69,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfNC01LTEtMS0yNzY5MA_6d55f6c9-e09a-426a-bb7a-5ebc62f31051">143,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfNC03LTEtMS0yNzY5MA_c86711fd-79d2-467f-b4af-ba00a2847905">128,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfNi0xLTEtMS0yNTk4OQ_088db93d-93cd-48f0-868c-a39d84afde9c">78,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfNi0zLTEtMS0yNTk4OQ_254c8bdd-d4b1-4716-8dca-3de6a7c294f6">63,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfNi00LTEtMS0yNjUyMA_c9d21d73-5ca7-4ce8-8fdd-fb89425b2797">159,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfNi02LTEtMS0yNjUyMA_7f6f60db-dd7b-4701-884f-8bafe8083eac">127,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfNy0xLTEtMS0yNTk4OQ_82500b3e-ce01-4942-b90b-314bcedbb70a">53,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfNy0zLTEtMS0yNTk4OQ_452634dc-a626-40ab-8e5e-68237afa4fb0">42,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfNy00LTEtMS0yNjUyMA_8df53872-49ff-41eb-a863-1b8ab0b9ed36">111,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfNy02LTEtMS0yNjUyMA_d2fc2e4e-531c-45ff-8537-2d3eab6230b7">89,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in fair value of contingent consideration payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfOC0xLTEtMS0yNTk4OQ_aae42c7e-b913-4f06-975f-43e15aac9a30">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfOC0zLTEtMS0yNTk4OQ_adec42db-5159-464b-a1af-1511545f0c4c">1,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfOC00LTEtMS0yNjUyMA_16b80c63-091d-4c97-b02e-df3d3cdd0bfe">1,073</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfOC02LTEtMS0yNjUyMA_6d366338-bb09-474e-a93a-2eb0c9429a33">1,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on impairment of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfOS0xLTEtMS0yNTk4OQ_b44553ff-f4e1-4d63-b824-a86ec80ab702">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfOS0zLTEtMS0yNTk4OQ_71a09d18-10a4-4f98-abeb-b566cb6fdcca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfOS00LTEtMS0yNjUyNw_302ab79d-4b4f-41b2-949f-63f3bb89727a">6,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfOS02LTEtMS0yNjUyNw_8f4496e8-dc1c-4db8-a4d0-af5b03163ecc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTAtMS0xLTEtMjU5ODk_89df2267-558a-49bc-b592-36978b59f568">1,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTAtMy0xLTEtMjU5ODk_7ff0996a-f31b-455d-bd0b-aa791d193a40">1,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTAtNC0xLTEtMjcyMzA_385745f7-350c-4439-b047-946feeb51c4d">2,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTAtNi0xLTEtMjcyMzA_292c5512-6c7a-44e6-a9a2-38dd67a4b5d9">3,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTEtMS0xLTEtMjU5ODk_422363b2-834b-4756-b232-c31c3f8b914a">133,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTEtMy0xLTEtMjU5ODk_a88edf67-ab73-440d-9683-feb4613a5a11">107,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTEtNS0xLTEtMjc2OTA_0dd738cd-382c-46d9-bf2d-dbb36c0402d1">279,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTEtNy0xLTEtMjc2OTA_d204bed3-2986-4e20-ad28-7ef8ba2df69a">220,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTItMS0xLTEtMjU5ODk_5402d1b8-d411-42e4-9ad2-d8310d8a1370">60,613</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTItMy0xLTEtMjU5ODk_a7030076-2796-40d3-ab87-b8b75ed5f2fc">38,834</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTItNS0xLTEtMjc2OTA_a8972ea0-069c-4d0b-ba0a-4af7f74fb678">135,952</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTItNy0xLTEtMjc2OTA_667cfa30-d7e0-4fc2-8eca-1d62d09e9fbc">91,889</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (expense) income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTQtMS0xLTEtMjU5ODk_7e390d79-099d-4302-8719-6a8514da952b">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTQtMy0xLTEtMjU5ODk_2df45bfc-476b-4411-b09d-b1dccc663742">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTQtNC0xLTEtMjY1NDg_e43287f4-bba2-4fd1-830f-74e0e50b8aaa">489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTQtNi0xLTEtMjY1NDg_fee4003b-478e-4987-9e31-d6b138889506">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTUtMS0xLTEtMjU5ODk_962acbf6-d645-4fac-82e6-e6876ef814d2">8,257</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTUtMy0xLTEtMjU5ODk_40a29f65-ad1c-45c3-948d-58c4d828f1b0">8,150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTUtNC0xLTEtMjY1NDg_1bb4e7f3-7f7e-44a6-8d1c-77453ddfb1d2">16,404</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTUtNi0xLTEtMjY1NDg_061e326e-eaa3-49f9-b273-22c73190a2ba">16,142</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTctMS0xLTEtMjU5ODk_3c62a922-778a-40a7-9e2a-3c82b0b89ee1">7,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTctMy0xLTEtMjU5ODk_ddd4bb0f-dc93-40dd-8969-3ac224ada6e0">234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTctNC0xLTEtMjY1NTU_0fcafa7b-7690-41bf-9bf6-16643bb64c45">9,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTctNi0xLTEtMjY1NTU_12d177ec-09f8-4d20-a6d1-5db4dbbd002d">2,966</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income tax </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTgtMS0xLTEtMjU5ODk_bb0d7f4f-a48e-4631-8847-afe0fd977146">61,246</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTgtMy0xLTEtMjU5ODk_2c35c02d-2781-43f6-9697-5d32f2e3a662">46,700</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTgtNS0xLTEtMjc2OTA_5aeebaa8-8efa-4287-afeb-63f4a30e1a55">142,697</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTgtNy0xLTEtMjc2OTA_8c0f9bdf-0520-4801-b419-c42f7826930e">110,782</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTktMS0xLTEtMjU5ODk_613ab3e0-326a-455b-9f4f-f01306703c8d">911</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTktMy0xLTEtMjU5ODk_395c2702-d9ec-4953-9471-bdfb50cc3246">4,525</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTktNC0xLTEtMjY1NjQ_b370e77c-fc80-4489-9fa4-dda85eea8783">4,720</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTktNi0xLTEtMjY1NjQ_76a44cb2-be38-4a4d-bd5e-e3f53499b784">6,107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjAtMS0xLTEtMjU5ODk_6322b21b-477e-4e42-92be-0d905f78702c">62,157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjAtMy0xLTEtMjU5ODk_b504f4f7-af37-417d-9f4e-83878046d7a2">51,225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjAtNS0xLTEtMjc2OTA_08f7340a-7419-4669-8c35-61cc594f04a7">147,417</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjAtNy0xLTEtMjc2OTA_3636be27-8376-490d-8923-81b73edfbf6b">116,889</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders per common share&#160;&#8212; basic and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cadPerShare" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjEtMS0xLTEtMjU5ODk_948e0826-11b4-4214-b993-1650ecd27cac"><ix:nonFraction unitRef="cadPerShare" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjEtMS0xLTEtMjU5ODk_d63d6b76-238b-4e0e-8d3b-a9bad565ae2d">0.21</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cadPerShare" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjEtMy0xLTEtMjU5ODk_1aad056d-1e5f-43db-b260-1aed5b0a437b"><ix:nonFraction unitRef="cadPerShare" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjEtMy0xLTEtMjU5ODk_521e0a97-9cfb-4525-a61d-ab195725a87b">0.19</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cadPerShare" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjEtNC0xLTEtMjcyMzM_5ddc40a8-3df5-43ab-802f-37f075776bc9"><ix:nonFraction unitRef="cadPerShare" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjEtNC0xLTEtMjcyMzM_5e68835d-6d41-4a22-a231-927e155aa729">0.51</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cadPerShare" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjEtNi0xLTEtMjcyMzM_4856a23d-39f6-4392-9dad-0b05c5134bad"><ix:nonFraction unitRef="cadPerShare" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjEtNi0xLTEtMjcyMzM_f1dbb8b3-db10-4b9f-ac8f-be600283d263">0.44</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding&#160;&#8212; basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjItMS0xLTEtMjU5ODk_2b23b1a1-43dc-48cf-a31e-8f3a77eb1d50"><ix:nonFraction unitRef="shares" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjItMS0xLTEtMjU5ODk_c14c4dd2-4936-45ed-ba2b-b1d7d018cbac">291,970,562</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjItMy0xLTEtMjU5ODk_fc104a0b-b0cb-4a1a-90fa-952fafa2f197"><ix:nonFraction unitRef="shares" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjItMy0xLTEtMjU5ODk_fea06fd0-6ad5-4aa9-8e81-2267b204ec8e">266,398,516</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjItNC0xLTEtMjcyMzM_068356e6-31fc-4f7e-8097-8adcd460e27d"><ix:nonFraction unitRef="shares" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjItNC0xLTEtMjcyMzM_aeac1143-bf5f-428c-aa10-0e0573274d71">288,646,587</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjItNi0xLTEtMjcyMzM_717a8067-dfa3-49eb-a155-fb842b71f666"><ix:nonFraction unitRef="shares" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjItNi0xLTEtMjcyMzM_b9b12440-0055-4c11-8035-3fc8608c9c94">265,384,865</ix:nonFraction></ix:nonFraction></span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Comprehensive Loss </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.091%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.091%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.091%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.096%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfMi0xLTEtMS0yNTk4OQ_7216938b-2c23-4d57-89d1-7b5a6b647616">62,157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfMi0zLTEtMS0yNTk4OQ_415713c0-5c95-4487-bbba-a3e9afc1d3dd">51,225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfMi00LTEtMS0yNzEzNA_805e537c-06de-4484-8ae6-051c24ec76bf">147,417</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfMi02LTEtMS0yNzEzNA_530a59ce-a856-41b3-9290-2cfef1535a4a">116,889</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) gain:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment (loss) gain</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfNC0xLTEtMS0yNTk4OQ_a91dd1b4-a5a9-4dbf-9796-fc918bc1770a">16,183</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfNC0zLTEtMS0yNTk4OQ_09b82cb5-02b8-499d-89c8-29e03453dbbb">235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfNC00LTEtMS0yNjU4NA_48a239a8-d436-41b4-a987-fe3caa6fd777">21,854</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfNC02LTEtMS0yNjU4NA_3fb72407-5eae-4559-88c3-b5a9a821e074">843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized (loss) gain on available-for-sale securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfNS0xLTEtMS0yNTk4OQ_cc1a4f73-70b2-4ea1-962d-e17833c9a2c4">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfNS0zLTEtMS0yNTk4OQ_192e4fca-5c24-4ea4-9e89-80f651a76767">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfNS00LTEtMS0yNjU4NA_69d5527d-d84c-49d1-adec-eafe142a3c35">367</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfNS02LTEtMS0yNjU4NA_576b6557-ee80-4bb9-aa54-05fe9e950946">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) gain</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfNi0xLTEtMS0yNTk4OQ_259963ea-ea25-433e-8233-597ff43f6dc1">16,212</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfNi0zLTEtMS0yNTk4OQ_6bb9d88b-e96e-4602-9d2b-52584f9bea59">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfNi00LTEtMS0yNjU4NA_3e387643-d672-471b-8107-150f78c9272a">22,221</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfNi02LTEtMS0yNjU4NA_c9ab6abe-9ad4-4f08-a688-7f696ae64f39">855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfNy0xLTEtMS0yNTk4OQ_e093a0fc-cf7e-4459-819c-066bc187f50f">78,369</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfNy0zLTEtMS0yNTk4OQ_a5102cbc-239d-4798-8392-e0e36f47a0d8">50,978</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfNy01LTEtMS0yNzcwNQ_ff3bce6a-4799-4a88-b97b-692e01c0be6d">169,638</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfNy03LTEtMS0yNzcwNQ_c1e786a2-f886-4723-a656-491830776052">116,034</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Changes in Stockholders' Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share amounts)</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.288%"></td><td style="width:0.1%"></td></tr><tr><td colspan="42" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2022</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:16pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warrants</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other<br/>Comprehensive<br/>Gain (Loss)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic9dcaac3e3f74257b9b5319bd5cd7e11_I20220331" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfNC0xLTEtMS0yNTk4OQ_dd755ddb-cc3d-4c35-905c-1816dec1097b">280,133,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9dcaac3e3f74257b9b5319bd5cd7e11_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfNC0zLTEtMS0yNTk4OQ_e63e3f60-ac57-4cb3-8bdb-35b40efe2142">2,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8964c1432633472c8bc58ddf38701965_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfNC01LTEtMS0yNTk4OQ_f5e97d73-0f2c-4bc9-ab4c-a894f80119e7">2,617,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d81a1ce547341fdbad1b2485e2b8dab_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfNC03LTEtMS0yNTk4OQ_8e306f58-5c26-4097-842d-ee7a4765315a">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i457540a06a0e4f12a8a6760a2e662d69_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfNC0xMS0xLTEtMjU5ODk_16c75613-6922-4033-8208-fcd196ef6a9f">1,028</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97d51d17e9f74441bbd0bd417ab532ee_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfNC0xMy0xLTEtMjU5ODk_d2699257-9acf-4829-af2c-081a7db3215f">2,381,182</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90601765a2f2418a9abfd28bd624e1fb_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfNC0xNS0xLTEtMjU5ODk_45e867ef-763c-4a94-8d3d-93f6cd3a382d">238,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options exercised, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib83568c208d34901bc8f2b3277a492eb_D20220401-20220630" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfNS0xLTEtMS0yNTk4OQ_a5c61ad4-d30a-4d26-bec9-0b065dcf700e">189,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib83568c208d34901bc8f2b3277a492eb_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfNS0zLTEtMS0yNTk4OQ_642f1a3f-05d3-468e-ac72-d8ac2bad198d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b3bca726f0d46f2b136309217acf4e2_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfNS01LTEtMS0yNTk4OQ_6857aeb3-01ca-4c19-a8cf-df43ef93a4cb">997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfNS0xNS0xLTEtMjU5ODk_ad277059-a4d6-4489-b13b-71d62cd4e4cc">999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vesting of restricted stock units, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib83568c208d34901bc8f2b3277a492eb_D20220401-20220630" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfNi0xLTEtMS0yNTk4OQ_8988f00e-d4dd-4cc4-822f-2dc4adc50b12">133,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b3bca726f0d46f2b136309217acf4e2_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfNi01LTEtMS0yNTk4OQ_1f6d54cb-a6d7-490e-9c0d-90b8ee272961">285</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfNi0xNS0xLTEtMjU5ODk_fff35808-4541-4c6a-95be-ae88a6e02543">285</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b3bca726f0d46f2b136309217acf4e2_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfNy01LTEtMS0yNTk4OQ_32e22422-0237-48b9-a460-4f3022a63daf">12,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfNy0xNS0xLTEtMjU5ODk_548a0704-482b-486d-95bb-7ec335d64f8f">12,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized holding loss on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6104ef486d1344d9b4a6249c99ecaa75_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfOC0xMS0xLTEtMjU5ODk_8a6f5c55-7c18-4daa-8274-8347a3990c01">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfOC0xNS0xLTEtMjU5ODk_a92cda87-93f4-4d4d-a521-0d5d8b1fdc40">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6104ef486d1344d9b4a6249c99ecaa75_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfOS0xMS0xLTEtMjU5ODk_31faa4f9-7c74-4cc2-81b9-616257b52a05">16,183</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfOS0xNS0xLTEtMjU5ODk_f925dc22-8ef8-4239-bf77-50fe1de362db">16,183</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id89ea44d86214f11955f8524c82ca59d_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfMTAtMTMtMS0xLTI1OTg5_832fc1ef-97e6-4da6-98de-a1a3a28bf5b7">62,157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfMTAtMTUtMS0xLTI1OTg5_0760e29a-0254-455a-81b1-fd95d4bc43b3">62,157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7cc23a72515148e9bdb594c0ffdc44d9_I20220630" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfMTEtMS0xLTEtMjU5ODk_9cc6c26f-373c-4986-9737-4397a1ce4217">280,456,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cc23a72515148e9bdb594c0ffdc44d9_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfMTEtMy0xLTEtMjU5ODk_14ccd750-e849-48f9-b5f2-10ec134406b4">2,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6af221862afe4ec8a95c4bd66bc29a83_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfMTEtNS0xLTEtMjU5ODk_17ce87b4-794e-46f2-8729-96f36a5a8db7">2,631,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66313300b8924ac38edbed17cd4621e8_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfMTEtNy0xLTEtMjU5ODk_bbe7fc70-9a02-45d4-8764-668f738ded24">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a67d85fc2bc4508827b7d6504191b86_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfMTEtMTEtMS0xLTI1OTg5_5268cd39-f0fb-4ab6-9c24-ea099adca261">17,240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d7fceb860b04c3284049f567598615f_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfMTEtMTMtMS0xLTI1OTg5_18d0fc1c-5a32-4d35-bf5b-17c9e0309f1f">2,443,339</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfMTEtMTUtMS0xLTI1OTg5_33f92a4f-b2fb-41b2-8da9-5748464b432f">173,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.874%"></td><td style="width:0.1%"></td></tr><tr><td colspan="42" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:16pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warrants</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other<br/>Comprehensive<br/>Gain (Loss)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20369be16fb64d618f19ff7c879c5f74_I20211231" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfNC0xLTEtMS0yNjYxMg_035e867c-0b9c-4633-a0c9-9dd729893195">278,912,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20369be16fb64d618f19ff7c879c5f74_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfNC0zLTEtMS0yNjYxMg_ec272cd9-6766-49ab-bf4f-643f1d7c8c4b">2,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i847ea7f79a9d45378381e71e73b6c2d6_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfNC01LTEtMS0yNjYxMg_cb61665b-281b-4afe-bd83-c755ed4aa974">2,595,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8850617c24a64a82b3ac49102d519aac_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfNC03LTEtMS0yNjYxMg_1c68d4e6-5332-4780-9f1d-c1c2b6f99d21">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b04ea28407641b98ad9d006e7f294a1_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfNC05LTEtMS0yNjYxMg_36205d80-a688-48cc-bac1-1048b6809d62">4,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f89399acbed48f4948a667624d93858_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfNC0xMS0xLTEtMjY2MTI_c17d4d16-09dc-4258-afd7-6578d8fd9eca">2,295,922</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfNC0xMy0xLTEtMjc3MDg_cf36cdb8-51c1-4126-868c-429d22bece40">307,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options exercised, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9b3ff93c685496a8f7db03682c9a6bc_D20220101-20220630" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfNS0xLTEtMS0yNjc0NQ_169569dd-f1a6-4949-8137-c7aca926a1fa">334,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9b3ff93c685496a8f7db03682c9a6bc_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfNS0zLTEtMS0yNjc0NQ_4b3843cd-6570-4845-9903-fa3444b9f8cd">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9145f98a12fd40a6a178726d7e2acfd7_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfNS01LTEtMS0yNjc0NQ_e31b4532-e23d-4223-9480-7421f1c5d80f">1,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfNS0xMy0xLTEtMjc3MDg_d446ff8c-48ff-406d-9f4c-80a1d8bf0ee6">1,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vesting of restricted stock units, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9b3ff93c685496a8f7db03682c9a6bc_D20220101-20220630" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfNi0xLTEtMS0yNjczMw_de34051f-c1b8-477f-ac4f-6c7ed7d0058b">1,209,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9145f98a12fd40a6a178726d7e2acfd7_D20220101-20220630" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfNi01LTEtMS0yNjczMw_db48efa9-97f4-4e4f-a742-7267ff27285e">9,278</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfNi0xMy0xLTEtMjc3MDg_b11e985c-1e05-4460-bd97-ab380cab79f7">9,278</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9145f98a12fd40a6a178726d7e2acfd7_D20220101-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfNy01LTEtMS0yNjcyMA_99f3f823-12c5-4f9d-9911-765f4010045c">43,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfNy0xMy0xLTEtMjc3MDg_73ec0d21-fc65-424b-9727-1882aa180ca9">43,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized holding loss on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b08ba7dfa164bffb946e42d5c6b0353_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfOC05LTEtMS0yNjcxMw_029005ee-57e5-4108-9359-bc27d6bfc67c">367</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfOC0xMy0xLTEtMjc3MDg_24337a35-712d-43ca-a3ff-7a0e0d18df27">367</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b08ba7dfa164bffb946e42d5c6b0353_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfOS05LTEtMS0yNjcxMw_c3b6797d-e78d-472b-ae54-2ec1fe0e742e">21,854</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfOS0xMy0xLTEtMjc3MDg_27137d2c-5663-4744-9ddb-3e13a61bc07b">21,854</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id499f57d04ef46548abf1e291e9d5885_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfMTAtMTEtMS0xLTI2NjUw_ee2cb4a9-14d3-46e8-81f9-e22fa815d12e">147,417</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfMTAtMTMtMS0xLTI3NzA4_dede0752-f737-461c-9a28-dbed5c3c191e">147,417</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7cc23a72515148e9bdb594c0ffdc44d9_I20220630" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfMTEtMS0xLTEtMjc3MDg_7b9a6ec4-0aea-450b-8e4f-4b1a8c08feac">280,456,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cc23a72515148e9bdb594c0ffdc44d9_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfMTEtMy0xLTEtMjc3MDg_d786936b-b6f1-43ee-9376-582bcf5ef1b1">2,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6af221862afe4ec8a95c4bd66bc29a83_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfMTEtNS0xLTEtMjc3MDg_69031102-fdd0-4406-9fd1-77138cee199b">2,631,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66313300b8924ac38edbed17cd4621e8_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfMTEtNy0xLTEtMjc3MDg_55ca26bb-8d72-4290-a8cf-46b4a55d7b03">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a67d85fc2bc4508827b7d6504191b86_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfMTEtOS0xLTEtMjc3MDg_72fb9b07-8c3b-4fcc-9d41-bb491b3ffd33">17,240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d7fceb860b04c3284049f567598615f_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfMTEtMTEtMS0xLTI3NzA4_5fadae9b-0067-4738-b37c-79b359c94d3e">2,443,339</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfMTEtMTMtMS0xLTI3NzA4_aeab08f7-8213-47fa-accf-a4ea8b97c457">173,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.520%"><tr><td style="width:1.0%"></td><td style="width:28.612%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.401%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.366%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.644%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.241%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2021</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:16pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other<br/>Comprehensive<br/>Gain (Loss)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03bf3913256a4b41be32f6db37aa316c_I20210331" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfNC0xLTEtMS0yNTk4OQ_15c0afa3-d774-4f33-841e-62ceb3785807">266,007,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bf3913256a4b41be32f6db37aa316c_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfNC0zLTEtMS0yNTk4OQ_fb9dc34b-4d30-405c-8647-ce453484f9ce">2,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de8ae1734aa4d599eb85d75fd49b941_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfNC01LTEtMS0yNTk4OQ_3812e433-384b-4976-b8df-487a7bc9f21e">2,350,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625ab03e96af4d8683f3acb33151056f_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfNC05LTEtMS0yNTk4OQ_a9c68d7e-de7c-4def-8914-09166c064f58">8,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6afdfc73ba542e78bfc05da8ba789e6_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfNC0xMS0xLTEtMjU5ODk_e611f88f-03f3-4a2d-9905-85c16bd0a6ca">2,111,126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib385a6b7137c45958b92a30dddce1f19_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfNC0xMy0xLTEtMjU5ODk_cda26eb4-2865-4a10-8092-400838d18ef8">250,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options exercised, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0236634b4cb14481acb0fb30723e7beb_D20210401-20210630" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfNS0xLTEtMS0yNTk4OQ_493e60f8-b1b8-4eb0-aecf-a0379651c6a1">434,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0236634b4cb14481acb0fb30723e7beb_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfNS0zLTEtMS0yNTk4OQ_9065ae19-888d-4635-bb3c-8cd3eb3de2fe">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaf9ecdf3e9d41aaaf315396d42a9e6e_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfNS01LTEtMS0yNTk4OQ_51509def-48b2-484b-a871-99e5b0800938">2,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfNS0xMy0xLTEtMjU5ODk_178c7fb2-98c1-4b4d-8476-17c2fed5ad92">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vesting of restricted stock units, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0236634b4cb14481acb0fb30723e7beb_D20210401-20210630" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfNi0xLTEtMS0yNTk4OQ_aeffc842-0874-4852-9d96-fbd23eda70f4">90,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaf9ecdf3e9d41aaaf315396d42a9e6e_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfNi01LTEtMS0yNTk4OQ_b953d310-2e30-4e56-9340-d6745d6ab802">244</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfNi0xMy0xLTEtMjU5ODk_17476b07-3ace-40d3-9388-2f9f112c3863">244</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaf9ecdf3e9d41aaaf315396d42a9e6e_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfNy01LTEtMS0yNTk4OQ_d43afef1-a7af-4a55-858c-8ee5d71c833f">11,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfNy0xMy0xLTEtMjU5ODk_05acc943-c2d5-4caa-ba13-6bb265c27368">11,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized holding gain on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0feda6c19ba4dde88c6ff31d463c64d_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfOS05LTEtMS0yNTk4OQ_0d0b4f14-9aa8-4c56-8aae-fdc8fc00652f">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfOS0xMy0xLTEtMjU5ODk_59d8868d-e2d9-4787-9bfc-dc0767bfa07e">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0feda6c19ba4dde88c6ff31d463c64d_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfMTAtOS0xLTEtMjU5ODk_91a35118-fa79-48d1-aa55-f71990dd4ed6">235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfMTAtMTMtMS0xLTI1OTg5_9c88b17c-578b-4535-b6f1-8deec50ab6d8">235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a489e0cac5148b098047e20f7b16d2c_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfMTEtMTEtMS0xLTI1OTg5_95e6b8e1-6eca-4d3e-9366-36d81628c1b3">51,225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfMTEtMTMtMS0xLTI1OTg5_fff99f12-d599-4300-88ed-da275c19950c">51,225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id197126c4925481fbd6568b6714249d7_I20210630" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfMTItMS0xLTEtMjU5ODk_d30f8ad4-72f5-4fb1-97c7-25eed9228cd7">266,532,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id197126c4925481fbd6568b6714249d7_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfMTItMy0xLTEtMjU5ODk_a53e1274-7771-4f13-bfa2-8646beccb441">2,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1575283eac554820897a66659337bdf4_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfMTItNS0xLTEtMjU5ODk_0d9d702e-6ea6-489d-8f42-f5a8111ca1fb">2,364,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia655833ddbb14af0823e080a718286f3_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfMTItOS0xLTEtMjU5ODk_f557c90b-5086-4ef7-8d80-ef85a9cb1615">9,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia265d46e7fdb4a6cbfc035ff181f41b7_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfMTItMTEtMS0xLTI1OTg5_5c7d0275-315b-40f2-87e2-42ae1d5a28b5">2,162,351</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd0bea669974aef88283f7ce9684c7f_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfMTItMTMtMS0xLTI1OTg5_3b26821b-20a2-463a-89d8-50053e50d597">213,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:15pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.874%"></td><td style="width:0.1%"></td></tr><tr><td colspan="42" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2021</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:16pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warrants</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other<br/>Comprehensive<br/>Gain (Loss)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15ca856684364a728cfb2cacad448766_I20201231" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfNC0xLTEtMS0yNjc5MQ_874aa81c-5016-44e5-aaea-03d257618bee">262,063,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15ca856684364a728cfb2cacad448766_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfNC0zLTEtMS0yNjc5MQ_0f815fb2-61b8-4c2a-9d0e-80f6e3994f84">2,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3250897ae664ba78fc2758e4d197424_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfNC01LTEtMS0yNjc5MQ_bbcd2995-6848-4d05-8b8f-067217da4a4b">2,308,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0726224b301248d2932ff84f9938870f_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfNC03LTEtMS0yNjc5MQ_7d8175fb-6c4e-49de-acbf-498ef6ee302e">12,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebfefb1a4b464d5ba21ad742a3619573_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfNC05LTEtMS0yNjc5MQ_ef81b255-cc4a-43c9-92ec-2c6a35527864">8,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic229e029b81044fdbb354018535e5d3b_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfNC0xMS0xLTEtMjY3OTE_0383858e-208b-4d3c-9f76-9da62e95fda3">2,045,462</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17008df080294bb0bf1240acd6c19c15_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfNC0xMy0xLTEtMjc3MjM_3aa6da83-6fc5-4180-81c4-401cc0d31c69">286,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options exercised, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia5f30d05cafe48b79410089e00859443_D20210101-20210630" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfNS0xLTEtMS0yNjc5MQ_9ba852b9-7da2-4e9b-9eb2-e6a12586b4c8">922,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5f30d05cafe48b79410089e00859443_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfNS0zLTEtMS0yNjc5MQ_6312e332-7d68-4bec-8377-06628a4b9c43">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44b8bffb160d45dda13b5e2b78abce7f_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfNS01LTEtMS0yNjc5MQ_441ece42-88f2-4950-bfce-9f2931fbb655">6,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfNS0xMy0xLTEtMjc3MjM_482fada8-1395-498b-9bbe-1718bde16dc2">6,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vesting of restricted stock units, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia5f30d05cafe48b79410089e00859443_D20210101-20210630" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfNi0xLTEtMS0yNjc5OA_853c016c-993c-49a5-8dbe-db94fe58e532">987,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44b8bffb160d45dda13b5e2b78abce7f_D20210101-20210630" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfNi01LTEtMS0yNjc5OA_6924a3c7-b9b3-440b-a62b-c98ac26f7347">14,438</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfNi0xMy0xLTEtMjc3MjM_b02e4105-b421-4142-a5cb-598e43ee44b7">14,438</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44b8bffb160d45dda13b5e2b78abce7f_D20210101-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfNy01LTEtMS0yNjgwNQ_50b27b65-3ded-4bb4-9bb6-54e952e8927f">32,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfNy0xMy0xLTEtMjc3MjM_adfd9b95-bd70-4936-ac86-3b42106afb3d">32,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrants exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia5f30d05cafe48b79410089e00859443_D20210101-20210630" decimals="0" name="fold:StockIssuedDuringPeriodSharesWarrantsExercised" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfOC0xLTEtMS0yNjgwNQ_10487831-3081-4ca6-a9f7-c3260ecbe61f">2,554,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5f30d05cafe48b79410089e00859443_D20210101-20210630" decimals="-3" name="fold:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfOC0zLTEtMS0yNjgwNQ_1af1b250-cea1-4c1e-94b8-4ac5a173f908">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44b8bffb160d45dda13b5e2b78abce7f_D20210101-20210630" decimals="-3" name="fold:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfOC01LTEtMS0yNjgwNQ_3c94ee76-9a7f-4bde-8802-8ed7a483b1f0">31,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i649bebfff85c4aeb81fb81bfe49eeb22_D20210101-20210630" decimals="-3" sign="-" name="fold:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfOC03LTEtMS0yNjgwNQ_629ba2ca-f55d-4017-8ba5-f81d2061205b">12,387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="fold:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfOC0xMy0xLTEtMjc3Mjg_849855a4-6b66-4d77-aee7-983949117cda">19,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity component of the convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia5f30d05cafe48b79410089e00859443_D20210101-20210630" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfOS0xLTEtMS0yNjgwNQ_6c3502d6-e739-4eff-b9cd-b7950fc423e5">4,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44b8bffb160d45dda13b5e2b78abce7f_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfOS01LTEtMS0yNjgwNQ_08410ddc-9057-4ae0-b5c5-cc83c943eb01">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfOS0xMy0xLTEtMjc3Mjg_49922b30-48e0-4abf-af7e-aabfaf375ab3">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized holding gain on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03ca42e2698e4878b362989f4df7933e_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfMTAtOS0xLTEtMjY4MjE_b769c858-5f73-49c8-ba1b-ea5489758c78">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfMTAtMTMtMS0xLTI3NzI2_7e210170-fb0d-49cd-bc2d-d47c1689ea47">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03ca42e2698e4878b362989f4df7933e_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfMTEtOS0xLTEtMjY4MjE_0239bfce-6772-4c86-a1fc-ac662076deca">843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfMTEtMTMtMS0xLTI3NzI2_4618b454-6911-45bd-b2b4-ce944eddd137">843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69530f8676834a24b6824dd3090f275c_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfMTItMTEtMS0xLTI2ODIx_90f7b82e-49c5-47fd-96d1-2f92b3c18f03">116,889</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfMTItMTMtMS0xLTI3NzI2_3e636d2f-3f40-43b5-947c-c8281786428e">116,889</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id197126c4925481fbd6568b6714249d7_I20210630" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfMTMtMS0xLTEtMjc3MTQ_1af33942-a4bb-450e-9bbc-98d15562a612">266,532,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id197126c4925481fbd6568b6714249d7_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfMTMtMy0xLTEtMjc3MTQ_70a19e9c-f16e-409f-adcc-dee8b29b81c1">2,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1575283eac554820897a66659337bdf4_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfMTMtNS0xLTEtMjc3MTQ_1da8472e-69da-4adc-a8fe-62e7946c4183">2,364,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie01bcbab6a39452c8f207bbd1040e82e_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfMTMtNy0xLTEtMjc3MTQ_fcfbf165-c20b-4505-bf94-5436c3002d9b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia655833ddbb14af0823e080a718286f3_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfMTMtOS0xLTEtMjc3MTQ_13ad7d75-0374-4dae-9c85-226b40bc30ea">9,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia265d46e7fdb4a6cbfc035ff181f41b7_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfMTMtMTEtMS0xLTI3NzE0_8ec98121-61bc-4bca-a9bd-f4a1e5f3ecd4">2,162,351</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd0bea669974aef88283f7ce9684c7f_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfMTMtMTMtMS0xLTI3NzI2_ff321a77-1b76-46e4-b368-d420079f0b15">213,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMy0xLTEtMS0yNTk4OQ_44b4355b-fb25-493d-b41d-9768bbc1ca53">147,417</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMy0zLTEtMS0yNTk4OQ_1b1ead17-ec28-4b17-adaa-081b8830a14e">116,889</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and deferred financing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfNS0xLTEtMS0yNTk4OQ_3feb4bec-ce1f-4a21-886a-a6dd7c448fdd">1,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfNS0zLTEtMS0yNTk4OQ_9a8fbe01-0c01-42fa-b540-103dbf10a2b7">1,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfNi0xLTEtMS0yNTk4OQ_a7fc9e1c-943d-4725-883e-0e485658381d">2,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfNi0zLTEtMS0yNTk4OQ_c0001e82-7f0b-4889-8efb-29d81d797105">3,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfNy0xLTEtMS0yNTk4OQ_3bc44452-d223-4687-a0a0-953fa3edb9b5">43,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfNy0zLTEtMS0yNTk4OQ_2be4f833-2573-42c6-a714-87322b53dfa4">32,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash changes in the fair value of contingent consideration payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfOS0xLTEtMS0yNTk4OQ_a9ddf636-f4ba-4d02-a949-6084ee0c2499">1,073</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfOS0zLTEtMS0yNTk4OQ_2fbe70d8-374e-4e06-bdf0-f3fefc65c3e9">1,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency remeasurement loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" sign="-" name="fold:ForeignCurrencyRemeasurementGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMTAtMS0xLTEtMjU5ODk_db0cb77a-f730-4d69-aac0-0a82e4b54003">353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" sign="-" name="fold:ForeignCurrencyRemeasurementGainLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMTAtMy0xLTEtMjU5ODk_add11662-47e9-49bb-968e-576e0452e2ea">3,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset impairment charges and other asset write-offs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="fold:AssetImpairmentChargesAndOtherAssetWriteOffs" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMTEtMS0xLTEtMjU5ODk_1a1fc9fd-b2a3-44e9-a7da-4dce9e2118e1">12,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="fold:AssetImpairmentChargesAndOtherAssetWriteOffs" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMTEtMy0xLTEtMjU5ODk_6f6df43b-af32-4f1c-bd7d-4c5392a8cf0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMTMtMS0xLTEtMjU5ODk_bf7e0115-eb27-4090-a29d-fe13ccbd5e0c">4,424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMTMtMy0xLTEtMjU5ODk_0b5f00d6-6341-4d1d-a349-b8292781de95">3,127</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMTQtMS0xLTEtMjU5ODk_d4e3bb3a-ba97-466a-8570-db9b703ebb54">3,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMTQtMy0xLTEtMjU5ODk_f27d4c08-7359-4792-aaf7-53ae1671a990">4,445</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMTUtMS0xLTEtMjU5ODk_0d348aff-4b31-4a82-b7dc-630f6409d2d6">4,481</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMTUtMy0xLTEtMjU5ODk_1d358ec5-ca45-4103-8f6b-5f3798e67147">5,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, accrued expenses, and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMTYtMS0xLTEtMjU5ODk_eaf36a33-92e0-4e60-99a0-0532e45a6b5a">22,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMTYtMy0xLTEtMjU5ODk_efd1d935-8bad-4b97-8db0-50898688f77a">28,485</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current assets and liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" sign="-" name="fold:IncreaseDecreaseInNoncurrentOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMTctMS0xLTEtMjU5ODk_47b01c4a-7179-47cd-bd34-25c28bac9410">2,762</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" sign="-" name="fold:IncreaseDecreaseInNoncurrentOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMTctMy0xLTEtMjU5ODk_e41bc596-fbe0-4980-a3a5-49feebd74330">1,784</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMTgtMS0xLTEtMjU5ODk_85bfe199-00f1-4b3b-a805-254d4a8b262b">74,177</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMTgtMy0xLTEtMjU5ODk_c1752d0e-9255-4303-baee-8dc882c502f4">108,277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sale and redemption of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjAtMS0xLTEtMjU5ODk_18964c4c-5c20-46de-b670-a0d9c2e4f8b1">184,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjAtMy0xLTEtMjU5ODk_7ff8455d-ee6a-4305-9467-dbd0a83e05d5">258,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjEtMS0xLTEtMjU5ODk_cfc7525b-ab20-420e-80d9-13fb25a2504b">98,330</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjEtMy0xLTEtMjU5ODk_5be54dc3-42d4-463c-9197-c59eed928966">145,255</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjItMS0xLTEtMjU5ODk_80f93eef-8edf-4628-af14-8a511e2a81ee">1,226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjItMy0xLTEtMjU5ODk_e9896032-2ac5-444e-b851-36ea403aced1">1,234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjMtMS0xLTEtMjU5ODk_1a2e79e7-f6e0-4a3f-8de6-13e681c56dbe">84,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjMtMy0xLTEtMjU5ODk_323ba966-0010-41b0-bd69-ea8e53da6c1a">112,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjUtMS0xLTEtMjU5ODk_cecfdfaa-553e-4d8b-9ddb-81e9f0552144">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjUtMy0xLTEtMjU5ODk_9e9db47d-bac1-4208-ac89-692db39af753">389</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from warrants exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjYtMS0xLTEtMjU5ODk_2b3f40b0-9732-43b4-99d8-d334bd720e15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjYtMy0xLTEtMjU5ODk_b96e7296-293e-4110-87eb-a323cc342026">19,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of vested restricted stock units, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjctMS0xLTEtMjU5ODk_1236c066-64c7-4136-a8ab-3c28f2403199">9,278</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjctMy0xLTEtMjU5ODk_46372afc-63f9-405e-95f3-d42393833759">14,438</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from stock options exercised, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjgtMS0xLTEtMjU5ODk_58b12f99-aafe-41c9-8373-34f1eef30df5">1,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjgtMy0xLTEtMjU5ODk_1c1b3d50-8e2e-4cd4-aae1-0eb739131e5b">6,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjktMS0xLTEtMjU5ODk_f0e4d993-01f2-486d-9106-414c4121f7a7">7,461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjktMy0xLTEtMjU5ODk_60fcf182-93eb-4261-b933-2be4e967faf2">11,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMzAtMS0xLTEtMjU5ODk_c8d90c09-bcc9-461c-b270-de81881eed3b">12,462</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMzAtMy0xLTEtMjU5ODk_d618ff62-e9da-42b7-94ca-42025fa0cf71">1,439</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net (decrease) increase in cash, cash equivalents, and restricted cash at the end of the period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMzEtMS0xLTEtMjU5ODk_d6aaa571-ab3c-4c53-8c35-230380e8ffae">9,595</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMzEtMy0xLTEtMjU5ODk_d69db568-a342-4164-9e8f-ef4975857303">13,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at the beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMzItMS0xLTEtMjU5ODk_d4931249-f3d5-435b-8ad6-11b0ee7c107d">249,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17008df080294bb0bf1240acd6c19c15_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMzItMy0xLTEtMjU5ODk_17e277c0-f919-4910-b2c3-d03c2ad11ecf">166,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash at the end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMzMtMS0xLTEtMjU5ODk_befbb50a-6f32-4390-bcef-344af579b2b2">239,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd0bea669974aef88283f7ce9684c7f_I20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMzMtMy0xLTEtMjU5ODk_1a992113-5abf-499f-b4b4-aad50da2849b">179,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosures of cash flow information</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid during the period for interest </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMzUtMS0xLTEtMjU5ODk_c9856b15-cbd3-4e25-a03f-ffd1fc40054b">15,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMzUtMy0xLTEtMjU5ODk_bc255d5a-0330-4356-9b1e-c52152ece7a0">15,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMzctMS0xLTEtMjkwNDQ_1d2da520-0ddd-4bb6-a786-5195a08a01a7">710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMzctMy0xLTEtMjkwNDc_2c8e3cd7-bc1a-4f0c-84d2-ce7ba030cfd3">4,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital expenditures unpaid at the end of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMzYtMS0xLTEtMjU5ODk_fc65fe9c-b44f-4af8-b44a-9f5638f077f7">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMzYtMy0xLTEtMjU5ODk_74487d89-0305-4617-9200-3817fbfeeef3">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tenant improvements paid through lease incentives</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsForTenantImprovements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfNDAtMS0xLTEtMjg4OTM_4ad1ad95-2ffb-42e0-bca4-66d73015203d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsForTenantImprovements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfNDAtMy0xLTEtMjg4OTM_cefc2f2d-57fa-4b0f-a240-51f6b3357af7">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_37"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zNy9mcmFnOjFlOTdhN2FhNjBhNjQ2NTJhYjFiN2ExZmM2M2Y4ZGMxL3RleHRyZWdpb246MWU5N2E3YWE2MGE2NDY1MmFiMWI3YTFmYzYzZjhkYzFfMzgyNg_e2d4c397-6c73-420c-84f4-47bd68649a7c" continuedAt="i960efa8245254fd19ba0685ab09b0df9" escape="true">Description of Business</ix:nonNumeric></span></div><ix:continuation id="i960efa8245254fd19ba0685ab09b0df9"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amicus Therapeutics, Inc. (the "Company") is a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. The Company has a portfolio of product opportunities including the first, oral monotherapy for Fabry disease that has achieved widespread global approval and a differentiated biologic for Pompe disease, that is under review with the U.S. Food and Drug Administration ("FDA") as well as the European Medicines Agency ("EMA"). The Company is committed to discovering and developing next generation therapies in Fabry and Pompe diseases.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cornerstone of the Company's portfolio is Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (also referred to as "migalastat"), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants. Migalastat is currently approved under the trade name Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States ("U.S."), European Union ("E.U."), United Kingdom ("U.K."), and Japan, with multiple additional approvals granted and applications pending in several geographies around the world. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lead biologics program of the Company's pipeline is Amicus Therapeutics GAA ("AT-GAA", also known as ATB200/AT2221, or cipaglucosidase alfa/miglustat), a novel, two-component, potential best-in-class treatment for Pompe disease. In February 2019, the FDA granted Breakthrough Therapy designation ("BTD") to AT-GAA for the treatment of late onset Pompe disease. In September 2021, the FDA set the Prescription Drug User Fee Act ("PDUFA") target action date of May 29, 2022 for the New Drug Application ("NDA") for miglustat and July 29, 2022 for the Biologics License Application ("BLA") for cipaglucosidase alfa. The EMA validated the Marketing Authorization Application (&#8220;MAA&#8221;) in the fourth quarter of 2021. On May 9, 2022, the FDA extended the review period for the NDA for miglustat and the BLA for cipaglucosidase alfa resulting in revised PDUFA action dates of August 29, 2022 and October 29, 2022, respectively. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operations have not been significantly impacted by the novel coronavirus (&#8220;COVID-19&#8221;) pandemic to date. The Company continued to observe increased lag time between patient identification and Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> initiation due to the continued prevalence of COVID-19 and its ongoing impact on access to treatment for people living with Fabry disease in certain markets. The Company has maintained operations in all geographies, secured its global supply chain for its commercial and clinical products, as well as maintained the operational integrity of its clinical trials, with minimal disruptions. Whether the Company will continue to operate without any significant disruptions will depend on the continued health of its employees, the ongoing demand for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the continued operation of its global supply chain. The Company has continued to provide uninterrupted access to medicines for those in need of treatment, while prioritizing the health and safety of its global workforce. However, the Company's results of operations in future periods may be negatively impacted by unknown future impacts from the COVID-19 pandemic.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-8" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zNy9mcmFnOjFlOTdhN2FhNjBhNjQ2NTJhYjFiN2ExZmM2M2Y4ZGMxL3RleHRyZWdpb246MWU5N2E3YWE2MGE2NDY1MmFiMWI3YTFmYzYzZjhkYzFfMzEzNg_f1e185c5-38d0-44fb-a802-3241cff1641d">2.4</ix:nonFraction> billion as of June 30, 2022 and anticipates incurring losses through the fiscal year ending December 31, 2022 and beyond. The Company has historically funded its operations through stock offerings, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues, debt issuances, collaborations, and other financing arrangements. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on its current operating model, the Company believes that the current cash position, which includes expected revenues, is sufficient to fund the Company's operations and ongoing research programs to achieve self-sustainability. Potential impacts of the COVID-19 pandemic, business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact the Company's future capital requirements.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfOTM2NA_e4881489-1071-407a-8194-00cfeb3e7371" continuedAt="i3dcfda6b7cd44d34af8a32cf08dd5393" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i3dcfda6b7cd44d34af8a32cf08dd5393" continuedAt="ie46ed9cb2738470fb25a2a482b5a8400"><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfOTQwMA_e284b422-c77f-49ad-984e-8978b30c9737" continuedAt="ibf74ca6c60744f7d99df604121c5a71f" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has prepared the accompanying unaudited Consolidated Financial Statements in accordance with the U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited Consolidated Financial Statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company's interim financial information.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibf74ca6c60744f7d99df604121c5a71f">The accompanying unaudited Consolidated Financial Statements and related notes should be read in conjunction with the Company's financial statements and related notes as contained in the Company's Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2021.&#160;For a complete description of the Company's accounting policies, please refer to the Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2021.</ix:continuation> </span></div><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfOTQwMQ_c6d0bf48-8dee-4250-b2a6-04fa99872111" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfOTM5NA_977eeeb4-b5b4-4d3e-a7b8-4f598b6e9c27" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Transactions</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfOTM3MQ_6c3a42b8-115b-49d0-8a54-09f214e540b1" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company assessed the impact COVID-19 pandemic has had on its operations and financial results as of June 30, 2022 and through the issuance of these financial statements. The Company&#8217;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfOTM4Nw_d9b41138-ac01-45ac-908f-617971acfe27" continuedAt="ie4de4b82164c4de0ae347146a6d1a1d9" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are reported within other comprehensive loss in the Company's Consolidated Statements of Comprehensive Loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations, or other observable inputs.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie4de4b82164c4de0ae347146a6d1a1d9">Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in other current assets and other non-current assets on the Company's Consolidated Balance Sheets.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie46ed9cb2738470fb25a2a482b5a8400" continuedAt="ic71a43d5a9be450d8bc85b9a96e62310"><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfOTM2MQ_12549fec-dbc4-486a-b7e6-8702c5be95c6" continuedAt="i8ba1863c7bdd4420868c446717d589d0" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><ix:continuation id="i8ba1863c7bdd4420868c446717d589d0" continuedAt="id73e5634e474408198bd0b37fd1ff348"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id73e5634e474408198bd0b37fd1ff348">. The Company's accounts receivable at June 30, 2022 have arisen from product sales primarily in Europe and the U.S. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis.</ix:continuation> As of June 30, 2022, the Company recorded an allowance for doubtful accounts of $<ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfNTE4OQ_d4721ecf-6d2b-4e90-8bff-8e23d40b845f">0.1</ix:nonFraction> million.</span></div><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfOTM2Ng_631cfd4c-b989-481a-ba06-ef85e71a0b84" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated over the estimated useful lives of the respective assets, which range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfNTM5Mg_89960747-9384-4345-bf43-26f7a60be61c">three</span> to <ix:nonNumeric contextRef="ia1ae6aeddaf442cba31cc61b672cf523_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfNTM5OA_e4977a96-1f9b-470d-bcb0-52296238ea7a">five years</ix:nonNumeric>, or the lesser of the related initial term of the lease or useful life for leasehold improvements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial cost of property and equipment consists of its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to income in the period in which the costs are incurred. Major replacements, improvements, and additions are capitalized in accordance with Company policy.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If indications of impairment exist, projected future undiscounted cash flows associated with the asset or asset group are compared to the carrying value of the asset to determine whether the asset or asset group's value is recoverable. If impairment is determined, the Company writes down the asset to its estimated fair value and records an impairment loss equal to the excess of the carrying value of the long-lived asset over its estimated fair value in the period at which such a determination is made.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2022, in connection with the strategic prioritization of its gene therapy portfolio, the Company performed an assessment of its fixed assets. As a result, the Company recognized an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfNjg4MA_8ab16d7a-64ee-4fcf-978c-db4e1906fd10">6.6</ix:nonFraction>&#160;million.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfOTM1OA_28629c3b-bd44-4e6b-be87-45e6480e6ea1" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's net product sales consist of sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Fabry disease. The Company has recorded revenue on sales where Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is available either on a commercial basis or through a reimbursed early access program. Orders for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are generally received from distributors and pharmacies, with the ultimate payor often a government authority. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The transaction price is determined based on fixed consideration in the Company's customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenue from the sale of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic71a43d5a9be450d8bc85b9a96e62310"><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfOTM3Nw_b1e21093-97ff-4ece-9497-58e3b4e89575" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's net product sales from Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disaggregated by geographic area:</span></div><div style="margin-bottom:12pt;margin-top:15pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.127%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.127%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.127%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.129%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4608585deb7447ecabc5d85a3a731ff7_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RhYmxlOjE0YjNlZTg4NzUxNDRjNzA4ZDg4NzdiOGRmNDBlYTZiL3RhYmxlcmFuZ2U6MTRiM2VlODg3NTE0NGM3MDhkODg3N2I4ZGY0MGVhNmJfMi0yLTEtMS0yNTk4OQ_d9eb75ee-7185-45d1-8c22-25956f8166ac">27,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia22486482e60492c860155dbff44d0c1_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RhYmxlOjE0YjNlZTg4NzUxNDRjNzA4ZDg4NzdiOGRmNDBlYTZiL3RhYmxlcmFuZ2U6MTRiM2VlODg3NTE0NGM3MDhkODg3N2I4ZGY0MGVhNmJfMi00LTEtMS0yNTk4OQ_296a22ba-d7ce-4550-b289-bf07bd78b4ca">23,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9888231cb6e4488995457f5adf3be783_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RhYmxlOjE0YjNlZTg4NzUxNDRjNzA4ZDg4NzdiOGRmNDBlYTZiL3RhYmxlcmFuZ2U6MTRiM2VlODg3NTE0NGM3MDhkODg3N2I4ZGY0MGVhNmJfMi01LTEtMS0yNjg5NQ_8ee9ada8-a3d7-443c-877f-3a556e4934f7">51,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe98a5affced4afd82274d759802ef32_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RhYmxlOjE0YjNlZTg4NzUxNDRjNzA4ZDg4NzdiOGRmNDBlYTZiL3RhYmxlcmFuZ2U6MTRiM2VlODg3NTE0NGM3MDhkODg3N2I4ZGY0MGVhNmJfMi03LTEtMS0yNjg5NQ_0a810778-19e0-445b-82eb-55974ade3a6d">44,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ex-U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aab62a215e24c70a98a8fa127a0c93e_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RhYmxlOjE0YjNlZTg4NzUxNDRjNzA4ZDg4NzdiOGRmNDBlYTZiL3RhYmxlcmFuZ2U6MTRiM2VlODg3NTE0NGM3MDhkODg3N2I4ZGY0MGVhNmJfMy0yLTEtMS0yNTk4OQ_76abc268-3d3a-49f2-a4dd-db3ef2cc7d84">53,191</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4736f08b10ec45f5a5791466daa3734d_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RhYmxlOjE0YjNlZTg4NzUxNDRjNzA4ZDg4NzdiOGRmNDBlYTZiL3RhYmxlcmFuZ2U6MTRiM2VlODg3NTE0NGM3MDhkODg3N2I4ZGY0MGVhNmJfMy00LTEtMS0yNTk4OQ_78b7e037-3d1e-40a0-bc14-7d101f44ccfb">53,735</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc644fbd473b4779827e095e604e1fa1_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RhYmxlOjE0YjNlZTg4NzUxNDRjNzA4ZDg4NzdiOGRmNDBlYTZiL3RhYmxlcmFuZ2U6MTRiM2VlODg3NTE0NGM3MDhkODg3N2I4ZGY0MGVhNmJfMy01LTEtMS0yNjg5NQ_25faa1c8-e650-4a89-9c7a-2987c3047ac8">107,728</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2058a237abf345d3a1df9a3c8c9c52b2_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RhYmxlOjE0YjNlZTg4NzUxNDRjNzA4ZDg4NzdiOGRmNDBlYTZiL3RhYmxlcmFuZ2U6MTRiM2VlODg3NTE0NGM3MDhkODg3N2I4ZGY0MGVhNmJfMy03LTEtMS0yNjg5NQ_2b2e85a5-db27-4f70-9b8b-b310f0ec487d">99,284</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RhYmxlOjE0YjNlZTg4NzUxNDRjNzA4ZDg4NzdiOGRmNDBlYTZiL3RhYmxlcmFuZ2U6MTRiM2VlODg3NTE0NGM3MDhkODg3N2I4ZGY0MGVhNmJfNC0yLTEtMS0yNTk4OQ_c7091845-99ba-4db4-aae9-81ed78de56e4">80,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RhYmxlOjE0YjNlZTg4NzUxNDRjNzA4ZDg4NzdiOGRmNDBlYTZiL3RhYmxlcmFuZ2U6MTRiM2VlODg3NTE0NGM3MDhkODg3N2I4ZGY0MGVhNmJfNC00LTEtMS0yNTk4OQ_95bba3c6-eb8c-4742-93d8-8bdaa148002d">77,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RhYmxlOjE0YjNlZTg4NzUxNDRjNzA4ZDg4NzdiOGRmNDBlYTZiL3RhYmxlcmFuZ2U6MTRiM2VlODg3NTE0NGM3MDhkODg3N2I4ZGY0MGVhNmJfNC01LTEtMS0yNzc2NQ_96f69ad7-8814-42ef-8f5d-f64e2e10121b">159,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RhYmxlOjE0YjNlZTg4NzUxNDRjNzA4ZDg4NzdiOGRmNDBlYTZiL3RhYmxlcmFuZ2U6MTRiM2VlODg3NTE0NGM3MDhkODg3N2I4ZGY0MGVhNmJfNC03LTEtMS0yNzc2NQ_c12a4f30-b9e2-45e8-a471-ce33fd8b3c65">143,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:InventoryCostsForContractsOrProgramsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfOTQwNw_eded099b-b352-42a3-be9e-11098d2a3ab0" continuedAt="id2a7ed2c4e5a4366809a4538730392b0" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories and Cost of Goods Sold</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of goods sold in the Consolidated Statements of Operations.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id2a7ed2c4e5a4366809a4538730392b0">Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable.</ix:continuation> </span></div><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfMzg0ODI5MDcwODkxMA_a9d460fb-73b6-4407-98d1-65a89db24d37" continuedAt="icf607f51ce7a429bad449fe499094ed6" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expense consist primarily of costs related to personnel, including salaries and other personnel related expenses, consulting fees, and the cost of facilities and support services used in drug development. Assets acquired that are used for research and development and have no future alternative use are expensed as in-process research and development. </span></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icf607f51ce7a429bad449fe499094ed6">In the second quarter of 2022, as part of the Company&#8217;s strategic prioritization of its gene therapy portfolio, the Company recorded a non-recurring $<ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-5" name="us-gaap:ContractualObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfNDk0NzgwMjMzNjYwMQ_0ad5896f-7739-477d-a826-d68aebb11724">20.0</ix:nonFraction>&#160;million liability associated with the expense of contractual obligations from which the Company will no longer receive further economic benefit. A liability for costs that will continue to be incurred under a contract for its remaining term without economic benefit to the entity is recognized at the cease-use date. This liability is presented as a component of accrued expenses and other current liabilities within the Company's Consolidated Balance Sheets.</ix:continuation> </span></div><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfOTM2Nw_805d3b69-a4e6-472a-bd38-7f31b75befac" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Developments</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated recent accounting pronouncements and believes that none of them will have a material effect on the Company's Consolidated Financial Statements or related disclosures.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_43"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;<ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RleHRyZWdpb246MjIwZDc4YzViYTQxNDMzOTkzNTExYzM5NzMzZTQ0YWJfMjc5Nw_285093dc-4320-4030-9d44-871ef8794e72" continuedAt="i283c70c8cc7244fa8484ad02b834c100" escape="true">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</ix:nonNumeric></span></div><ix:continuation id="i283c70c8cc7244fa8484ad02b834c100" continuedAt="i793155d7289b4055ac0fa23efd516d9b"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the Company held $<ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RleHRyZWdpb246MjIwZDc4YzViYTQxNDMzOTkzNTExYzM5NzMzZTQ0YWJfMTAy_392f441f-fcdc-4854-924d-f1553aa668c6">235.6</ix:nonFraction> million in cash and cash equivalents and $<ix:nonFraction unitRef="usd" contextRef="i33bee7e70d4f41ae98aea43eaf262df5_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RleHRyZWdpb246MjIwZDc4YzViYTQxNDMzOTkzNTExYzM5NzMzZTQ0YWJfMTM4_0749d9f4-1f20-4b0e-a152-ce6bbf7ee59a">151.2</ix:nonFraction> million of marketable securities which are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are generally reported within other comprehensive loss in the Company's Consolidated Statements of Comprehensive Loss. If a decline in the fair value of a marketable security below the Company's cost basis is determined to be other-than-temporary or if an available-for-sale debt security&#8217;s fair value is determined to be less than the amortized cost and the Company intends or is more than likely to sell the security before recovery and it is not considered a credit loss, such security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. If the unrealized loss of an available-for-sale debt security is determined to be a result of credit loss, the Company would recognize an allowance and the corresponding credit loss would be included in earnings.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly invests excess operating cash in deposits with major financial institutions, money market funds, notes issued by the U.S. government, as well as fixed income investments and U.S. bond funds, both of which can be readily purchased and sold using established markets. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated as many of these securities are either government backed or of the highest credit rating. Investments that have original maturities greater than three months but less than one year are classified as current.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i793155d7289b4055ac0fa23efd516d9b"><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RleHRyZWdpb246MjIwZDc4YzViYTQxNDMzOTkzNTExYzM5NzMzZTQ0YWJfMjc5NA_0c12e8ab-e1c2-4a47-9033-a5a46c2e3806" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and marketable securities are classified as current unless mentioned otherwise below and consisted of the following: </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfMi0yLTEtMS0yNTk4OQ_be0b3a70-1803-4fc1-8786-925a9bf22042">235,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfMi04LTEtMS0yNTk4OQ_8f9f4b37-f607-4c74-9490-a25a6a644b01">235,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313bc2d8be6b49deab3982d26fd646fd_I20220630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfMy0yLTEtMS0yNTk4OQ_59b3b02f-05f4-49aa-a466-1ea88edc8573">103,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313bc2d8be6b49deab3982d26fd646fd_I20220630" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfMy00LTEtMS0yNTk4OQ_fab87c85-37bc-44d2-bc24-5564d144e75e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i313bc2d8be6b49deab3982d26fd646fd_I20220630" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfMy02LTEtMS0yNTk4OQ_b87448ef-40c6-4871-9b78-6ff944b33734">239</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313bc2d8be6b49deab3982d26fd646fd_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfMy04LTEtMS0yNTk4OQ_c618d52c-07ec-4470-8363-f2a81eca76a3">102,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a5beaca54dc4603a5614a45876a29e0_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfNC0yLTEtMS0yNTk4OQ_c38e6350-011e-479d-9aa1-aa354110738d">45,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a5beaca54dc4603a5614a45876a29e0_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfNC00LTEtMS0yNTk4OQ_c5713e21-de35-46d8-8826-5c7bda9ebe7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a5beaca54dc4603a5614a45876a29e0_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfNC02LTEtMS0yNTk4OQ_b5fb75c0-43c8-4e21-9479-49f6882e0e1e">193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a5beaca54dc4603a5614a45876a29e0_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfNC04LTEtMS0yNTk4OQ_33325459-d8fc-42d4-8843-d75f6d37d8fb">44,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie925c891e72c47cea99fa4b411e16d37_I20220630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfNS0yLTEtMS0yNTk4OQ_a7afc408-9678-4df2-992c-f30b9d5d524d">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie925c891e72c47cea99fa4b411e16d37_I20220630" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfNS00LTEtMS0yNTk4OQ_0364aa68-3aaa-4ced-b985-985b3a1da9db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie925c891e72c47cea99fa4b411e16d37_I20220630" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfNS02LTEtMS0yNTk4OQ_7ef347e9-fedf-4c53-bf33-09aa5af27c43">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie925c891e72c47cea99fa4b411e16d37_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfNS04LTEtMS0yNTk4OQ_3fc1ab6a-9601-4f71-afa8-6e5713a216f3">2,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2786cde9d4554d08836966e040d3dd88_I20220630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfNi0yLTEtMS0yNTk4OQ_64a173ba-be8b-4208-8d68-3bdd53a16bf2">350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2786cde9d4554d08836966e040d3dd88_I20220630" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfNi00LTEtMS0yNTk4OQ_64bba9d8-34fc-40ad-9d60-fb0876e0aa47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2786cde9d4554d08836966e040d3dd88_I20220630" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfNi02LTEtMS0yNTk4OQ_cacde0de-601a-4276-9014-17471568fa9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2786cde9d4554d08836966e040d3dd88_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfNi04LTEtMS0yNTk4OQ_620a964a-9e8a-4d1a-b679-672b6960dbec">350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee2998a9354d4afca4c7ca59fa536817_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfNy0yLTEtMS0yNTk4OQ_4879b18d-1785-47f4-95f8-4f4a682ce174">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee2998a9354d4afca4c7ca59fa536817_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfNy00LTEtMS0yNTk4OQ_57378330-b477-47c8-b97b-9d8bfb426efb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee2998a9354d4afca4c7ca59fa536817_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfNy02LTEtMS0yNTk4OQ_293c66ef-26db-4c64-8717-f777a1ffe816">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee2998a9354d4afca4c7ca59fa536817_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfNy04LTEtMS0yNTk4OQ_c1c48a2a-61c4-432d-8e53-7c2cbdbb00da">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfOS0yLTEtMS0yNTk4OQ_d79edaaa-bd47-4b20-a631-ab83ad87e6ba">387,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfOS00LTEtMS0yNTk4OQ_baeaacf5-4fd0-432c-83a8-a762bbbd4ce7">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfOS02LTEtMS0yNTk4OQ_fda8909f-17a3-42d6-a6af-e966ad366268">441</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfOS04LTEtMS0yNTk4OQ_a44850d2-fb91-4d23-8048-28eb1a9281dd">386,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfMTAtMi0xLTEtMjU5ODk_6ec05b40-c5b7-49d6-8f5f-868af7933eb1">235,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfMTAtOC0xLTEtMjU5ODk_757897ce-ff30-4f4d-8638-5570555266f7">235,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfMTEtMi0xLTEtMjU5ODk_38199a82-b8fe-449e-8124-f566a7cac6d9">151,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfMTEtNC0xLTEtMjU5ODk_531f51b4-34c4-4256-9101-6c274d1c6bec">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfMTEtNi0xLTEtMjU5ODk_ca004a1a-5c34-4292-8ebb-b59f959a039d">441</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfMTEtOC0xLTEtMjU5ODk_48f7685b-7383-411e-9e51-0e3e53c26dc8">151,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfMTItMi0xLTEtMjU5ODk_409021e5-bec9-4ce2-ba70-7942d57e799a">387,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfMTItNC0xLTEtMjU5ODk_8c022d9d-a69a-47d2-8c67-0e71cb5b9289">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfMTItNi0xLTEtMjU5ODk_caf4735d-0d56-4c23-abb9-65e1dd97b43b">441</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfMTItOC0xLTEtMjU5ODk_5da44edb-56f7-4db7-8f74-8cec8e7d5281">386,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfMi0yLTEtMS0yNTk4OQ_10140cdf-e241-4db3-ad33-6244cd0254e3">245,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfMi04LTEtMS0yNTk4OQ_06730f1b-7814-494c-a8ae-55b735b0243b">245,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18a1d906c5a545e698385837607d8ddb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfMy0yLTEtMS0yNTk4OQ_0b0b1aa2-ed83-40f2-a90c-b565939cd1b4">174,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18a1d906c5a545e698385837607d8ddb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfMy00LTEtMS0yNTk4OQ_9d8cdf9c-2ad1-4f09-a4d4-7c0a44e6df41">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18a1d906c5a545e698385837607d8ddb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfMy02LTEtMS0yNTk4OQ_38185bea-c6b1-4107-93dc-19d7d3cab8c2">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18a1d906c5a545e698385837607d8ddb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfMy04LTEtMS0yNTk4OQ_07d3b6a4-27a4-4d1c-b87e-e336ef3c6840">174,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b99930e76ff4d129e26d8c1981c9dee_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfNC0yLTEtMS0yNTk4OQ_f5720c61-283f-46d7-8c38-0a143610124d">32,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b99930e76ff4d129e26d8c1981c9dee_I20211231" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfNC00LTEtMS0yNTk4OQ_836246f4-2439-4c12-a611-df2a250c5621">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b99930e76ff4d129e26d8c1981c9dee_I20211231" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfNC02LTEtMS0yNTk4OQ_746c3290-ba3d-4a35-a2e8-4e4905cf65b0">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b99930e76ff4d129e26d8c1981c9dee_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfNC04LTEtMS0yNTk4OQ_04b90d57-1dd7-492b-93b1-e9dc318ce9c9">32,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifae0d641d44e4d74bd462bf49ef538ec_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfNS0yLTEtMS0yNTk4OQ_e71ba771-4533-4afc-9f09-309222c0f34c">30,070</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifae0d641d44e4d74bd462bf49ef538ec_I20211231" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfNS00LTEtMS0yNTk4OQ_276bb09c-1324-4170-94f3-d06c40bdbbf4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifae0d641d44e4d74bd462bf49ef538ec_I20211231" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfNS02LTEtMS0yNTk4OQ_d9e0b052-3b1a-4bfb-abe0-e33bd845c7d7">14</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifae0d641d44e4d74bd462bf49ef538ec_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfNS04LTEtMS0yNTk4OQ_676d046f-a7c1-4887-bcb4-b030b35cda33">30,056</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b41065183b64de594c948fc62b3fd96_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfNi0yLTEtMS0yNTk4OQ_f2a3d6d4-9fd3-414c-8a24-bf15e35b8399">350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b41065183b64de594c948fc62b3fd96_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfNi00LTEtMS0yNTk4OQ_6b857400-615e-4237-b05c-eb22722ae0b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b41065183b64de594c948fc62b3fd96_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfNi02LTEtMS0yNTk4OQ_873b75a9-0858-43bd-877f-067b80b8e6ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b41065183b64de594c948fc62b3fd96_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfNi04LTEtMS0yNTk4OQ_17bc7194-0c11-4c28-a0c8-ac457cd66f4c">350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia21576db6b004494a12be3e92fdd6c66_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfNy0yLTEtMS0yNTk4OQ_a874a0a9-5548-4db8-abe1-b9eb16063047">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia21576db6b004494a12be3e92fdd6c66_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfNy00LTEtMS0yNTk4OQ_3411f2f4-4f97-4fee-9aa9-8998688f9002">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia21576db6b004494a12be3e92fdd6c66_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfNy02LTEtMS0yNTk4OQ_e5f6b1c7-9b95-4e05-8973-7fe0e098e4d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia21576db6b004494a12be3e92fdd6c66_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfNy04LTEtMS0yNTk4OQ_9efb829d-02f5-4d61-b900-87d4a9a1f37c">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfOC0yLTEtMS0yNTk4OQ_d342a881-bfaf-46b4-9c93-5cdcdceb5a11">482,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfOC00LTEtMS0yNTk4OQ_6130b911-62d2-43e6-822b-6dc5a50d5cbd">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfOC02LTEtMS0yNTk4OQ_03cf96cd-175e-43ed-b2a9-4434542b6424">79</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfOC04LTEtMS0yNTk4OQ_c637e637-01da-45df-93be-83097c921c7a">482,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfOS0yLTEtMS0yNTk4OQ_83008671-af62-4bb4-8420-13a0c4c38dc9">245,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfOS04LTEtMS0yNTk4OQ_a0fe61e3-6357-4f7c-8e22-ed1d50b1535a">245,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfMTAtMi0xLTEtMjU5ODk_62daedef-83c4-4f92-b4da-5c0efe52840c">237,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfMTAtNC0xLTEtMjU5ODk_48517f50-1cc0-4ec3-a6cf-4f33b00e6560">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfMTAtNi0xLTEtMjU5ODk_7d93cc56-aa29-431f-95d3-c5a1e0e44e30">79</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfMTAtOC0xLTEtMjU5ODk_41a6cd50-c9d3-499e-8659-36211db225ae">237,299</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfMTEtMi0xLTEtMjU5ODk_2d5af98f-1688-49c8-8ddc-e10006472aa9">482,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfMTEtNC0xLTEtMjU5ODk_88d0d982-0803-464b-8691-f380ebaf38cf">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfMTEtNi0xLTEtMjU5ODk_7b4e6ab4-a1d2-4274-b0e1-801863155b2f">79</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfMTEtOC0xLTEtMjU5ODk_abb94240-ee55-4ff9-a1dd-771194cbbbf6">482,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For both the six months ended June 30, 2022 and the fiscal year ended December 31, 2021, there were <ix:nonFraction unitRef="usd" contextRef="i7b96f9892c1f46b79e86ebc2d8e82423_D20210101-20211231" decimals="INF" name="us-gaap:DebtSecuritiesRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RleHRyZWdpb246MjIwZDc4YzViYTQxNDMzOTkzNTExYzM5NzMzZTQ0YWJfMTk1Ng_610521ee-14f5-463a-a15f-ec9ab36136c0"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="INF" name="us-gaap:DebtSecuritiesRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RleHRyZWdpb246MjIwZDc4YzViYTQxNDMzOTkzNTExYzM5NzMzZTQ0YWJfMTk1Ng_8690377d-9e2b-4359-9bb6-78d9aaaf4077">no</ix:nonFraction></ix:nonFraction> realized gains or losses. The cost of securities sold is based on the specific identification method.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized loss positions in the marketable securities as of June 30, 2022 and December 31, 2021 reflect temporary impairments and are not a result of credit loss. Additionally, as these positions have been in a loss position for less than twelve months and the Company does not intend to sell these securities before recovery, the losses are recognized in other comprehensive (loss) gain. The fair value of these marketable securities in unrealized loss positions was $<ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RleHRyZWdpb246MjIwZDc4YzViYTQxNDMzOTkzNTExYzM5NzMzZTQ0YWJfMjUwNA_2b9d0d3d-ecbd-4b31-9190-f6754a824e37">140.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RleHRyZWdpb246MjIwZDc4YzViYTQxNDMzOTkzNTExYzM5NzMzZTQ0YWJfMjUxMQ_87dbb3c5-3e85-4a2b-95cb-6ad55c8b99fc">173.4</ix:nonFraction> million as of June 30, 2022 and December 31, 2021, respectively.</span></div><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RleHRyZWdpb246MjIwZDc4YzViYTQxNDMzOTkzNTExYzM5NzMzZTQ0YWJfMjc5Mg_6e621353-7b29-4b49-816f-5526a28cac67" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjI1MzNhNTQ0NjJkZTRjYjhiM2VlYzMxOTk1MjA3ZDVjL3RhYmxlcmFuZ2U6MjUzM2E1NDQ2MmRlNGNiOGIzZWVjMzE5OTUyMDdkNWNfMi0yLTEtMS0yNTk4OQ_8b623bc0-ea7e-47be-aadd-a684c34c8107">235,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd0bea669974aef88283f7ce9684c7f_I20210630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjI1MzNhNTQ0NjJkZTRjYjhiM2VlYzMxOTk1MjA3ZDVjL3RhYmxlcmFuZ2U6MjUzM2E1NDQ2MmRlNGNiOGIzZWVjMzE5OTUyMDdkNWNfMi00LTEtMS0yNTk4OQ_df23d4bf-0688-40f8-bbe5-3f4cda99e1ec">176,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjI1MzNhNTQ0NjJkZTRjYjhiM2VlYzMxOTk1MjA3ZDVjL3RhYmxlcmFuZ2U6MjUzM2E1NDQ2MmRlNGNiOGIzZWVjMzE5OTUyMDdkNWNfMy0yLTEtMS0yNTk4OQ_59c43e1b-4bed-4ab1-82dc-f5b9c4ff9a46">4,222</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd0bea669974aef88283f7ce9684c7f_I20210630" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjI1MzNhNTQ0NjJkZTRjYjhiM2VlYzMxOTk1MjA3ZDVjL3RhYmxlcmFuZ2U6MjUzM2E1NDQ2MmRlNGNiOGIzZWVjMzE5OTUyMDdkNWNfMy00LTEtMS0yNTk4OQ_f3a26157-4887-41fe-9fbc-a83cafc56b91">3,250</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjI1MzNhNTQ0NjJkZTRjYjhiM2VlYzMxOTk1MjA3ZDVjL3RhYmxlcmFuZ2U6MjUzM2E1NDQ2MmRlNGNiOGIzZWVjMzE5OTUyMDdkNWNfNC0yLTEtMS0yNTk4OQ_694006f6-435c-495a-b9a9-c87ed642d0e8">239,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd0bea669974aef88283f7ce9684c7f_I20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjI1MzNhNTQ0NjJkZTRjYjhiM2VlYzMxOTk1MjA3ZDVjL3RhYmxlcmFuZ2U6MjUzM2E1NDQ2MmRlNGNiOGIzZWVjMzE5OTUyMDdkNWNfNC00LTEtMS0yNTk4OQ_0a85d223-1a34-4516-a800-0d0bb1ccf1bd">179,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;<ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80Ni9mcmFnOmFiY2NlMWFiMTgzMjQxNTQ4YjFiZTVkYzA3M2ZjNzBmL3RleHRyZWdpb246YWJjY2UxYWIxODMyNDE1NDhiMWJlNWRjMDczZmM3MGZfMjkx_86bca13c-beb8-4b2e-9da0-d2093f48db93" continuedAt="i4208435746c74de4b1831706987746b6" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="i4208435746c74de4b1831706987746b6"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of raw materials, work-in-process, and finished goods related to the manufacture of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. <ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80Ni9mcmFnOmFiY2NlMWFiMTgzMjQxNTQ4YjFiZTVkYzA3M2ZjNzBmL3RleHRyZWdpb246YWJjY2UxYWIxODMyNDE1NDhiMWJlNWRjMDczZmM3MGZfMjky_e163e325-0e3c-44a6-b400-f1ec49b67760" continuedAt="i33012e74fd6344419bd9fc1967e10e1e" escape="true">The following table summarizes the components of inventories: </ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><ix:continuation id="i33012e74fd6344419bd9fc1967e10e1e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80Ni9mcmFnOmFiY2NlMWFiMTgzMjQxNTQ4YjFiZTVkYzA3M2ZjNzBmL3RhYmxlOmI5ZWM1MDdiYzY3NjQwY2NiY2IxYjliNzNjMmY0NzIwL3RhYmxlcmFuZ2U6YjllYzUwN2JjNjc2NDBjY2JjYjFiOWI3M2MyZjQ3MjBfMS0yLTEtMS0yNTk4OQ_7fd23d59-b2a6-4135-8424-68699bf1fbac">11,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80Ni9mcmFnOmFiY2NlMWFiMTgzMjQxNTQ4YjFiZTVkYzA3M2ZjNzBmL3RhYmxlOmI5ZWM1MDdiYzY3NjQwY2NiY2IxYjliNzNjMmY0NzIwL3RhYmxlcmFuZ2U6YjllYzUwN2JjNjc2NDBjY2JjYjFiOWI3M2MyZjQ3MjBfMS00LTEtMS0yNTk4OQ_d0af1914-53cc-4c59-bc6d-0ea74677de7b">12,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80Ni9mcmFnOmFiY2NlMWFiMTgzMjQxNTQ4YjFiZTVkYzA3M2ZjNzBmL3RhYmxlOmI5ZWM1MDdiYzY3NjQwY2NiY2IxYjliNzNjMmY0NzIwL3RhYmxlcmFuZ2U6YjllYzUwN2JjNjc2NDBjY2JjYjFiOWI3M2MyZjQ3MjBfMi0yLTEtMS0yNTk4OQ_e493ad96-b38c-44fa-9e26-4e4bf31f3b0b">5,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80Ni9mcmFnOmFiY2NlMWFiMTgzMjQxNTQ4YjFiZTVkYzA3M2ZjNzBmL3RhYmxlOmI5ZWM1MDdiYzY3NjQwY2NiY2IxYjliNzNjMmY0NzIwL3RhYmxlcmFuZ2U6YjllYzUwN2JjNjc2NDBjY2JjYjFiOWI3M2MyZjQ3MjBfMi00LTEtMS0yNTk4OQ_792469c2-7e35-4454-becd-ae7f320e2ae1">10,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80Ni9mcmFnOmFiY2NlMWFiMTgzMjQxNTQ4YjFiZTVkYzA3M2ZjNzBmL3RhYmxlOmI5ZWM1MDdiYzY3NjQwY2NiY2IxYjliNzNjMmY0NzIwL3RhYmxlcmFuZ2U6YjllYzUwN2JjNjc2NDBjY2JjYjFiOWI3M2MyZjQ3MjBfMy0yLTEtMS0yNTk4OQ_1b91a3e9-2a01-4ca1-80e6-1d92e01383b0">3,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80Ni9mcmFnOmFiY2NlMWFiMTgzMjQxNTQ4YjFiZTVkYzA3M2ZjNzBmL3RhYmxlOmI5ZWM1MDdiYzY3NjQwY2NiY2IxYjliNzNjMmY0NzIwL3RhYmxlcmFuZ2U6YjllYzUwN2JjNjc2NDBjY2JjYjFiOWI3M2MyZjQ3MjBfMy00LTEtMS0yNTk4OQ_5cc0b5f3-8ff0-4f5a-8e1f-dd684f16b058">3,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80Ni9mcmFnOmFiY2NlMWFiMTgzMjQxNTQ4YjFiZTVkYzA3M2ZjNzBmL3RhYmxlOmI5ZWM1MDdiYzY3NjQwY2NiY2IxYjliNzNjMmY0NzIwL3RhYmxlcmFuZ2U6YjllYzUwN2JjNjc2NDBjY2JjYjFiOWI3M2MyZjQ3MjBfNC0yLTEtMS0yNTk4OQ_3010e4d0-39f8-484a-a0ef-17eab418d6b8">20,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80Ni9mcmFnOmFiY2NlMWFiMTgzMjQxNTQ4YjFiZTVkYzA3M2ZjNzBmL3RhYmxlOmI5ZWM1MDdiYzY3NjQwY2NiY2IxYjliNzNjMmY0NzIwL3RhYmxlcmFuZ2U6YjllYzUwN2JjNjc2NDBjY2JjYjFiOWI3M2MyZjQ3MjBfNC00LTEtMS0yNTk4OQ_a9644b44-5340-463f-b12f-1a5048e08e93">26,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a reserve for inventory of $<ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80Ni9mcmFnOmFiY2NlMWFiMTgzMjQxNTQ4YjFiZTVkYzA3M2ZjNzBmL3RleHRyZWdpb246YWJjY2UxYWIxODMyNDE1NDhiMWJlNWRjMDczZmM3MGZfMjQ4_128b66fb-8953-4130-8d84-9b325ff2ad08"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80Ni9mcmFnOmFiY2NlMWFiMTgzMjQxNTQ4YjFiZTVkYzA3M2ZjNzBmL3RleHRyZWdpb246YWJjY2UxYWIxODMyNDE1NDhiMWJlNWRjMDczZmM3MGZfMjQ4_cfe2dab4-9dd0-4d1a-a3a6-f324a55505ce">1.1</ix:nonFraction></ix:nonFraction> million as of both June 30, 2022 and December 31, 2021.</span></div></ix:continuation><div id="ic325ed1a45484718a7ea1ead2bcfd471_49"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;<ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RleHRyZWdpb246NjNlYTZhYjkzYWFiNDJmZmI5ZjBmODY4NmMxYWQ5MjVfNDU3_c5bd4395-412a-426c-a72e-4244d8cc753f" continuedAt="i85f84f3c62334223967a7f101a8126d0" escape="true">Debt </ix:nonNumeric></span></div><ix:continuation id="i85f84f3c62334223967a7f101a8126d0"><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:ConvertibleDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RleHRyZWdpb246NjNlYTZhYjkzYWFiNDJmZmI5ZjBmODY4NmMxYWQ5MjVfNDYz_bb2e5c3c-4afa-47b2-b103-55d25a59bad1" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's debt consists of the following: </span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Term Loan due 2026:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7817625b346c448d9777f5897c0b43fb_I20220630" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOjQ5Y2RkY2FmZGMzZTQ3Zjg4MzQ1OWEyNjVkM2RjNTRlL3RhYmxlcmFuZ2U6NDljZGRjYWZkYzNlNDdmODgzNDU5YTI2NWQzZGM1NGVfMi0yLTEtMS0yNTk4OQ_eb42ef7e-0f7e-46e1-97d9-4548f30f9c36">400,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f9f50188a747e78f96bbbe4336d3aa_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOjQ5Y2RkY2FmZGMzZTQ3Zjg4MzQ1OWEyNjVkM2RjNTRlL3RhYmxlcmFuZ2U6NDljZGRjYWZkYzNlNDdmODgzNDU5YTI2NWQzZGM1NGVfMi00LTEtMS0yNTk4OQ_20e17d55-fc5e-45f4-bd1e-1b7e8c2e5638">400,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: debt discount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7817625b346c448d9777f5897c0b43fb_I20220630" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOjQ5Y2RkY2FmZGMzZTQ3Zjg4MzQ1OWEyNjVkM2RjNTRlL3RhYmxlcmFuZ2U6NDljZGRjYWZkYzNlNDdmODgzNDU5YTI2NWQzZGM1NGVfMy0yLTEtMS0yNTk4OQ_a4e7bfe9-d5bc-4e7f-b89f-66359e2ca3ae">5,334</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11f9f50188a747e78f96bbbe4336d3aa_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOjQ5Y2RkY2FmZGMzZTQ3Zjg4MzQ1OWEyNjVkM2RjNTRlL3RhYmxlcmFuZ2U6NDljZGRjYWZkYzNlNDdmODgzNDU5YTI2NWQzZGM1NGVfMy00LTEtMS0yNTk4OQ_c0c48552-eda3-4f9d-a987-9ba534cad14f">6,074</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: deferred financing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7817625b346c448d9777f5897c0b43fb_I20220630" decimals="-3" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOjQ5Y2RkY2FmZGMzZTQ3Zjg4MzQ1OWEyNjVkM2RjNTRlL3RhYmxlcmFuZ2U6NDljZGRjYWZkYzNlNDdmODgzNDU5YTI2NWQzZGM1NGVfNC0yLTEtMS0yNTk4OQ_9596fee1-4c00-422a-806b-3f8fdb543764">4,014</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11f9f50188a747e78f96bbbe4336d3aa_I20211231" decimals="-3" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOjQ5Y2RkY2FmZGMzZTQ3Zjg4MzQ1OWEyNjVkM2RjNTRlL3RhYmxlcmFuZ2U6NDljZGRjYWZkYzNlNDdmODgzNDU5YTI2NWQzZGM1NGVfNC00LTEtMS0yNTk4OQ_eeb04c6a-909d-4daf-8cfc-e9277eacb18c">4,569</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying value of Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOjQ5Y2RkY2FmZGMzZTQ3Zjg4MzQ1OWEyNjVkM2RjNTRlL3RhYmxlcmFuZ2U6NDljZGRjYWZkYzNlNDdmODgzNDU5YTI2NWQzZGM1NGVfNS0yLTEtMS0yNTk4OQ_d98d92f2-4ae6-4705-bbae-7c540016400f">390,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOjQ5Y2RkY2FmZGMzZTQ3Zjg4MzQ1OWEyNjVkM2RjNTRlL3RhYmxlcmFuZ2U6NDljZGRjYWZkYzNlNDdmODgzNDU5YTI2NWQzZGM1NGVfNS00LTEtMS0yNTk4OQ_3508fdc6-7c60-41e1-9de2-e2a4f78c3083">389,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Included in the Consolidated Balance Sheets within long-term debt and amortized to interest expense over the remaining life of the Senior Secured Term Loan due 2026 using the effective interest rate method.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RleHRyZWdpb246NjNlYTZhYjkzYWFiNDJmZmI5ZjBmODY4NmMxYWQ5MjVfNDU2_85ac7693-4517-4d04-8ed0-75ad051358c7" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth interest expense recognized related to the Company's debt for the three and six months ended June 30, 2022 and 2021, respectively:</span></div><div style="margin-bottom:6pt;margin-top:15pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.447%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.899%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOmY5OWRlYjU3M2ExNTQ4MmE5NzIwMGYxYmVjN2MzODVkL3RhYmxlcmFuZ2U6Zjk5ZGViNTczYTE1NDgyYTk3MjAwZjFiZWM3YzM4NWRfMi0yLTEtMS0yNTk4OQ_1312fef6-4b85-4e88-bce7-456563116638">7,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOmY5OWRlYjU3M2ExNTQ4MmE5NzIwMGYxYmVjN2MzODVkL3RhYmxlcmFuZ2U6Zjk5ZGViNTczYTE1NDgyYTk3MjAwZjFiZWM3YzM4NWRfMi00LTEtMS0yNTk4OQ_55405f10-ac8b-454a-bb0a-234bf62d4618">7,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOmY5OWRlYjU3M2ExNTQ4MmE5NzIwMGYxYmVjN2MzODVkL3RhYmxlcmFuZ2U6Zjk5ZGViNTczYTE1NDgyYTk3MjAwZjFiZWM3YzM4NWRfMi02LTEtMS0yNzc3NA_50cd898a-c23b-435a-822e-78d0ff176f4d">15,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOmY5OWRlYjU3M2ExNTQ4MmE5NzIwMGYxYmVjN2MzODVkL3RhYmxlcmFuZ2U6Zjk5ZGViNTczYTE1NDgyYTk3MjAwZjFiZWM3YzM4NWRfMi03LTEtMS0yNjkxMA_296823dd-bfb0-4a57-95fa-f7caf9ea27f7">15,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOmY5OWRlYjU3M2ExNTQ4MmE5NzIwMGYxYmVjN2MzODVkL3RhYmxlcmFuZ2U6Zjk5ZGViNTczYTE1NDgyYTk3MjAwZjFiZWM3YzM4NWRfMy0yLTEtMS0yNTk4OQ_dfad0efc-b23a-44e3-be1e-47924993e481">375</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOmY5OWRlYjU3M2ExNTQ4MmE5NzIwMGYxYmVjN2MzODVkL3RhYmxlcmFuZ2U6Zjk5ZGViNTczYTE1NDgyYTk3MjAwZjFiZWM3YzM4NWRfMy00LTEtMS0yNTk4OQ_ab41377a-e15e-479f-a9db-b8f594f8fff6">383</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOmY5OWRlYjU3M2ExNTQ4MmE5NzIwMGYxYmVjN2MzODVkL3RhYmxlcmFuZ2U6Zjk5ZGViNTczYTE1NDgyYTk3MjAwZjFiZWM3YzM4NWRfMy02LTEtMS0yNzc3NA_0bbf25c0-1512-439a-941d-b5b023d50dcb">739</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOmY5OWRlYjU3M2ExNTQ4MmE5NzIwMGYxYmVjN2MzODVkL3RhYmxlcmFuZ2U6Zjk5ZGViNTczYTE1NDgyYTk3MjAwZjFiZWM3YzM4NWRfMy03LTEtMS0yNjkxMA_d76b66d1-98ab-4aeb-9cb8-492db67109db">720</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of deferred financing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" name="fold:AmortizationDeferredFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOmY5OWRlYjU3M2ExNTQ4MmE5NzIwMGYxYmVjN2MzODVkL3RhYmxlcmFuZ2U6Zjk5ZGViNTczYTE1NDgyYTk3MjAwZjFiZWM3YzM4NWRfNC0yLTEtMS0yNTk4OQ_d18555e1-9165-4e44-9eaa-cd5614952a41">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" name="fold:AmortizationDeferredFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOmY5OWRlYjU3M2ExNTQ4MmE5NzIwMGYxYmVjN2MzODVkL3RhYmxlcmFuZ2U6Zjk5ZGViNTczYTE1NDgyYTk3MjAwZjFiZWM3YzM4NWRfNC00LTEtMS0yNTk4OQ_e9305902-f161-46e8-8dd0-ee1c5a8782ab">262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="fold:AmortizationDeferredFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOmY5OWRlYjU3M2ExNTQ4MmE5NzIwMGYxYmVjN2MzODVkL3RhYmxlcmFuZ2U6Zjk5ZGViNTczYTE1NDgyYTk3MjAwZjFiZWM3YzM4NWRfNC02LTEtMS0yNzc3NA_cef02c01-250e-4097-9d07-ee0a5416b59e">556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="fold:AmortizationDeferredFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOmY5OWRlYjU3M2ExNTQ4MmE5NzIwMGYxYmVjN2MzODVkL3RhYmxlcmFuZ2U6Zjk5ZGViNTczYTE1NDgyYTk3MjAwZjFiZWM3YzM4NWRfNC03LTEtMS0yNjkxMA_b7dfebc3-1bdd-48cc-b751-e6f12f0ec24d">485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:3pt"><span><br/></span></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_52"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RleHRyZWdpb246ODM3NGZmYzRlMTI5NDJlN2I5MzM5OGQ3NmQ0YjNkOTJfMjM0OA_c359229b-23eb-455f-9490-31ff2b16aedd" continuedAt="if396a32864f04724bdcab597f3597912" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if396a32864f04724bdcab597f3597912" continuedAt="i49a75b87b153487b892a7e18c4de838a">The Company's Amended and Restated 2007 Equity Incentive Plan (the "Plan") provides for the granting of restricted stock units and options to purchase common stock in the Company to employees, directors, advisors, and consultants at a price to be determined by the Company's Board of Directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company's business. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option. </ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i49a75b87b153487b892a7e18c4de838a" continuedAt="id707292465d64aa2a84ea1d37ea6e2b5"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Option Grants</span></div><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RleHRyZWdpb246ODM3NGZmYzRlMTI5NDJlN2I5MzM5OGQ3NmQ0YjNkOTJfMjM0MQ_fc53174d-d9f4-4299-b72d-275dc3862c56" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.474%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7db5d4a26355471cb3592c15bd783d1c_D20220401-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjY2ZWYyNGUxMDExYzRiNTZhNjYzMzM3ODJkZTc5YzE2L3RhYmxlcmFuZ2U6NjZlZjI0ZTEwMTFjNGI1NmE2NjMzMzc4MmRlNzljMTZfMi0xLTEtMS0yNTk4OQ_1d57a329-ae42-4df8-a9a3-5aa4ff8dd72a">61.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4699991b02604e23976f7eb8d6c9a55f_D20210401-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjY2ZWYyNGUxMDExYzRiNTZhNjYzMzM3ODJkZTc5YzE2L3RhYmxlcmFuZ2U6NjZlZjI0ZTEwMTFjNGI1NmE2NjMzMzc4MmRlNzljMTZfMi0zLTEtMS0yNTk4OQ_aae78047-b908-4118-bf32-ee0bc18d4cf2">65.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5d570dfe70e7454f85640ff0afc44736_D20220101-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjY2ZWYyNGUxMDExYzRiNTZhNjYzMzM3ODJkZTc5YzE2L3RhYmxlcmFuZ2U6NjZlZjI0ZTEwMTFjNGI1NmE2NjMzMzc4MmRlNzljMTZfMi01LTEtMS0yNzE2MQ_88069161-0048-4a8f-b9f0-79528f4e2948">62.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3501524d91e94a18bfac0415f9e68531_D20210101-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjY2ZWYyNGUxMDExYzRiNTZhNjYzMzM3ODJkZTc5YzE2L3RhYmxlcmFuZ2U6NjZlZjI0ZTEwMTFjNGI1NmE2NjMzMzc4MmRlNzljMTZfMi02LTEtMS0yNjkyNw_adf36898-8f41-41c9-a36a-340427914464">66.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7db5d4a26355471cb3592c15bd783d1c_D20220401-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjY2ZWYyNGUxMDExYzRiNTZhNjYzMzM3ODJkZTc5YzE2L3RhYmxlcmFuZ2U6NjZlZjI0ZTEwMTFjNGI1NmE2NjMzMzc4MmRlNzljMTZfMy0xLTEtMS0yNTk4OQ_5521678a-d95c-4531-8376-6ca7cc57489a">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4699991b02604e23976f7eb8d6c9a55f_D20210401-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjY2ZWYyNGUxMDExYzRiNTZhNjYzMzM3ODJkZTc5YzE2L3RhYmxlcmFuZ2U6NjZlZjI0ZTEwMTFjNGI1NmE2NjMzMzc4MmRlNzljMTZfMy0zLTEtMS0yNTk4OQ_1dfdd281-3a56-42d4-b0e9-ca9b06c6d166">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5d570dfe70e7454f85640ff0afc44736_D20220101-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjY2ZWYyNGUxMDExYzRiNTZhNjYzMzM3ODJkZTc5YzE2L3RhYmxlcmFuZ2U6NjZlZjI0ZTEwMTFjNGI1NmE2NjMzMzc4MmRlNzljMTZfMy01LTEtMS0yNzE2MQ_bec5a0bb-451c-420e-b366-878cea8f0e09">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3501524d91e94a18bfac0415f9e68531_D20210101-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjY2ZWYyNGUxMDExYzRiNTZhNjYzMzM3ODJkZTc5YzE2L3RhYmxlcmFuZ2U6NjZlZjI0ZTEwMTFjNGI1NmE2NjMzMzc4MmRlNzljMTZfMy02LTEtMS0yNjkyNw_5f68cea5-78fb-40de-89bd-d46385c3177a">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected life of options (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7db5d4a26355471cb3592c15bd783d1c_D20220401-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjY2ZWYyNGUxMDExYzRiNTZhNjYzMzM3ODJkZTc5YzE2L3RhYmxlcmFuZ2U6NjZlZjI0ZTEwMTFjNGI1NmE2NjMzMzc4MmRlNzljMTZfNC0xLTEtMS0yNTk4OQ_75ec4c81-38b4-4422-b8f5-1d124b66930c">5.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4699991b02604e23976f7eb8d6c9a55f_D20210401-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjY2ZWYyNGUxMDExYzRiNTZhNjYzMzM3ODJkZTc5YzE2L3RhYmxlcmFuZ2U6NjZlZjI0ZTEwMTFjNGI1NmE2NjMzMzc4MmRlNzljMTZfNC0zLTEtMS0yNTk4OQ_386717bb-0850-469b-82af-99ddc0e0578b">5.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5d570dfe70e7454f85640ff0afc44736_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjY2ZWYyNGUxMDExYzRiNTZhNjYzMzM3ODJkZTc5YzE2L3RhYmxlcmFuZ2U6NjZlZjI0ZTEwMTFjNGI1NmE2NjMzMzc4MmRlNzljMTZfNC01LTEtMS0yNzE2MQ_dec3494f-55c8-47cc-a61d-4e37fa3a8879">5.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3501524d91e94a18bfac0415f9e68531_D20210101-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjY2ZWYyNGUxMDExYzRiNTZhNjYzMzM3ODJkZTc5YzE2L3RhYmxlcmFuZ2U6NjZlZjI0ZTEwMTFjNGI1NmE2NjMzMzc4MmRlNzljMTZfNC02LTEtMS0yNjkyNw_922fa5ff-ed23-4c80-b45e-35b31a2f74b1">5.4</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected annual dividend per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i7db5d4a26355471cb3592c15bd783d1c_D20220401-20220630" decimals="INF" name="fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjY2ZWYyNGUxMDExYzRiNTZhNjYzMzM3ODJkZTc5YzE2L3RhYmxlcmFuZ2U6NjZlZjI0ZTEwMTFjNGI1NmE2NjMzMzc4MmRlNzljMTZfNS0xLTEtMS0yNTk4OQ_8ad1bea3-2abb-4fa4-8af7-734ffd610600">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i4699991b02604e23976f7eb8d6c9a55f_D20210401-20210630" decimals="INF" name="fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjY2ZWYyNGUxMDExYzRiNTZhNjYzMzM3ODJkZTc5YzE2L3RhYmxlcmFuZ2U6NjZlZjI0ZTEwMTFjNGI1NmE2NjMzMzc4MmRlNzljMTZfNS0zLTEtMS0yNTk4OQ_dff68c29-e602-4bfe-9fc0-ca311628fc46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i5d570dfe70e7454f85640ff0afc44736_D20220101-20220630" decimals="INF" name="fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjY2ZWYyNGUxMDExYzRiNTZhNjYzMzM3ODJkZTc5YzE2L3RhYmxlcmFuZ2U6NjZlZjI0ZTEwMTFjNGI1NmE2NjMzMzc4MmRlNzljMTZfNS01LTEtMS0yNzE2MQ_a91c6c4f-055c-4086-9577-83957cef9556">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i3501524d91e94a18bfac0415f9e68531_D20210101-20210630" decimals="INF" name="fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjY2ZWYyNGUxMDExYzRiNTZhNjYzMzM3ODJkZTc5YzE2L3RhYmxlcmFuZ2U6NjZlZjI0ZTEwMTFjNGI1NmE2NjMzMzc4MmRlNzljMTZfNS03LTEtMS0yNzE2Ng_4f454e91-eb19-4452-83c0-7ba92ce120c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;<ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RleHRyZWdpb246ODM3NGZmYzRlMTI5NDJlN2I5MzM5OGQ3NmQ0YjNkOTJfMjM2MQ_773ac1c0-1396-4f1e-b8cb-0dfa9456e40c" continuedAt="i48d4e16a775f4f77b0e03f426c23a23f" escape="true">A summary of the Company's stock options for the six months ended June 30, 2022 were as follows:</ix:nonNumeric></span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center;text-indent:18pt"><ix:continuation id="i48d4e16a775f4f77b0e03f426c23a23f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.479%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise&#160;<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining <br/>Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options outstanding, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfMi0xLTEtMS0yNTk4OQ_abbff6c3-09dc-442b-ae86-4f0ca947a2eb">14,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfMi0zLTEtMS0yNTk4OQ_ae6ca333-af1c-4f49-a657-ac543ed98ab7">11.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfMy0xLTEtMS0yNTk4OQ_54a3005d-8a33-447d-88fa-765a8a7ac03c">5,402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfMy0zLTEtMS0yNTk4OQ_0247dffd-db99-4e5c-8795-84962e1890ac">11.55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfNC0xLTEtMS0yNTk4OQ_ab36e165-eeca-4f16-b265-aea09b35182e">339</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfNC0zLTEtMS0yNTk4OQ_aae31d62-f282-43c0-82ae-640083318fb6">5.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfNS0xLTEtMS0yNTk4OQ_2c83bcb6-9b87-4c47-a9bb-4df0bd20a336">333</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfNS0zLTEtMS0yNTk4OQ_527be906-75d9-497f-b00c-55617b68bf48">12.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfNi0xLTEtMS0yNTk4OQ_aa528777-d2a8-445a-a348-5232db4b3fdf">178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfNi0zLTEtMS0yNTk4OQ_9e549afc-71f3-49a5-866a-43e7880dad00">11.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options outstanding, June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfNy0xLTEtMS0yNTk4OQ_3d7ad4f0-9b01-4cdb-b778-48828fbf345b">19,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfNy0zLTEtMS0yNTk4OQ_b23c8968-0ab6-4c7d-9062-f13c7dcf36ce">11.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfNy01LTEtMS0yNTk4OQ_21d9d7c7-0f71-4138-adc2-4b4cb2e9d141">7.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfNy03LTEtMS0yNTk4OQ_82cccb85-7479-499c-8a82-2a1657705395">22.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and unvested expected to vest, June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfOC0xLTEtMS0yNTk4OQ_6e43e609-0aa0-4afd-bd7d-55d50b183ea7">17,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfOC0zLTEtMS0yNTk4OQ_26975482-39ae-402a-9ce9-0c7d8e5c4325">11.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfOC01LTEtMS0yNTk4OQ_fd17c951-f875-459d-a7e6-9dda70cd4dcf">6.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfOC03LTEtMS0yNTk4OQ_7137b298-2f06-4fbc-894c-7ae508b4de26">21.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfOS0xLTEtMS0yNTk4OQ_f8af5a4a-1b28-4687-8e54-8ce1e601a7a9">10,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfOS0zLTEtMS0yNTk4OQ_2cfc3113-0bba-47e8-bdcc-1899fccaa33c">10.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfOS01LTEtMS0yNTk4OQ_2dd7455d-d91d-4028-a979-338b0db2e58f">5.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfOS03LTEtMS0yNTk4OQ_22f51c11-70e9-4565-ba55-524fb27f9517">18.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the total unrecognized compensation cost related to non-vested stock options granted was $<ix:nonFraction unitRef="usd" contextRef="i4c027874ad0b4c14b107e9e7d4d2a4b3_I20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RleHRyZWdpb246ODM3NGZmYzRlMTI5NDJlN2I5MzM5OGQ3NmQ0YjNkOTJfMTEzMw_f8e32a97-2760-43d5-b03d-8ac6f5005efc">39.5</ix:nonFraction> million and is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i5d570dfe70e7454f85640ff0afc44736_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RleHRyZWdpb246ODM3NGZmYzRlMTI5NDJlN2I5MzM5OGQ3NmQ0YjNkOTJfMTIwMw_63ea5a4a-0cfb-434b-a2bb-da0640f938dd">three years</ix:nonNumeric>.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and Performance-Based Restricted Stock Units (collectively "RSUs")</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs awarded under the Plan are generally subject to graded vesting and are contingent on an employee's continued service. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. <ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RleHRyZWdpb246ODM3NGZmYzRlMTI5NDJlN2I5MzM5OGQ3NmQ0YjNkOTJfMjM1MQ_4be27adf-cadc-4959-ad8d-28b09ffc4516" continuedAt="i00df66c0f3374cbfa550ae07fa24b979" escape="true">A summary of non-vested RSU activity under the Plan for the six months ended June 30, 2022 is as follows:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center;text-indent:18pt"><ix:continuation id="i00df66c0f3374cbfa550ae07fa24b979"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:38.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average Grant<br/>Date Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;<br/>Average<br/>Remaining&#160;<br/>Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2ccbe1db3305487c82f9fcfe73e288b9_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOmEzYTBhMWFiZTIyODQ5Njg4YWYxNDgyMTVjMWI3ZWZjL3RhYmxlcmFuZ2U6YTNhMGExYWJlMjI4NDk2ODhhZjE0ODIxNWMxYjdlZmNfMi0xLTEtMS0yNTk4OQ_87cc542d-f7df-430b-95e0-399abc373edd">7,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i2ccbe1db3305487c82f9fcfe73e288b9_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOmEzYTBhMWFiZTIyODQ5Njg4YWYxNDgyMTVjMWI3ZWZjL3RhYmxlcmFuZ2U6YTNhMGExYWJlMjI4NDk2ODhhZjE0ODIxNWMxYjdlZmNfMi0zLTEtMS0yNTk4OQ_899d072a-b68a-4d65-950e-151780ea2044">13.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i245ad67e6079446eae628bd054c5451c_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOmEzYTBhMWFiZTIyODQ5Njg4YWYxNDgyMTVjMWI3ZWZjL3RhYmxlcmFuZ2U6YTNhMGExYWJlMjI4NDk2ODhhZjE0ODIxNWMxYjdlZmNfMy0xLTEtMS0yNTk4OQ_a5cbbd68-5df5-4053-b591-c90e5b50b81e">4,815</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i245ad67e6079446eae628bd054c5451c_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOmEzYTBhMWFiZTIyODQ5Njg4YWYxNDgyMTVjMWI3ZWZjL3RhYmxlcmFuZ2U6YTNhMGExYWJlMjI4NDk2ODhhZjE0ODIxNWMxYjdlZmNfMy0zLTEtMS0yNTk4OQ_cd776bd4-d3e2-4451-92b8-afe6d4986786">11.97</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i245ad67e6079446eae628bd054c5451c_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOmEzYTBhMWFiZTIyODQ5Njg4YWYxNDgyMTVjMWI3ZWZjL3RhYmxlcmFuZ2U6YTNhMGExYWJlMjI4NDk2ODhhZjE0ODIxNWMxYjdlZmNfNC0xLTEtMS0yNTk4OQ_89fd6dc0-92fd-4767-bb83-3c47a0def3f6">1,738</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i245ad67e6079446eae628bd054c5451c_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOmEzYTBhMWFiZTIyODQ5Njg4YWYxNDgyMTVjMWI3ZWZjL3RhYmxlcmFuZ2U6YTNhMGExYWJlMjI4NDk2ODhhZjE0ODIxNWMxYjdlZmNfNC0zLTEtMS0yNTk4OQ_418e6173-bcba-4acf-8b90-e5bcf959b5e1">12.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i245ad67e6079446eae628bd054c5451c_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOmEzYTBhMWFiZTIyODQ5Njg4YWYxNDgyMTVjMWI3ZWZjL3RhYmxlcmFuZ2U6YTNhMGExYWJlMjI4NDk2ODhhZjE0ODIxNWMxYjdlZmNfNS0xLTEtMS0yNTk4OQ_b7e228d4-e6ae-4f04-9d2d-d60713d74238">252</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i245ad67e6079446eae628bd054c5451c_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOmEzYTBhMWFiZTIyODQ5Njg4YWYxNDgyMTVjMWI3ZWZjL3RhYmxlcmFuZ2U6YTNhMGExYWJlMjI4NDk2ODhhZjE0ODIxNWMxYjdlZmNfNS0zLTEtMS0yNTk4OQ_0605898a-a213-4afb-839c-3260ef78d525">12.10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i45525b12c16f4e50b69bac633525c7c7_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOmEzYTBhMWFiZTIyODQ5Njg4YWYxNDgyMTVjMWI3ZWZjL3RhYmxlcmFuZ2U6YTNhMGExYWJlMjI4NDk2ODhhZjE0ODIxNWMxYjdlZmNfNi0xLTEtMS0yNTk4OQ_c467d0b5-1949-4abc-a383-bae9eb8de75a">10,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i45525b12c16f4e50b69bac633525c7c7_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOmEzYTBhMWFiZTIyODQ5Njg4YWYxNDgyMTVjMWI3ZWZjL3RhYmxlcmFuZ2U6YTNhMGExYWJlMjI4NDk2ODhhZjE0ODIxNWMxYjdlZmNfNi0zLTEtMS0yNTk4OQ_5a6356c8-3bf2-45fa-b277-e233bd07c850">13.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i245ad67e6079446eae628bd054c5451c_D20220101-20220630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOmEzYTBhMWFiZTIyODQ5Njg4YWYxNDgyMTVjMWI3ZWZjL3RhYmxlcmFuZ2U6YTNhMGExYWJlMjI4NDk2ODhhZjE0ODIxNWMxYjdlZmNfNi01LTEtMS0yNTk4OQ_7f4f288f-c311-422d-a958-3dd670cedbab">2.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45525b12c16f4e50b69bac633525c7c7_I20220630" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOmEzYTBhMWFiZTIyODQ5Njg4YWYxNDgyMTVjMWI3ZWZjL3RhYmxlcmFuZ2U6YTNhMGExYWJlMjI4NDk2ODhhZjE0ODIxNWMxYjdlZmNfNi03LTEtMS0yNTk4OQ_36ca2711-4955-4b16-a7fb-bb98cf481423">109.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All non-vested units are expected to vest over their normal term. As of June 30, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i45525b12c16f4e50b69bac633525c7c7_I20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RleHRyZWdpb246ODM3NGZmYzRlMTI5NDJlN2I5MzM5OGQ3NmQ0YjNkOTJfMTk0Ng_d74a51f9-3a79-4680-acbd-a08b0fc4a919">65.8</ix:nonFraction> million of total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions. These costs are expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i245ad67e6079446eae628bd054c5451c_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RleHRyZWdpb246ODM3NGZmYzRlMTI5NDJlN2I5MzM5OGQ3NmQ0YjNkOTJfMjEyOQ_7c3a8a3d-5cdf-4344-92ca-04e38b309315">two years</ix:nonNumeric>.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id707292465d64aa2a84ea1d37ea6e2b5"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Expense Related to Equity Awards</span></div><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RleHRyZWdpb246ODM3NGZmYzRlMTI5NDJlN2I5MzM5OGQ3NmQ0YjNkOTJfMjM1Nw_a112233c-5d0f-483e-ac28-17a369f07083" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.702%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e34834a2be94b8e8074f10f13edbcb6_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjhjZjBjZjkxZmIxNjQxNDc4Yjk5MDhjNTFkZGJlY2ZiL3RhYmxlcmFuZ2U6OGNmMGNmOTFmYjE2NDE0NzhiOTkwOGM1MWRkYmVjZmJfMi0yLTEtMS0yNTk4OQ_b7abddc3-4413-453d-a307-09b54f3c8529">4,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd36bef22694ce9b71e55b1717ed5db_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjhjZjBjZjkxZmIxNjQxNDc4Yjk5MDhjNTFkZGJlY2ZiL3RhYmxlcmFuZ2U6OGNmMGNmOTFmYjE2NDE0NzhiOTkwOGM1MWRkYmVjZmJfMi00LTEtMS0yNTk4OQ_cd73e24d-2d71-4306-9654-43ef13912967">3,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i613cc31dd21945f18cc9aca69ab98da3_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjhjZjBjZjkxZmIxNjQxNDc4Yjk5MDhjNTFkZGJlY2ZiL3RhYmxlcmFuZ2U6OGNmMGNmOTFmYjE2NDE0NzhiOTkwOGM1MWRkYmVjZmJfMi02LTEtMS0yNzE3OQ_0bad032c-35b8-482b-bcca-24688ff2734b">13,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b06cd373bbe47dcbce2f3dabed11f52_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjhjZjBjZjkxZmIxNjQxNDc4Yjk5MDhjNTFkZGJlY2ZiL3RhYmxlcmFuZ2U6OGNmMGNmOTFmYjE2NDE0NzhiOTkwOGM1MWRkYmVjZmJfMi04LTEtMS0yNjk1Mw_2b015f11-7e11-4475-afb6-8a9e3dc1efd5">9,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie40dbd39b0544892a3797b1b64ad108e_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjhjZjBjZjkxZmIxNjQxNDc4Yjk5MDhjNTFkZGJlY2ZiL3RhYmxlcmFuZ2U6OGNmMGNmOTFmYjE2NDE0NzhiOTkwOGM1MWRkYmVjZmJfMy0yLTEtMS0yNTk4OQ_52189f54-0a1f-4fc5-9ffa-ab4310f34799">8,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1217c1798fd34a71be289e7051cd1b47_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjhjZjBjZjkxZmIxNjQxNDc4Yjk5MDhjNTFkZGJlY2ZiL3RhYmxlcmFuZ2U6OGNmMGNmOTFmYjE2NDE0NzhiOTkwOGM1MWRkYmVjZmJfMy00LTEtMS0yNTk4OQ_2853918f-949a-4c5f-97a1-451e19142a4b">8,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c83b69fa62485e98e97922a5e49b57_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjhjZjBjZjkxZmIxNjQxNDc4Yjk5MDhjNTFkZGJlY2ZiL3RhYmxlcmFuZ2U6OGNmMGNmOTFmYjE2NDE0NzhiOTkwOGM1MWRkYmVjZmJfMy02LTEtMS0yNzE3OQ_b1809426-d644-4584-aa0e-8890499e1fea">29,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i659ab50b47154e78b47ef9e839307808_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjhjZjBjZjkxZmIxNjQxNDc4Yjk5MDhjNTFkZGJlY2ZiL3RhYmxlcmFuZ2U6OGNmMGNmOTFmYjE2NDE0NzhiOTkwOGM1MWRkYmVjZmJfMy04LTEtMS0yNjk1Mw_f9b3efc5-3df6-475b-a447-c2b0cac70cf0">22,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjhjZjBjZjkxZmIxNjQxNDc4Yjk5MDhjNTFkZGJlY2ZiL3RhYmxlcmFuZ2U6OGNmMGNmOTFmYjE2NDE0NzhiOTkwOGM1MWRkYmVjZmJfNC0yLTEtMS0yNTk4OQ_0ff9e6f1-dbd5-4492-bf55-119248efdfcb">12,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjhjZjBjZjkxZmIxNjQxNDc4Yjk5MDhjNTFkZGJlY2ZiL3RhYmxlcmFuZ2U6OGNmMGNmOTFmYjE2NDE0NzhiOTkwOGM1MWRkYmVjZmJfNC00LTEtMS0yNTk4OQ_f1d9c725-8c36-4eb3-a030-97021102575c">11,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjhjZjBjZjkxZmIxNjQxNDc4Yjk5MDhjNTFkZGJlY2ZiL3RhYmxlcmFuZ2U6OGNmMGNmOTFmYjE2NDE0NzhiOTkwOGM1MWRkYmVjZmJfNC02LTEtMS0yNzc3OQ_aefe2a15-a47a-41ae-893e-a63287addd06">43,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjhjZjBjZjkxZmIxNjQxNDc4Yjk5MDhjNTFkZGJlY2ZiL3RhYmxlcmFuZ2U6OGNmMGNmOTFmYjE2NDE0NzhiOTkwOGM1MWRkYmVjZmJfNC04LTEtMS0yNzc3OQ_e9f3572e-40cb-4848-9b54-62382774faab">32,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_55"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;<ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RleHRyZWdpb246NDNkNjcxZTdjYjJhNDc5MGFjMWVjMjM3YTM0MTc0YjFfMzk4Mw_8f55a5b8-a871-4522-a5d5-4ab16f2f16c4" continuedAt="i1c19b16263fc4fb284a1affb1522697d" escape="true">Assets and Liabilities Measured at Fair Value</ix:nonNumeric></span></div><ix:continuation id="i1c19b16263fc4fb284a1affb1522697d" continuedAt="id768279879054e289353dca895785648"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial assets and liabilities are measured at fair value and classified within the fair value hierarchy, which is defined as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs that are unobservable for the asset or liability.</span></div><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RleHRyZWdpb246NDNkNjcxZTdjYjJhNDc5MGFjMWVjMjM3YTM0MTc0YjFfMzk3MA_2b7376f2-a4ec-499b-a590-bf0e1d370a8b" continuedAt="i3d3e7c64a9ef49fa8efd3d52b001e89b" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of June 30, 2022 are identified in the following tables:</span></div><div style="margin-bottom:15pt;margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:72.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.677%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9f84953690247a48cc8d3be225dedce_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmY0ODczOTFiNTg3ZDQ1ZGRiMDYzNDA1NTAyMmMyYmZkL3RhYmxlcmFuZ2U6ZjQ4NzM5MWI1ODdkNDVkZGIwNjM0MDU1MDIyYzJiZmRfMi0yLTEtMS0yNTk4OQ_2be9872a-9f8a-4430-b854-6e6c99a33e8a">102,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313bc2d8be6b49deab3982d26fd646fd_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmY0ODczOTFiNTg3ZDQ1ZGRiMDYzNDA1NTAyMmMyYmZkL3RhYmxlcmFuZ2U6ZjQ4NzM5MWI1ODdkNDVkZGIwNjM0MDU1MDIyYzJiZmRfMi00LTEtMS0yNTk4OQ_99f07ac6-61d4-441a-9808-ea602f4464e6">102,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddfa60f46e544df947c8b0ff919e9db_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmY0ODczOTFiNTg3ZDQ1ZGRiMDYzNDA1NTAyMmMyYmZkL3RhYmxlcmFuZ2U6ZjQ4NzM5MWI1ODdkNDVkZGIwNjM0MDU1MDIyYzJiZmRfMy0yLTEtMS0yNTk4OQ_66cce1af-bcda-45af-a84f-ee58fa457d75">44,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a5beaca54dc4603a5614a45876a29e0_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmY0ODczOTFiNTg3ZDQ1ZGRiMDYzNDA1NTAyMmMyYmZkL3RhYmxlcmFuZ2U6ZjQ4NzM5MWI1ODdkNDVkZGIwNjM0MDU1MDIyYzJiZmRfMy00LTEtMS0yNTk4OQ_415f5adb-ff94-453c-8a07-7ad9ee663913">44,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cce6f2cd8d64779a3cb98b16bc6010c_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmY0ODczOTFiNTg3ZDQ1ZGRiMDYzNDA1NTAyMmMyYmZkL3RhYmxlcmFuZ2U6ZjQ4NzM5MWI1ODdkNDVkZGIwNjM0MDU1MDIyYzJiZmRfNC0yLTEtMS0yNTk4OQ_847b56d8-f36a-4859-b3d2-68c6c1e41e86">2,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie925c891e72c47cea99fa4b411e16d37_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmY0ODczOTFiNTg3ZDQ1ZGRiMDYzNDA1NTAyMmMyYmZkL3RhYmxlcmFuZ2U6ZjQ4NzM5MWI1ODdkNDVkZGIwNjM0MDU1MDIyYzJiZmRfNC00LTEtMS0yNTk4OQ_779178e4-3c34-41ec-a1c5-0256f54a2126">2,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaa7d76b8bf74f59b0911c381d40613e_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmY0ODczOTFiNTg3ZDQ1ZGRiMDYzNDA1NTAyMmMyYmZkL3RhYmxlcmFuZ2U6ZjQ4NzM5MWI1ODdkNDVkZGIwNjM0MDU1MDIyYzJiZmRfNS0yLTEtMS0yNTk4OQ_6c62f614-2045-487c-8270-2325e861c7bf">5,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2786cde9d4554d08836966e040d3dd88_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmY0ODczOTFiNTg3ZDQ1ZGRiMDYzNDA1NTAyMmMyYmZkL3RhYmxlcmFuZ2U6ZjQ4NzM5MWI1ODdkNDVkZGIwNjM0MDU1MDIyYzJiZmRfNS00LTEtMS0yNTk4OQ_941dd746-8dde-490e-8d0d-3d8e17882e50">5,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667b2117b7d6414692a884314d59ed80_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmY0ODczOTFiNTg3ZDQ1ZGRiMDYzNDA1NTAyMmMyYmZkL3RhYmxlcmFuZ2U6ZjQ4NzM5MWI1ODdkNDVkZGIwNjM0MDU1MDIyYzJiZmRfNy0yLTEtMS0yNTk4OQ_40ffa34f-b9ce-431a-8275-16d29ecd89b9">156,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmY0ODczOTFiNTg3ZDQ1ZGRiMDYzNDA1NTAyMmMyYmZkL3RhYmxlcmFuZ2U6ZjQ4NzM5MWI1ODdkNDVkZGIwNjM0MDU1MDIyYzJiZmRfNy00LTEtMS0yNTk4OQ_60f18f77-ac69-46cb-a6ac-da428895265f">156,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:58.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667b2117b7d6414692a884314d59ed80_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmQ1NGM4NjU3YjRmYTQ2NTg4Y2I4YzFmOTA3MDZhMjJkL3RhYmxlcmFuZ2U6ZDU0Yzg2NTdiNGZhNDY1ODhjYjhjMWY5MDcwNmEyMmRfMi0yLTEtMS0yNTk4OQ_d2ca7464-b70f-4352-a80d-ef36ec88d552">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc49c8cd141a4141b4d1b6b88a3c8ee3_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmQ1NGM4NjU3YjRmYTQ2NTg4Y2I4YzFmOTA3MDZhMjJkL3RhYmxlcmFuZ2U6ZDU0Yzg2NTdiNGZhNDY1ODhjYjhjMWY5MDcwNmEyMmRfMi00LTEtMS0yNTk4OQ_1ecc7065-3470-4c89-a2ce-407f0cc36e96">19,266</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmQ1NGM4NjU3YjRmYTQ2NTg4Y2I4YzFmOTA3MDZhMjJkL3RhYmxlcmFuZ2U6ZDU0Yzg2NTdiNGZhNDY1ODhjYjhjMWY5MDcwNmEyMmRfMi02LTEtMS0yNTk4OQ_9e6f502e-92da-4715-8696-962dc494db73">19,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667b2117b7d6414692a884314d59ed80_I20220630" decimals="-3" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmQ1NGM4NjU3YjRmYTQ2NTg4Y2I4YzFmOTA3MDZhMjJkL3RhYmxlcmFuZ2U6ZDU0Yzg2NTdiNGZhNDY1ODhjYjhjMWY5MDcwNmEyMmRfMy0yLTEtMS0yNTk4OQ_d9b5eb87-f935-465f-9914-e701b4bce7b5">4,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc49c8cd141a4141b4d1b6b88a3c8ee3_I20220630" decimals="-3" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmQ1NGM4NjU3YjRmYTQ2NTg4Y2I4YzFmOTA3MDZhMjJkL3RhYmxlcmFuZ2U6ZDU0Yzg2NTdiNGZhNDY1ODhjYjhjMWY5MDcwNmEyMmRfMy00LTEtMS0yNTk4OQ_6afe07c4-d6ed-47e1-b9e7-a7dd5d20ab1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmQ1NGM4NjU3YjRmYTQ2NTg4Y2I4YzFmOTA3MDZhMjJkL3RhYmxlcmFuZ2U6ZDU0Yzg2NTdiNGZhNDY1ODhjYjhjMWY5MDcwNmEyMmRfMy02LTEtMS0yNTk4OQ_57dbe0bd-bbc3-48d5-b401-97bd78170802">4,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667b2117b7d6414692a884314d59ed80_I20220630" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmQ1NGM4NjU3YjRmYTQ2NTg4Y2I4YzFmOTA3MDZhMjJkL3RhYmxlcmFuZ2U6ZDU0Yzg2NTdiNGZhNDY1ODhjYjhjMWY5MDcwNmEyMmRfNC0yLTEtMS0yNTk4OQ_1a0e3508-9c1b-4519-8bd2-d222e4867013">4,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc49c8cd141a4141b4d1b6b88a3c8ee3_I20220630" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmQ1NGM4NjU3YjRmYTQ2NTg4Y2I4YzFmOTA3MDZhMjJkL3RhYmxlcmFuZ2U6ZDU0Yzg2NTdiNGZhNDY1ODhjYjhjMWY5MDcwNmEyMmRfNC00LTEtMS0yNTk4OQ_e210a573-67b1-4329-943e-a350d58f687a">19,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmQ1NGM4NjU3YjRmYTQ2NTg4Y2I4YzFmOTA3MDZhMjJkL3RhYmxlcmFuZ2U6ZDU0Yzg2NTdiNGZhNDY1ODhjYjhjMWY5MDcwNmEyMmRfNC02LTEtMS0yNTk4OQ_11bc3e44-c3f0-4e67-8554-4a0d63fd974c">24,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id768279879054e289353dca895785648" continuedAt="i6be66fab5ed44d9199ca9aa293e1c5f9"><ix:continuation id="i3d3e7c64a9ef49fa8efd3d52b001e89b"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2021 are identified in the following tables:</span></div><div style="margin-bottom:15pt;margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:72.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.677%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18a1d906c5a545e698385837607d8ddb_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjllOTZjMmMyODM3ZTQ5NzY4OGFjMTI5NjFmNzI0NmVkL3RhYmxlcmFuZ2U6OWU5NmMyYzI4MzdlNDk3Njg4YWMxMjk2MWY3MjQ2ZWRfMi0yLTEtMS0yNTk4OQ_f040a75e-0bd9-4cc5-ba40-1cb8ec4d8170">174,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18a1d906c5a545e698385837607d8ddb_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjllOTZjMmMyODM3ZTQ5NzY4OGFjMTI5NjFmNzI0NmVkL3RhYmxlcmFuZ2U6OWU5NmMyYzI4MzdlNDk3Njg4YWMxMjk2MWY3MjQ2ZWRfMi00LTEtMS0yNTk4OQ_cb9309a9-378c-4b14-ae1a-067cd9b3d851">174,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddabb7fdfb774233b59ea3d5ebb33de8_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjllOTZjMmMyODM3ZTQ5NzY4OGFjMTI5NjFmNzI0NmVkL3RhYmxlcmFuZ2U6OWU5NmMyYzI4MzdlNDk3Njg4YWMxMjk2MWY3MjQ2ZWRfMy0yLTEtMS0yNTk4OQ_5b4ae043-d396-4745-898c-4c18ea1d39b1">32,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddabb7fdfb774233b59ea3d5ebb33de8_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjllOTZjMmMyODM3ZTQ5NzY4OGFjMTI5NjFmNzI0NmVkL3RhYmxlcmFuZ2U6OWU5NmMyYzI4MzdlNDk3Njg4YWMxMjk2MWY3MjQ2ZWRfMy00LTEtMS0yNTk4OQ_6743556b-8f77-4505-95a9-7fa0b6556916">32,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i582299724ae3474088b179e8999bf21b_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjllOTZjMmMyODM3ZTQ5NzY4OGFjMTI5NjFmNzI0NmVkL3RhYmxlcmFuZ2U6OWU5NmMyYzI4MzdlNDk3Njg4YWMxMjk2MWY3MjQ2ZWRfNC0yLTEtMS0yNTk4OQ_6677f0e2-a72c-40f3-ad8e-8524683c6988">30,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifae0d641d44e4d74bd462bf49ef538ec_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjllOTZjMmMyODM3ZTQ5NzY4OGFjMTI5NjFmNzI0NmVkL3RhYmxlcmFuZ2U6OWU5NmMyYzI4MzdlNDk3Njg4YWMxMjk2MWY3MjQ2ZWRfNC00LTEtMS0yNTk4OQ_ffa367e7-e0b7-451a-bde7-341913320d56">30,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f84ce5d8994d548056b41c664b19c0_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjllOTZjMmMyODM3ZTQ5NzY4OGFjMTI5NjFmNzI0NmVkL3RhYmxlcmFuZ2U6OWU5NmMyYzI4MzdlNDk3Njg4YWMxMjk2MWY3MjQ2ZWRfNS0yLTEtMS0yNTk4OQ_73197862-d905-4ebe-907f-185a39b87267">5,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b41065183b64de594c948fc62b3fd96_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjllOTZjMmMyODM3ZTQ5NzY4OGFjMTI5NjFmNzI0NmVkL3RhYmxlcmFuZ2U6OWU5NmMyYzI4MzdlNDk3Njg4YWMxMjk2MWY3MjQ2ZWRfNS00LTEtMS0yNTk4OQ_10f00738-c2e8-4f9e-83ef-581e7dabf0b6">5,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56ccbb8636664d06a097e18deeca55d4_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjllOTZjMmMyODM3ZTQ5NzY4OGFjMTI5NjFmNzI0NmVkL3RhYmxlcmFuZ2U6OWU5NmMyYzI4MzdlNDk3Njg4YWMxMjk2MWY3MjQ2ZWRfNi0yLTEtMS0yNTk4OQ_0c22e3f9-5325-4d9d-97da-4886ed240c38">242,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjllOTZjMmMyODM3ZTQ5NzY4OGFjMTI5NjFmNzI0NmVkL3RhYmxlcmFuZ2U6OWU5NmMyYzI4MzdlNDk3Njg4YWMxMjk2MWY3MjQ2ZWRfNi00LTEtMS0yNTk4OQ_652bdd70-4255-4e33-815f-7c008431bef3">242,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:63.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.193%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56ccbb8636664d06a097e18deeca55d4_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjc3OTI4ODcyOTNhNTRlZWNiYzI1NTNjN2JjZGM1NDE3L3RhYmxlcmFuZ2U6Nzc5Mjg4NzI5M2E1NGVlY2JjMjU1M2M3YmNkYzU0MTdfMi0yLTEtMS0yNTk4OQ_2f865a1a-6b72-497c-9be9-32e872aa4619">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7023ba5f3b3416e833c03c3b04dfd39_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjc3OTI4ODcyOTNhNTRlZWNiYzI1NTNjN2JjZGM1NDE3L3RhYmxlcmFuZ2U6Nzc5Mjg4NzI5M2E1NGVlY2JjMjU1M2M3YmNkYzU0MTdfMi00LTEtMS0yNTk4OQ_c4e71f9f-472a-40cf-be75-fd53df8b7bc3">20,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjc3OTI4ODcyOTNhNTRlZWNiYzI1NTNjN2JjZGM1NDE3L3RhYmxlcmFuZ2U6Nzc5Mjg4NzI5M2E1NGVlY2JjMjU1M2M3YmNkYzU0MTdfMi02LTEtMS0yNTk4OQ_f497ef31-3da5-4b5e-9945-fa567c201080">20,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56ccbb8636664d06a097e18deeca55d4_I20211231" decimals="-3" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjc3OTI4ODcyOTNhNTRlZWNiYzI1NTNjN2JjZGM1NDE3L3RhYmxlcmFuZ2U6Nzc5Mjg4NzI5M2E1NGVlY2JjMjU1M2M3YmNkYzU0MTdfMy0yLTEtMS0yNTk4OQ_06ec52a3-4e62-412e-b5e2-443e9494aa9b">4,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7023ba5f3b3416e833c03c3b04dfd39_I20211231" decimals="-3" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjc3OTI4ODcyOTNhNTRlZWNiYzI1NTNjN2JjZGM1NDE3L3RhYmxlcmFuZ2U6Nzc5Mjg4NzI5M2E1NGVlY2JjMjU1M2M3YmNkYzU0MTdfMy00LTEtMS0yNTk4OQ_75092207-76af-4e46-99c5-29080b1abaa4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjc3OTI4ODcyOTNhNTRlZWNiYzI1NTNjN2JjZGM1NDE3L3RhYmxlcmFuZ2U6Nzc5Mjg4NzI5M2E1NGVlY2JjMjU1M2M3YmNkYzU0MTdfMy02LTEtMS0yNTk4OQ_5705136a-2f0a-4608-b0d7-47f58b9d54a5">4,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56ccbb8636664d06a097e18deeca55d4_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjc3OTI4ODcyOTNhNTRlZWNiYzI1NTNjN2JjZGM1NDE3L3RhYmxlcmFuZ2U6Nzc5Mjg4NzI5M2E1NGVlY2JjMjU1M2M3YmNkYzU0MTdfNC0yLTEtMS0yNTk4OQ_1e8523d5-0fb8-4e18-b903-9c3d7c930291">4,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7023ba5f3b3416e833c03c3b04dfd39_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjc3OTI4ODcyOTNhNTRlZWNiYzI1NTNjN2JjZGM1NDE3L3RhYmxlcmFuZ2U6Nzc5Mjg4NzI5M2E1NGVlY2JjMjU1M2M3YmNkYzU0MTdfNC00LTEtMS0yNTk4OQ_62d0f422-49cf-4614-a56f-ef50ef778b39">20,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjc3OTI4ODcyOTNhNTRlZWNiYzI1NTNjN2JjZGM1NDE3L3RhYmxlcmFuZ2U6Nzc5Mjg4NzI5M2E1NGVlY2JjMjU1M2M3YmNkYzU0MTdfNC02LTEtMS0yNTk4OQ_8cba3709-0718-4cdb-ab97-712a1b9a1727">25,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Senior Secured Term Loan due 2026 falls into the Level 2 category within the fair value level hierarchy and the fair value was determined using quoted prices for similar liabilities in active markets, as well as inputs that are observable for the liability (other than quoted prices), such as interest rates that are observable at commonly quoted intervals. The carrying value of the Senior Secured Term Loan due 2026 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximates the fair value.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any Level 3 assets as of June 30, 2022 or December 31, 2021.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Money Market Funds, and Marketable Securities</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its cash within the fair value hierarchy as Level&#160;1 as these assets are valued using quoted prices in an active market for identical assets at the measurement date. The Company considers its investments in marketable securities as available-for-sale and classifies these assets and the money market funds within the fair value hierarchy as Level&#160;2 primarily utilizing broker quotes in a non-active market for valuation of these securities. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Payable</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration payable resulted from the acquisition of Callidus Biopharma, Inc. ("Callidus") in November 2013. The most recent valuation was determined using a probability weighted discounted cash flow valuation approach. Gains and losses are included in the Consolidated Statements of Operations. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration payable for Callidus has been classified as a Level 3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market.&#160;If different assumptions </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6be66fab5ed44d9199ca9aa293e1c5f9"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were used for the various inputs to the valuation approach, the estimated fair value could be significantly higher or lower than the fair value the Company determined. </span></div><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RleHRyZWdpb246NDNkNjcxZTdjYjJhNDc5MGFjMWVjMjM3YTM0MTc0YjFfMzk3OQ_16940efb-704e-49d8-8a87-05ac954e453b" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB200 Pompe disease program: </span></div><div style="margin-bottom:15pt;margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.917%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent&#160;Consideration</span></div><div style="margin-bottom:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value as of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation&#160;Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable&#160;Input</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iccc9fcd06a114cdc9b7fd7bcc33f41ce_I20220630" decimals="3" name="fold:ContingentConsiderationMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjg5OGViNDQ4YTM2NDQyNTBhNDAyMzI5ZmZjNGQ0MzQzL3RhYmxlcmFuZ2U6ODk4ZWI0NDhhMzY0NDI1MGE0MDIzMjlmZmM0ZDQzNDNfMy04LTEtMS0yNTk4OQ_c098d61b-16d8-47a7-b861-bb4986c4a1e0">7.5</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical and regulatory milestones</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0df4cd98b90b48bbac276b1d955f92ae_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjg5OGViNDQ4YTM2NDQyNTBhNDAyMzI5ZmZjNGQ0MzQzL3RhYmxlcmFuZ2U6ODk4ZWI0NDhhMzY0NDI1MGE0MDIzMjlmZmM0ZDQzNDNfNS0yLTEtMS0yNTk4OQ_d8a6a9d2-61a8-4b8b-92c1-ce9893949def">19,266</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Probability weighted discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Probability of achievement of milestones</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b66abc5705c43f5b528d365e1c87cb4_I20220630" decimals="2" name="fold:ContingentConsiderationMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjg5OGViNDQ4YTM2NDQyNTBhNDAyMzI5ZmZjNGQ0MzQzL3RhYmxlcmFuZ2U6ODk4ZWI0NDhhMzY0NDI1MGE0MDIzMjlmZmM0ZDQzNDNfNS04LTEtMS0yNTk4OS90ZXh0cmVnaW9uOjNmYjI3ZDE2MTZjMDRkYWVhNDZjMDYzYjk4ZmJkMjQwXzQ_9e58bfe1-fd76-4e06-ab2c-8d7dde2c8958">75</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ieeee7b9e37734d74a6b642a88110192e_I20220630" decimals="2" name="fold:ContingentConsiderationMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjg5OGViNDQ4YTM2NDQyNTBhNDAyMzI5ZmZjNGQ0MzQzL3RhYmxlcmFuZ2U6ODk4ZWI0NDhhMzY0NDI1MGE0MDIzMjlmZmM0ZDQzNDNfNS04LTEtMS0yNTk4OS90ZXh0cmVnaW9uOjNmYjI3ZDE2MTZjMDRkYWVhNDZjMDYzYjk4ZmJkMjQwXzk_b27d4ca5-3b63-488f-bb63-d15c587f3807">88</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected year of payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022 - 2023</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration liabilities are remeasured to fair value each reporting period using discount rates, probabilities of payment, and projected payment dates. Projected contingent payment amounts related to clinical and regulatory based milestones are discounted back to the current period using a discounted cash flow model. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs together, or in isolation, may result in a significantly lower or higher fair value measurement. There is no assurance that any of the conditions for the milestone payments will be met. </span></div><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RleHRyZWdpb246NDNkNjcxZTdjYjJhNDc5MGFjMWVjMjM3YTM0MTc0YjFfMzk4Mg_44e46f4c-4a5f-408e-a764-fe876bd88ea3" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the change in the balance of contingent consideration payable for the three and six months ended June 30, 2022 and 2021, respectively:</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.702%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, beginning of the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90601765a2f2418a9abfd28bd624e1fb_I20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjVkYjAzYmI2NGQzOTRkZmM4OWVlMWU0MGYzOTRjNTIwL3RhYmxlcmFuZ2U6NWRiMDNiYjY0ZDM5NGRmYzg5ZWUxZTQwZjM5NGM1MjBfMi0yLTEtMS0yNTk4OQ_3f13aeda-4550-4ed7-95f3-f36c30e219f6">19,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib385a6b7137c45958b92a30dddce1f19_I20210331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjVkYjAzYmI2NGQzOTRkZmM4OWVlMWU0MGYzOTRjNTIwL3RhYmxlcmFuZ2U6NWRiMDNiYjY0ZDM5NGRmYzg5ZWUxZTQwZjM5NGM1MjBfMi00LTEtMS0yNTk4OQ_50639b28-29e6-4074-978d-e50b833f31dc">26,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjVkYjAzYmI2NGQzOTRkZmM4OWVlMWU0MGYzOTRjNTIwL3RhYmxlcmFuZ2U6NWRiMDNiYjY0ZDM5NGRmYzg5ZWUxZTQwZjM5NGM1MjBfMi02LTEtMS0yNjk5OQ_1375269a-7b7c-43f3-b7e6-23fa7b838062">20,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17008df080294bb0bf1240acd6c19c15_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjVkYjAzYmI2NGQzOTRkZmM4OWVlMWU0MGYzOTRjNTIwL3RhYmxlcmFuZ2U6NWRiMDNiYjY0ZDM5NGRmYzg5ZWUxZTQwZjM5NGM1MjBfMi04LTEtMS0yNjk4Mw_d1132cbd-3428-4b59-856c-e578c5fa7a36">25,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in fair value during the period, included in the Consolidated Statements of Operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjVkYjAzYmI2NGQzOTRkZmM4OWVlMWU0MGYzOTRjNTIwL3RhYmxlcmFuZ2U6NWRiMDNiYjY0ZDM5NGRmYzg5ZWUxZTQwZjM5NGM1MjBfMy0yLTEtMS0yNTk4OQ_c45977b6-79dd-4727-9da2-606a41bd5bec">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjVkYjAzYmI2NGQzOTRkZmM4OWVlMWU0MGYzOTRjNTIwL3RhYmxlcmFuZ2U6NWRiMDNiYjY0ZDM5NGRmYzg5ZWUxZTQwZjM5NGM1MjBfMy00LTEtMS0yNTk4OQ_fe4519b4-343f-44b2-a868-c9e17490c316">1,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjVkYjAzYmI2NGQzOTRkZmM4OWVlMWU0MGYzOTRjNTIwL3RhYmxlcmFuZ2U6NWRiMDNiYjY0ZDM5NGRmYzg5ZWUxZTQwZjM5NGM1MjBfMy02LTEtMS0yNjk5Mg_00695ea6-9d33-402a-90f9-b985b4f8c171">1,073</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjVkYjAzYmI2NGQzOTRkZmM4OWVlMWU0MGYzOTRjNTIwL3RhYmxlcmFuZ2U6NWRiMDNiYjY0ZDM5NGRmYzg5ZWUxZTQwZjM5NGM1MjBfMy04LTEtMS0yNjk5Mg_312fc02e-95e3-4aa3-82f4-ac10efd9a45e">1,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, end of the period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjVkYjAzYmI2NGQzOTRkZmM4OWVlMWU0MGYzOTRjNTIwL3RhYmxlcmFuZ2U6NWRiMDNiYjY0ZDM5NGRmYzg5ZWUxZTQwZjM5NGM1MjBfNC0yLTEtMS0yNTk4OQ_98ca15cd-bc11-466a-b8b2-44bfc2f7bd9f">19,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd0bea669974aef88283f7ce9684c7f_I20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjVkYjAzYmI2NGQzOTRkZmM4OWVlMWU0MGYzOTRjNTIwL3RhYmxlcmFuZ2U6NWRiMDNiYjY0ZDM5NGRmYzg5ZWUxZTQwZjM5NGM1MjBfNC00LTEtMS0yNTk4OQ_03df531d-7078-43f2-ad21-b79329112d33">27,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjVkYjAzYmI2NGQzOTRkZmM4OWVlMWU0MGYzOTRjNTIwL3RhYmxlcmFuZ2U6NWRiMDNiYjY0ZDM5NGRmYzg5ZWUxZTQwZjM5NGM1MjBfNC02LTEtMS0yNzc4MQ_e80484a4-c269-4051-adc7-44833f55302f">19,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd0bea669974aef88283f7ce9684c7f_I20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjVkYjAzYmI2NGQzOTRkZmM4OWVlMWU0MGYzOTRjNTIwL3RhYmxlcmFuZ2U6NWRiMDNiYjY0ZDM5NGRmYzg5ZWUxZTQwZjM5NGM1MjBfNC04LTEtMS0yNzc4MQ_eaf8fffb-5419-4042-8e2c-bb3090d59080">27,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> As certain milestones are expected to be reached within the next twelve months, the June 30, 2022 balance was recorded as a current liability in the Consolidated Balance Sheets.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;<ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RleHRyZWdpb246Nzk2ZmM1NTg2NDIzNGIwM2JhODU4NjY0YWJlZGE1NzJfODQz_c3b84a35-d6fc-42e4-ae22-dd81921c67ba" continuedAt="icfd2aa5a3bd04aa4b8feb7a6dabd57ee" escape="true">Basic and Diluted Net Loss per Common Share</ix:nonNumeric></span></div><ix:continuation id="icfd2aa5a3bd04aa4b8feb7a6dabd57ee"><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RleHRyZWdpb246Nzk2ZmM1NTg2NDIzNGIwM2JhODU4NjY0YWJlZGE1NzJfODQ1_fd29a9bc-6ece-44f6-a41f-f1637fb10bfd" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.254%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.254%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.254%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.259%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands,&#160;except&#160;per&#160;share amounts)&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOjRmNDg5M2Y4OGZmMjQ5Yjg4NzM4ZDc5OThlY2RkZjcxL3RhYmxlcmFuZ2U6NGY0ODkzZjg4ZmYyNDliODg3MzhkNzk5OGVjZGRmNzFfMy0yLTEtMS0yNTk4OQ_25ccc0b8-239d-44b9-937c-3d955d36af05">62,157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOjRmNDg5M2Y4OGZmMjQ5Yjg4NzM4ZDc5OThlY2RkZjcxL3RhYmxlcmFuZ2U6NGY0ODkzZjg4ZmYyNDliODg3MzhkNzk5OGVjZGRmNzFfMy00LTEtMS0yNTk4OQ_cf81e05a-95f3-48c0-b8e0-277f9780a4aa">51,225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOjRmNDg5M2Y4OGZmMjQ5Yjg4NzM4ZDc5OThlY2RkZjcxL3RhYmxlcmFuZ2U6NGY0ODkzZjg4ZmYyNDliODg3MzhkNzk5OGVjZGRmNzFfMy02LTEtMS0yNzAyMA_858103b3-3786-4aac-bcf8-5f0112721463">147,417</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOjRmNDg5M2Y4OGZmMjQ5Yjg4NzM4ZDc5OThlY2RkZjcxL3RhYmxlcmFuZ2U6NGY0ODkzZjg4ZmYyNDliODg3MzhkNzk5OGVjZGRmNzFfMy04LTEtMS0yNzAyMA_04679536-19fe-40e3-a7a4-c75ffdbedfde">116,889</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding&#160;&#8212; basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOjRmNDg5M2Y4OGZmMjQ5Yjg4NzM4ZDc5OThlY2RkZjcxL3RhYmxlcmFuZ2U6NGY0ODkzZjg4ZmYyNDliODg3MzhkNzk5OGVjZGRmNzFfNS0yLTEtMS0yNTk4OQ_88d3c53e-45ca-4e2b-9f77-afd8522b7690"><ix:nonFraction unitRef="shares" contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOjRmNDg5M2Y4OGZmMjQ5Yjg4NzM4ZDc5OThlY2RkZjcxL3RhYmxlcmFuZ2U6NGY0ODkzZjg4ZmYyNDliODg3MzhkNzk5OGVjZGRmNzFfNS0yLTEtMS0yNTk4OQ_bef5876d-6604-4dce-a90d-e6b1471806cd">291,970,562</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOjRmNDg5M2Y4OGZmMjQ5Yjg4NzM4ZDc5OThlY2RkZjcxL3RhYmxlcmFuZ2U6NGY0ODkzZjg4ZmYyNDliODg3MzhkNzk5OGVjZGRmNzFfNS00LTEtMS0yNTk4OQ_3e62dbce-ca5c-4251-b9fb-eeef5cc9339e"><ix:nonFraction unitRef="shares" contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOjRmNDg5M2Y4OGZmMjQ5Yjg4NzM4ZDc5OThlY2RkZjcxL3RhYmxlcmFuZ2U6NGY0ODkzZjg4ZmYyNDliODg3MzhkNzk5OGVjZGRmNzFfNS00LTEtMS0yNTk4OQ_c39e0e63-9b18-4595-882b-0d1f70c9e50b">266,398,516</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOjRmNDg5M2Y4OGZmMjQ5Yjg4NzM4ZDc5OThlY2RkZjcxL3RhYmxlcmFuZ2U6NGY0ODkzZjg4ZmYyNDliODg3MzhkNzk5OGVjZGRmNzFfNS02LTEtMS0yNzAzNg_069c0fe4-1a66-4123-b51b-716f4e82ef25"><ix:nonFraction unitRef="shares" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOjRmNDg5M2Y4OGZmMjQ5Yjg4NzM4ZDc5OThlY2RkZjcxL3RhYmxlcmFuZ2U6NGY0ODkzZjg4ZmYyNDliODg3MzhkNzk5OGVjZGRmNzFfNS02LTEtMS0yNzAzNg_a2fd724f-a4b4-4ac9-ab5b-2e4b94afc21f">288,646,587</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOjRmNDg5M2Y4OGZmMjQ5Yjg4NzM4ZDc5OThlY2RkZjcxL3RhYmxlcmFuZ2U6NGY0ODkzZjg4ZmYyNDliODg3MzhkNzk5OGVjZGRmNzFfNS04LTEtMS0yNzAzNg_bda1608a-9992-4315-add0-1b7ab1665e44"><ix:nonFraction unitRef="shares" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOjRmNDg5M2Y4OGZmMjQ5Yjg4NzM4ZDc5OThlY2RkZjcxL3RhYmxlcmFuZ2U6NGY0ODkzZjg4ZmYyNDliODg3MzhkNzk5OGVjZGRmNzFfNS04LTEtMS0yNzAzNg_e0e23150-fa16-431a-9c3f-04ab3127a85c">265,384,865</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive common stock equivalents would include the dilutive effect of common stock options, convertible debt units, RSUs, and warrants for common stock equivalents.&#160;Potentially dilutive common stock equivalents were excluded from the diluted earnings per share denominator for all periods because of their anti-dilutive effect. Weighted average common shares outstanding includes outstanding pre-funded warrants with an exercise price of $<ix:nonFraction unitRef="cadPerShare" contextRef="i62b5a7d4e59f4a0cb528290f1c8d251f_I20220630" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RleHRyZWdpb246Nzk2ZmM1NTg2NDIzNGIwM2JhODU4NjY0YWJlZGE1NzJfNjcx_85704aa8-8862-4346-bd50-45ec22911f85">0.01</ix:nonFraction>. </span></div><ix:nonNumeric contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RleHRyZWdpb246Nzk2ZmM1NTg2NDIzNGIwM2JhODU4NjY0YWJlZGE1NzJfODM1_b9bc3df5-5d06-4acb-ac5e-2903bf4cee9d" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia41bb3d6e6b341469638797bd696c267_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOmMxMDAyMGZmNGM5MjQxYzY5NzgyMTE2YmUxMmVlYTFkL3RhYmxlcmFuZ2U6YzEwMDIwZmY0YzkyNDFjNjk3ODIxMTZiZTEyZWVhMWRfMi0yLTEtMS0yNTk4OQ_6e1239ff-dfb4-4f2e-910d-3d9e617e851d">19,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3206f3ebb21741d5af011059960d7b2d_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOmMxMDAyMGZmNGM5MjQxYzY5NzgyMTE2YmUxMmVlYTFkL3RhYmxlcmFuZ2U6YzEwMDIwZmY0YzkyNDFjNjk3ODIxMTZiZTEyZWVhMWRfMi00LTEtMS0yNTk4OQ_eb61bc51-9d75-4d33-abd5-0f400718529b">14,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67808a739f5e477b8929ea199cdf1917_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOmMxMDAyMGZmNGM5MjQxYzY5NzgyMTE2YmUxMmVlYTFkL3RhYmxlcmFuZ2U6YzEwMDIwZmY0YzkyNDFjNjk3ODIxMTZiZTEyZWVhMWRfMy0yLTEtMS0yNTk4OQ_7cbae613-2210-4a7e-a0b8-f7155ffff982">10,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia9642de7b1214086a13a7ba1bbf1e23a_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOmMxMDAyMGZmNGM5MjQxYzY5NzgyMTE2YmUxMmVlYTFkL3RhYmxlcmFuZ2U6YzEwMDIwZmY0YzkyNDFjNjk3ODIxMTZiZTEyZWVhMWRfMy00LTEtMS0yNTk4OQ_8e119b05-6956-4868-ba40-e24dea409cbc">7,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6d84939f6a24c2dbbebe6fd3cbbd1ff_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOmMxMDAyMGZmNGM5MjQxYzY5NzgyMTE2YmUxMmVlYTFkL3RhYmxlcmFuZ2U6YzEwMDIwZmY0YzkyNDFjNjk3ODIxMTZiZTEyZWVhMWRfNC0yLTEtMS0yNTk4OQ_e58d7537-6c46-4b88-8b79-1316f6eb7090">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i391211c299184c4890fc3d8186f647fa_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOmMxMDAyMGZmNGM5MjQxYzY5NzgyMTE2YmUxMmVlYTFkL3RhYmxlcmFuZ2U6YzEwMDIwZmY0YzkyNDFjNjk3ODIxMTZiZTEyZWVhMWRfNC00LTEtMS0yNTk4OQ_2ef675f2-4371-4572-a392-3a539bb6eb2b">458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total number of potentially issuable shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOmMxMDAyMGZmNGM5MjQxYzY5NzgyMTE2YmUxMmVlYTFkL3RhYmxlcmFuZ2U6YzEwMDIwZmY0YzkyNDFjNjk3ODIxMTZiZTEyZWVhMWRfNS0yLTEtMS0yNTk4OQ_781b7695-4430-4839-9a2b-942bcbd4e8e0">29,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOmMxMDAyMGZmNGM5MjQxYzY5NzgyMTE2YmUxMmVlYTFkL3RhYmxlcmFuZ2U6YzEwMDIwZmY0YzkyNDFjNjk3ODIxMTZiZTEyZWVhMWRfNS00LTEtMS0yNTk4OQ_f3c0526c-e529-4cdd-9eb1-50ea778a325e">22,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion should be read in conjunction with the unaudited Consolidated Financial Statements and the notes thereto included in this Quarterly Report on Form 10-Q and the audited Consolidated Financial Statements and the notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. Some of the statements we make in this section are forward-looking statements within the meaning of the federal securities laws. For a complete discussion of forward-looking statements, see the section in this Quarterly Report on Form 10-Q entitled &#8220;Special Note Regarding Forward-Looking Statements&#8221;. Certain risk factors may cause actual results, performance or achievements to differ materially from those expressed or implied by the following discussion. For a discussion of such risk factors, see the section in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 entitled &#8220;Risk Factors&#8221;.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. We have a portfolio of product opportunities including the first, oral monotherapy for Fabry disease that has achieved widespread global approval and a differentiated biologic for Pompe disease that is under review with the U.S. Food and Drug Administration ("FDA") as well as the European Medicines Agency ("EMA"). We are committed to discovering and developing next generation therapies in Fabry and Pompe diseases.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cornerstone of our portfolio is Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (also referred to as "migalastat"), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants. Migalastat is currently approved under the trade name Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States ("U.S."), European Union ("E.U."), United Kingdom ("U.K."), and Japan, with multiple additional approvals granted and applications pending in several geographies around the world. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lead biologics program of our pipeline is Amicus Therapeutics GAA ("AT-GAA", also known as ATB200/AT2221, or cipaglucosidase alfa/miglustat), a novel, two-component, potential best-in-class treatment for Pompe disease. In February 2019, the FDA granted Breakthrough Therapy designation ("BTD") to AT-GAA for the treatment of late onset Pompe disease. In September 2021, the FDA set the Prescription Drug User Fee Act ("PDUFA") target action date of May 29, 2022 for the New Drug Application ("NDA") for miglustat and July 29, 2022 for the Biologics License Application ("BLA") for cipaglucosidase alfa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The EMA validated the Marketing Authorization Application (&#8220;MAA&#8221;) in the fourth quarter of 2021. On May 9, 2022, the FDA extended the review period for the NDA for miglustat and the BLA for cipaglucosidase alfa resulting in revised PDUFA action dates of August 29, 2022 and October 29, 2022, respectively. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy is to create, manufacture, test, and deliver the highest quality medicines for people living with rare diseases through internally developed, jointly developed, acquired, or in-licensed products and product candidates that have the potential to obsolete current treatments, provide significant benefits to patients, and be first- or best-in-class. We are leveraging our global capabilities to develop and broaden our lead franchises in Fabry and Pompe disease, with focused discovery work on next generation therapies and novel platform technologies.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have not been significantly impacted by the novel coronavirus (&#8220;COVID-19&#8221;) pandemic thus far. The Company continued to observe increased lag time between patient identification and Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> initiation due to the continued prevalence of COVID-19 and its ongoing impact on access to treatment for people living with Fabry disease in certain markets. We have maintained operations in all geographies, secured our global supply chain for our commercial and clinical products, as well as maintained the operational integrity of our clinical trials, with minimum disruptions. Our ability to continue to operate without any significant disruptions will depend on the continued health of our employees, the ongoing demand for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the continued operation of our global supply chain. We have continued to provide uninterrupted access to medicines for those in need of treatment, while prioritizing the health and safety of our global workforce. However, our results of operations in future periods may be negatively impacted by unknown future impacts from the COVID-19 pandemic.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Highlights of our progress include:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Commercial and regulatory success in Fabry disease.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For the six months ended June 30, 2022, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenue totaled $159.4 million, an increase of $15.6 million compared to the same period in the prior year. We continue to see strong commercial momentum and expansion into additional geographies. In countries where we have been operating the longest, we see an increasing proportion of previously untreated patients come onto Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the U.S., we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">continue to see a significant increase in patients from a growing and very wide prescriber base. Across all markets, we see a high rate of compliance and adherence to this oral treatment option.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Pompe disease clinical program milestones.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In February 2021, we reported topline results from the Phase 3 study of AT-GAA (ATB200-03, also known as "PROPEL"). In June 2021, the MHRA granted AT-GAA a positive scientific opinion through the Early Access to Medicines Scheme ("EAMS") which permits eligible adults living with late-onset Pompe disease ("LOPD") who have received alglucosidase alfa for at least 2 years to switch to AT-GAA prior to marketing authorization in the U.K. We completed the submission of the rolling BLA and NDA to the FDA, which was accepted for review in September 2021, and in the fourth quarter of 2021, the MAA was submitted and validated by the EMA. In March 2022, we announced positive long-term data from our ongoing phase 1/2 clinical study. Study participants treated with AT-GAA for up to 36 months demonstrated persistent and durable effects on six-minute walk test distance and measures of motor function and muscle strength, stability, or increase in forced vital capacity, and reductions in biomarkers of muscle damage and disease substrate. In June 2022, the French National Agency for the Medicines and Health Products Safety granted the first reimbursed access to AT-GAA under their compassionate access program.&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Pipeline advancement and growth.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are leveraging our global capabilities to develop and broaden our lead franchises in Fabry and Pompe disease, with focused discovery work on next generation therapies and novel platform technologies. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Manufacturing. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have managed our clinical and commercial supply chains during the COVID-19 pandemic such that as of the date hereof we have not experienced supply impacts. We have been able to continue to meet required commercial demand for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as supply our ongoing Pompe disease clinical studies and access programs including EAMS without interruption. We have secured supply for our continued needs for the Pompe disease program through a long-term supply agreement with Wuxi Biologics. The agreement allows for the continuous manufacture of our biologic to support future clinical needs and our anticipated commercial requirements should we garner regulatory approvals as planned. We have contracts in place to supply miglustat, our small molecule component of AT-GAA, to support both clinical and future commercial requirements.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Financial strength</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Total cash, cash equivalents, and marketable securities as of June 30, 2022 was $386.8 million. Based on the current operating model, we believe that the current cash position, which includes expected revenues, is sufficient to fund our operations and ongoing research programs to achieve self-sustainability. Potential impacts of the COVID-19 pandemic, business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact our future capital requirements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Commercial Product and Product Candidates</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(migalastat HCl) for Fabry Disease</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our oral precision medicine Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was granted accelerated approval by the FDA in August 2018 under the brand name Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene ("GLA") variant based on in vitro assay data. The FDA has approved Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for 350 amenable GLA variants. Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved in the E.U. and U.K. in May 2016 as a first-line therapy for long-term treatment of adults and adolescents, aged 16 years and older, with a confirmed diagnosis of Fabry disease and who have an amenable mutation (variant). The approved E.U. and U.K. labels include 1,384 mutations amenable to Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> treatment, which represent up to half of all patients with Fabry disease. In countries where mutations are provided only on the amenability website, these 1,384 amenable mutations are now available. Marketing authorization approvals have been granted in over 40 countries around the world, including the U.S., E.U., U.K., Japan, and others. In July 2021, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved in the E.U. for adolescents aged 12 years and older weighing 45 kg or more. We plan to continue to launch Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in additional countries during 2022, including for adolescents aged 12 years and older. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an orally administered monotherapy, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is designed to bind to and stabilize an endogenous alpha-galactosidase A ("alpha-Gal A") enzyme in those patients with genetic variants identified as amenable in a GLP cell-based amenability assay. Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral precision medicine intended to treat Fabry disease in patients who have amenable genetic variants, and at this time, it is not intended for concomitant use with ERT. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> U.S. patent portfolio encompasses 44 orange book listed patents, including 4 U.S. Composition of Matter patents, of which 27 provide protection through at least 2038.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Next Generation for Fabry Disease</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to continued innovation for all people living with Fabry disease. Our pipeline includes a Fabry gene therapy and an academic research collaboration agreement with the University of Seville to explore next generation pharmacological chaperones for Fabry disease. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novel ERT for Pompe Disease</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are leveraging our biologics capabilities to develop AT-GAA, a novel treatment paradigm for Pompe disease. AT-GAA consists of a uniquely engineered rhGAA enzyme, ATB200, or cipaglucosidase alfa, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with AT2221, or miglustat, that functions as an enzyme stabilizer. Miglustat binds to and stabilizes ATB200 preventing inactivation of rhGAA in circulation to improve the uptake of active enzyme in key disease-relevant tissues, resulting in increased clearance of accumulated substrate, ("glycogen"). Miglustat is not an active ingredient that contributes directly to glycogen reduction. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we reported topline results from the Phase 3 PROPEL study. Of the Pompe disease patients enrolled, 77% were being treated with alglucosidase alfa (n=95) immediately prior to enrollment (&#8220;Switch&#8221;) and 23% had never been treated with any ERT (n=28) (&#8220;Na&#239;ve&#8221;).  Nearly all patients from the PROPEL study continue to be treated with AT-GAA in the extension clinical study.  The clinical data from the PROPEL study, the extension study as well as the Phase 1/2 study were included in the AT-GAA submissions to the FDA and the EMA. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we announced positive long-term data from our ongoing phase 1/2 clinical study. Study participants treated with AT-GAA for up to 36 months demonstrated persistent and durable effects on six-minute walk test distance and measures of motor function and muscle strength, stability, or increase in forced vital capacity, and reductions in biomarkers of muscle damage and disease substrate.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are conducting ongoing clinical studies in pediatric patients for both LOPD and infantile-onset Pompe disease ("IOPD") populations. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Next Generation for Pompe Disease</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our long-term commitment to provide multiple solutions to address the significant unmet needs of the Pompe disease community, we are also continuing discovery for next-generation genetic medicines for Pompe disease. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CDKL5 Deficiency Disorder</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are researching a potential first-in-class genetic medicine for CDKL5 deficiency disorder consisting of a CDKL5 protein engineered for cross correction, delivered as either a protein replacement or as a gene therapy through our collaboration with Penn. We are collaborating with the LouLou Foundation to assess the natural history of the disease to identify endpoints for potential use in future studies.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Next Generation Programs</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a number of additional gene therapies in clinical and preclinical development, including potential gene therapies in multiple forms of Batten disease. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strategic Alliances and Arrangements</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to evaluate business development opportunities as appropriate to build stockholder value and provide us with access to the financial, technical, clinical, and commercial resources necessary to develop and market technologies or products with a focus on rare and orphan diseases. We are exploring potential collaborations, alliances, and other business development opportunities on a regular basis. These opportunities may include business combinations, partnerships, the strategic out-licensing of certain assets, or the acquisition of preclinical-stage, clinical-stage, or marketed products or platform technologies consistent with our strategic plan to develop and provide therapies to patients living with rare and orphan diseases.</span></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_64"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Results of Operations</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three Months Ended June 30, 2022 compared to June 30, 2021 </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides selected financial information for the Company:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:58.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,413&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of goods sold as a percentage of net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in fair value of contingent consideration payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,021&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(906)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (expense) income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,257)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(911)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,525)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62,157)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51,225)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,932)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Product Sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net product sales increased $3.3 million during the three months ended June 30, 2022 compared to the same period in the prior year. The increase was primarily due to continued growth in the U.S., Europe and Japan markets, partially offset by the $6.7 million unfavorable impact of foreign currency exchange.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our principal development programs and the out-of-pocket, third-party expenses incurred:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:68.048%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Projects</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Third party direct project expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:6.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (Fabry Disease)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AT-GAA (Pompe Disease)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gene therapy programs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-clinical and other programs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total third-party direct project expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,229&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,415&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other project costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Personnel costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other project costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,090&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,588&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total research and development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,319&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,003&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $15.3 million increase in research and development costs was primarily driven by the strategic prioritization of our gene therapy portfolio resulting in the non-recurring expense of a contractual obligation from which we will no longer receive further economic benefit. Additionally, personnel costs increased primarily due to share-based compensation. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General, and Administrative Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Selling, general, and administrative expense increased $11.1 million, primarily driven by the strategic prioritization of our gene therapy portfolio that resulted in the write-off of cloud computing costs and software licensing fees.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $7.0 million variance was primarily related to foreign exchange gains caused by local currency remeasurement of U.S. dollar balances.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Expense.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The income tax expense for the three months ended June 30, 2022 was $0.9 million. We are subject to income taxes in various jurisdictions. Our tax liabilities are largely dependent on the distribution of pre-tax earnings among the many jurisdictions in which we operate.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Six Months Ended June 30, 2022 compared to June 30, 2021 </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides selected financial information for the Company:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:58.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159,446&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,815&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,631&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of goods sold as a percentage of net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in fair value of contingent consideration payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,073)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on impairment of assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(426)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (expense) income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,404)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,142)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(262)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,966)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,720)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,107)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(147,417)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(116,889)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,528)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Product Sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net product sales increased $15.6 million during the six months ended June 30, 2022 compared to the same period in the prior year. The increase was primarily due to continued growth in the U.S., Europe and Japan markets, partially offset by the $9.9 million unfavorable impact of foreign currency exchange.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our principal development programs and the out-of-pocket, third-party expenses incurred:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:68.048%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Projects</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Third party direct project expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:6.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (Fabry Disease)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AT-GAA (Pompe Disease)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gene therapy programs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-clinical and other programs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total third-party direct project expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,612&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,640&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other project costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Personnel costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other project costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,224&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,480&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total research and development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159,836&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,120&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $32.7 million increase in research and development costs was primarily due to the strategic prioritization of our gene therapy portfolio resulting in the non-recurring expense of contractual obligations from which we will no longer receive further economic benefit, an increase in personnel costs primarily due to share-based compensation, an increase in the Pompe disease program associated with the timing of manufacturing costs, and an increase in clinical research costs in the Fabry disease program.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General, and Administrative Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Selling, general, and administrative expense increased $22.5 million, primarily driven by the strategic prioritization of our gene therapy portfolio that resulted in the write-off of cloud computing costs and software licensing fees and an increase in share-based compensation and marketing expenses.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on Impairment of Assets. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the strategic prioritization of our gene therapy portfolio, the Company performed an assessment of its assets and recognized a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.6 million loss on impairment of assets.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense).&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $12.1&#160;million variance was primarily related to foreign exchange gains caused by local currency remeasurement of U.S. dollar balances.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Expense.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The income tax expense for the six months ended June 30, 2022 was $4.7 million. We are subject to income taxes in various jurisdictions. Our tax liabilities are largely dependent on the distribution of pre-tax earnings among the many jurisdictions in which we operate.</span></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_67"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our significant research and development expenditures, as well as expenditures to build a commercial organization to support the launch of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we have not been profitable and have generated operating losses since we were incorporated in 2002. We have historically funded our operations through stock offerings, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues, debt issuance, collaborations, and other financing arrangements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow Discussion</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, we had cash, cash equivalents, and marketable securities of $386.8 million. We invest cash in excess of our immediate requirements in regard to liquidity and capital preservation in a variety of interest-bearing instruments, including obligations of U.S. government agencies and money market accounts. Wherever possible, we seek to minimize the potential effects of concentration and degrees of risk. Although we maintain cash balances with financial institutions in excess of insured limits, we do not anticipate any losses with respect to such cash balances. For more details on the cash, cash equivalents, and marketable securities, refer to "&#8212; Note 3.&#160;Cash, Cash Equivalents, Marketable Securities, and Restricted Cash," in our Notes to Consolidated Financial Statements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Used in Operating Activities</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operations for the six months ended June 30, 2022 was $74.2 million. The components of net cash used in operations included the net loss for the six months ended June 30, 2022 of $147.4 million offset by $43.1 million of stock compensation, $15.6 million of other non-cash adjustments, and a net increase in changes in operating assets and liabilities of $14.5 million.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in operating assets and liabilities were primarily due to an increase in accounts payable and accrued expenses of $22.7&#160;million associated with the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">strategic prioritization of our gene therapy portfolio resulting in the non-recurring expense of contractual obligations from which we will no longer receive further economic benefit</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and tax accruals, offset by payments of contract manufacturing, third party research and development services, and annual performance bonus. The net cash used in operations was also impacted by an increase in accounts receivable of $4.4&#160;million due to increased commercial sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operations for the six months ended June 30, 2021 was $108.3 million. The components of net cash used in operations included the net loss for the six months ended June 30, 2021 of $116.9 million and an overall decrease in cash from changes in operating assets and liabilities of $32.6 million, primarily related to the timing of contract manufacturing and research payments. This was partially offset by $32.1 million of stock compensation and $9.1 million of other non-cash adjustments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Provided by Investing Activities</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the six months ended June 30, 2022 was $84.5 million. Our investing activities have consisted primarily of purchases, sales, and maturities of investments and capital expenditures. Net cash provided by investing activities reflects $184.1 million for the sale and redemption of marketable securities, partially offset by</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$98.3 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the purchase of marketable securities and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.2 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for capital expenditures.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the six months ended June 30, 2021 was $112.3 million. Our investing activities have consisted primarily of purchases and sales and maturities of investments and capital expenditures. Net cash provided by investing activities reflects $258.8 million for the sale and redemption of marketable securities, partially offset by $145.3 million for the purchase of marketable securities and $1.2 million for capital expenditures.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash (Used in) Provided by Financing Activities</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities for the six months ended June 30, 2022 was $7.5 million. Net cash used in financing activities primarily reflects the purchase of vested restricted stock units of $9.3 million, partially offset by $1.9 million of proceeds from the exercise of stock options.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the six months ended June 30, 2021 was $11.1 million. Net cash provided by financing activities primarily reflects $19.2 million from the exercise of the remaining outstanding warrants and $6.7 million from the exercise of stock options, partially offset by $14.4 million from the purchase of vested restricted stock units.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur losses from operations for the foreseeable future primarily due to research and development expenses, including expenses related to conducting clinical trials.&#160;Our future capital requirements will depend on a number of factors, including:</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of our clinical trials of our drug candidates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing drug supply for our commercial, clinical and preclinical studies, including the cost of manufacturing Pompe Enzyme Replacement Therapy ("ERT" or "ATB200" or "cipaglucosidase alfa");</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the future results of preclinical research and subsequent clinical trials for pipeline candidates we may identify from time to time, including our ability to obtain regulatory approvals and commercialize these therapies and obtain market acceptance for such therapies;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing, and outcome of regulatory review of our product candidates, including AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any changes in regulatory standards relating to the review of our product candidates, including AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and development requirements of other product candidates that we pursue;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of commercialization activities, including product marketing, sales, and distribution;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the emergence of competing technologies and other adverse market developments;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully commercialize Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (also referred to as "migalastat HCl") and, if our regulatory applications are approved, AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manufacture or supply sufficient clinical or commercial products, including Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain reimbursement for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and, if our regulatory applications are approved, AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to satisfy post-marketing commitments or requirements for continued regulatory approval of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and, if approved and applicable, AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain market acceptance of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and, if our regulatory applications are approved, AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing, and prosecuting patent applications and maintaining, enforcing, and defending intellectual property-related claims, including Hatch-Waxman litigation;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of litigation that has been or may be brought against us or of litigation that we are pursuing or may pursue against others;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or invest in businesses, products, and technologies;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully integrate our acquired products and technologies into our business, or successfully divest or license existing products and technologies from our business, including the possibility that the expected benefits of the transactions will not be fully realized by us or may take longer to realize than expected;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish licensing agreements, collaborations, partnerships or other similar arrangements and to obtain milestone, royalty, or other payments from any such collaborators;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our business could be adversely impacted by the effects of the novel coronavirus ("COVID-19") outbreak, including due to actions by us, governments, our customers, our suppliers, or other third parties to control the spread of COVID-19, or by other health epidemics or pandemics;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with, and our ability to comply with, emerging environmental, social and governance standards;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to accurately forecast revenue, operating expenditures, or other metrics impacting profitability;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in foreign currency exchange rates; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting standards.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we continue to generate revenue from product sales, in the absence of additional funding, we expect our continuing operating losses to result in increases in our net cash used over the next several quarters and years. We may seek additional funding through public or private financings of debt or equity. Based on our current operating model, we believe that the current cash position, which includes expected revenues, is sufficient to fund our operations and ongoing research programs to achieve self-sustainability. Potential impacts of the COVID-19 pandemic, business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact our future capital requirements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Uncertainties Related to Potential Future Payments</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestone Payments / Royaltie</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">s</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Callidus - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Callidus in 2013, we agreed to pay up to an additional $35 million in connection with the achievement of certain clinical milestones and up to $80 million in connection with the achievement of certain regulatory approval milestones. As of June 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,  $20&#160;million and $68&#160;million remain outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively. Refer to &#8220;&#8212; Note 7. Assets and Liabilities Measured at Fair Value,&#8221; to the Consolidated Financial Statements. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Celenex - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Celenex in 2018, we agreed to pay up to an additional $10 million in connection with the achievement of certain development milestones, $220 million in connection with the achievement of certain regulatory approval milestones across multiple programs and up to $75 million in tiered sales milestone payments.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nationwide Children&#8217;s Hospital -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Celenex has an exclusive license agreement with Nationwide Children's Hospital ("Nationwide Children&#8217;s"). Under this license agreement, Nationwide Children&#8217;s is eligible to receive development and sales-based milestones of up to $7.8 million from us for each product.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">University of Pennsylvania -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under our collaboration agreement with the University of Pennsylvania ("Penn"), Penn is eligible to receive certain milestone, royalty, and discovery research payments with respect to licensed products for each indication. Milestone payments are payable following the achievement of certain development and commercial milestone events in each indication, up to an aggregate of $88.0 million per indication. Royalty payments are based on net sales of licensed products on a licensed product-by-licensed product and country-by-country basis. We provide $10.0 million each year during the five-year agreement to fund the discovery research program.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GlaxoSmithKline -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In July 2012, as amended in November 2013, we entered into an agreement with GlaxoSmithKline ("GSK"), pursuant to which we obtained global rights to develop and commercialize Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a monotherapy and in combination with ERT for Fabry disease (&#8220;Collaboration Agreement&#8221;). Under the terms of the Collaboration Agreement, GSK is eligible to receive post-approval and sales-based milestones up to $40 million, as well as tiered royalties in the mid-teens in eight major markets outside the U.S. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis of our financial condition and results of operations are based on our financial statements, which we have prepared in accordance with U.S.&#160;GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no significant changes during the six months ended June 30, 2022 to the items that we disclosed as our significant accounting policies and estimates described in "&#8212;Note 2. Summary of Significant Accounting Policies" to the Company's financial statements as contained in the Company's Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2021.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to "&#8212;Note 2. Summary of Significant Accounting Policies" in our Notes to Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our market risks, and the way we manage them, are summarized in Part II, Item 7A, "Quantitative and Qualitative Disclosures About Market Risk" of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. As of June 30, 2022, there have been no material changes to our market risks or to our management of such risks since December 31, 2021.</span></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_76"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the period covered by this Quarterly Report on Form&#160;10-Q, an evaluation of the effectiveness of our disclosure controls and procedures (pursuant to Rule&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934, as amended (the "Exchange Act") was carried out under the supervision of our Principal Executive Officer and Principal Financial Officer, with the participation of our management.&#160;Based on that evaluation, the Principal Executive Officer and the Principal Financial Officer concluded that, as of the end of such period, our disclosure controls and procedures are effective in recording, processing, summarizing and reporting, on a timely basis, information required to be disclosed by us in the reports that we file or submit under the Exchange Act and are effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal quarter covered by this report, there has been no change in our internal control over financial reporting (as defined in Rules&#160;13a-15(f)&#160;and 15d-15(f)&#160;under the Exchange Act) that occurred during the last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_79"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II. OTHER INFORMATION</span></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_82"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. LEGAL PROCEEDINGS</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings.</span></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_85"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;RISK FACTORS</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.</span></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_88"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides certain information with respect to purchase of our common stock during the three months ended June 30, 2022:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Price Paid per Share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Number (or Approximate Dollar Value) of Shares That May Yet Be Purchased Under the Plans or Programs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 1, 2022 through April 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 1, 2022 through May 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 1, 2022 through June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,812&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.15&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Represents shares of common stock withheld to satisfy taxes associated with the vesting of restricted stock units</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_94"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_97"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. OTHER INFORMATION</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="fold-06302022xex311.htm">Certification of Principal Executive Officer pursuant to Rules&#160;13a-14 and 15d-14 promulgated pursuant to the Securities Exchange Act of 1934, as amended</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="fold-06302022xex312.htm">Certification of Principal Financial Officer pursuant to Rules&#160;13a-14 and 15d-14 promulgated pursuant to the Securities Exchange Act of 1934, as amended</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="fold-06302022xex321.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted in Inline XBRL and included in Exhibit 101)</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic325ed1a45484718a7ea1ead2bcfd471_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMICUS THERAPEUTICS,&#160;INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 4, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Bradley L. Campbell</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bradley L. Campbell</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 4, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Daphne Quimi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daphne Quimi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Accounting Officer)</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>fold-06302022xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i95efbcad627b400b8811b1509ce4458b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION BY PRINCIPAL EXECUTIVE OFFICER</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Bradley L. Campbell, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">I have reviewed this quarterly report on Form&#160;10-Q of Amicus Therapeutics,&#160;Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 4, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Bradley L. Campbell</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bradley L. Campbell</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>fold-06302022xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i8471598762b64ac8bf11c855fcd02ece_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION BY PRINCIPAL FINANCIAL OFFICER</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Daphne Quimi, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">I have reviewed this quarterly report on Form&#160;10-Q of Amicus Therapeutics,&#160;Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 4, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daphne Quimi</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daphne Quimi</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>fold-06302022xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i9681b5d2f1634dafba00838ab302e8d9_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRINCIPAL FINANCIAL OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION&#160;1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Each of the undersigned hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, in his or her capacity as an officer of Amicus Therapeutics,&#160;Inc. (the &#8220;Company&#8221;), that, to his or her knowledge, the Quarterly Report of the Company on Form&#160;10-Q for the period ended June 30, 2022, fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of the Company. This written statement is being furnished to the Securities and Exchange Commission as an exhibit to such Form&#160;10-Q. A signed original of this statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.725%"><tr><td style="width:1.0%"></td><td style="width:46.663%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 4, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Bradley L. Campbell</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bradley L. Campbell</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 4, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daphne Quimi</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daphne Quimi</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>fold-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:3889360d-46b3-4f4f-a1c0-074f51e18b3e,g:d5204adc-c100-4730-97cf-6188f145481c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:fold="http://www.amicustherapeutics.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.amicustherapeutics.com/20220630">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fold-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fold-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fold-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fold-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.amicustherapeutics.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsUnaudited" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsUnaudited" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited">
        <link:definition>1003004 - Statement - Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLossUnaudited" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited">
        <link:definition>1004005 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinStockholdersEquityUnaudited" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited">
        <link:definition>1005006 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1006007 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://www.amicustherapeutics.com/role/DescriptionofBusiness">
        <link:definition>2101101 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessDetails" roleURI="http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails">
        <link:definition>2402401 - Disclosure - Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesandRestrictedCash" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash">
        <link:definition>2107103 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables">
        <link:definition>2308302 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails">
        <link:definition>2409403 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails">
        <link:definition>2410404 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1">
        <link:definition>2410404 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2">
        <link:definition>2410404 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>2411405 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash, Cash Equivalents, And Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.amicustherapeutics.com/role/Inventories">
        <link:definition>2112104 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.amicustherapeutics.com/role/InventoriesTables">
        <link:definition>2313303 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.amicustherapeutics.com/role/InventoriesDetails">
        <link:definition>2414406 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.amicustherapeutics.com/role/Debt">
        <link:definition>2115105 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.amicustherapeutics.com/role/DebtTables">
        <link:definition>2316304 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSummaryofLongTermDebtDetails" roleURI="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails">
        <link:definition>2417407 - Disclosure - Debt - Summary of Long Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtInterestExpenseDetails" roleURI="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails">
        <link:definition>2418408 - Disclosure - Debt - Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensation">
        <link:definition>2119106 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationTables">
        <link:definition>2320305 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationWeightedaverageAssumptionsDetails" roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails">
        <link:definition>2421409 - Disclosure - Share-Based Compensation - Weighted-average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationStockOptionActivityDetails" roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails">
        <link:definition>2422410 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationNarrativeDetails" roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails">
        <link:definition>2423411 - Disclosure - Share-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationRSUsandPBRSUsSummaryDetails" roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails">
        <link:definition>2424412 - Disclosure - Share-Based Compensation - RSUs and PBRSUs Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationExpenseSummaryDetails" roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails">
        <link:definition>2425413 - Disclosure - Share-Based Compensation - Expense Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandLiabilitiesMeasuredatFairValue" roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue">
        <link:definition>2126107 - Disclosure - Assets and Liabilities Measured at Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandLiabilitiesMeasuredatFairValueTables" roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables">
        <link:definition>2327306 - Disclosure - Assets and Liabilities Measured at Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails" roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails">
        <link:definition>2428414 - Disclosure - Assets and Liabilities Measured at Fair Value - Components by Hierarchy Level (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails" roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails">
        <link:definition>2429415 - Disclosure - Assets and Liabilities Measured at Fair Value - Significant Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandLiabilitiesMeasuredatFairValueContingentConsiderationRollForwardDetails" roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueContingentConsiderationRollForwardDetails">
        <link:definition>2430416 - Disclosure - Assets and Liabilities Measured at Fair Value - Contingent Consideration Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasicandDilutedNetLossperCommonShare" roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare">
        <link:definition>2131108 - Disclosure - Basic and Diluted Net Loss per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasicandDilutedNetLossperCommonShareTables" roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables">
        <link:definition>2332307 - Disclosure - Basic and Diluted Net Loss per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasicandDilutedNetLossperCommonShareDetails" roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails">
        <link:definition>2433417 - Disclosure - Basic and Diluted Net Loss per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_ContingentConsiderationMeasurementInput" abstract="false" name="ContingentConsiderationMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_ATB200PompeProgramMember" abstract="true" name="ATB200PompeProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_ForeignCurrencyRemeasurementGainLossBeforeTax" abstract="false" name="ForeignCurrencyRemeasurementGainLossBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_SeniorSecuredTermLoanDue2026Member" abstract="true" name="SeniorSecuredTermLoanDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_StockIssuedDuringPeriodValueWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_CallidusBiopharmaIncMember" abstract="true" name="CallidusBiopharmaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_MeasurementInputProbabilityOfMilestoneAchievementMember" abstract="true" name="MeasurementInputProbabilityOfMilestoneAchievementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_ProbabilityWeightedDiscountedCashFlowMember" abstract="true" name="ProbabilityWeightedDiscountedCashFlowMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" abstract="false" name="CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_MarketableSecuritiesMember" abstract="true" name="MarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_ShortTermCorporateDebtSecuritiesMember" abstract="true" name="ShortTermCorporateDebtSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" abstract="false" name="CashCashEquivalentsAndAvailableforsaleDebtSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" abstract="true" name="ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_AmortizationDeferredFinancingCosts" abstract="false" name="AmortizationDeferredFinancingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" abstract="false" name="IncreaseDecreaseInNoncurrentOperatingLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_AssetImpairmentChargesAndOtherAssetWriteOffs" abstract="false" name="AssetImpairmentChargesAndOtherAssetWriteOffs" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>fold-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:3889360d-46b3-4f4f-a1c0-074f51e18b3e,g:d5204adc-c100-4730-97cf-6188f145481c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="fold-20220630.xsd#ConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_61c3080c-cb9e-486f-9444-742662c73692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b97dc78d-2982-4d57-aef2-bebb6bb91707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_61c3080c-cb9e-486f-9444-742662c73692" xlink:to="loc_us-gaap_AccountsPayableCurrent_b97dc78d-2982-4d57-aef2-bebb6bb91707" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_cd693123-aef4-44e5-bbdf-aa17302377db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_61c3080c-cb9e-486f-9444-742662c73692" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_cd693123-aef4-44e5-bbdf-aa17302377db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_64c98be6-7611-490e-a0d3-3c52fb08697d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_61c3080c-cb9e-486f-9444-742662c73692" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_64c98be6-7611-490e-a0d3-3c52fb08697d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_376b3990-f2a1-48f7-94c9-c26ffc406794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_61c3080c-cb9e-486f-9444-742662c73692" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_376b3990-f2a1-48f7-94c9-c26ffc406794" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7ddbeaef-4ba7-4bce-a522-d42ac1f1367e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1c6af7cb-88e1-499b-8e64-12c50dca220d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7ddbeaef-4ba7-4bce-a522-d42ac1f1367e" xlink:to="loc_us-gaap_AssetsCurrent_1c6af7cb-88e1-499b-8e64-12c50dca220d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_336000ba-eeca-419d-ad61-326ce56ae4df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7ddbeaef-4ba7-4bce-a522-d42ac1f1367e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_336000ba-eeca-419d-ad61-326ce56ae4df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_82331b2f-4a43-4198-be9b-652a6086e063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7ddbeaef-4ba7-4bce-a522-d42ac1f1367e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_82331b2f-4a43-4198-be9b-652a6086e063" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_cebfc0d7-1927-403e-8bf9-4a134123b9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7ddbeaef-4ba7-4bce-a522-d42ac1f1367e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_cebfc0d7-1927-403e-8bf9-4a134123b9bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ba95314b-829c-4728-b357-3569fe82eda0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7ddbeaef-4ba7-4bce-a522-d42ac1f1367e" xlink:to="loc_us-gaap_Goodwill_ba95314b-829c-4728-b357-3569fe82eda0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e11f9fca-f19d-4fb3-b1de-987fea8a0f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7ddbeaef-4ba7-4bce-a522-d42ac1f1367e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e11f9fca-f19d-4fb3-b1de-987fea8a0f78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b0bc4ecf-f736-4d0c-b638-6773b261a072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3f79ad6a-2a13-4091-8d56-1781888b839d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b0bc4ecf-f736-4d0c-b638-6773b261a072" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3f79ad6a-2a13-4091-8d56-1781888b839d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_4998190e-ee95-46f5-8489-81d89399b435" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b0bc4ecf-f736-4d0c-b638-6773b261a072" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_4998190e-ee95-46f5-8489-81d89399b435" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_eaa52426-eb3f-4253-b9ec-1b13bfd631e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b0bc4ecf-f736-4d0c-b638-6773b261a072" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_eaa52426-eb3f-4253-b9ec-1b13bfd631e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_3d75d035-cdbf-4dbb-bbaa-3934ca38ff21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b0bc4ecf-f736-4d0c-b638-6773b261a072" xlink:to="loc_us-gaap_LongTermDebt_3d75d035-cdbf-4dbb-bbaa-3934ca38ff21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f18e362a-2502-4dac-84a2-d85931630e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b0bc4ecf-f736-4d0c-b638-6773b261a072" xlink:to="loc_us-gaap_LiabilitiesCurrent_f18e362a-2502-4dac-84a2-d85931630e8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_2a1b4800-2770-42ea-8501-69f615c2a0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b0bc4ecf-f736-4d0c-b638-6773b261a072" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_2a1b4800-2770-42ea-8501-69f615c2a0d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9aeb638a-7d2b-434c-8a8a-6d2d197fd7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_df4476b4-3ecb-4f24-954d-92ee4ed371e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9aeb638a-7d2b-434c-8a8a-6d2d197fd7d3" xlink:to="loc_us-gaap_CommonStockValue_df4476b4-3ecb-4f24-954d-92ee4ed371e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_d3698cdf-37c3-4cd0-a967-06f2f1e2d71e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9aeb638a-7d2b-434c-8a8a-6d2d197fd7d3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_d3698cdf-37c3-4cd0-a967-06f2f1e2d71e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_7759e9cb-90ca-42d2-b9ab-210ae5134bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9aeb638a-7d2b-434c-8a8a-6d2d197fd7d3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_7759e9cb-90ca-42d2-b9ab-210ae5134bc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_897ee830-7642-48da-a547-96138d3ea91a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9aeb638a-7d2b-434c-8a8a-6d2d197fd7d3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_897ee830-7642-48da-a547-96138d3ea91a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_d9df0096-83f3-4932-a0a4-9d804566ea6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9aeb638a-7d2b-434c-8a8a-6d2d197fd7d3" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_d9df0096-83f3-4932-a0a4-9d804566ea6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d85b4da2-a9e6-4cb9-8532-031429d64bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9aeb638a-7d2b-434c-8a8a-6d2d197fd7d3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d85b4da2-a9e6-4cb9-8532-031429d64bc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5230c191-1cc5-4d4f-9581-1eda9d494813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_44412256-2a8a-48c2-80f0-9c542d7ed3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5230c191-1cc5-4d4f-9581-1eda9d494813" xlink:to="loc_us-gaap_Liabilities_44412256-2a8a-48c2-80f0-9c542d7ed3c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f79ac921-35af-4919-80ca-3b21f0b9b33f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5230c191-1cc5-4d4f-9581-1eda9d494813" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f79ac921-35af-4919-80ca-3b21f0b9b33f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_213752fa-996f-4e98-8e19-681e3bf25055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5230c191-1cc5-4d4f-9581-1eda9d494813" xlink:to="loc_us-gaap_StockholdersEquity_213752fa-996f-4e98-8e19-681e3bf25055" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d8068a64-ea4c-401a-88a5-d92a35ef14cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8d0ce917-dfe0-4914-8ffa-34e05047d746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d8068a64-ea4c-401a-88a5-d92a35ef14cf" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8d0ce917-dfe0-4914-8ffa-34e05047d746" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_d5709cbd-733a-4f48-a99d-e72587277f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d8068a64-ea4c-401a-88a5-d92a35ef14cf" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_d5709cbd-733a-4f48-a99d-e72587277f1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ac53c997-c8ff-4941-b61d-cc7306a43a08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d8068a64-ea4c-401a-88a5-d92a35ef14cf" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ac53c997-c8ff-4941-b61d-cc7306a43a08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d69694bb-3c2b-4be0-a7d5-83190d811682" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d8068a64-ea4c-401a-88a5-d92a35ef14cf" xlink:to="loc_us-gaap_InventoryNet_d69694bb-3c2b-4be0-a7d5-83190d811682" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_00a24ed3-8036-4e41-a9ef-fa84880fb595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d8068a64-ea4c-401a-88a5-d92a35ef14cf" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_00a24ed3-8036-4e41-a9ef-fa84880fb595" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="fold-20220630.xsd#ConsolidatedStatementsofOperationsUnaudited"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ec684dc2-ac9d-4195-a70e-f6ec0e820c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2e7e9e47-7332-4ce8-ad52-243099d87d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ec684dc2-ac9d-4195-a70e-f6ec0e820c4e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2e7e9e47-7332-4ce8-ad52-243099d87d34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7bd4354e-4514-4d78-b777-a8e413a027fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ec684dc2-ac9d-4195-a70e-f6ec0e820c4e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7bd4354e-4514-4d78-b777-a8e413a027fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_d4997a57-44a2-4edd-92c0-139f2d59ea33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ec684dc2-ac9d-4195-a70e-f6ec0e820c4e" xlink:to="loc_us-gaap_AssetImpairmentCharges_d4997a57-44a2-4edd-92c0-139f2d59ea33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ea17d2c1-469f-4596-8e6c-c8b158a5cc86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ec684dc2-ac9d-4195-a70e-f6ec0e820c4e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ea17d2c1-469f-4596-8e6c-c8b158a5cc86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e22c3f94-a59d-42db-95d8-d59f31dc71cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ec684dc2-ac9d-4195-a70e-f6ec0e820c4e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e22c3f94-a59d-42db-95d8-d59f31dc71cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d90fe98b-61fc-425e-b35b-c566a0f4d8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d80b3fa-b932-4c79-a847-83c2e00dd02e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d90fe98b-61fc-425e-b35b-c566a0f4d8b6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d80b3fa-b932-4c79-a847-83c2e00dd02e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_fe3f4699-8815-43f3-a724-66eb9d5c72cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d90fe98b-61fc-425e-b35b-c566a0f4d8b6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_fe3f4699-8815-43f3-a724-66eb9d5c72cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_300a0605-ef22-47ee-a9d9-ff5804ac34e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bd5d16de-19d6-4304-82b5-911cb34a53c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_300a0605-ef22-47ee-a9d9-ff5804ac34e5" xlink:to="loc_us-gaap_OperatingIncomeLoss_bd5d16de-19d6-4304-82b5-911cb34a53c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_7e62a7e0-6809-41f6-8508-d43c02b494a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_300a0605-ef22-47ee-a9d9-ff5804ac34e5" xlink:to="loc_us-gaap_InterestExpense_7e62a7e0-6809-41f6-8508-d43c02b494a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_0bbb7283-6c78-4188-aace-2cfbdce92ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_300a0605-ef22-47ee-a9d9-ff5804ac34e5" xlink:to="loc_us-gaap_InvestmentIncomeInterest_0bbb7283-6c78-4188-aace-2cfbdce92ebe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9ebb45f4-7874-4dd7-890f-3a894e0d6864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_300a0605-ef22-47ee-a9d9-ff5804ac34e5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9ebb45f4-7874-4dd7-890f-3a894e0d6864" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_b4bbedef-1b8b-4010-935d-b18b53ec8b32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_373279bf-12d4-4d7b-9376-a8cbc1e9dfd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_b4bbedef-1b8b-4010-935d-b18b53ec8b32" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_373279bf-12d4-4d7b-9376-a8cbc1e9dfd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_df88554c-b743-4cdd-8285-5b256bb7291d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_b4bbedef-1b8b-4010-935d-b18b53ec8b32" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_df88554c-b743-4cdd-8285-5b256bb7291d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c58616c3-87e3-451a-908a-520585d7bcd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_6dedac44-df74-4e16-aae3-9e5bf9d577d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c58616c3-87e3-451a-908a-520585d7bcd8" xlink:to="loc_us-gaap_GrossProfit_6dedac44-df74-4e16-aae3-9e5bf9d577d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d9d62bd9-decd-4056-bdc9-ba8f8c886ead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c58616c3-87e3-451a-908a-520585d7bcd8" xlink:to="loc_us-gaap_OperatingExpenses_d9d62bd9-decd-4056-bdc9-ba8f8c886ead" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="fold-20220630.xsd#ConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_bc3b3e5b-c1ce-41f4-b15f-c3cc12b21290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dbb236e0-37c8-4c20-b4b1-f820d9a9d383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_bc3b3e5b-c1ce-41f4-b15f-c3cc12b21290" xlink:to="loc_us-gaap_NetIncomeLoss_dbb236e0-37c8-4c20-b4b1-f820d9a9d383" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e515ba48-3d65-4349-9e62-223bf9587398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_bc3b3e5b-c1ce-41f4-b15f-c3cc12b21290" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e515ba48-3d65-4349-9e62-223bf9587398" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ae75ab79-c981-451c-89c2-d8c7acebd4a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_9c028818-ee02-480d-aadf-fee5336bd95c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ae75ab79-c981-451c-89c2-d8c7acebd4a5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_9c028818-ee02-480d-aadf-fee5336bd95c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_0820ad1a-0494-4271-87f8-224c979b0745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ae75ab79-c981-451c-89c2-d8c7acebd4a5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_0820ad1a-0494-4271-87f8-224c979b0745" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="fold-20220630.xsd#ConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2eb57c18-85b8-4c62-95fd-5606c095e3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_faa27a17-bf7a-4fb1-83b4-067a293e8800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2eb57c18-85b8-4c62-95fd-5606c095e3d7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_faa27a17-bf7a-4fb1-83b4-067a293e8800" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_32abefcb-7804-4c61-adf5-5ed0717230ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2eb57c18-85b8-4c62-95fd-5606c095e3d7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_32abefcb-7804-4c61-adf5-5ed0717230ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7137a64e-292a-40d9-849d-856f6e67266d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2eb57c18-85b8-4c62-95fd-5606c095e3d7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7137a64e-292a-40d9-849d-856f6e67266d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_12fe8d19-6638-4ab1-abbf-265f23c1ec58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2eb57c18-85b8-4c62-95fd-5606c095e3d7" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_12fe8d19-6638-4ab1-abbf-265f23c1ec58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a3b1e51-14c7-4b75-8f2a-7df1be724f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_9765a1cf-73e3-439e-b971-1cddb9575109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a3b1e51-14c7-4b75-8f2a-7df1be724f6e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_9765a1cf-73e3-439e-b971-1cddb9575109" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0f31dbb1-79d7-40dc-9816-f26e538e118b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a3b1e51-14c7-4b75-8f2a-7df1be724f6e" xlink:to="loc_us-gaap_ProfitLoss_0f31dbb1-79d7-40dc-9816-f26e538e118b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_b5c245f8-0232-423e-8c1f-a1afe5a2c5da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a3b1e51-14c7-4b75-8f2a-7df1be724f6e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_b5c245f8-0232-423e-8c1f-a1afe5a2c5da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1d54b3ca-ef36-48bd-8029-6d2f70b7cf3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a3b1e51-14c7-4b75-8f2a-7df1be724f6e" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1d54b3ca-ef36-48bd-8029-6d2f70b7cf3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AssetImpairmentChargesAndOtherAssetWriteOffs_47867789-e593-42d2-b55d-283f37e708fd" xlink:href="fold-20220630.xsd#fold_AssetImpairmentChargesAndOtherAssetWriteOffs"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a3b1e51-14c7-4b75-8f2a-7df1be724f6e" xlink:to="loc_fold_AssetImpairmentChargesAndOtherAssetWriteOffs_47867789-e593-42d2-b55d-283f37e708fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_56bbc954-17b9-47cb-8021-18566221e332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a3b1e51-14c7-4b75-8f2a-7df1be724f6e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_56bbc954-17b9-47cb-8021-18566221e332" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_11c6782a-250f-4fc1-a5e3-5a0d76ea0ba0" xlink:href="fold-20220630.xsd#fold_ForeignCurrencyRemeasurementGainLossBeforeTax"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a3b1e51-14c7-4b75-8f2a-7df1be724f6e" xlink:to="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_11c6782a-250f-4fc1-a5e3-5a0d76ea0ba0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_8be362e3-0bbc-46a1-a743-72b129d1bce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a3b1e51-14c7-4b75-8f2a-7df1be724f6e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_8be362e3-0bbc-46a1-a743-72b129d1bce3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_a7fd9ba8-dbb6-42ae-8807-5961966ca092" xlink:href="fold-20220630.xsd#fold_IncreaseDecreaseInNoncurrentOperatingLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a3b1e51-14c7-4b75-8f2a-7df1be724f6e" xlink:to="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_a7fd9ba8-dbb6-42ae-8807-5961966ca092" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b0e4313b-b24f-4b28-a508-285a35f1aba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a3b1e51-14c7-4b75-8f2a-7df1be724f6e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b0e4313b-b24f-4b28-a508-285a35f1aba2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_2ff38973-1d0b-4858-b3c9-91fdc4b791e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a3b1e51-14c7-4b75-8f2a-7df1be724f6e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_2ff38973-1d0b-4858-b3c9-91fdc4b791e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6efc2879-065c-4a8f-95a5-9dbbf158eb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a3b1e51-14c7-4b75-8f2a-7df1be724f6e" xlink:to="loc_us-gaap_ShareBasedCompensation_6efc2879-065c-4a8f-95a5-9dbbf158eb4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4598c370-f0f0-46bb-aa0c-5528e3e0080c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_ad5107f8-8f76-440c-9857-a4b8edf96317" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4598c370-f0f0-46bb-aa0c-5528e3e0080c" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_ad5107f8-8f76-440c-9857-a4b8edf96317" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_93655d02-f3f4-410a-9e9e-b83fb132da14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4598c370-f0f0-46bb-aa0c-5528e3e0080c" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_93655d02-f3f4-410a-9e9e-b83fb132da14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c492a9bd-06e5-403c-88bc-febda850e5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4598c370-f0f0-46bb-aa0c-5528e3e0080c" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c492a9bd-06e5-403c-88bc-febda850e5fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_5243cdef-926f-4c4c-988d-0d5204250af4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4598c370-f0f0-46bb-aa0c-5528e3e0080c" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_5243cdef-926f-4c4c-988d-0d5204250af4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eea5d834-7d31-4c53-b962-1d1650a6785b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2188233c-921e-46e4-a190-a3605b61585c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eea5d834-7d31-4c53-b962-1d1650a6785b" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2188233c-921e-46e4-a190-a3605b61585c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ef0bb7ae-677b-4d36-872b-a5be43b33311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eea5d834-7d31-4c53-b962-1d1650a6785b" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ef0bb7ae-677b-4d36-872b-a5be43b33311" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1eab4ad4-617b-4f91-893a-eaf4ade3e39e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eea5d834-7d31-4c53-b962-1d1650a6785b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1eab4ad4-617b-4f91-893a-eaf4ade3e39e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_94cf830a-a04c-4187-9896-6c26a475ddb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_22584adb-a605-4b09-8a1a-419aba07ce3a" xlink:href="fold-20220630.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_94cf830a-a04c-4187-9896-6c26a475ddb3" xlink:to="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_22584adb-a605-4b09-8a1a-419aba07ce3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_e826c9cb-03c0-49e2-ac29-905c23022739" xlink:href="fold-20220630.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_94cf830a-a04c-4187-9896-6c26a475ddb3" xlink:to="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_e826c9cb-03c0-49e2-ac29-905c23022739" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_66a80e10-a5a1-4601-ba0e-a1403f7c5032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_94cf830a-a04c-4187-9896-6c26a475ddb3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_66a80e10-a5a1-4601-ba0e-a1403f7c5032" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_548ef43f-cef1-4e5f-93ea-4996882996c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4929112c-703a-4de4-9fd2-351080149812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_548ef43f-cef1-4e5f-93ea-4996882996c9" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4929112c-703a-4de4-9fd2-351080149812" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_ce4e94a7-3799-4e82-a101-e57cf00ea710" xlink:href="fold-20220630.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a2b1b353-f67a-453b-80be-544965fafe9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_ce4e94a7-3799-4e82-a101-e57cf00ea710" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a2b1b353-f67a-453b-80be-544965fafe9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c143891b-13bc-4957-8fe8-a55096627326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_ce4e94a7-3799-4e82-a101-e57cf00ea710" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c143891b-13bc-4957-8fe8-a55096627326" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_f5838ec0-2ccf-4b3f-9401-8de445af9f11" xlink:href="fold-20220630.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dfd67c68-cd2f-4b7e-86a1-72697c951fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_f5838ec0-2ccf-4b3f-9401-8de445af9f11" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dfd67c68-cd2f-4b7e-86a1-72697c951fe0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_49b8db9f-4eba-4c35-ad12-efe0321a79de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_f5838ec0-2ccf-4b3f-9401-8de445af9f11" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_49b8db9f-4eba-4c35-ad12-efe0321a79de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fcc76523-0e98-4db7-b1a8-85ec92f5c446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1744247c-b582-4be9-98c0-0f52b5be7d58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fcc76523-0e98-4db7-b1a8-85ec92f5c446" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1744247c-b582-4be9-98c0-0f52b5be7d58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3f187cad-eec3-47fd-b9d4-c62164ecf22f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fcc76523-0e98-4db7-b1a8-85ec92f5c446" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3f187cad-eec3-47fd-b9d4-c62164ecf22f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b4fc3759-5683-4d2b-ba34-2dcb34a81e75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fcc76523-0e98-4db7-b1a8-85ec92f5c446" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b4fc3759-5683-4d2b-ba34-2dcb34a81e75" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1" xlink:type="simple" xlink:href="fold-20220630.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_e6ff9864-2733-4db7-8397-b6cd83f1849a" xlink:href="fold-20220630.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1a203f95-d807-437c-82fe-ae4ba0ba87ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_e6ff9864-2733-4db7-8397-b6cd83f1849a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1a203f95-d807-437c-82fe-ae4ba0ba87ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_5becb4fb-6e48-444b-980b-46da1ca613a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_e6ff9864-2733-4db7-8397-b6cd83f1849a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_5becb4fb-6e48-444b-980b-46da1ca613a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_84f22ed4-05ba-4ed7-b121-7b793d9576b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_e6ff9864-2733-4db7-8397-b6cd83f1849a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_84f22ed4-05ba-4ed7-b121-7b793d9576b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_a019b386-3012-4c31-aa97-da120401040e" xlink:href="fold-20220630.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_9a3d0f27-579d-4dda-9946-d713db7544e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_a019b386-3012-4c31-aa97-da120401040e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_9a3d0f27-579d-4dda-9946-d713db7544e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3fe8f409-abd4-4abd-8a2f-461084623337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_a019b386-3012-4c31-aa97-da120401040e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3fe8f409-abd4-4abd-8a2f-461084623337" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8e0886a6-f725-4895-a794-33794995d7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_a019b386-3012-4c31-aa97-da120401040e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8e0886a6-f725-4895-a794-33794995d7e4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2" xlink:type="simple" xlink:href="fold-20220630.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_b18f5ceb-5baa-47fd-b963-c17717529c4d" xlink:href="fold-20220630.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b08bac5d-262d-4f58-8936-2e2f20712c89" xlink:href="fold-20220630.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_b18f5ceb-5baa-47fd-b963-c17717529c4d" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b08bac5d-262d-4f58-8936-2e2f20712c89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3a9455d4-061f-4b74-922e-5d5e9a5994e5" xlink:href="fold-20220630.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_b18f5ceb-5baa-47fd-b963-c17717529c4d" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3a9455d4-061f-4b74-922e-5d5e9a5994e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_0d71a81a-7cd5-4068-aa52-b644477d0791" xlink:href="fold-20220630.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_b18f5ceb-5baa-47fd-b963-c17717529c4d" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_0d71a81a-7cd5-4068-aa52-b644477d0791" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eb8df30c-af7f-4258-b2f5-cee0915bb11d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_89952963-00dc-4a0d-8771-cbd2b4f7cb76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eb8df30c-af7f-4258-b2f5-cee0915bb11d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_89952963-00dc-4a0d-8771-cbd2b4f7cb76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_54ffb5a6-b634-4702-90ab-6b8479799632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eb8df30c-af7f-4258-b2f5-cee0915bb11d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_54ffb5a6-b634-4702-90ab-6b8479799632" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/InventoriesDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_cf580fab-4943-4fa9-9f2c-6395f1b5f3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2964cf78-540c-402f-8011-db87625cf69b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_cf580fab-4943-4fa9-9f2c-6395f1b5f3eb" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2964cf78-540c-402f-8011-db87625cf69b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_38b23562-757c-4328-bbee-4525813611b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_cf580fab-4943-4fa9-9f2c-6395f1b5f3eb" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_38b23562-757c-4328-bbee-4525813611b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_85692f48-05c3-428d-a9f2-9c3dd4a6f434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_cf580fab-4943-4fa9-9f2c-6395f1b5f3eb" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_85692f48-05c3-428d-a9f2-9c3dd4a6f434" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#DebtSummaryofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c7b40890-f780-4080-889c-dce2c0178928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_dee5a736-a571-44c5-a9f2-abdf2dfdf2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_c7b40890-f780-4080-889c-dce2c0178928" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_dee5a736-a571-44c5-a9f2-abdf2dfdf2f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_96ae72ac-9966-4063-a16c-96b3b832d2be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_c7b40890-f780-4080-889c-dce2c0178928" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_96ae72ac-9966-4063-a16c-96b3b832d2be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_3321c804-7bfa-4144-9144-b3a83e30e617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_c7b40890-f780-4080-889c-dce2c0178928" xlink:to="loc_us-gaap_DeferredOfferingCosts_3321c804-7bfa-4144-9144-b3a83e30e617" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_ea84707a-60b7-4d7b-acd1-5c3e69ed8fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6c4b61c0-c413-431d-8168-dcba54d35b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_ea84707a-60b7-4d7b-acd1-5c3e69ed8fd4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6c4b61c0-c413-431d-8168-dcba54d35b3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_63b98663-d0bb-410a-a4b9-9e4769006bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_ea84707a-60b7-4d7b-acd1-5c3e69ed8fd4" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_63b98663-d0bb-410a-a4b9-9e4769006bfa" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>fold-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:3889360d-46b3-4f4f-a1c0-074f51e18b3e,g:d5204adc-c100-4730-97cf-6188f145481c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited" xlink:type="simple" xlink:href="fold-20220630.xsd#ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited" xlink:type="extended" id="if8ccf810b7e948488bc506eb611a0146_ConsolidatedStatementsofChangesinStockholdersEquityUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_cc947fb9-ae9c-4b6f-b425-890e62923fff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cc947fb9-ae9c-4b6f-b425-890e62923fff" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_573b9c9d-bbff-49ff-b9e1-0b316ce2b1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_573b9c9d-bbff-49ff-b9e1-0b316ce2b1bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d8ef37ce-15bc-412e-aff1-457ebb39fbc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:to="loc_us-gaap_StockholdersEquity_d8ef37ce-15bc-412e-aff1-457ebb39fbc9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1fe86b3a-bf51-4337-8739-1c9287841854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1fe86b3a-bf51-4337-8739-1c9287841854" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7e14726c-4267-4e7b-8a7a-b77b0c8faacb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7e14726c-4267-4e7b-8a7a-b77b0c8faacb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_26b8c904-8cb5-4e5f-8be5-fc64c3d5b670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_26b8c904-8cb5-4e5f-8be5-fc64c3d5b670" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_463fed5a-3ff2-4810-808c-df4961edda0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_463fed5a-3ff2-4810-808c-df4961edda0a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7e9ce906-bc42-4351-bded-f0097767b4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7e9ce906-bc42-4351-bded-f0097767b4aa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_b737a59b-869c-4065-88b8-1e34243ac31f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_b737a59b-869c-4065-88b8-1e34243ac31f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_83413c6a-04a5-4b77-a068-c7801c258cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_83413c6a-04a5-4b77-a068-c7801c258cf6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9a1f75d9-5845-4a7e-914a-0bb92cce4b69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:to="loc_us-gaap_NetIncomeLoss_9a1f75d9-5845-4a7e-914a-0bb92cce4b69" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised_a280b7ea-1219-4100-a508-c5116326e979" xlink:href="fold-20220630.xsd#fold_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:to="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised_a280b7ea-1219-4100-a508-c5116326e979" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised_a5d5f454-8cd6-41d0-add7-06d63ad87559" xlink:href="fold-20220630.xsd#fold_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:to="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised_a5d5f454-8cd6-41d0-add7-06d63ad87559" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_038c035a-5ac3-461c-b978-52cc1b7917bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_038c035a-5ac3-461c-b978-52cc1b7917bc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_7f3d1d7a-f0f9-4bd3-a21b-11ed1384655e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_7f3d1d7a-f0f9-4bd3-a21b-11ed1384655e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4c3b3e4a-9395-4681-8a7c-ddd75de3a6db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_02f34002-f019-477a-8231-02890cfee089" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_783310eb-58c3-4250-af78-8f63a70f8f81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_cc947fb9-ae9c-4b6f-b425-890e62923fff" xlink:to="loc_us-gaap_StatementTable_783310eb-58c3-4250-af78-8f63a70f8f81" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7fccab92-e79b-434d-8aea-570c8ec0593c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_783310eb-58c3-4250-af78-8f63a70f8f81" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7fccab92-e79b-434d-8aea-570c8ec0593c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7fccab92-e79b-434d-8aea-570c8ec0593c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7fccab92-e79b-434d-8aea-570c8ec0593c" xlink:to="loc_us-gaap_EquityComponentDomain_7fccab92-e79b-434d-8aea-570c8ec0593c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e8d0decd-0c6c-436c-9d46-f9f0def39e41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7fccab92-e79b-434d-8aea-570c8ec0593c" xlink:to="loc_us-gaap_EquityComponentDomain_e8d0decd-0c6c-436c-9d46-f9f0def39e41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_276f2b7b-1b78-4e38-b366-2b7118aaecb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e8d0decd-0c6c-436c-9d46-f9f0def39e41" xlink:to="loc_us-gaap_CommonStockMember_276f2b7b-1b78-4e38-b366-2b7118aaecb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_cff3a437-c6be-493f-b765-b58ab3a74bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e8d0decd-0c6c-436c-9d46-f9f0def39e41" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_cff3a437-c6be-493f-b765-b58ab3a74bd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_ed8983cc-f34e-4652-bc36-f37706114ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e8d0decd-0c6c-436c-9d46-f9f0def39e41" xlink:to="loc_us-gaap_WarrantMember_ed8983cc-f34e-4652-bc36-f37706114ad2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeMember_f5236a4f-970b-4a25-9759-e211da520033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e8d0decd-0c6c-436c-9d46-f9f0def39e41" xlink:to="loc_us-gaap_ComprehensiveIncomeMember_f5236a4f-970b-4a25-9759-e211da520033" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_197c56bd-c878-4c4e-b9b7-207cd1577656" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e8d0decd-0c6c-436c-9d46-f9f0def39e41" xlink:to="loc_us-gaap_RetainedEarningsMember_197c56bd-c878-4c4e-b9b7-207cd1577656" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="i81a3ca2403e747b59aaeff7c06d20779_SummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5eafd15d-ae74-4999-8d52-8ab8839592dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_3e56d62f-91f4-413c-b22a-ee1b29068384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5eafd15d-ae74-4999-8d52-8ab8839592dc" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_3e56d62f-91f4-413c-b22a-ee1b29068384" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4c0dd725-42a4-41eb-85e2-fc2c86f06517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5eafd15d-ae74-4999-8d52-8ab8839592dc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4c0dd725-42a4-41eb-85e2-fc2c86f06517" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_0c1f3773-5d44-429d-b1b7-257400c42c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5eafd15d-ae74-4999-8d52-8ab8839592dc" xlink:to="loc_us-gaap_AssetImpairmentCharges_0c1f3773-5d44-429d-b1b7-257400c42c89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_60c43ca3-7c11-439a-9dc6-c87bcecbf088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5eafd15d-ae74-4999-8d52-8ab8839592dc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_60c43ca3-7c11-439a-9dc6-c87bcecbf088" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_7d46edef-cebb-4f60-bc31-ac9c3f78452e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5eafd15d-ae74-4999-8d52-8ab8839592dc" xlink:to="loc_us-gaap_ContractualObligation_7d46edef-cebb-4f60-bc31-ac9c3f78452e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_2fbdf08f-1423-440d-85ac-8467527af8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5eafd15d-ae74-4999-8d52-8ab8839592dc" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_2fbdf08f-1423-440d-85ac-8467527af8b9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ae7144c0-3626-4864-9ee2-fdbe25035592" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_2fbdf08f-1423-440d-85ac-8467527af8b9" xlink:to="loc_srt_StatementGeographicalAxis_ae7144c0-3626-4864-9ee2-fdbe25035592" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ae7144c0-3626-4864-9ee2-fdbe25035592_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_ae7144c0-3626-4864-9ee2-fdbe25035592" xlink:to="loc_srt_SegmentGeographicalDomain_ae7144c0-3626-4864-9ee2-fdbe25035592_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f2e3c8da-2abd-4fc7-99cb-628e8201d20d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_ae7144c0-3626-4864-9ee2-fdbe25035592" xlink:to="loc_srt_SegmentGeographicalDomain_f2e3c8da-2abd-4fc7-99cb-628e8201d20d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_fe396eef-1028-401a-b168-557678e94840" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f2e3c8da-2abd-4fc7-99cb-628e8201d20d" xlink:to="loc_country_US_fe396eef-1028-401a-b168-557678e94840" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_ca6787d8-f460-4b04-a35f-ef6d7343b4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f2e3c8da-2abd-4fc7-99cb-628e8201d20d" xlink:to="loc_us-gaap_NonUsMember_ca6787d8-f460-4b04-a35f-ef6d7343b4d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dd4671ad-33f0-4c1f-96db-173fd836ea85" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_2fbdf08f-1423-440d-85ac-8467527af8b9" xlink:to="loc_srt_RangeAxis_dd4671ad-33f0-4c1f-96db-173fd836ea85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dd4671ad-33f0-4c1f-96db-173fd836ea85_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_dd4671ad-33f0-4c1f-96db-173fd836ea85" xlink:to="loc_srt_RangeMember_dd4671ad-33f0-4c1f-96db-173fd836ea85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6bd78a96-e0bf-4a64-92b4-3850719e9f8c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_dd4671ad-33f0-4c1f-96db-173fd836ea85" xlink:to="loc_srt_RangeMember_6bd78a96-e0bf-4a64-92b4-3850719e9f8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_381d21ef-5d43-46b1-91c5-3c932839f65f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6bd78a96-e0bf-4a64-92b4-3850719e9f8c" xlink:to="loc_srt_MinimumMember_381d21ef-5d43-46b1-91c5-3c932839f65f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_106b68c4-8fec-4eca-87bd-1d9a8142e1a5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6bd78a96-e0bf-4a64-92b4-3850719e9f8c" xlink:to="loc_srt_MaximumMember_106b68c4-8fec-4eca-87bd-1d9a8142e1a5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails" xlink:type="extended" id="i1af27cc3189748bf979ba5b27e793092_CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3a0112dc-b6b7-42c2-809d-0fc73c6009b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_146159d7-7ded-454c-afd4-908d4f5c5e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3a0112dc-b6b7-42c2-809d-0fc73c6009b2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_146159d7-7ded-454c-afd4-908d4f5c5e45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_250bbc97-c95a-4a3a-8953-1071f13d3a93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3a0112dc-b6b7-42c2-809d-0fc73c6009b2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_250bbc97-c95a-4a3a-8953-1071f13d3a93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesRealizedGainLoss_52406603-4ae9-49a5-be2d-66882f1815aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3a0112dc-b6b7-42c2-809d-0fc73c6009b2" xlink:to="loc_us-gaap_DebtSecuritiesRealizedGainLoss_52406603-4ae9-49a5-be2d-66882f1815aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_5d7f7bea-3734-432a-b7f9-74e38f5a7607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3a0112dc-b6b7-42c2-809d-0fc73c6009b2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_5d7f7bea-3734-432a-b7f9-74e38f5a7607" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_78c4a9dc-2ab9-49ab-8d3a-b613934e83be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3a0112dc-b6b7-42c2-809d-0fc73c6009b2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_78c4a9dc-2ab9-49ab-8d3a-b613934e83be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_156ac635-432f-47c7-b8b3-0f2aa9c7efa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_78c4a9dc-2ab9-49ab-8d3a-b613934e83be" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_156ac635-432f-47c7-b8b3-0f2aa9c7efa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_156ac635-432f-47c7-b8b3-0f2aa9c7efa8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_156ac635-432f-47c7-b8b3-0f2aa9c7efa8" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_156ac635-432f-47c7-b8b3-0f2aa9c7efa8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8294bd5d-79e7-4119-bf80-199433c6e906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_156ac635-432f-47c7-b8b3-0f2aa9c7efa8" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8294bd5d-79e7-4119-bf80-199433c6e906" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_MarketableSecuritiesMember_bfc61fb2-a0fe-41df-b34c-1810757e1314" xlink:href="fold-20220630.xsd#fold_MarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8294bd5d-79e7-4119-bf80-199433c6e906" xlink:to="loc_fold_MarketableSecuritiesMember_bfc61fb2-a0fe-41df-b34c-1810757e1314" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails" xlink:type="extended" id="i87dceb7af51d469eb26f9847f1075fae_CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43dba368-2ff6-4c6f-b175-5bb320ecff44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_43ade129-d2d8-4246-9ad3-5c05f8c6bdea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43dba368-2ff6-4c6f-b175-5bb320ecff44" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_43ade129-d2d8-4246-9ad3-5c05f8c6bdea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_481ac7c4-942c-4865-835d-b034c46173b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43dba368-2ff6-4c6f-b175-5bb320ecff44" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_481ac7c4-942c-4865-835d-b034c46173b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_e5587bfe-7932-4289-b666-165c3c6c78b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43dba368-2ff6-4c6f-b175-5bb320ecff44" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_e5587bfe-7932-4289-b666-165c3c6c78b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_89165249-b2b5-49a1-9a52-1369dd072bfa" xlink:href="fold-20220630.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43dba368-2ff6-4c6f-b175-5bb320ecff44" xlink:to="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_89165249-b2b5-49a1-9a52-1369dd072bfa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_dcc14eea-b6e5-49bb-abcb-63f49387c5cd" xlink:href="fold-20220630.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43dba368-2ff6-4c6f-b175-5bb320ecff44" xlink:to="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_dcc14eea-b6e5-49bb-abcb-63f49387c5cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_740d3318-a155-409a-bafc-b83a8bbd209a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43dba368-2ff6-4c6f-b175-5bb320ecff44" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_740d3318-a155-409a-bafc-b83a8bbd209a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b42c0d51-c503-4e8a-ae66-91a625dfe773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43dba368-2ff6-4c6f-b175-5bb320ecff44" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b42c0d51-c503-4e8a-ae66-91a625dfe773" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_343d7c0d-8ca6-4a48-a278-df4ab429b276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43dba368-2ff6-4c6f-b175-5bb320ecff44" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_343d7c0d-8ca6-4a48-a278-df4ab429b276" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7dc4f2b5-3e28-47fb-bcfb-367cbb9f334a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43dba368-2ff6-4c6f-b175-5bb320ecff44" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7dc4f2b5-3e28-47fb-bcfb-367cbb9f334a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0b7cb83c-3135-4444-9ead-af1b923279bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43dba368-2ff6-4c6f-b175-5bb320ecff44" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0b7cb83c-3135-4444-9ead-af1b923279bc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_28dc163a-5fd7-46bd-a1fd-c6cb1ed40f52" xlink:href="fold-20220630.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43dba368-2ff6-4c6f-b175-5bb320ecff44" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_28dc163a-5fd7-46bd-a1fd-c6cb1ed40f52" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2de8e603-311b-464f-b293-6f3ea6f8f569" xlink:href="fold-20220630.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43dba368-2ff6-4c6f-b175-5bb320ecff44" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2de8e603-311b-464f-b293-6f3ea6f8f569" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6c6a8894-df58-414e-bd9e-7a24944209a5" xlink:href="fold-20220630.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43dba368-2ff6-4c6f-b175-5bb320ecff44" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6c6a8894-df58-414e-bd9e-7a24944209a5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_620c4521-73cb-44c8-a195-58a8fad7f835" xlink:href="fold-20220630.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43dba368-2ff6-4c6f-b175-5bb320ecff44" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_620c4521-73cb-44c8-a195-58a8fad7f835" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c3e4e3d8-d289-4155-a1e7-085333f2b8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43dba368-2ff6-4c6f-b175-5bb320ecff44" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c3e4e3d8-d289-4155-a1e7-085333f2b8b1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a198dad5-6c64-4fb1-9eeb-9b43f8472ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c3e4e3d8-d289-4155-a1e7-085333f2b8b1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a198dad5-6c64-4fb1-9eeb-9b43f8472ffa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a198dad5-6c64-4fb1-9eeb-9b43f8472ffa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a198dad5-6c64-4fb1-9eeb-9b43f8472ffa" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a198dad5-6c64-4fb1-9eeb-9b43f8472ffa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_70986e8e-bba6-4227-b12e-8231f6b6ce1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a198dad5-6c64-4fb1-9eeb-9b43f8472ffa" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_70986e8e-bba6-4227-b12e-8231f6b6ce1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_91a7a176-7ceb-4859-8d88-217a78924f57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_70986e8e-bba6-4227-b12e-8231f6b6ce1a" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_91a7a176-7ceb-4859-8d88-217a78924f57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_b2b6dadd-d587-4e05-b3da-fe4e000a450a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_70986e8e-bba6-4227-b12e-8231f6b6ce1a" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_b2b6dadd-d587-4e05-b3da-fe4e000a450a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_2ae1cfcb-99de-4010-ae17-09d2f5642768" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_70986e8e-bba6-4227-b12e-8231f6b6ce1a" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_2ae1cfcb-99de-4010-ae17-09d2f5642768" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2aff0e39-022c-45f9-bbd9-b815842da5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_70986e8e-bba6-4227-b12e-8231f6b6ce1a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2aff0e39-022c-45f9-bbd9-b815842da5d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShortTermCorporateDebtSecuritiesMember_9630f234-82f6-4fa7-9e51-3ae81a079b31" xlink:href="fold-20220630.xsd#fold_ShortTermCorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_70986e8e-bba6-4227-b12e-8231f6b6ce1a" xlink:to="loc_fold_ShortTermCorporateDebtSecuritiesMember_9630f234-82f6-4fa7-9e51-3ae81a079b31" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_e0deb64c-a79e-41f8-b86e-c1cbb1626697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_70986e8e-bba6-4227-b12e-8231f6b6ce1a" xlink:to="loc_us-gaap_CertificatesOfDepositMember_e0deb64c-a79e-41f8-b86e-c1cbb1626697" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#DebtSummaryofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="extended" id="i38d126a67db249acb5e9a96093263bb4_DebtSummaryofLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f2bc6b60-888a-4277-8dea-a97058bf3c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_6bbaba00-d844-4320-a5fa-652e5fe3719d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2bc6b60-888a-4277-8dea-a97058bf3c3a" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_6bbaba00-d844-4320-a5fa-652e5fe3719d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_2533a7cc-32c9-4d8f-9cf8-409521cb2345" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2bc6b60-888a-4277-8dea-a97058bf3c3a" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_2533a7cc-32c9-4d8f-9cf8-409521cb2345" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_88aa710c-c6d8-4a42-a8a2-cf553b137314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2bc6b60-888a-4277-8dea-a97058bf3c3a" xlink:to="loc_us-gaap_DeferredOfferingCosts_88aa710c-c6d8-4a42-a8a2-cf553b137314" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_429bf338-a564-4a76-a155-914244753289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2bc6b60-888a-4277-8dea-a97058bf3c3a" xlink:to="loc_us-gaap_LongTermDebt_429bf338-a564-4a76-a155-914244753289" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1ad7f8f8-0c3e-4c48-81bc-43d554ebf1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2bc6b60-888a-4277-8dea-a97058bf3c3a" xlink:to="loc_us-gaap_DebtInstrumentTable_1ad7f8f8-0c3e-4c48-81bc-43d554ebf1f6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c430ef17-3f8c-4bf4-9fba-16eb2c9a97e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1ad7f8f8-0c3e-4c48-81bc-43d554ebf1f6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c430ef17-3f8c-4bf4-9fba-16eb2c9a97e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c430ef17-3f8c-4bf4-9fba-16eb2c9a97e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c430ef17-3f8c-4bf4-9fba-16eb2c9a97e6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c430ef17-3f8c-4bf4-9fba-16eb2c9a97e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e19d599c-1b8e-4090-9d3e-3ac845f7045b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c430ef17-3f8c-4bf4-9fba-16eb2c9a97e6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e19d599c-1b8e-4090-9d3e-3ac845f7045b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLoansMember_654d35c8-b6ce-4b5c-a682-756906704bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e19d599c-1b8e-4090-9d3e-3ac845f7045b" xlink:to="loc_us-gaap_SeniorLoansMember_654d35c8-b6ce-4b5c-a682-756906704bd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6719ad5c-6d8a-4d69-9cd4-319946cc365f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1ad7f8f8-0c3e-4c48-81bc-43d554ebf1f6" xlink:to="loc_us-gaap_DebtInstrumentAxis_6719ad5c-6d8a-4d69-9cd4-319946cc365f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6719ad5c-6d8a-4d69-9cd4-319946cc365f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_6719ad5c-6d8a-4d69-9cd4-319946cc365f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6719ad5c-6d8a-4d69-9cd4-319946cc365f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_dc555a2f-5564-4ec0-8dad-e2fe0be5b9c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_6719ad5c-6d8a-4d69-9cd4-319946cc365f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_dc555a2f-5564-4ec0-8dad-e2fe0be5b9c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_SeniorSecuredTermLoanDue2026Member_fcc9d9d5-6026-459f-b286-a5f98c13d48c" xlink:href="fold-20220630.xsd#fold_SeniorSecuredTermLoanDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dc555a2f-5564-4ec0-8dad-e2fe0be5b9c3" xlink:to="loc_fold_SeniorSecuredTermLoanDue2026Member_fcc9d9d5-6026-459f-b286-a5f98c13d48c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#ShareBasedCompensationWeightedaverageAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails" xlink:type="extended" id="ib10f0092bc434a719156e733aadc54dc_ShareBasedCompensationWeightedaverageAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_465c4f18-85c1-4677-8fe8-010edede7857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2787d625-56ad-4b1d-95a9-6c892ab33caf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_465c4f18-85c1-4677-8fe8-010edede7857" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2787d625-56ad-4b1d-95a9-6c892ab33caf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_34d3c3b9-f4b4-4a70-a1c9-6231106848b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_465c4f18-85c1-4677-8fe8-010edede7857" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_34d3c3b9-f4b4-4a70-a1c9-6231106848b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e6e64848-464d-401d-b84a-4f6a9f455951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_465c4f18-85c1-4677-8fe8-010edede7857" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e6e64848-464d-401d-b84a-4f6a9f455951" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_e3040e85-cda5-4c9c-b9d3-1f7dcbd9b1f4" xlink:href="fold-20220630.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_465c4f18-85c1-4677-8fe8-010edede7857" xlink:to="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_e3040e85-cda5-4c9c-b9d3-1f7dcbd9b1f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_292f349a-af07-465d-98b8-05633fe22172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_465c4f18-85c1-4677-8fe8-010edede7857" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_292f349a-af07-465d-98b8-05633fe22172" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b553f32c-925e-4983-b686-11209d85aa12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_292f349a-af07-465d-98b8-05633fe22172" xlink:to="loc_us-gaap_AwardTypeAxis_b553f32c-925e-4983-b686-11209d85aa12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b553f32c-925e-4983-b686-11209d85aa12_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b553f32c-925e-4983-b686-11209d85aa12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b553f32c-925e-4983-b686-11209d85aa12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abadc1cf-c4f8-491e-9d57-06a131a4778b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b553f32c-925e-4983-b686-11209d85aa12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abadc1cf-c4f8-491e-9d57-06a131a4778b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_53e05a42-1a4d-452f-b0a8-237f661f7f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abadc1cf-c4f8-491e-9d57-06a131a4778b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_53e05a42-1a4d-452f-b0a8-237f661f7f0c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended" id="i9a2a971b271a41df8b0ec80542576db3_ShareBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ea1652c-62e8-4aeb-85a7-165c3a0b4c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_81007c3e-73bf-41db-b5be-19295b6fbdd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ea1652c-62e8-4aeb-85a7-165c3a0b4c3f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_81007c3e-73bf-41db-b5be-19295b6fbdd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_819b5d6d-74ad-4575-962e-972de47454bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ea1652c-62e8-4aeb-85a7-165c3a0b4c3f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_819b5d6d-74ad-4575-962e-972de47454bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1f94e7f-fd2d-4912-9bfa-5b7cd010d924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ea1652c-62e8-4aeb-85a7-165c3a0b4c3f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1f94e7f-fd2d-4912-9bfa-5b7cd010d924" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c51c89ff-e89e-4d03-815d-90714c606ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1f94e7f-fd2d-4912-9bfa-5b7cd010d924" xlink:to="loc_us-gaap_AwardTypeAxis_c51c89ff-e89e-4d03-815d-90714c606ba3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c51c89ff-e89e-4d03-815d-90714c606ba3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c51c89ff-e89e-4d03-815d-90714c606ba3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c51c89ff-e89e-4d03-815d-90714c606ba3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25ffb200-d5a1-4f96-b8b3-06e46343353a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c51c89ff-e89e-4d03-815d-90714c606ba3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25ffb200-d5a1-4f96-b8b3-06e46343353a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_da88ea37-f006-4c19-9f5e-ed06146bf0be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25ffb200-d5a1-4f96-b8b3-06e46343353a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_da88ea37-f006-4c19-9f5e-ed06146bf0be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9ac7f688-e5cb-49d9-b46b-48c2a0556ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25ffb200-d5a1-4f96-b8b3-06e46343353a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9ac7f688-e5cb-49d9-b46b-48c2a0556ce7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#ShareBasedCompensationRSUsandPBRSUsSummaryDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails" xlink:type="extended" id="ide36227970774f41bc20fd08d88eff15_ShareBasedCompensationRSUsandPBRSUsSummaryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8eace8a-ee8e-4b26-a4cf-52493e9bab15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3312b543-ec3b-4df1-ab55-0b6353c53f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8eace8a-ee8e-4b26-a4cf-52493e9bab15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3312b543-ec3b-4df1-ab55-0b6353c53f0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_19c6002b-7ba1-41d0-a3a5-32f03860c642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3312b543-ec3b-4df1-ab55-0b6353c53f0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_19c6002b-7ba1-41d0-a3a5-32f03860c642" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3d696ecd-b35d-4fdc-82b8-99e7dc62ff4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3312b543-ec3b-4df1-ab55-0b6353c53f0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3d696ecd-b35d-4fdc-82b8-99e7dc62ff4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4f791dc7-0296-4794-bd68-ca15801f645d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3312b543-ec3b-4df1-ab55-0b6353c53f0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4f791dc7-0296-4794-bd68-ca15801f645d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b4376cf2-ea35-4dd2-a26d-e74d3805ef40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3312b543-ec3b-4df1-ab55-0b6353c53f0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b4376cf2-ea35-4dd2-a26d-e74d3805ef40" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f5163dff-190d-4ec3-86d0-da2f83aa4ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b382ca3-d45a-4702-80a0-09a3ed0d671e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8eace8a-ee8e-4b26-a4cf-52493e9bab15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b382ca3-d45a-4702-80a0-09a3ed0d671e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_196ef4a4-729f-4a8b-8973-2efdc3a1948c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b382ca3-d45a-4702-80a0-09a3ed0d671e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_196ef4a4-729f-4a8b-8973-2efdc3a1948c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b93b45ce-9786-43ac-a22e-f50a83fd7339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b382ca3-d45a-4702-80a0-09a3ed0d671e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b93b45ce-9786-43ac-a22e-f50a83fd7339" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_973336e4-5225-4ec1-9a86-3ae41a3171f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b382ca3-d45a-4702-80a0-09a3ed0d671e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_973336e4-5225-4ec1-9a86-3ae41a3171f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_641a0d7a-174d-487b-85a9-aae38d40a466" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b382ca3-d45a-4702-80a0-09a3ed0d671e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_641a0d7a-174d-487b-85a9-aae38d40a466" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0bdc30c9-0ad8-4e42-b04f-8f34e4501578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_27bea2dd-6ce3-43fe-9c0f-c67d469d2c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8eace8a-ee8e-4b26-a4cf-52493e9bab15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_27bea2dd-6ce3-43fe-9c0f-c67d469d2c9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_d363bc08-795e-4961-9c29-434d015bc98e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_27bea2dd-6ce3-43fe-9c0f-c67d469d2c9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_d363bc08-795e-4961-9c29-434d015bc98e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_d820e987-895b-4c73-8005-799339122d71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_27bea2dd-6ce3-43fe-9c0f-c67d469d2c9c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_d820e987-895b-4c73-8005-799339122d71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_20b933b2-78e7-4e6f-b2b4-ba31d4da243e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8eace8a-ee8e-4b26-a4cf-52493e9bab15" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_20b933b2-78e7-4e6f-b2b4-ba31d4da243e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_156ea48e-9c06-4337-a2dd-f0ea47f8314b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_20b933b2-78e7-4e6f-b2b4-ba31d4da243e" xlink:to="loc_us-gaap_AwardTypeAxis_156ea48e-9c06-4337-a2dd-f0ea47f8314b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_156ea48e-9c06-4337-a2dd-f0ea47f8314b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_156ea48e-9c06-4337-a2dd-f0ea47f8314b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_156ea48e-9c06-4337-a2dd-f0ea47f8314b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03235e5c-eab4-4590-93e5-635427133de1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_156ea48e-9c06-4337-a2dd-f0ea47f8314b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03235e5c-eab4-4590-93e5-635427133de1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f6799d2c-a7de-48b1-bb29-32441cbb8a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03235e5c-eab4-4590-93e5-635427133de1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f6799d2c-a7de-48b1-bb29-32441cbb8a5a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#ShareBasedCompensationExpenseSummaryDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails" xlink:type="extended" id="i90275f717a3940008ab1c0e6329f89e7_ShareBasedCompensationExpenseSummaryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da42fbcd-b844-4156-b98a-7c46d25ba8f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_bc80b821-2986-438d-b59f-502fb98920e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da42fbcd-b844-4156-b98a-7c46d25ba8f8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_bc80b821-2986-438d-b59f-502fb98920e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_640f6946-eff1-4f93-9d69-9091418a1540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da42fbcd-b844-4156-b98a-7c46d25ba8f8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_640f6946-eff1-4f93-9d69-9091418a1540" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_49bcf907-ca01-4482-b9e3-a9ff575c90ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_640f6946-eff1-4f93-9d69-9091418a1540" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_49bcf907-ca01-4482-b9e3-a9ff575c90ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_49bcf907-ca01-4482-b9e3-a9ff575c90ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_49bcf907-ca01-4482-b9e3-a9ff575c90ce" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_49bcf907-ca01-4482-b9e3-a9ff575c90ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d372966c-2326-40e9-9881-051e599a014e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_49bcf907-ca01-4482-b9e3-a9ff575c90ce" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d372966c-2326-40e9-9881-051e599a014e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a70a2019-b854-492d-ba97-2010aeaaeb2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d372966c-2326-40e9-9881-051e599a014e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a70a2019-b854-492d-ba97-2010aeaaeb2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3e9fc53e-f5ba-4508-ac93-d53da7e162c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d372966c-2326-40e9-9881-051e599a014e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3e9fc53e-f5ba-4508-ac93-d53da7e162c0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails" xlink:type="extended" id="ib07e600ba8b34971a812fc70ed9ef724_AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a43df6be-3c83-4268-a58d-4cf56f0457fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_6e4f05e1-0187-4c36-a2af-280fb521690a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a43df6be-3c83-4268-a58d-4cf56f0457fa" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_6e4f05e1-0187-4c36-a2af-280fb521690a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1934e3de-4ed9-48ac-86f2-b248b85bc928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_6e4f05e1-0187-4c36-a2af-280fb521690a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_1934e3de-4ed9-48ac-86f2-b248b85bc928" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b3880f6e-cbeb-4f6c-ab55-bf3a306cbc35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a43df6be-3c83-4268-a58d-4cf56f0457fa" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b3880f6e-cbeb-4f6c-ab55-bf3a306cbc35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_dc866160-51ed-4b9e-bb76-e27ff5af748e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b3880f6e-cbeb-4f6c-ab55-bf3a306cbc35" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_dc866160-51ed-4b9e-bb76-e27ff5af748e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_bb976e0d-7908-48ff-8288-449cb83cf6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b3880f6e-cbeb-4f6c-ab55-bf3a306cbc35" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_bb976e0d-7908-48ff-8288-449cb83cf6d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_949f1076-c0dd-4b81-9e9d-29289c0b3ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b3880f6e-cbeb-4f6c-ab55-bf3a306cbc35" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_949f1076-c0dd-4b81-9e9d-29289c0b3ff3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4a830849-7171-425e-9110-8a1ec84dc3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a43df6be-3c83-4268-a58d-4cf56f0457fa" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4a830849-7171-425e-9110-8a1ec84dc3f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b1f7e2ff-6a9d-45de-884f-07dd0e2a887d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4a830849-7171-425e-9110-8a1ec84dc3f1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b1f7e2ff-6a9d-45de-884f-07dd0e2a887d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b1f7e2ff-6a9d-45de-884f-07dd0e2a887d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b1f7e2ff-6a9d-45de-884f-07dd0e2a887d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b1f7e2ff-6a9d-45de-884f-07dd0e2a887d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5f8b07e1-0582-43db-8db6-ece904e02236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b1f7e2ff-6a9d-45de-884f-07dd0e2a887d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5f8b07e1-0582-43db-8db6-ece904e02236" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_10e74f8c-d490-43d9-860f-1145dc7a3aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5f8b07e1-0582-43db-8db6-ece904e02236" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_10e74f8c-d490-43d9-860f-1145dc7a3aac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_35bd8cb1-b907-417e-b12b-ea85f60e304a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5f8b07e1-0582-43db-8db6-ece904e02236" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_35bd8cb1-b907-417e-b12b-ea85f60e304a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f8a7c2db-ff1d-40cf-9e10-128b3044e866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4a830849-7171-425e-9110-8a1ec84dc3f1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f8a7c2db-ff1d-40cf-9e10-128b3044e866" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f8a7c2db-ff1d-40cf-9e10-128b3044e866_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f8a7c2db-ff1d-40cf-9e10-128b3044e866" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f8a7c2db-ff1d-40cf-9e10-128b3044e866_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_668f4a21-3b29-4158-b860-5d1a889e6069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f8a7c2db-ff1d-40cf-9e10-128b3044e866" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_668f4a21-3b29-4158-b860-5d1a889e6069" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_ef6b29c9-ffb9-47a3-92a2-a4f7a58e5441" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_668f4a21-3b29-4158-b860-5d1a889e6069" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_ef6b29c9-ffb9-47a3-92a2-a4f7a58e5441" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_ff99e364-1c1d-4822-94d5-4f7941c0cb73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_668f4a21-3b29-4158-b860-5d1a889e6069" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_ff99e364-1c1d-4822-94d5-4f7941c0cb73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_62e2d0a5-8e45-4542-b66d-f904cf4cd12d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_668f4a21-3b29-4158-b860-5d1a889e6069" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_62e2d0a5-8e45-4542-b66d-f904cf4cd12d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_26023fc5-2504-4803-b352-90eca3d28662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_668f4a21-3b29-4158-b860-5d1a889e6069" xlink:to="loc_us-gaap_MoneyMarketFundsMember_26023fc5-2504-4803-b352-90eca3d28662" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7aa3e03a-9ca3-473f-b7bd-9833a1557363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_668f4a21-3b29-4158-b860-5d1a889e6069" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_7aa3e03a-9ca3-473f-b7bd-9833a1557363" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails" xlink:type="extended" id="i49230c492b33423db132e6ed4c35eda4_AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d12ff7f4-5ceb-4012-8f5a-07e433c53324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1d75a109-c87f-4523-8086-29e1b68e3fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d12ff7f4-5ceb-4012-8f5a-07e433c53324" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1d75a109-c87f-4523-8086-29e1b68e3fe6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationMeasurementInput_66db4869-16ad-49ef-a7fe-dc561639ccd8" xlink:href="fold-20220630.xsd#fold_ContingentConsiderationMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d12ff7f4-5ceb-4012-8f5a-07e433c53324" xlink:to="loc_fold_ContingentConsiderationMeasurementInput_66db4869-16ad-49ef-a7fe-dc561639ccd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1426b447-fc11-4e28-8406-c0fcd97aadf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d12ff7f4-5ceb-4012-8f5a-07e433c53324" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1426b447-fc11-4e28-8406-c0fcd97aadf2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4b8dd7e2-d001-45bc-9eb8-8f9c9c584ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1426b447-fc11-4e28-8406-c0fcd97aadf2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4b8dd7e2-d001-45bc-9eb8-8f9c9c584ab8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4b8dd7e2-d001-45bc-9eb8-8f9c9c584ab8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4b8dd7e2-d001-45bc-9eb8-8f9c9c584ab8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4b8dd7e2-d001-45bc-9eb8-8f9c9c584ab8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2c5195d3-1f4c-4b5e-b3af-1426cca6a586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4b8dd7e2-d001-45bc-9eb8-8f9c9c584ab8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2c5195d3-1f4c-4b5e-b3af-1426cca6a586" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CallidusBiopharmaIncMember_00e19520-82b1-4f54-9d92-c55e65501d3b" xlink:href="fold-20220630.xsd#fold_CallidusBiopharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2c5195d3-1f4c-4b5e-b3af-1426cca6a586" xlink:to="loc_fold_CallidusBiopharmaIncMember_00e19520-82b1-4f54-9d92-c55e65501d3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_db1bd26e-71f1-4c9d-9aea-f0df415f6662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1426b447-fc11-4e28-8406-c0fcd97aadf2" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_db1bd26e-71f1-4c9d-9aea-f0df415f6662" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_db1bd26e-71f1-4c9d-9aea-f0df415f6662_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_db1bd26e-71f1-4c9d-9aea-f0df415f6662" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_db1bd26e-71f1-4c9d-9aea-f0df415f6662_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_53a56e66-e362-4ac4-ad87-cb4902c217bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_db1bd26e-71f1-4c9d-9aea-f0df415f6662" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_53a56e66-e362-4ac4-ad87-cb4902c217bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_d2bd6c8c-f3e4-4418-b775-e97324b9e77c" xlink:href="fold-20220630.xsd#fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_53a56e66-e362-4ac4-ad87-cb4902c217bd" xlink:to="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_d2bd6c8c-f3e4-4418-b775-e97324b9e77c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5450fe81-8bbb-442d-825b-876de1771720" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1426b447-fc11-4e28-8406-c0fcd97aadf2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5450fe81-8bbb-442d-825b-876de1771720" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5450fe81-8bbb-442d-825b-876de1771720_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5450fe81-8bbb-442d-825b-876de1771720" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5450fe81-8bbb-442d-825b-876de1771720_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4db513dd-ba47-40f5-8ca5-fc2bf4d6269d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5450fe81-8bbb-442d-825b-876de1771720" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4db513dd-ba47-40f5-8ca5-fc2bf4d6269d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ce8f145d-ef32-4b2c-9125-e04a14c22796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4db513dd-ba47-40f5-8ca5-fc2bf4d6269d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ce8f145d-ef32-4b2c-9125-e04a14c22796" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_5f01362b-4bc7-4f15-9d1f-b0591cfab2cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1426b447-fc11-4e28-8406-c0fcd97aadf2" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_5f01362b-4bc7-4f15-9d1f-b0591cfab2cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_5f01362b-4bc7-4f15-9d1f-b0591cfab2cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_5f01362b-4bc7-4f15-9d1f-b0591cfab2cc" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_5f01362b-4bc7-4f15-9d1f-b0591cfab2cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_4248471e-6b38-46a1-b51a-b4c390512815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_5f01362b-4bc7-4f15-9d1f-b0591cfab2cc" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_4248471e-6b38-46a1-b51a-b4c390512815" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_a74a8628-a489-4697-8b88-84cdacdd409b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4248471e-6b38-46a1-b51a-b4c390512815" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_a74a8628-a489-4697-8b88-84cdacdd409b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_346611b4-374b-4d03-8962-93dad95ba2c4" xlink:href="fold-20220630.xsd#fold_MeasurementInputProbabilityOfMilestoneAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4248471e-6b38-46a1-b51a-b4c390512815" xlink:to="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_346611b4-374b-4d03-8962-93dad95ba2c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b7e36710-95af-4dd3-bbf7-1cd6c7c3c40f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1426b447-fc11-4e28-8406-c0fcd97aadf2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b7e36710-95af-4dd3-bbf7-1cd6c7c3c40f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7e36710-95af-4dd3-bbf7-1cd6c7c3c40f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b7e36710-95af-4dd3-bbf7-1cd6c7c3c40f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7e36710-95af-4dd3-bbf7-1cd6c7c3c40f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9eec2c15-ca3d-44d8-b044-0e5b89a30ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b7e36710-95af-4dd3-bbf7-1cd6c7c3c40f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9eec2c15-ca3d-44d8-b044-0e5b89a30ec2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ATB200PompeProgramMember_d5c3045d-287b-4ddf-8882-9b1c0dc13c7f" xlink:href="fold-20220630.xsd#fold_ATB200PompeProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9eec2c15-ca3d-44d8-b044-0e5b89a30ec2" xlink:to="loc_fold_ATB200PompeProgramMember_d5c3045d-287b-4ddf-8882-9b1c0dc13c7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_1ed30abe-4a9b-4932-8428-7ec5d9ce9276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1426b447-fc11-4e28-8406-c0fcd97aadf2" xlink:to="loc_us-gaap_ValuationTechniqueAxis_1ed30abe-4a9b-4932-8428-7ec5d9ce9276" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_1ed30abe-4a9b-4932-8428-7ec5d9ce9276_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_1ed30abe-4a9b-4932-8428-7ec5d9ce9276" xlink:to="loc_us-gaap_ValuationTechniqueDomain_1ed30abe-4a9b-4932-8428-7ec5d9ce9276_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_43c5ffa6-12c5-4545-b98b-f5dd443d022a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_1ed30abe-4a9b-4932-8428-7ec5d9ce9276" xlink:to="loc_us-gaap_ValuationTechniqueDomain_43c5ffa6-12c5-4545-b98b-f5dd443d022a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProbabilityWeightedDiscountedCashFlowMember_472600b9-6145-4076-a519-f1ee29c96f0a" xlink:href="fold-20220630.xsd#fold_ProbabilityWeightedDiscountedCashFlowMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_43c5ffa6-12c5-4545-b98b-f5dd443d022a" xlink:to="loc_fold_ProbabilityWeightedDiscountedCashFlowMember_472600b9-6145-4076-a519-f1ee29c96f0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_42a27186-a6e7-498e-8831-f1b544ec6beb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1426b447-fc11-4e28-8406-c0fcd97aadf2" xlink:to="loc_srt_RangeAxis_42a27186-a6e7-498e-8831-f1b544ec6beb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_42a27186-a6e7-498e-8831-f1b544ec6beb_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_42a27186-a6e7-498e-8831-f1b544ec6beb" xlink:to="loc_srt_RangeMember_42a27186-a6e7-498e-8831-f1b544ec6beb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ed327476-46fa-4592-b3bd-ab058de68216" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_42a27186-a6e7-498e-8831-f1b544ec6beb" xlink:to="loc_srt_RangeMember_ed327476-46fa-4592-b3bd-ab058de68216" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4c848707-f605-4c44-b3e9-55544ac2244f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ed327476-46fa-4592-b3bd-ab058de68216" xlink:to="loc_srt_MinimumMember_4c848707-f605-4c44-b3e9-55544ac2244f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_65cb6029-5034-4d74-a1f9-095ff9cabcb7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ed327476-46fa-4592-b3bd-ab058de68216" xlink:to="loc_srt_MaximumMember_65cb6029-5034-4d74-a1f9-095ff9cabcb7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#BasicandDilutedNetLossperCommonShareDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails" xlink:type="extended" id="id13eb13995e1409f8a1d386372c74310_BasicandDilutedNetLossperCommonShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b0c5a4d1-7271-4e36-afce-7f742d367f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_db2c0c79-5724-48cc-b220-b0537b3d4624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b0c5a4d1-7271-4e36-afce-7f742d367f98" xlink:to="loc_us-gaap_NetIncomeLossAbstract_db2c0c79-5724-48cc-b220-b0537b3d4624" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7fa3ee12-91c1-4be3-918b-41c576ef9da0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_db2c0c79-5724-48cc-b220-b0537b3d4624" xlink:to="loc_us-gaap_NetIncomeLoss_7fa3ee12-91c1-4be3-918b-41c576ef9da0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_684b7c33-b242-4e37-8ae1-cc26784c40d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b0c5a4d1-7271-4e36-afce-7f742d367f98" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_684b7c33-b242-4e37-8ae1-cc26784c40d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_81d062d4-eb20-4708-87a0-4cb55edd998a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_684b7c33-b242-4e37-8ae1-cc26784c40d6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_81d062d4-eb20-4708-87a0-4cb55edd998a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_66df2b30-3281-495f-8c3e-5685b94d5aca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_684b7c33-b242-4e37-8ae1-cc26784c40d6" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_66df2b30-3281-495f-8c3e-5685b94d5aca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_81ab8b18-d94d-46bf-9d6f-e81344b9f87e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b0c5a4d1-7271-4e36-afce-7f742d367f98" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_81ab8b18-d94d-46bf-9d6f-e81344b9f87e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_61d52fc9-c741-460b-b99d-4ef1945cbd31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b0c5a4d1-7271-4e36-afce-7f742d367f98" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_61d52fc9-c741-460b-b99d-4ef1945cbd31" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b8e8545c-859f-41d2-b1af-4d02b3885e35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b0c5a4d1-7271-4e36-afce-7f742d367f98" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b8e8545c-859f-41d2-b1af-4d02b3885e35" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1183c8a2-85d7-488d-84bb-719a91f8c1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b8e8545c-859f-41d2-b1af-4d02b3885e35" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1183c8a2-85d7-488d-84bb-719a91f8c1f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1183c8a2-85d7-488d-84bb-719a91f8c1f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1183c8a2-85d7-488d-84bb-719a91f8c1f7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1183c8a2-85d7-488d-84bb-719a91f8c1f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3dc00851-59de-4bc0-a1c9-5b64545c746e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1183c8a2-85d7-488d-84bb-719a91f8c1f7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3dc00851-59de-4bc0-a1c9-5b64545c746e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_81fcbb1f-8aee-4523-a2ef-3980685a0f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3dc00851-59de-4bc0-a1c9-5b64545c746e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_81fcbb1f-8aee-4523-a2ef-3980685a0f39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6dfa6406-f6df-40ec-a413-7ed3c5b4d2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3dc00851-59de-4bc0-a1c9-5b64545c746e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6dfa6406-f6df-40ec-a413-7ed3c5b4d2ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_f514ae81-44cd-463f-8c35-2142b2af3fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3dc00851-59de-4bc0-a1c9-5b64545c746e" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_f514ae81-44cd-463f-8c35-2142b2af3fd1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_48312353-c691-42dd-bab6-c8e060cbae9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b8e8545c-859f-41d2-b1af-4d02b3885e35" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_48312353-c691-42dd-bab6-c8e060cbae9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_48312353-c691-42dd-bab6-c8e060cbae9b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_48312353-c691-42dd-bab6-c8e060cbae9b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_48312353-c691-42dd-bab6-c8e060cbae9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_29ed4705-571d-4825-9917-de7abd32fb9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_48312353-c691-42dd-bab6-c8e060cbae9b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_29ed4705-571d-4825-9917-de7abd32fb9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_ed9d722f-bde8-4477-89bf-96c3a80377b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_29ed4705-571d-4825-9917-de7abd32fb9a" xlink:to="loc_us-gaap_PrivatePlacementMember_ed9d722f-bde8-4477-89bf-96c3a80377b5" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>fold-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:3889360d-46b3-4f4f-a1c0-074f51e18b3e,g:d5204adc-c100-4730-97cf-6188f145481c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_b2db97b5-bcca-49e0-bc3a-8ee0cf43f8ca_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_3214a8d3-3d9f-45ce-b770-d627c7b81a56_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_SeniorSecuredTermLoanDue2026Member_b26f876c-720a-4a4c-89f6-dca883c8e103_terseLabel_en-US" xlink:label="lab_fold_SeniorSecuredTermLoanDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Term Loan due 2026</link:label>
    <link:label id="lab_fold_SeniorSecuredTermLoanDue2026Member_label_en-US" xlink:label="lab_fold_SeniorSecuredTermLoanDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Term Loan due 2026 [Member]</link:label>
    <link:label id="lab_fold_SeniorSecuredTermLoanDue2026Member_documentation_en-US" xlink:label="lab_fold_SeniorSecuredTermLoanDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Term Loan due 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_SeniorSecuredTermLoanDue2026Member" xlink:href="fold-20220630.xsd#fold_SeniorSecuredTermLoanDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_SeniorSecuredTermLoanDue2026Member" xlink:to="lab_fold_SeniorSecuredTermLoanDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_713bfbcf-ec17-4298-9cfa-6820236d7863_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred reimbursements</link:label>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Credits and Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cdc3e29f-e21e-4ffa-9735-5592767e118b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da8f542c-3d5e-419f-990c-8aee76ae4733_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_49ff7130-6426-4748-99fe-264069775397_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_a76d01dd-bfef-4d4c-ac8e-dc7272ea229b_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_86a07e65-2dc3-4957-9ea7-f5fa2d96e3a9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_1e908d5a-b5bd-402e-b2e4-2b22b37e8bdd_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0cce5595-8d80-4b66-acf0-6838c6a91888_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_c81c4cd8-c12d-45d4-9276-42f37206afc9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_12828832-bc95-42dd-abda-e076b84c7d62_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_605e8c14-3983-4cfc-91ed-00868b8a7b6c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_df73a787-59a9-4117-94b8-f1dc4e2ea398_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b179fc51-3d4a-4f60-84f2-b5a1ef40b394_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_b677f2d5-bd8d-4c58-b654-839099d7ec56_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_a57f6ed7-c6bf-4a57-99c9-52e618d92518_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_d92d5b78-a2b0-47d0-bfd8-5bb39be4ead1_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_5cda602e-eab3-489a-a4b5-cfd123ef308a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ShortTermCorporateDebtSecuritiesMember_b677c7b7-d55e-4170-a4ac-5ab258dd51ae_terseLabel_en-US" xlink:label="lab_fold_ShortTermCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_fold_ShortTermCorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_fold_ShortTermCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Corporate Debt Securities [Member]</link:label>
    <link:label id="lab_fold_ShortTermCorporateDebtSecuritiesMember_documentation_en-US" xlink:label="lab_fold_ShortTermCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShortTermCorporateDebtSecuritiesMember" xlink:href="fold-20220630.xsd#fold_ShortTermCorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ShortTermCorporateDebtSecuritiesMember" xlink:to="lab_fold_ShortTermCorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised_821ce4a2-d205-4a5e-aacc-317f1432e873_terseLabel_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised_label_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised_documentation_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents Stock issued from exercise of warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:href="fold-20220630.xsd#fold_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_aea8df70-4f93-4041-96cc-7d34d1df4034_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesRealizedGainLoss_8ede7863-f3db-4619-aff6-32f95d849bfe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gain (loss) on debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_0002b97e-9a8b-4ca9-ba68-66a3b3bd8d3b_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (loss) gain on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_331bb508-69ca-462b-9926-357b031a6da2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding loss on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_706f22b1-4c3c-4af3-9471-eee5830d3962_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ContingentConsiderationMeasurementInput_745b5ad7-b320-4e5c-9801-405af245dfc2_terseLabel_en-US" xlink:label="lab_fold_ContingentConsiderationMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, measurement input</link:label>
    <link:label id="lab_fold_ContingentConsiderationMeasurementInput_label_en-US" xlink:label="lab_fold_ContingentConsiderationMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Measurement Input</link:label>
    <link:label id="lab_fold_ContingentConsiderationMeasurementInput_documentation_en-US" xlink:label="lab_fold_ContingentConsiderationMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationMeasurementInput" xlink:href="fold-20220630.xsd#fold_ContingentConsiderationMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ContingentConsiderationMeasurementInput" xlink:to="lab_fold_ContingentConsiderationMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ProbabilityWeightedDiscountedCashFlowMember_814a6dbb-1da1-49c4-ac23-d1e5465153b9_terseLabel_en-US" xlink:label="lab_fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability weighted discounted cash flow</link:label>
    <link:label id="lab_fold_ProbabilityWeightedDiscountedCashFlowMember_label_en-US" xlink:label="lab_fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability Weighted Discounted Cash Flow [Member]</link:label>
    <link:label id="lab_fold_ProbabilityWeightedDiscountedCashFlowMember_documentation_en-US" xlink:label="lab_fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to valuation technique of probability weighted discounted cash flow.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:href="fold-20220630.xsd#fold_ProbabilityWeightedDiscountedCashFlowMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:to="lab_fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c483836a-dd87-4ec8-a571-46d05478ea53_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation of property and equipment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_a23ae24b-1fa3-4cd3-a271-48282e2ae2c8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventories for the Period</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ce5ec0d1-fa0a-4de2-b2d1-aa0379edfb85_negatedTerseLabel_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized loss, cash balances and available-for-sale securities</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="fold-20220630.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_fe513d21-1601-41dc-aaed-896a31c2f5e1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b8b2a6e9-162b-4e57-b595-ed9c601b627f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life of options (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2883f203-c924-4345-9ced-fe847645c353_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a61a31d6-45ca-4d67-9c70-8ed45e37d934_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Money Market Funds, and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_2b6a8cb8-c709-45f8-8b12-2cd5ac543742_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash, Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_3a7e6281-8ef7-4ea1-b2d4-39e474df656b_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value, 500,000,000 shares authorized, 280,456,667 and 278,912,800 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_e7d537c4-e68d-4484-bee5-8e5316dcc168_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_ae617475-bca8-4232-afe6-8759316a29c8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f72d76f6-f9ea-4de3-a06e-ea0a70c3d635_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_927a771d-8181-4b12-9b78-d467c6c8b14d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_2708c1c5-10b8-4f31-b9d0-2951c934d843_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ATB200PompeProgramMember_497f2c22-0449-465c-8326-e69b32e31d75_terseLabel_en-US" xlink:label="lab_fold_ATB200PompeProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATB200 Pompe Program</link:label>
    <link:label id="lab_fold_ATB200PompeProgramMember_label_en-US" xlink:label="lab_fold_ATB200PompeProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATB200 Pompe Program [Member]</link:label>
    <link:label id="lab_fold_ATB200PompeProgramMember_documentation_en-US" xlink:label="lab_fold_ATB200PompeProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to ATB-200 Pompe program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ATB200PompeProgramMember" xlink:href="fold-20220630.xsd#fold_ATB200PompeProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ATB200PompeProgramMember" xlink:to="lab_fold_ATB200PompeProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f10d59a5-9849-4633-8257-b6bb42f54f0a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potential Shares of Common Stock that were Excluded from the Computation as they were Anti-Dilutive Using the Treasury Stock Method</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_baa94ed0-dad5-47f1-9f85-fcc70f83cf1f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercised, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_00b4d1bf-8617-42f5-8608-879da18dc283_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_f2a6dfc4-4f62-4bbe-907b-7a170d428c54_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_91c56a1a-b7e9-47aa-8b87-5a6f83f3ccf5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock units, net of tax (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_2e78e424-cddd-4789-a3d6-df34c1dc9b5a_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_7933180c-48d9-44c7-ba0e-de0ee26cef03_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Continent Consideration Payable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2ea3d396-6561-4f5f-90b5-de0c413a392a_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_d7218961-0787-484e-9203-e9d768594746_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1b3e1053-2fde-409a-b900-a49099f5251e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of the convertible notes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_AmortizationDeferredFinancingCosts_5644ac85-a082-4c14-97fb-696081154770_terseLabel_en-US" xlink:label="lab_fold_AmortizationDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred financing</link:label>
    <link:label id="lab_fold_AmortizationDeferredFinancingCosts_label_en-US" xlink:label="lab_fold_AmortizationDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Deferred Financing Costs</link:label>
    <link:label id="lab_fold_AmortizationDeferredFinancingCosts_documentation_en-US" xlink:label="lab_fold_AmortizationDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AmortizationDeferredFinancingCosts" xlink:href="fold-20220630.xsd#fold_AmortizationDeferredFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_AmortizationDeferredFinancingCosts" xlink:to="lab_fold_AmortizationDeferredFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_86afe229-5cef-411f-8392-b990e1a3ff6f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b13a8f1a-db4c-4057-b6f1-aae2b827598c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at the beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_62a4c3ff-d57b-46e0-ab09-488f785ebfe4_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at the end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_818fabd9-d07c-4074-9a1a-b3399bab4de9_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_fa5adc10-3089-472b-b2a1-feb383bbb7ce_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_e66991b4-5b1d-4a81-8f88-1d978b30c11d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock options exercised, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_f7748b07-8b9e-49fb-a2a4-3e4632d82678_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_d0c79ea5-a516-4851-a394-63f9a63ceb33_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life, options vested and unvested expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_b9ca377d-298f-4d80-952b-d6f9783caef7_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b2ac0533-7460-4b54-9b4d-bc5fe00bc5a6_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_8d89dd23-790e-42c2-b613-2d026f710663_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_abcb6ac5-bbb5-4286-a2cc-a26123d030ed_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_18764689-20a2-4820-beae-09e7624d7240_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1131f0bf-4109-4577-a4da-b2fe139b86db_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3b5f91ca-915a-435d-99eb-ef5b2dad50a7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_f4bdb0ed-fd7c-46d5-9a6e-c1628ac646eb_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a62dd508-6322-4d25-b90b-e01d2510a359_terseLabel_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gain, cash balances and available-for-sale securities</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="fold-20220630.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_9a5e4794-7523-4614-bf81-ef7559e0b930_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures unpaid at the end of period</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_f4cf2cc9-f370-4e6e-8f16-f53a587d57cd_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_af340e1b-a85f-4b4e-a23b-acc8dc0fbe8f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df490dff-031c-4ee1-ae6d-928669eb8288_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets and liabilities subject to fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8ccccf28-776b-45dd-9d5c-c18259b5c49f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units, weighted average remaining years</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_0c4f8f12-4186-4f04-af3c-6ab3c9cc582a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of available-for-sale debt securities in unrealized loss positions</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_e602e4e3-327d-47bf-9814-1574d63dfccb_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_0c9e711f-1a9f-4b76-8755-6d5cb1148a2b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_c19c8d3d-6fc6-4662-ac95-1735b4ba2449_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_6665554b-f953-497b-95ac-d9538f4049aa_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0c6f0e47-d613-4229-8b1b-ede34e70c41b_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_27b71dad-35b8-44fb-a699-6d80d8c63c52_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_d5c44471-79a4-4298-9017-b0908672e638_terseLabel_en-US" xlink:label="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of achievement of milestones</link:label>
    <link:label id="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_label_en-US" xlink:label="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Probability Of Milestone Achievement [Member]</link:label>
    <link:label id="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_documentation_en-US" xlink:label="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Probability Of Milestone Achievement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:href="fold-20220630.xsd#fold_MeasurementInputProbabilityOfMilestoneAchievementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:to="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_bdf44cca-6886-47cc-8e2a-66ab1afeac4c_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_552b85a6-c672-490c-85dc-4994aed75c04_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_45453ac8-bfec-420b-b010-67c3f5f8e257_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_994ec5f0-e1c6-485e-8b77-7d9dadb3d049_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gain, available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_62c6fdde-b63b-4566-a410-af458c811fd7_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_AssetImpairmentChargesAndOtherAssetWriteOffs_2383c3ca-1461-4717-8c1f-7aca0a102826_verboseLabel_en-US" xlink:label="lab_fold_AssetImpairmentChargesAndOtherAssetWriteOffs" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment charges and other asset write-offs</link:label>
    <link:label id="lab_fold_AssetImpairmentChargesAndOtherAssetWriteOffs_label_en-US" xlink:label="lab_fold_AssetImpairmentChargesAndOtherAssetWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges And Other Asset Write-Offs</link:label>
    <link:label id="lab_fold_AssetImpairmentChargesAndOtherAssetWriteOffs_documentation_en-US" xlink:label="lab_fold_AssetImpairmentChargesAndOtherAssetWriteOffs" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges And Other Asset Write-Offs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AssetImpairmentChargesAndOtherAssetWriteOffs" xlink:href="fold-20220630.xsd#fold_AssetImpairmentChargesAndOtherAssetWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_AssetImpairmentChargesAndOtherAssetWriteOffs" xlink:to="lab_fold_AssetImpairmentChargesAndOtherAssetWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_9cdc66bf-607f-4b0f-af53-f64f70392db8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e926901e-f23b-4446-9107-35d49f88353e_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_47fcdcdf-cbf4-4a03-afc4-9bd5c789a63e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_30c05e7f-caef-4204-81cf-ac7a66f24dbd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_db69e750-ea33-4d10-9bf0-89feeec60b54_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_8d8c38b2-8e6e-4f30-a203-2ecfbc9341fb_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_103923e7-4ae0-4f44-b706-31e57e5abd77_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_854c51eb-a95b-4092-94c6-51488570733d_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_d12051ab-76d4-48da-b870-a4489df2f605_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_af8630bb-44f0-4a08-ba6f-5f73d1c8feee_terseLabel_en-US" xlink:label="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical and regulatory milestones</link:label>
    <link:label id="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Liability Clinical And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to clinical and regulatory contingent consideration milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:href="fold-20220630.xsd#fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:to="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_ad58bceb-910a-43a7-b93b-9ecc7f22678e_negatedTerseLabel_en-US" xlink:label="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities, gross unrealized loss</link:label>
    <link:label id="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_label_en-US" xlink:label="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Before Tax, Current</link:label>
    <link:label id="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_documentation_en-US" xlink:label="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Before Tax, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:href="fold-20220630.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:to="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForTenantImprovements_10581aba-81f5-4508-abae-4304319197da_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvements paid through lease incentives</link:label>
    <link:label id="lab_us-gaap_PaymentsForTenantImprovements_label_en-US" xlink:label="lab_us-gaap_PaymentsForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Tenant Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForTenantImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForTenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForTenantImprovements" xlink:to="lab_us-gaap_PaymentsForTenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_d538cdbe-615b-41e0-b8a9-e10a9911e3e5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_41e113a0-0e91-4586-9652-766f16841526_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_261018ba-1934-48c3-aa67-3683fe4c9e0a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life, options outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1a56d9ff-ebaa-4dca-9e0e-d8545faa3134_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_024d4189-78d1-4765-a969-f5aa802cdd2f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_589c92ad-501b-4400-9c11-094115265eca_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Total Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_ce0f0598-9c14-4a0d-b351-a695846d6a05_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_ddc7b126-f825-484b-a5f0-a3331b914c66_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1677b355-2fe5-483a-80eb-b39b50d9a326_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_a57ba95e-24e4-46bf-9951-27a854f30f68_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_29e38b27-0e11-487f-a988-10b64860eb64_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_540bedd6-9351-4618-89fb-dbf67b01b6eb_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a3655dae-4d4c-4295-8aeb-95ddcfcd66a4_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ee24e456-e689-4cb8-a0c5-2a681b7d3cd2_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_106aa467-24a7-4726-a075-8252a4c34852_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, less accumulated depreciation of $22,188 and $19,882 at June 30, 2022 and December 31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2ef547f4-f707-4d08-aace-c3579ba91f65_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_0e30ca4e-9594-4023-b3ee-0bc70a0f2c3f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Non-Vested RSU Activity under the Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_5ba23da4-f455-4c08-b905-98fb293ebf79_terseLabel_en-US" xlink:label="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets and liabilities</link:label>
    <link:label id="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_label_en-US" xlink:label="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Noncurrent Operating Liabilities</link:label>
    <link:label id="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_documentation_en-US" xlink:label="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in the aggregate amount of noncurrent liabilities that result from activities that generate operating income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:href="fold-20220630.xsd#fold_IncreaseDecreaseInNoncurrentOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:to="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_855e6117-4bab-49a7-b64f-b63f56751f67_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in fair value of contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a00ba318-7706-4736-a774-4b925bbdb357_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in fair value during the period, included in the Consolidated Statements of Operations</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_53505888-fe4b-4850-9a02-10771976517d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_42e3e572-6754-4154-a60e-99e3bb638d12_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_87cf8e67-32c5-4218-aed5-6ad830342798_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6dd79b6d-ed06-474a-9ac6-08f3b86a2567_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9da14f69-2282-4a61-bda7-fea880254b11_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercised, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9f0ed1e7-26db-4e57-b49c-6f5ec37af7ac_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_69701cb7-c817-4ba1-8ba5-355f122f29ae_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_00e24af7-6c08-44bd-a7e5-01f3df4bd0bf_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_ce0e2937-0ab8-4f22-a6cf-67299aa484df_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying value of Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_75bdf56a-1311-458c-9731-75c5c3d43e60_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised_070c9b4c-91d3-455e-917f-8076863352db_terseLabel_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents Stock issued from exercise of warrants (in shares).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="fold-20220630.xsd#fold_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_3c0cfbae-73e4-4a07-8968-94df4c6ea9f6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_fd1edb23-49e5-47a5-9448-27a333374c1f_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_9cc31b23-f896-4db1-92ec-c2b617b04845_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1d07435a-1878-4978-9a49-312bde1a5a60_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f4c8308-1c47-4a1e-ac1b-7a635ebbdc89_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_037bfba5-f53f-445d-b069-957d862e15eb_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_292d9e2f-4c0f-4867-9962-b3436b404ba2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_2ed6d2f9-0707-45de-b3b4-a60875d4fada_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cd98a7ad-54c8-4650-a9ac-028919d43005_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7c9580d0-d561-43c9-a989-c342deec5f0e_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ccd09314-6ac4-4f14-9ecb-ed3004619e4d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_80339df0-0563-47c8-ae0f-6518007087af_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities, cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_7d19e4eb-247a-4baf-8183-bd88f7c69a3c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Marketable Securities and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_f82874a4-b19e-4bd5-902c-95c930f9bc5a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_fbbe70fd-51f3-4782-ab75-2cb382aa7007_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_4c1cc14f-f55a-4f0b-86a9-1dc4e2e13fb0_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1dc47073-bf78-4cf6-8cc3-7dc6d7ec0c7a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9a6c3c44-fd0a-483c-b5f6-c8b3c443d872_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_c97d9fc7-28a5-47d5-96d3-0cb279b62aa6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_8fc0aef7-020e-4339-99e4-bdbd58f33492_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_713b9e0c-0378-4e15-8d1c-bd7eb8341edc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise&#160; Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_66110b20-e28f-4f5a-82d2-a58290c82864_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_79ee8868-2712-4ec5-bc06-f44f18e1f15a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_eb1b3626-e718-4c59-9ee9-1bd8f641b6fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_2a10e324-047f-4ec4-8ff6-8dcffa024ebc_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_a00cb9d6-d29a-409c-b8d8-030cd98bb58d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f4412f9e-ee66-47dd-98d5-7f952ffa41dd_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2d8e1c21-582d-4e89-b60b-d42fd9388724_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_f8c18094-890e-4ef0-be59-6ea60aac60da_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_9a631dcf-26fc-4926-b2f7-71b703bebba9_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_7d5ac73b-eab9-4eb1-b476-ab52037c3845_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0fbbb312-8bf9-4155-8044-5550586bc0e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_d6403a8d-fd4b-4cca-be4d-4334e1ac4b72_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ff22f1bf-6ae3-4569-9cc7-5757f6365e82_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_30805058-7936-408f-8f97-a343a0519ac4_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_ee2ec1cb-9bac-4ba4-8c12-46906a8164f3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from warrants exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1aec6c7e-a152-4887-a183-5e40f4527a2f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_6087027d-be36-4466-9849-3db96cf4754e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_939fb9fb-bb05-40e7-b6de-8546dc9ea456_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_a6585d76-6d13-45dd-b6bc-dea59c61ea6f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_65f270cd-d711-4c7c-b302-749a4a4d44bd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_25be9f7f-72d0-4405-abeb-f174b70bbf3d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_bde7cb9b-6cc1-4660-bc3d-d22387314468_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_f0882820-eac5-4ec9-b200-5f49786178d9_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_ed6bf4f4-3103-427f-a774-bc5b5804f8e5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_ba87a1e9-1ff8-4d74-8fc4-5d070943f85d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_75c9c46a-e90d-41bc-bc7f-ca89a09d66fe_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general, and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_MarketableSecuritiesMember_d60ee4ed-a42b-4d3d-a473-f6ad96c2883d_terseLabel_en-US" xlink:label="lab_fold_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_fold_MarketableSecuritiesMember_label_en-US" xlink:label="lab_fold_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Member]</link:label>
    <link:label id="lab_fold_MarketableSecuritiesMember_documentation_en-US" xlink:label="lab_fold_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_MarketableSecuritiesMember" xlink:href="fold-20220630.xsd#fold_MarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_MarketableSecuritiesMember" xlink:to="lab_fold_MarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_16e8077d-416a-41d4-a91a-cfdd134a4305_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_c2fc512e-2f84-486b-86fd-77030f380edd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Assets and Liabilities Subject to Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_57cd4337-7818-4996-a4c3-b0fa335f08ee_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dbf51a9b-3c58-42af-b256-e94cdf8326c5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_b4fcaa91-ed60-4b09-8e71-7ce0b42f3116_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment (loss) gain</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_a3a1602a-721b-4158-a7cd-1cf652926507_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_387fb1f4-6e96-4cd7-aaaa-206cc726b116_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7a321223-01b8-4bf6-9b31-3b7778359284_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_04523e86-bc13-4f2e-9529-ab6d17a74b94_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5a4633f6-74a2-4b91-aec5-c038cbd81da7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1482929d-23c6-4597-a9e4-692acc04af84_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_cd28f558-a19b-48f7-8b0c-5cf0cb45abb9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_22ebdca5-f801-4d96-83a1-f3fd40179a7c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_06c74576-90b2-4e3e-bbdb-bb2e000f9067_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_45223c75-08da-405a-a23c-02c419c963b8_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_3ff65811-b9f8-442e-b014-554feb7a7759_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_9a1d7398-d94b-417f-8235-de111728bdf5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1c6527cf-47b4-4ca3-a001-b4069d204c78_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_0caee4ce-ef0a-4d19-9120-e30335af5da7_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_192b5f2d-3738-49bb-a481-0c9e4e3e1a42_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_f97a625a-3004-45f8-a2cf-fd7c441fa179_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_d62800be-afc5-4428-95e2-a3a9d7a3e8fa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, vested and unvested expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_5a8232f6-6df4-4e3b-ab0b-94df7501e959_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and deferred financing</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_bd2ff4a6-90f8-47e4-8a4c-b36e981086b3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Net Loss per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_61b2845f-ca4c-442b-bb90-84e46b57282f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_c0fb3c1b-5abe-4bdf-8535-5fef02641a7e_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_3c0c2caf-00d3-4663-9409-510f1bc8055b_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d6a6266b-e610-47ee-8ac9-6a4684944753_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d2e3f206-47d8-412c-9cf7-3d90917a6f76_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_53e5ee41-26f8-4062-aa0e-ced23e75ea94_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation costs, period for recognition (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_a5fffab1-aef6-435a-87ff-5808f270fec7_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_32d7034e-a623-4790-b3b6-45632716f717_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life, options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_beb46db6-0d4c-42fb-af1f-1e9e47bd0072_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_36fdbc74-fd1e-48e0-9e39-bf5e28c0edf3_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_f379cab0-921d-4b9e-ae22-e6d220f225be_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_a07dde43-6825-4a8f-91e2-e0f1ef45df95_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_52005eb6-ed0e-4521-9584-5aa6db74708c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b396f42a-a059-4f89-8254-4372c39f304b_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2f67cd19-d417-4660-8d5d-d6a5246a07c8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_45446c34-3631-44d6-8771-3b1679b96559_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_c2afce5b-2346-41d7-a887-75259b1b7768_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_aa102573-8c6d-47e8-950e-1ba280140931_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4260394d-af5f-4f51-a7df-da80d64b9fe3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_ad5afaeb-7722-4683-8f18-2a3ad1f51dc2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of the convertible notes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_cee16f96-7081-41d9-b644-b7dc3209d93f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_119a3f49-7fe6-4d68-a720-803afd562029_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_4465cc70-a3ea-4600-a450-1fb279d38c11_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_cf9d790f-baf3-48fa-a645-53065a0ca1db_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt Instruments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_b32bd435-b2c1-44a8-87c4-ad258f2c5925_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_cb0e2f92-7754-4b5b-ba4b-91e8229663a2_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_854f73f5-781b-47ae-bd22-2e0813fbda82_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8b910e01-0ae9-4807-911c-d6ad295f4feb_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_fdea8742-131a-41f8-acdc-7e615ed9dd38_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts receivable</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_dc92ea67-8b87-42f4-82bb-37bb13235bf9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_c97fa055-a36f-4d45-8958-496efc61e5b9_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_2d9e767c-9951-426e-9312-8617a88a19ea_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9b11a74a-2a58-4479-9327-e94521bf21ce_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_5ff22a8d-4e7c-45d0-8a32-00713ce051b8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_6aac41ad-a5ce-4822-8a71-863300f58692_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_e05eaf9c-122d-41c9-9b14-52ed40c6b673_totalLabel_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, cash balances and available-for-sale securities</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_label_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities Fair Value Disclosure</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_documentation_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents cash and cash equivalents and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:href="fold-20220630.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:to="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_741fd864-9ae1-49ec-88f7-d63665146e45_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation plan liability</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-Based Arrangements, Liability, Current and Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_f66add89-4387-4f0e-8977-19b6ec4b6a9d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual obligation</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d87d00f3-2c90-42cd-9f13-4efa9477ab2d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_375b7c4d-f2fc-464f-b3e8-3fdf0f977aa2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_bebab9d9-29c0-4460-a2c3-45b2a065516b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of vested restricted stock units, net of taxes</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_c42452f3-6e15-49cc-a8a1-8d82b435db87_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_5fae4c19-fdc2-4300-9491-10ddd81e0c52_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_265f0c50-abe6-4594-8ee0-099b3b46857e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_5297fa88-e53a-49ca-8008-687e42bfc570_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_36383058-85bd-4e1d-aceb-a28b86e6ab5f_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_35b74e32-97d7-41fe-8608-45898efa87d7_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_fd32df04-c776-44b1-ad40-9e1bbf9117c6_terseLabel_en-US" xlink:label="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities, gross unrealized gain</link:label>
    <link:label id="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_label_en-US" xlink:label="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current</link:label>
    <link:label id="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_documentation_en-US" xlink:label="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:href="fold-20220630.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:to="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_fee5f179-29ad-495f-846c-00b7dede2912_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ex-U.S.</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d6e1e0a5-5634-4c8d-a1f2-f4bb4bc5caf7_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_0af28700-e643-4ab7-87ed-1a17d42a347d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_d94d71d8-ed0d-402b-beb8-c471ebe16ab0_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeMember_4e8df047-f8da-4093-84d7-c50f8243c792_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeMember" xlink:to="lab_us-gaap_ComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4b6acc54-c3b9-45e0-9691-c67a39b2b35f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_7e2ad8b9-1982-476b-a511-0737389243f2_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_342d6943-fee1-4a13-893d-672046966d5f_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_651fdab5-1999-4fc1-b1ff-6cb2a52df286_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_3805df2d-aa2e-4a4c-b991-6f78d26ebe64_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders per common share&#160;&#8212; diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_dab23eb5-1ff6-44ca-8868-5fc1fdeb8deb_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research&#160;&amp; development</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_498e50e8-d602-48ad-aa64-a5dfda39c8a0_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_ac718cda-528b-4243-8757-05b4cf522160_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, vested and unvested expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_2e8fb101-5eb2-44f7-b5bb-8fcda68b1faa_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7d8366aa-3adc-4853-a111-186bbc8a9c4f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, cash balances</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_74aab7f4-7a12-401f-a18c-8e5f82659a84_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) gain:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1051bc86-1d13-4d62-aa8c-e9cbffeb116e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d2f279a1-c34d-4210-9d11-3bd27f4b8f4a_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of the period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b0200b06-0fb8-4f7a-9a58-259c1bc1aa50_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of the period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_1e63e5bd-b1e9-4b83-b922-87d4720977fa_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorLoansMember_e3d27ef1-9b91-4e8f-b4f5-68804994e105_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Loans</link:label>
    <link:label id="lab_us-gaap_SeniorLoansMember_label_en-US" xlink:label="lab_us-gaap_SeniorLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Loans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLoansMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorLoansMember" xlink:to="lab_us-gaap_SeniorLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_8b66de04-5723-41d5-ac22-90edbada0715_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued expenses, and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_c6f36ee2-76eb-43f1-9c99-926bf5d9f303_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e6455c38-2f2d-4669-9061-c358d9c34f5a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_16b5f2bd-7c16-4359-ba68-cee9d0c4f7eb_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid during the period for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_b14a67c3-0261-45a1-82e4-72aeaf142f81_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders per common share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_ecbf69f0-0361-4cee-bcac-45a65f448274_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_ed0ac5cb-e8af-48f0-b96c-edff9a8addfe_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a3fd9f0f-5e67-4b77-aac0-d100f2f8f9c2_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_1a526d58-472e-4b04-b06f-e33a502c4fe6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_6e4240b5-8a8b-439e-a184-7445f5debcb2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_8f814002-c440-45e9-af3a-a7188849c2b4_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_4410a076-bd37-48e1-bd50-c8986161c39e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_ba288b07-2f63-4df7-9a25-e6a8e3b60419_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fb28e5c5-2509-4986-89e4-a476a0d42e2c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_0e20161e-a65e-4730-9bfa-385677ac9fc4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_b8507725-b3b5-4490-b784-4ced18e7bdb1_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_581a71c4-fc69-4907-8698-d72e8200f7d0_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_c57a0f42-f67b-44f2-82a2-b470b3956a68_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_b65a63da-1a17-490a-be8e-f943c5a2190f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale and redemption of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_0c660f45-1e9e-468b-94c4-d6bbbb5342db_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government agency bonds</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5f05bb1d-3b6a-46c0-97ac-4b7ef7180b63_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_2c5a4041-b44c-4388-8db9-b467ff22d3c4_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_f507f3eb-609a-400f-a7ad-03e380b8d53c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for inventory</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_f1b06087-5a8c-4d52-abb4-7ef87f4260f1_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_d94eaa75-e141-4308-a79b-9d3a75f7e5ce_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_79e20edb-918a-40f7-b3b3-b2be3e1e9897_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_9fddd387-9ce5-46f3-b468-fa3f94f38364_terseLabel_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected annual dividend per share (in dollars per share)</link:label>
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_label_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions Expected Dividend Per Share</link:label>
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_documentation_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the estimated dividend per share to be paid (expected dividends) to holders of the underlying shares over the option's term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:href="fold-20220630.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:to="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_628b7723-3436-435a-bc00-d53937c46b89_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_42b31cfd-1849-4efa-8cdc-4f5af1ea4c5b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1b928749-72b5-40c2-9029-fe74a9ad692e_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_3f608242-7193-42c4-a300-3afd5c0763f0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CallidusBiopharmaIncMember_8e5af4bb-7798-497a-9a60-1ea806613e71_terseLabel_en-US" xlink:label="lab_fold_CallidusBiopharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Callidus Biopharma Inc</link:label>
    <link:label id="lab_fold_CallidusBiopharmaIncMember_label_en-US" xlink:label="lab_fold_CallidusBiopharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Callidus Biopharma Inc [Member]</link:label>
    <link:label id="lab_fold_CallidusBiopharmaIncMember_documentation_en-US" xlink:label="lab_fold_CallidusBiopharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Callidus Biopharma, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CallidusBiopharmaIncMember" xlink:href="fold-20220630.xsd#fold_CallidusBiopharmaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CallidusBiopharmaIncMember" xlink:to="lab_fold_CallidusBiopharmaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_b48dd7ae-d4a9-413f-9dab-397e7c59f0dc_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_98e2ca94-40cb-48a9-8dfd-4da24140a832_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ae795782-ce12-4be1-a979-65556451f357_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Compensation Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1d3ec066-534b-4c70-86d6-6b28597453a3_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) gain</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_64404b9c-376b-4e07-9596-259f1d984810_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_923a70b9-b57b-41ec-8f7b-990c157b1cd4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_55ad0929-5485-4ad1-98ab-05b280c294f8_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_23a78874-4023-47d2-93aa-9285129c3a61_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_aee05b20-b159-4192-b6a2-6bb345816c91_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_88a01803-a325-4724-b0bf-dccf5dcac2bb_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_44ca8381-76b3-4dc9-b2cc-6d96f14c862e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4a941ead-e1b2-435d-944b-bd52a90daae2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_66575f1c-b627-4470-bd0e-a7a950cc6381_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_cb0d7539-6846-4413-9a59-eab49dd91b40_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Significant Unobservable Inputs Used in the Valuation of the Contingent Consideration Payable</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b423f410-5630-43a0-b033-ac08d544cc59_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_b45e1af4-32be-4476-91ea-f714ba0bf24e_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0b09e4c3-e732-41ad-a6ec-2cc32c69d7b4_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents, and restricted cash at the end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_68e1d329-c2ea-4972-98ef-fb51c5109078_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_abb641d5-e104-4b87-ba2c-5cbe947b1ed1_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_fd50063f-956f-4651-a070-b59c29842203_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_b4add3cd-b145-4794-8051-718ad386ddf4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_b12a6a27-8971-45f4-97b4-98f667a17938_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_f5b793a3-81f3-49fb-984c-e0452ed5f1e8_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_635ec2d9-1d7a-4f99-b1b3-fcd7ff72a3b6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_7161d1a9-f6ed-42d8-aa03-dbbdd153016e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_5fc82822-68e2-42cd-9465-a072efca229a_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_38a0c0b6-d00f-4f64-a093-d75a711c0eaf_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f5056763-4389-43b6-b90a-f81c155b4b4e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_6ae8acb5-c809-4413-bba9-6dcd4507fb10_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock units, net of taxes</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0fa0fd8c-e90c-42c4-81aa-63d129ec6027_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_29ec332f-187a-4476-96a0-84d960006493_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_69bdfb01-110b-43b9-a8f7-04551c2726f1_totalLabel_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, cash balances and available-for-sale securities</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_label_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_documentation_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Also includes amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:href="fold-20220630.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:to="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_8de15bc4-6f19-4bed-b9dc-7ff889f566e3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_65604df3-931e-44a6-a7c1-854b4ce646fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_74d5441f-130f-4f6d-83bd-64f4eaac09c6_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_c4275ba0-b060-4e26-b682-0b3ac80aa452_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e8c05980-d015-4885-92ac-9b1851a59022_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a725d980-eb11-4dc0-a71b-cdbb39ec40f9_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_5df83acb-6882-4abf-a617-8e5a10bf7831_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_124941eb-1095-49d0-9dcf-6b1ae7abda7a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_8f28f784-49f9-430e-9bca-4666943ba89b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_7b8115d4-17fb-4613-91e6-f997d3e58c0b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_c0d17c78-ebfe-4119-b1b5-c0786e8fb868_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e6a0822f-b027-4f78-9212-05ad2cc24d23_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9635f94c-5b99-4f8d-ae1c-d7b87afc38f7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_ba831774-4dd1-4273-b92e-6c4a20633aa6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_70191169-105e-4ed5-a12c-742067aec1a2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_05695dcc-50ba-4461-b74c-8e98824bd09c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive (loss) gain:</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_984c7d88-1cb1-4208-b4c6-64043a41bef3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_9369a1fb-b52c-4021-a818-77d24fec02b5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_1554224a-070c-4e56-ba7f-2f1916d29cf3_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general, and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_422a10a3-bd48-4a90-ba40-bfd94ef9ed11_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash changes in the fair value of contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_27957f64-5bfb-45e5-8ebc-e459ff7cdb5e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_620f592e-033f-4b07-b50c-95a5145f16b2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized loss, available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_626720e9-f52b-48ce-a71f-c0a2a8b343a3_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_7137fe80-b1df-4e3f-a82f-9e83d8910507_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_6d8e63cb-d4e2-4d06-beaa-e78d87cd7244_negatedLabel_en-US" xlink:label="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency remeasurement loss</link:label>
    <link:label id="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_label_en-US" xlink:label="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Remeasurement Gain (Loss), Before Tax</link:label>
    <link:label id="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_documentation_en-US" xlink:label="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Remeasurement Gain (Loss), Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:href="fold-20220630.xsd#fold_ForeignCurrencyRemeasurementGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:to="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_a2cb68a7-546c-404f-abbc-7f33324e2634_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7b78e5a6-dd63-4753-bbef-9bfec73c7443_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, vested and unvested expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_fceddabc-5319-4afb-bf4c-0ca17e0c8ed3_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_b4c206d3-17d4-455a-aa59-1f1270b7bc34_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_69b3d453-258c-41b5-a4d8-5af13fdaa10c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_26aa110d-ca1a-438b-be1f-8213d2f3efa0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on impairment of assets</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d0036ed4-42dc-4a4f-9ca2-bc66d6342311_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_871115c7-8ec6-4c66-a6bb-9f781f96feab_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: deferred financing</link:label>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_label_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts" xlink:to="lab_us-gaap_DeferredOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_b8033115-d1fb-4446-8585-9503701ce51f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6ef852c6-2af5-40c7-b5d0-816f427a2cf3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_480d95f5-b796-403c-ac08-4cb55cb255d0_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4a6ce2ac-2126-4388-8351-6192b6f217bf_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Developments</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_cd489712-4efe-482c-b063-5dbe35c0a977_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of the Numerator and Denominator Used in Computing Basic and Diluted Net Loss per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_40e71879-1397-4c76-b127-99825ce56804_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_4639099d-37e3-4074-8fd1-f1ac03668da8_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability Components of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_a604e52b-6c16-404b-83b6-55ced13577ee_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_500787ec-2837-4463-8dca-94b03a3c3178_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_3d0111f1-d9d2-4c9a-a2e9-2cacebdea00a_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_0a61eebd-3982-4f64-9ce2-f7bb1209fc0a_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCostsForContractsOrProgramsPolicy_b07b7101-3365-4634-b70a-5f2481612be7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCostsForContractsOrProgramsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories and Cost of Goods Sold</link:label>
    <link:label id="lab_us-gaap_InventoryCostsForContractsOrProgramsPolicy_label_en-US" xlink:label="lab_us-gaap_InventoryCostsForContractsOrProgramsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Costs for Contracts or Programs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCostsForContractsOrProgramsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCostsForContractsOrProgramsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCostsForContractsOrProgramsPolicy" xlink:to="lab_us-gaap_InventoryCostsForContractsOrProgramsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_dc4f32f9-cbc5-4309-8a8f-352db5d320ec_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>fold-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:3889360d-46b3-4f4f-a1c0-074f51e18b3e,g:d5204adc-c100-4730-97cf-6188f145481c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CoverPage" xlink:type="simple" xlink:href="fold-20220630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_bb24b6d3-052d-4a61-8955-146c2ca17c0e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_bf1b88c6-a492-48b6-83ac-dbe5c7ad68fe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb24b6d3-052d-4a61-8955-146c2ca17c0e" xlink:to="loc_dei_DocumentType_bf1b88c6-a492-48b6-83ac-dbe5c7ad68fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_1fd6848a-b39b-47ea-9f22-a22ffb0d58dd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb24b6d3-052d-4a61-8955-146c2ca17c0e" xlink:to="loc_dei_DocumentQuarterlyReport_1fd6848a-b39b-47ea-9f22-a22ffb0d58dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_19fd51ef-f053-4242-ae35-1886915142ce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb24b6d3-052d-4a61-8955-146c2ca17c0e" xlink:to="loc_dei_DocumentPeriodEndDate_19fd51ef-f053-4242-ae35-1886915142ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_b2011d8f-23d8-4ab3-abf0-4b141ddf31cb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb24b6d3-052d-4a61-8955-146c2ca17c0e" xlink:to="loc_dei_DocumentTransitionReport_b2011d8f-23d8-4ab3-abf0-4b141ddf31cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_8015bcba-7aaf-4791-b703-b7a7978b7d6f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb24b6d3-052d-4a61-8955-146c2ca17c0e" xlink:to="loc_dei_EntityFileNumber_8015bcba-7aaf-4791-b703-b7a7978b7d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a3f46945-f75c-4834-9c6f-a860063db275" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb24b6d3-052d-4a61-8955-146c2ca17c0e" xlink:to="loc_dei_EntityRegistrantName_a3f46945-f75c-4834-9c6f-a860063db275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1960f4e5-7f0e-49f0-9637-93f4ab4c5988" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb24b6d3-052d-4a61-8955-146c2ca17c0e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1960f4e5-7f0e-49f0-9637-93f4ab4c5988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_362f2c28-855f-47d6-9b2c-98590c5a0723" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb24b6d3-052d-4a61-8955-146c2ca17c0e" xlink:to="loc_dei_EntityTaxIdentificationNumber_362f2c28-855f-47d6-9b2c-98590c5a0723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_f8d4dd96-1fd5-42e7-b7db-532b6be8aab7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb24b6d3-052d-4a61-8955-146c2ca17c0e" xlink:to="loc_dei_EntityAddressAddressLine1_f8d4dd96-1fd5-42e7-b7db-532b6be8aab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_fc335b24-1347-4d89-bc8b-7807b9e9a845" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb24b6d3-052d-4a61-8955-146c2ca17c0e" xlink:to="loc_dei_EntityAddressCityOrTown_fc335b24-1347-4d89-bc8b-7807b9e9a845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_27c29730-2262-4d21-a54f-4d1a95737829" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb24b6d3-052d-4a61-8955-146c2ca17c0e" xlink:to="loc_dei_EntityAddressStateOrProvince_27c29730-2262-4d21-a54f-4d1a95737829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_817ba15c-66ea-4b45-8e87-e9fbb9dbaed3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb24b6d3-052d-4a61-8955-146c2ca17c0e" xlink:to="loc_dei_EntityAddressPostalZipCode_817ba15c-66ea-4b45-8e87-e9fbb9dbaed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_45c0f6a1-3afe-4fd0-a286-3b0ea23c8f3c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb24b6d3-052d-4a61-8955-146c2ca17c0e" xlink:to="loc_dei_CityAreaCode_45c0f6a1-3afe-4fd0-a286-3b0ea23c8f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_dc71e062-f31e-4660-b9aa-90a6b3cb90fe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb24b6d3-052d-4a61-8955-146c2ca17c0e" xlink:to="loc_dei_LocalPhoneNumber_dc71e062-f31e-4660-b9aa-90a6b3cb90fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_910d2b42-23ff-4e5f-9adc-b22455588c1f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb24b6d3-052d-4a61-8955-146c2ca17c0e" xlink:to="loc_dei_Security12bTitle_910d2b42-23ff-4e5f-9adc-b22455588c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_68867c9a-79f8-4fab-bbe1-34dff7f6e3a7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb24b6d3-052d-4a61-8955-146c2ca17c0e" xlink:to="loc_dei_TradingSymbol_68867c9a-79f8-4fab-bbe1-34dff7f6e3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d18d6bc6-ce55-4103-a5a5-2860b8725a4c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb24b6d3-052d-4a61-8955-146c2ca17c0e" xlink:to="loc_dei_SecurityExchangeName_d18d6bc6-ce55-4103-a5a5-2860b8725a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_16294a1d-11e0-479f-a14b-e9e27e9ad592" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb24b6d3-052d-4a61-8955-146c2ca17c0e" xlink:to="loc_dei_EntityCurrentReportingStatus_16294a1d-11e0-479f-a14b-e9e27e9ad592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_5aaa059a-9eb4-4fb0-847e-e48867937916" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb24b6d3-052d-4a61-8955-146c2ca17c0e" xlink:to="loc_dei_EntityInteractiveDataCurrent_5aaa059a-9eb4-4fb0-847e-e48867937916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_7015e6f7-125a-4b88-805a-6cbeaab14253" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb24b6d3-052d-4a61-8955-146c2ca17c0e" xlink:to="loc_dei_EntityFilerCategory_7015e6f7-125a-4b88-805a-6cbeaab14253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_d2602d1b-3d66-45d7-8d2e-04def595b64e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb24b6d3-052d-4a61-8955-146c2ca17c0e" xlink:to="loc_dei_EntitySmallBusiness_d2602d1b-3d66-45d7-8d2e-04def595b64e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6c7b2ced-3a5d-44ba-9181-78c1d7d4dc56" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb24b6d3-052d-4a61-8955-146c2ca17c0e" xlink:to="loc_dei_EntityEmergingGrowthCompany_6c7b2ced-3a5d-44ba-9181-78c1d7d4dc56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_06e3bd97-d97b-44f2-8d8a-a7081a26a79a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb24b6d3-052d-4a61-8955-146c2ca17c0e" xlink:to="loc_dei_EntityShellCompany_06e3bd97-d97b-44f2-8d8a-a7081a26a79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d3a3accd-6afe-4b11-94f2-571049532e61" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb24b6d3-052d-4a61-8955-146c2ca17c0e" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d3a3accd-6afe-4b11-94f2-571049532e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_05278676-12ad-480c-bd74-caff278dacb1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb24b6d3-052d-4a61-8955-146c2ca17c0e" xlink:to="loc_dei_EntityCentralIndexKey_05278676-12ad-480c-bd74-caff278dacb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_d5867a9f-a1ec-40a2-acdb-c3d8e9b26931" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb24b6d3-052d-4a61-8955-146c2ca17c0e" xlink:to="loc_dei_AmendmentFlag_d5867a9f-a1ec-40a2-acdb-c3d8e9b26931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_713e09f8-d4d8-4ac5-a74e-d0559c3340e7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb24b6d3-052d-4a61-8955-146c2ca17c0e" xlink:to="loc_dei_CurrentFiscalYearEndDate_713e09f8-d4d8-4ac5-a74e-d0559c3340e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_33f866bb-3458-4af7-a275-5877eae0f55f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb24b6d3-052d-4a61-8955-146c2ca17c0e" xlink:to="loc_dei_DocumentFiscalYearFocus_33f866bb-3458-4af7-a275-5877eae0f55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_6ae5a66f-ff86-43ad-8a93-001016219e86" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb24b6d3-052d-4a61-8955-146c2ca17c0e" xlink:to="loc_dei_DocumentFiscalPeriodFocus_6ae5a66f-ff86-43ad-8a93-001016219e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="fold-20220630.xsd#ConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_83d57d2f-7a18-46f0-a294-e4115e9f5f19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_47f1f099-7ea8-4e0b-bbad-6e11f52cd330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_83d57d2f-7a18-46f0-a294-e4115e9f5f19" xlink:to="loc_us-gaap_AssetsAbstract_47f1f099-7ea8-4e0b-bbad-6e11f52cd330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_f2873275-3fdd-4f89-9790-7bc1527fa16d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_47f1f099-7ea8-4e0b-bbad-6e11f52cd330" xlink:to="loc_us-gaap_AssetsCurrentAbstract_f2873275-3fdd-4f89-9790-7bc1527fa16d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d0d6c4a6-f873-415e-aad9-cb9b4b0269cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f2873275-3fdd-4f89-9790-7bc1527fa16d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d0d6c4a6-f873-415e-aad9-cb9b4b0269cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_2469ae5d-b61d-4bad-90c2-f9270e0087df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f2873275-3fdd-4f89-9790-7bc1527fa16d" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_2469ae5d-b61d-4bad-90c2-f9270e0087df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_89aed890-7397-4279-9798-1ca17cd3eb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f2873275-3fdd-4f89-9790-7bc1527fa16d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_89aed890-7397-4279-9798-1ca17cd3eb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b4fa4c08-a4ab-4056-8bb1-344b7f4ce8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f2873275-3fdd-4f89-9790-7bc1527fa16d" xlink:to="loc_us-gaap_InventoryNet_b4fa4c08-a4ab-4056-8bb1-344b7f4ce8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_877d7a42-c088-4efb-aebd-4316b5676066" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f2873275-3fdd-4f89-9790-7bc1527fa16d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_877d7a42-c088-4efb-aebd-4316b5676066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c26ae8ff-9964-478f-9366-5e30dfb804c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f2873275-3fdd-4f89-9790-7bc1527fa16d" xlink:to="loc_us-gaap_AssetsCurrent_c26ae8ff-9964-478f-9366-5e30dfb804c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c8dcaa66-baec-4b02-9a93-63c738bb9e38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_47f1f099-7ea8-4e0b-bbad-6e11f52cd330" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c8dcaa66-baec-4b02-9a93-63c738bb9e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a613a1ea-7e03-4ae0-be3a-edc822c8e2ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_47f1f099-7ea8-4e0b-bbad-6e11f52cd330" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a613a1ea-7e03-4ae0-be3a-edc822c8e2ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c98b379e-0010-48f4-8859-c9c84cdad297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_47f1f099-7ea8-4e0b-bbad-6e11f52cd330" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c98b379e-0010-48f4-8859-c9c84cdad297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0e14ccf0-0fac-497b-9eac-5a2cbfbf65e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_47f1f099-7ea8-4e0b-bbad-6e11f52cd330" xlink:to="loc_us-gaap_Goodwill_0e14ccf0-0fac-497b-9eac-5a2cbfbf65e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_fde07531-c827-43f6-9d79-de7530db2fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_47f1f099-7ea8-4e0b-bbad-6e11f52cd330" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_fde07531-c827-43f6-9d79-de7530db2fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c076e247-8ec1-49d3-861b-e3e34cbe6a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_47f1f099-7ea8-4e0b-bbad-6e11f52cd330" xlink:to="loc_us-gaap_Assets_c076e247-8ec1-49d3-861b-e3e34cbe6a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ffc5dba-0b96-4a5e-b9e8-9bc98ee85b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_83d57d2f-7a18-46f0-a294-e4115e9f5f19" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ffc5dba-0b96-4a5e-b9e8-9bc98ee85b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_fe8aa330-9d3b-421f-8b35-76d0b69aff1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ffc5dba-0b96-4a5e-b9e8-9bc98ee85b6a" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_fe8aa330-9d3b-421f-8b35-76d0b69aff1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3d89a4cd-476b-4e34-9821-495f1c5757f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fe8aa330-9d3b-421f-8b35-76d0b69aff1d" xlink:to="loc_us-gaap_AccountsPayableCurrent_3d89a4cd-476b-4e34-9821-495f1c5757f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_385ce9a1-357d-457a-94ab-52699de55def" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fe8aa330-9d3b-421f-8b35-76d0b69aff1d" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_385ce9a1-357d-457a-94ab-52699de55def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_0d8773c3-5b42-41ab-beb2-678c4be7efbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fe8aa330-9d3b-421f-8b35-76d0b69aff1d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_0d8773c3-5b42-41ab-beb2-678c4be7efbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_84efa499-f817-48b2-b044-9cdd03a5241f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fe8aa330-9d3b-421f-8b35-76d0b69aff1d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_84efa499-f817-48b2-b044-9cdd03a5241f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d6ab50d9-c826-4107-aca8-c94fa32a871e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fe8aa330-9d3b-421f-8b35-76d0b69aff1d" xlink:to="loc_us-gaap_LiabilitiesCurrent_d6ab50d9-c826-4107-aca8-c94fa32a871e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_1b1f7fa5-c54b-4211-968b-4ec0f64899d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ffc5dba-0b96-4a5e-b9e8-9bc98ee85b6a" xlink:to="loc_us-gaap_LongTermDebt_1b1f7fa5-c54b-4211-968b-4ec0f64899d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7b5fe9b1-efa7-4bde-882e-fe50d633524a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ffc5dba-0b96-4a5e-b9e8-9bc98ee85b6a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7b5fe9b1-efa7-4bde-882e-fe50d633524a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_597a1ac4-5516-4fd7-9d29-af404488746c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ffc5dba-0b96-4a5e-b9e8-9bc98ee85b6a" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_597a1ac4-5516-4fd7-9d29-af404488746c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_ad2a9b39-6b1a-400a-b46d-035fbb33cc66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ffc5dba-0b96-4a5e-b9e8-9bc98ee85b6a" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_ad2a9b39-6b1a-400a-b46d-035fbb33cc66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b9565008-ed9d-46b3-9859-051ad5111bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ffc5dba-0b96-4a5e-b9e8-9bc98ee85b6a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b9565008-ed9d-46b3-9859-051ad5111bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3e2f1c16-372b-46f4-81b8-d7f63e5b6957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ffc5dba-0b96-4a5e-b9e8-9bc98ee85b6a" xlink:to="loc_us-gaap_Liabilities_3e2f1c16-372b-46f4-81b8-d7f63e5b6957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a835fcd0-c71c-46fc-ba0d-25fc115f0810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ffc5dba-0b96-4a5e-b9e8-9bc98ee85b6a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a835fcd0-c71c-46fc-ba0d-25fc115f0810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_edf88a5c-d1a2-440f-b624-6a7ba635e24f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ffc5dba-0b96-4a5e-b9e8-9bc98ee85b6a" xlink:to="loc_us-gaap_StockholdersEquityAbstract_edf88a5c-d1a2-440f-b624-6a7ba635e24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_583ed58b-ba70-4a7c-a4d9-a3e5662e9c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_edf88a5c-d1a2-440f-b624-6a7ba635e24f" xlink:to="loc_us-gaap_CommonStockValue_583ed58b-ba70-4a7c-a4d9-a3e5662e9c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_697ce952-c53c-4e96-86ee-f09b496d6207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_edf88a5c-d1a2-440f-b624-6a7ba635e24f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_697ce952-c53c-4e96-86ee-f09b496d6207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_5c16ed89-b377-430f-9548-f9c0722237f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_edf88a5c-d1a2-440f-b624-6a7ba635e24f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_5c16ed89-b377-430f-9548-f9c0722237f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_d71be66b-3dab-4408-b6de-f49306afa64c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_5c16ed89-b377-430f-9548-f9c0722237f9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_d71be66b-3dab-4408-b6de-f49306afa64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_ad539d79-0e16-445a-aff0-4e44af81548a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_5c16ed89-b377-430f-9548-f9c0722237f9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_ad539d79-0e16-445a-aff0-4e44af81548a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_29128ebe-3aed-4c36-97ba-32afdbf95838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_edf88a5c-d1a2-440f-b624-6a7ba635e24f" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_29128ebe-3aed-4c36-97ba-32afdbf95838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3d04c0a1-a32a-4fff-8055-592e66bc3356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_edf88a5c-d1a2-440f-b624-6a7ba635e24f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3d04c0a1-a32a-4fff-8055-592e66bc3356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_42330335-3fa3-4e09-ae9e-f3eadf4fd06b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_edf88a5c-d1a2-440f-b624-6a7ba635e24f" xlink:to="loc_us-gaap_StockholdersEquity_42330335-3fa3-4e09-ae9e-f3eadf4fd06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e645189a-490d-44ec-9bcd-f9cc13ca34ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ffc5dba-0b96-4a5e-b9e8-9bc98ee85b6a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_e645189a-490d-44ec-9bcd-f9cc13ca34ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="fold-20220630.xsd#ConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b2f2b5c4-a823-4bf8-8b16-106c3421fa98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_18a2e788-6c18-41c6-b289-3aac0c7a77a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b2f2b5c4-a823-4bf8-8b16-106c3421fa98" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_18a2e788-6c18-41c6-b289-3aac0c7a77a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_27d0933e-655f-4469-9e74-50f616b37e13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b2f2b5c4-a823-4bf8-8b16-106c3421fa98" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_27d0933e-655f-4469-9e74-50f616b37e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_14e480ed-6a99-45bd-aeed-891a344fce9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b2f2b5c4-a823-4bf8-8b16-106c3421fa98" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_14e480ed-6a99-45bd-aeed-891a344fce9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b472ddde-cb2e-436d-bf3b-82e40b6eca89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b2f2b5c4-a823-4bf8-8b16-106c3421fa98" xlink:to="loc_us-gaap_CommonStockSharesIssued_b472ddde-cb2e-436d-bf3b-82e40b6eca89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c889fb12-f845-4c29-a52a-67823d1d7c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b2f2b5c4-a823-4bf8-8b16-106c3421fa98" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c889fb12-f845-4c29-a52a-67823d1d7c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="fold-20220630.xsd#ConsolidatedStatementsofOperationsUnaudited"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_638a3da6-e7bf-4a7b-8399-b41bb09d1139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_77135d28-f1e9-42c9-90ad-e9ce485f7428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_638a3da6-e7bf-4a7b-8399-b41bb09d1139" xlink:to="loc_us-gaap_RevenuesAbstract_77135d28-f1e9-42c9-90ad-e9ce485f7428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_931c11a8-ec72-4a55-a479-5985181016f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_77135d28-f1e9-42c9-90ad-e9ce485f7428" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_931c11a8-ec72-4a55-a479-5985181016f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_a473529c-97b9-40bc-8f33-5fcabbf4cbc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_77135d28-f1e9-42c9-90ad-e9ce485f7428" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_a473529c-97b9-40bc-8f33-5fcabbf4cbc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_9f37a038-fad9-49a7-a81a-72d6c16910a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_77135d28-f1e9-42c9-90ad-e9ce485f7428" xlink:to="loc_us-gaap_GrossProfit_9f37a038-fad9-49a7-a81a-72d6c16910a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_ed9c82d0-628b-4ddd-8ff9-bc3d892f8a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_638a3da6-e7bf-4a7b-8399-b41bb09d1139" xlink:to="loc_us-gaap_OperatingExpensesAbstract_ed9c82d0-628b-4ddd-8ff9-bc3d892f8a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1e7f8333-c191-42c4-a55b-97ca211033c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ed9c82d0-628b-4ddd-8ff9-bc3d892f8a0e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1e7f8333-c191-42c4-a55b-97ca211033c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7c444a70-4e28-41dc-b6d1-67dd98c14292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ed9c82d0-628b-4ddd-8ff9-bc3d892f8a0e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7c444a70-4e28-41dc-b6d1-67dd98c14292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c9c4d462-2e17-45c7-af20-cc2cbade9fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ed9c82d0-628b-4ddd-8ff9-bc3d892f8a0e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c9c4d462-2e17-45c7-af20-cc2cbade9fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_51f04112-f5dc-415b-89af-b4263ed60ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ed9c82d0-628b-4ddd-8ff9-bc3d892f8a0e" xlink:to="loc_us-gaap_AssetImpairmentCharges_51f04112-f5dc-415b-89af-b4263ed60ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_e9327abc-8071-46c0-83e8-1567efbd44cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ed9c82d0-628b-4ddd-8ff9-bc3d892f8a0e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_e9327abc-8071-46c0-83e8-1567efbd44cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_42e42131-1307-4ecb-8030-bf97fbe3001b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ed9c82d0-628b-4ddd-8ff9-bc3d892f8a0e" xlink:to="loc_us-gaap_OperatingExpenses_42e42131-1307-4ecb-8030-bf97fbe3001b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_94afb426-f1ff-4967-82d1-bfced72915d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_638a3da6-e7bf-4a7b-8399-b41bb09d1139" xlink:to="loc_us-gaap_OperatingIncomeLoss_94afb426-f1ff-4967-82d1-bfced72915d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_926b5dcc-cad5-48ca-9769-e6d531bad63b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_638a3da6-e7bf-4a7b-8399-b41bb09d1139" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_926b5dcc-cad5-48ca-9769-e6d531bad63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_3faa1fe8-5cf9-4a8c-a98e-4c2521b78811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_926b5dcc-cad5-48ca-9769-e6d531bad63b" xlink:to="loc_us-gaap_InvestmentIncomeInterest_3faa1fe8-5cf9-4a8c-a98e-4c2521b78811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_80dbde5a-2363-4b28-b92a-8538fe7f9ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_926b5dcc-cad5-48ca-9769-e6d531bad63b" xlink:to="loc_us-gaap_InterestExpense_80dbde5a-2363-4b28-b92a-8538fe7f9ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_11303928-a466-412b-bf9f-a4e63cc01e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_926b5dcc-cad5-48ca-9769-e6d531bad63b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_11303928-a466-412b-bf9f-a4e63cc01e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ff91b37b-9aaf-4b57-8d83-bc2bdbb9a834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_638a3da6-e7bf-4a7b-8399-b41bb09d1139" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ff91b37b-9aaf-4b57-8d83-bc2bdbb9a834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_fd2904b4-a500-4ed8-9fe7-31eb1ee233bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_638a3da6-e7bf-4a7b-8399-b41bb09d1139" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_fd2904b4-a500-4ed8-9fe7-31eb1ee233bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9dba8a12-1f8d-453d-9579-ed4bd82c92ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_638a3da6-e7bf-4a7b-8399-b41bb09d1139" xlink:to="loc_us-gaap_NetIncomeLoss_9dba8a12-1f8d-453d-9579-ed4bd82c92ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1de6a5a3-f7f4-43dc-94be-a734a622c3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_638a3da6-e7bf-4a7b-8399-b41bb09d1139" xlink:to="loc_us-gaap_EarningsPerShareBasic_1de6a5a3-f7f4-43dc-94be-a734a622c3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d00b1f1e-8576-4a9f-a608-dab08255eb74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_638a3da6-e7bf-4a7b-8399-b41bb09d1139" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d00b1f1e-8576-4a9f-a608-dab08255eb74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_47bb68eb-792b-403b-a95f-35c3fdee942d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_638a3da6-e7bf-4a7b-8399-b41bb09d1139" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_47bb68eb-792b-403b-a95f-35c3fdee942d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0d8df930-5f74-433f-98df-8d82c695299b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_638a3da6-e7bf-4a7b-8399-b41bb09d1139" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0d8df930-5f74-433f-98df-8d82c695299b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="fold-20220630.xsd#ConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1f6ea0d2-9690-48ac-b9de-39d76042b2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_19256ca4-710d-43b0-8401-416cb57b8866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1f6ea0d2-9690-48ac-b9de-39d76042b2f6" xlink:to="loc_us-gaap_NetIncomeLoss_19256ca4-710d-43b0-8401-416cb57b8866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5013a41b-b393-4962-beaa-4b69e4133b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1f6ea0d2-9690-48ac-b9de-39d76042b2f6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5013a41b-b393-4962-beaa-4b69e4133b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_035078bd-a564-4f87-85a1-9994687095ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5013a41b-b393-4962-beaa-4b69e4133b1e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_035078bd-a564-4f87-85a1-9994687095ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_b914c55f-96d8-43a1-8660-f201d56ac649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5013a41b-b393-4962-beaa-4b69e4133b1e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_b914c55f-96d8-43a1-8660-f201d56ac649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_25f5d5ec-ffb6-4984-8216-4a777310e4de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5013a41b-b393-4962-beaa-4b69e4133b1e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_25f5d5ec-ffb6-4984-8216-4a777310e4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_52940b09-3b45-4887-b624-cf1c6c133fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1f6ea0d2-9690-48ac-b9de-39d76042b2f6" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_52940b09-3b45-4887-b624-cf1c6c133fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited" xlink:type="simple" xlink:href="fold-20220630.xsd#ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_4202366f-c57a-42f3-84c7-17b159cb5074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_783310eb-58c3-4250-af78-8f63a70f8f81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_4202366f-c57a-42f3-84c7-17b159cb5074" xlink:to="loc_us-gaap_StatementTable_783310eb-58c3-4250-af78-8f63a70f8f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7fccab92-e79b-434d-8aea-570c8ec0593c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_783310eb-58c3-4250-af78-8f63a70f8f81" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7fccab92-e79b-434d-8aea-570c8ec0593c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e8d0decd-0c6c-436c-9d46-f9f0def39e41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7fccab92-e79b-434d-8aea-570c8ec0593c" xlink:to="loc_us-gaap_EquityComponentDomain_e8d0decd-0c6c-436c-9d46-f9f0def39e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_276f2b7b-1b78-4e38-b366-2b7118aaecb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e8d0decd-0c6c-436c-9d46-f9f0def39e41" xlink:to="loc_us-gaap_CommonStockMember_276f2b7b-1b78-4e38-b366-2b7118aaecb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_cff3a437-c6be-493f-b765-b58ab3a74bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e8d0decd-0c6c-436c-9d46-f9f0def39e41" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_cff3a437-c6be-493f-b765-b58ab3a74bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_ed8983cc-f34e-4652-bc36-f37706114ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e8d0decd-0c6c-436c-9d46-f9f0def39e41" xlink:to="loc_us-gaap_WarrantMember_ed8983cc-f34e-4652-bc36-f37706114ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeMember_f5236a4f-970b-4a25-9759-e211da520033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e8d0decd-0c6c-436c-9d46-f9f0def39e41" xlink:to="loc_us-gaap_ComprehensiveIncomeMember_f5236a4f-970b-4a25-9759-e211da520033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_197c56bd-c878-4c4e-b9b7-207cd1577656" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e8d0decd-0c6c-436c-9d46-f9f0def39e41" xlink:to="loc_us-gaap_RetainedEarningsMember_197c56bd-c878-4c4e-b9b7-207cd1577656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_cc947fb9-ae9c-4b6f-b425-890e62923fff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_783310eb-58c3-4250-af78-8f63a70f8f81" xlink:to="loc_us-gaap_StatementLineItems_cc947fb9-ae9c-4b6f-b425-890e62923fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cc947fb9-ae9c-4b6f-b425-890e62923fff" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_573b9c9d-bbff-49ff-b9e1-0b316ce2b1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_573b9c9d-bbff-49ff-b9e1-0b316ce2b1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d8ef37ce-15bc-412e-aff1-457ebb39fbc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:to="loc_us-gaap_StockholdersEquity_d8ef37ce-15bc-412e-aff1-457ebb39fbc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1fe86b3a-bf51-4337-8739-1c9287841854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1fe86b3a-bf51-4337-8739-1c9287841854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7e14726c-4267-4e7b-8a7a-b77b0c8faacb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7e14726c-4267-4e7b-8a7a-b77b0c8faacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_26b8c904-8cb5-4e5f-8be5-fc64c3d5b670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_26b8c904-8cb5-4e5f-8be5-fc64c3d5b670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_463fed5a-3ff2-4810-808c-df4961edda0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_463fed5a-3ff2-4810-808c-df4961edda0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7e9ce906-bc42-4351-bded-f0097767b4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7e9ce906-bc42-4351-bded-f0097767b4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_b737a59b-869c-4065-88b8-1e34243ac31f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_b737a59b-869c-4065-88b8-1e34243ac31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_83413c6a-04a5-4b77-a068-c7801c258cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_83413c6a-04a5-4b77-a068-c7801c258cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9a1f75d9-5845-4a7e-914a-0bb92cce4b69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:to="loc_us-gaap_NetIncomeLoss_9a1f75d9-5845-4a7e-914a-0bb92cce4b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised_a280b7ea-1219-4100-a508-c5116326e979" xlink:href="fold-20220630.xsd#fold_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:to="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised_a280b7ea-1219-4100-a508-c5116326e979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised_a5d5f454-8cd6-41d0-add7-06d63ad87559" xlink:href="fold-20220630.xsd#fold_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:to="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised_a5d5f454-8cd6-41d0-add7-06d63ad87559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_038c035a-5ac3-461c-b978-52cc1b7917bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_038c035a-5ac3-461c-b978-52cc1b7917bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_7f3d1d7a-f0f9-4bd3-a21b-11ed1384655e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_7f3d1d7a-f0f9-4bd3-a21b-11ed1384655e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4c3b3e4a-9395-4681-8a7c-ddd75de3a6db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4c3b3e4a-9395-4681-8a7c-ddd75de3a6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_02f34002-f019-477a-8231-02890cfee089" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33fed96c-4eab-40e8-83e0-adc9ccb1d75f" xlink:to="loc_us-gaap_StockholdersEquity_02f34002-f019-477a-8231-02890cfee089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="fold-20220630.xsd#ConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_a2f22e0e-54b5-4b10-a77b-2a4481fce0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b8208a84-c2ec-4b0a-ada3-bcf99a33cd48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a2f22e0e-54b5-4b10-a77b-2a4481fce0f9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b8208a84-c2ec-4b0a-ada3-bcf99a33cd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9fd9dd0d-0f7c-46f8-a3a4-9cd0ea88a782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b8208a84-c2ec-4b0a-ada3-bcf99a33cd48" xlink:to="loc_us-gaap_ProfitLoss_9fd9dd0d-0f7c-46f8-a3a4-9cd0ea88a782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3aab4fea-d036-485e-a3c6-15c079ffcdfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b8208a84-c2ec-4b0a-ada3-bcf99a33cd48" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3aab4fea-d036-485e-a3c6-15c079ffcdfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a4df123f-fa05-4840-82b4-6c495540c026" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3aab4fea-d036-485e-a3c6-15c079ffcdfb" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a4df123f-fa05-4840-82b4-6c495540c026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_cfa43dda-5c00-47c3-8694-45cd1787c839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3aab4fea-d036-485e-a3c6-15c079ffcdfb" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_cfa43dda-5c00-47c3-8694-45cd1787c839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d2fce16e-cec3-4fee-a628-43e136accb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3aab4fea-d036-485e-a3c6-15c079ffcdfb" xlink:to="loc_us-gaap_ShareBasedCompensation_d2fce16e-cec3-4fee-a628-43e136accb8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_d6c17902-cb08-4ca4-86e9-21ae8a8cc106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3aab4fea-d036-485e-a3c6-15c079ffcdfb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_d6c17902-cb08-4ca4-86e9-21ae8a8cc106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_ab79227c-9c7b-4822-8382-d1cba7b60c21" xlink:href="fold-20220630.xsd#fold_ForeignCurrencyRemeasurementGainLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3aab4fea-d036-485e-a3c6-15c079ffcdfb" xlink:to="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_ab79227c-9c7b-4822-8382-d1cba7b60c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AssetImpairmentChargesAndOtherAssetWriteOffs_b0d0cd26-7916-4a49-a82f-3dbcffc8ce84" xlink:href="fold-20220630.xsd#fold_AssetImpairmentChargesAndOtherAssetWriteOffs"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3aab4fea-d036-485e-a3c6-15c079ffcdfb" xlink:to="loc_fold_AssetImpairmentChargesAndOtherAssetWriteOffs_b0d0cd26-7916-4a49-a82f-3dbcffc8ce84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f669c5ce-5773-43d0-a5d0-54a999c069ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3aab4fea-d036-485e-a3c6-15c079ffcdfb" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f669c5ce-5773-43d0-a5d0-54a999c069ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_472c9fd7-6735-42bc-bf80-dd7d7b4a9a76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f669c5ce-5773-43d0-a5d0-54a999c069ce" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_472c9fd7-6735-42bc-bf80-dd7d7b4a9a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f358fa5a-a6ed-44ad-ab63-7ab35c39fbbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f669c5ce-5773-43d0-a5d0-54a999c069ce" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f358fa5a-a6ed-44ad-ab63-7ab35c39fbbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6037b522-dd5c-44de-9b1b-d4c0a15791d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f669c5ce-5773-43d0-a5d0-54a999c069ce" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6037b522-dd5c-44de-9b1b-d4c0a15791d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4128feae-5873-471f-8784-9e8466964a99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f669c5ce-5773-43d0-a5d0-54a999c069ce" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4128feae-5873-471f-8784-9e8466964a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_e403b7a3-5a64-4957-b386-87743f97f72f" xlink:href="fold-20220630.xsd#fold_IncreaseDecreaseInNoncurrentOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f669c5ce-5773-43d0-a5d0-54a999c069ce" xlink:to="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_e403b7a3-5a64-4957-b386-87743f97f72f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70ccd2da-67d1-4014-ac6e-6c0717ad8eba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b8208a84-c2ec-4b0a-ada3-bcf99a33cd48" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70ccd2da-67d1-4014-ac6e-6c0717ad8eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_adf94977-6131-4b7e-ab92-315b2fca7e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a2f22e0e-54b5-4b10-a77b-2a4481fce0f9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_adf94977-6131-4b7e-ab92-315b2fca7e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_3f06774d-6b03-4daa-bda2-847c6169b2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_adf94977-6131-4b7e-ab92-315b2fca7e2a" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_3f06774d-6b03-4daa-bda2-847c6169b2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_00afd245-e3be-4622-9b3f-e00b19c4bf7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_adf94977-6131-4b7e-ab92-315b2fca7e2a" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_00afd245-e3be-4622-9b3f-e00b19c4bf7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3d4d1baa-6cb4-44d0-b828-1d8b1c517d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_adf94977-6131-4b7e-ab92-315b2fca7e2a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3d4d1baa-6cb4-44d0-b828-1d8b1c517d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_64d0f0b9-8cbd-4cd0-b754-99f5d6ce04bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_adf94977-6131-4b7e-ab92-315b2fca7e2a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_64d0f0b9-8cbd-4cd0-b754-99f5d6ce04bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_42ccf98a-0aa5-4fb2-85fd-c6fa2c24c913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a2f22e0e-54b5-4b10-a77b-2a4481fce0f9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_42ccf98a-0aa5-4fb2-85fd-c6fa2c24c913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_6a742b17-c8e9-46aa-9d36-ddf79dd9a3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_42ccf98a-0aa5-4fb2-85fd-c6fa2c24c913" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_6a742b17-c8e9-46aa-9d36-ddf79dd9a3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_b6e41d8c-6edd-4647-bd2a-29852fd8b661" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_42ccf98a-0aa5-4fb2-85fd-c6fa2c24c913" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_b6e41d8c-6edd-4647-bd2a-29852fd8b661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_60da3225-36ca-42ec-ac87-75d85c6bbda8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_42ccf98a-0aa5-4fb2-85fd-c6fa2c24c913" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_60da3225-36ca-42ec-ac87-75d85c6bbda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_da6aeb34-3ab7-4570-89c9-b818072b6856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_42ccf98a-0aa5-4fb2-85fd-c6fa2c24c913" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_da6aeb34-3ab7-4570-89c9-b818072b6856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_344a9f91-374d-437f-96a4-a2e034330ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_42ccf98a-0aa5-4fb2-85fd-c6fa2c24c913" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_344a9f91-374d-437f-96a4-a2e034330ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_631f1644-02fd-46f2-940b-0d9f8b6c6af4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a2f22e0e-54b5-4b10-a77b-2a4481fce0f9" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_631f1644-02fd-46f2-940b-0d9f8b6c6af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_478b69cd-b8c8-447d-b7b3-a46bcf61e085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a2f22e0e-54b5-4b10-a77b-2a4481fce0f9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_478b69cd-b8c8-447d-b7b3-a46bcf61e085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_92162f6e-4182-4b2d-8af5-172aff57f3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a2f22e0e-54b5-4b10-a77b-2a4481fce0f9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_92162f6e-4182-4b2d-8af5-172aff57f3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ee306c8f-254e-489c-9782-6142a105353d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a2f22e0e-54b5-4b10-a77b-2a4481fce0f9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ee306c8f-254e-489c-9782-6142a105353d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_071cd6dd-bc36-47b1-bf54-b42da7f257e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a2f22e0e-54b5-4b10-a77b-2a4481fce0f9" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_071cd6dd-bc36-47b1-bf54-b42da7f257e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_8333bf33-40b7-480b-93f8-a28ef8205250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_071cd6dd-bc36-47b1-bf54-b42da7f257e4" xlink:to="loc_us-gaap_InterestPaidNet_8333bf33-40b7-480b-93f8-a28ef8205250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_593ae5d2-68c2-436b-bf62-5e809cdf2841" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_071cd6dd-bc36-47b1-bf54-b42da7f257e4" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_593ae5d2-68c2-436b-bf62-5e809cdf2841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a6b9c25a-3d77-4a08-b573-6847fbbeab06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_071cd6dd-bc36-47b1-bf54-b42da7f257e4" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a6b9c25a-3d77-4a08-b573-6847fbbeab06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForTenantImprovements_6bfc9c6c-b2cd-436d-b538-75111fe652a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForTenantImprovements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_071cd6dd-bc36-47b1-bf54-b42da7f257e4" xlink:to="loc_us-gaap_PaymentsForTenantImprovements_6bfc9c6c-b2cd-436d-b538-75111fe652a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="fold-20220630.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7532db8d-ce76-4a6d-b69c-c4008a13d1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d8d95c75-e529-486e-920c-1877b055a653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7532db8d-ce76-4a6d-b69c-c4008a13d1d1" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d8d95c75-e529-486e-920c-1877b055a653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#DescriptionofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_86261e6e-2563-4d8e-a03b-87271852582d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cc296576-81da-4404-b5da-f578ab54a629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_86261e6e-2563-4d8e-a03b-87271852582d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cc296576-81da-4404-b5da-f578ab54a629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="fold-20220630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5961faf2-ea8b-439d-979e-d6f34e428b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_81fd92fe-0b84-48d5-ad02-cc91ace1124e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5961faf2-ea8b-439d-979e-d6f34e428b06" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_81fd92fe-0b84-48d5-ad02-cc91ace1124e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="fold-20220630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5c34adab-9ce8-47b9-9450-7f87814643bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5b61c730-7795-4d76-a0db-83c454759226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c34adab-9ce8-47b9-9450-7f87814643bd" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5b61c730-7795-4d76-a0db-83c454759226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_3488995d-75d6-4a0d-82ff-793ff3a45386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c34adab-9ce8-47b9-9450-7f87814643bd" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_3488995d-75d6-4a0d-82ff-793ff3a45386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_67598d18-af23-4b0a-9968-302bcfbe4641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c34adab-9ce8-47b9-9450-7f87814643bd" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_67598d18-af23-4b0a-9968-302bcfbe4641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_40c3cd99-dbf9-4793-a282-7f4212400c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c34adab-9ce8-47b9-9450-7f87814643bd" xlink:to="loc_us-gaap_UseOfEstimates_40c3cd99-dbf9-4793-a282-7f4212400c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_d1ed0901-e882-40bf-9bd3-436c3d9be20d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c34adab-9ce8-47b9-9450-7f87814643bd" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_d1ed0901-e882-40bf-9bd3-436c3d9be20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_3f348139-a35e-46bf-919b-7da2ddfab54c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c34adab-9ce8-47b9-9450-7f87814643bd" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_3f348139-a35e-46bf-919b-7da2ddfab54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_29ec48ab-4614-481f-84d3-3950e8b99de4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c34adab-9ce8-47b9-9450-7f87814643bd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_29ec48ab-4614-481f-84d3-3950e8b99de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1ba0f84e-6b49-4777-a680-d6f82a88c678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c34adab-9ce8-47b9-9450-7f87814643bd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1ba0f84e-6b49-4777-a680-d6f82a88c678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCostsForContractsOrProgramsPolicy_5da362ba-0a61-4176-81ae-0047591f0a49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCostsForContractsOrProgramsPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c34adab-9ce8-47b9-9450-7f87814643bd" xlink:to="loc_us-gaap_InventoryCostsForContractsOrProgramsPolicy_5da362ba-0a61-4176-81ae-0047591f0a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1db71187-9698-48a5-a865-71a76e4050e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c34adab-9ce8-47b9-9450-7f87814643bd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1db71187-9698-48a5-a865-71a76e4050e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_eb8a8552-0886-4229-957c-4d4620ea3bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c34adab-9ce8-47b9-9450-7f87814643bd" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_eb8a8552-0886-4229-957c-4d4620ea3bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="fold-20220630.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_20b8f6e4-4574-4b83-8efd-4f90a2f81188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_61660e2e-69f4-425d-af86-e6b4ec90b06c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_20b8f6e4-4574-4b83-8efd-4f90a2f81188" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_61660e2e-69f4-425d-af86-e6b4ec90b06c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_667903f0-5dab-41b3-ad2e-67c772f1a3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_2fbdf08f-1423-440d-85ac-8467527af8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_667903f0-5dab-41b3-ad2e-67c772f1a3aa" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_2fbdf08f-1423-440d-85ac-8467527af8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ae7144c0-3626-4864-9ee2-fdbe25035592" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_2fbdf08f-1423-440d-85ac-8467527af8b9" xlink:to="loc_srt_StatementGeographicalAxis_ae7144c0-3626-4864-9ee2-fdbe25035592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f2e3c8da-2abd-4fc7-99cb-628e8201d20d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_ae7144c0-3626-4864-9ee2-fdbe25035592" xlink:to="loc_srt_SegmentGeographicalDomain_f2e3c8da-2abd-4fc7-99cb-628e8201d20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_fe396eef-1028-401a-b168-557678e94840" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f2e3c8da-2abd-4fc7-99cb-628e8201d20d" xlink:to="loc_country_US_fe396eef-1028-401a-b168-557678e94840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_ca6787d8-f460-4b04-a35f-ef6d7343b4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f2e3c8da-2abd-4fc7-99cb-628e8201d20d" xlink:to="loc_us-gaap_NonUsMember_ca6787d8-f460-4b04-a35f-ef6d7343b4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dd4671ad-33f0-4c1f-96db-173fd836ea85" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_2fbdf08f-1423-440d-85ac-8467527af8b9" xlink:to="loc_srt_RangeAxis_dd4671ad-33f0-4c1f-96db-173fd836ea85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6bd78a96-e0bf-4a64-92b4-3850719e9f8c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_dd4671ad-33f0-4c1f-96db-173fd836ea85" xlink:to="loc_srt_RangeMember_6bd78a96-e0bf-4a64-92b4-3850719e9f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_381d21ef-5d43-46b1-91c5-3c932839f65f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6bd78a96-e0bf-4a64-92b4-3850719e9f8c" xlink:to="loc_srt_MinimumMember_381d21ef-5d43-46b1-91c5-3c932839f65f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_106b68c4-8fec-4eca-87bd-1d9a8142e1a5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6bd78a96-e0bf-4a64-92b4-3850719e9f8c" xlink:to="loc_srt_MaximumMember_106b68c4-8fec-4eca-87bd-1d9a8142e1a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5eafd15d-ae74-4999-8d52-8ab8839592dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_2fbdf08f-1423-440d-85ac-8467527af8b9" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5eafd15d-ae74-4999-8d52-8ab8839592dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_3e56d62f-91f4-413c-b22a-ee1b29068384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5eafd15d-ae74-4999-8d52-8ab8839592dc" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_3e56d62f-91f4-413c-b22a-ee1b29068384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4c0dd725-42a4-41eb-85e2-fc2c86f06517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5eafd15d-ae74-4999-8d52-8ab8839592dc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4c0dd725-42a4-41eb-85e2-fc2c86f06517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_0c1f3773-5d44-429d-b1b7-257400c42c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5eafd15d-ae74-4999-8d52-8ab8839592dc" xlink:to="loc_us-gaap_AssetImpairmentCharges_0c1f3773-5d44-429d-b1b7-257400c42c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_60c43ca3-7c11-439a-9dc6-c87bcecbf088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5eafd15d-ae74-4999-8d52-8ab8839592dc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_60c43ca3-7c11-439a-9dc6-c87bcecbf088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_7d46edef-cebb-4f60-bc31-ac9c3f78452e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5eafd15d-ae74-4999-8d52-8ab8839592dc" xlink:to="loc_us-gaap_ContractualObligation_7d46edef-cebb-4f60-bc31-ac9c3f78452e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash" xlink:type="simple" xlink:href="fold-20220630.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCash"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_95c7f434-5f5b-4944-95c4-e691e6f05c51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_79d94509-cc1b-4196-8764-7f9c5b03adbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_95c7f434-5f5b-4944-95c4-e691e6f05c51" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_79d94509-cc1b-4196-8764-7f9c5b03adbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables" xlink:type="simple" xlink:href="fold-20220630.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_687aca16-4a1a-47c3-9674-74b9e8d393ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_ef87d07d-8988-4c84-8e43-8428a4346cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_687aca16-4a1a-47c3-9674-74b9e8d393ce" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_ef87d07d-8988-4c84-8e43-8428a4346cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_87d78613-5670-483f-9a4c-834b4f9ae55f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_687aca16-4a1a-47c3-9674-74b9e8d393ce" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_87d78613-5670-483f-9a4c-834b4f9ae55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_572be5cf-eb8e-45b4-97a9-92d40cb6fc95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_78c4a9dc-2ab9-49ab-8d3a-b613934e83be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_572be5cf-eb8e-45b4-97a9-92d40cb6fc95" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_78c4a9dc-2ab9-49ab-8d3a-b613934e83be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_156ac635-432f-47c7-b8b3-0f2aa9c7efa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_78c4a9dc-2ab9-49ab-8d3a-b613934e83be" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_156ac635-432f-47c7-b8b3-0f2aa9c7efa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8294bd5d-79e7-4119-bf80-199433c6e906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_156ac635-432f-47c7-b8b3-0f2aa9c7efa8" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8294bd5d-79e7-4119-bf80-199433c6e906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_MarketableSecuritiesMember_bfc61fb2-a0fe-41df-b34c-1810757e1314" xlink:href="fold-20220630.xsd#fold_MarketableSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8294bd5d-79e7-4119-bf80-199433c6e906" xlink:to="loc_fold_MarketableSecuritiesMember_bfc61fb2-a0fe-41df-b34c-1810757e1314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3a0112dc-b6b7-42c2-809d-0fc73c6009b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_78c4a9dc-2ab9-49ab-8d3a-b613934e83be" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3a0112dc-b6b7-42c2-809d-0fc73c6009b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_146159d7-7ded-454c-afd4-908d4f5c5e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3a0112dc-b6b7-42c2-809d-0fc73c6009b2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_146159d7-7ded-454c-afd4-908d4f5c5e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_250bbc97-c95a-4a3a-8953-1071f13d3a93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3a0112dc-b6b7-42c2-809d-0fc73c6009b2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_250bbc97-c95a-4a3a-8953-1071f13d3a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesRealizedGainLoss_52406603-4ae9-49a5-be2d-66882f1815aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesRealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3a0112dc-b6b7-42c2-809d-0fc73c6009b2" xlink:to="loc_us-gaap_DebtSecuritiesRealizedGainLoss_52406603-4ae9-49a5-be2d-66882f1815aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_5d7f7bea-3734-432a-b7f9-74e38f5a7607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3a0112dc-b6b7-42c2-809d-0fc73c6009b2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_5d7f7bea-3734-432a-b7f9-74e38f5a7607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_b9177b7e-e49c-4a0b-94d4-31556512b7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c3e4e3d8-d289-4155-a1e7-085333f2b8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_b9177b7e-e49c-4a0b-94d4-31556512b7b2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c3e4e3d8-d289-4155-a1e7-085333f2b8b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a198dad5-6c64-4fb1-9eeb-9b43f8472ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c3e4e3d8-d289-4155-a1e7-085333f2b8b1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a198dad5-6c64-4fb1-9eeb-9b43f8472ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_70986e8e-bba6-4227-b12e-8231f6b6ce1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a198dad5-6c64-4fb1-9eeb-9b43f8472ffa" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_70986e8e-bba6-4227-b12e-8231f6b6ce1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_91a7a176-7ceb-4859-8d88-217a78924f57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_70986e8e-bba6-4227-b12e-8231f6b6ce1a" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_91a7a176-7ceb-4859-8d88-217a78924f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_b2b6dadd-d587-4e05-b3da-fe4e000a450a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_70986e8e-bba6-4227-b12e-8231f6b6ce1a" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_b2b6dadd-d587-4e05-b3da-fe4e000a450a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_2ae1cfcb-99de-4010-ae17-09d2f5642768" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_70986e8e-bba6-4227-b12e-8231f6b6ce1a" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_2ae1cfcb-99de-4010-ae17-09d2f5642768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2aff0e39-022c-45f9-bbd9-b815842da5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_70986e8e-bba6-4227-b12e-8231f6b6ce1a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2aff0e39-022c-45f9-bbd9-b815842da5d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShortTermCorporateDebtSecuritiesMember_9630f234-82f6-4fa7-9e51-3ae81a079b31" xlink:href="fold-20220630.xsd#fold_ShortTermCorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_70986e8e-bba6-4227-b12e-8231f6b6ce1a" xlink:to="loc_fold_ShortTermCorporateDebtSecuritiesMember_9630f234-82f6-4fa7-9e51-3ae81a079b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_e0deb64c-a79e-41f8-b86e-c1cbb1626697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_70986e8e-bba6-4227-b12e-8231f6b6ce1a" xlink:to="loc_us-gaap_CertificatesOfDepositMember_e0deb64c-a79e-41f8-b86e-c1cbb1626697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43dba368-2ff6-4c6f-b175-5bb320ecff44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c3e4e3d8-d289-4155-a1e7-085333f2b8b1" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43dba368-2ff6-4c6f-b175-5bb320ecff44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_43ade129-d2d8-4246-9ad3-5c05f8c6bdea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43dba368-2ff6-4c6f-b175-5bb320ecff44" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_43ade129-d2d8-4246-9ad3-5c05f8c6bdea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_481ac7c4-942c-4865-835d-b034c46173b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43dba368-2ff6-4c6f-b175-5bb320ecff44" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_481ac7c4-942c-4865-835d-b034c46173b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_e5587bfe-7932-4289-b666-165c3c6c78b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43dba368-2ff6-4c6f-b175-5bb320ecff44" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_e5587bfe-7932-4289-b666-165c3c6c78b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_89165249-b2b5-49a1-9a52-1369dd072bfa" xlink:href="fold-20220630.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43dba368-2ff6-4c6f-b175-5bb320ecff44" xlink:to="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_89165249-b2b5-49a1-9a52-1369dd072bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_dcc14eea-b6e5-49bb-abcb-63f49387c5cd" xlink:href="fold-20220630.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43dba368-2ff6-4c6f-b175-5bb320ecff44" xlink:to="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_dcc14eea-b6e5-49bb-abcb-63f49387c5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_740d3318-a155-409a-bafc-b83a8bbd209a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43dba368-2ff6-4c6f-b175-5bb320ecff44" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_740d3318-a155-409a-bafc-b83a8bbd209a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b42c0d51-c503-4e8a-ae66-91a625dfe773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43dba368-2ff6-4c6f-b175-5bb320ecff44" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b42c0d51-c503-4e8a-ae66-91a625dfe773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_343d7c0d-8ca6-4a48-a278-df4ab429b276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43dba368-2ff6-4c6f-b175-5bb320ecff44" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_343d7c0d-8ca6-4a48-a278-df4ab429b276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7dc4f2b5-3e28-47fb-bcfb-367cbb9f334a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43dba368-2ff6-4c6f-b175-5bb320ecff44" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7dc4f2b5-3e28-47fb-bcfb-367cbb9f334a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0b7cb83c-3135-4444-9ead-af1b923279bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43dba368-2ff6-4c6f-b175-5bb320ecff44" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0b7cb83c-3135-4444-9ead-af1b923279bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_28dc163a-5fd7-46bd-a1fd-c6cb1ed40f52" xlink:href="fold-20220630.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43dba368-2ff6-4c6f-b175-5bb320ecff44" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_28dc163a-5fd7-46bd-a1fd-c6cb1ed40f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2de8e603-311b-464f-b293-6f3ea6f8f569" xlink:href="fold-20220630.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43dba368-2ff6-4c6f-b175-5bb320ecff44" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2de8e603-311b-464f-b293-6f3ea6f8f569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6c6a8894-df58-414e-bd9e-7a24944209a5" xlink:href="fold-20220630.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43dba368-2ff6-4c6f-b175-5bb320ecff44" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6c6a8894-df58-414e-bd9e-7a24944209a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_620c4521-73cb-44c8-a195-58a8fad7f835" xlink:href="fold-20220630.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43dba368-2ff6-4c6f-b175-5bb320ecff44" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_620c4521-73cb-44c8-a195-58a8fad7f835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1" xlink:type="simple" xlink:href="fold-20220630.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2" xlink:type="simple" xlink:href="fold-20220630.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_05dbdbee-a603-4e93-895b-9eee0a1a28f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_560e154f-4310-497f-ba88-0ade3260faa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_05dbdbee-a603-4e93-895b-9eee0a1a28f3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_560e154f-4310-497f-ba88-0ade3260faa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_ec466161-0dde-4826-ac74-9a7161077244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_05dbdbee-a603-4e93-895b-9eee0a1a28f3" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_ec466161-0dde-4826-ac74-9a7161077244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0a2a4b46-1c12-45e6-a33f-93feb9c7b734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_05dbdbee-a603-4e93-895b-9eee0a1a28f3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0a2a4b46-1c12-45e6-a33f-93feb9c7b734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Inventories" xlink:type="simple" xlink:href="fold-20220630.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_2fc077f6-c470-4752-8bcc-074222f89042" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_a616b07f-89a0-4df6-a6bb-b31451a107ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2fc077f6-c470-4752-8bcc-074222f89042" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_a616b07f-89a0-4df6-a6bb-b31451a107ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/InventoriesTables" xlink:type="simple" xlink:href="fold-20220630.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_5a7b972b-2f6c-4454-9fac-e13c46dff7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_fe859338-dd1b-4a38-b27a-f156fcfec84c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5a7b972b-2f6c-4454-9fac-e13c46dff7d4" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_fe859338-dd1b-4a38-b27a-f156fcfec84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/InventoriesDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_b7af9ab1-772c-4ee2-a5b7-4ec087b1ea48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_4f7fe321-c69c-4099-81d5-c72ee5896f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b7af9ab1-772c-4ee2-a5b7-4ec087b1ea48" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_4f7fe321-c69c-4099-81d5-c72ee5896f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_529f6823-6be1-4679-9b86-009cf4cc6b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b7af9ab1-772c-4ee2-a5b7-4ec087b1ea48" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_529f6823-6be1-4679-9b86-009cf4cc6b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_ef0045df-491f-48f7-bafc-2b9d4ffd2355" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b7af9ab1-772c-4ee2-a5b7-4ec087b1ea48" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_ef0045df-491f-48f7-bafc-2b9d4ffd2355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7fc771d4-140b-4b64-8b89-75de8966a62a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b7af9ab1-772c-4ee2-a5b7-4ec087b1ea48" xlink:to="loc_us-gaap_InventoryNet_7fc771d4-140b-4b64-8b89-75de8966a62a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_942973a1-177e-4959-80e8-187128f438e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b7af9ab1-772c-4ee2-a5b7-4ec087b1ea48" xlink:to="loc_us-gaap_InventoryValuationReserves_942973a1-177e-4959-80e8-187128f438e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Debt" xlink:type="simple" xlink:href="fold-20220630.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_fdce1ee9-6c65-4b3e-ba79-c5fb0e7f4dda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_d0f4f18a-95ec-43ba-874e-bee30b145392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fdce1ee9-6c65-4b3e-ba79-c5fb0e7f4dda" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_d0f4f18a-95ec-43ba-874e-bee30b145392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtTables" xlink:type="simple" xlink:href="fold-20220630.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5184586a-f2d7-4fa9-8cf4-b5b2d468bb19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_28aa47c2-4e86-431d-9a18-53247efa75d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5184586a-f2d7-4fa9-8cf4-b5b2d468bb19" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_28aa47c2-4e86-431d-9a18-53247efa75d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_fd037d49-ca62-40b2-92ed-8362979d7e06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5184586a-f2d7-4fa9-8cf4-b5b2d468bb19" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_fd037d49-ca62-40b2-92ed-8362979d7e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#DebtSummaryofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_41fdc017-1bc3-4501-958c-fadb25064405" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1ad7f8f8-0c3e-4c48-81bc-43d554ebf1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_41fdc017-1bc3-4501-958c-fadb25064405" xlink:to="loc_us-gaap_DebtInstrumentTable_1ad7f8f8-0c3e-4c48-81bc-43d554ebf1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c430ef17-3f8c-4bf4-9fba-16eb2c9a97e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1ad7f8f8-0c3e-4c48-81bc-43d554ebf1f6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c430ef17-3f8c-4bf4-9fba-16eb2c9a97e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e19d599c-1b8e-4090-9d3e-3ac845f7045b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c430ef17-3f8c-4bf4-9fba-16eb2c9a97e6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e19d599c-1b8e-4090-9d3e-3ac845f7045b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLoansMember_654d35c8-b6ce-4b5c-a682-756906704bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e19d599c-1b8e-4090-9d3e-3ac845f7045b" xlink:to="loc_us-gaap_SeniorLoansMember_654d35c8-b6ce-4b5c-a682-756906704bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6719ad5c-6d8a-4d69-9cd4-319946cc365f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1ad7f8f8-0c3e-4c48-81bc-43d554ebf1f6" xlink:to="loc_us-gaap_DebtInstrumentAxis_6719ad5c-6d8a-4d69-9cd4-319946cc365f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_dc555a2f-5564-4ec0-8dad-e2fe0be5b9c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_6719ad5c-6d8a-4d69-9cd4-319946cc365f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_dc555a2f-5564-4ec0-8dad-e2fe0be5b9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_SeniorSecuredTermLoanDue2026Member_fcc9d9d5-6026-459f-b286-a5f98c13d48c" xlink:href="fold-20220630.xsd#fold_SeniorSecuredTermLoanDue2026Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dc555a2f-5564-4ec0-8dad-e2fe0be5b9c3" xlink:to="loc_fold_SeniorSecuredTermLoanDue2026Member_fcc9d9d5-6026-459f-b286-a5f98c13d48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f2bc6b60-888a-4277-8dea-a97058bf3c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1ad7f8f8-0c3e-4c48-81bc-43d554ebf1f6" xlink:to="loc_us-gaap_DebtInstrumentLineItems_f2bc6b60-888a-4277-8dea-a97058bf3c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_6bbaba00-d844-4320-a5fa-652e5fe3719d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2bc6b60-888a-4277-8dea-a97058bf3c3a" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_6bbaba00-d844-4320-a5fa-652e5fe3719d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_2533a7cc-32c9-4d8f-9cf8-409521cb2345" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2bc6b60-888a-4277-8dea-a97058bf3c3a" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_2533a7cc-32c9-4d8f-9cf8-409521cb2345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_88aa710c-c6d8-4a42-a8a2-cf553b137314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2bc6b60-888a-4277-8dea-a97058bf3c3a" xlink:to="loc_us-gaap_DeferredOfferingCosts_88aa710c-c6d8-4a42-a8a2-cf553b137314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_429bf338-a564-4a76-a155-914244753289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2bc6b60-888a-4277-8dea-a97058bf3c3a" xlink:to="loc_us-gaap_LongTermDebt_429bf338-a564-4a76-a155-914244753289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#DebtInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ac51b58e-55c2-4d0d-a502-0bb03a8594c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_05b74e29-b9c5-46d1-82dd-119b3549d051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ac51b58e-55c2-4d0d-a502-0bb03a8594c2" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_05b74e29-b9c5-46d1-82dd-119b3549d051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_61a22f40-f1f2-4d88-8b19-033045db9457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ac51b58e-55c2-4d0d-a502-0bb03a8594c2" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_61a22f40-f1f2-4d88-8b19-033045db9457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AmortizationDeferredFinancingCosts_a231e6af-fa33-4afd-b706-499cdc037ad9" xlink:href="fold-20220630.xsd#fold_AmortizationDeferredFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ac51b58e-55c2-4d0d-a502-0bb03a8594c2" xlink:to="loc_fold_AmortizationDeferredFinancingCosts_a231e6af-fa33-4afd-b706-499cdc037ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="fold-20220630.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e9695c4d-add5-43e4-b7ba-1a6fafead4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a0c2135a-d42b-41a8-a2a1-bd0080cdf8f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e9695c4d-add5-43e4-b7ba-1a6fafead4c4" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a0c2135a-d42b-41a8-a2a1-bd0080cdf8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="fold-20220630.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ba63615b-92fd-4d9c-9532-ffcb933ca00f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_48ac9966-fc70-4592-9743-e8f0337027a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ba63615b-92fd-4d9c-9532-ffcb933ca00f" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_48ac9966-fc70-4592-9743-e8f0337027a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ef79ed54-9fad-425b-a343-49fa38c7eaaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ba63615b-92fd-4d9c-9532-ffcb933ca00f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ef79ed54-9fad-425b-a343-49fa38c7eaaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_6285abbf-23a0-474e-8fd7-6c996cfec3be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ba63615b-92fd-4d9c-9532-ffcb933ca00f" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_6285abbf-23a0-474e-8fd7-6c996cfec3be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_53574cdb-5754-4745-bd3d-eea11d7bcef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ba63615b-92fd-4d9c-9532-ffcb933ca00f" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_53574cdb-5754-4745-bd3d-eea11d7bcef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#ShareBasedCompensationWeightedaverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b497c1b9-bb5f-4fea-9b30-41d26d390e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_292f349a-af07-465d-98b8-05633fe22172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b497c1b9-bb5f-4fea-9b30-41d26d390e4c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_292f349a-af07-465d-98b8-05633fe22172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b553f32c-925e-4983-b686-11209d85aa12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_292f349a-af07-465d-98b8-05633fe22172" xlink:to="loc_us-gaap_AwardTypeAxis_b553f32c-925e-4983-b686-11209d85aa12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abadc1cf-c4f8-491e-9d57-06a131a4778b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b553f32c-925e-4983-b686-11209d85aa12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abadc1cf-c4f8-491e-9d57-06a131a4778b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_53e05a42-1a4d-452f-b0a8-237f661f7f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abadc1cf-c4f8-491e-9d57-06a131a4778b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_53e05a42-1a4d-452f-b0a8-237f661f7f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_465c4f18-85c1-4677-8fe8-010edede7857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_292f349a-af07-465d-98b8-05633fe22172" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_465c4f18-85c1-4677-8fe8-010edede7857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2787d625-56ad-4b1d-95a9-6c892ab33caf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_465c4f18-85c1-4677-8fe8-010edede7857" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2787d625-56ad-4b1d-95a9-6c892ab33caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_34d3c3b9-f4b4-4a70-a1c9-6231106848b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_465c4f18-85c1-4677-8fe8-010edede7857" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_34d3c3b9-f4b4-4a70-a1c9-6231106848b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e6e64848-464d-401d-b84a-4f6a9f455951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_465c4f18-85c1-4677-8fe8-010edede7857" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e6e64848-464d-401d-b84a-4f6a9f455951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_e3040e85-cda5-4c9c-b9d3-1f7dcbd9b1f4" xlink:href="fold-20220630.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_465c4f18-85c1-4677-8fe8-010edede7857" xlink:to="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_e3040e85-cda5-4c9c-b9d3-1f7dcbd9b1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#ShareBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_14bf61cc-44c3-4522-97d1-c0b91ebc1f55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d98af0ff-dd6c-4360-ab00-5ef72a08c2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_14bf61cc-44c3-4522-97d1-c0b91ebc1f55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d98af0ff-dd6c-4360-ab00-5ef72a08c2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b8b23f4d-1a0e-4ce0-9d19-32c488f2aaea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d98af0ff-dd6c-4360-ab00-5ef72a08c2c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b8b23f4d-1a0e-4ce0-9d19-32c488f2aaea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3e47a69a-8f14-40bb-8911-5c947603e84c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d98af0ff-dd6c-4360-ab00-5ef72a08c2c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3e47a69a-8f14-40bb-8911-5c947603e84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_70c904c3-e750-47cb-856a-79489b03a712" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d98af0ff-dd6c-4360-ab00-5ef72a08c2c3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_70c904c3-e750-47cb-856a-79489b03a712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_956087d7-a061-4a7e-a055-6cac4378bc82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d98af0ff-dd6c-4360-ab00-5ef72a08c2c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_956087d7-a061-4a7e-a055-6cac4378bc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_fe213da1-e665-420a-8a3b-7ea7ff663f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d98af0ff-dd6c-4360-ab00-5ef72a08c2c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_fe213da1-e665-420a-8a3b-7ea7ff663f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5ed3454a-db76-43f9-82e3-a27f509a0e59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d98af0ff-dd6c-4360-ab00-5ef72a08c2c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5ed3454a-db76-43f9-82e3-a27f509a0e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_e843d49a-5d39-4ffe-a608-a7b7389f4bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_14bf61cc-44c3-4522-97d1-c0b91ebc1f55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_e843d49a-5d39-4ffe-a608-a7b7389f4bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4f49569f-03f5-4d37-8cc8-9553ad7872b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_14bf61cc-44c3-4522-97d1-c0b91ebc1f55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4f49569f-03f5-4d37-8cc8-9553ad7872b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6b231520-05e5-4837-97e1-b86d736a0aed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_14bf61cc-44c3-4522-97d1-c0b91ebc1f55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6b231520-05e5-4837-97e1-b86d736a0aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_19b0f8dd-dd8b-4f3f-97a8-77db4f9fb50c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6b231520-05e5-4837-97e1-b86d736a0aed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_19b0f8dd-dd8b-4f3f-97a8-77db4f9fb50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_42bb2a7a-65cd-4f01-b9a4-dfcd29b6f0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6b231520-05e5-4837-97e1-b86d736a0aed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_42bb2a7a-65cd-4f01-b9a4-dfcd29b6f0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5cb9b501-4005-4514-b0c1-91a44d62f6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6b231520-05e5-4837-97e1-b86d736a0aed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5cb9b501-4005-4514-b0c1-91a44d62f6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1c6cae57-41f6-40a9-9eb5-4184e19da240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6b231520-05e5-4837-97e1-b86d736a0aed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1c6cae57-41f6-40a9-9eb5-4184e19da240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_47a07919-93cb-42bf-8e8a-32e3c692c0ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6b231520-05e5-4837-97e1-b86d736a0aed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_47a07919-93cb-42bf-8e8a-32e3c692c0ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d0720678-c916-4517-9008-d6d8e4b43f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6b231520-05e5-4837-97e1-b86d736a0aed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d0720678-c916-4517-9008-d6d8e4b43f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_e3ad1b4f-f2aa-4c1a-846a-1277e2cf5437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_14bf61cc-44c3-4522-97d1-c0b91ebc1f55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_e3ad1b4f-f2aa-4c1a-846a-1277e2cf5437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e642dfd9-dc20-4b41-8fe0-0a61a3cdddb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_14bf61cc-44c3-4522-97d1-c0b91ebc1f55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e642dfd9-dc20-4b41-8fe0-0a61a3cdddb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_af220359-8355-48b2-b28b-dd47f02d5571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_14bf61cc-44c3-4522-97d1-c0b91ebc1f55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_af220359-8355-48b2-b28b-dd47f02d5571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_fbeb51a2-b5b5-496c-9ec7-0a5de37d26d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_af220359-8355-48b2-b28b-dd47f02d5571" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_fbeb51a2-b5b5-496c-9ec7-0a5de37d26d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_20a64474-1e40-42ef-afb0-caf921b3c3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_af220359-8355-48b2-b28b-dd47f02d5571" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_20a64474-1e40-42ef-afb0-caf921b3c3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f9e8d6ba-b358-4600-97f1-95fba907a111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_af220359-8355-48b2-b28b-dd47f02d5571" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f9e8d6ba-b358-4600-97f1-95fba907a111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ccc685e4-6c06-45d4-9f47-781bcdc1f829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_af220359-8355-48b2-b28b-dd47f02d5571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ccc685e4-6c06-45d4-9f47-781bcdc1f829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_788ff1bf-b963-476c-a931-5d4628bb925b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_af220359-8355-48b2-b28b-dd47f02d5571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_788ff1bf-b963-476c-a931-5d4628bb925b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_0bdbc390-9494-4d8b-846c-0d8b6403e53c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_af220359-8355-48b2-b28b-dd47f02d5571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_0bdbc390-9494-4d8b-846c-0d8b6403e53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_516aabba-49f7-42d4-b854-6630faa54853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1f94e7f-fd2d-4912-9bfa-5b7cd010d924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_516aabba-49f7-42d4-b854-6630faa54853" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1f94e7f-fd2d-4912-9bfa-5b7cd010d924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c51c89ff-e89e-4d03-815d-90714c606ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1f94e7f-fd2d-4912-9bfa-5b7cd010d924" xlink:to="loc_us-gaap_AwardTypeAxis_c51c89ff-e89e-4d03-815d-90714c606ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25ffb200-d5a1-4f96-b8b3-06e46343353a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c51c89ff-e89e-4d03-815d-90714c606ba3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25ffb200-d5a1-4f96-b8b3-06e46343353a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_da88ea37-f006-4c19-9f5e-ed06146bf0be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25ffb200-d5a1-4f96-b8b3-06e46343353a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_da88ea37-f006-4c19-9f5e-ed06146bf0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9ac7f688-e5cb-49d9-b46b-48c2a0556ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25ffb200-d5a1-4f96-b8b3-06e46343353a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9ac7f688-e5cb-49d9-b46b-48c2a0556ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ea1652c-62e8-4aeb-85a7-165c3a0b4c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1f94e7f-fd2d-4912-9bfa-5b7cd010d924" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ea1652c-62e8-4aeb-85a7-165c3a0b4c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_81007c3e-73bf-41db-b5be-19295b6fbdd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ea1652c-62e8-4aeb-85a7-165c3a0b4c3f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_81007c3e-73bf-41db-b5be-19295b6fbdd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_819b5d6d-74ad-4575-962e-972de47454bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ea1652c-62e8-4aeb-85a7-165c3a0b4c3f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_819b5d6d-74ad-4575-962e-972de47454bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#ShareBasedCompensationRSUsandPBRSUsSummaryDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a9a1b832-69b7-475e-9120-4f6a4944f038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_20b933b2-78e7-4e6f-b2b4-ba31d4da243e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a9a1b832-69b7-475e-9120-4f6a4944f038" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_20b933b2-78e7-4e6f-b2b4-ba31d4da243e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_156ea48e-9c06-4337-a2dd-f0ea47f8314b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_20b933b2-78e7-4e6f-b2b4-ba31d4da243e" xlink:to="loc_us-gaap_AwardTypeAxis_156ea48e-9c06-4337-a2dd-f0ea47f8314b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03235e5c-eab4-4590-93e5-635427133de1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_156ea48e-9c06-4337-a2dd-f0ea47f8314b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03235e5c-eab4-4590-93e5-635427133de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f6799d2c-a7de-48b1-bb29-32441cbb8a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03235e5c-eab4-4590-93e5-635427133de1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f6799d2c-a7de-48b1-bb29-32441cbb8a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8eace8a-ee8e-4b26-a4cf-52493e9bab15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_20b933b2-78e7-4e6f-b2b4-ba31d4da243e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8eace8a-ee8e-4b26-a4cf-52493e9bab15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3312b543-ec3b-4df1-ab55-0b6353c53f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8eace8a-ee8e-4b26-a4cf-52493e9bab15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3312b543-ec3b-4df1-ab55-0b6353c53f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_19c6002b-7ba1-41d0-a3a5-32f03860c642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3312b543-ec3b-4df1-ab55-0b6353c53f0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_19c6002b-7ba1-41d0-a3a5-32f03860c642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3d696ecd-b35d-4fdc-82b8-99e7dc62ff4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3312b543-ec3b-4df1-ab55-0b6353c53f0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3d696ecd-b35d-4fdc-82b8-99e7dc62ff4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4f791dc7-0296-4794-bd68-ca15801f645d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3312b543-ec3b-4df1-ab55-0b6353c53f0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4f791dc7-0296-4794-bd68-ca15801f645d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b4376cf2-ea35-4dd2-a26d-e74d3805ef40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3312b543-ec3b-4df1-ab55-0b6353c53f0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b4376cf2-ea35-4dd2-a26d-e74d3805ef40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f5163dff-190d-4ec3-86d0-da2f83aa4ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3312b543-ec3b-4df1-ab55-0b6353c53f0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f5163dff-190d-4ec3-86d0-da2f83aa4ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b382ca3-d45a-4702-80a0-09a3ed0d671e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8eace8a-ee8e-4b26-a4cf-52493e9bab15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b382ca3-d45a-4702-80a0-09a3ed0d671e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_196ef4a4-729f-4a8b-8973-2efdc3a1948c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b382ca3-d45a-4702-80a0-09a3ed0d671e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_196ef4a4-729f-4a8b-8973-2efdc3a1948c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b93b45ce-9786-43ac-a22e-f50a83fd7339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b382ca3-d45a-4702-80a0-09a3ed0d671e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b93b45ce-9786-43ac-a22e-f50a83fd7339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_973336e4-5225-4ec1-9a86-3ae41a3171f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b382ca3-d45a-4702-80a0-09a3ed0d671e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_973336e4-5225-4ec1-9a86-3ae41a3171f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_641a0d7a-174d-487b-85a9-aae38d40a466" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b382ca3-d45a-4702-80a0-09a3ed0d671e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_641a0d7a-174d-487b-85a9-aae38d40a466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0bdc30c9-0ad8-4e42-b04f-8f34e4501578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b382ca3-d45a-4702-80a0-09a3ed0d671e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0bdc30c9-0ad8-4e42-b04f-8f34e4501578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_27bea2dd-6ce3-43fe-9c0f-c67d469d2c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8eace8a-ee8e-4b26-a4cf-52493e9bab15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_27bea2dd-6ce3-43fe-9c0f-c67d469d2c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_d363bc08-795e-4961-9c29-434d015bc98e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_27bea2dd-6ce3-43fe-9c0f-c67d469d2c9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_d363bc08-795e-4961-9c29-434d015bc98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_d820e987-895b-4c73-8005-799339122d71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_27bea2dd-6ce3-43fe-9c0f-c67d469d2c9c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_d820e987-895b-4c73-8005-799339122d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#ShareBasedCompensationExpenseSummaryDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f82d43f1-97bc-493e-a797-4fd49c6563db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_640f6946-eff1-4f93-9d69-9091418a1540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f82d43f1-97bc-493e-a797-4fd49c6563db" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_640f6946-eff1-4f93-9d69-9091418a1540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_49bcf907-ca01-4482-b9e3-a9ff575c90ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_640f6946-eff1-4f93-9d69-9091418a1540" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_49bcf907-ca01-4482-b9e3-a9ff575c90ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d372966c-2326-40e9-9881-051e599a014e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_49bcf907-ca01-4482-b9e3-a9ff575c90ce" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d372966c-2326-40e9-9881-051e599a014e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a70a2019-b854-492d-ba97-2010aeaaeb2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d372966c-2326-40e9-9881-051e599a014e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a70a2019-b854-492d-ba97-2010aeaaeb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3e9fc53e-f5ba-4508-ac93-d53da7e162c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d372966c-2326-40e9-9881-051e599a014e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3e9fc53e-f5ba-4508-ac93-d53da7e162c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da42fbcd-b844-4156-b98a-7c46d25ba8f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_640f6946-eff1-4f93-9d69-9091418a1540" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da42fbcd-b844-4156-b98a-7c46d25ba8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_bc80b821-2986-438d-b59f-502fb98920e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da42fbcd-b844-4156-b98a-7c46d25ba8f8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_bc80b821-2986-438d-b59f-502fb98920e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue" xlink:type="simple" xlink:href="fold-20220630.xsd#AssetsandLiabilitiesMeasuredatFairValue"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e1c85a04-cbbe-43e2-9c67-860a885efca4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_9533d5fb-e513-4ec4-84e6-4354fc5ec8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e1c85a04-cbbe-43e2-9c67-860a885efca4" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_9533d5fb-e513-4ec4-84e6-4354fc5ec8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables" xlink:type="simple" xlink:href="fold-20220630.xsd#AssetsandLiabilitiesMeasuredatFairValueTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_dddaf6ec-988f-4e55-b8a0-0020f53177f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_5f8be850-86a0-4193-92c2-ee07decacf18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dddaf6ec-988f-4e55-b8a0-0020f53177f1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_5f8be850-86a0-4193-92c2-ee07decacf18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_3ce46187-a83f-4a00-9b75-d29906447e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dddaf6ec-988f-4e55-b8a0-0020f53177f1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_3ce46187-a83f-4a00-9b75-d29906447e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_9feab1e8-c68b-4ea4-a3c6-344d500072f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dddaf6ec-988f-4e55-b8a0-0020f53177f1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_9feab1e8-c68b-4ea4-a3c6-344d500072f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2da457aa-882c-48c3-ae2a-822f202bc320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4a830849-7171-425e-9110-8a1ec84dc3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2da457aa-882c-48c3-ae2a-822f202bc320" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4a830849-7171-425e-9110-8a1ec84dc3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b1f7e2ff-6a9d-45de-884f-07dd0e2a887d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4a830849-7171-425e-9110-8a1ec84dc3f1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b1f7e2ff-6a9d-45de-884f-07dd0e2a887d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5f8b07e1-0582-43db-8db6-ece904e02236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b1f7e2ff-6a9d-45de-884f-07dd0e2a887d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5f8b07e1-0582-43db-8db6-ece904e02236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_10e74f8c-d490-43d9-860f-1145dc7a3aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5f8b07e1-0582-43db-8db6-ece904e02236" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_10e74f8c-d490-43d9-860f-1145dc7a3aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_35bd8cb1-b907-417e-b12b-ea85f60e304a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5f8b07e1-0582-43db-8db6-ece904e02236" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_35bd8cb1-b907-417e-b12b-ea85f60e304a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f8a7c2db-ff1d-40cf-9e10-128b3044e866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4a830849-7171-425e-9110-8a1ec84dc3f1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f8a7c2db-ff1d-40cf-9e10-128b3044e866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_668f4a21-3b29-4158-b860-5d1a889e6069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f8a7c2db-ff1d-40cf-9e10-128b3044e866" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_668f4a21-3b29-4158-b860-5d1a889e6069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_ef6b29c9-ffb9-47a3-92a2-a4f7a58e5441" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_668f4a21-3b29-4158-b860-5d1a889e6069" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_ef6b29c9-ffb9-47a3-92a2-a4f7a58e5441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_ff99e364-1c1d-4822-94d5-4f7941c0cb73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_668f4a21-3b29-4158-b860-5d1a889e6069" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_ff99e364-1c1d-4822-94d5-4f7941c0cb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_62e2d0a5-8e45-4542-b66d-f904cf4cd12d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_668f4a21-3b29-4158-b860-5d1a889e6069" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_62e2d0a5-8e45-4542-b66d-f904cf4cd12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_26023fc5-2504-4803-b352-90eca3d28662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_668f4a21-3b29-4158-b860-5d1a889e6069" xlink:to="loc_us-gaap_MoneyMarketFundsMember_26023fc5-2504-4803-b352-90eca3d28662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7aa3e03a-9ca3-473f-b7bd-9833a1557363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_668f4a21-3b29-4158-b860-5d1a889e6069" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_7aa3e03a-9ca3-473f-b7bd-9833a1557363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a43df6be-3c83-4268-a58d-4cf56f0457fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4a830849-7171-425e-9110-8a1ec84dc3f1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a43df6be-3c83-4268-a58d-4cf56f0457fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_6e4f05e1-0187-4c36-a2af-280fb521690a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a43df6be-3c83-4268-a58d-4cf56f0457fa" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_6e4f05e1-0187-4c36-a2af-280fb521690a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1934e3de-4ed9-48ac-86f2-b248b85bc928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_6e4f05e1-0187-4c36-a2af-280fb521690a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_1934e3de-4ed9-48ac-86f2-b248b85bc928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b3880f6e-cbeb-4f6c-ab55-bf3a306cbc35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a43df6be-3c83-4268-a58d-4cf56f0457fa" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b3880f6e-cbeb-4f6c-ab55-bf3a306cbc35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_dc866160-51ed-4b9e-bb76-e27ff5af748e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b3880f6e-cbeb-4f6c-ab55-bf3a306cbc35" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_dc866160-51ed-4b9e-bb76-e27ff5af748e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_bb976e0d-7908-48ff-8288-449cb83cf6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b3880f6e-cbeb-4f6c-ab55-bf3a306cbc35" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_bb976e0d-7908-48ff-8288-449cb83cf6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_949f1076-c0dd-4b81-9e9d-29289c0b3ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b3880f6e-cbeb-4f6c-ab55-bf3a306cbc35" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_949f1076-c0dd-4b81-9e9d-29289c0b3ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ced3047c-0817-4dd7-83b3-c04bfda36feb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1426b447-fc11-4e28-8406-c0fcd97aadf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ced3047c-0817-4dd7-83b3-c04bfda36feb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1426b447-fc11-4e28-8406-c0fcd97aadf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4b8dd7e2-d001-45bc-9eb8-8f9c9c584ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1426b447-fc11-4e28-8406-c0fcd97aadf2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4b8dd7e2-d001-45bc-9eb8-8f9c9c584ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2c5195d3-1f4c-4b5e-b3af-1426cca6a586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4b8dd7e2-d001-45bc-9eb8-8f9c9c584ab8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2c5195d3-1f4c-4b5e-b3af-1426cca6a586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CallidusBiopharmaIncMember_00e19520-82b1-4f54-9d92-c55e65501d3b" xlink:href="fold-20220630.xsd#fold_CallidusBiopharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2c5195d3-1f4c-4b5e-b3af-1426cca6a586" xlink:to="loc_fold_CallidusBiopharmaIncMember_00e19520-82b1-4f54-9d92-c55e65501d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_db1bd26e-71f1-4c9d-9aea-f0df415f6662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1426b447-fc11-4e28-8406-c0fcd97aadf2" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_db1bd26e-71f1-4c9d-9aea-f0df415f6662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_53a56e66-e362-4ac4-ad87-cb4902c217bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_db1bd26e-71f1-4c9d-9aea-f0df415f6662" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_53a56e66-e362-4ac4-ad87-cb4902c217bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_d2bd6c8c-f3e4-4418-b775-e97324b9e77c" xlink:href="fold-20220630.xsd#fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_53a56e66-e362-4ac4-ad87-cb4902c217bd" xlink:to="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_d2bd6c8c-f3e4-4418-b775-e97324b9e77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5450fe81-8bbb-442d-825b-876de1771720" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1426b447-fc11-4e28-8406-c0fcd97aadf2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5450fe81-8bbb-442d-825b-876de1771720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4db513dd-ba47-40f5-8ca5-fc2bf4d6269d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5450fe81-8bbb-442d-825b-876de1771720" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4db513dd-ba47-40f5-8ca5-fc2bf4d6269d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ce8f145d-ef32-4b2c-9125-e04a14c22796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4db513dd-ba47-40f5-8ca5-fc2bf4d6269d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ce8f145d-ef32-4b2c-9125-e04a14c22796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_5f01362b-4bc7-4f15-9d1f-b0591cfab2cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1426b447-fc11-4e28-8406-c0fcd97aadf2" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_5f01362b-4bc7-4f15-9d1f-b0591cfab2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_4248471e-6b38-46a1-b51a-b4c390512815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_5f01362b-4bc7-4f15-9d1f-b0591cfab2cc" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_4248471e-6b38-46a1-b51a-b4c390512815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_a74a8628-a489-4697-8b88-84cdacdd409b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4248471e-6b38-46a1-b51a-b4c390512815" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_a74a8628-a489-4697-8b88-84cdacdd409b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_346611b4-374b-4d03-8962-93dad95ba2c4" xlink:href="fold-20220630.xsd#fold_MeasurementInputProbabilityOfMilestoneAchievementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4248471e-6b38-46a1-b51a-b4c390512815" xlink:to="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_346611b4-374b-4d03-8962-93dad95ba2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b7e36710-95af-4dd3-bbf7-1cd6c7c3c40f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1426b447-fc11-4e28-8406-c0fcd97aadf2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b7e36710-95af-4dd3-bbf7-1cd6c7c3c40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9eec2c15-ca3d-44d8-b044-0e5b89a30ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b7e36710-95af-4dd3-bbf7-1cd6c7c3c40f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9eec2c15-ca3d-44d8-b044-0e5b89a30ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ATB200PompeProgramMember_d5c3045d-287b-4ddf-8882-9b1c0dc13c7f" xlink:href="fold-20220630.xsd#fold_ATB200PompeProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9eec2c15-ca3d-44d8-b044-0e5b89a30ec2" xlink:to="loc_fold_ATB200PompeProgramMember_d5c3045d-287b-4ddf-8882-9b1c0dc13c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_1ed30abe-4a9b-4932-8428-7ec5d9ce9276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1426b447-fc11-4e28-8406-c0fcd97aadf2" xlink:to="loc_us-gaap_ValuationTechniqueAxis_1ed30abe-4a9b-4932-8428-7ec5d9ce9276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_43c5ffa6-12c5-4545-b98b-f5dd443d022a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_1ed30abe-4a9b-4932-8428-7ec5d9ce9276" xlink:to="loc_us-gaap_ValuationTechniqueDomain_43c5ffa6-12c5-4545-b98b-f5dd443d022a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProbabilityWeightedDiscountedCashFlowMember_472600b9-6145-4076-a519-f1ee29c96f0a" xlink:href="fold-20220630.xsd#fold_ProbabilityWeightedDiscountedCashFlowMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_43c5ffa6-12c5-4545-b98b-f5dd443d022a" xlink:to="loc_fold_ProbabilityWeightedDiscountedCashFlowMember_472600b9-6145-4076-a519-f1ee29c96f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_42a27186-a6e7-498e-8831-f1b544ec6beb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1426b447-fc11-4e28-8406-c0fcd97aadf2" xlink:to="loc_srt_RangeAxis_42a27186-a6e7-498e-8831-f1b544ec6beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ed327476-46fa-4592-b3bd-ab058de68216" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_42a27186-a6e7-498e-8831-f1b544ec6beb" xlink:to="loc_srt_RangeMember_ed327476-46fa-4592-b3bd-ab058de68216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4c848707-f605-4c44-b3e9-55544ac2244f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ed327476-46fa-4592-b3bd-ab058de68216" xlink:to="loc_srt_MinimumMember_4c848707-f605-4c44-b3e9-55544ac2244f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_65cb6029-5034-4d74-a1f9-095ff9cabcb7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ed327476-46fa-4592-b3bd-ab058de68216" xlink:to="loc_srt_MaximumMember_65cb6029-5034-4d74-a1f9-095ff9cabcb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d12ff7f4-5ceb-4012-8f5a-07e433c53324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1426b447-fc11-4e28-8406-c0fcd97aadf2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d12ff7f4-5ceb-4012-8f5a-07e433c53324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1d75a109-c87f-4523-8086-29e1b68e3fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d12ff7f4-5ceb-4012-8f5a-07e433c53324" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1d75a109-c87f-4523-8086-29e1b68e3fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationMeasurementInput_66db4869-16ad-49ef-a7fe-dc561639ccd8" xlink:href="fold-20220630.xsd#fold_ContingentConsiderationMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d12ff7f4-5ceb-4012-8f5a-07e433c53324" xlink:to="loc_fold_ContingentConsiderationMeasurementInput_66db4869-16ad-49ef-a7fe-dc561639ccd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueContingentConsiderationRollForwardDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#AssetsandLiabilitiesMeasuredatFairValueContingentConsiderationRollForwardDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueContingentConsiderationRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1a040181-5563-40a7-b62d-b9d148cd1730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_33d6d83e-4422-4c62-89f6-c5eea09c4bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1a040181-5563-40a7-b62d-b9d148cd1730" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_33d6d83e-4422-4c62-89f6-c5eea09c4bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6f1bfad8-f68d-4a1a-a284-4bdb0e75a858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_33d6d83e-4422-4c62-89f6-c5eea09c4bb4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6f1bfad8-f68d-4a1a-a284-4bdb0e75a858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b5085878-64f8-492e-bc71-89eb180b6ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_33d6d83e-4422-4c62-89f6-c5eea09c4bb4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b5085878-64f8-492e-bc71-89eb180b6ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_af9cd41d-55a8-47c4-8f2f-5a384affdea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_33d6d83e-4422-4c62-89f6-c5eea09c4bb4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_af9cd41d-55a8-47c4-8f2f-5a384affdea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare" xlink:type="simple" xlink:href="fold-20220630.xsd#BasicandDilutedNetLossperCommonShare"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0328ad98-930b-4225-ac98-5cbe7d544a71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_8d978c18-36a4-4d0e-bb3e-f32878a97c86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0328ad98-930b-4225-ac98-5cbe7d544a71" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_8d978c18-36a4-4d0e-bb3e-f32878a97c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables" xlink:type="simple" xlink:href="fold-20220630.xsd#BasicandDilutedNetLossperCommonShareTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2a9d49f8-f270-40c2-8ba9-b337015e51d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a62fd529-24ca-4a11-8536-81dbaacc4638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2a9d49f8-f270-40c2-8ba9-b337015e51d1" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a62fd529-24ca-4a11-8536-81dbaacc4638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4d69cb97-d86d-4201-8067-795ef5dca568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2a9d49f8-f270-40c2-8ba9-b337015e51d1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4d69cb97-d86d-4201-8067-795ef5dca568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails" xlink:type="simple" xlink:href="fold-20220630.xsd#BasicandDilutedNetLossperCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_33a0e4fd-b5b9-4456-9477-0eed529b90c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b8e8545c-859f-41d2-b1af-4d02b3885e35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_33a0e4fd-b5b9-4456-9477-0eed529b90c7" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b8e8545c-859f-41d2-b1af-4d02b3885e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1183c8a2-85d7-488d-84bb-719a91f8c1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b8e8545c-859f-41d2-b1af-4d02b3885e35" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1183c8a2-85d7-488d-84bb-719a91f8c1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3dc00851-59de-4bc0-a1c9-5b64545c746e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1183c8a2-85d7-488d-84bb-719a91f8c1f7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3dc00851-59de-4bc0-a1c9-5b64545c746e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_81fcbb1f-8aee-4523-a2ef-3980685a0f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3dc00851-59de-4bc0-a1c9-5b64545c746e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_81fcbb1f-8aee-4523-a2ef-3980685a0f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6dfa6406-f6df-40ec-a413-7ed3c5b4d2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3dc00851-59de-4bc0-a1c9-5b64545c746e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6dfa6406-f6df-40ec-a413-7ed3c5b4d2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_f514ae81-44cd-463f-8c35-2142b2af3fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3dc00851-59de-4bc0-a1c9-5b64545c746e" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_f514ae81-44cd-463f-8c35-2142b2af3fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_48312353-c691-42dd-bab6-c8e060cbae9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b8e8545c-859f-41d2-b1af-4d02b3885e35" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_48312353-c691-42dd-bab6-c8e060cbae9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_29ed4705-571d-4825-9917-de7abd32fb9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_48312353-c691-42dd-bab6-c8e060cbae9b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_29ed4705-571d-4825-9917-de7abd32fb9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_ed9d722f-bde8-4477-89bf-96c3a80377b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_29ed4705-571d-4825-9917-de7abd32fb9a" xlink:to="loc_us-gaap_PrivatePlacementMember_ed9d722f-bde8-4477-89bf-96c3a80377b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b0c5a4d1-7271-4e36-afce-7f742d367f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b8e8545c-859f-41d2-b1af-4d02b3885e35" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b0c5a4d1-7271-4e36-afce-7f742d367f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_db2c0c79-5724-48cc-b220-b0537b3d4624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b0c5a4d1-7271-4e36-afce-7f742d367f98" xlink:to="loc_us-gaap_NetIncomeLossAbstract_db2c0c79-5724-48cc-b220-b0537b3d4624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7fa3ee12-91c1-4be3-918b-41c576ef9da0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_db2c0c79-5724-48cc-b220-b0537b3d4624" xlink:to="loc_us-gaap_NetIncomeLoss_7fa3ee12-91c1-4be3-918b-41c576ef9da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_684b7c33-b242-4e37-8ae1-cc26784c40d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b0c5a4d1-7271-4e36-afce-7f742d367f98" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_684b7c33-b242-4e37-8ae1-cc26784c40d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_81d062d4-eb20-4708-87a0-4cb55edd998a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_684b7c33-b242-4e37-8ae1-cc26784c40d6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_81d062d4-eb20-4708-87a0-4cb55edd998a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_66df2b30-3281-495f-8c3e-5685b94d5aca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_684b7c33-b242-4e37-8ae1-cc26784c40d6" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_66df2b30-3281-495f-8c3e-5685b94d5aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_81ab8b18-d94d-46bf-9d6f-e81344b9f87e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b0c5a4d1-7271-4e36-afce-7f742d367f98" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_81ab8b18-d94d-46bf-9d6f-e81344b9f87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_61d52fc9-c741-460b-b99d-4ef1945cbd31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b0c5a4d1-7271-4e36-afce-7f742d367f98" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_61d52fc9-c741-460b-b99d-4ef1945cbd31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566911246432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Amicus Therapeutics,&#160;Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">71-0869350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3675 Market Street,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Philadelphia,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">921-7600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FOLD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,498,461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001178879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566913999600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 235,639<span></span>
</td>
<td class="nump">$ 245,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments in marketable securities</a></td>
<td class="nump">151,202<span></span>
</td>
<td class="nump">237,299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">52,556<span></span>
</td>
<td class="nump">52,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">20,879<span></span>
</td>
<td class="nump">26,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">37,367<span></span>
</td>
<td class="nump">34,848<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">497,643<span></span>
</td>
<td class="nump">596,834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">30,447<span></span>
</td>
<td class="nump">20,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, less accumulated depreciation of $22,188 and $19,882 at June 30, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">33,657<span></span>
</td>
<td class="nump">42,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">In-process research&#160;&amp; development</a></td>
<td class="nump">23,000<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">197,797<span></span>
</td>
<td class="nump">197,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">18,045<span></span>
</td>
<td class="nump">24,427<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">800,589<span></span>
</td>
<td class="nump">905,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">23,113<span></span>
</td>
<td class="nump">21,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">114,703<span></span>
</td>
<td class="nump">98,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration payable</a></td>
<td class="nump">19,266<span></span>
</td>
<td class="nump">18,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">7,543<span></span>
</td>
<td class="nump">7,409<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">164,625<span></span>
</td>
<td class="nump">145,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">390,652<span></span>
</td>
<td class="nump">389,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">52,844<span></span>
</td>
<td class="nump">43,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent', window );">Deferred reimbursements</a></td>
<td class="nump">5,906<span></span>
</td>
<td class="nump">5,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">4,930<span></span>
</td>
<td class="nump">4,930<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">8,207<span></span>
</td>
<td class="nump">8,240<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">627,164<span></span>
</td>
<td class="nump">597,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value, 500,000,000 shares authorized, 280,456,667 and 278,912,800 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">2,811<span></span>
</td>
<td class="nump">2,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">2,631,110<span></span>
</td>
<td class="nump">2,595,419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated other comprehensive (loss) gain:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(16,603)<span></span>
</td>
<td class="nump">5,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on available-for-sale securities</a></td>
<td class="num">(637)<span></span>
</td>
<td class="num">(270)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(2,443,339)<span></span>
</td>
<td class="num">(2,295,922)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">173,425<span></span>
</td>
<td class="nump">307,369<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 800,589<span></span>
</td>
<td class="nump">$ 905,140<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594809&amp;loc=SL116692626-108610<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income after one year or beyond the normal operating cycle, if longer and noncurrent obligations not separately disclosed in the balance sheet (other liabilities, noncurrent).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566911215664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation of property and equipment | $</a></td>
<td class="nump">$ 22,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">280,456,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,912,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">280,456,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,912,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566908541152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations (Unaudited)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="4">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">$ 80,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 159,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">8,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">72,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">78,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="nump">53,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value of contingent consideration payable</a></td>
<td class="nump">115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,073)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Loss on impairment of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">133,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(60,613)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38,834)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(135,952)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(91,889)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(8,257)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,404)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">7,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,966)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="num">(61,246)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(142,697)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(110,782)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(911)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,525)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,720)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,107)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (62,157)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (51,225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (147,417)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (116,889)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss attributable to common stockholders per common share - basic (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss attributable to common stockholders per common share&#160;&#8212; diluted (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic (in shares) | shares</a></td>
<td class="nump">291,970,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,398,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288,646,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265,384,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding - diluted (in shares) | shares</a></td>
<td class="nump">291,970,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,398,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288,646,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265,384,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566908464768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (62,157)<span></span>
</td>
<td class="num">$ (51,225)<span></span>
</td>
<td class="num">$ (147,417)<span></span>
</td>
<td class="num">$ (116,889)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive (loss) gain:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment (loss) gain</a></td>
<td class="num">(16,183)<span></span>
</td>
<td class="nump">235<span></span>
</td>
<td class="num">(21,854)<span></span>
</td>
<td class="nump">843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized (loss) gain on available-for-sale securities</a></td>
<td class="num">(29)<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="num">(367)<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) gain</a></td>
<td class="num">(16,212)<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="num">(22,221)<span></span>
</td>
<td class="nump">855<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (78,369)<span></span>
</td>
<td class="num">$ (50,978)<span></span>
</td>
<td class="num">$ (169,638)<span></span>
</td>
<td class="num">$ (116,034)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566913279264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Warrants</div></th>
<th class="th"><div>Other Comprehensive Gain (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262,063,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 286,380<span></span>
</td>
<td class="nump">$ 2,650<span></span>
</td>
<td class="nump">$ 2,308,578<span></span>
</td>
<td class="nump">$ 12,387<span></span>
</td>
<td class="nump">$ 8,227<span></span>
</td>
<td class="num">$ (2,045,462)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">922,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised, net</a></td>
<td class="nump">6,661<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">6,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">987,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Vesting of restricted stock units, net of taxes</a></td>
<td class="num">(14,438)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,438)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">32,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized holding loss on available-for-sale securities</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(116,889)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(116,889)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,554,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodValueWarrantsExercised', window );">Warrants exercised</a></td>
<td class="nump">19,230<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">31,591<span></span>
</td>
<td class="num">(12,387)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Equity component of the convertible notes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Equity component of the convertible notes</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,532,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">213,910<span></span>
</td>
<td class="nump">$ 2,685<span></span>
</td>
<td class="nump">2,364,494<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,082<span></span>
</td>
<td class="num">(2,162,351)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,007,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">250,896<span></span>
</td>
<td class="nump">$ 2,680<span></span>
</td>
<td class="nump">2,350,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,835<span></span>
</td>
<td class="num">(2,111,126)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised, net</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">2,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Vesting of restricted stock units, net of taxes</a></td>
<td class="num">(244)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(244)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">11,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized holding loss on available-for-sale securities</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(51,225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51,225)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,532,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">$ 213,910<span></span>
</td>
<td class="nump">$ 2,685<span></span>
</td>
<td class="nump">2,364,494<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,082<span></span>
</td>
<td class="num">(2,162,351)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">278,912,800<span></span>
</td>
<td class="nump">278,912,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 307,369<span></span>
</td>
<td class="nump">$ 2,808<span></span>
</td>
<td class="nump">2,595,419<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">4,981<span></span>
</td>
<td class="num">(2,295,922)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised, net (in shares)</a></td>
<td class="nump">339,000<span></span>
</td>
<td class="nump">334,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised, net</a></td>
<td class="nump">$ 1,858<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">1,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,209,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Vesting of restricted stock units, net of taxes</a></td>
<td class="num">(9,278)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,278)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">43,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized holding loss on available-for-sale securities</a></td>
<td class="num">(367)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(367)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(21,854)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,854)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (147,417)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(147,417)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="nump">280,456,667<span></span>
</td>
<td class="nump">280,456,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 173,425<span></span>
</td>
<td class="nump">$ 2,811<span></span>
</td>
<td class="nump">2,631,110<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="num">(17,240)<span></span>
</td>
<td class="num">(2,443,339)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,133,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">238,617<span></span>
</td>
<td class="nump">$ 2,809<span></span>
</td>
<td class="nump">2,617,935<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="num">(1,028)<span></span>
</td>
<td class="num">(2,381,182)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised, net</a></td>
<td class="nump">999<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Vesting of restricted stock units, net of taxes</a></td>
<td class="num">(285)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(285)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">12,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized holding loss on available-for-sale securities</a></td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(16,183)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,183)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (62,157)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62,157)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="nump">280,456,667<span></span>
</td>
<td class="nump">280,456,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 173,425<span></span>
</td>
<td class="nump">$ 2,811<span></span>
</td>
<td class="nump">$ 2,631,110<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
<td class="num">$ (17,240)<span></span>
</td>
<td class="num">$ (2,443,339)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents Stock issued from exercise of warrants (in shares).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents Stock issued from exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566911300768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (147,417)<span></span>
</td>
<td class="num">$ (116,889)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and deferred financing</a></td>
<td class="nump">1,295<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,745<span></span>
</td>
<td class="nump">3,171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">43,114<span></span>
</td>
<td class="nump">32,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Non-cash changes in the fair value of contingent consideration payable</a></td>
<td class="num">(1,073)<span></span>
</td>
<td class="nump">1,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ForeignCurrencyRemeasurementGainLossBeforeTax', window );">Foreign currency remeasurement loss</a></td>
<td class="nump">353<span></span>
</td>
<td class="nump">3,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_AssetImpairmentChargesAndOtherAssetWriteOffs', window );">Asset impairment charges and other asset write-offs</a></td>
<td class="nump">12,265<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(4,424)<span></span>
</td>
<td class="num">(3,127)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">3,537<span></span>
</td>
<td class="num">(4,445)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(4,481)<span></span>
</td>
<td class="nump">5,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses, and other current liabilities</a></td>
<td class="nump">22,671<span></span>
</td>
<td class="num">(28,485)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities', window );">Other non-current assets and liabilities</a></td>
<td class="num">(2,762)<span></span>
</td>
<td class="num">(1,784)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(74,177)<span></span>
</td>
<td class="num">(108,277)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sale and redemption of marketable securities</a></td>
<td class="nump">184,061<span></span>
</td>
<td class="nump">258,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(98,330)<span></span>
</td>
<td class="num">(145,255)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(1,226)<span></span>
</td>
<td class="num">(1,234)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">84,505<span></span>
</td>
<td class="nump">112,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance leases</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(389)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrants exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Purchase of vested restricted stock units, net of taxes</a></td>
<td class="num">(9,278)<span></span>
</td>
<td class="num">(14,438)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised, net</a></td>
<td class="nump">1,858<span></span>
</td>
<td class="nump">6,661<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(7,461)<span></span>
</td>
<td class="nump">11,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</a></td>
<td class="num">(12,462)<span></span>
</td>
<td class="num">(1,439)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents, and restricted cash at the end of the period</a></td>
<td class="num">(9,595)<span></span>
</td>
<td class="nump">13,626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at the beginning of period</a></td>
<td class="nump">249,456<span></span>
</td>
<td class="nump">166,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at the end of period</a></td>
<td class="nump">239,861<span></span>
</td>
<td class="nump">179,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the period for interest</a></td>
<td class="nump">15,108<span></span>
</td>
<td class="nump">15,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes</a></td>
<td class="nump">710<span></span>
</td>
<td class="nump">4,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures unpaid at the end of period</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForTenantImprovements', window );">Tenant improvements paid through lease incentives</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AssetImpairmentChargesAndOtherAssetWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Impairment Charges And Other Asset Write-Offs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AssetImpairmentChargesAndOtherAssetWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ForeignCurrencyRemeasurementGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign Currency Remeasurement Gain (Loss), Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ForeignCurrencyRemeasurementGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of noncurrent liabilities that result from activities that generate operating income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_IncreaseDecreaseInNoncurrentOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566916370272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business</a></td>
<td class="text">Description of Business<div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amicus Therapeutics, Inc. (the "Company") is a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. The Company has a portfolio of product opportunities including the first, oral monotherapy for Fabry disease that has achieved widespread global approval and a differentiated biologic for Pompe disease, that is under review with the U.S. Food and Drug Administration ("FDA") as well as the European Medicines Agency ("EMA"). The Company is committed to discovering and developing next generation therapies in Fabry and Pompe diseases.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cornerstone of the Company's portfolio is Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (also referred to as "migalastat"), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants. Migalastat is currently approved under the trade name Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States ("U.S."), European Union ("E.U."), United Kingdom ("U.K."), and Japan, with multiple additional approvals granted and applications pending in several geographies around the world. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lead biologics program of the Company's pipeline is Amicus Therapeutics GAA ("AT-GAA", also known as ATB200/AT2221, or cipaglucosidase alfa/miglustat), a novel, two-component, potential best-in-class treatment for Pompe disease. In February 2019, the FDA granted Breakthrough Therapy designation ("BTD") to AT-GAA for the treatment of late onset Pompe disease. In September 2021, the FDA set the Prescription Drug User Fee Act ("PDUFA") target action date of May 29, 2022 for the New Drug Application ("NDA") for miglustat and July 29, 2022 for the Biologics License Application ("BLA") for cipaglucosidase alfa. The EMA validated the Marketing Authorization Application (&#8220;MAA&#8221;) in the fourth quarter of 2021. On May 9, 2022, the FDA extended the review period for the NDA for miglustat and the BLA for cipaglucosidase alfa resulting in revised PDUFA action dates of August 29, 2022 and October 29, 2022, respectively. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operations have not been significantly impacted by the novel coronavirus (&#8220;COVID-19&#8221;) pandemic to date. The Company continued to observe increased lag time between patient identification and Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> initiation due to the continued prevalence of COVID-19 and its ongoing impact on access to treatment for people living with Fabry disease in certain markets. The Company has maintained operations in all geographies, secured its global supply chain for its commercial and clinical products, as well as maintained the operational integrity of its clinical trials, with minimal disruptions. Whether the Company will continue to operate without any significant disruptions will depend on the continued health of its employees, the ongoing demand for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the continued operation of its global supply chain. The Company has continued to provide uninterrupted access to medicines for those in need of treatment, while prioritizing the health and safety of its global workforce. However, the Company's results of operations in future periods may be negatively impacted by unknown future impacts from the COVID-19 pandemic.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had an accumulated deficit of $2.4 billion as of June 30, 2022 and anticipates incurring losses through the fiscal year ending December 31, 2022 and beyond. The Company has historically funded its operations through stock offerings, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues, debt issuances, collaborations, and other financing arrangements. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on its current operating model, the Company believes that the current cash position, which includes expected revenues, is sufficient to fund the Company's operations and ongoing research programs to achieve self-sustainability. Potential impacts of the COVID-19 pandemic, business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact the Company's future capital requirements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140567000538656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has prepared the accompanying unaudited Consolidated Financial Statements in accordance with the U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited Consolidated Financial Statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company's interim financial information.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements and related notes should be read in conjunction with the Company's financial statements and related notes as contained in the Company's Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2021.&#160;For a complete description of the Company's accounting policies, please refer to the Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2021. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Transactions</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company assessed the impact COVID-19 pandemic has had on its operations and financial results as of June 30, 2022 and through the issuance of these financial statements. The Company&#8217;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are reported within other comprehensive loss in the Company's Consolidated Statements of Comprehensive Loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations, or other observable inputs.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in other current assets and other non-current assets on the Company's Consolidated Balance Sheets. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company's accounts receivable at June 30, 2022 have arisen from product sales primarily in Europe and the U.S. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis. As of June 30, 2022, the Company recorded an allowance for doubtful accounts of $0.1 million.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated over the estimated useful lives of the respective assets, which range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfNTM5Mg_89960747-9384-4345-bf43-26f7a60be61c">three</span> to five years, or the lesser of the related initial term of the lease or useful life for leasehold improvements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial cost of property and equipment consists of its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to income in the period in which the costs are incurred. Major replacements, improvements, and additions are capitalized in accordance with Company policy.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If indications of impairment exist, projected future undiscounted cash flows associated with the asset or asset group are compared to the carrying value of the asset to determine whether the asset or asset group's value is recoverable. If impairment is determined, the Company writes down the asset to its estimated fair value and records an impairment loss equal to the excess of the carrying value of the long-lived asset over its estimated fair value in the period at which such a determination is made.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2022, in connection with the strategic prioritization of its gene therapy portfolio, the Company performed an assessment of its fixed assets. As a result, the Company recognized an impairment charge of $6.6&#160;million.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's net product sales consist of sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Fabry disease. The Company has recorded revenue on sales where Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is available either on a commercial basis or through a reimbursed early access program. Orders for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are generally received from distributors and pharmacies, with the ultimate payor often a government authority. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The transaction price is determined based on fixed consideration in the Company's customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenue from the sale of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's net product sales from Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disaggregated by geographic area:</span></div><div style="margin-bottom:12pt;margin-top:15pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.127%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.127%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.127%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,540&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,678&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ex-U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,191&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,735&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99,284&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,731&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,413&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159,446&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,815&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories and Cost of Goods Sold</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of goods sold in the Consolidated Statements of Operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expense consist primarily of costs related to personnel, including salaries and other personnel related expenses, consulting fees, and the cost of facilities and support services used in drug development. Assets acquired that are used for research and development and have no future alternative use are expensed as in-process research and development. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2022, as part of the Company&#8217;s strategic prioritization of its gene therapy portfolio, the Company recorded a non-recurring $20.0&#160;million liability associated with the expense of contractual obligations from which the Company will no longer receive further economic benefit. A liability for costs that will continue to be incurred under a contract for its remaining term without economic benefit to the entity is recognized at the cease-use date. This liability is presented as a component of accrued expenses and other current liabilities within the Company's Consolidated Balance Sheets. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Developments</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated recent accounting pronouncements and believes that none of them will have a material effect on the Company's Consolidated Financial Statements or related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140567000589760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-Term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock', window );">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</a></td>
<td class="text">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash<div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the Company held $235.6 million in cash and cash equivalents and $151.2 million of marketable securities which are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are generally reported within other comprehensive loss in the Company's Consolidated Statements of Comprehensive Loss. If a decline in the fair value of a marketable security below the Company's cost basis is determined to be other-than-temporary or if an available-for-sale debt security&#8217;s fair value is determined to be less than the amortized cost and the Company intends or is more than likely to sell the security before recovery and it is not considered a credit loss, such security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. If the unrealized loss of an available-for-sale debt security is determined to be a result of credit loss, the Company would recognize an allowance and the corresponding credit loss would be included in earnings.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly invests excess operating cash in deposits with major financial institutions, money market funds, notes issued by the U.S. government, as well as fixed income investments and U.S. bond funds, both of which can be readily purchased and sold using established markets. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated as many of these securities are either government backed or of the highest credit rating. Investments that have original maturities greater than three months but less than one year are classified as current.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and marketable securities are classified as current unless mentioned otherwise below and consisted of the following: </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(239)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">387,281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(441)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">386,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235,639&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235,639&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(441)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">387,281&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(441)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">386,841&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.020%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">245,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">245,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,070&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,056&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">245,197&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">245,197&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237,299</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482,568&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482,496&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For both the six months ended June 30, 2022 and the fiscal year ended December 31, 2021, there were no realized gains or losses. The cost of securities sold is based on the specific identification method.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized loss positions in the marketable securities as of June 30, 2022 and December 31, 2021 reflect temporary impairments and are not a result of credit loss. Additionally, as these positions have been in a loss position for less than twelve months and the Company does not intend to sell these securities before recovery, the losses are recognized in other comprehensive (loss) gain. The fair value of these marketable securities in unrealized loss positions was $140.5 million and $173.4 million as of June 30, 2022 and December 31, 2021, respectively.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">176,538&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,222&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">239,861&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,788&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140567000568064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of raw materials, work-in-process, and finished goods related to the manufacture of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The following table summarizes the components of inventories: </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,879&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,818&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a reserve for inventory of $1.1 million as of both June 30, 2022 and December 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140567000603904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt <div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's debt consists of the following: </span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Term Loan due 2026:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: debt discount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,334)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,074)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: deferred financing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,014)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,569)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying value of Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">390,652&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389,357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Included in the Consolidated Balance Sheets within long-term debt and amortized to interest expense over the remaining life of the Senior Secured Term Loan due 2026 using the effective interest rate method.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth interest expense recognized related to the Company's debt for the three and six months ended June 30, 2022 and 2021, respectively:</span></div><div style="margin-bottom:6pt;margin-top:15pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.447%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.899%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,089&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">739&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of deferred financing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566916205104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based CompensationThe Company's Amended and Restated 2007 Equity Incentive Plan (the "Plan") provides for the granting of restricted stock units and options to purchase common stock in the Company to employees, directors, advisors, and consultants at a price to be determined by the Company's Board of Directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company's business. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option. <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Option Grants</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.154%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.522%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.474%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected life of options (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected annual dividend per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;A summary of the Company's stock options for the six months ended June 30, 2022 were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.479%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise&#160;<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining <br/>Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options outstanding, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(339)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(333)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(178)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options outstanding, June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,283&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and unvested expected to vest, June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,589&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the total unrecognized compensation cost related to non-vested stock options granted was $39.5 million and is expected to be recognized over a weighted average period of three years.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and Performance-Based Restricted Stock Units (collectively "RSUs")</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs awarded under the Plan are generally subject to graded vesting and are contingent on an employee's continued service. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. A summary of non-vested RSU activity under the Plan for the six months ended June 30, 2022 is as follows:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:38.107%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average Grant<br/>Date Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;<br/>Average<br/>Remaining&#160;<br/>Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,815&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,738)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(252)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,166&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All non-vested units are expected to vest over their normal term. As of June 30, 2022, there was $65.8 million of total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions. These costs are expected to be recognized over a weighted average period of two years.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Expense Related to Equity Awards</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.702%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.549%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,152&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,744&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,457&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,463&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,736&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,114&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,090&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566916745088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Assets and Liabilities Measured at Fair Value</a></td>
<td class="text">Assets and Liabilities Measured at Fair Value<div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial assets and liabilities are measured at fair value and classified within the fair value hierarchy, which is defined as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs that are unobservable for the asset or liability.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of June 30, 2022 are identified in the following tables:</span></div><div style="margin-bottom:15pt;margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:72.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.677%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156,163&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156,163&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:58.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,266&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,977&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,266&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,243&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2021 are identified in the following tables:</span></div><div style="margin-bottom:15pt;margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:72.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.677%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">242,048&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">242,048&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:63.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.193%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,800&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,339&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,139&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Senior Secured Term Loan due 2026 falls into the Level 2 category within the fair value level hierarchy and the fair value was determined using quoted prices for similar liabilities in active markets, as well as inputs that are observable for the liability (other than quoted prices), such as interest rates that are observable at commonly quoted intervals. The carrying value of the Senior Secured Term Loan due 2026 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximates the fair value.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any Level 3 assets as of June 30, 2022 or December 31, 2021.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Money Market Funds, and Marketable Securities</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its cash within the fair value hierarchy as Level&#160;1 as these assets are valued using quoted prices in an active market for identical assets at the measurement date. The Company considers its investments in marketable securities as available-for-sale and classifies these assets and the money market funds within the fair value hierarchy as Level&#160;2 primarily utilizing broker quotes in a non-active market for valuation of these securities. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Payable</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration payable resulted from the acquisition of Callidus Biopharma, Inc. ("Callidus") in November 2013. The most recent valuation was determined using a probability weighted discounted cash flow valuation approach. Gains and losses are included in the Consolidated Statements of Operations. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration payable for Callidus has been classified as a Level 3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market.&#160;If different assumptions </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were used for the various inputs to the valuation approach, the estimated fair value could be significantly higher or lower than the fair value the Company determined. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB200 Pompe disease program: </span></div><div style="margin-bottom:15pt;margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.917%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent&#160;Consideration</span></div><div style="margin-bottom:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value as of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation&#160;Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable&#160;Input</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical and regulatory milestones</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,266&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Probability weighted discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Probability of achievement of milestones</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75% - 88%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected year of payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022 - 2023</span></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration liabilities are remeasured to fair value each reporting period using discount rates, probabilities of payment, and projected payment dates. Projected contingent payment amounts related to clinical and regulatory based milestones are discounted back to the current period using a discounted cash flow model. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs together, or in isolation, may result in a significantly lower or higher fair value measurement. There is no assurance that any of the conditions for the milestone payments will be met. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the change in the balance of contingent consideration payable for the three and six months ended June 30, 2022 and 2021, respectively:</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.702%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.549%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, beginning of the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in fair value during the period, included in the Consolidated Statements of Operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,073)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, end of the period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,266&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,317&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,266&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,317&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> As certain milestones are expected to be reached within the next twelve months, the June 30, 2022 balance was recorded as a current liability in the Consolidated Balance Sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566916218512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss per Common Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Basic and Diluted Net Loss per Common Share</a></td>
<td class="text">Basic and Diluted Net Loss per Common Share<div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.865%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.254%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.254%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.254%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.259%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands,&#160;except&#160;per&#160;share amounts)&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51,225)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(147,417)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(116,889)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding&#160;&#8212; basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">291,970,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266,398,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288,646,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,384,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive common stock equivalents would include the dilutive effect of common stock options, convertible debt units, RSUs, and warrants for common stock equivalents.&#160;Potentially dilutive common stock equivalents were excluded from the diluted earnings per share denominator for all periods because of their anti-dilutive effect. Weighted average common shares outstanding includes outstanding pre-funded warrants with an exercise price of $0.01. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,283&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,962&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total number of potentially issuable shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,449&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566914019280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has prepared the accompanying unaudited Consolidated Financial Statements in accordance with the U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited Consolidated Financial Statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company's interim financial information.</span></div>The accompanying unaudited Consolidated Financial Statements and related notes should be read in conjunction with the Company's financial statements and related notes as contained in the Company's Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2021.&#160;For a complete description of the Company's accounting policies, please refer to the Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2021.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Transactions</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company assessed the impact COVID-19 pandemic has had on its operations and financial results as of June 30, 2022 and through the issuance of these financial statements. The Company&#8217;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents, Marketable Securities and Restricted Cash</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are reported within other comprehensive loss in the Company's Consolidated Statements of Comprehensive Loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations, or other observable inputs.</span></div>Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in other current assets and other non-current assets on the Company's Consolidated Balance Sheets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span>. The Company's accounts receivable at June 30, 2022 have arisen from product sales primarily in Europe and the U.S. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated over the estimated useful lives of the respective assets, which range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfNTM5Mg_89960747-9384-4345-bf43-26f7a60be61c">three</span> to five years, or the lesser of the related initial term of the lease or useful life for leasehold improvements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial cost of property and equipment consists of its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to income in the period in which the costs are incurred. Major replacements, improvements, and additions are capitalized in accordance with Company policy.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If indications of impairment exist, projected future undiscounted cash flows associated with the asset or asset group are compared to the carrying value of the asset to determine whether the asset or asset group's value is recoverable. If impairment is determined, the Company writes down the asset to its estimated fair value and records an impairment loss equal to the excess of the carrying value of the long-lived asset over its estimated fair value in the period at which such a determination is made.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2022, in connection with the strategic prioritization of its gene therapy portfolio, the Company performed an assessment of its fixed assets. As a result, the Company recognized an impairment charge of $6.6&#160;million.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's net product sales consist of sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Fabry disease. The Company has recorded revenue on sales where Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is available either on a commercial basis or through a reimbursed early access program. Orders for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are generally received from distributors and pharmacies, with the ultimate payor often a government authority. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The transaction price is determined based on fixed consideration in the Company's customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenue from the sale of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryCostsForContractsOrProgramsPolicy', window );">Inventories and Cost of Goods Sold</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories and Cost of Goods Sold</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of goods sold in the Consolidated Statements of Operations.</span></div>Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expense consist primarily of costs related to personnel, including salaries and other personnel related expenses, consulting fees, and the cost of facilities and support services used in drug development. Assets acquired that are used for research and development and have no future alternative use are expensed as in-process research and development. </span></div>In the second quarter of 2022, as part of the Company&#8217;s strategic prioritization of its gene therapy portfolio, the Company recorded a non-recurring $20.0&#160;million liability associated with the expense of contractual obligations from which the Company will no longer receive further economic benefit. A liability for costs that will continue to be incurred under a contract for its remaining term without economic benefit to the entity is recognized at the cease-use date. This liability is presented as a component of accrued expenses and other current liabilities within the Company's Consolidated Balance Sheets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Developments</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Developments</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated recent accounting pronouncements and believes that none of them will have a material effect on the Company's Consolidated Financial Statements or related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryCostsForContractsOrProgramsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the basis and manner that goods are added and removed from inventory for costs relating to long-term contracts or programs. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory and how cost is determined (such as FIFO, LIFO, average). Elements of costs in inventory may include retained costs representing the excess of manufacturing or production costs over the amounts charged to cost of sales or delivered or in-process units, initial tooling or other deferred startup costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryCostsForContractsOrProgramsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566912565648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's net product sales from Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disaggregated by geographic area:</span></div><div style="margin-bottom:12pt;margin-top:15pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.127%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.127%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.127%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,540&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,678&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ex-U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,191&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,735&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99,284&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,731&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,413&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159,446&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,815&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566914064928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-Term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash, Cash Equivalents and Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and marketable securities are classified as current unless mentioned otherwise below and consisted of the following: </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(239)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">387,281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(441)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">386,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235,639&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235,639&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(441)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">387,281&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(441)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">386,841&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.020%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">245,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">245,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,070&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,056&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">245,197&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">245,197&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237,299</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482,568&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482,496&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">176,538&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,222&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">239,861&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,788&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566916953552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories for the Period</a></td>
<td class="text">The following table summarizes the components of inventories: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,879&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,818&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566912639984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of Liability Components of Long-Term Debt</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's debt consists of the following: </span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Term Loan due 2026:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: debt discount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,334)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,074)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: deferred financing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,014)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,569)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying value of Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">390,652&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389,357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Included in the Consolidated Balance Sheets within long-term debt and amortized to interest expense over the remaining life of the Senior Secured Term Loan due 2026 using the effective interest rate method.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Components of Total Interest Expense</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth interest expense recognized related to the Company's debt for the three and six months ended June 30, 2022 and 2021, respectively:</span></div><div style="margin-bottom:6pt;margin-top:15pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.447%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.899%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,089&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">739&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of deferred financing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566913915616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Options</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.154%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.522%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.474%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected life of options (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected annual dividend per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text">A summary of the Company's stock options for the six months ended June 30, 2022 were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.479%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise&#160;<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining <br/>Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options outstanding, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(339)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(333)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(178)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options outstanding, June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,283&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and unvested expected to vest, June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,589&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Non-Vested RSU Activity under the Plan</a></td>
<td class="text">A summary of non-vested RSU activity under the Plan for the six months ended June 30, 2022 is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:38.107%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average Grant<br/>Date Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;<br/>Average<br/>Remaining&#160;<br/>Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,815&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,738)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(252)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,166&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Equity Compensation Expenses</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.702%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.549%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,152&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,744&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,457&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,463&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,736&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,114&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,090&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566916799328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Assets and Liabilities Subject to Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of June 30, 2022 are identified in the following tables:</span></div><div style="margin-bottom:15pt;margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:72.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.677%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156,163&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156,163&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:58.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,266&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,977&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,266&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,243&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2021 are identified in the following tables:</span></div><div style="margin-bottom:15pt;margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:72.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.677%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">242,048&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">242,048&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:63.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.193%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,800&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,339&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,139&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Significant Unobservable Inputs Used in the Valuation of the Contingent Consideration Payable</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB200 Pompe disease program: </span></div><div style="margin-bottom:15pt;margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.917%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent&#160;Consideration</span></div><div style="margin-bottom:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value as of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation&#160;Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable&#160;Input</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical and regulatory milestones</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,266&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Probability weighted discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Probability of achievement of milestones</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75% - 88%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected year of payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022 - 2023</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of Changes in Continent Consideration Payable</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the change in the balance of contingent consideration payable for the three and six months ended June 30, 2022 and 2021, respectively:</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.702%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.549%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, beginning of the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in fair value during the period, included in the Consolidated Statements of Operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,073)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, end of the period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,266&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,317&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,266&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,317&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> As certain milestones are expected to be reached within the next twelve months, the June 30, 2022 balance was recorded as a current liability in the Consolidated Balance Sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566912634368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Reconciliation of the Numerator and Denominator Used in Computing Basic and Diluted Net Loss per Common Share</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.865%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.254%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.254%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.254%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.259%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands,&#160;except&#160;per&#160;share amounts)&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51,225)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(147,417)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(116,889)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding&#160;&#8212; basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">291,970,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266,398,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288,646,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,384,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Shares of Common Stock that were Excluded from the Computation as they were Anti-Dilutive Using the Treasury Stock Method</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,283&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,962&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total number of potentially issuable shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,449&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566916287184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Business (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 2,443,339<span></span>
</td>
<td class="nump">$ 2,295,922<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566913974544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts receivable</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Loss on impairment of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,616<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">80,731<span></span>
</td>
<td class="nump">77,413<span></span>
</td>
<td class="nump">159,446<span></span>
</td>
<td class="nump">143,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">27,540<span></span>
</td>
<td class="nump">23,678<span></span>
</td>
<td class="nump">$ 51,718<span></span>
</td>
<td class="nump">44,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Ex-U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">$ 53,191<span></span>
</td>
<td class="nump">$ 53,735<span></span>
</td>
<td class="nump">$ 107,728<span></span>
</td>
<td class="nump">$ 99,284<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566914033184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, Money Market Funds, and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 235,639,000<span></span>
</td>
<td class="nump">$ 245,197,000<span></span>
</td>
<td class="nump">$ 176,538,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">151,202,000<span></span>
</td>
<td class="nump">237,299,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesRealizedGainLoss', window );">Realized gain (loss) on debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair value of available-for-sale debt securities in unrealized loss positions</a></td>
<td class="nump">140,500,000<span></span>
</td>
<td class="nump">$ 173,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=fold_MarketableSecuritiesMember', window );">Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, Money Market Funds, and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">$ 151,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=fold_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=fold_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566908073136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Components (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, Money Market Funds, and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 235,639<span></span>
</td>
<td class="nump">$ 245,197<span></span>
</td>
<td class="nump">$ 176,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair value, cash balances</a></td>
<td class="nump">235,639<span></span>
</td>
<td class="nump">245,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost, available-for-sale securities</a></td>
<td class="nump">151,642<span></span>
</td>
<td class="nump">237,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gain, available-for-sale securities</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss, available-for-sale securities</a></td>
<td class="num">(441)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale debt securities</a></td>
<td class="nump">151,202<span></span>
</td>
<td class="nump">237,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities', window );">Cost, cash balances and available-for-sale securities</a></td>
<td class="nump">387,281<span></span>
</td>
<td class="nump">482,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gain, cash balances and available-for-sale securities</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss, cash balances and available-for-sale securities</a></td>
<td class="num">(441)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure', window );">Fair value, cash balances and available-for-sale securities</a></td>
<td class="nump">386,841<span></span>
</td>
<td class="nump">482,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, Money Market Funds, and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Corporate debt securities, cost</a></td>
<td class="nump">103,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Corporate debt securities, gross unrealized gain</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Corporate debt securities, gross unrealized loss</a></td>
<td class="num">(239)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Corporate debt securities, fair value</a></td>
<td class="nump">102,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost, available-for-sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gain, available-for-sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss, available-for-sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, Money Market Funds, and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost, available-for-sale securities</a></td>
<td class="nump">45,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gain, available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss, available-for-sale securities</a></td>
<td class="num">(193)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale debt securities</a></td>
<td class="nump">44,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, Money Market Funds, and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Corporate debt securities, cost</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">30,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Corporate debt securities, gross unrealized gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Corporate debt securities, gross unrealized loss</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Corporate debt securities, fair value</a></td>
<td class="nump">2,991<span></span>
</td>
<td class="nump">30,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, Money Market Funds, and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Corporate debt securities, cost</a></td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Corporate debt securities, gross unrealized gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Corporate debt securities, gross unrealized loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Corporate debt securities, fair value</a></td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost, available-for-sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gain, available-for-sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss, available-for-sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=fold_ShortTermCorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, Money Market Funds, and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Corporate debt securities, cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Corporate debt securities, gross unrealized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Corporate debt securities, gross unrealized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Corporate debt securities, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, Money Market Funds, and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost, available-for-sale securities</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gain, available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss, available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale debt securities</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Also includes amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents cash and cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Before Tax, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=fold_ShortTermCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=fold_ShortTermCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566908435664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash, Cash Equivalents, And Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-Term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 235,639<span></span>
</td>
<td class="nump">$ 245,197<span></span>
</td>
<td class="nump">$ 176,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">4,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows</a></td>
<td class="nump">$ 239,861<span></span>
</td>
<td class="nump">$ 249,456<span></span>
</td>
<td class="nump">$ 179,788<span></span>
</td>
<td class="nump">$ 166,162<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566913951472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 11,508<span></span>
</td>
<td class="nump">$ 12,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">5,943<span></span>
</td>
<td class="nump">10,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">3,428<span></span>
</td>
<td class="nump">3,830<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">20,879<span></span>
</td>
<td class="nump">26,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Reserve for inventory</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566905941376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Summary of Long Term Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying value of Long-term debt</a></td>
<td class="nump">$ 390,652<span></span>
</td>
<td class="nump">$ 389,357<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorLoansMember', window );">Senior Loans | Senior Secured Term Loan due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: debt discount</a></td>
<td class="num">(5,334)<span></span>
</td>
<td class="num">(6,074)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Less: deferred financing</a></td>
<td class="num">$ (4,014)<span></span>
</td>
<td class="num">$ (4,569)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fold_SeniorSecuredTermLoanDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fold_SeniorSecuredTermLoanDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566905859728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Interest Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="nump">$ 7,589<span></span>
</td>
<td class="nump">$ 7,604<span></span>
</td>
<td class="nump">$ 15,089<span></span>
</td>
<td class="nump">$ 15,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">375<span></span>
</td>
<td class="nump">383<span></span>
</td>
<td class="nump">739<span></span>
</td>
<td class="nump">720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_AmortizationDeferredFinancingCosts', window );">Amortization of deferred financing</a></td>
<td class="nump">$ 283<span></span>
</td>
<td class="nump">$ 262<span></span>
</td>
<td class="nump">$ 556<span></span>
</td>
<td class="nump">$ 485<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AmortizationDeferredFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AmortizationDeferredFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566911205712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Weighted-average Assumptions (Details) - Options to purchase common stock - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">61.30%<span></span>
</td>
<td class="nump">65.50%<span></span>
</td>
<td class="nump">62.20%<span></span>
</td>
<td class="nump">66.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare', window );">Expected annual dividend per share (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the estimated dividend per share to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566908036640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Stock Option Activity (Details)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number&#160;of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">14,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, granted (in shares) | shares</a></td>
<td class="nump">5,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, exercised (in shares) | shares</a></td>
<td class="num">(339)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options, forfeited (in shares) | shares</a></td>
<td class="num">(333)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options, expired (in shares) | shares</a></td>
<td class="num">(178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">19,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options, vested and unvested expected to vest (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options, exercisable (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise&#160; Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options, granted (in dollars per share) | $ / shares</a></td>
<td class="nump">11.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options, exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">5.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options, forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">12.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options, expired (in dollars per share) | $ / shares</a></td>
<td class="nump">11.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding (in dollars per share) | $ / shares</a></td>
<td class="nump">11.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options, vested and unvested expected to vest (in dollars per share) | $ / shares</a></td>
<td class="nump">11.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options, exercisable (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, options outstanding</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, options vested and unvested expected to vest</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, options exercisable</a></td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, options outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested and unvested expected to vest | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value, exercisable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566911226128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized compensation costs</a></td>
<td class="nump">$ 39.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation costs, period for recognition (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized compensation costs</a></td>
<td class="nump">$ 65.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation costs, period for recognition (in years)</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566914040000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - RSUs and PBRSUs Summary (Details) - Unvested restricted stock units<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number&#160;of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested units (in shares) | shares</a></td>
<td class="nump">7,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">4,815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(1,738)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(252)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested units (in shares) | shares</a></td>
<td class="nump">10,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested units (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 13.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">11.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">12.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">12.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested units (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 13.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Non-vested units, weighted average remaining years</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Non-vested units, aggregate intrinsic value | $</a></td>
<td class="nump">$ 109.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566911747440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Expense Summary (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity compensation expense</a></td>
<td class="nump">$ 12,463<span></span>
</td>
<td class="nump">$ 11,736<span></span>
</td>
<td class="nump">$ 43,114<span></span>
</td>
<td class="nump">$ 32,090<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity compensation expense</a></td>
<td class="nump">4,379<span></span>
</td>
<td class="nump">3,152<span></span>
</td>
<td class="nump">13,744<span></span>
</td>
<td class="nump">9,457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general, and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity compensation expense</a></td>
<td class="nump">$ 8,084<span></span>
</td>
<td class="nump">$ 8,584<span></span>
</td>
<td class="nump">$ 29,370<span></span>
</td>
<td class="nump">$ 22,633<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566911536960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value - Components by Hierarchy Level (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">$ 156,163<span></span>
</td>
<td class="nump">$ 242,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="nump">19,266<span></span>
</td>
<td class="nump">20,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Deferred compensation plan liability</a></td>
<td class="nump">4,977<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of liabilities</a></td>
<td class="nump">24,243<span></span>
</td>
<td class="nump">25,139<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">102,846<span></span>
</td>
<td class="nump">174,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">44,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">2,991<span></span>
</td>
<td class="nump">30,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">5,362<span></span>
</td>
<td class="nump">5,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">156,163<span></span>
</td>
<td class="nump">242,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Deferred compensation plan liability</a></td>
<td class="nump">4,977<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of liabilities</a></td>
<td class="nump">4,977<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">102,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | U.S. government agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">44,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">2,991<span></span>
</td>
<td class="nump">30,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Money market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">5,362<span></span>
</td>
<td class="nump">5,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="nump">19,266<span></span>
</td>
<td class="nump">20,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Deferred compensation plan liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of liabilities</a></td>
<td class="nump">$ 19,266<span></span>
</td>
<td class="nump">$ 20,339<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566911702128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value - Significant Unobservable Inputs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="nump">$ 19,266<span></span>
</td>
<td class="nump">$ 20,339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="nump">19,266<span></span>
</td>
<td class="nump">$ 20,339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember', window );">Callidus Biopharma Inc | Clinical and regulatory milestones | ATB200 Pompe Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="nump">$ 19,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember', window );">Callidus Biopharma Inc | Clinical and regulatory milestones | Probability of achievement of milestones | ATB200 Pompe Program | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ContingentConsiderationMeasurementInput', window );">Contingent consideration, measurement input</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember', window );">Callidus Biopharma Inc | Clinical and regulatory milestones | Probability of achievement of milestones | ATB200 Pompe Program | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ContingentConsiderationMeasurementInput', window );">Contingent consideration, measurement input</a></td>
<td class="nump">88.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember', window );">Callidus Biopharma Inc | Clinical and regulatory milestones | Discount rate | Discount rate | ATB200 Pompe Program | Probability weighted discounted cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ContingentConsiderationMeasurementInput', window );">Contingent consideration, measurement input</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ContingentConsiderationMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ContingentConsiderationMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fold_ATB200PompeProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fold_ATB200PompeProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=fold_MeasurementInputProbabilityOfMilestoneAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=fold_MeasurementInputProbabilityOfMilestoneAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=fold_ProbabilityWeightedDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=fold_ProbabilityWeightedDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566916603744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value - Contingent Consideration Roll Forward (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, beginning of the period</a></td>
<td class="nump">$ 19,151<span></span>
</td>
<td class="nump">$ 26,296<span></span>
</td>
<td class="nump">$ 20,339<span></span>
</td>
<td class="nump">$ 25,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value during the period, included in the Consolidated Statements of Operations</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">1,021<span></span>
</td>
<td class="num">(1,073)<span></span>
</td>
<td class="nump">1,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, end of the period</a></td>
<td class="nump">$ 19,266<span></span>
</td>
<td class="nump">$ 27,317<span></span>
</td>
<td class="nump">$ 19,266<span></span>
</td>
<td class="nump">$ 27,317<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140566911704960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss per Common Share (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common stockholders | $</a></td>
<td class="num">$ (62,157)<span></span>
</td>
<td class="num">$ (51,225)<span></span>
</td>
<td class="num">$ (147,417)<span></span>
</td>
<td class="num">$ (116,889)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic (in shares)</a></td>
<td class="nump">291,970,562<span></span>
</td>
<td class="nump">266,398,516<span></span>
</td>
<td class="nump">288,646,587<span></span>
</td>
<td class="nump">265,384,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding - diluted (in shares)</a></td>
<td class="nump">291,970,562<span></span>
</td>
<td class="nump">266,398,516<span></span>
</td>
<td class="nump">288,646,587<span></span>
</td>
<td class="nump">265,384,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,449,000<span></span>
</td>
<td class="nump">22,832,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,283,000<span></span>
</td>
<td class="nump">14,962,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,166,000<span></span>
</td>
<td class="nump">7,412,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">458,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>fold-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:fold="http://www.amicustherapeutics.com/20220630"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="fold-20220630.xsd" xlink:type="simple"/>
    <context id="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1072316a8ef24e96928b3d944127fe65_I20220727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2022-07-27</instant>
        </period>
    </context>
    <context id="i11f13f2826434e75ba7e1100f8e58792_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib23d91f5ea064297be63d22df3cfdee1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie3538d27fff444d092acd57eb241f871_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic9dcaac3e3f74257b9b5319bd5cd7e11_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8964c1432633472c8bc58ddf38701965_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7d81a1ce547341fdbad1b2485e2b8dab_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i457540a06a0e4f12a8a6760a2e662d69_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i97d51d17e9f74441bbd0bd417ab532ee_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i90601765a2f2418a9abfd28bd624e1fb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib83568c208d34901bc8f2b3277a492eb_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2b3bca726f0d46f2b136309217acf4e2_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6104ef486d1344d9b4a6249c99ecaa75_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id89ea44d86214f11955f8524c82ca59d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7cc23a72515148e9bdb594c0ffdc44d9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6af221862afe4ec8a95c4bd66bc29a83_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i66313300b8924ac38edbed17cd4621e8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2a67d85fc2bc4508827b7d6504191b86_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4d7fceb860b04c3284049f567598615f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i20369be16fb64d618f19ff7c879c5f74_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i847ea7f79a9d45378381e71e73b6c2d6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8850617c24a64a82b3ac49102d519aac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8b04ea28407641b98ad9d006e7f294a1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7f89399acbed48f4948a667624d93858_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie9b3ff93c685496a8f7db03682c9a6bc_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9145f98a12fd40a6a178726d7e2acfd7_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3b08ba7dfa164bffb946e42d5c6b0353_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id499f57d04ef46548abf1e291e9d5885_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i03bf3913256a4b41be32f6db37aa316c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6de8ae1734aa4d599eb85d75fd49b941_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i625ab03e96af4d8683f3acb33151056f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id6afdfc73ba542e78bfc05da8ba789e6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib385a6b7137c45958b92a30dddce1f19_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0236634b4cb14481acb0fb30723e7beb_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ieaf9ecdf3e9d41aaaf315396d42a9e6e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id0feda6c19ba4dde88c6ff31d463c64d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1a489e0cac5148b098047e20f7b16d2c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id197126c4925481fbd6568b6714249d7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1575283eac554820897a66659337bdf4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia655833ddbb14af0823e080a718286f3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia265d46e7fdb4a6cbfc035ff181f41b7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibdd0bea669974aef88283f7ce9684c7f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i15ca856684364a728cfb2cacad448766_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie3250897ae664ba78fc2758e4d197424_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0726224b301248d2932ff84f9938870f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iebfefb1a4b464d5ba21ad742a3619573_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic229e029b81044fdbb354018535e5d3b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i17008df080294bb0bf1240acd6c19c15_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia5f30d05cafe48b79410089e00859443_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i44b8bffb160d45dda13b5e2b78abce7f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i649bebfff85c4aeb81fb81bfe49eeb22_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i03ca42e2698e4878b362989f4df7933e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i69530f8676834a24b6824dd3090f275c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie01bcbab6a39452c8f207bbd1040e82e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6d38f6fadc98426f9e4074b1ab54e9d6_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia1ae6aeddaf442cba31cc61b672cf523_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4608585deb7447ecabc5d85a3a731ff7_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia22486482e60492c860155dbff44d0c1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9888231cb6e4488995457f5adf3be783_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibe98a5affced4afd82274d759802ef32_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5aab62a215e24c70a98a8fa127a0c93e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4736f08b10ec45f5a5791466daa3734d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idc644fbd473b4779827e095e604e1fa1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2058a237abf345d3a1df9a3c8c9c52b2_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i33bee7e70d4f41ae98aea43eaf262df5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fold:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i313bc2d8be6b49deab3982d26fd646fd_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2a5beaca54dc4603a5614a45876a29e0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie925c891e72c47cea99fa4b411e16d37_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2786cde9d4554d08836966e040d3dd88_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iee2998a9354d4afca4c7ca59fa536817_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i18a1d906c5a545e698385837607d8ddb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3b99930e76ff4d129e26d8c1981c9dee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fold:ShortTermCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifae0d641d44e4d74bd462bf49ef538ec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9b41065183b64de594c948fc62b3fd96_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia21576db6b004494a12be3e92fdd6c66_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7b96f9892c1f46b79e86ebc2d8e82423_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7817625b346c448d9777f5897c0b43fb_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:SeniorSecuredTermLoanDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i11f9f50188a747e78f96bbbe4336d3aa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:SeniorSecuredTermLoanDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7db5d4a26355471cb3592c15bd783d1c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4699991b02604e23976f7eb8d6c9a55f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5d570dfe70e7454f85640ff0afc44736_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3501524d91e94a18bfac0415f9e68531_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4c027874ad0b4c14b107e9e7d4d2a4b3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2ccbe1db3305487c82f9fcfe73e288b9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i245ad67e6079446eae628bd054c5451c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i45525b12c16f4e50b69bac633525c7c7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4e34834a2be94b8e8074f10f13edbcb6_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iabd36bef22694ce9b71e55b1717ed5db_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i613cc31dd21945f18cc9aca69ab98da3_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1b06cd373bbe47dcbce2f3dabed11f52_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie40dbd39b0544892a3797b1b64ad108e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1217c1798fd34a71be289e7051cd1b47_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id4c83b69fa62485e98e97922a5e49b57_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i659ab50b47154e78b47ef9e839307808_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie9f84953690247a48cc8d3be225dedce_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4ddfa60f46e544df947c8b0ff919e9db_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3cce6f2cd8d64779a3cb98b16bc6010c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iaaa7d76b8bf74f59b0911c381d40613e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i667b2117b7d6414692a884314d59ed80_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idc49c8cd141a4141b4d1b6b88a3c8ee3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iddabb7fdfb774233b59ea3d5ebb33de8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i582299724ae3474088b179e8999bf21b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if2f84ce5d8994d548056b41c664b19c0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i56ccbb8636664d06a097e18deeca55d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib7023ba5f3b3416e833c03c3b04dfd39_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iccc9fcd06a114cdc9b7fd7bcc33f41ce_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:ATB200PompeProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">fold:ProbabilityWeightedDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0df4cd98b90b48bbac276b1d955f92ae_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:ATB200PompeProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3b66abc5705c43f5b528d365e1c87cb4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">fold:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:ATB200PompeProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ieeee7b9e37734d74a6b642a88110192e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">fold:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:ATB200PompeProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i62b5a7d4e59f4a0cb528290f1c8d251f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia41bb3d6e6b341469638797bd696c267_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3206f3ebb21741d5af011059960d7b2d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i67808a739f5e477b8929ea199cdf1917_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia9642de7b1214086a13a7ba1bbf1e23a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie6d84939f6a24c2dbbebe6fd3cbbd1ff_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i391211c299184c4890fc3d8186f647fa_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="cadPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:CAD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80L2ZyYWc6NWRlNGY0MTA0NzNhNDRlZmE4NWNhOTUyYjhiOGE3NTIvdGFibGU6ZTE3MzdmZWRiMzQ5NDc3YmE1ZjI5ODhmYjM0Y2E1N2IvdGFibGVyYW5nZTplMTczN2ZlZGIzNDk0NzdiYTVmMjk4OGZiMzRjYTU3Yl8zLTEtMS0xLTI1OTg5_ac139126-e727-4aac-8987-07eb7af37df5">0001178879</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80L2ZyYWc6NWRlNGY0MTA0NzNhNDRlZmE4NWNhOTUyYjhiOGE3NTIvdGFibGU6ZTE3MzdmZWRiMzQ5NDc3YmE1ZjI5ODhmYjM0Y2E1N2IvdGFibGVyYW5nZTplMTczN2ZlZGIzNDk0NzdiYTVmMjk4OGZiMzRjYTU3Yl80LTEtMS0xLTI1OTg5_869f4241-cf48-4043-b18f-72af83c1e04b">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80L2ZyYWc6NWRlNGY0MTA0NzNhNDRlZmE4NWNhOTUyYjhiOGE3NTIvdGFibGU6ZTE3MzdmZWRiMzQ5NDc3YmE1ZjI5ODhmYjM0Y2E1N2IvdGFibGVyYW5nZTplMTczN2ZlZGIzNDk0NzdiYTVmMjk4OGZiMzRjYTU3Yl81LTEtMS0xLTI1OTg5_d7e30d1f-fbc6-4b4d-b17f-369e0282a733">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80L2ZyYWc6NWRlNGY0MTA0NzNhNDRlZmE4NWNhOTUyYjhiOGE3NTIvdGFibGU6ZTE3MzdmZWRiMzQ5NDc3YmE1ZjI5ODhmYjM0Y2E1N2IvdGFibGVyYW5nZTplMTczN2ZlZGIzNDk0NzdiYTVmMjk4OGZiMzRjYTU3Yl82LTEtMS0xLTI1OTg5_3077f6ce-e31a-48f6-a3f1-c660a39f1c80">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80L2ZyYWc6NWRlNGY0MTA0NzNhNDRlZmE4NWNhOTUyYjhiOGE3NTIvdGFibGU6ZTE3MzdmZWRiMzQ5NDc3YmE1ZjI5ODhmYjM0Y2E1N2IvdGFibGVyYW5nZTplMTczN2ZlZGIzNDk0NzdiYTVmMjk4OGZiMzRjYTU3Yl83LTEtMS0xLTI1OTg5_eb5491c8-e8fc-496d-95ec-72de79bf5583">Q2</dei:DocumentFiscalPeriodFocus>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6d38f6fadc98426f9e4074b1ab54e9d6_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfNTM5Mg_89960747-9384-4345-bf43-26f7a60be61c">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <dei:DocumentType
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGV4dHJlZ2lvbjphODg5NDY2OTAyNDg0M2U1OTliMjA3YmRkZWE2ZDFjNF8yMDkz_a65a0cb0-001a-4fab-b659-595ce3e98cb5">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGV4dHJlZ2lvbjphODg5NDY2OTAyNDg0M2U1OTliMjA3YmRkZWE2ZDFjNF8yMDk0_9a973e94-c954-4289-bb6d-bef1128ec928">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGV4dHJlZ2lvbjphODg5NDY2OTAyNDg0M2U1OTliMjA3YmRkZWE2ZDFjNF8yMzE_12b1946a-90e5-4ea1-9e66-d459240d215b">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGV4dHJlZ2lvbjphODg5NDY2OTAyNDg0M2U1OTliMjA3YmRkZWE2ZDFjNF8yMDk1_4d2e4c87-3de2-4d67-ae39-c834382fcf53">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGV4dHJlZ2lvbjphODg5NDY2OTAyNDg0M2U1OTliMjA3YmRkZWE2ZDFjNF8yMDk2_2fae5ac1-e5e8-48e9-a75a-645e01fb3401">001-33497</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGV4dHJlZ2lvbjphODg5NDY2OTAyNDg0M2U1OTliMjA3YmRkZWE2ZDFjNF8yMDk3_92347a33-aa68-4009-b45e-9735121d1db9">Amicus Therapeutics,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGFibGU6NzAxYTRmYmM0ODYyNGM5YmIzZjg0NDM1Yjg0YTJjMGUvdGFibGVyYW5nZTo3MDFhNGZiYzQ4NjI0YzliYjNmODQ0MzViODRhMmMwZV8wLTAtMS0xLTI1OTg5_9c15498e-18dc-41bc-8db4-67bb020f79c0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGFibGU6NzAxYTRmYmM0ODYyNGM5YmIzZjg0NDM1Yjg0YTJjMGUvdGFibGVyYW5nZTo3MDFhNGZiYzQ4NjI0YzliYjNmODQ0MzViODRhMmMwZV8wLTQtMS0xLTI1OTg5_27c9e1f0-b597-47df-ae40-860b1ee64a2d">71-0869350</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGFibGU6NzAxYTRmYmM0ODYyNGM5YmIzZjg0NDM1Yjg0YTJjMGUvdGFibGVyYW5nZTo3MDFhNGZiYzQ4NjI0YzliYjNmODQ0MzViODRhMmMwZV80LTAtMS0xLTI1OTg5_13b6633c-74d8-41db-b74b-5cee127d53ec">3675 Market Street,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGFibGU6NzAxYTRmYmM0ODYyNGM5YmIzZjg0NDM1Yjg0YTJjMGUvdGFibGVyYW5nZTo3MDFhNGZiYzQ4NjI0YzliYjNmODQ0MzViODRhMmMwZV80LTEtMS0xLTI1OTg5_912aed5f-60b4-4688-bc3a-890475cff3e3">Philadelphia,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGFibGU6NzAxYTRmYmM0ODYyNGM5YmIzZjg0NDM1Yjg0YTJjMGUvdGFibGVyYW5nZTo3MDFhNGZiYzQ4NjI0YzliYjNmODQ0MzViODRhMmMwZV80LTItMS0xLTI1OTg5_a2042b9a-43a8-4beb-b40d-06a2693ae4f0">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGFibGU6NzAxYTRmYmM0ODYyNGM5YmIzZjg0NDM1Yjg0YTJjMGUvdGFibGVyYW5nZTo3MDFhNGZiYzQ4NjI0YzliYjNmODQ0MzViODRhMmMwZV80LTQtMS0xLTI1OTg5_dcd5d1a6-7f36-4e51-bde2-b65079006dc6">19104</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGFibGU6NzAxYTRmYmM0ODYyNGM5YmIzZjg0NDM1Yjg0YTJjMGUvdGFibGVyYW5nZTo3MDFhNGZiYzQ4NjI0YzliYjNmODQ0MzViODRhMmMwZV83LTAtMS0xLTI1OTg5_410445ca-4fd2-4d69-b3a9-f38e3fb3cbb4">(215)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGFibGU6NzAxYTRmYmM0ODYyNGM5YmIzZjg0NDM1Yjg0YTJjMGUvdGFibGVyYW5nZTo3MDFhNGZiYzQ4NjI0YzliYjNmODQ0MzViODRhMmMwZV83LTMtMS0xLTI1OTg5_712878e7-364a-483a-a1e9-75c9269b3b35">921-7600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGFibGU6ZmY4ZjAyZWI2ZmEzNDI0OWIzMjRjODkzZjI5ZmRlZDUvdGFibGVyYW5nZTpmZjhmMDJlYjZmYTM0MjQ5YjMyNGM4OTNmMjlmZGVkNV8xLTAtMS0xLTI1OTg5_7217b401-80cd-4746-876f-2ef287fbb305">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGFibGU6ZmY4ZjAyZWI2ZmEzNDI0OWIzMjRjODkzZjI5ZmRlZDUvdGFibGVyYW5nZTpmZjhmMDJlYjZmYTM0MjQ5YjMyNGM4OTNmMjlmZGVkNV8xLTEtMS0xLTI1OTg5_76c60299-e6bc-40c4-8158-3169a4b7dc25">FOLD</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGFibGU6ZmY4ZjAyZWI2ZmEzNDI0OWIzMjRjODkzZjI5ZmRlZDUvdGFibGVyYW5nZTpmZjhmMDJlYjZmYTM0MjQ5YjMyNGM4OTNmMjlmZGVkNV8xLTItMS0xLTI1OTg5_1bfae59e-fbd9-4462-8d05-7bf1e9b7fe67">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGV4dHJlZ2lvbjphODg5NDY2OTAyNDg0M2U1OTliMjA3YmRkZWE2ZDFjNF8yMDk4_0d9373fe-573d-4ddd-ba0c-ced272e1d199">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGV4dHJlZ2lvbjphODg5NDY2OTAyNDg0M2U1OTliMjA3YmRkZWE2ZDFjNF8yMDkx_faef37fa-4ade-4788-a19d-0e402e496780">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGFibGU6ODJjZjVlZTQxNzI2NDliNTg2MDJkNzcyMTQ2ODQzYmQvdGFibGVyYW5nZTo4MmNmNWVlNDE3MjY0OWI1ODYwMmQ3NzIxNDY4NDNiZF8wLTAtMS0xLTI1OTg5_fe6ab060-c586-46f5-b5ff-910eba69a129">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGFibGU6ODJjZjVlZTQxNzI2NDliNTg2MDJkNzcyMTQ2ODQzYmQvdGFibGVyYW5nZTo4MmNmNWVlNDE3MjY0OWI1ODYwMmQ3NzIxNDY4NDNiZF8xLTQtMS0xLTI1OTg5_7b32643b-8c57-44c5-8a35-9592198e2f2a">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGFibGU6ODJjZjVlZTQxNzI2NDliNTg2MDJkNzcyMTQ2ODQzYmQvdGFibGVyYW5nZTo4MmNmNWVlNDE3MjY0OWI1ODYwMmQ3NzIxNDY4NDNiZF8yLTQtMS0xLTI1OTg5_f72f3c25-0440-4811-bb5b-89d75edd8db1">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGV4dHJlZ2lvbjphODg5NDY2OTAyNDg0M2U1OTliMjA3YmRkZWE2ZDFjNF8yMDky_1a25afd8-beaf-4f96-ad05-bad323938996">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i1072316a8ef24e96928b3d944127fe65_I20220727"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xL2ZyYWc6YTg4OTQ2NjkwMjQ4NDNlNTk5YjIwN2JkZGVhNmQxYzQvdGV4dHJlZ2lvbjphODg5NDY2OTAyNDg0M2U1OTliMjA3YmRkZWE2ZDFjNF80OTQ3ODAyMzI3MTEz_dc1109f2-7f24-4645-8247-20801c4ccae8"
      unitRef="shares">280498461</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMy0xLTEtMS0yNTk4OQ_3d39c0a5-be35-4ee1-8b97-3d4a2d11681e"
      unitRef="usd">235639000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMy0zLTEtMS0yNTk4OQ_ad7b7f57-be44-4e59-822a-000f0787254a"
      unitRef="usd">245197000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfNC0xLTEtMS0yNTk4OQ_258fa5b7-3c50-46e7-a008-2dd9bf633203"
      unitRef="usd">151202000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfNC0zLTEtMS0yNTk4OQ_1f4a3c2d-9ccd-43bd-bd65-a02456e798e7"
      unitRef="usd">237299000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfNS0xLTEtMS0yNTk4OQ_74ed57b6-a7d0-4475-ba1f-90cb1a87d90c"
      unitRef="usd">52556000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfNS0zLTEtMS0yNTk4OQ_6dca14b8-e662-454a-88ff-e1e64922c4bf"
      unitRef="usd">52672000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfNi0xLTEtMS0yNTk4OQ_0b452e72-87d4-4261-b3fc-4af8dcf3dbb6"
      unitRef="usd">20879000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfNi0zLTEtMS0yNTk4OQ_acb2b81b-a283-4a08-8181-60caa5dd151b"
      unitRef="usd">26818000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfNy0xLTEtMS0yNTk4OQ_7d61250a-4267-414c-bdaa-3e3caa3c10ca"
      unitRef="usd">37367000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfNy0zLTEtMS0yNTk4OQ_b22e3e5b-635e-4518-864f-24b2494da985"
      unitRef="usd">34848000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfOC0xLTEtMS0yNTk4OQ_2ddaf7b9-4ef1-4ef0-8eb6-7e84e545b697"
      unitRef="usd">497643000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfOC0zLTEtMS0yNTk4OQ_85c593f5-6b02-4be6-9af6-5903168ce19e"
      unitRef="usd">596834000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfOS0xLTEtMS0yNTk4OQ_6c24f3b8-77d4-4c31-8b70-abe8a18fdcd2"
      unitRef="usd">30447000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfOS0zLTEtMS0yNTk4OQ_e56b31c7-fe46-4e53-aee4-ad0ce5cdcf7f"
      unitRef="usd">20586000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTAtMC0xLTEtMjU5ODkvdGV4dHJlZ2lvbjplY2NmMWRiNDU1NjA0NTAwOTYxMTU2MTllYTM1ZTI3MF82MQ_5dfb700d-823e-4a07-8a90-ea5d666ac6a6"
      unitRef="usd">22188000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTAtMC0xLTEtMjU5ODkvdGV4dHJlZ2lvbjplY2NmMWRiNDU1NjA0NTAwOTYxMTU2MTllYTM1ZTI3MF82OA_44793374-325c-40b0-a308-c399ccabb461"
      unitRef="usd">19882000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTAtMS0xLTEtMjU5ODk_37ecef22-21cc-42c5-9e89-b23f2e1641e5"
      unitRef="usd">33657000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTAtMy0xLTEtMjU5ODk_2024c6ef-ebbd-489c-bb0b-941361d0896f"
      unitRef="usd">42496000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTEtMS0xLTEtMjU5ODk_cef3a118-40b6-48a2-9600-edd82d2a8b3b"
      unitRef="usd">23000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTEtMy0xLTEtMjU5ODk_65e4595b-0d34-42ed-8b6b-80594ca156e9"
      unitRef="usd">23000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTItMS0xLTEtMjU5ODk_7fd91603-5a7d-4c76-9fe1-df9925ad8b66"
      unitRef="usd">197797000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTItMy0xLTEtMjU5ODk_824e2e0e-a89c-45a7-9ed7-8508533b5dc9"
      unitRef="usd">197797000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTMtMS0xLTEtMjU5ODk_166a06ad-0cbb-4696-a42c-bcd36cc95798"
      unitRef="usd">18045000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTMtMy0xLTEtMjU5ODk_926ea2fa-03ff-4f4a-ae5d-2fcb3441ddd2"
      unitRef="usd">24427000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTQtMS0xLTEtMjU5ODk_6a2706e8-8788-463b-ab07-391711676330"
      unitRef="usd">800589000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTQtMy0xLTEtMjU5ODk_ed9469d6-11e6-4a2a-8578-ba7e421ed582"
      unitRef="usd">905140000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTctMS0xLTEtMjU5ODk_e73272f7-0662-471c-94c8-144a59bf7dfa"
      unitRef="usd">23113000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTctMy0xLTEtMjU5ODk_1fe36aaa-0077-49db-9281-a4396492c858"
      unitRef="usd">21513000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTgtMS0xLTEtMjU5ODk_6de94bdd-3457-4515-8d26-3ac785951bb4"
      unitRef="usd">114703000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTgtMy0xLTEtMjU5ODk_dda57382-8f26-4182-8e73-68329c2c59cd"
      unitRef="usd">98153000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTktMS0xLTEtMjU5ODk_a3d83ae5-fe38-4242-bcb3-ba8e33a24068"
      unitRef="usd">19266000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMTktMy0xLTEtMjU5ODk_b37d4cad-b3f1-4190-8048-c182af727ff9"
      unitRef="usd">18900000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjAtMS0xLTEtMjU5ODk_8e53d308-589c-49b3-b37a-17c71045e357"
      unitRef="usd">7543000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjAtMy0xLTEtMjU5ODk_168fb924-01e3-4052-bf7a-eb124b7d97e8"
      unitRef="usd">7409000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjEtMS0xLTEtMjU5ODk_71195d34-5984-4d0f-bdd1-5c6bd6d6ee9d"
      unitRef="usd">164625000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjEtMy0xLTEtMjU5ODk_d6c90a61-a862-4b64-842c-686d2e9da2fd"
      unitRef="usd">145975000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebt
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjItMS0xLTEtMjU5ODk_f4f29919-5cad-4c31-ae9d-e283c64ad656"
      unitRef="usd">390652000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjItMy0xLTEtMjU5ODk_78f7f0e5-0ad0-48f5-afde-a39cfc964f2b"
      unitRef="usd">389357000</us-gaap:LongTermDebt>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjMtMS0xLTEtMjU5ODk_07407a55-c286-40ea-9a5b-73e659d797ea"
      unitRef="usd">52844000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjMtMy0xLTEtMjU5ODk_528175fe-1fc9-4cdf-b935-373ca133fbf1"
      unitRef="usd">43363000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjQtMS0xLTEtMjU5ODk_57d2179a-3574-4a9c-bbee-b6f029cd3f43"
      unitRef="usd">5906000</us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent>
    <us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjQtMy0xLTEtMjU5ODk_fd5aae21-fb54-468a-915e-8be64b22c49c"
      unitRef="usd">5906000</us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjUtMS0xLTEtMjU5ODk_eddd6341-cf2c-40b1-8899-0acf676b6157"
      unitRef="usd">4930000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjUtMy0xLTEtMjU5ODk_53bc09c6-02c2-4b57-9fb1-e86bb8322f53"
      unitRef="usd">4930000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjYtMS0xLTEtMjU5ODk_f41e8bb0-839b-445b-a204-794f926a2330"
      unitRef="usd">8207000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjYtMy0xLTEtMjU5ODk_7a9a4a08-0084-4ceb-9e81-4d151c11b59f"
      unitRef="usd">8240000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjctMS0xLTEtMjU5ODk_24dd2334-f680-492a-b7a3-4a6376426d64"
      unitRef="usd">627164000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjctMy0xLTEtMjU5ODk_f1282bff-b535-4c5f-8a0b-d708724b4a97"
      unitRef="usd">597771000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjgtMS0xLTEtMjU5ODk_0cc4b4ff-99e7-4549-a410-2162dbdb14cc"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMjgtMy0xLTEtMjU5ODk_d6794b74-9533-4389-8bb0-bd56c666135b"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzAtMC0xLTEtMjU5ODkvdGV4dHJlZ2lvbjplNGY1N2U5MjUyNTQ0NmFmYmI2Y2E3Yjc0ZmJmNjA0Yl8xOA_7005ba8a-6237-44a0-9486-a5a5d9cdf927"
      unitRef="cadPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzAtMC0xLTEtMjU5ODkvdGV4dHJlZ2lvbjplNGY1N2U5MjUyNTQ0NmFmYmI2Y2E3Yjc0ZmJmNjA0Yl8xOA_dd3c2c2a-6193-4b8f-91a5-941f1d9eb382"
      unitRef="cadPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzAtMC0xLTEtMjU5ODkvdGV4dHJlZ2lvbjplNGY1N2U5MjUyNTQ0NmFmYmI2Y2E3Yjc0ZmJmNjA0Yl8zMg_ad75ab37-5928-4115-bc02-fe31b5f440ea"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzAtMC0xLTEtMjU5ODkvdGV4dHJlZ2lvbjplNGY1N2U5MjUyNTQ0NmFmYmI2Y2E3Yjc0ZmJmNjA0Yl8zMg_d8ede20d-4490-4d5c-94c4-64418b47e638"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzAtMC0xLTEtMjU5ODkvdGV4dHJlZ2lvbjplNGY1N2U5MjUyNTQ0NmFmYmI2Y2E3Yjc0ZmJmNjA0Yl81NA_5f019ca4-4f80-4fbe-8d89-aea5ced4400d"
      unitRef="shares">280456667</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzAtMC0xLTEtMjU5ODkvdGV4dHJlZ2lvbjplNGY1N2U5MjUyNTQ0NmFmYmI2Y2E3Yjc0ZmJmNjA0Yl81NA_a199fe21-13bb-4723-8f12-2044ff28ac9a"
      unitRef="shares">280456667</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzAtMC0xLTEtMjU5ODkvdGV4dHJlZ2lvbjplNGY1N2U5MjUyNTQ0NmFmYmI2Y2E3Yjc0ZmJmNjA0Yl82MQ_29a40d49-949f-4f42-bbeb-e682289237cd"
      unitRef="shares">278912800</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzAtMC0xLTEtMjU5ODkvdGV4dHJlZ2lvbjplNGY1N2U5MjUyNTQ0NmFmYmI2Y2E3Yjc0ZmJmNjA0Yl82MQ_b110ea20-16db-495b-8524-15a679515396"
      unitRef="shares">278912800</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzAtMS0xLTEtMjU5ODk_f2955ce6-d1d4-4204-aefe-68277e665aac"
      unitRef="usd">2811000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzAtMy0xLTEtMjU5ODk_860b2b66-d91a-4dc2-9b9d-32e0556b9756"
      unitRef="usd">2808000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzEtMS0xLTEtMjU5ODk_f8cdb9ff-9dad-4069-a2a0-5364d8063fa6"
      unitRef="usd">2631110000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzEtMy0xLTEtMjU5ODk_5edf81ae-7ab8-4785-a41e-a79443a0bd81"
      unitRef="usd">2595419000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzMtMS0xLTEtMjU5ODk_b43b5ff2-e304-4c2c-ad3e-650c7807e65e"
      unitRef="usd">-16603000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzMtMy0xLTEtMjU5ODk_a40ed397-d48f-4db6-ab66-4a98370f9408"
      unitRef="usd">5251000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzQtMS0xLTEtMjU5ODk_7dcc97e4-bfb7-4bab-b77a-f912eb6a1b15"
      unitRef="usd">-637000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzQtMy0xLTEtMjU5ODk_c9d674e9-8699-426e-9239-3d4e52bc6834"
      unitRef="usd">-270000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzUtMS0xLTEtMjU5ODk_0e1a0b79-c63a-48bc-980c-447c7ff287d3"
      unitRef="usd">83000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzUtMy0xLTEtMjU5ODk_4844e19a-f415-4616-a2da-a38d14662dca"
      unitRef="usd">83000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzYtMS0xLTEtMjU5ODk_6d3b78bb-7a60-4d0c-9404-0e244a2fd044"
      unitRef="usd">-2443339000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzYtMy0xLTEtMjU5ODk_5251f6b5-acf3-45f0-96a6-15b4c5b801f5"
      unitRef="usd">-2295922000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzctMS0xLTEtMjU5ODk_4e14c86a-36c9-4e03-85ee-632c0d914a25"
      unitRef="usd">173425000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzctMy0xLTEtMjU5ODk_13b0314c-1da8-4c97-ba38-39776eb16f32"
      unitRef="usd">307369000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzgtMS0xLTEtMjU5ODk_6adb0450-9740-4737-954f-122ea1985acc"
      unitRef="usd">800589000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8xOS9mcmFnOjNlZWI0MTVhZjEyMjQ5YTQ4NDg5OGU3Mzc1ZDI2ZGNkL3RhYmxlOjc5MTMzOTVmM2VjZDQ2NDE4Mzg5YTFlOTE0NGEwZDIxL3RhYmxlcmFuZ2U6NzkxMzM5NWYzZWNkNDY0MTgzODlhMWU5MTQ0YTBkMjFfMzgtMy0xLTEtMjU5ODk_11e4faa3-106b-41ea-af65-8f56df5234f9"
      unitRef="usd">905140000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMi0xLTEtMS0yNTk4OQ_db96c553-29ee-4a58-97ae-be9c51d675ea"
      unitRef="usd">80731000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMi0zLTEtMS0yNTk4OQ_d986c2bd-6574-4900-ba01-a8e2fee02618"
      unitRef="usd">77413000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMi00LTEtMS0yNjUxMQ_0d783240-b7bb-4a1b-a4dc-f907d4055cd3"
      unitRef="usd">159446000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMi02LTEtMS0yNjUxMQ_489ea54e-1067-4f00-9f72-7ece8194ea2e"
      unitRef="usd">143815000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMy0xLTEtMS0yNTk4OQ_95b3ddfa-be22-4247-b867-e0b1c8717354"
      unitRef="usd">8197000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMy0zLTEtMS0yNTk4OQ_52d197c4-1e46-43bf-89bc-ca1d284f592b"
      unitRef="usd">8380000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMy00LTEtMS0yNjUxMQ_c3aa7b99-2e75-4671-b065-d5b5d71a2b3d"
      unitRef="usd">15779000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMy02LTEtMS0yNjUxMQ_bd4aa07b-a781-4efa-bc56-c6113825719f"
      unitRef="usd">14919000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfNC0xLTEtMS0yNTk4OQ_fee09b4e-0733-481c-9502-4b24e168fc92"
      unitRef="usd">72534000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfNC0zLTEtMS0yNTk4OQ_6f3d97e4-fb17-4b63-8556-5cbabba17672"
      unitRef="usd">69033000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfNC01LTEtMS0yNzY5MA_6d55f6c9-e09a-426a-bb7a-5ebc62f31051"
      unitRef="usd">143667000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfNC03LTEtMS0yNzY5MA_c86711fd-79d2-467f-b4af-ba00a2847905"
      unitRef="usd">128896000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfNi0xLTEtMS0yNTk4OQ_088db93d-93cd-48f0-868c-a39d84afde9c"
      unitRef="usd">78319000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfNi0zLTEtMS0yNTk4OQ_254c8bdd-d4b1-4716-8dca-3de6a7c294f6"
      unitRef="usd">63003000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfNi00LTEtMS0yNjUyMA_c9d21d73-5ca7-4ce8-8fdd-fb89425b2797"
      unitRef="usd">159836000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfNi02LTEtMS0yNjUyMA_7f6f60db-dd7b-4701-884f-8bafe8083eac"
      unitRef="usd">127120000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfNy0xLTEtMS0yNTk4OQ_82500b3e-ce01-4942-b90b-314bcedbb70a"
      unitRef="usd">53379000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfNy0zLTEtMS0yNTk4OQ_452634dc-a626-40ab-8e5e-68237afa4fb0"
      unitRef="usd">42276000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfNy00LTEtMS0yNjUyMA_8df53872-49ff-41eb-a863-1b8ab0b9ed36"
      unitRef="usd">111495000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfNy02LTEtMS0yNjUyMA_d2fc2e4e-531c-45ff-8537-2d3eab6230b7"
      unitRef="usd">89002000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfOC0xLTEtMS0yNTk4OQ_aae42c7e-b913-4f06-975f-43e15aac9a30"
      unitRef="usd">-115000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfOC0zLTEtMS0yNTk4OQ_adec42db-5159-464b-a1af-1511545f0c4c"
      unitRef="usd">-1021000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfOC00LTEtMS0yNjUyMA_16b80c63-091d-4c97-b02e-df3d3cdd0bfe"
      unitRef="usd">1073000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfOC02LTEtMS0yNjUyMA_6d366338-bb09-474e-a93a-2eb0c9429a33"
      unitRef="usd">-1492000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:AssetImpairmentCharges
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfOS0xLTEtMS0yNTk4OQ_b44553ff-f4e1-4d63-b824-a86ec80ab702"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfOS0zLTEtMS0yNTk4OQ_71a09d18-10a4-4f98-abeb-b566cb6fdcca"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfOS00LTEtMS0yNjUyNw_302ab79d-4b4f-41b2-949f-63f3bb89727a"
      unitRef="usd">6616000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfOS02LTEtMS0yNjUyNw_8f4496e8-dc1c-4db8-a4d0-af5b03163ecc"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTAtMS0xLTEtMjU5ODk_89df2267-558a-49bc-b592-36978b59f568"
      unitRef="usd">1334000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTAtMy0xLTEtMjU5ODk_7ff0996a-f31b-455d-bd0b-aa791d193a40"
      unitRef="usd">1567000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTAtNC0xLTEtMjcyMzA_385745f7-350c-4439-b047-946feeb51c4d"
      unitRef="usd">2745000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTAtNi0xLTEtMjcyMzA_292c5512-6c7a-44e6-a9a2-38dd67a4b5d9"
      unitRef="usd">3171000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTEtMS0xLTEtMjU5ODk_422363b2-834b-4756-b232-c31c3f8b914a"
      unitRef="usd">133147000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTEtMy0xLTEtMjU5ODk_a88edf67-ab73-440d-9683-feb4613a5a11"
      unitRef="usd">107867000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTEtNS0xLTEtMjc2OTA_0dd738cd-382c-46d9-bf2d-dbb36c0402d1"
      unitRef="usd">279619000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTEtNy0xLTEtMjc2OTA_d204bed3-2986-4e20-ad28-7ef8ba2df69a"
      unitRef="usd">220785000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTItMS0xLTEtMjU5ODk_5402d1b8-d411-42e4-9ad2-d8310d8a1370"
      unitRef="usd">-60613000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTItMy0xLTEtMjU5ODk_a7030076-2796-40d3-ab87-b8b75ed5f2fc"
      unitRef="usd">-38834000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTItNS0xLTEtMjc2OTA_a8972ea0-069c-4d0b-ba0a-4af7f74fb678"
      unitRef="usd">-135952000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTItNy0xLTEtMjc2OTA_667cfa30-d7e0-4fc2-8eca-1d62d09e9fbc"
      unitRef="usd">-91889000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTQtMS0xLTEtMjU5ODk_7e390d79-099d-4302-8719-6a8514da952b"
      unitRef="usd">356000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTQtMy0xLTEtMjU5ODk_2df45bfc-476b-4411-b09d-b1dccc663742"
      unitRef="usd">50000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTQtNC0xLTEtMjY1NDg_e43287f4-bba2-4fd1-830f-74e0e50b8aaa"
      unitRef="usd">489000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTQtNi0xLTEtMjY1NDg_fee4003b-478e-4987-9e31-d6b138889506"
      unitRef="usd">215000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTUtMS0xLTEtMjU5ODk_962acbf6-d645-4fac-82e6-e6876ef814d2"
      unitRef="usd">8257000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTUtMy0xLTEtMjU5ODk_40a29f65-ad1c-45c3-948d-58c4d828f1b0"
      unitRef="usd">8150000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTUtNC0xLTEtMjY1NDg_1bb4e7f3-7f7e-44a6-8d1c-77453ddfb1d2"
      unitRef="usd">16404000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTUtNi0xLTEtMjY1NDg_061e326e-eaa3-49f9-b273-22c73190a2ba"
      unitRef="usd">16142000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTctMS0xLTEtMjU5ODk_3c62a922-778a-40a7-9e2a-3c82b0b89ee1"
      unitRef="usd">7268000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTctMy0xLTEtMjU5ODk_ddd4bb0f-dc93-40dd-8969-3ac224ada6e0"
      unitRef="usd">234000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTctNC0xLTEtMjY1NTU_0fcafa7b-7690-41bf-9bf6-16643bb64c45"
      unitRef="usd">9170000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTctNi0xLTEtMjY1NTU_12d177ec-09f8-4d20-a6d1-5db4dbbd002d"
      unitRef="usd">-2966000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTgtMS0xLTEtMjU5ODk_bb0d7f4f-a48e-4631-8847-afe0fd977146"
      unitRef="usd">-61246000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTgtMy0xLTEtMjU5ODk_2c35c02d-2781-43f6-9697-5d32f2e3a662"
      unitRef="usd">-46700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTgtNS0xLTEtMjc2OTA_5aeebaa8-8efa-4287-afeb-63f4a30e1a55"
      unitRef="usd">-142697000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTgtNy0xLTEtMjc2OTA_8c0f9bdf-0520-4801-b419-c42f7826930e"
      unitRef="usd">-110782000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTktMS0xLTEtMjU5ODk_613ab3e0-326a-455b-9f4f-f01306703c8d"
      unitRef="usd">911000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTktMy0xLTEtMjU5ODk_395c2702-d9ec-4953-9471-bdfb50cc3246"
      unitRef="usd">4525000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTktNC0xLTEtMjY1NjQ_b370e77c-fc80-4489-9fa4-dda85eea8783"
      unitRef="usd">4720000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMTktNi0xLTEtMjY1NjQ_76a44cb2-be38-4a4d-bd5e-e3f53499b784"
      unitRef="usd">6107000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjAtMS0xLTEtMjU5ODk_6322b21b-477e-4e42-92be-0d905f78702c"
      unitRef="usd">-62157000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjAtMy0xLTEtMjU5ODk_b504f4f7-af37-417d-9f4e-83878046d7a2"
      unitRef="usd">-51225000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjAtNS0xLTEtMjc2OTA_08f7340a-7419-4669-8c35-61cc594f04a7"
      unitRef="usd">-147417000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjAtNy0xLTEtMjc2OTA_3636be27-8376-490d-8923-81b73edfbf6b"
      unitRef="usd">-116889000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjEtMS0xLTEtMjU5ODk_948e0826-11b4-4214-b993-1650ecd27cac"
      unitRef="cadPerShare">-0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjEtMS0xLTEtMjU5ODk_d63d6b76-238b-4e0e-8d3b-a9bad565ae2d"
      unitRef="cadPerShare">-0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjEtMy0xLTEtMjU5ODk_1aad056d-1e5f-43db-b260-1aed5b0a437b"
      unitRef="cadPerShare">-0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjEtMy0xLTEtMjU5ODk_521e0a97-9cfb-4525-a61d-ab195725a87b"
      unitRef="cadPerShare">-0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjEtNC0xLTEtMjcyMzM_5ddc40a8-3df5-43ab-802f-37f075776bc9"
      unitRef="cadPerShare">-0.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjEtNC0xLTEtMjcyMzM_5e68835d-6d41-4a22-a231-927e155aa729"
      unitRef="cadPerShare">-0.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjEtNi0xLTEtMjcyMzM_4856a23d-39f6-4392-9dad-0b05c5134bad"
      unitRef="cadPerShare">-0.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjEtNi0xLTEtMjcyMzM_f1dbb8b3-db10-4b9f-ac8f-be600283d263"
      unitRef="cadPerShare">-0.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjItMS0xLTEtMjU5ODk_2b23b1a1-43dc-48cf-a31e-8f3a77eb1d50"
      unitRef="shares">291970562</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjItMS0xLTEtMjU5ODk_c14c4dd2-4936-45ed-ba2b-b1d7d018cbac"
      unitRef="shares">291970562</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjItMy0xLTEtMjU5ODk_fc104a0b-b0cb-4a1a-90fa-952fafa2f197"
      unitRef="shares">266398516</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjItMy0xLTEtMjU5ODk_fea06fd0-6ad5-4aa9-8e81-2267b204ec8e"
      unitRef="shares">266398516</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjItNC0xLTEtMjcyMzM_068356e6-31fc-4f7e-8097-8adcd460e27d"
      unitRef="shares">288646587</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjItNC0xLTEtMjcyMzM_aeac1143-bf5f-428c-aa10-0e0573274d71"
      unitRef="shares">288646587</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjItNi0xLTEtMjcyMzM_717a8067-dfa3-49eb-a155-fb842b71f666"
      unitRef="shares">265384865</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yMi9mcmFnOmUzZDdkNzYwMGYyZjQ3MjFiNTg3N2QzZjQyN2Y3NmM3L3RhYmxlOmE5YzVjOTUwNmRhMjRlN2VhZDMwMjdhMGZiMTBjZTgyL3RhYmxlcmFuZ2U6YTljNWM5NTA2ZGEyNGU3ZWFkMzAyN2EwZmIxMGNlODJfMjItNi0xLTEtMjcyMzM_b9b12440-0055-4c11-8035-3fc8608c9c94"
      unitRef="shares">265384865</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfMi0xLTEtMS0yNTk4OQ_7216938b-2c23-4d57-89d1-7b5a6b647616"
      unitRef="usd">-62157000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfMi0zLTEtMS0yNTk4OQ_415713c0-5c95-4487-bbba-a3e9afc1d3dd"
      unitRef="usd">-51225000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfMi00LTEtMS0yNzEzNA_805e537c-06de-4484-8ae6-051c24ec76bf"
      unitRef="usd">-147417000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfMi02LTEtMS0yNzEzNA_530a59ce-a856-41b3-9290-2cfef1535a4a"
      unitRef="usd">-116889000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfNC0xLTEtMS0yNTk4OQ_a91dd1b4-a5a9-4dbf-9796-fc918bc1770a"
      unitRef="usd">-16183000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfNC0zLTEtMS0yNTk4OQ_09b82cb5-02b8-499d-89c8-29e03453dbbb"
      unitRef="usd">235000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfNC00LTEtMS0yNjU4NA_48a239a8-d436-41b4-a987-fe3caa6fd777"
      unitRef="usd">-21854000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfNC02LTEtMS0yNjU4NA_3fb72407-5eae-4559-88c3-b5a9a821e074"
      unitRef="usd">843000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfNS0xLTEtMS0yNTk4OQ_cc1a4f73-70b2-4ea1-962d-e17833c9a2c4"
      unitRef="usd">-29000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfNS0zLTEtMS0yNTk4OQ_192e4fca-5c24-4ea4-9e89-80f651a76767"
      unitRef="usd">12000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfNS00LTEtMS0yNjU4NA_69d5527d-d84c-49d1-adec-eafe142a3c35"
      unitRef="usd">-367000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfNS02LTEtMS0yNjU4NA_576b6557-ee80-4bb9-aa54-05fe9e950946"
      unitRef="usd">12000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfNi0xLTEtMS0yNTk4OQ_259963ea-ea25-433e-8233-597ff43f6dc1"
      unitRef="usd">-16212000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfNi0zLTEtMS0yNTk4OQ_6bb9d88b-e96e-4602-9d2b-52584f9bea59"
      unitRef="usd">247000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfNi00LTEtMS0yNjU4NA_3e387643-d672-471b-8107-150f78c9272a"
      unitRef="usd">-22221000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfNi02LTEtMS0yNjU4NA_c9ab6abe-9ad4-4f08-a688-7f696ae64f39"
      unitRef="usd">855000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfNy0xLTEtMS0yNTk4OQ_e093a0fc-cf7e-4459-819c-066bc187f50f"
      unitRef="usd">-78369000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfNy0zLTEtMS0yNTk4OQ_a5102cbc-239d-4798-8392-e0e36f47a0d8"
      unitRef="usd">-50978000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfNy01LTEtMS0yNzcwNQ_ff3bce6a-4799-4a88-b97b-692e01c0be6d"
      unitRef="usd">-169638000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yNS9mcmFnOjA3ZGQ2Mzk1MGQ1YzQ1NmY4ODlhODhjZDU3MjJhZmFkL3RhYmxlOmI0YTQ1MGFhYjVkMTQzNmE4N2E1NmVkNGQxMGQwZWQ3L3RhYmxlcmFuZ2U6YjRhNDUwYWFiNWQxNDM2YTg3YTU2ZWQ0ZDEwZDBlZDdfNy03LTEtMS0yNzcwNQ_c1e786a2-f886-4723-a656-491830776052"
      unitRef="usd">-116034000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic9dcaac3e3f74257b9b5319bd5cd7e11_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfNC0xLTEtMS0yNTk4OQ_dd755ddb-cc3d-4c35-905c-1816dec1097b"
      unitRef="shares">280133856</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic9dcaac3e3f74257b9b5319bd5cd7e11_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfNC0zLTEtMS0yNTk4OQ_e63e3f60-ac57-4cb3-8bdb-35b40efe2142"
      unitRef="usd">2809000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8964c1432633472c8bc58ddf38701965_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfNC01LTEtMS0yNTk4OQ_f5e97d73-0f2c-4bc9-ab4c-a894f80119e7"
      unitRef="usd">2617935000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7d81a1ce547341fdbad1b2485e2b8dab_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfNC03LTEtMS0yNTk4OQ_8e306f58-5c26-4097-842d-ee7a4765315a"
      unitRef="usd">83000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i457540a06a0e4f12a8a6760a2e662d69_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfNC0xMS0xLTEtMjU5ODk_16c75613-6922-4033-8208-fcd196ef6a9f"
      unitRef="usd">-1028000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i97d51d17e9f74441bbd0bd417ab532ee_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfNC0xMy0xLTEtMjU5ODk_d2699257-9acf-4829-af2c-081a7db3215f"
      unitRef="usd">-2381182000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i90601765a2f2418a9abfd28bd624e1fb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfNC0xNS0xLTEtMjU5ODk_45e867ef-763c-4a94-8d3d-93f6cd3a382d"
      unitRef="usd">238617000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ib83568c208d34901bc8f2b3277a492eb_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfNS0xLTEtMS0yNTk4OQ_a5c61ad4-d30a-4d26-bec9-0b065dcf700e"
      unitRef="shares">189256</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib83568c208d34901bc8f2b3277a492eb_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfNS0zLTEtMS0yNTk4OQ_642f1a3f-05d3-468e-ac72-d8ac2bad198d"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2b3bca726f0d46f2b136309217acf4e2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfNS01LTEtMS0yNTk4OQ_6857aeb3-01ca-4c19-a8cf-df43ef93a4cb"
      unitRef="usd">997000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfNS0xNS0xLTEtMjU5ODk_ad277059-a4d6-4489-b13b-71d62cd4e4cc"
      unitRef="usd">999000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ib83568c208d34901bc8f2b3277a492eb_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfNi0xLTEtMS0yNTk4OQ_8988f00e-d4dd-4cc4-822f-2dc4adc50b12"
      unitRef="shares">133555</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i2b3bca726f0d46f2b136309217acf4e2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfNi01LTEtMS0yNTk4OQ_1f6d54cb-a6d7-490e-9c0d-90b8ee272961"
      unitRef="usd">285000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfNi0xNS0xLTEtMjU5ODk_fff35808-4541-4c6a-95be-ae88a6e02543"
      unitRef="usd">285000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2b3bca726f0d46f2b136309217acf4e2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfNy01LTEtMS0yNTk4OQ_32e22422-0237-48b9-a460-4f3022a63daf"
      unitRef="usd">12463000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfNy0xNS0xLTEtMjU5ODk_548a0704-482b-486d-95bb-7ec335d64f8f"
      unitRef="usd">12463000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i6104ef486d1344d9b4a6249c99ecaa75_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfOC0xMS0xLTEtMjU5ODk_8a6f5c55-7c18-4daa-8274-8347a3990c01"
      unitRef="usd">-29000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfOC0xNS0xLTEtMjU5ODk_a92cda87-93f4-4d4d-a521-0d5d8b1fdc40"
      unitRef="usd">-29000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i6104ef486d1344d9b4a6249c99ecaa75_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfOS0xMS0xLTEtMjU5ODk_31faa4f9-7c74-4cc2-81b9-616257b52a05"
      unitRef="usd">-16183000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfOS0xNS0xLTEtMjU5ODk_f925dc22-8ef8-4239-bf77-50fe1de362db"
      unitRef="usd">-16183000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="id89ea44d86214f11955f8524c82ca59d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfMTAtMTMtMS0xLTI1OTg5_832fc1ef-97e6-4da6-98de-a1a3a28bf5b7"
      unitRef="usd">-62157000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfMTAtMTUtMS0xLTI1OTg5_0760e29a-0254-455a-81b1-fd95d4bc43b3"
      unitRef="usd">-62157000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7cc23a72515148e9bdb594c0ffdc44d9_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfMTEtMS0xLTEtMjU5ODk_9cc6c26f-373c-4986-9737-4397a1ce4217"
      unitRef="shares">280456667</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7cc23a72515148e9bdb594c0ffdc44d9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfMTEtMy0xLTEtMjU5ODk_14ccd750-e849-48f9-b5f2-10ec134406b4"
      unitRef="usd">2811000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6af221862afe4ec8a95c4bd66bc29a83_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfMTEtNS0xLTEtMjU5ODk_17ce87b4-794e-46f2-8729-96f36a5a8db7"
      unitRef="usd">2631110000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i66313300b8924ac38edbed17cd4621e8_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfMTEtNy0xLTEtMjU5ODk_bbe7fc70-9a02-45d4-8764-668f738ded24"
      unitRef="usd">83000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2a67d85fc2bc4508827b7d6504191b86_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfMTEtMTEtMS0xLTI1OTg5_5268cd39-f0fb-4ab6-9c24-ea099adca261"
      unitRef="usd">-17240000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4d7fceb860b04c3284049f567598615f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfMTEtMTMtMS0xLTI1OTg5_18d0fc1c-5a32-4d35-bf5b-17c9e0309f1f"
      unitRef="usd">-2443339000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmNkNzE5YzJlYzc3MDQ3ZjA5YjQ0ZjIwYmFmODdhOTcyL3RhYmxlcmFuZ2U6Y2Q3MTljMmVjNzcwNDdmMDliNDRmMjBiYWY4N2E5NzJfMTEtMTUtMS0xLTI1OTg5_33f92a4f-b2fb-41b2-8da9-5748464b432f"
      unitRef="usd">173425000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i20369be16fb64d618f19ff7c879c5f74_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfNC0xLTEtMS0yNjYxMg_035e867c-0b9c-4633-a0c9-9dd729893195"
      unitRef="shares">278912800</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i20369be16fb64d618f19ff7c879c5f74_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfNC0zLTEtMS0yNjYxMg_ec272cd9-6766-49ab-bf4f-643f1d7c8c4b"
      unitRef="usd">2808000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i847ea7f79a9d45378381e71e73b6c2d6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfNC01LTEtMS0yNjYxMg_cb61665b-281b-4afe-bd83-c755ed4aa974"
      unitRef="usd">2595419000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8850617c24a64a82b3ac49102d519aac_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfNC03LTEtMS0yNjYxMg_1c68d4e6-5332-4780-9f1d-c1c2b6f99d21"
      unitRef="usd">83000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8b04ea28407641b98ad9d006e7f294a1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfNC05LTEtMS0yNjYxMg_36205d80-a688-48cc-bac1-1048b6809d62"
      unitRef="usd">4981000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7f89399acbed48f4948a667624d93858_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfNC0xMS0xLTEtMjY2MTI_c17d4d16-09dc-4258-afd7-6578d8fd9eca"
      unitRef="usd">-2295922000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfNC0xMy0xLTEtMjc3MDg_cf36cdb8-51c1-4126-868c-429d22bece40"
      unitRef="usd">307369000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie9b3ff93c685496a8f7db03682c9a6bc_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfNS0xLTEtMS0yNjc0NQ_169569dd-f1a6-4949-8137-c7aca926a1fa"
      unitRef="shares">334705</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie9b3ff93c685496a8f7db03682c9a6bc_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfNS0zLTEtMS0yNjc0NQ_4b3843cd-6570-4845-9903-fa3444b9f8cd"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9145f98a12fd40a6a178726d7e2acfd7_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfNS01LTEtMS0yNjc0NQ_e31b4532-e23d-4223-9480-7421f1c5d80f"
      unitRef="usd">1855000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfNS0xMy0xLTEtMjc3MDg_d446ff8c-48ff-406d-9f4c-80a1d8bf0ee6"
      unitRef="usd">1858000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ie9b3ff93c685496a8f7db03682c9a6bc_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfNi0xLTEtMS0yNjczMw_de34051f-c1b8-477f-ac4f-6c7ed7d0058b"
      unitRef="shares">1209162</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i9145f98a12fd40a6a178726d7e2acfd7_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfNi01LTEtMS0yNjczMw_db48efa9-97f4-4e4f-a742-7267ff27285e"
      unitRef="usd">9278000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfNi0xMy0xLTEtMjc3MDg_b11e985c-1e05-4460-bd97-ab380cab79f7"
      unitRef="usd">9278000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9145f98a12fd40a6a178726d7e2acfd7_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfNy01LTEtMS0yNjcyMA_99f3f823-12c5-4f9d-9911-765f4010045c"
      unitRef="usd">43114000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfNy0xMy0xLTEtMjc3MDg_73ec0d21-fc65-424b-9727-1882aa180ca9"
      unitRef="usd">43114000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i3b08ba7dfa164bffb946e42d5c6b0353_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfOC05LTEtMS0yNjcxMw_029005ee-57e5-4108-9359-bc27d6bfc67c"
      unitRef="usd">-367000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfOC0xMy0xLTEtMjc3MDg_24337a35-712d-43ca-a3ff-7a0e0d18df27"
      unitRef="usd">-367000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i3b08ba7dfa164bffb946e42d5c6b0353_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfOS05LTEtMS0yNjcxMw_c3b6797d-e78d-472b-ae54-2ec1fe0e742e"
      unitRef="usd">-21854000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfOS0xMy0xLTEtMjc3MDg_27137d2c-5663-4744-9ddb-3e13a61bc07b"
      unitRef="usd">-21854000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="id499f57d04ef46548abf1e291e9d5885_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfMTAtMTEtMS0xLTI2NjUw_ee2cb4a9-14d3-46e8-81f9-e22fa815d12e"
      unitRef="usd">-147417000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfMTAtMTMtMS0xLTI3NzA4_dede0752-f737-461c-9a28-dbed5c3c191e"
      unitRef="usd">-147417000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7cc23a72515148e9bdb594c0ffdc44d9_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfMTEtMS0xLTEtMjc3MDg_7b9a6ec4-0aea-450b-8e4f-4b1a8c08feac"
      unitRef="shares">280456667</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7cc23a72515148e9bdb594c0ffdc44d9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfMTEtMy0xLTEtMjc3MDg_d786936b-b6f1-43ee-9376-582bcf5ef1b1"
      unitRef="usd">2811000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6af221862afe4ec8a95c4bd66bc29a83_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfMTEtNS0xLTEtMjc3MDg_69031102-fdd0-4406-9fd1-77138cee199b"
      unitRef="usd">2631110000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i66313300b8924ac38edbed17cd4621e8_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfMTEtNy0xLTEtMjc3MDg_55ca26bb-8d72-4290-a8cf-46b4a55d7b03"
      unitRef="usd">83000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2a67d85fc2bc4508827b7d6504191b86_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfMTEtOS0xLTEtMjc3MDg_72fb9b07-8c3b-4fcc-9d41-bb491b3ffd33"
      unitRef="usd">-17240000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4d7fceb860b04c3284049f567598615f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfMTEtMTEtMS0xLTI3NzA4_5fadae9b-0067-4738-b37c-79b359c94d3e"
      unitRef="usd">-2443339000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjcxZmI2MmFlMDM5NzRhNzM5MWIyOGI2MjA3N2NkZDFhL3RhYmxlcmFuZ2U6NzFmYjYyYWUwMzk3NGE3MzkxYjI4YjYyMDc3Y2RkMWFfMTEtMTMtMS0xLTI3NzA4_aeab08f7-8213-47fa-accf-a4ea8b97c457"
      unitRef="usd">173425000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i03bf3913256a4b41be32f6db37aa316c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfNC0xLTEtMS0yNTk4OQ_15c0afa3-d774-4f33-841e-62ceb3785807"
      unitRef="shares">266007718</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i03bf3913256a4b41be32f6db37aa316c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfNC0zLTEtMS0yNTk4OQ_fb9dc34b-4d30-405c-8647-ce453484f9ce"
      unitRef="usd">2680000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6de8ae1734aa4d599eb85d75fd49b941_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfNC01LTEtMS0yNTk4OQ_3812e433-384b-4976-b8df-487a7bc9f21e"
      unitRef="usd">2350507000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i625ab03e96af4d8683f3acb33151056f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfNC05LTEtMS0yNTk4OQ_a9c68d7e-de7c-4def-8914-09166c064f58"
      unitRef="usd">8835000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id6afdfc73ba542e78bfc05da8ba789e6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfNC0xMS0xLTEtMjU5ODk_e611f88f-03f3-4a2d-9905-85c16bd0a6ca"
      unitRef="usd">-2111126000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib385a6b7137c45958b92a30dddce1f19_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfNC0xMy0xLTEtMjU5ODk_cda26eb4-2865-4a10-8092-400838d18ef8"
      unitRef="usd">250896000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i0236634b4cb14481acb0fb30723e7beb_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfNS0xLTEtMS0yNTk4OQ_493e60f8-b1b8-4eb0-aecf-a0379651c6a1"
      unitRef="shares">434551</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0236634b4cb14481acb0fb30723e7beb_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfNS0zLTEtMS0yNTk4OQ_9065ae19-888d-4635-bb3c-8cd3eb3de2fe"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ieaf9ecdf3e9d41aaaf315396d42a9e6e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfNS01LTEtMS0yNTk4OQ_51509def-48b2-484b-a871-99e5b0800938"
      unitRef="usd">2495000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfNS0xMy0xLTEtMjU5ODk_178c7fb2-98c1-4b4d-8476-17c2fed5ad92"
      unitRef="usd">2500000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i0236634b4cb14481acb0fb30723e7beb_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfNi0xLTEtMS0yNTk4OQ_aeffc842-0874-4852-9d96-fbd23eda70f4"
      unitRef="shares">90267</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ieaf9ecdf3e9d41aaaf315396d42a9e6e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfNi01LTEtMS0yNTk4OQ_b953d310-2e30-4e56-9340-d6745d6ab802"
      unitRef="usd">244000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfNi0xMy0xLTEtMjU5ODk_17476b07-3ace-40d3-9388-2f9f112c3863"
      unitRef="usd">244000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ieaf9ecdf3e9d41aaaf315396d42a9e6e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfNy01LTEtMS0yNTk4OQ_d43afef1-a7af-4a55-858c-8ee5d71c833f"
      unitRef="usd">11736000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfNy0xMy0xLTEtMjU5ODk_05acc943-c2d5-4caa-ba13-6bb265c27368"
      unitRef="usd">11736000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="id0feda6c19ba4dde88c6ff31d463c64d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfOS05LTEtMS0yNTk4OQ_0d0b4f14-9aa8-4c56-8aae-fdc8fc00652f"
      unitRef="usd">12000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfOS0xMy0xLTEtMjU5ODk_59d8868d-e2d9-4787-9bfc-dc0767bfa07e"
      unitRef="usd">12000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="id0feda6c19ba4dde88c6ff31d463c64d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfMTAtOS0xLTEtMjU5ODk_91a35118-fa79-48d1-aa55-f71990dd4ed6"
      unitRef="usd">235000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfMTAtMTMtMS0xLTI1OTg5_9c88b17c-578b-4535-b6f1-8deec50ab6d8"
      unitRef="usd">235000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i1a489e0cac5148b098047e20f7b16d2c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfMTEtMTEtMS0xLTI1OTg5_95e6b8e1-6eca-4d3e-9366-36d81628c1b3"
      unitRef="usd">-51225000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfMTEtMTMtMS0xLTI1OTg5_fff99f12-d599-4300-88ed-da275c19950c"
      unitRef="usd">-51225000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id197126c4925481fbd6568b6714249d7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfMTItMS0xLTEtMjU5ODk_d30f8ad4-72f5-4fb1-97c7-25eed9228cd7"
      unitRef="shares">266532536</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id197126c4925481fbd6568b6714249d7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfMTItMy0xLTEtMjU5ODk_a53e1274-7771-4f13-bfa2-8646beccb441"
      unitRef="usd">2685000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1575283eac554820897a66659337bdf4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfMTItNS0xLTEtMjU5ODk_0d9d702e-6ea6-489d-8f42-f5a8111ca1fb"
      unitRef="usd">2364494000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia655833ddbb14af0823e080a718286f3_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfMTItOS0xLTEtMjU5ODk_f557c90b-5086-4ef7-8d80-ef85a9cb1615"
      unitRef="usd">9082000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia265d46e7fdb4a6cbfc035ff181f41b7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfMTItMTEtMS0xLTI1OTg5_5c7d0275-315b-40f2-87e2-42ae1d5a28b5"
      unitRef="usd">-2162351000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibdd0bea669974aef88283f7ce9684c7f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOmRiZWI1MGM2ZjZkNDQ3MGFhNGEwOGQ5MjljMjM4OTliL3RhYmxlcmFuZ2U6ZGJlYjUwYzZmNmQ0NDcwYWE0YTA4ZDkyOWMyMzg5OWJfMTItMTMtMS0xLTI1OTg5_3b26821b-20a2-463a-89d8-50053e50d597"
      unitRef="usd">213910000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i15ca856684364a728cfb2cacad448766_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfNC0xLTEtMS0yNjc5MQ_874aa81c-5016-44e5-aaea-03d257618bee"
      unitRef="shares">262063461</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i15ca856684364a728cfb2cacad448766_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfNC0zLTEtMS0yNjc5MQ_0f815fb2-61b8-4c2a-9d0e-80f6e3994f84"
      unitRef="usd">2650000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie3250897ae664ba78fc2758e4d197424_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfNC01LTEtMS0yNjc5MQ_bbcd2995-6848-4d05-8b8f-067217da4a4b"
      unitRef="usd">2308578000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0726224b301248d2932ff84f9938870f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfNC03LTEtMS0yNjc5MQ_7d8175fb-6c4e-49de-acbf-498ef6ee302e"
      unitRef="usd">12387000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iebfefb1a4b464d5ba21ad742a3619573_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfNC05LTEtMS0yNjc5MQ_ef81b255-cc4a-43c9-92ec-2c6a35527864"
      unitRef="usd">8227000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic229e029b81044fdbb354018535e5d3b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfNC0xMS0xLTEtMjY3OTE_0383858e-208b-4d3c-9f76-9da62e95fda3"
      unitRef="usd">-2045462000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i17008df080294bb0bf1240acd6c19c15_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfNC0xMy0xLTEtMjc3MjM_3aa6da83-6fc5-4180-81c4-401cc0d31c69"
      unitRef="usd">286380000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia5f30d05cafe48b79410089e00859443_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfNS0xLTEtMS0yNjc5MQ_9ba852b9-7da2-4e9b-9eb2-e6a12586b4c8"
      unitRef="shares">922662</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia5f30d05cafe48b79410089e00859443_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfNS0zLTEtMS0yNjc5MQ_6312e332-7d68-4bec-8377-06628a4b9c43"
      unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i44b8bffb160d45dda13b5e2b78abce7f_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfNS01LTEtMS0yNjc5MQ_441ece42-88f2-4950-bfce-9f2931fbb655"
      unitRef="usd">6652000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfNS0xMy0xLTEtMjc3MjM_482fada8-1395-498b-9bbe-1718bde16dc2"
      unitRef="usd">6661000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ia5f30d05cafe48b79410089e00859443_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfNi0xLTEtMS0yNjc5OA_853c016c-993c-49a5-8dbe-db94fe58e532"
      unitRef="shares">987330</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i44b8bffb160d45dda13b5e2b78abce7f_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfNi01LTEtMS0yNjc5OA_6924a3c7-b9b3-440b-a62b-c98ac26f7347"
      unitRef="usd">14438000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfNi0xMy0xLTEtMjc3MjM_b02e4105-b421-4142-a5cb-598e43ee44b7"
      unitRef="usd">14438000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i44b8bffb160d45dda13b5e2b78abce7f_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfNy01LTEtMS0yNjgwNQ_50b27b65-3ded-4bb4-9bb6-54e952e8927f"
      unitRef="usd">32090000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfNy0xMy0xLTEtMjc3MjM_adfd9b95-bd70-4936-ac86-3b42106afb3d"
      unitRef="usd">32090000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <fold:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="ia5f30d05cafe48b79410089e00859443_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfOC0xLTEtMS0yNjgwNQ_10487831-3081-4ca6-a9f7-c3260ecbe61f"
      unitRef="shares">2554999</fold:StockIssuedDuringPeriodSharesWarrantsExercised>
    <fold:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="ia5f30d05cafe48b79410089e00859443_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfOC0zLTEtMS0yNjgwNQ_1af1b250-cea1-4c1e-94b8-4ac5a173f908"
      unitRef="usd">26000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
    <fold:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i44b8bffb160d45dda13b5e2b78abce7f_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfOC01LTEtMS0yNjgwNQ_3c94ee76-9a7f-4bde-8802-8ed7a483b1f0"
      unitRef="usd">31591000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
    <fold:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i649bebfff85c4aeb81fb81bfe49eeb22_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfOC03LTEtMS0yNjgwNQ_629ba2ca-f55d-4017-8ba5-f81d2061205b"
      unitRef="usd">-12387000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
    <fold:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfOC0xMy0xLTEtMjc3Mjg_849855a4-6b66-4d77-aee7-983949117cda"
      unitRef="usd">19230000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ia5f30d05cafe48b79410089e00859443_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfOS0xLTEtMS0yNjgwNQ_6c3502d6-e739-4eff-b9cd-b7950fc423e5"
      unitRef="shares">4084</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i44b8bffb160d45dda13b5e2b78abce7f_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfOS01LTEtMS0yNjgwNQ_08410ddc-9057-4ae0-b5c5-cc83c943eb01"
      unitRef="usd">21000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfOS0xMy0xLTEtMjc3Mjg_49922b30-48e0-4abf-af7e-aabfaf375ab3"
      unitRef="usd">21000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i03ca42e2698e4878b362989f4df7933e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfMTAtOS0xLTEtMjY4MjE_b769c858-5f73-49c8-ba1b-ea5489758c78"
      unitRef="usd">12000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfMTAtMTMtMS0xLTI3NzI2_7e210170-fb0d-49cd-bc2d-d47c1689ea47"
      unitRef="usd">12000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i03ca42e2698e4878b362989f4df7933e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfMTEtOS0xLTEtMjY4MjE_0239bfce-6772-4c86-a1fc-ac662076deca"
      unitRef="usd">843000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfMTEtMTMtMS0xLTI3NzI2_4618b454-6911-45bd-b2b4-ce944eddd137"
      unitRef="usd">843000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i69530f8676834a24b6824dd3090f275c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfMTItMTEtMS0xLTI2ODIx_90f7b82e-49c5-47fd-96d1-2f92b3c18f03"
      unitRef="usd">-116889000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfMTItMTMtMS0xLTI3NzI2_3e636d2f-3f40-43b5-947c-c8281786428e"
      unitRef="usd">-116889000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id197126c4925481fbd6568b6714249d7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfMTMtMS0xLTEtMjc3MTQ_1af33942-a4bb-450e-9bbc-98d15562a612"
      unitRef="shares">266532536</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id197126c4925481fbd6568b6714249d7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfMTMtMy0xLTEtMjc3MTQ_70a19e9c-f16e-409f-adcc-dee8b29b81c1"
      unitRef="usd">2685000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1575283eac554820897a66659337bdf4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfMTMtNS0xLTEtMjc3MTQ_1da8472e-69da-4adc-a8fe-62e7946c4183"
      unitRef="usd">2364494000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie01bcbab6a39452c8f207bbd1040e82e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfMTMtNy0xLTEtMjc3MTQ_fcfbf165-c20b-4505-bf94-5436c3002d9b"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia655833ddbb14af0823e080a718286f3_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfMTMtOS0xLTEtMjc3MTQ_13ad7d75-0374-4dae-9c85-226b40bc30ea"
      unitRef="usd">9082000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia265d46e7fdb4a6cbfc035ff181f41b7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfMTMtMTEtMS0xLTI3NzE0_8ec98121-61bc-4bca-a9bd-f4a1e5f3ecd4"
      unitRef="usd">-2162351000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibdd0bea669974aef88283f7ce9684c7f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8yOC9mcmFnOjk2NjkxNmZlMTEwNzQ1ODY4Nzk4YThlNjIxMzAxN2QyL3RhYmxlOjdjNTRiYjY0YjkyYTQ3YTZhODJlZTExMmI5NGI2NDA3L3RhYmxlcmFuZ2U6N2M1NGJiNjRiOTJhNDdhNmE4MmVlMTEyYjk0YjY0MDdfMTMtMTMtMS0xLTI3NzI2_ff321a77-1b76-46e4-b368-d420079f0b15"
      unitRef="usd">213910000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMy0xLTEtMS0yNTk4OQ_44b4355b-fb25-493d-b41d-9768bbc1ca53"
      unitRef="usd">-147417000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMy0zLTEtMS0yNTk4OQ_1b1ead17-ec28-4b17-adaa-081b8830a14e"
      unitRef="usd">-116889000</us-gaap:ProfitLoss>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfNS0xLTEtMS0yNTk4OQ_3feb4bec-ce1f-4a21-886a-a6dd7c448fdd"
      unitRef="usd">1295000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfNS0zLTEtMS0yNTk4OQ_9a8fbe01-0c01-42fa-b540-103dbf10a2b7"
      unitRef="usd">1200000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfNi0xLTEtMS0yNTk4OQ_a7fc9e1c-943d-4725-883e-0e485658381d"
      unitRef="usd">2745000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfNi0zLTEtMS0yNTk4OQ_c0001e82-7f0b-4889-8efb-29d81d797105"
      unitRef="usd">3171000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfNy0xLTEtMS0yNTk4OQ_3bc44452-d223-4687-a0a0-953fa3edb9b5"
      unitRef="usd">43114000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfNy0zLTEtMS0yNTk4OQ_2be4f833-2573-42c6-a714-87322b53dfa4"
      unitRef="usd">32090000</us-gaap:ShareBasedCompensation>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfOS0xLTEtMS0yNTk4OQ_a9ddf636-f4ba-4d02-a949-6084ee0c2499"
      unitRef="usd">-1073000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfOS0zLTEtMS0yNTk4OQ_2fbe70d8-374e-4e06-bdf0-f3fefc65c3e9"
      unitRef="usd">1492000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <fold:ForeignCurrencyRemeasurementGainLossBeforeTax
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMTAtMS0xLTEtMjU5ODk_db0cb77a-f730-4d69-aac0-0a82e4b54003"
      unitRef="usd">-353000</fold:ForeignCurrencyRemeasurementGainLossBeforeTax>
    <fold:ForeignCurrencyRemeasurementGainLossBeforeTax
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMTAtMy0xLTEtMjU5ODk_add11662-47e9-49bb-968e-576e0452e2ea"
      unitRef="usd">-3235000</fold:ForeignCurrencyRemeasurementGainLossBeforeTax>
    <fold:AssetImpairmentChargesAndOtherAssetWriteOffs
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMTEtMS0xLTEtMjU5ODk_1a1fc9fd-b2a3-44e9-a7da-4dce9e2118e1"
      unitRef="usd">12265000</fold:AssetImpairmentChargesAndOtherAssetWriteOffs>
    <fold:AssetImpairmentChargesAndOtherAssetWriteOffs
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMTEtMy0xLTEtMjU5ODk_6f6df43b-af32-4f1c-bd7d-4c5392a8cf0a"
      unitRef="usd">0</fold:AssetImpairmentChargesAndOtherAssetWriteOffs>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMTMtMS0xLTEtMjU5ODk_bf7e0115-eb27-4090-a29d-fe13ccbd5e0c"
      unitRef="usd">4424000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMTMtMy0xLTEtMjU5ODk_0b5f00d6-6341-4d1d-a349-b8292781de95"
      unitRef="usd">3127000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMTQtMS0xLTEtMjU5ODk_d4e3bb3a-ba97-466a-8570-db9b703ebb54"
      unitRef="usd">-3537000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMTQtMy0xLTEtMjU5ODk_f27d4c08-7359-4792-aaf7-53ae1671a990"
      unitRef="usd">4445000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMTUtMS0xLTEtMjU5ODk_0d348aff-4b31-4a82-b7dc-630f6409d2d6"
      unitRef="usd">4481000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMTUtMy0xLTEtMjU5ODk_1d358ec5-ca45-4103-8f6b-5f3798e67147"
      unitRef="usd">-5265000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMTYtMS0xLTEtMjU5ODk_eaf36a33-92e0-4e60-99a0-0532e45a6b5a"
      unitRef="usd">22671000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMTYtMy0xLTEtMjU5ODk_efd1d935-8bad-4b97-8db0-50898688f77a"
      unitRef="usd">-28485000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <fold:IncreaseDecreaseInNoncurrentOperatingLiabilities
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMTctMS0xLTEtMjU5ODk_47b01c4a-7179-47cd-bd34-25c28bac9410"
      unitRef="usd">-2762000</fold:IncreaseDecreaseInNoncurrentOperatingLiabilities>
    <fold:IncreaseDecreaseInNoncurrentOperatingLiabilities
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMTctMy0xLTEtMjU5ODk_e41bc596-fbe0-4980-a3a5-49feebd74330"
      unitRef="usd">-1784000</fold:IncreaseDecreaseInNoncurrentOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMTgtMS0xLTEtMjU5ODk_85bfe199-00f1-4b3b-a805-254d4a8b262b"
      unitRef="usd">-74177000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMTgtMy0xLTEtMjU5ODk_c1752d0e-9255-4303-baee-8dc882c502f4"
      unitRef="usd">-108277000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjAtMS0xLTEtMjU5ODk_18964c4c-5c20-46de-b670-a0d9c2e4f8b1"
      unitRef="usd">184061000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjAtMy0xLTEtMjU5ODk_7ff8455d-ee6a-4305-9467-dbd0a83e05d5"
      unitRef="usd">258767000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjEtMS0xLTEtMjU5ODk_cfc7525b-ab20-420e-80d9-13fb25a2504b"
      unitRef="usd">98330000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjEtMy0xLTEtMjU5ODk_5be54dc3-42d4-463c-9197-c59eed928966"
      unitRef="usd">145255000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjItMS0xLTEtMjU5ODk_80f93eef-8edf-4628-af14-8a511e2a81ee"
      unitRef="usd">1226000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjItMy0xLTEtMjU5ODk_e9896032-2ac5-444e-b851-36ea403aced1"
      unitRef="usd">1234000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjMtMS0xLTEtMjU5ODk_1a2e79e7-f6e0-4a3f-8de6-13e681c56dbe"
      unitRef="usd">84505000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjMtMy0xLTEtMjU5ODk_323ba966-0010-41b0-bd69-ea8e53da6c1a"
      unitRef="usd">112278000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjUtMS0xLTEtMjU5ODk_cecfdfaa-553e-4d8b-9ddb-81e9f0552144"
      unitRef="usd">41000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjUtMy0xLTEtMjU5ODk_9e9db47d-bac1-4208-ac89-692db39af753"
      unitRef="usd">389000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjYtMS0xLTEtMjU5ODk_2b3f40b0-9732-43b4-99d8-d334bd720e15"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjYtMy0xLTEtMjU5ODk_b96e7296-293e-4110-87eb-a323cc342026"
      unitRef="usd">19230000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjctMS0xLTEtMjU5ODk_1236c066-64c7-4136-a8ab-3c28f2403199"
      unitRef="usd">9278000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjctMy0xLTEtMjU5ODk_46372afc-63f9-405e-95f3-d42393833759"
      unitRef="usd">14438000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjgtMS0xLTEtMjU5ODk_58b12f99-aafe-41c9-8373-34f1eef30df5"
      unitRef="usd">1858000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjgtMy0xLTEtMjU5ODk_1c1b3d50-8e2e-4cd4-aae1-0eb739131e5b"
      unitRef="usd">6661000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjktMS0xLTEtMjU5ODk_f0e4d993-01f2-486d-9106-414c4121f7a7"
      unitRef="usd">-7461000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMjktMy0xLTEtMjU5ODk_60fcf182-93eb-4261-b933-2be4e967faf2"
      unitRef="usd">11064000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMzAtMS0xLTEtMjU5ODk_c8d90c09-bcc9-461c-b270-de81881eed3b"
      unitRef="usd">-12462000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMzAtMy0xLTEtMjU5ODk_d618ff62-e9da-42b7-94ca-42025fa0cf71"
      unitRef="usd">-1439000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMzEtMS0xLTEtMjU5ODk_d6aaa571-ab3c-4c53-8c35-230380e8ffae"
      unitRef="usd">-9595000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMzEtMy0xLTEtMjU5ODk_d69db568-a342-4164-9e8f-ef4975857303"
      unitRef="usd">13626000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMzItMS0xLTEtMjU5ODk_d4931249-f3d5-435b-8ad6-11b0ee7c107d"
      unitRef="usd">249456000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i17008df080294bb0bf1240acd6c19c15_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMzItMy0xLTEtMjU5ODk_17e277c0-f919-4910-b2c3-d03c2ad11ecf"
      unitRef="usd">166162000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMzMtMS0xLTEtMjU5ODk_befbb50a-6f32-4390-bcef-344af579b2b2"
      unitRef="usd">239861000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibdd0bea669974aef88283f7ce9684c7f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMzMtMy0xLTEtMjU5ODk_1a992113-5abf-499f-b4b4-aad50da2849b"
      unitRef="usd">179788000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMzUtMS0xLTEtMjU5ODk_c9856b15-cbd3-4e25-a03f-ffd1fc40054b"
      unitRef="usd">15108000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMzUtMy0xLTEtMjU5ODk_bc255d5a-0330-4356-9b1e-c52152ece7a0"
      unitRef="usd">15109000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMzctMS0xLTEtMjkwNDQ_1d2da520-0ddd-4bb6-a786-5195a08a01a7"
      unitRef="usd">710000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMzctMy0xLTEtMjkwNDc_2c8e3cd7-bc1a-4f0c-84d2-ce7ba030cfd3"
      unitRef="usd">4526000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMzYtMS0xLTEtMjU5ODk_fc65fe9c-b44f-4af8-b44a-9f5638f077f7"
      unitRef="usd">53000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfMzYtMy0xLTEtMjU5ODk_74487d89-0305-4617-9200-3817fbfeeef3"
      unitRef="usd">191000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfNDAtMS0xLTEtMjg4OTM_4ad1ad95-2ffb-42e0-bca4-66d73015203d"
      unitRef="usd">0</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zMS9mcmFnOjdhNDJiOWMzYzNhMjQwMzU5M2U0NmVlMjY2OTU4YzRjL3RhYmxlOmIyM2VjZWUxY2Q3ODQ4ZmQ4YWM5YTBkNTc3ODAyYTk5L3RhYmxlcmFuZ2U6YjIzZWNlZTFjZDc4NDhmZDhhYzlhMGQ1Nzc4MDJhOTlfNDAtMy0xLTEtMjg4OTM_cefc2f2d-57fa-4b0f-a240-51f6b3357af7"
      unitRef="usd">67000</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zNy9mcmFnOjFlOTdhN2FhNjBhNjQ2NTJhYjFiN2ExZmM2M2Y4ZGMxL3RleHRyZWdpb246MWU5N2E3YWE2MGE2NDY1MmFiMWI3YTFmYzYzZjhkYzFfMzgyNg_e2d4c397-6c73-420c-84f4-47bd68649a7c">Description of Business&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amicus Therapeutics, Inc. (the "Company") is a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. The Company has a portfolio of product opportunities including the first, oral monotherapy for Fabry disease that has achieved widespread global approval and a differentiated biologic for Pompe disease, that is under review with the U.S. Food and Drug Administration ("FDA") as well as the European Medicines Agency ("EMA"). The Company is committed to discovering and developing next generation therapies in Fabry and Pompe diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cornerstone of the Company's portfolio is Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (also referred to as "migalastat"), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants. Migalastat is currently approved under the trade name Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States ("U.S."), European Union ("E.U."), United Kingdom ("U.K."), and Japan, with multiple additional approvals granted and applications pending in several geographies around the world. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lead biologics program of the Company's pipeline is Amicus Therapeutics GAA ("AT-GAA", also known as ATB200/AT2221, or cipaglucosidase alfa/miglustat), a novel, two-component, potential best-in-class treatment for Pompe disease. In February 2019, the FDA granted Breakthrough Therapy designation ("BTD") to AT-GAA for the treatment of late onset Pompe disease. In September 2021, the FDA set the Prescription Drug User Fee Act ("PDUFA") target action date of May 29, 2022 for the New Drug Application ("NDA") for miglustat and July 29, 2022 for the Biologics License Application ("BLA") for cipaglucosidase alfa. The EMA validated the Marketing Authorization Application (&#x201c;MAA&#x201d;) in the fourth quarter of 2021. On May 9, 2022, the FDA extended the review period for the NDA for miglustat and the BLA for cipaglucosidase alfa resulting in revised PDUFA action dates of August 29, 2022 and October 29, 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's operations have not been significantly impacted by the novel coronavirus (&#x201c;COVID-19&#x201d;) pandemic to date. The Company continued to observe increased lag time between patient identification and Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; initiation due to the continued prevalence of COVID-19 and its ongoing impact on access to treatment for people living with Fabry disease in certain markets. The Company has maintained operations in all geographies, secured its global supply chain for its commercial and clinical products, as well as maintained the operational integrity of its clinical trials, with minimal disruptions. Whether the Company will continue to operate without any significant disruptions will depend on the continued health of its employees, the ongoing demand for Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and the continued operation of its global supply chain. The Company has continued to provide uninterrupted access to medicines for those in need of treatment, while prioritizing the health and safety of its global workforce. However, the Company's results of operations in future periods may be negatively impacted by unknown future impacts from the COVID-19 pandemic.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had an accumulated deficit of $2.4 billion as of June 30, 2022 and anticipates incurring losses through the fiscal year ending December 31, 2022 and beyond. The Company has historically funded its operations through stock offerings, Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; revenues, debt issuances, collaborations, and other financing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on its current operating model, the Company believes that the current cash position, which includes expected revenues, is sufficient to fund the Company's operations and ongoing research programs to achieve self-sustainability. Potential impacts of the COVID-19 pandemic, business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact the Company's future capital requirements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV8zNy9mcmFnOjFlOTdhN2FhNjBhNjQ2NTJhYjFiN2ExZmM2M2Y4ZGMxL3RleHRyZWdpb246MWU5N2E3YWE2MGE2NDY1MmFiMWI3YTFmYzYzZjhkYzFfMzEzNg_f1e185c5-38d0-44fb-a802-3241cff1641d"
      unitRef="usd">-2400000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfOTM2NA_e4881489-1071-407a-8194-00cfeb3e7371">Summary of Significant Accounting Policies&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has prepared the accompanying unaudited Consolidated Financial Statements in accordance with the U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited Consolidated Financial Statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company's interim financial information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Consolidated Financial Statements and related notes should be read in conjunction with the Company's financial statements and related notes as contained in the Company's Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2021.&#160;For a complete description of the Company's accounting policies, please refer to the Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company assessed the impact COVID-19 pandemic has had on its operations and financial results as of June 30, 2022 and through the issuance of these financial statements. The Company&#x2019;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Marketable Securities, and Restricted Cash &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are reported within other comprehensive loss in the Company's Consolidated Statements of Comprehensive Loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations, or other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in other current assets and other non-current assets on the Company's Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company's accounts receivable at June 30, 2022 have arisen from product sales primarily in Europe and the U.S. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis. As of June 30, 2022, the Company recorded an allowance for doubtful accounts of $0.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated over the estimated useful lives of the respective assets, which range from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfNTM5Mg_89960747-9384-4345-bf43-26f7a60be61c"&gt;three&lt;/span&gt; to five years, or the lesser of the related initial term of the lease or useful life for leasehold improvements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial cost of property and equipment consists of its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to income in the period in which the costs are incurred. Major replacements, improvements, and additions are capitalized in accordance with Company policy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If indications of impairment exist, projected future undiscounted cash flows associated with the asset or asset group are compared to the carrying value of the asset to determine whether the asset or asset group's value is recoverable. If impairment is determined, the Company writes down the asset to its estimated fair value and records an impairment loss equal to the excess of the carrying value of the long-lived asset over its estimated fair value in the period at which such a determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June 30, 2022, in connection with the strategic prioritization of its gene therapy portfolio, the Company performed an assessment of its fixed assets. As a result, the Company recognized an impairment charge of $6.6&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's net product sales consist of sales of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the treatment of Fabry disease. The Company has recorded revenue on sales where Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is available either on a commercial basis or through a reimbursed early access program. Orders for Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are generally received from distributors and pharmacies, with the ultimate payor often a government authority. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The transaction price is determined based on fixed consideration in the Company's customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenue from the sale of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's net product sales from Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; disaggregated by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:15pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ex-U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total net product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;159,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories and Cost of Goods Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of goods sold in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expense consist primarily of costs related to personnel, including salaries and other personnel related expenses, consulting fees, and the cost of facilities and support services used in drug development. Assets acquired that are used for research and development and have no future alternative use are expensed as in-process research and development. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the second quarter of 2022, as part of the Company&#x2019;s strategic prioritization of its gene therapy portfolio, the Company recorded a non-recurring $20.0&#160;million liability associated with the expense of contractual obligations from which the Company will no longer receive further economic benefit. A liability for costs that will continue to be incurred under a contract for its remaining term without economic benefit to the entity is recognized at the cease-use date. This liability is presented as a component of accrued expenses and other current liabilities within the Company's Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Developments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated recent accounting pronouncements and believes that none of them will have a material effect on the Company's Consolidated Financial Statements or related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfOTQwMA_e284b422-c77f-49ad-984e-8978b30c9737">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has prepared the accompanying unaudited Consolidated Financial Statements in accordance with the U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited Consolidated Financial Statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company's interim financial information.&lt;/span&gt;&lt;/div&gt;The accompanying unaudited Consolidated Financial Statements and related notes should be read in conjunction with the Company's financial statements and related notes as contained in the Company's Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2021.&#160;For a complete description of the Company's accounting policies, please refer to the Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2021.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfOTQwMQ_c6d0bf48-8dee-4250-b2a6-04fa99872111">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfOTM5NA_977eeeb4-b5b4-4d3e-a7b8-4f598b6e9c27">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfOTM3MQ_6c3a42b8-115b-49d0-8a54-09f214e540b1">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company assessed the impact COVID-19 pandemic has had on its operations and financial results as of June 30, 2022 and through the issuance of these financial statements. The Company&#x2019;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfOTM4Nw_d9b41138-ac01-45ac-908f-617971acfe27">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Marketable Securities, and Restricted Cash &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are reported within other comprehensive loss in the Company's Consolidated Statements of Comprehensive Loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations, or other observable inputs.&lt;/span&gt;&lt;/div&gt;Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in other current assets and other non-current assets on the Company's Consolidated Balance Sheets.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfOTM2MQ_12549fec-dbc4-486a-b7e6-8702c5be95c6">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;. The Company's accounts receivable at June 30, 2022 have arisen from product sales primarily in Europe and the U.S. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfNTE4OQ_d4721ecf-6d2b-4e90-8bff-8e23d40b845f"
      unitRef="usd">100000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfOTM2Ng_631cfd4c-b989-481a-ba06-ef85e71a0b84">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated over the estimated useful lives of the respective assets, which range from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfNTM5Mg_89960747-9384-4345-bf43-26f7a60be61c"&gt;three&lt;/span&gt; to five years, or the lesser of the related initial term of the lease or useful life for leasehold improvements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial cost of property and equipment consists of its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to income in the period in which the costs are incurred. Major replacements, improvements, and additions are capitalized in accordance with Company policy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If indications of impairment exist, projected future undiscounted cash flows associated with the asset or asset group are compared to the carrying value of the asset to determine whether the asset or asset group's value is recoverable. If impairment is determined, the Company writes down the asset to its estimated fair value and records an impairment loss equal to the excess of the carrying value of the long-lived asset over its estimated fair value in the period at which such a determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June 30, 2022, in connection with the strategic prioritization of its gene therapy portfolio, the Company performed an assessment of its fixed assets. As a result, the Company recognized an impairment charge of $6.6&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ia1ae6aeddaf442cba31cc61b672cf523_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfNTM5OA_e4977a96-1f9b-470d-bcb0-52296238ea7a">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:AssetImpairmentCharges
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfNjg4MA_8ab16d7a-64ee-4fcf-978c-db4e1906fd10"
      unitRef="usd">6600000</us-gaap:AssetImpairmentCharges>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfOTM1OA_28629c3b-bd44-4e6b-be87-45e6480e6ea1">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's net product sales consist of sales of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the treatment of Fabry disease. The Company has recorded revenue on sales where Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is available either on a commercial basis or through a reimbursed early access program. Orders for Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are generally received from distributors and pharmacies, with the ultimate payor often a government authority. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The transaction price is determined based on fixed consideration in the Company's customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenue from the sale of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfOTM3Nw_b1e21093-97ff-4ece-9497-58e3b4e89575">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's net product sales from Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; disaggregated by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:15pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ex-U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total net product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;159,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4608585deb7447ecabc5d85a3a731ff7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RhYmxlOjE0YjNlZTg4NzUxNDRjNzA4ZDg4NzdiOGRmNDBlYTZiL3RhYmxlcmFuZ2U6MTRiM2VlODg3NTE0NGM3MDhkODg3N2I4ZGY0MGVhNmJfMi0yLTEtMS0yNTk4OQ_d9eb75ee-7185-45d1-8c22-25956f8166ac"
      unitRef="usd">27540000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia22486482e60492c860155dbff44d0c1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RhYmxlOjE0YjNlZTg4NzUxNDRjNzA4ZDg4NzdiOGRmNDBlYTZiL3RhYmxlcmFuZ2U6MTRiM2VlODg3NTE0NGM3MDhkODg3N2I4ZGY0MGVhNmJfMi00LTEtMS0yNTk4OQ_296a22ba-d7ce-4550-b289-bf07bd78b4ca"
      unitRef="usd">23678000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9888231cb6e4488995457f5adf3be783_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RhYmxlOjE0YjNlZTg4NzUxNDRjNzA4ZDg4NzdiOGRmNDBlYTZiL3RhYmxlcmFuZ2U6MTRiM2VlODg3NTE0NGM3MDhkODg3N2I4ZGY0MGVhNmJfMi01LTEtMS0yNjg5NQ_8ee9ada8-a3d7-443c-877f-3a556e4934f7"
      unitRef="usd">51718000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe98a5affced4afd82274d759802ef32_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RhYmxlOjE0YjNlZTg4NzUxNDRjNzA4ZDg4NzdiOGRmNDBlYTZiL3RhYmxlcmFuZ2U6MTRiM2VlODg3NTE0NGM3MDhkODg3N2I4ZGY0MGVhNmJfMi03LTEtMS0yNjg5NQ_0a810778-19e0-445b-82eb-55974ade3a6d"
      unitRef="usd">44531000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5aab62a215e24c70a98a8fa127a0c93e_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RhYmxlOjE0YjNlZTg4NzUxNDRjNzA4ZDg4NzdiOGRmNDBlYTZiL3RhYmxlcmFuZ2U6MTRiM2VlODg3NTE0NGM3MDhkODg3N2I4ZGY0MGVhNmJfMy0yLTEtMS0yNTk4OQ_76abc268-3d3a-49f2-a4dd-db3ef2cc7d84"
      unitRef="usd">53191000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4736f08b10ec45f5a5791466daa3734d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RhYmxlOjE0YjNlZTg4NzUxNDRjNzA4ZDg4NzdiOGRmNDBlYTZiL3RhYmxlcmFuZ2U6MTRiM2VlODg3NTE0NGM3MDhkODg3N2I4ZGY0MGVhNmJfMy00LTEtMS0yNTk4OQ_78b7e037-3d1e-40a0-bc14-7d101f44ccfb"
      unitRef="usd">53735000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc644fbd473b4779827e095e604e1fa1_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RhYmxlOjE0YjNlZTg4NzUxNDRjNzA4ZDg4NzdiOGRmNDBlYTZiL3RhYmxlcmFuZ2U6MTRiM2VlODg3NTE0NGM3MDhkODg3N2I4ZGY0MGVhNmJfMy01LTEtMS0yNjg5NQ_25faa1c8-e650-4a89-9c7a-2987c3047ac8"
      unitRef="usd">107728000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2058a237abf345d3a1df9a3c8c9c52b2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RhYmxlOjE0YjNlZTg4NzUxNDRjNzA4ZDg4NzdiOGRmNDBlYTZiL3RhYmxlcmFuZ2U6MTRiM2VlODg3NTE0NGM3MDhkODg3N2I4ZGY0MGVhNmJfMy03LTEtMS0yNjg5NQ_2b2e85a5-db27-4f70-9b8b-b310f0ec487d"
      unitRef="usd">99284000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RhYmxlOjE0YjNlZTg4NzUxNDRjNzA4ZDg4NzdiOGRmNDBlYTZiL3RhYmxlcmFuZ2U6MTRiM2VlODg3NTE0NGM3MDhkODg3N2I4ZGY0MGVhNmJfNC0yLTEtMS0yNTk4OQ_c7091845-99ba-4db4-aae9-81ed78de56e4"
      unitRef="usd">80731000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RhYmxlOjE0YjNlZTg4NzUxNDRjNzA4ZDg4NzdiOGRmNDBlYTZiL3RhYmxlcmFuZ2U6MTRiM2VlODg3NTE0NGM3MDhkODg3N2I4ZGY0MGVhNmJfNC00LTEtMS0yNTk4OQ_95bba3c6-eb8c-4742-93d8-8bdaa148002d"
      unitRef="usd">77413000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RhYmxlOjE0YjNlZTg4NzUxNDRjNzA4ZDg4NzdiOGRmNDBlYTZiL3RhYmxlcmFuZ2U6MTRiM2VlODg3NTE0NGM3MDhkODg3N2I4ZGY0MGVhNmJfNC01LTEtMS0yNzc2NQ_96f69ad7-8814-42ef-8f5d-f64e2e10121b"
      unitRef="usd">159446000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RhYmxlOjE0YjNlZTg4NzUxNDRjNzA4ZDg4NzdiOGRmNDBlYTZiL3RhYmxlcmFuZ2U6MTRiM2VlODg3NTE0NGM3MDhkODg3N2I4ZGY0MGVhNmJfNC03LTEtMS0yNzc2NQ_c12a4f30-b9e2-45e8-a471-ce33fd8b3c65"
      unitRef="usd">143815000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:InventoryCostsForContractsOrProgramsPolicy
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfOTQwNw_eded099b-b352-42a3-be9e-11098d2a3ab0">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories and Cost of Goods Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of goods sold in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable.</us-gaap:InventoryCostsForContractsOrProgramsPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfMzg0ODI5MDcwODkxMA_a9d460fb-73b6-4407-98d1-65a89db24d37">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expense consist primarily of costs related to personnel, including salaries and other personnel related expenses, consulting fees, and the cost of facilities and support services used in drug development. Assets acquired that are used for research and development and have no future alternative use are expensed as in-process research and development. &lt;/span&gt;&lt;/div&gt;In the second quarter of 2022, as part of the Company&#x2019;s strategic prioritization of its gene therapy portfolio, the Company recorded a non-recurring $20.0&#160;million liability associated with the expense of contractual obligations from which the Company will no longer receive further economic benefit. A liability for costs that will continue to be incurred under a contract for its remaining term without economic benefit to the entity is recognized at the cease-use date. This liability is presented as a component of accrued expenses and other current liabilities within the Company's Consolidated Balance Sheets.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ContractualObligation
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfNDk0NzgwMjMzNjYwMQ_0ad5896f-7739-477d-a826-d68aebb11724"
      unitRef="usd">20000000</us-gaap:ContractualObligation>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80MC9mcmFnOjMwYmI1ODdlYzFlYTQ3MDhhYjllMzZlNjM2YThjYTI2L3RleHRyZWdpb246MzBiYjU4N2VjMWVhNDcwOGFiOWUzNmU2MzZhOGNhMjZfOTM2Nw_805d3b69-a4e6-472a-bd38-7f31b75befac">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Developments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated recent accounting pronouncements and believes that none of them will have a material effect on the Company's Consolidated Financial Statements or related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RleHRyZWdpb246MjIwZDc4YzViYTQxNDMzOTkzNTExYzM5NzMzZTQ0YWJfMjc5Nw_285093dc-4320-4030-9d44-871ef8794e72">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2022, the Company held $235.6 million in cash and cash equivalents and $151.2 million of marketable securities which are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are generally reported within other comprehensive loss in the Company's Consolidated Statements of Comprehensive Loss. If a decline in the fair value of a marketable security below the Company's cost basis is determined to be other-than-temporary or if an available-for-sale debt security&#x2019;s fair value is determined to be less than the amortized cost and the Company intends or is more than likely to sell the security before recovery and it is not considered a credit loss, such security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. If the unrealized loss of an available-for-sale debt security is determined to be a result of credit loss, the Company would recognize an allowance and the corresponding credit loss would be included in earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company regularly invests excess operating cash in deposits with major financial institutions, money market funds, notes issued by the U.S. government, as well as fixed income investments and U.S. bond funds, both of which can be readily purchased and sold using established markets. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated as many of these securities are either government backed or of the highest credit rating. Investments that have original maturities greater than three months but less than one year are classified as current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents and marketable securities are classified as current unless mentioned otherwise below and consisted of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;387,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;386,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Included in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;151,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;151,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;387,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;386,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;245,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;245,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;174,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;174,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;245,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;245,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Included in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237,299&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For both the six months ended June 30, 2022 and the fiscal year ended December 31, 2021, there were no realized gains or losses. The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized loss positions in the marketable securities as of June 30, 2022 and December 31, 2021 reflect temporary impairments and are not a result of credit loss. Additionally, as these positions have been in a loss position for less than twelve months and the Company does not intend to sell these securities before recovery, the losses are recognized in other comprehensive (loss) gain. The fair value of these marketable securities in unrealized loss positions was $140.5 million and $173.4 million as of June 30, 2022 and December 31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;176,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;239,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;179,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RleHRyZWdpb246MjIwZDc4YzViYTQxNDMzOTkzNTExYzM5NzMzZTQ0YWJfMTAy_392f441f-fcdc-4854-924d-f1553aa668c6"
      unitRef="usd">235600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i33bee7e70d4f41ae98aea43eaf262df5_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RleHRyZWdpb246MjIwZDc4YzViYTQxNDMzOTkzNTExYzM5NzMzZTQ0YWJfMTM4_0749d9f4-1f20-4b0e-a152-ce6bbf7ee59a"
      unitRef="usd">151200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RleHRyZWdpb246MjIwZDc4YzViYTQxNDMzOTkzNTExYzM5NzMzZTQ0YWJfMjc5NA_0c12e8ab-e1c2-4a47-9033-a5a46c2e3806">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents and marketable securities are classified as current unless mentioned otherwise below and consisted of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;387,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;386,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Included in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;151,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;151,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;387,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;386,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;245,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;245,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;174,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;174,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;245,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;245,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Included in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237,299&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfMi0yLTEtMS0yNTk4OQ_be0b3a70-1803-4fc1-8786-925a9bf22042"
      unitRef="usd">235639000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfMi04LTEtMS0yNTk4OQ_8f9f4b37-f607-4c74-9490-a25a6a644b01"
      unitRef="usd">235639000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i313bc2d8be6b49deab3982d26fd646fd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfMy0yLTEtMS0yNTk4OQ_59b3b02f-05f4-49aa-a466-1ea88edc8573"
      unitRef="usd">103084000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i313bc2d8be6b49deab3982d26fd646fd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfMy00LTEtMS0yNTk4OQ_fab87c85-37bc-44d2-bc24-5564d144e75e"
      unitRef="usd">1000</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i313bc2d8be6b49deab3982d26fd646fd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfMy02LTEtMS0yNTk4OQ_b87448ef-40c6-4871-9b78-6ff944b33734"
      unitRef="usd">239000</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i313bc2d8be6b49deab3982d26fd646fd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfMy04LTEtMS0yNTk4OQ_c618d52c-07ec-4470-8363-f2a81eca76a3"
      unitRef="usd">102846000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2a5beaca54dc4603a5614a45876a29e0_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfNC0yLTEtMS0yNTk4OQ_c38e6350-011e-479d-9aa1-aa354110738d"
      unitRef="usd">45157000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2a5beaca54dc4603a5614a45876a29e0_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfNC00LTEtMS0yNTk4OQ_c5713e21-de35-46d8-8826-5c7bda9ebe7d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2a5beaca54dc4603a5614a45876a29e0_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfNC02LTEtMS0yNTk4OQ_b5fb75c0-43c8-4e21-9479-49f6882e0e1e"
      unitRef="usd">193000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2a5beaca54dc4603a5614a45876a29e0_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfNC04LTEtMS0yNTk4OQ_33325459-d8fc-42d4-8843-d75f6d37d8fb"
      unitRef="usd">44964000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ie925c891e72c47cea99fa4b411e16d37_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfNS0yLTEtMS0yNTk4OQ_a7afc408-9678-4df2-992c-f30b9d5d524d"
      unitRef="usd">3000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="ie925c891e72c47cea99fa4b411e16d37_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfNS00LTEtMS0yNTk4OQ_0364aa68-3aaa-4ced-b985-985b3a1da9db"
      unitRef="usd">0</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="ie925c891e72c47cea99fa4b411e16d37_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfNS02LTEtMS0yNTk4OQ_7ef347e9-fedf-4c53-bf33-09aa5af27c43"
      unitRef="usd">9000</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie925c891e72c47cea99fa4b411e16d37_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfNS04LTEtMS0yNTk4OQ_3fc1ab6a-9601-4f71-afa8-6e5713a216f3"
      unitRef="usd">2991000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i2786cde9d4554d08836966e040d3dd88_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfNi0yLTEtMS0yNTk4OQ_64a173ba-be8b-4208-8d68-3bdd53a16bf2"
      unitRef="usd">350000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i2786cde9d4554d08836966e040d3dd88_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfNi00LTEtMS0yNTk4OQ_64bba9d8-34fc-40ad-9d60-fb0876e0aa47"
      unitRef="usd">0</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i2786cde9d4554d08836966e040d3dd88_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfNi02LTEtMS0yNTk4OQ_cacde0de-601a-4276-9014-17471568fa9c"
      unitRef="usd">0</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i2786cde9d4554d08836966e040d3dd88_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfNi04LTEtMS0yNTk4OQ_620a964a-9e8a-4d1a-b679-672b6960dbec"
      unitRef="usd">350000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iee2998a9354d4afca4c7ca59fa536817_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfNy0yLTEtMS0yNTk4OQ_4879b18d-1785-47f4-95f8-4f4a682ce174"
      unitRef="usd">51000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iee2998a9354d4afca4c7ca59fa536817_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfNy00LTEtMS0yNTk4OQ_57378330-b477-47c8-b97b-9d8bfb426efb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iee2998a9354d4afca4c7ca59fa536817_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfNy02LTEtMS0yNTk4OQ_293c66ef-26db-4c64-8717-f777a1ffe816"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iee2998a9354d4afca4c7ca59fa536817_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfNy04LTEtMS0yNTk4OQ_c1c48a2a-61c4-432d-8e53-7c2cbdbb00da"
      unitRef="usd">51000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfOS0yLTEtMS0yNTk4OQ_d79edaaa-bd47-4b20-a631-ab83ad87e6ba"
      unitRef="usd">387281000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfOS00LTEtMS0yNTk4OQ_baeaacf5-4fd0-432c-83a8-a762bbbd4ce7"
      unitRef="usd">1000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfOS02LTEtMS0yNTk4OQ_fda8909f-17a3-42d6-a6af-e966ad366268"
      unitRef="usd">441000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfOS04LTEtMS0yNTk4OQ_a44850d2-fb91-4d23-8048-28eb1a9281dd"
      unitRef="usd">386841000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfMTAtMi0xLTEtMjU5ODk_6ec05b40-c5b7-49d6-8f5f-868af7933eb1"
      unitRef="usd">235639000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfMTAtOC0xLTEtMjU5ODk_757897ce-ff30-4f4d-8638-5570555266f7"
      unitRef="usd">235639000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfMTEtMi0xLTEtMjU5ODk_38199a82-b8fe-449e-8124-f566a7cac6d9"
      unitRef="usd">151642000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfMTEtNC0xLTEtMjU5ODk_531f51b4-34c4-4256-9101-6c274d1c6bec"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfMTEtNi0xLTEtMjU5ODk_ca004a1a-5c34-4292-8ebb-b59f959a039d"
      unitRef="usd">441000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfMTEtOC0xLTEtMjU5ODk_48f7685b-7383-411e-9e51-0e3e53c26dc8"
      unitRef="usd">151202000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfMTItMi0xLTEtMjU5ODk_409021e5-bec9-4ce2-ba70-7942d57e799a"
      unitRef="usd">387281000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfMTItNC0xLTEtMjU5ODk_8c022d9d-a69a-47d2-8c67-0e71cb5b9289"
      unitRef="usd">1000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfMTItNi0xLTEtMjU5ODk_caf4735d-0d56-4c23-abb9-65e1dd97b43b"
      unitRef="usd">441000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOmQ3ODhjZDNiODRjNTQxMmRiMjZlN2U3NzY0NTIwZDE5L3RhYmxlcmFuZ2U6ZDc4OGNkM2I4NGM1NDEyZGIyNmU3ZTc3NjQ1MjBkMTlfMTItOC0xLTEtMjU5ODk_5da44edb-56f7-4db7-8f74-8cec8e7d5281"
      unitRef="usd">386841000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfMi0yLTEtMS0yNTk4OQ_10140cdf-e241-4db3-ad33-6244cd0254e3"
      unitRef="usd">245197000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfMi04LTEtMS0yNTk4OQ_06730f1b-7814-494c-a8ae-55b735b0243b"
      unitRef="usd">245197000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i18a1d906c5a545e698385837607d8ddb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfMy0yLTEtMS0yNTk4OQ_0b0b1aa2-ed83-40f2-a90c-b565939cd1b4"
      unitRef="usd">174578000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i18a1d906c5a545e698385837607d8ddb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfMy00LTEtMS0yNTk4OQ_9d8cdf9c-2ad1-4f09-a4d4-7c0a44e6df41"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i18a1d906c5a545e698385837607d8ddb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfMy02LTEtMS0yNTk4OQ_38185bea-c6b1-4107-93dc-19d7d3cab8c2"
      unitRef="usd">54000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i18a1d906c5a545e698385837607d8ddb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfMy04LTEtMS0yNTk4OQ_07d3b6a4-27a4-4d1c-b87e-e336ef3c6840"
      unitRef="usd">174531000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i3b99930e76ff4d129e26d8c1981c9dee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfNC0yLTEtMS0yNTk4OQ_f5720c61-283f-46d7-8c38-0a143610124d"
      unitRef="usd">32322000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i3b99930e76ff4d129e26d8c1981c9dee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfNC00LTEtMS0yNTk4OQ_836246f4-2439-4c12-a611-df2a250c5621"
      unitRef="usd">0</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i3b99930e76ff4d129e26d8c1981c9dee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfNC02LTEtMS0yNTk4OQ_746c3290-ba3d-4a35-a2e8-4e4905cf65b0"
      unitRef="usd">11000</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i3b99930e76ff4d129e26d8c1981c9dee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfNC04LTEtMS0yNTk4OQ_04b90d57-1dd7-492b-93b1-e9dc318ce9c9"
      unitRef="usd">32311000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ifae0d641d44e4d74bd462bf49ef538ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfNS0yLTEtMS0yNTk4OQ_e71ba771-4533-4afc-9f09-309222c0f34c"
      unitRef="usd">30070000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="ifae0d641d44e4d74bd462bf49ef538ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfNS00LTEtMS0yNTk4OQ_276bb09c-1324-4170-94f3-d06c40bdbbf4"
      unitRef="usd">0</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="ifae0d641d44e4d74bd462bf49ef538ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfNS02LTEtMS0yNTk4OQ_d9e0b052-3b1a-4bfb-abe0-e33bd845c7d7"
      unitRef="usd">14000</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ifae0d641d44e4d74bd462bf49ef538ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfNS04LTEtMS0yNTk4OQ_676d046f-a7c1-4887-bcb4-b030b35cda33"
      unitRef="usd">30056000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9b41065183b64de594c948fc62b3fd96_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfNi0yLTEtMS0yNTk4OQ_f2a3d6d4-9fd3-414c-8a24-bf15e35b8399"
      unitRef="usd">350000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9b41065183b64de594c948fc62b3fd96_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfNi00LTEtMS0yNTk4OQ_6b857400-615e-4237-b05c-eb22722ae0b0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9b41065183b64de594c948fc62b3fd96_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfNi02LTEtMS0yNTk4OQ_873b75a9-0858-43bd-877f-067b80b8e6ba"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9b41065183b64de594c948fc62b3fd96_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfNi04LTEtMS0yNTk4OQ_17bc7194-0c11-4c28-a0c8-ac457cd66f4c"
      unitRef="usd">350000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia21576db6b004494a12be3e92fdd6c66_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfNy0yLTEtMS0yNTk4OQ_a874a0a9-5548-4db8-abe1-b9eb16063047"
      unitRef="usd">51000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia21576db6b004494a12be3e92fdd6c66_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfNy00LTEtMS0yNTk4OQ_3411f2f4-4f97-4fee-9aa9-8998688f9002"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia21576db6b004494a12be3e92fdd6c66_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfNy02LTEtMS0yNTk4OQ_e5f6b1c7-9b95-4e05-8973-7fe0e098e4d9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia21576db6b004494a12be3e92fdd6c66_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfNy04LTEtMS0yNTk4OQ_9efb829d-02f5-4d61-b900-87d4a9a1f37c"
      unitRef="usd">51000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfOC0yLTEtMS0yNTk4OQ_d342a881-bfaf-46b4-9c93-5cdcdceb5a11"
      unitRef="usd">482568000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfOC00LTEtMS0yNTk4OQ_6130b911-62d2-43e6-822b-6dc5a50d5cbd"
      unitRef="usd">7000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfOC02LTEtMS0yNTk4OQ_03cf96cd-175e-43ed-b2a9-4434542b6424"
      unitRef="usd">79000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfOC04LTEtMS0yNTk4OQ_c637e637-01da-45df-93be-83097c921c7a"
      unitRef="usd">482496000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfOS0yLTEtMS0yNTk4OQ_83008671-af62-4bb4-8420-13a0c4c38dc9"
      unitRef="usd">245197000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfOS04LTEtMS0yNTk4OQ_a0fe61e3-6357-4f7c-8e22-ed1d50b1535a"
      unitRef="usd">245197000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfMTAtMi0xLTEtMjU5ODk_62daedef-83c4-4f92-b4da-5c0efe52840c"
      unitRef="usd">237371000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfMTAtNC0xLTEtMjU5ODk_48517f50-1cc0-4ec3-a6cf-4f33b00e6560"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfMTAtNi0xLTEtMjU5ODk_7d93cc56-aa29-431f-95d3-c5a1e0e44e30"
      unitRef="usd">79000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfMTAtOC0xLTEtMjU5ODk_41a6cd50-c9d3-499e-8659-36211db225ae"
      unitRef="usd">237299000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfMTEtMi0xLTEtMjU5ODk_2d5af98f-1688-49c8-8ddc-e10006472aa9"
      unitRef="usd">482568000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfMTEtNC0xLTEtMjU5ODk_88d0d982-0803-464b-8691-f380ebaf38cf"
      unitRef="usd">7000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfMTEtNi0xLTEtMjU5ODk_7b4e6ab4-a1d2-4274-b0e1-801863155b2f"
      unitRef="usd">79000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjZhOGM5YTU3N2I1ZDQwY2E4MDhhNzY5YTc3OGVmNDdiL3RhYmxlcmFuZ2U6NmE4YzlhNTc3YjVkNDBjYTgwOGE3NjlhNzc4ZWY0N2JfMTEtOC0xLTEtMjU5ODk_abb94240-ee55-4ff9-a1dd-771194cbbbf6"
      unitRef="usd">482496000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure>
    <us-gaap:DebtSecuritiesRealizedGainLoss
      contextRef="i7b96f9892c1f46b79e86ebc2d8e82423_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RleHRyZWdpb246MjIwZDc4YzViYTQxNDMzOTkzNTExYzM5NzMzZTQ0YWJfMTk1Ng_610521ee-14f5-463a-a15f-ec9ab36136c0"
      unitRef="usd">0</us-gaap:DebtSecuritiesRealizedGainLoss>
    <us-gaap:DebtSecuritiesRealizedGainLoss
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RleHRyZWdpb246MjIwZDc4YzViYTQxNDMzOTkzNTExYzM5NzMzZTQ0YWJfMTk1Ng_8690377d-9e2b-4359-9bb6-78d9aaaf4077"
      unitRef="usd">0</us-gaap:DebtSecuritiesRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RleHRyZWdpb246MjIwZDc4YzViYTQxNDMzOTkzNTExYzM5NzMzZTQ0YWJfMjUwNA_2b9d0d3d-ecbd-4b31-9190-f6754a824e37"
      unitRef="usd">140500000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RleHRyZWdpb246MjIwZDc4YzViYTQxNDMzOTkzNTExYzM5NzMzZTQ0YWJfMjUxMQ_87dbb3c5-3e85-4a2b-95cb-6ad55c8b99fc"
      unitRef="usd">173400000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RleHRyZWdpb246MjIwZDc4YzViYTQxNDMzOTkzNTExYzM5NzMzZTQ0YWJfMjc5Mg_6e621353-7b29-4b49-816f-5526a28cac67">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;176,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;239,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;179,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjI1MzNhNTQ0NjJkZTRjYjhiM2VlYzMxOTk1MjA3ZDVjL3RhYmxlcmFuZ2U6MjUzM2E1NDQ2MmRlNGNiOGIzZWVjMzE5OTUyMDdkNWNfMi0yLTEtMS0yNTk4OQ_8b623bc0-ea7e-47be-aadd-a684c34c8107"
      unitRef="usd">235639000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibdd0bea669974aef88283f7ce9684c7f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjI1MzNhNTQ0NjJkZTRjYjhiM2VlYzMxOTk1MjA3ZDVjL3RhYmxlcmFuZ2U6MjUzM2E1NDQ2MmRlNGNiOGIzZWVjMzE5OTUyMDdkNWNfMi00LTEtMS0yNTk4OQ_df23d4bf-0688-40f8-bbe5-3f4cda99e1ec"
      unitRef="usd">176538000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjI1MzNhNTQ0NjJkZTRjYjhiM2VlYzMxOTk1MjA3ZDVjL3RhYmxlcmFuZ2U6MjUzM2E1NDQ2MmRlNGNiOGIzZWVjMzE5OTUyMDdkNWNfMy0yLTEtMS0yNTk4OQ_59c43e1b-4bed-4ab1-82dc-f5b9c4ff9a46"
      unitRef="usd">4222000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ibdd0bea669974aef88283f7ce9684c7f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjI1MzNhNTQ0NjJkZTRjYjhiM2VlYzMxOTk1MjA3ZDVjL3RhYmxlcmFuZ2U6MjUzM2E1NDQ2MmRlNGNiOGIzZWVjMzE5OTUyMDdkNWNfMy00LTEtMS0yNTk4OQ_f3a26157-4887-41fe-9fbc-a83cafc56b91"
      unitRef="usd">3250000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjI1MzNhNTQ0NjJkZTRjYjhiM2VlYzMxOTk1MjA3ZDVjL3RhYmxlcmFuZ2U6MjUzM2E1NDQ2MmRlNGNiOGIzZWVjMzE5OTUyMDdkNWNfNC0yLTEtMS0yNTk4OQ_694006f6-435c-495a-b9a9-c87ed642d0e8"
      unitRef="usd">239861000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibdd0bea669974aef88283f7ce9684c7f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80My9mcmFnOjIyMGQ3OGM1YmE0MTQzMzk5MzUxMWMzOTczM2U0NGFiL3RhYmxlOjI1MzNhNTQ0NjJkZTRjYjhiM2VlYzMxOTk1MjA3ZDVjL3RhYmxlcmFuZ2U6MjUzM2E1NDQ2MmRlNGNiOGIzZWVjMzE5OTUyMDdkNWNfNC00LTEtMS0yNTk4OQ_0a85d223-1a34-4516-a800-0d0bb1ccf1bd"
      unitRef="usd">179788000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80Ni9mcmFnOmFiY2NlMWFiMTgzMjQxNTQ4YjFiZTVkYzA3M2ZjNzBmL3RleHRyZWdpb246YWJjY2UxYWIxODMyNDE1NDhiMWJlNWRjMDczZmM3MGZfMjkx_86bca13c-beb8-4b2e-9da0-d2093f48db93">Inventories&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of raw materials, work-in-process, and finished goods related to the manufacture of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The following table summarizes the components of inventories: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded a reserve for inventory of $1.1 million as of both June 30, 2022 and December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80Ni9mcmFnOmFiY2NlMWFiMTgzMjQxNTQ4YjFiZTVkYzA3M2ZjNzBmL3RleHRyZWdpb246YWJjY2UxYWIxODMyNDE1NDhiMWJlNWRjMDczZmM3MGZfMjky_e163e325-0e3c-44a6-b400-f1ec49b67760">The following table summarizes the components of inventories: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80Ni9mcmFnOmFiY2NlMWFiMTgzMjQxNTQ4YjFiZTVkYzA3M2ZjNzBmL3RhYmxlOmI5ZWM1MDdiYzY3NjQwY2NiY2IxYjliNzNjMmY0NzIwL3RhYmxlcmFuZ2U6YjllYzUwN2JjNjc2NDBjY2JjYjFiOWI3M2MyZjQ3MjBfMS0yLTEtMS0yNTk4OQ_7fd23d59-b2a6-4135-8424-68699bf1fbac"
      unitRef="usd">11508000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80Ni9mcmFnOmFiY2NlMWFiMTgzMjQxNTQ4YjFiZTVkYzA3M2ZjNzBmL3RhYmxlOmI5ZWM1MDdiYzY3NjQwY2NiY2IxYjliNzNjMmY0NzIwL3RhYmxlcmFuZ2U6YjllYzUwN2JjNjc2NDBjY2JjYjFiOWI3M2MyZjQ3MjBfMS00LTEtMS0yNTk4OQ_d0af1914-53cc-4c59-bc6d-0ea74677de7b"
      unitRef="usd">12289000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80Ni9mcmFnOmFiY2NlMWFiMTgzMjQxNTQ4YjFiZTVkYzA3M2ZjNzBmL3RhYmxlOmI5ZWM1MDdiYzY3NjQwY2NiY2IxYjliNzNjMmY0NzIwL3RhYmxlcmFuZ2U6YjllYzUwN2JjNjc2NDBjY2JjYjFiOWI3M2MyZjQ3MjBfMi0yLTEtMS0yNTk4OQ_e493ad96-b38c-44fa-9e26-4e4bf31f3b0b"
      unitRef="usd">5943000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80Ni9mcmFnOmFiY2NlMWFiMTgzMjQxNTQ4YjFiZTVkYzA3M2ZjNzBmL3RhYmxlOmI5ZWM1MDdiYzY3NjQwY2NiY2IxYjliNzNjMmY0NzIwL3RhYmxlcmFuZ2U6YjllYzUwN2JjNjc2NDBjY2JjYjFiOWI3M2MyZjQ3MjBfMi00LTEtMS0yNTk4OQ_792469c2-7e35-4454-becd-ae7f320e2ae1"
      unitRef="usd">10699000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80Ni9mcmFnOmFiY2NlMWFiMTgzMjQxNTQ4YjFiZTVkYzA3M2ZjNzBmL3RhYmxlOmI5ZWM1MDdiYzY3NjQwY2NiY2IxYjliNzNjMmY0NzIwL3RhYmxlcmFuZ2U6YjllYzUwN2JjNjc2NDBjY2JjYjFiOWI3M2MyZjQ3MjBfMy0yLTEtMS0yNTk4OQ_1b91a3e9-2a01-4ca1-80e6-1d92e01383b0"
      unitRef="usd">3428000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80Ni9mcmFnOmFiY2NlMWFiMTgzMjQxNTQ4YjFiZTVkYzA3M2ZjNzBmL3RhYmxlOmI5ZWM1MDdiYzY3NjQwY2NiY2IxYjliNzNjMmY0NzIwL3RhYmxlcmFuZ2U6YjllYzUwN2JjNjc2NDBjY2JjYjFiOWI3M2MyZjQ3MjBfMy00LTEtMS0yNTk4OQ_5cc0b5f3-8ff0-4f5a-8e1f-dd684f16b058"
      unitRef="usd">3830000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80Ni9mcmFnOmFiY2NlMWFiMTgzMjQxNTQ4YjFiZTVkYzA3M2ZjNzBmL3RhYmxlOmI5ZWM1MDdiYzY3NjQwY2NiY2IxYjliNzNjMmY0NzIwL3RhYmxlcmFuZ2U6YjllYzUwN2JjNjc2NDBjY2JjYjFiOWI3M2MyZjQ3MjBfNC0yLTEtMS0yNTk4OQ_3010e4d0-39f8-484a-a0ef-17eab418d6b8"
      unitRef="usd">20879000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80Ni9mcmFnOmFiY2NlMWFiMTgzMjQxNTQ4YjFiZTVkYzA3M2ZjNzBmL3RhYmxlOmI5ZWM1MDdiYzY3NjQwY2NiY2IxYjliNzNjMmY0NzIwL3RhYmxlcmFuZ2U6YjllYzUwN2JjNjc2NDBjY2JjYjFiOWI3M2MyZjQ3MjBfNC00LTEtMS0yNTk4OQ_a9644b44-5340-463f-b12f-1a5048e08e93"
      unitRef="usd">26818000</us-gaap:InventoryNet>
    <us-gaap:InventoryValuationReserves
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80Ni9mcmFnOmFiY2NlMWFiMTgzMjQxNTQ4YjFiZTVkYzA3M2ZjNzBmL3RleHRyZWdpb246YWJjY2UxYWIxODMyNDE1NDhiMWJlNWRjMDczZmM3MGZfMjQ4_128b66fb-8953-4130-8d84-9b325ff2ad08"
      unitRef="usd">1100000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80Ni9mcmFnOmFiY2NlMWFiMTgzMjQxNTQ4YjFiZTVkYzA3M2ZjNzBmL3RleHRyZWdpb246YWJjY2UxYWIxODMyNDE1NDhiMWJlNWRjMDczZmM3MGZfMjQ4_cfe2dab4-9dd0-4d1a-a3a6-f324a55505ce"
      unitRef="usd">1100000</us-gaap:InventoryValuationReserves>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RleHRyZWdpb246NjNlYTZhYjkzYWFiNDJmZmI5ZjBmODY4NmMxYWQ5MjVfNDU3_c5bd4395-412a-426c-a72e-4244d8cc753f">Debt &lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's debt consists of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Term Loan due 2026:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: debt discount &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: deferred financing &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,014)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net carrying value of Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;390,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;389,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Included in the Consolidated Balance Sheets within long-term debt and amortized to interest expense over the remaining life of the Senior Secured Term Loan due 2026 using the effective interest rate method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth interest expense recognized related to the Company's debt for the three and six months ended June 30, 2022 and 2021, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:15pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.899%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of deferred financing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RleHRyZWdpb246NjNlYTZhYjkzYWFiNDJmZmI5ZjBmODY4NmMxYWQ5MjVfNDYz_bb2e5c3c-4afa-47b2-b103-55d25a59bad1">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's debt consists of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Term Loan due 2026:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: debt discount &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: deferred financing &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,014)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net carrying value of Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;390,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;389,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Included in the Consolidated Balance Sheets within long-term debt and amortized to interest expense over the remaining life of the Senior Secured Term Loan due 2026 using the effective interest rate method.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7817625b346c448d9777f5897c0b43fb_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOjQ5Y2RkY2FmZGMzZTQ3Zjg4MzQ1OWEyNjVkM2RjNTRlL3RhYmxlcmFuZ2U6NDljZGRjYWZkYzNlNDdmODgzNDU5YTI2NWQzZGM1NGVfMi0yLTEtMS0yNTk4OQ_eb42ef7e-0f7e-46e1-97d9-4548f30f9c36"
      unitRef="usd">400000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i11f9f50188a747e78f96bbbe4336d3aa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOjQ5Y2RkY2FmZGMzZTQ3Zjg4MzQ1OWEyNjVkM2RjNTRlL3RhYmxlcmFuZ2U6NDljZGRjYWZkYzNlNDdmODgzNDU5YTI2NWQzZGM1NGVfMi00LTEtMS0yNTk4OQ_20e17d55-fc5e-45f4-bd1e-1b7e8c2e5638"
      unitRef="usd">400000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i7817625b346c448d9777f5897c0b43fb_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOjQ5Y2RkY2FmZGMzZTQ3Zjg4MzQ1OWEyNjVkM2RjNTRlL3RhYmxlcmFuZ2U6NDljZGRjYWZkYzNlNDdmODgzNDU5YTI2NWQzZGM1NGVfMy0yLTEtMS0yNTk4OQ_a4e7bfe9-d5bc-4e7f-b89f-66359e2ca3ae"
      unitRef="usd">5334000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i11f9f50188a747e78f96bbbe4336d3aa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOjQ5Y2RkY2FmZGMzZTQ3Zjg4MzQ1OWEyNjVkM2RjNTRlL3RhYmxlcmFuZ2U6NDljZGRjYWZkYzNlNDdmODgzNDU5YTI2NWQzZGM1NGVfMy00LTEtMS0yNTk4OQ_c0c48552-eda3-4f9d-a987-9ba534cad14f"
      unitRef="usd">6074000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredOfferingCosts
      contextRef="i7817625b346c448d9777f5897c0b43fb_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOjQ5Y2RkY2FmZGMzZTQ3Zjg4MzQ1OWEyNjVkM2RjNTRlL3RhYmxlcmFuZ2U6NDljZGRjYWZkYzNlNDdmODgzNDU5YTI2NWQzZGM1NGVfNC0yLTEtMS0yNTk4OQ_9596fee1-4c00-422a-806b-3f8fdb543764"
      unitRef="usd">4014000</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="i11f9f50188a747e78f96bbbe4336d3aa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOjQ5Y2RkY2FmZGMzZTQ3Zjg4MzQ1OWEyNjVkM2RjNTRlL3RhYmxlcmFuZ2U6NDljZGRjYWZkYzNlNDdmODgzNDU5YTI2NWQzZGM1NGVfNC00LTEtMS0yNTk4OQ_eeb04c6a-909d-4daf-8cfc-e9277eacb18c"
      unitRef="usd">4569000</us-gaap:DeferredOfferingCosts>
    <us-gaap:LongTermDebt
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOjQ5Y2RkY2FmZGMzZTQ3Zjg4MzQ1OWEyNjVkM2RjNTRlL3RhYmxlcmFuZ2U6NDljZGRjYWZkYzNlNDdmODgzNDU5YTI2NWQzZGM1NGVfNS0yLTEtMS0yNTk4OQ_d98d92f2-4ae6-4705-bbae-7c540016400f"
      unitRef="usd">390652000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOjQ5Y2RkY2FmZGMzZTQ3Zjg4MzQ1OWEyNjVkM2RjNTRlL3RhYmxlcmFuZ2U6NDljZGRjYWZkYzNlNDdmODgzNDU5YTI2NWQzZGM1NGVfNS00LTEtMS0yNTk4OQ_3508fdc6-7c60-41e1-9de2-e2a4f78c3083"
      unitRef="usd">389357000</us-gaap:LongTermDebt>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RleHRyZWdpb246NjNlYTZhYjkzYWFiNDJmZmI5ZjBmODY4NmMxYWQ5MjVfNDU2_85ac7693-4517-4d04-8ed0-75ad051358c7">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth interest expense recognized related to the Company's debt for the three and six months ended June 30, 2022 and 2021, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:15pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.899%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of deferred financing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOmY5OWRlYjU3M2ExNTQ4MmE5NzIwMGYxYmVjN2MzODVkL3RhYmxlcmFuZ2U6Zjk5ZGViNTczYTE1NDgyYTk3MjAwZjFiZWM3YzM4NWRfMi0yLTEtMS0yNTk4OQ_1312fef6-4b85-4e88-bce7-456563116638"
      unitRef="usd">7589000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOmY5OWRlYjU3M2ExNTQ4MmE5NzIwMGYxYmVjN2MzODVkL3RhYmxlcmFuZ2U6Zjk5ZGViNTczYTE1NDgyYTk3MjAwZjFiZWM3YzM4NWRfMi00LTEtMS0yNTk4OQ_55405f10-ac8b-454a-bb0a-234bf62d4618"
      unitRef="usd">7604000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOmY5OWRlYjU3M2ExNTQ4MmE5NzIwMGYxYmVjN2MzODVkL3RhYmxlcmFuZ2U6Zjk5ZGViNTczYTE1NDgyYTk3MjAwZjFiZWM3YzM4NWRfMi02LTEtMS0yNzc3NA_50cd898a-c23b-435a-822e-78d0ff176f4d"
      unitRef="usd">15089000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOmY5OWRlYjU3M2ExNTQ4MmE5NzIwMGYxYmVjN2MzODVkL3RhYmxlcmFuZ2U6Zjk5ZGViNTczYTE1NDgyYTk3MjAwZjFiZWM3YzM4NWRfMi03LTEtMS0yNjkxMA_296823dd-bfb0-4a57-95fa-f7caf9ea27f7"
      unitRef="usd">15125000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOmY5OWRlYjU3M2ExNTQ4MmE5NzIwMGYxYmVjN2MzODVkL3RhYmxlcmFuZ2U6Zjk5ZGViNTczYTE1NDgyYTk3MjAwZjFiZWM3YzM4NWRfMy0yLTEtMS0yNTk4OQ_dfad0efc-b23a-44e3-be1e-47924993e481"
      unitRef="usd">375000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOmY5OWRlYjU3M2ExNTQ4MmE5NzIwMGYxYmVjN2MzODVkL3RhYmxlcmFuZ2U6Zjk5ZGViNTczYTE1NDgyYTk3MjAwZjFiZWM3YzM4NWRfMy00LTEtMS0yNTk4OQ_ab41377a-e15e-479f-a9db-b8f594f8fff6"
      unitRef="usd">383000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOmY5OWRlYjU3M2ExNTQ4MmE5NzIwMGYxYmVjN2MzODVkL3RhYmxlcmFuZ2U6Zjk5ZGViNTczYTE1NDgyYTk3MjAwZjFiZWM3YzM4NWRfMy02LTEtMS0yNzc3NA_0bbf25c0-1512-439a-941d-b5b023d50dcb"
      unitRef="usd">739000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOmY5OWRlYjU3M2ExNTQ4MmE5NzIwMGYxYmVjN2MzODVkL3RhYmxlcmFuZ2U6Zjk5ZGViNTczYTE1NDgyYTk3MjAwZjFiZWM3YzM4NWRfMy03LTEtMS0yNjkxMA_d76b66d1-98ab-4aeb-9cb8-492db67109db"
      unitRef="usd">720000</us-gaap:AmortizationOfDebtDiscountPremium>
    <fold:AmortizationDeferredFinancingCosts
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOmY5OWRlYjU3M2ExNTQ4MmE5NzIwMGYxYmVjN2MzODVkL3RhYmxlcmFuZ2U6Zjk5ZGViNTczYTE1NDgyYTk3MjAwZjFiZWM3YzM4NWRfNC0yLTEtMS0yNTk4OQ_d18555e1-9165-4e44-9eaa-cd5614952a41"
      unitRef="usd">283000</fold:AmortizationDeferredFinancingCosts>
    <fold:AmortizationDeferredFinancingCosts
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOmY5OWRlYjU3M2ExNTQ4MmE5NzIwMGYxYmVjN2MzODVkL3RhYmxlcmFuZ2U6Zjk5ZGViNTczYTE1NDgyYTk3MjAwZjFiZWM3YzM4NWRfNC00LTEtMS0yNTk4OQ_e9305902-f161-46e8-8dd0-ee1c5a8782ab"
      unitRef="usd">262000</fold:AmortizationDeferredFinancingCosts>
    <fold:AmortizationDeferredFinancingCosts
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOmY5OWRlYjU3M2ExNTQ4MmE5NzIwMGYxYmVjN2MzODVkL3RhYmxlcmFuZ2U6Zjk5ZGViNTczYTE1NDgyYTk3MjAwZjFiZWM3YzM4NWRfNC02LTEtMS0yNzc3NA_cef02c01-250e-4097-9d07-ee0a5416b59e"
      unitRef="usd">556000</fold:AmortizationDeferredFinancingCosts>
    <fold:AmortizationDeferredFinancingCosts
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV80OS9mcmFnOjYzZWE2YWI5M2FhYjQyZmZiOWYwZjg2ODZjMWFkOTI1L3RhYmxlOmY5OWRlYjU3M2ExNTQ4MmE5NzIwMGYxYmVjN2MzODVkL3RhYmxlcmFuZ2U6Zjk5ZGViNTczYTE1NDgyYTk3MjAwZjFiZWM3YzM4NWRfNC03LTEtMS0yNjkxMA_b7dfebc3-1bdd-48cc-b751-e6f12f0ec24d"
      unitRef="usd">485000</fold:AmortizationDeferredFinancingCosts>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RleHRyZWdpb246ODM3NGZmYzRlMTI5NDJlN2I5MzM5OGQ3NmQ0YjNkOTJfMjM0OA_c359229b-23eb-455f-9490-31ff2b16aedd">Share-Based CompensationThe Company's Amended and Restated 2007 Equity Incentive Plan (the "Plan") provides for the granting of restricted stock units and options to purchase common stock in the Company to employees, directors, advisors, and consultants at a price to be determined by the Company's Board of Directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company's business. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option. &lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Option Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.154%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected life of options (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected annual dividend per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;A summary of the Company's stock options for the six months ended June 30, 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.479%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise&#160;&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining &lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options outstanding, June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested and unvested expected to vest, June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2022, the total unrecognized compensation cost related to non-vested stock options granted was $39.5 million and is expected to be recognized over a weighted average period of three years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;and Performance-Based Restricted Stock Units (collectively "RSUs")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs awarded under the Plan are generally subject to graded vesting and are contingent on an employee's continued service. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. A summary of non-vested RSU activity under the Plan for the six months ended June 30, 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.789%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average Grant&lt;br/&gt;Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;br/&gt;Average&lt;br/&gt;Remaining&#160;&lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-vested units as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,738)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(252)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-vested units as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All non-vested units are expected to vest over their normal term. As of June 30, 2022, there was $65.8 million of total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions. These costs are expected to be recognized over a weighted average period of two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation Expense Related to Equity Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.702%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total equity compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RleHRyZWdpb246ODM3NGZmYzRlMTI5NDJlN2I5MzM5OGQ3NmQ0YjNkOTJfMjM0MQ_fc53174d-d9f4-4299-b72d-275dc3862c56">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.154%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected life of options (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected annual dividend per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i7db5d4a26355471cb3592c15bd783d1c_D20220401-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjY2ZWYyNGUxMDExYzRiNTZhNjYzMzM3ODJkZTc5YzE2L3RhYmxlcmFuZ2U6NjZlZjI0ZTEwMTFjNGI1NmE2NjMzMzc4MmRlNzljMTZfMi0xLTEtMS0yNTk4OQ_1d57a329-ae42-4df8-a9a3-5aa4ff8dd72a"
      unitRef="number">0.613</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i4699991b02604e23976f7eb8d6c9a55f_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjY2ZWYyNGUxMDExYzRiNTZhNjYzMzM3ODJkZTc5YzE2L3RhYmxlcmFuZ2U6NjZlZjI0ZTEwMTFjNGI1NmE2NjMzMzc4MmRlNzljMTZfMi0zLTEtMS0yNTk4OQ_aae78047-b908-4118-bf32-ee0bc18d4cf2"
      unitRef="number">0.655</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i5d570dfe70e7454f85640ff0afc44736_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjY2ZWYyNGUxMDExYzRiNTZhNjYzMzM3ODJkZTc5YzE2L3RhYmxlcmFuZ2U6NjZlZjI0ZTEwMTFjNGI1NmE2NjMzMzc4MmRlNzljMTZfMi01LTEtMS0yNzE2MQ_88069161-0048-4a8f-b9f0-79528f4e2948"
      unitRef="number">0.622</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i3501524d91e94a18bfac0415f9e68531_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjY2ZWYyNGUxMDExYzRiNTZhNjYzMzM3ODJkZTc5YzE2L3RhYmxlcmFuZ2U6NjZlZjI0ZTEwMTFjNGI1NmE2NjMzMzc4MmRlNzljMTZfMi02LTEtMS0yNjkyNw_adf36898-8f41-41c9-a36a-340427914464"
      unitRef="number">0.664</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i7db5d4a26355471cb3592c15bd783d1c_D20220401-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjY2ZWYyNGUxMDExYzRiNTZhNjYzMzM3ODJkZTc5YzE2L3RhYmxlcmFuZ2U6NjZlZjI0ZTEwMTFjNGI1NmE2NjMzMzc4MmRlNzljMTZfMy0xLTEtMS0yNTk4OQ_5521678a-d95c-4531-8376-6ca7cc57489a"
      unitRef="number">0.030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i4699991b02604e23976f7eb8d6c9a55f_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjY2ZWYyNGUxMDExYzRiNTZhNjYzMzM3ODJkZTc5YzE2L3RhYmxlcmFuZ2U6NjZlZjI0ZTEwMTFjNGI1NmE2NjMzMzc4MmRlNzljMTZfMy0zLTEtMS0yNTk4OQ_1dfdd281-3a56-42d4-b0e9-ca9b06c6d166"
      unitRef="number">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i5d570dfe70e7454f85640ff0afc44736_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjY2ZWYyNGUxMDExYzRiNTZhNjYzMzM3ODJkZTc5YzE2L3RhYmxlcmFuZ2U6NjZlZjI0ZTEwMTFjNGI1NmE2NjMzMzc4MmRlNzljMTZfMy01LTEtMS0yNzE2MQ_bec5a0bb-451c-420e-b366-878cea8f0e09"
      unitRef="number">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i3501524d91e94a18bfac0415f9e68531_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjY2ZWYyNGUxMDExYzRiNTZhNjYzMzM3ODJkZTc5YzE2L3RhYmxlcmFuZ2U6NjZlZjI0ZTEwMTFjNGI1NmE2NjMzMzc4MmRlNzljMTZfMy02LTEtMS0yNjkyNw_5f68cea5-78fb-40de-89bd-d46385c3177a"
      unitRef="number">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7db5d4a26355471cb3592c15bd783d1c_D20220401-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjY2ZWYyNGUxMDExYzRiNTZhNjYzMzM3ODJkZTc5YzE2L3RhYmxlcmFuZ2U6NjZlZjI0ZTEwMTFjNGI1NmE2NjMzMzc4MmRlNzljMTZfNC0xLTEtMS0yNTk4OQ_75ec4c81-38b4-4422-b8f5-1d124b66930c">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4699991b02604e23976f7eb8d6c9a55f_D20210401-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjY2ZWYyNGUxMDExYzRiNTZhNjYzMzM3ODJkZTc5YzE2L3RhYmxlcmFuZ2U6NjZlZjI0ZTEwMTFjNGI1NmE2NjMzMzc4MmRlNzljMTZfNC0zLTEtMS0yNTk4OQ_386717bb-0850-469b-82af-99ddc0e0578b">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i5d570dfe70e7454f85640ff0afc44736_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjY2ZWYyNGUxMDExYzRiNTZhNjYzMzM3ODJkZTc5YzE2L3RhYmxlcmFuZ2U6NjZlZjI0ZTEwMTFjNGI1NmE2NjMzMzc4MmRlNzljMTZfNC01LTEtMS0yNzE2MQ_dec3494f-55c8-47cc-a61d-4e37fa3a8879">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i3501524d91e94a18bfac0415f9e68531_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjY2ZWYyNGUxMDExYzRiNTZhNjYzMzM3ODJkZTc5YzE2L3RhYmxlcmFuZ2U6NjZlZjI0ZTEwMTFjNGI1NmE2NjMzMzc4MmRlNzljMTZfNC02LTEtMS0yNjkyNw_922fa5ff-ed23-4c80-b45e-35b31a2f74b1">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare
      contextRef="i7db5d4a26355471cb3592c15bd783d1c_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjY2ZWYyNGUxMDExYzRiNTZhNjYzMzM3ODJkZTc5YzE2L3RhYmxlcmFuZ2U6NjZlZjI0ZTEwMTFjNGI1NmE2NjMzMzc4MmRlNzljMTZfNS0xLTEtMS0yNTk4OQ_8ad1bea3-2abb-4fa4-8af7-734ffd610600"
      unitRef="cadPerShare">0</fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare>
    <fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare
      contextRef="i4699991b02604e23976f7eb8d6c9a55f_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjY2ZWYyNGUxMDExYzRiNTZhNjYzMzM3ODJkZTc5YzE2L3RhYmxlcmFuZ2U6NjZlZjI0ZTEwMTFjNGI1NmE2NjMzMzc4MmRlNzljMTZfNS0zLTEtMS0yNTk4OQ_dff68c29-e602-4bfe-9fc0-ca311628fc46"
      unitRef="cadPerShare">0</fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare>
    <fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare
      contextRef="i5d570dfe70e7454f85640ff0afc44736_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjY2ZWYyNGUxMDExYzRiNTZhNjYzMzM3ODJkZTc5YzE2L3RhYmxlcmFuZ2U6NjZlZjI0ZTEwMTFjNGI1NmE2NjMzMzc4MmRlNzljMTZfNS01LTEtMS0yNzE2MQ_a91c6c4f-055c-4086-9577-83957cef9556"
      unitRef="cadPerShare">0</fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare>
    <fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare
      contextRef="i3501524d91e94a18bfac0415f9e68531_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjY2ZWYyNGUxMDExYzRiNTZhNjYzMzM3ODJkZTc5YzE2L3RhYmxlcmFuZ2U6NjZlZjI0ZTEwMTFjNGI1NmE2NjMzMzc4MmRlNzljMTZfNS03LTEtMS0yNzE2Ng_4f454e91-eb19-4452-83c0-7ba92ce120c7"
      unitRef="cadPerShare">0</fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RleHRyZWdpb246ODM3NGZmYzRlMTI5NDJlN2I5MzM5OGQ3NmQ0YjNkOTJfMjM2MQ_773ac1c0-1396-4f1e-b8cb-0dfa9456e40c">A summary of the Company's stock options for the six months ended June 30, 2022 were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.479%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise&#160;&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining &lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options outstanding, June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested and unvested expected to vest, June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfMi0xLTEtMS0yNTk4OQ_abbff6c3-09dc-442b-ae86-4f0ca947a2eb"
      unitRef="shares">14731000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfMi0zLTEtMS0yNTk4OQ_ae6ca333-af1c-4f49-a657-ac543ed98ab7"
      unitRef="cadPerShare">11.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfMy0xLTEtMS0yNTk4OQ_54a3005d-8a33-447d-88fa-765a8a7ac03c"
      unitRef="shares">5402000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfMy0zLTEtMS0yNTk4OQ_0247dffd-db99-4e5c-8795-84962e1890ac"
      unitRef="cadPerShare">11.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfNC0xLTEtMS0yNTk4OQ_ab36e165-eeca-4f16-b265-aea09b35182e"
      unitRef="shares">339000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfNC0zLTEtMS0yNTk4OQ_aae31d62-f282-43c0-82ae-640083318fb6"
      unitRef="cadPerShare">5.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfNS0xLTEtMS0yNTk4OQ_2c83bcb6-9b87-4c47-a9bb-4df0bd20a336"
      unitRef="shares">333000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfNS0zLTEtMS0yNTk4OQ_527be906-75d9-497f-b00c-55617b68bf48"
      unitRef="cadPerShare">12.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfNi0xLTEtMS0yNTk4OQ_aa528777-d2a8-445a-a348-5232db4b3fdf"
      unitRef="shares">178000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfNi0zLTEtMS0yNTk4OQ_9e549afc-71f3-49a5-866a-43e7880dad00"
      unitRef="cadPerShare">11.98</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfNy0xLTEtMS0yNTk4OQ_3d7ad4f0-9b01-4cdb-b778-48828fbf345b"
      unitRef="shares">19283000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfNy0zLTEtMS0yNTk4OQ_b23c8968-0ab6-4c7d-9062-f13c7dcf36ce"
      unitRef="cadPerShare">11.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfNy01LTEtMS0yNTk4OQ_21d9d7c7-0f71-4138-adc2-4b4cb2e9d141">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfNy03LTEtMS0yNTk4OQ_82cccb85-7479-499c-8a82-2a1657705395"
      unitRef="usd">22200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfOC0xLTEtMS0yNTk4OQ_6e43e609-0aa0-4afd-bd7d-55d50b183ea7"
      unitRef="shares">17589000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfOC0zLTEtMS0yNTk4OQ_26975482-39ae-402a-9ce9-0c7d8e5c4325"
      unitRef="cadPerShare">11.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfOC01LTEtMS0yNTk4OQ_fd17c951-f875-459d-a7e6-9dda70cd4dcf">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfOC03LTEtMS0yNTk4OQ_7137b298-2f06-4fbc-894c-7ae508b4de26"
      unitRef="usd">21500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfOS0xLTEtMS0yNTk4OQ_f8af5a4a-1b28-4687-8e54-8ce1e601a7a9"
      unitRef="shares">10377000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfOS0zLTEtMS0yNTk4OQ_2cfc3113-0bba-47e8-bdcc-1899fccaa33c"
      unitRef="cadPerShare">10.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfOS01LTEtMS0yNTk4OQ_2dd7455d-d91d-4028-a979-338b0db2e58f">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjYwYTNmOTI2M2ViMjRjNDY5N2VlNjQzYmU5ZmM2NWU3L3RhYmxlcmFuZ2U6NjBhM2Y5MjYzZWIyNGM0Njk3ZWU2NDNiZTlmYzY1ZTdfOS03LTEtMS0yNTk4OQ_22f51c11-70e9-4565-ba55-524fb27f9517"
      unitRef="usd">18300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i4c027874ad0b4c14b107e9e7d4d2a4b3_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RleHRyZWdpb246ODM3NGZmYzRlMTI5NDJlN2I5MzM5OGQ3NmQ0YjNkOTJfMTEzMw_f8e32a97-2760-43d5-b03d-8ac6f5005efc"
      unitRef="usd">39500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i5d570dfe70e7454f85640ff0afc44736_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RleHRyZWdpb246ODM3NGZmYzRlMTI5NDJlN2I5MzM5OGQ3NmQ0YjNkOTJfMTIwMw_63ea5a4a-0cfb-434b-a2bb-da0640f938dd">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RleHRyZWdpb246ODM3NGZmYzRlMTI5NDJlN2I5MzM5OGQ3NmQ0YjNkOTJfMjM1MQ_4be27adf-cadc-4959-ad8d-28b09ffc4516">A summary of non-vested RSU activity under the Plan for the six months ended June 30, 2022 is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.789%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average Grant&lt;br/&gt;Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;br/&gt;Average&lt;br/&gt;Remaining&#160;&lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-vested units as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,738)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(252)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-vested units as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i2ccbe1db3305487c82f9fcfe73e288b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOmEzYTBhMWFiZTIyODQ5Njg4YWYxNDgyMTVjMWI3ZWZjL3RhYmxlcmFuZ2U6YTNhMGExYWJlMjI4NDk2ODhhZjE0ODIxNWMxYjdlZmNfMi0xLTEtMS0yNTk4OQ_87cc542d-f7df-430b-95e0-399abc373edd"
      unitRef="shares">7341000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i2ccbe1db3305487c82f9fcfe73e288b9_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOmEzYTBhMWFiZTIyODQ5Njg4YWYxNDgyMTVjMWI3ZWZjL3RhYmxlcmFuZ2U6YTNhMGExYWJlMjI4NDk2ODhhZjE0ODIxNWMxYjdlZmNfMi0zLTEtMS0yNTk4OQ_899d072a-b68a-4d65-950e-151780ea2044"
      unitRef="cadPerShare">13.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i245ad67e6079446eae628bd054c5451c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOmEzYTBhMWFiZTIyODQ5Njg4YWYxNDgyMTVjMWI3ZWZjL3RhYmxlcmFuZ2U6YTNhMGExYWJlMjI4NDk2ODhhZjE0ODIxNWMxYjdlZmNfMy0xLTEtMS0yNTk4OQ_a5cbbd68-5df5-4053-b591-c90e5b50b81e"
      unitRef="shares">4815000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i245ad67e6079446eae628bd054c5451c_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOmEzYTBhMWFiZTIyODQ5Njg4YWYxNDgyMTVjMWI3ZWZjL3RhYmxlcmFuZ2U6YTNhMGExYWJlMjI4NDk2ODhhZjE0ODIxNWMxYjdlZmNfMy0zLTEtMS0yNTk4OQ_cd776bd4-d3e2-4451-92b8-afe6d4986786"
      unitRef="cadPerShare">11.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i245ad67e6079446eae628bd054c5451c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOmEzYTBhMWFiZTIyODQ5Njg4YWYxNDgyMTVjMWI3ZWZjL3RhYmxlcmFuZ2U6YTNhMGExYWJlMjI4NDk2ODhhZjE0ODIxNWMxYjdlZmNfNC0xLTEtMS0yNTk4OQ_89fd6dc0-92fd-4767-bb83-3c47a0def3f6"
      unitRef="shares">1738000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i245ad67e6079446eae628bd054c5451c_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOmEzYTBhMWFiZTIyODQ5Njg4YWYxNDgyMTVjMWI3ZWZjL3RhYmxlcmFuZ2U6YTNhMGExYWJlMjI4NDk2ODhhZjE0ODIxNWMxYjdlZmNfNC0zLTEtMS0yNTk4OQ_418e6173-bcba-4acf-8b90-e5bcf959b5e1"
      unitRef="cadPerShare">12.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i245ad67e6079446eae628bd054c5451c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOmEzYTBhMWFiZTIyODQ5Njg4YWYxNDgyMTVjMWI3ZWZjL3RhYmxlcmFuZ2U6YTNhMGExYWJlMjI4NDk2ODhhZjE0ODIxNWMxYjdlZmNfNS0xLTEtMS0yNTk4OQ_b7e228d4-e6ae-4f04-9d2d-d60713d74238"
      unitRef="shares">252000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i245ad67e6079446eae628bd054c5451c_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOmEzYTBhMWFiZTIyODQ5Njg4YWYxNDgyMTVjMWI3ZWZjL3RhYmxlcmFuZ2U6YTNhMGExYWJlMjI4NDk2ODhhZjE0ODIxNWMxYjdlZmNfNS0zLTEtMS0yNTk4OQ_0605898a-a213-4afb-839c-3260ef78d525"
      unitRef="cadPerShare">12.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i45525b12c16f4e50b69bac633525c7c7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOmEzYTBhMWFiZTIyODQ5Njg4YWYxNDgyMTVjMWI3ZWZjL3RhYmxlcmFuZ2U6YTNhMGExYWJlMjI4NDk2ODhhZjE0ODIxNWMxYjdlZmNfNi0xLTEtMS0yNTk4OQ_c467d0b5-1949-4abc-a383-bae9eb8de75a"
      unitRef="shares">10166000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i45525b12c16f4e50b69bac633525c7c7_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOmEzYTBhMWFiZTIyODQ5Njg4YWYxNDgyMTVjMWI3ZWZjL3RhYmxlcmFuZ2U6YTNhMGExYWJlMjI4NDk2ODhhZjE0ODIxNWMxYjdlZmNfNi0zLTEtMS0yNTk4OQ_5a6356c8-3bf2-45fa-b277-e233bd07c850"
      unitRef="cadPerShare">13.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i245ad67e6079446eae628bd054c5451c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOmEzYTBhMWFiZTIyODQ5Njg4YWYxNDgyMTVjMWI3ZWZjL3RhYmxlcmFuZ2U6YTNhMGExYWJlMjI4NDk2ODhhZjE0ODIxNWMxYjdlZmNfNi01LTEtMS0yNTk4OQ_7f4f288f-c311-422d-a958-3dd670cedbab">P2Y4M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="i45525b12c16f4e50b69bac633525c7c7_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOmEzYTBhMWFiZTIyODQ5Njg4YWYxNDgyMTVjMWI3ZWZjL3RhYmxlcmFuZ2U6YTNhMGExYWJlMjI4NDk2ODhhZjE0ODIxNWMxYjdlZmNfNi03LTEtMS0yNTk4OQ_36ca2711-4955-4b16-a7fb-bb98cf481423"
      unitRef="usd">109200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i45525b12c16f4e50b69bac633525c7c7_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RleHRyZWdpb246ODM3NGZmYzRlMTI5NDJlN2I5MzM5OGQ3NmQ0YjNkOTJfMTk0Ng_d74a51f9-3a79-4680-acbd-a08b0fc4a919"
      unitRef="usd">65800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i245ad67e6079446eae628bd054c5451c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RleHRyZWdpb246ODM3NGZmYzRlMTI5NDJlN2I5MzM5OGQ3NmQ0YjNkOTJfMjEyOQ_7c3a8a3d-5cdf-4344-92ca-04e38b309315">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RleHRyZWdpb246ODM3NGZmYzRlMTI5NDJlN2I5MzM5OGQ3NmQ0YjNkOTJfMjM1Nw_a112233c-5d0f-483e-ac28-17a369f07083">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.702%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total equity compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4e34834a2be94b8e8074f10f13edbcb6_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjhjZjBjZjkxZmIxNjQxNDc4Yjk5MDhjNTFkZGJlY2ZiL3RhYmxlcmFuZ2U6OGNmMGNmOTFmYjE2NDE0NzhiOTkwOGM1MWRkYmVjZmJfMi0yLTEtMS0yNTk4OQ_b7abddc3-4413-453d-a307-09b54f3c8529"
      unitRef="usd">4379000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iabd36bef22694ce9b71e55b1717ed5db_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjhjZjBjZjkxZmIxNjQxNDc4Yjk5MDhjNTFkZGJlY2ZiL3RhYmxlcmFuZ2U6OGNmMGNmOTFmYjE2NDE0NzhiOTkwOGM1MWRkYmVjZmJfMi00LTEtMS0yNTk4OQ_cd73e24d-2d71-4306-9654-43ef13912967"
      unitRef="usd">3152000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i613cc31dd21945f18cc9aca69ab98da3_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjhjZjBjZjkxZmIxNjQxNDc4Yjk5MDhjNTFkZGJlY2ZiL3RhYmxlcmFuZ2U6OGNmMGNmOTFmYjE2NDE0NzhiOTkwOGM1MWRkYmVjZmJfMi02LTEtMS0yNzE3OQ_0bad032c-35b8-482b-bcca-24688ff2734b"
      unitRef="usd">13744000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1b06cd373bbe47dcbce2f3dabed11f52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjhjZjBjZjkxZmIxNjQxNDc4Yjk5MDhjNTFkZGJlY2ZiL3RhYmxlcmFuZ2U6OGNmMGNmOTFmYjE2NDE0NzhiOTkwOGM1MWRkYmVjZmJfMi04LTEtMS0yNjk1Mw_2b015f11-7e11-4475-afb6-8a9e3dc1efd5"
      unitRef="usd">9457000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie40dbd39b0544892a3797b1b64ad108e_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjhjZjBjZjkxZmIxNjQxNDc4Yjk5MDhjNTFkZGJlY2ZiL3RhYmxlcmFuZ2U6OGNmMGNmOTFmYjE2NDE0NzhiOTkwOGM1MWRkYmVjZmJfMy0yLTEtMS0yNTk4OQ_52189f54-0a1f-4fc5-9ffa-ab4310f34799"
      unitRef="usd">8084000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1217c1798fd34a71be289e7051cd1b47_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjhjZjBjZjkxZmIxNjQxNDc4Yjk5MDhjNTFkZGJlY2ZiL3RhYmxlcmFuZ2U6OGNmMGNmOTFmYjE2NDE0NzhiOTkwOGM1MWRkYmVjZmJfMy00LTEtMS0yNTk4OQ_2853918f-949a-4c5f-97a1-451e19142a4b"
      unitRef="usd">8584000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id4c83b69fa62485e98e97922a5e49b57_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjhjZjBjZjkxZmIxNjQxNDc4Yjk5MDhjNTFkZGJlY2ZiL3RhYmxlcmFuZ2U6OGNmMGNmOTFmYjE2NDE0NzhiOTkwOGM1MWRkYmVjZmJfMy02LTEtMS0yNzE3OQ_b1809426-d644-4584-aa0e-8890499e1fea"
      unitRef="usd">29370000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i659ab50b47154e78b47ef9e839307808_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjhjZjBjZjkxZmIxNjQxNDc4Yjk5MDhjNTFkZGJlY2ZiL3RhYmxlcmFuZ2U6OGNmMGNmOTFmYjE2NDE0NzhiOTkwOGM1MWRkYmVjZmJfMy04LTEtMS0yNjk1Mw_f9b3efc5-3df6-475b-a447-c2b0cac70cf0"
      unitRef="usd">22633000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjhjZjBjZjkxZmIxNjQxNDc4Yjk5MDhjNTFkZGJlY2ZiL3RhYmxlcmFuZ2U6OGNmMGNmOTFmYjE2NDE0NzhiOTkwOGM1MWRkYmVjZmJfNC0yLTEtMS0yNTk4OQ_0ff9e6f1-dbd5-4492-bf55-119248efdfcb"
      unitRef="usd">12463000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjhjZjBjZjkxZmIxNjQxNDc4Yjk5MDhjNTFkZGJlY2ZiL3RhYmxlcmFuZ2U6OGNmMGNmOTFmYjE2NDE0NzhiOTkwOGM1MWRkYmVjZmJfNC00LTEtMS0yNTk4OQ_f1d9c725-8c36-4eb3-a030-97021102575c"
      unitRef="usd">11736000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjhjZjBjZjkxZmIxNjQxNDc4Yjk5MDhjNTFkZGJlY2ZiL3RhYmxlcmFuZ2U6OGNmMGNmOTFmYjE2NDE0NzhiOTkwOGM1MWRkYmVjZmJfNC02LTEtMS0yNzc3OQ_aefe2a15-a47a-41ae-893e-a63287addd06"
      unitRef="usd">43114000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81Mi9mcmFnOjgzNzRmZmM0ZTEyOTQyZTdiOTMzOThkNzZkNGIzZDkyL3RhYmxlOjhjZjBjZjkxZmIxNjQxNDc4Yjk5MDhjNTFkZGJlY2ZiL3RhYmxlcmFuZ2U6OGNmMGNmOTFmYjE2NDE0NzhiOTkwOGM1MWRkYmVjZmJfNC04LTEtMS0yNzc3OQ_e9f3572e-40cb-4848-9b54-62382774faab"
      unitRef="usd">32090000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RleHRyZWdpb246NDNkNjcxZTdjYjJhNDc5MGFjMWVjMjM3YTM0MTc0YjFfMzk4Mw_8f55a5b8-a871-4522-a5d5-4ab16f2f16c4">Assets and Liabilities Measured at Fair Value&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial assets and liabilities are measured at fair value and classified within the fair value hierarchy, which is defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Inputs that are unobservable for the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of June 30, 2022 are identified in the following tables:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;156,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;156,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2021 are identified in the following tables:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;174,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;174,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;242,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;242,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.193%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Senior Secured Term Loan due 2026 falls into the Level 2 category within the fair value level hierarchy and the fair value was determined using quoted prices for similar liabilities in active markets, as well as inputs that are observable for the liability (other than quoted prices), such as interest rates that are observable at commonly quoted intervals. The carrying value of the Senior Secured Term Loan due 2026 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;approximates the fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have any Level 3 assets as of June 30, 2022 or December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Money Market Funds, and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies its cash within the fair value hierarchy as Level&#160;1 as these assets are valued using quoted prices in an active market for identical assets at the measurement date. The Company considers its investments in marketable securities as available-for-sale and classifies these assets and the money market funds within the fair value hierarchy as Level&#160;2 primarily utilizing broker quotes in a non-active market for valuation of these securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration payable resulted from the acquisition of Callidus Biopharma, Inc. ("Callidus") in November 2013. The most recent valuation was determined using a probability weighted discounted cash flow valuation approach. Gains and losses are included in the Consolidated Statements of Operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration payable for Callidus has been classified as a Level 3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market.&#160;If different assumptions &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;were used for the various inputs to the valuation approach, the estimated fair value could be significantly higher or lower than the fair value the Company determined. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB200 Pompe disease program: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contingent&#160;Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation&#160;Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable&#160;Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Clinical and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Probability weighted discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Probability of achievement of milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75% - 88%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Projected year of payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022 - 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration liabilities are remeasured to fair value each reporting period using discount rates, probabilities of payment, and projected payment dates. Projected contingent payment amounts related to clinical and regulatory based milestones are discounted back to the current period using a discounted cash flow model. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs together, or in isolation, may result in a significantly lower or higher fair value measurement. There is no assurance that any of the conditions for the milestone payments will be met. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the change in the balance of contingent consideration payable for the three and six months ended June 30, 2022 and 2021, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.702%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance, beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in fair value during the period, included in the Consolidated Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,073)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance, end of the period &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; As certain milestones are expected to be reached within the next twelve months, the June 30, 2022 balance was recorded as a current liability in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RleHRyZWdpb246NDNkNjcxZTdjYjJhNDc5MGFjMWVjMjM3YTM0MTc0YjFfMzk3MA_2b7376f2-a4ec-499b-a590-bf0e1d370a8b">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of June 30, 2022 are identified in the following tables:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;156,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;156,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2021 are identified in the following tables:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;174,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;174,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;242,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;242,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.193%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie9f84953690247a48cc8d3be225dedce_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmY0ODczOTFiNTg3ZDQ1ZGRiMDYzNDA1NTAyMmMyYmZkL3RhYmxlcmFuZ2U6ZjQ4NzM5MWI1ODdkNDVkZGIwNjM0MDU1MDIyYzJiZmRfMi0yLTEtMS0yNTk4OQ_2be9872a-9f8a-4430-b854-6e6c99a33e8a"
      unitRef="usd">102846000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i313bc2d8be6b49deab3982d26fd646fd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmY0ODczOTFiNTg3ZDQ1ZGRiMDYzNDA1NTAyMmMyYmZkL3RhYmxlcmFuZ2U6ZjQ4NzM5MWI1ODdkNDVkZGIwNjM0MDU1MDIyYzJiZmRfMi00LTEtMS0yNTk4OQ_99f07ac6-61d4-441a-9808-ea602f4464e6"
      unitRef="usd">102846000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4ddfa60f46e544df947c8b0ff919e9db_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmY0ODczOTFiNTg3ZDQ1ZGRiMDYzNDA1NTAyMmMyYmZkL3RhYmxlcmFuZ2U6ZjQ4NzM5MWI1ODdkNDVkZGIwNjM0MDU1MDIyYzJiZmRfMy0yLTEtMS0yNTk4OQ_66cce1af-bcda-45af-a84f-ee58fa457d75"
      unitRef="usd">44964000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2a5beaca54dc4603a5614a45876a29e0_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmY0ODczOTFiNTg3ZDQ1ZGRiMDYzNDA1NTAyMmMyYmZkL3RhYmxlcmFuZ2U6ZjQ4NzM5MWI1ODdkNDVkZGIwNjM0MDU1MDIyYzJiZmRfMy00LTEtMS0yNTk4OQ_415f5adb-ff94-453c-8a07-7ad9ee663913"
      unitRef="usd">44964000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3cce6f2cd8d64779a3cb98b16bc6010c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmY0ODczOTFiNTg3ZDQ1ZGRiMDYzNDA1NTAyMmMyYmZkL3RhYmxlcmFuZ2U6ZjQ4NzM5MWI1ODdkNDVkZGIwNjM0MDU1MDIyYzJiZmRfNC0yLTEtMS0yNTk4OQ_847b56d8-f36a-4859-b3d2-68c6c1e41e86"
      unitRef="usd">2991000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie925c891e72c47cea99fa4b411e16d37_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmY0ODczOTFiNTg3ZDQ1ZGRiMDYzNDA1NTAyMmMyYmZkL3RhYmxlcmFuZ2U6ZjQ4NzM5MWI1ODdkNDVkZGIwNjM0MDU1MDIyYzJiZmRfNC00LTEtMS0yNTk4OQ_779178e4-3c34-41ec-a1c5-0256f54a2126"
      unitRef="usd">2991000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iaaa7d76b8bf74f59b0911c381d40613e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmY0ODczOTFiNTg3ZDQ1ZGRiMDYzNDA1NTAyMmMyYmZkL3RhYmxlcmFuZ2U6ZjQ4NzM5MWI1ODdkNDVkZGIwNjM0MDU1MDIyYzJiZmRfNS0yLTEtMS0yNTk4OQ_6c62f614-2045-487c-8270-2325e861c7bf"
      unitRef="usd">5362000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2786cde9d4554d08836966e040d3dd88_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmY0ODczOTFiNTg3ZDQ1ZGRiMDYzNDA1NTAyMmMyYmZkL3RhYmxlcmFuZ2U6ZjQ4NzM5MWI1ODdkNDVkZGIwNjM0MDU1MDIyYzJiZmRfNS00LTEtMS0yNTk4OQ_941dd746-8dde-490e-8d0d-3d8e17882e50"
      unitRef="usd">5362000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i667b2117b7d6414692a884314d59ed80_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmY0ODczOTFiNTg3ZDQ1ZGRiMDYzNDA1NTAyMmMyYmZkL3RhYmxlcmFuZ2U6ZjQ4NzM5MWI1ODdkNDVkZGIwNjM0MDU1MDIyYzJiZmRfNy0yLTEtMS0yNTk4OQ_40ffa34f-b9ce-431a-8275-16d29ecd89b9"
      unitRef="usd">156163000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmY0ODczOTFiNTg3ZDQ1ZGRiMDYzNDA1NTAyMmMyYmZkL3RhYmxlcmFuZ2U6ZjQ4NzM5MWI1ODdkNDVkZGIwNjM0MDU1MDIyYzJiZmRfNy00LTEtMS0yNTk4OQ_60f18f77-ac69-46cb-a6ac-da428895265f"
      unitRef="usd">156163000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i667b2117b7d6414692a884314d59ed80_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmQ1NGM4NjU3YjRmYTQ2NTg4Y2I4YzFmOTA3MDZhMjJkL3RhYmxlcmFuZ2U6ZDU0Yzg2NTdiNGZhNDY1ODhjYjhjMWY5MDcwNmEyMmRfMi0yLTEtMS0yNTk4OQ_d2ca7464-b70f-4352-a80d-ef36ec88d552"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="idc49c8cd141a4141b4d1b6b88a3c8ee3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmQ1NGM4NjU3YjRmYTQ2NTg4Y2I4YzFmOTA3MDZhMjJkL3RhYmxlcmFuZ2U6ZDU0Yzg2NTdiNGZhNDY1ODhjYjhjMWY5MDcwNmEyMmRfMi00LTEtMS0yNTk4OQ_1ecc7065-3470-4c89-a2ce-407f0cc36e96"
      unitRef="usd">19266000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmQ1NGM4NjU3YjRmYTQ2NTg4Y2I4YzFmOTA3MDZhMjJkL3RhYmxlcmFuZ2U6ZDU0Yzg2NTdiNGZhNDY1ODhjYjhjMWY5MDcwNmEyMmRfMi02LTEtMS0yNTk4OQ_9e6f502e-92da-4715-8696-962dc494db73"
      unitRef="usd">19266000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="i667b2117b7d6414692a884314d59ed80_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmQ1NGM4NjU3YjRmYTQ2NTg4Y2I4YzFmOTA3MDZhMjJkL3RhYmxlcmFuZ2U6ZDU0Yzg2NTdiNGZhNDY1ODhjYjhjMWY5MDcwNmEyMmRfMy0yLTEtMS0yNTk4OQ_d9b5eb87-f935-465f-9914-e701b4bce7b5"
      unitRef="usd">4977000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="idc49c8cd141a4141b4d1b6b88a3c8ee3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmQ1NGM4NjU3YjRmYTQ2NTg4Y2I4YzFmOTA3MDZhMjJkL3RhYmxlcmFuZ2U6ZDU0Yzg2NTdiNGZhNDY1ODhjYjhjMWY5MDcwNmEyMmRfMy00LTEtMS0yNTk4OQ_6afe07c4-d6ed-47e1-b9e7-a7dd5d20ab1b"
      unitRef="usd">0</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmQ1NGM4NjU3YjRmYTQ2NTg4Y2I4YzFmOTA3MDZhMjJkL3RhYmxlcmFuZ2U6ZDU0Yzg2NTdiNGZhNDY1ODhjYjhjMWY5MDcwNmEyMmRfMy02LTEtMS0yNTk4OQ_57dbe0bd-bbc3-48d5-b401-97bd78170802"
      unitRef="usd">4977000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i667b2117b7d6414692a884314d59ed80_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmQ1NGM4NjU3YjRmYTQ2NTg4Y2I4YzFmOTA3MDZhMjJkL3RhYmxlcmFuZ2U6ZDU0Yzg2NTdiNGZhNDY1ODhjYjhjMWY5MDcwNmEyMmRfNC0yLTEtMS0yNTk4OQ_1a0e3508-9c1b-4519-8bd2-d222e4867013"
      unitRef="usd">4977000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="idc49c8cd141a4141b4d1b6b88a3c8ee3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmQ1NGM4NjU3YjRmYTQ2NTg4Y2I4YzFmOTA3MDZhMjJkL3RhYmxlcmFuZ2U6ZDU0Yzg2NTdiNGZhNDY1ODhjYjhjMWY5MDcwNmEyMmRfNC00LTEtMS0yNTk4OQ_e210a573-67b1-4329-943e-a350d58f687a"
      unitRef="usd">19266000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOmQ1NGM4NjU3YjRmYTQ2NTg4Y2I4YzFmOTA3MDZhMjJkL3RhYmxlcmFuZ2U6ZDU0Yzg2NTdiNGZhNDY1ODhjYjhjMWY5MDcwNmEyMmRfNC02LTEtMS0yNTk4OQ_11bc3e44-c3f0-4e67-8554-4a0d63fd974c"
      unitRef="usd">24243000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i18a1d906c5a545e698385837607d8ddb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjllOTZjMmMyODM3ZTQ5NzY4OGFjMTI5NjFmNzI0NmVkL3RhYmxlcmFuZ2U6OWU5NmMyYzI4MzdlNDk3Njg4YWMxMjk2MWY3MjQ2ZWRfMi0yLTEtMS0yNTk4OQ_f040a75e-0bd9-4cc5-ba40-1cb8ec4d8170"
      unitRef="usd">174531000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i18a1d906c5a545e698385837607d8ddb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjllOTZjMmMyODM3ZTQ5NzY4OGFjMTI5NjFmNzI0NmVkL3RhYmxlcmFuZ2U6OWU5NmMyYzI4MzdlNDk3Njg4YWMxMjk2MWY3MjQ2ZWRfMi00LTEtMS0yNTk4OQ_cb9309a9-378c-4b14-ae1a-067cd9b3d851"
      unitRef="usd">174531000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iddabb7fdfb774233b59ea3d5ebb33de8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjllOTZjMmMyODM3ZTQ5NzY4OGFjMTI5NjFmNzI0NmVkL3RhYmxlcmFuZ2U6OWU5NmMyYzI4MzdlNDk3Njg4YWMxMjk2MWY3MjQ2ZWRfMy0yLTEtMS0yNTk4OQ_5b4ae043-d396-4745-898c-4c18ea1d39b1"
      unitRef="usd">32311000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iddabb7fdfb774233b59ea3d5ebb33de8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjllOTZjMmMyODM3ZTQ5NzY4OGFjMTI5NjFmNzI0NmVkL3RhYmxlcmFuZ2U6OWU5NmMyYzI4MzdlNDk3Njg4YWMxMjk2MWY3MjQ2ZWRfMy00LTEtMS0yNTk4OQ_6743556b-8f77-4505-95a9-7fa0b6556916"
      unitRef="usd">32311000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i582299724ae3474088b179e8999bf21b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjllOTZjMmMyODM3ZTQ5NzY4OGFjMTI5NjFmNzI0NmVkL3RhYmxlcmFuZ2U6OWU5NmMyYzI4MzdlNDk3Njg4YWMxMjk2MWY3MjQ2ZWRfNC0yLTEtMS0yNTk4OQ_6677f0e2-a72c-40f3-ad8e-8524683c6988"
      unitRef="usd">30056000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifae0d641d44e4d74bd462bf49ef538ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjllOTZjMmMyODM3ZTQ5NzY4OGFjMTI5NjFmNzI0NmVkL3RhYmxlcmFuZ2U6OWU5NmMyYzI4MzdlNDk3Njg4YWMxMjk2MWY3MjQ2ZWRfNC00LTEtMS0yNTk4OQ_ffa367e7-e0b7-451a-bde7-341913320d56"
      unitRef="usd">30056000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if2f84ce5d8994d548056b41c664b19c0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjllOTZjMmMyODM3ZTQ5NzY4OGFjMTI5NjFmNzI0NmVkL3RhYmxlcmFuZ2U6OWU5NmMyYzI4MzdlNDk3Njg4YWMxMjk2MWY3MjQ2ZWRfNS0yLTEtMS0yNTk4OQ_73197862-d905-4ebe-907f-185a39b87267"
      unitRef="usd">5150000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9b41065183b64de594c948fc62b3fd96_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjllOTZjMmMyODM3ZTQ5NzY4OGFjMTI5NjFmNzI0NmVkL3RhYmxlcmFuZ2U6OWU5NmMyYzI4MzdlNDk3Njg4YWMxMjk2MWY3MjQ2ZWRfNS00LTEtMS0yNTk4OQ_10f00738-c2e8-4f9e-83ef-581e7dabf0b6"
      unitRef="usd">5150000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i56ccbb8636664d06a097e18deeca55d4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjllOTZjMmMyODM3ZTQ5NzY4OGFjMTI5NjFmNzI0NmVkL3RhYmxlcmFuZ2U6OWU5NmMyYzI4MzdlNDk3Njg4YWMxMjk2MWY3MjQ2ZWRfNi0yLTEtMS0yNTk4OQ_0c22e3f9-5325-4d9d-97da-4886ed240c38"
      unitRef="usd">242048000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjllOTZjMmMyODM3ZTQ5NzY4OGFjMTI5NjFmNzI0NmVkL3RhYmxlcmFuZ2U6OWU5NmMyYzI4MzdlNDk3Njg4YWMxMjk2MWY3MjQ2ZWRfNi00LTEtMS0yNTk4OQ_652bdd70-4255-4e33-815f-7c008431bef3"
      unitRef="usd">242048000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i56ccbb8636664d06a097e18deeca55d4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjc3OTI4ODcyOTNhNTRlZWNiYzI1NTNjN2JjZGM1NDE3L3RhYmxlcmFuZ2U6Nzc5Mjg4NzI5M2E1NGVlY2JjMjU1M2M3YmNkYzU0MTdfMi0yLTEtMS0yNTk4OQ_2f865a1a-6b72-497c-9be9-32e872aa4619"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib7023ba5f3b3416e833c03c3b04dfd39_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjc3OTI4ODcyOTNhNTRlZWNiYzI1NTNjN2JjZGM1NDE3L3RhYmxlcmFuZ2U6Nzc5Mjg4NzI5M2E1NGVlY2JjMjU1M2M3YmNkYzU0MTdfMi00LTEtMS0yNTk4OQ_c4e71f9f-472a-40cf-be75-fd53df8b7bc3"
      unitRef="usd">20339000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjc3OTI4ODcyOTNhNTRlZWNiYzI1NTNjN2JjZGM1NDE3L3RhYmxlcmFuZ2U6Nzc5Mjg4NzI5M2E1NGVlY2JjMjU1M2M3YmNkYzU0MTdfMi02LTEtMS0yNTk4OQ_f497ef31-3da5-4b5e-9945-fa567c201080"
      unitRef="usd">20339000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="i56ccbb8636664d06a097e18deeca55d4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjc3OTI4ODcyOTNhNTRlZWNiYzI1NTNjN2JjZGM1NDE3L3RhYmxlcmFuZ2U6Nzc5Mjg4NzI5M2E1NGVlY2JjMjU1M2M3YmNkYzU0MTdfMy0yLTEtMS0yNTk4OQ_06ec52a3-4e62-412e-b5e2-443e9494aa9b"
      unitRef="usd">4800000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="ib7023ba5f3b3416e833c03c3b04dfd39_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjc3OTI4ODcyOTNhNTRlZWNiYzI1NTNjN2JjZGM1NDE3L3RhYmxlcmFuZ2U6Nzc5Mjg4NzI5M2E1NGVlY2JjMjU1M2M3YmNkYzU0MTdfMy00LTEtMS0yNTk4OQ_75092207-76af-4e46-99c5-29080b1abaa4"
      unitRef="usd">0</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjc3OTI4ODcyOTNhNTRlZWNiYzI1NTNjN2JjZGM1NDE3L3RhYmxlcmFuZ2U6Nzc5Mjg4NzI5M2E1NGVlY2JjMjU1M2M3YmNkYzU0MTdfMy02LTEtMS0yNTk4OQ_5705136a-2f0a-4608-b0d7-47f58b9d54a5"
      unitRef="usd">4800000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i56ccbb8636664d06a097e18deeca55d4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjc3OTI4ODcyOTNhNTRlZWNiYzI1NTNjN2JjZGM1NDE3L3RhYmxlcmFuZ2U6Nzc5Mjg4NzI5M2E1NGVlY2JjMjU1M2M3YmNkYzU0MTdfNC0yLTEtMS0yNTk4OQ_1e8523d5-0fb8-4e18-b903-9c3d7c930291"
      unitRef="usd">4800000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib7023ba5f3b3416e833c03c3b04dfd39_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjc3OTI4ODcyOTNhNTRlZWNiYzI1NTNjN2JjZGM1NDE3L3RhYmxlcmFuZ2U6Nzc5Mjg4NzI5M2E1NGVlY2JjMjU1M2M3YmNkYzU0MTdfNC00LTEtMS0yNTk4OQ_62d0f422-49cf-4614-a56f-ef50ef778b39"
      unitRef="usd">20339000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjc3OTI4ODcyOTNhNTRlZWNiYzI1NTNjN2JjZGM1NDE3L3RhYmxlcmFuZ2U6Nzc5Mjg4NzI5M2E1NGVlY2JjMjU1M2M3YmNkYzU0MTdfNC02LTEtMS0yNTk4OQ_8cba3709-0718-4cdb-ab97-712a1b9a1727"
      unitRef="usd">25139000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RleHRyZWdpb246NDNkNjcxZTdjYjJhNDc5MGFjMWVjMjM3YTM0MTc0YjFfMzk3OQ_16940efb-704e-49d8-8a87-05ac954e453b">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB200 Pompe disease program: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contingent&#160;Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation&#160;Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable&#160;Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Clinical and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Probability weighted discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Probability of achievement of milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75% - 88%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Projected year of payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022 - 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <fold:ContingentConsiderationMeasurementInput
      contextRef="iccc9fcd06a114cdc9b7fd7bcc33f41ce_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjg5OGViNDQ4YTM2NDQyNTBhNDAyMzI5ZmZjNGQ0MzQzL3RhYmxlcmFuZ2U6ODk4ZWI0NDhhMzY0NDI1MGE0MDIzMjlmZmM0ZDQzNDNfMy04LTEtMS0yNTk4OQ_c098d61b-16d8-47a7-b861-bb4986c4a1e0"
      unitRef="number">0.075</fold:ContingentConsiderationMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0df4cd98b90b48bbac276b1d955f92ae_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjg5OGViNDQ4YTM2NDQyNTBhNDAyMzI5ZmZjNGQ0MzQzL3RhYmxlcmFuZ2U6ODk4ZWI0NDhhMzY0NDI1MGE0MDIzMjlmZmM0ZDQzNDNfNS0yLTEtMS0yNTk4OQ_d8a6a9d2-61a8-4b8b-92c1-ce9893949def"
      unitRef="usd">19266000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <fold:ContingentConsiderationMeasurementInput
      contextRef="i3b66abc5705c43f5b528d365e1c87cb4_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjg5OGViNDQ4YTM2NDQyNTBhNDAyMzI5ZmZjNGQ0MzQzL3RhYmxlcmFuZ2U6ODk4ZWI0NDhhMzY0NDI1MGE0MDIzMjlmZmM0ZDQzNDNfNS04LTEtMS0yNTk4OS90ZXh0cmVnaW9uOjNmYjI3ZDE2MTZjMDRkYWVhNDZjMDYzYjk4ZmJkMjQwXzQ_9e58bfe1-fd76-4e06-ab2c-8d7dde2c8958"
      unitRef="number">0.75</fold:ContingentConsiderationMeasurementInput>
    <fold:ContingentConsiderationMeasurementInput
      contextRef="ieeee7b9e37734d74a6b642a88110192e_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjg5OGViNDQ4YTM2NDQyNTBhNDAyMzI5ZmZjNGQ0MzQzL3RhYmxlcmFuZ2U6ODk4ZWI0NDhhMzY0NDI1MGE0MDIzMjlmZmM0ZDQzNDNfNS04LTEtMS0yNTk4OS90ZXh0cmVnaW9uOjNmYjI3ZDE2MTZjMDRkYWVhNDZjMDYzYjk4ZmJkMjQwXzk_b27d4ca5-3b63-488f-bb63-d15c587f3807"
      unitRef="number">0.88</fold:ContingentConsiderationMeasurementInput>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RleHRyZWdpb246NDNkNjcxZTdjYjJhNDc5MGFjMWVjMjM3YTM0MTc0YjFfMzk4Mg_44e46f4c-4a5f-408e-a764-fe876bd88ea3">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the change in the balance of contingent consideration payable for the three and six months ended June 30, 2022 and 2021, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.702%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance, beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in fair value during the period, included in the Consolidated Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,073)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance, end of the period &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; As certain milestones are expected to be reached within the next twelve months, the June 30, 2022 balance was recorded as a current liability in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i90601765a2f2418a9abfd28bd624e1fb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjVkYjAzYmI2NGQzOTRkZmM4OWVlMWU0MGYzOTRjNTIwL3RhYmxlcmFuZ2U6NWRiMDNiYjY0ZDM5NGRmYzg5ZWUxZTQwZjM5NGM1MjBfMi0yLTEtMS0yNTk4OQ_3f13aeda-4550-4ed7-95f3-f36c30e219f6"
      unitRef="usd">19151000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ib385a6b7137c45958b92a30dddce1f19_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjVkYjAzYmI2NGQzOTRkZmM4OWVlMWU0MGYzOTRjNTIwL3RhYmxlcmFuZ2U6NWRiMDNiYjY0ZDM5NGRmYzg5ZWUxZTQwZjM5NGM1MjBfMi00LTEtMS0yNTk4OQ_50639b28-29e6-4074-978d-e50b833f31dc"
      unitRef="usd">26296000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ib23d91f5ea064297be63d22df3cfdee1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjVkYjAzYmI2NGQzOTRkZmM4OWVlMWU0MGYzOTRjNTIwL3RhYmxlcmFuZ2U6NWRiMDNiYjY0ZDM5NGRmYzg5ZWUxZTQwZjM5NGM1MjBfMi02LTEtMS0yNjk5OQ_1375269a-7b7c-43f3-b7e6-23fa7b838062"
      unitRef="usd">20339000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i17008df080294bb0bf1240acd6c19c15_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjVkYjAzYmI2NGQzOTRkZmM4OWVlMWU0MGYzOTRjNTIwL3RhYmxlcmFuZ2U6NWRiMDNiYjY0ZDM5NGRmYzg5ZWUxZTQwZjM5NGM1MjBfMi04LTEtMS0yNjk4Mw_d1132cbd-3428-4b59-856c-e578c5fa7a36"
      unitRef="usd">25825000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjVkYjAzYmI2NGQzOTRkZmM4OWVlMWU0MGYzOTRjNTIwL3RhYmxlcmFuZ2U6NWRiMDNiYjY0ZDM5NGRmYzg5ZWUxZTQwZjM5NGM1MjBfMy0yLTEtMS0yNTk4OQ_c45977b6-79dd-4727-9da2-606a41bd5bec"
      unitRef="usd">-115000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjVkYjAzYmI2NGQzOTRkZmM4OWVlMWU0MGYzOTRjNTIwL3RhYmxlcmFuZ2U6NWRiMDNiYjY0ZDM5NGRmYzg5ZWUxZTQwZjM5NGM1MjBfMy00LTEtMS0yNTk4OQ_fe4519b4-343f-44b2-a868-c9e17490c316"
      unitRef="usd">-1021000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjVkYjAzYmI2NGQzOTRkZmM4OWVlMWU0MGYzOTRjNTIwL3RhYmxlcmFuZ2U6NWRiMDNiYjY0ZDM5NGRmYzg5ZWUxZTQwZjM5NGM1MjBfMy02LTEtMS0yNjk5Mg_00695ea6-9d33-402a-90f9-b985b4f8c171"
      unitRef="usd">1073000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjVkYjAzYmI2NGQzOTRkZmM4OWVlMWU0MGYzOTRjNTIwL3RhYmxlcmFuZ2U6NWRiMDNiYjY0ZDM5NGRmYzg5ZWUxZTQwZjM5NGM1MjBfMy04LTEtMS0yNjk5Mg_312fc02e-95e3-4aa3-82f4-ac10efd9a45e"
      unitRef="usd">-1492000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjVkYjAzYmI2NGQzOTRkZmM4OWVlMWU0MGYzOTRjNTIwL3RhYmxlcmFuZ2U6NWRiMDNiYjY0ZDM5NGRmYzg5ZWUxZTQwZjM5NGM1MjBfNC0yLTEtMS0yNTk4OQ_98ca15cd-bc11-466a-b8b2-44bfc2f7bd9f"
      unitRef="usd">19266000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ibdd0bea669974aef88283f7ce9684c7f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjVkYjAzYmI2NGQzOTRkZmM4OWVlMWU0MGYzOTRjNTIwL3RhYmxlcmFuZ2U6NWRiMDNiYjY0ZDM5NGRmYzg5ZWUxZTQwZjM5NGM1MjBfNC00LTEtMS0yNTk4OQ_03df531d-7078-43f2-ad21-b79329112d33"
      unitRef="usd">27317000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i11f13f2826434e75ba7e1100f8e58792_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjVkYjAzYmI2NGQzOTRkZmM4OWVlMWU0MGYzOTRjNTIwL3RhYmxlcmFuZ2U6NWRiMDNiYjY0ZDM5NGRmYzg5ZWUxZTQwZjM5NGM1MjBfNC02LTEtMS0yNzc4MQ_e80484a4-c269-4051-adc7-44833f55302f"
      unitRef="usd">19266000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ibdd0bea669974aef88283f7ce9684c7f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81NS9mcmFnOjQzZDY3MWU3Y2IyYTQ3OTBhYzFlYzIzN2EzNDE3NGIxL3RhYmxlOjVkYjAzYmI2NGQzOTRkZmM4OWVlMWU0MGYzOTRjNTIwL3RhYmxlcmFuZ2U6NWRiMDNiYjY0ZDM5NGRmYzg5ZWUxZTQwZjM5NGM1MjBfNC04LTEtMS0yNzc4MQ_eaf8fffb-5419-4042-8e2c-bb3090d59080"
      unitRef="usd">27317000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RleHRyZWdpb246Nzk2ZmM1NTg2NDIzNGIwM2JhODU4NjY0YWJlZGE1NzJfODQz_c3b84a35-d6fc-42e4-ae22-dd81921c67ba">Basic and Diluted Net Loss per Common Share&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.865%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;thousands,&#160;except&#160;per&#160;share amounts)&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(51,225)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(147,417)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(116,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding&#160;&#x2014; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;291,970,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;266,398,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288,646,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265,384,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dilutive common stock equivalents would include the dilutive effect of common stock options, convertible debt units, RSUs, and warrants for common stock equivalents.&#160;Potentially dilutive common stock equivalents were excluded from the diluted earnings per share denominator for all periods because of their anti-dilutive effect. Weighted average common shares outstanding includes outstanding pre-funded warrants with an exercise price of $0.01. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;thousands)&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total number of potentially issuable shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RleHRyZWdpb246Nzk2ZmM1NTg2NDIzNGIwM2JhODU4NjY0YWJlZGE1NzJfODQ1_fd29a9bc-6ece-44f6-a41f-f1637fb10bfd">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.865%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;thousands,&#160;except&#160;per&#160;share amounts)&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(51,225)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(147,417)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(116,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding&#160;&#x2014; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;291,970,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;266,398,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288,646,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265,384,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOjRmNDg5M2Y4OGZmMjQ5Yjg4NzM4ZDc5OThlY2RkZjcxL3RhYmxlcmFuZ2U6NGY0ODkzZjg4ZmYyNDliODg3MzhkNzk5OGVjZGRmNzFfMy0yLTEtMS0yNTk4OQ_25ccc0b8-239d-44b9-937c-3d955d36af05"
      unitRef="usd">-62157000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOjRmNDg5M2Y4OGZmMjQ5Yjg4NzM4ZDc5OThlY2RkZjcxL3RhYmxlcmFuZ2U6NGY0ODkzZjg4ZmYyNDliODg3MzhkNzk5OGVjZGRmNzFfMy00LTEtMS0yNTk4OQ_cf81e05a-95f3-48c0-b8e0-277f9780a4aa"
      unitRef="usd">-51225000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOjRmNDg5M2Y4OGZmMjQ5Yjg4NzM4ZDc5OThlY2RkZjcxL3RhYmxlcmFuZ2U6NGY0ODkzZjg4ZmYyNDliODg3MzhkNzk5OGVjZGRmNzFfMy02LTEtMS0yNzAyMA_858103b3-3786-4aac-bcf8-5f0112721463"
      unitRef="usd">-147417000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOjRmNDg5M2Y4OGZmMjQ5Yjg4NzM4ZDc5OThlY2RkZjcxL3RhYmxlcmFuZ2U6NGY0ODkzZjg4ZmYyNDliODg3MzhkNzk5OGVjZGRmNzFfMy04LTEtMS0yNzAyMA_04679536-19fe-40e3-a7a4-c75ffdbedfde"
      unitRef="usd">-116889000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOjRmNDg5M2Y4OGZmMjQ5Yjg4NzM4ZDc5OThlY2RkZjcxL3RhYmxlcmFuZ2U6NGY0ODkzZjg4ZmYyNDliODg3MzhkNzk5OGVjZGRmNzFfNS0yLTEtMS0yNTk4OQ_88d3c53e-45ca-4e2b-9f77-afd8522b7690"
      unitRef="shares">291970562</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOjRmNDg5M2Y4OGZmMjQ5Yjg4NzM4ZDc5OThlY2RkZjcxL3RhYmxlcmFuZ2U6NGY0ODkzZjg4ZmYyNDliODg3MzhkNzk5OGVjZGRmNzFfNS0yLTEtMS0yNTk4OQ_bef5876d-6604-4dce-a90d-e6b1471806cd"
      unitRef="shares">291970562</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOjRmNDg5M2Y4OGZmMjQ5Yjg4NzM4ZDc5OThlY2RkZjcxL3RhYmxlcmFuZ2U6NGY0ODkzZjg4ZmYyNDliODg3MzhkNzk5OGVjZGRmNzFfNS00LTEtMS0yNTk4OQ_3e62dbce-ca5c-4251-b9fb-eeef5cc9339e"
      unitRef="shares">266398516</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie3538d27fff444d092acd57eb241f871_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOjRmNDg5M2Y4OGZmMjQ5Yjg4NzM4ZDc5OThlY2RkZjcxL3RhYmxlcmFuZ2U6NGY0ODkzZjg4ZmYyNDliODg3MzhkNzk5OGVjZGRmNzFfNS00LTEtMS0yNTk4OQ_c39e0e63-9b18-4595-882b-0d1f70c9e50b"
      unitRef="shares">266398516</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOjRmNDg5M2Y4OGZmMjQ5Yjg4NzM4ZDc5OThlY2RkZjcxL3RhYmxlcmFuZ2U6NGY0ODkzZjg4ZmYyNDliODg3MzhkNzk5OGVjZGRmNzFfNS02LTEtMS0yNzAzNg_069c0fe4-1a66-4123-b51b-716f4e82ef25"
      unitRef="shares">288646587</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOjRmNDg5M2Y4OGZmMjQ5Yjg4NzM4ZDc5OThlY2RkZjcxL3RhYmxlcmFuZ2U6NGY0ODkzZjg4ZmYyNDliODg3MzhkNzk5OGVjZGRmNzFfNS02LTEtMS0yNzAzNg_a2fd724f-a4b4-4ac9-ab5b-2e4b94afc21f"
      unitRef="shares">288646587</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOjRmNDg5M2Y4OGZmMjQ5Yjg4NzM4ZDc5OThlY2RkZjcxL3RhYmxlcmFuZ2U6NGY0ODkzZjg4ZmYyNDliODg3MzhkNzk5OGVjZGRmNzFfNS04LTEtMS0yNzAzNg_bda1608a-9992-4315-add0-1b7ab1665e44"
      unitRef="shares">265384865</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOjRmNDg5M2Y4OGZmMjQ5Yjg4NzM4ZDc5OThlY2RkZjcxL3RhYmxlcmFuZ2U6NGY0ODkzZjg4ZmYyNDliODg3MzhkNzk5OGVjZGRmNzFfNS04LTEtMS0yNzAzNg_e0e23150-fa16-431a-9c3f-04ab3127a85c"
      unitRef="shares">265384865</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i62b5a7d4e59f4a0cb528290f1c8d251f_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RleHRyZWdpb246Nzk2ZmM1NTg2NDIzNGIwM2JhODU4NjY0YWJlZGE1NzJfNjcx_85704aa8-8862-4346-bd50-45ec22911f85"
      unitRef="cadPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RleHRyZWdpb246Nzk2ZmM1NTg2NDIzNGIwM2JhODU4NjY0YWJlZGE1NzJfODM1_b9bc3df5-5d06-4acb-ac5e-2903bf4cee9d">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;thousands)&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total number of potentially issuable shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia41bb3d6e6b341469638797bd696c267_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOmMxMDAyMGZmNGM5MjQxYzY5NzgyMTE2YmUxMmVlYTFkL3RhYmxlcmFuZ2U6YzEwMDIwZmY0YzkyNDFjNjk3ODIxMTZiZTEyZWVhMWRfMi0yLTEtMS0yNTk4OQ_6e1239ff-dfb4-4f2e-910d-3d9e617e851d"
      unitRef="shares">19283000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3206f3ebb21741d5af011059960d7b2d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOmMxMDAyMGZmNGM5MjQxYzY5NzgyMTE2YmUxMmVlYTFkL3RhYmxlcmFuZ2U6YzEwMDIwZmY0YzkyNDFjNjk3ODIxMTZiZTEyZWVhMWRfMi00LTEtMS0yNTk4OQ_eb61bc51-9d75-4d33-abd5-0f400718529b"
      unitRef="shares">14962000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i67808a739f5e477b8929ea199cdf1917_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOmMxMDAyMGZmNGM5MjQxYzY5NzgyMTE2YmUxMmVlYTFkL3RhYmxlcmFuZ2U6YzEwMDIwZmY0YzkyNDFjNjk3ODIxMTZiZTEyZWVhMWRfMy0yLTEtMS0yNTk4OQ_7cbae613-2210-4a7e-a0b8-f7155ffff982"
      unitRef="shares">10166000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia9642de7b1214086a13a7ba1bbf1e23a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOmMxMDAyMGZmNGM5MjQxYzY5NzgyMTE2YmUxMmVlYTFkL3RhYmxlcmFuZ2U6YzEwMDIwZmY0YzkyNDFjNjk3ODIxMTZiZTEyZWVhMWRfMy00LTEtMS0yNTk4OQ_8e119b05-6956-4868-ba40-e24dea409cbc"
      unitRef="shares">7412000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie6d84939f6a24c2dbbebe6fd3cbbd1ff_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOmMxMDAyMGZmNGM5MjQxYzY5NzgyMTE2YmUxMmVlYTFkL3RhYmxlcmFuZ2U6YzEwMDIwZmY0YzkyNDFjNjk3ODIxMTZiZTEyZWVhMWRfNC0yLTEtMS0yNTk4OQ_e58d7537-6c46-4b88-8b79-1316f6eb7090"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i391211c299184c4890fc3d8186f647fa_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOmMxMDAyMGZmNGM5MjQxYzY5NzgyMTE2YmUxMmVlYTFkL3RhYmxlcmFuZ2U6YzEwMDIwZmY0YzkyNDFjNjk3ODIxMTZiZTEyZWVhMWRfNC00LTEtMS0yNTk4OQ_2ef675f2-4371-4572-a392-3a539bb6eb2b"
      unitRef="shares">458000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOmMxMDAyMGZmNGM5MjQxYzY5NzgyMTE2YmUxMmVlYTFkL3RhYmxlcmFuZ2U6YzEwMDIwZmY0YzkyNDFjNjk3ODIxMTZiZTEyZWVhMWRfNS0yLTEtMS0yNTk4OQ_781b7695-4430-4839-9a2b-942bcbd4e8e0"
      unitRef="shares">29449000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie61d867ed2574bbeaaf84b5a61c1737e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMzMjVlZDFhNDU0ODQ3MThhN2VhMWVhZDJiY2ZkNDcxL3NlYzpjMzI1ZWQxYTQ1NDg0NzE4YTdlYTFlYWQyYmNmZDQ3MV81OC9mcmFnOjc5NmZjNTU4NjQyMzRiMDNiYTg1ODY2NGFiZWRhNTcyL3RhYmxlOmMxMDAyMGZmNGM5MjQxYzY5NzgyMTE2YmUxMmVlYTFkL3RhYmxlcmFuZ2U6YzEwMDIwZmY0YzkyNDFjNjk3ODIxMTZiZTEyZWVhMWRfNS00LTEtMS0yNTk4OQ_f3c0526c-e529-4cdd-9eb1-50ea778a325e"
      unitRef="shares">22832000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>51
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MWGS;80WBY9F6\3882A"'R>8_?]I6Q(N ME,3P+8![$T ;=<$N-L MP#=E*S
MNN*:CX9*KHDR7X.:N2CJIH@&FC Q:9QI!6]#B-.CB5P)1::0,=(D6<"5R(8M
M#<+F=<O;BEQN1%B-2)=\E(D.,G*=^,)_'=^" I6E8KM273)4\)<\.2>N<T:8
MPYBE/)-]X=$Y83U;^*OBN&4EN86>BU;27^-YIA6TN[]M-;11:-L53&?\D*7<
M$Q<-Z&V94"O1&/WP'>TZ/]KPOI'8*]AV"=O&U$=7TLNAGVKR\)P*&RD>3IWF
M%QL2&G4D4J=$ZAR&]"7G2@L5/9-[D4JE;7BXE%:YK5(F:-21>-T2KWL8WE2H
M4/JF%Q(8#*S)PY7*?E?;\=#X(SE[)6?OP):I.,PCQ310GT=<:\&CS)I(-.Q(
MP'X)V$<+=9WH4#^3FS 2Y%,>SX6R@>$:CD.;KML>]&QP:.B1<(,2;G (W+U8
MAF88A31^XK&UC>(ZXSB$>9$\!$+Q5.0Z]+*S32%O$^_<1HWJ'4E-G6J"=0[A
MAL))!6V5FV9[1F8:.BB1BDQDGFCU#/]]:V7L4;^ZMA'C0<<BO_ 4]!#D!_Y$
M;GWHL.$B] INI%7OD>S1IM/O#MR.8^5%@X_E914O.X1W[/N@GIWM+L@=?$<^
M)_:\XI)NM]<A'[EZ!"</S\'>G5G!495CP2M?1%$G\A_PB;F#1OT@UXD5&I>;
M!F'$?1&E0<CMN*<P1K1R1A3W-F]QRTX\57(5)IX]T;CF=&P%/85=HI5?HKC+
M>0LZE9GF$?DS3.O'*5R1#JC3MI*>PCG1RCI1W/$4+78,"^!Z,%S@':.=]U:P
M4U@E6GDEBAN<.^E!QJ:!3# OL4=DP&BSUW7L8^XIG!*MK!+%?<Y#J,$ER06A
M[-W\/9D)+U>02RLDKC21<0Q3TTQ+[_&,I%R1%8]R0;YWSAU*4ECY%>MB:QV<
MPE#1RE%1W J!#_;#9$EFS_%<1E9T7.#F\]V5E>L4EHE5EHGAIF:73'+]Y 4\
M68I:J[A'Z--X=C6V+D?QP&,)*X?$#G)(DUPILZ#9K&**5,*4DENW8/8H?K5N
MW$SPJ&,Y*V?$#G)&MPFLNC<[=F9ERG?@5DY<L8[S%$:(54:('62$S,H-+#VX
M@J54UK%HC\X=5]#:QYXG0 AD_(VDE?@47HA57H@=Y(5F,8\B<IEG\#JSMUM<
MIW8ACL<=RU=9(':0!;J.A5J:COD3*.@ 7$*<\L2>6ERP'O04#HA5#HCA!F:7
MR$! (C$\7*8>[Q0^B%4^B.$69C?2OIKD9\5&-_F<:_"U23&'O@N3[?ZWS<U=
MXK_R?_=WMVJ=0LV<M*Q&K.^T!_UVEPY;*QMP98S809M($QA>%3C V\073^17
M8<_IOKTDA])>O]\;6"%.87Y897[8OGT@D?C%=N!-Q)=6.ER@OL6>POVXE?MQ
M<=.R,P4W868L_%<!CA3;TMTCUVQ2UG2I]9CA%";(K4R0BUN6<C_W)>D-/+3.
M(WO$ZC:L\;!C&2L#Y.)VY2WC=HN^GA*7^V)G_*;FI_7B--',?L4A:T8\LU&Y
M.5@LGY8'N>/B^+)5?;XY!?[(S>29D4@L(-0Y[\&(IS8'JYL;+=/B;'(NM99Q
M<1D([@ME/H#W"RGU[L;\0'F\/?H74$L#!!0    (  ^!!%75O18?00<  #X>
M   8    >&PO=V]R:W-H965T<R]S:&5E=#(N>&ULK5EM;]LX$OXKA#<H6L"N
M15*O;6(@36_O]K"'+3;;V\^,1,>\2J*7I)+F?OT-9<>R18IN</G01K)F1L\,
MR7D>4I>/4GW3&\X-^M[4K;Z:;8S9?E@N=;GA#=/OY9:W\&0M5<,,W*K[I=XJ
MSJK>J:F7)(K29<-$.UM=]K]]4:M+V9E:M/R+0KIK&J:>/O%:/E[-\.SYA]_%
M_<;8'Y:KRRV[Y[?<?-U^47"W/$2I1,-;+62+%%]?S:[QAQN:68?>XM^"/^JC
M:V13N9/RF[WYI;J:1181KWEI; @&?Q[X#:]K&PEP_+4/.CN\TSH>7S]'_[E/
M'I*Y8YK?R/I/49G-U2R?H8JO65>;W^7C/_@^H<3&*V6M^__1X]XVFJ&RTT8V
M>V= T(AV]Y=]WQ?BR ''$PYD[T!^U('N'6B?Z Y9G]9G9MCJ4LE'I*PU1+,7
M?6UZ;\A&M'88;XV"IP+\S.I&MEK6HF*&5^@3JUE;<G1KPVGT]FO+NDK DW=H
M@;[>?D9O+]ZA"R1:],=&=IJUE;Y<&D!A8RW+_1L_[=Y()M[XSZY]CV@T1R0B
MQ.-^$W;_S$MPQ[T[/G5?0NZ' I!# 4@?CTX5H%.*MP8QK2'G#[Y\=@%B?P"[
MSC[H+2OYU0P6DN;J@<]6;W[":?31E]TK!3O)E1YRI:'HJQNF-PA&#97V@O_5
MB0=60_+>4=R%2OM0MAD\K A-4EI<+A^.\_&8Q0DNLH/9"=+X@#0.(OVE?>#:
M-!:;G6[08;YQP^YJCC0O.R6,X%[0NZC)$1J<8)@I(]"N&:$9*0H_Z.0 .@F"
MOBY+V5G$BI<<2@MP?1@3Y^4)29)T!-%GE6;$CS ]($S/EK4U4DU4+W7+$N79
M>,0]5FF.<S^R[( L"R+[HOB6B0KQ[T!0FNM^FDJSX0JZX/$*]>'.'$0THVDV
MPNVQBO-X G=^P)T'<?\A#:M_ &+NO#PNLC2F(XRN65*D.8W]((L#R"((\K<M
M5\R(]A[5'"@/*<MM"[E>='"SPSQ'+3<^X(5;M2B.Q[5UK4B4Y*D?-HX&<HK.
MS K0*\H\];/!]JNM;0ES2$/##"G+KNGJGKDJ#NVR%*R7!G*-+@B9XSSO_2YP
M,<]S@IA!P#W\P#W]0Z 3WMS!+'NFE#FL7KWEO;JHG[ST%KDEH6DR+HG'+"9Q
M,563(\+&9];P8JMD:2M@&8*I<K,CB#>LV7Z$2@!NV=?)"QY[6E\416/PY\Q.
MP0]DBX/\MOJ[E-6CJ&LO-.(V[R++"J>P9^U.P0WLB,/T^%O?;EK9+LZOYWVH
M$Q!Y%"=CK*X9B6,R!76@1QSFQUW;N9Z&YS)<'L&*'/=RCUT1)3B>&NB!"G'R
M0[*J%NQ.U#U?>[45#E+J2\75:T4[37I@5QRFUX, V+*G*?;''OJD&(^)P&<&
M4H9.C,M LSC,LP!1=3S(LT=#YDW Y5&,XRQR,G#MBAPG4QD,A(O#C L[%DME
M%FD)FQ=1]=P&;3]4=)=7<4'2L>;RF>7%9-<;Z!>_C'_/5=AETRQQI(+/*HXF
M)"P9*)>$*?=4T)Q!2ER.PVF<DG$;]-G%29$E$V@',B1A,OQ5MO<+PU4#O'?G
M)3SB,ADMHC09;PE\=GE!DXE638[VEV'*>^'@$Y?=$I+'\1BN:Q:#"IE8763@
M0!+FP,]\S6'H*] 6HKGKE.;-U :1N-R60&7'0,]8G>(<")"$"?" 4[2E;#@R
M[/M$/5V&BPLZUCOGK$Y1#BQ(PCM"5U&<&WUWVY>3:*R O%93G$T&^B)A^MHM
M_7,(76)*20:K?HS1M8,%GV5X N7 8"3,8#>R:<3^:* _RWCF@W(*<3">7Q0@
M[]'-_Q_H-.>!\T@>5%.W1I;?-K(&KM-O?LH)SC[VVR'SY#^P"C+HBT^L7BG:
M:>X#>9(P>=KQ!G;7M@1S=!&]CS!0O4(/K.[X'"51-(]V_Y#>,&4E36<V4HG_
M\@JV='DTCY-TGJ99/UM(EL\+3.;Y8"ZTMHJH%T*=T08N;+=^K>TB\>R-<XS'
MR\5G%4T<3M"!S6F8S:^K2EAQ!.O:'J\L1(M*MA6PSKU'?BY-DQ3$*1ZW2Y]A
M4B0QGI ?="!TBH,S_?IH4[^7I;*!>;6Q7PX>.'I;2ZW?H7LF6N_4IT&]\-*I
M_UK13HLQ2 <:E@X_2V#A^W:OQLHG9!1K=;V3NZSZ3[<[(O76P=4'"YRFCDKW
MV"4DF6C2].B@.2PCOK:*L]HN060'#%F\#TS45J OUE(M-#M[EDM=Y;!(Z9@+
M?58DF^!".N@+&M87?S(%M9XX&?=LKIVZ!FU.00UR@IX]8#XZ\5J+4OC'WI4'
M"Q*#/'0/[WV6I$@*,G'03 <Q07]$3.A)XO("=S4#SFCL;"<\=C3*:#K5?09M
M0</:8@?ZUT$!]4W?Q[Y_FTXB<[Z(>(]>/';>HY?ET<<]^V7U7TS=BU;#;F(-
MCM'[#,J@=A\K=S=&;OOO?7?2&-GTEQO. +PU@.=K*<WSC?V$>/ADO/H?4$L#
M!!0    (  ^!!%69#<]G60,  /H,   8    >&PO=V]R:W-H965T<R]S:&5E
M=#,N>&ULK9==;]HP%(;_BI554Y&FY@-(: >16F#:)DU"8]TNIEVXB2%6'3NU
M'=BF_?@=.VD$+:2-!!<D3GS>]_@YMN6,MT+>JXP0C7[GC*N)DVE=7+FN2C*2
M8W4A"L+AS4K('&MHRK6K"DEP:H-RY@:>%[HYIMR)Q_;90L9C46I&.5E(I,H\
MQ_+/#6%B.W%\Y_'!5[K.M'G@QN,"K\F2Z-MB(:'E-BHIS0E75' DR6KB7/M7
M\\CTMQV^4[)5._?(C.1.B'O3^)1.',\D1!A)M%' <-F0*6',"$$:#[6FTUB:
MP-W[1_4/=NPPECNLR%2P'S35V<09.2@E*UPR_55L/Y)Z/$.CEPBF[#_:5GTC
M<$Q*I45>!T,[I[RZXM\UAYV X/)(0% '!$\#AD<"^G5 _[4.@SI@\%J'81U@
MA^Y68[?@9ECC>"S%%DG3&]3,C:5OHX$7Y6:>++6$MQ3B=#P57 E&4ZQ)BFXP
MPSPA:&GD%#J_Y;A,*;SIH?,%EH3KC&B:8-9#9XAR]"T3I<(\56-70RY&T4UJ
MWYO*-SCB^[GD%ZCOO4.!%P3H=CE#YV<]I#)P.:0V[:)VAMSC2K-VI1E)0,FW
M2O[+><V[J!W+RX6:-84+FL(%5KI_1'JIH62P8#42*_2!<B@<Q0PMA*)V!?Z\
MOE-:PCK\=:@XE?;@L+;9FZY4@1,R<6#S441NB!._?>.'WOM#M3FEV.R48O,3
MB>T5J-\4J-^F'E\G29F7S"ZLE( !U,=6!NI52-CHI?Z#8/$@\E#2PE;R'SH[
M5*S*)[0^9M_?Q$'@CT9C=[-;A=9LNE;AN:5_.1H%^Y;S$UGNX1TT> >M>*<B
MSP$F;)#)_3M48(DVF)4$G<.^E K&L%0(&%<+KF?0MNT*-ZUF71=$)1;MT/,N
M/'\?WNR4CO,7'/<(#QO"PPZ$*W0(ESH3DOZ%26U(5T][AXA6XL.=E(9>_7LR
M<UO3Z#IS7VT[/Y'M'MNP81MV9TN5*E_F&CX;8##R!L,P#*,G7%M3Z,KU@&TT
MNO3!^RG7$]GN<8T:KE%WKG \5AIV6LK7+\&-7@VW-8^N< _8'H%[(ML*KKMS
M;C1?!5^P7%.N$",KD/<N(LA(5B?MJJ%%88^2=T+#P=3>9O!Q0J3I .]70NC'
MACF=-I\[\7]02P,$%     @ #X$$50-RY0-6"   A#P  !@   !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6RUF^]SVC8<A_\5'>OMVKNV6/+O+.%N(1BSVX]>
MLVZO'2S 5]MBMDBZW?[X2<8!+ DU;-^]2<"@[V.9!TG^8%\_L>9SNZ&4HR]5
M6;<WHPWGVZOQN%UN:)6U[]F6UN*5%6NJC(NGS7K<;AN:Y5VCJAP3QPG&55;4
MH\EUM^U#,[EF.UX6-?W0H'9755GSYRTMV=/-"(^>-WPLUALN-XPGU]ML3>\I
M_[3]T(AGXT.5O*AHW1:L1@U=W8R^QU<+XLL&W3M^*^A3>_(8R:X\,/99/EGD
M-R-'[A$MZ9++$IGX]TBGM"QE);$??_1%1P>F;'CZ^+EZTG5>=.8A:^F4E;\7
M.=_<C*(1RNDJVY7\(WM*:=^A;@>7K&R[O^BI?Z\S0LM=RUG5-Q9[4!7U_G_V
MI3\0)PU(?*8!Z1L0M8%_IH';-W!?2O#Z!MY+"7[?P'\I(>@;!"\EA'V#\*6$
MJ&\0O900]PWB3H?]Y]=]^'<9SR;7#7M"C7RWJ"8?= 9UK<5G7M12]GO>B%<+
MT8Y/IJQN65GD&:<YNN?BGS"9MXBMT"];VF32R!:]_E1GN[P0[WF#7J&B1K]N
MV*[-ZKR]'G.Q%[+6>-D3;_=$<H;HHI]8S3<MFM4YS0WM$WO[P-)^+'I_. 3D
M^1#<$FO!'W;U>^0Z;Q%Q"$&?[N_0ZU=O4+O)&FKJWO22:J_0^'RENY=7PE_?
MK]DEU:S[E8 >KSG8\4I!C]<"XG@-A',/WSFW*^V>*?V1/M)Z1Z],WYU]2\_<
M4LY\5^TV6]*;D9C:6MH\TM'DVV]PX'QG,A6RV!UDL1EDL02RV!RR6 I9; %4
M;*"L=U#6LU6?_"R67=N&Y;LE1VU6&K]0M_L205="+K(>)Y$3NOAZ_'@JI15T
MJ90Z,@P][ Z1,TADHB.Q'WM>,&3.(9FI@>FY$?:'S 40<V"(?S#$MQHR92V7
MJX8U8WF+Q)K"-+7?[FOXIXK@.%0,L8(N-<1 ="-'$022F.A$[(=AK/@!B4P-
M2"_&"G(!A!SH$1ST"*QZS!O6MG((617<)$:@]2 DONLI9E@9EYJA(X/8<=6Q
M Q*9Z$CQ/0X"Y0LPAV2F!B:)HE@9KQ9 S($<X4&.T+H@ZL\TZC6B7\19?$M;
MX]HHA%P;01:[@RPV@RR60!:;0Q9+(8LM@(H-[(T.]D;6H>VCJ)@URPT2Y\,H
M%VO[DFWE2;1)X4@?YB)7':BG5MZE;NK(P'4<=9B#1"8Z4BR1(E==(D$R4P.3
MA)@H,_T"B#D0)3Z($EM%N:>EV+1^B]:T%@->^;8S)LNKHBY:+D? 1VJ2)M:Z
MYKNNNJ"86MF72J,C/4)"Y0.<02(3'8FQ6,4H:]PY)#/5F5'L.$1Q!@@Y< 8[
MQX#.L2^L-UF]IJU,W599T:#'K-Q1N=)>LEK.F6*DD0_;(N_C.K3-_LP>2J-*
M/6MXE)5#/+7OT*4JF9 .4<X*9Z#,Q,!\A\6YJ.(2*#0U==2+59F@F$.;3N)>
M;+7I1[D,%XX4U5;()*<IJ5+6MI2;LURL=<I1=;$2+];EJ\ 9*# Q (, JW,5
M*#/]>B<74,"A)^3H";%Z<D=%V66Q'U"Z::IB#2_^ZC8812&Z_:YV F>G7NR*
M@>FK9U,S4&9B8)+04V<I4&9J8+HXQ*HQ0,RA,<=0&UL#R,FOC&<E8MJIG%$6
MUR0+]M0DR(Z\6!<#U0DC71C0=-I )6$<J(O^.2@U-5&)Z*P:&4)1A](<8V5L
MSY6[Z6C5L.I9'+&0,0KCZ1-ZX 1JTCNUXRX6QD!UHT@=U6:@U,1$Q:X?^T0U
M!C1C-F%C'$5JB@A%'1ISC)FQ;\^*^(8VZ'4_NKP1R^(EJ\R_I6'(C'4*6NT.
MM-H,M%H"6FT.6BT%K;: JC9T^9B)8WLHOJ@Y%75Y+['183V^=?U '?5 <W$#
MTM>6X*"QN('HJ>/.'!29&I!$^ST-"CG4XYB*8VML>=2C'^R,?H3ZJ!T17UM(
M@<;=1BC6)0%-LDU0''B.IWH"FE*;J=C33NO_CP0:'R-H;,^@][.B91@Q!,\D
MB%1+0(-G Y/H2R?0X-F C''HJ(: !L\&YCL2!^KO:U#0H2#'Z!G;L^=NH?U
M5ZRAO2:(9U^,JNBAZ+L $_4"AZD=>+$L!JH7A(XVIH!FSB:J^&X'ZB4)<U!L
M:L3*4U%M5/D_HF=RC)Z)/7I>'$2Q34'$$+;&6+WLQXZZ5!<3T_.),H'/0*&)
M$1JJ/S'-0:&I"1H(5Q13H*!#4XZQ,K''RO+ZL%(.,1GG3?&PX_('",09$@)5
MK$8M9\O/&U;FM#&>W_?E@T$OQ8),7<?8=^-BBPQ4'Q-=(]# V43%7NAA== !
MQ:9&+ [T$WPH[%"E8_),[,GS)2JAK5CU/&^7E^>B=_+6AV*)7A<UREE99OV;
MNE??H+_M5QC?VO?MTLB@KQ:>'G+GO?K;UQTH=&:&JG%C @J=FZ&^TM,4%+HP
M0[WC$G-HX#'))O8D^S\9N-_=;[^)"";?H;PH=_+.BG^K(^CEX'VUK^H(>J6W
M&:KK"'H1MQFJZPAZ?;89>E;'8T9.[!GY[]T-6T*B[)$VV9H.=&L1V_&69W4N
M?W,Y'?WV+TO'+'[IF2^)<1PZ?D#4F1<T63>!@\"-(U_]Y74&"DY,X"@*O,"/
MM.D7-%XW]MAW(R\*U-@)"CST[9BP$_N5W)IO]:YZ$&,66YF5.QWC7B2=?K7R
M6>E ,W<3^)QTH(&Z"7Q..M"TW-CC,]*!1N'CDSL2*]JLN]M96S%R[6J^OU'J
ML/5PR^SWW8VBRO9;?#7#ANT)OEKL;X@]EM_?G_M3UJR+ND4E70F4\SX4'6OV
MM[SNGW"V[>Z'?&"<LZI[N*&9F,SE&\3K*\;X\Q,).-QX//D'4$L#!!0    (
M  ^!!%79EPO=L@,  'X-   8    >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL
MK5==;]LV%/TKA%8,";!$$O5AV;,-)+:'=6BWH%FVAV$/M$1;7"72)6F[[:_?
MI:1HELQHP68_6")U[R'/N9?DY?0HY$>54ZK1Y[+@:N;D6N\FKJO2G)9$W8H=
MY?!E(V1)-#3EUE4[24E6.96%BSTO=DO"N#.?5GT/<CX5>UTP3A\D4ONR)/++
M/2W$<>;XSG/'![;-M>EPY],=V=)'JI]V#Q):;HN2L9)RQ01'DFYFSIT_68V-
M?67P&Z-'=?*.#).U$!]-XVTV<SPS(5K05!L$ H\#7="B,$ PC4\-IM,.:1Q/
MWY_1?ZBX Y<U470ABM]9IO.9DS@HHQNR+_0'<?R1-GPB@Y>*0E7_Z-C8>@Y*
M]TJ+LG&&&92,UT_RN='AQ %P[ ZX<<!]A_ %AZ!Q"%X[0M@XA*\=(6H<*NIN
MS;T2;DDTF4^E.")IK '-O%3J5]Z@%^,F3QZUA*\,_/1\(;@2!<N(IAEZU/"
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M6#UC/;4W]P..W9P?T#1)E#&:).:C&:C;%!0M T7C4&AZ1"@A#WFU'D=$.*.
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M;D2^%DUO(/]^4]?=MQ_ZCSH[?CS?]?\!4$L#!!0    (  ^!!%7*/,4XMP<
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M9X=G:3H_VIU!FQZA38-S<9?_%\C4K&TMH !EHLZ*DJ.ZQ6R^-<^96?4[!6R
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M[6TT\!*]W(9[("H1<QDWT%P%GC%5GQ:)' M,WC4P99XL10ST0[F>:FU/ME:
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M;ZY/E)=/H.6/SFWXL^.YZ]"S\,^5T? Z6H#W"^>Z] <=D+]#?_M_4$L#!!0
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ML98ISKFDF\J!V%T@U'#<GRTE3OW_(U69NY,]\TR@P0:3T1Q/7("C]WM/VZ^
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M&_!]:7!*:5Y(0'L]?/-?4$L#!!0    (  ^!!%4NSVD(Z@(  %X&   9
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MTJODIS5]!J!V"K1?*65W"^=@_V$Q_P]02P,$%     @ #X$$54B+;P; !P
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M%0JRKX2N'GU=S+EV)*3?^<)A11='2$_?</H\,3XICK7Y:A3;J@[#]O\Z7 >
M_ -6];*&/XPY85'HV?JNR3KP]V&-DZD']W<5_MJ@YW%@C)#C^P+W?Q*-494L
MN<=(O A9G"]^@>S<I],>7]=Y>OD<5O[?K=IGN7"J<P-\PV#(<X+54@"MU<8!
M7Z?/&T1]/J52F4?IV-6[/)J.*"XOHM%XRNX% H;J=0!6WSWSDCIX^OMU_V\=
MMUF4S$9XCO',+L X00V/)GG.?G7!%M0^:5E*I&@T\3T <H[29 2A4I(ESZ($
MF7KJUWBX=Y=1"[UR-S94(]K&^FN-?K:_%)K[NY#G[?Y&Z2>N5Y*P3RQ!BMYT
M/&#:W]+X@54;=S.R4-:JVGVN!<J7I@U87RK\184!'=!?E5W_!5!+ P04
M"  /@015 +#L_B()  !!&@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6S566MSV[@5_2L8;7:;S-"R1#W\6-LSMM.TZ22M&R?IATZG Y&0B U), !I
M6?OK]UP )"%%LC-M]T/]P01)X.(^SCWW@KI8*_W%9$+4[+'(2W,YR.JZ.C\^
M-DDF"FZ&JA(EWBR5+GB-6[TZ-I46/+6+BOPX'HWFQP67Y>#JPCZ[TU<7JJES
M68H[S4Q3%%QO;D2NUI>#\:!]\$&NLIH>'%]=5'PE[D7]J;K3N#ONI*2R$*61
MJF1:+"\'U^/SFRG-MQ,^2[$VP9B1)0NEOM#-V_1R,"*%1"Z2FB1P7![$K<AS
M$@0UOGJ9@VY+6AB.6^EOK.VP9<&-N%7Y/V1:9Y>#TP%+Q9(W>?U!K?\LO#TS
MDI>HW-C_;.WF3N<#EC2F5H5?# T*6;HK?_1^"!:<C@XLB/V"V.KM-K):ON8U
MO[K0:LTTS88T&EA3[6HH)TL*RGVM\59B77UU;8RH#>-ERMY)OI"YK*4P[+W@
MIM$B9;QF;[C4[#//&W%Q7&-+6GB<>/$W3GQ\0/R<O5=EG1GVQS(5Z?;Z8ZC:
MZ1NW^M[$3PK\2U,.V604L7@4QT_(FW3V3ZR\R0%YO7'LM31)KLALP_YYO3"U
M!F3^M<]F)W*Z7R2ET;FI>"(N!\@3(_2#&%S]],-X/OKY"86GG<+3IZ3_]P'[
M'XIG'S/!;E51\7+S!\.6LN1E(GG.>"\E#Z1P+5@12%J2I <KB:8F.=;)I<3+
MM:PS6;(:\H-)F12:ZR3;1&R=R21CTE &P@2(P_XJ!\>8<_9./(B<C=E//YS&
MX_AG]O=&U9A2:9E "]ER ?)(?R$]P6U,IJ*L9=(KCV>A[G4&A>O>7I9Q8^_=
ME VK%<1"OF%^HK<4#%:SE-=BZ/6*.[W>EE5#.V&VI@U*]O493:T6Y$:U(&#Q
M12ZL]E81TCM4&VX2TLI.I08+YAMZ*\OVKE5HLJM0MTM3?M<^0W;=LCI3R]VH
M^2<]3K![H[4L5P=QLEIIL>+DB<7&+LZMHD\@HD6,PT6=*;,5 ,28YQ1:T@8<
M(CH.L7:ZX%ODM7M8+)&.-1D/4+VT;U1CH*UYU<7RHZJ!&9<VYV1D(;3-@8I7
M\/P+-A[%T>ET'HP^#>^';*4>A"XM.%#\RF3#%@J"V70:G<VG[<7*/5KPY M4
M,^0WYZ$X.CL;^_]@6+'Q"&&S:#*/_7_L.)M'X_DD&!VPH@6"LR;(?#()KBE7
MI&BB4(Q3>-P6U(IO+"Y>=/#!-F=1/)_W@]=B*31E>X+HHY3[E3F@WJ&'P=23
MDTZ(NWO173N1\32*IY/_+ZB]%HDH%L#!9&SA-O[]X78RC6:3<3"Z5;I2B)D
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M*#2V9<X 77XA0>B,1E:Y>R'0Z\BR12\C4S>1P(#<ZI#J\\3H- ?C%K/JAW&
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M;\:_CO@@/VX:+N7L+OF^A.MROE*(4XU!X2C^Y?Q4Q@'K6$TYE Y!F+!'5$E
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M@5 ?_[E1U$PZ+*#W*VM#_H$#^D]:K_X+4$L#!!0    (  ^!!%5L)$M%X (
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M[R0EWLFN[>X&6JQMJSL7FAIG^[FB?RHHC0+-+X30]P,38/_?9_(?4$L#!!0
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M-$[]MJ3O%]2.@>X+I>SAX!1T7T3S_P!02P,$%     @ #X$$5>FV&TET!0
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MGB?[U,=3V)-E4S$BY^0CY8I\I55C2W^M<-5TG\-[)?L=OETR,D?]]5;?0 W
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M!,.M)X=;\MP7>)_5.C^="9Q1=9U@52BD (R#Q1;1#=9SH"%&:$)V&09_?E)
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MS_:NN<+[&BAK@-\74II=QT[0W0!G_P)02P,$%     @ #X$$548I(FO&!P
MED0  !D   !X;"]W;W)K<VAE971S+W-H965T,C<N>&ULO9QK;]LV%(;_BN 5
M0P<DL7B1;'>)@39:=P$*%,VZ?99MVA:BBRO)2;M?/TI638MD*(L]\I?$L@\/
MR<<B^;Z4K-OG+'\LMHR5SM<D3HN[T;8L=V_&XV*Y94E8W&0[EO)/UEF>A"4_
MS#?C8I>S<%472N(Q=EU_G(11.IK?UN]]S.>WV;Z,HY1]S)UBGR1A_NT=B[/G
MNQ$:?7_C4[39EM4;X_GM+MRP!U9^WGW,^='XF&45)2PMHBQU<K:^&[U%;P+/
MKPK4$?]$[+DX>>U475EDV6-U\.?J;N16+6(Q6Y95BI#_>V+W+(ZK3+P=7YJD
MHV.=5<'3U]^SOZ\[SSNS" MVG\7_1JMR>S>:CIP56X?[N/R4/?_!F@YY5;YE
M%A?U7^>YB75'SG)?E%G2%.8M2*+T\#_\VH X*8#H"P5P4P"?6X T!<BY!6A3
M@-9D#EVI.01A&<YO\^S9R:MHGJUZ4<.L2_/N1VGUO3^4.?\TXN7*^7U8;*^<
MZJ_SVY=]]!3&+"V+*^=#F#^R,ES$S'E@RWT>E1'C;X?IROG$BC*/EB5;'<I=
M._=9LLO2JJ#S.N"EHKCXA;_]^2%P7K_ZQ7GE1*GS]S;;%[QX<3LN>;NKVL?+
MIHWO#FW$+[3QKWUZXQ#WRL$NQIKB]^;B 5ORXJ@NCC3%@_-KEXJ/.>PC<7PD
MCNM\Q$C\ ^?UK:'LO-]S+@>X6NXZ9(=*J+Z2:K9X4^S");L;\>F@8/D3&\U_
M_@GY[J\Z@)#) J!D+;CD")>8LM=P:X[+Z@439[0.X2&57Z>JYL>G.2:>3V:W
MXZ=3.)HPZJ'9I!T6J&%HXGMD>@QK=8@>.T2-'7H?1KG#^[!G5X<^+<(X3)?Z
M<^*0RNOJD"9,UR%CPRR_1^_8;<_\/69%R0?$$Y]*JK%PS1>XZX)_DTYA'!2>
MTC/D(9]B"8 :ALF$3) $P-A$2P#^$8!O!/![GA6%LT_Y6AY'__&I=L/7< LB
MODI$@J%&R">"L:66'"9'#I-^'&)^;,%AHO3RFE(9A29H(@V>P-A<2QC3(XSI
MV9.!AL"*+<H.#%/= .$+FP1"#>,#!,]D%L;66K*8'5G,SI@A6E-B/?'W/C-F
M2E_)=(*G\KFAAM$I]ORIA,38:$LDR!5BSK69-0 H-16;)A)-B#R3F)MOB^=$
MZR*;R00"#SIG?M%%*1.,N0^VC(0Z149]]K+@L 2#-</+GZIHU#@^ONC,E^D,
MH2Z1D)>H0U]F2<+R913&SB[<L5S;96.*OM(<-%L E:V-3XA91"_A?1"0-&T(
M0V8+H+*U"0O=C+J$<[[+\K!4U  ?S7S%U-+4J&:7N%,J#U$@/=QP&D)=(R&O
MD5E?&SAM=(NH%ERWN#:WHC>S(90X$E(<F;5X'V;5RJIEIM'86'&HYH;TQC:$
M9D="M".S:C=@6Q\76RTKC5IW\93Z,BT@'=[0&D+5(R'KT3FZOK_. !+>#5%5
M[:,)]2:RVH>JM;V1*.0^MI+[O>&9J^F]F=CM Z J;',3/@!;^8#^W("D>L--
MXPX\*I,;PAW@D[WK\]V!W0Z$N8+>S%3;4 U4(F_E0=7:QB9L S;;AL\W#S?.
M)GMB>9JPM'3"#4N7WYQ%]L+U$'.ZWI! +014MC9*82'P12P$!K40H-D"J&QM
MPL)"X$'VWK%J(ZB'/&GJOS=7WAO5$"X""Q>!+[-+CU4GX<K<0)T$5+8V-^$D
M\&5V];'&3: 9D=&!N@FH;&UTPDW@H:\!8-564#KS9;MO;D=O:D.X"BQ<!3:[
MBK=%P<KK1;A\Y"=;!QY0)P&:+8#*UKZV+OP&<2^Q]A)0NP&:+8#*UB8LG DQ
M.Q.+[3NBV@;BNO+RH8^:2&&!N7FVW1?V@ICM!<2N'%$M@0*C,R0P-]06Q,EM
M+%W7&7Y\JZVIHK4X*O>V:&*0[#G-;;5E(10_,=\"8[U_1C0WNLQF\A:M)HJ/
M#$^^\&1NI"T$(<J)690?)MVDGF*U?864U?>@V0*H;&UT0J03_R*K%J0 OP?-
M%D!E:Q,6<IY87QAX<=52E3OQE'D:5+A#96M#$L*=6%\&.']M4Z6[P@Q4MD-E
M:S,3LIUT70P 6 ;5O7R%&:A(A\K6OE]4B'1JOBA@O5Q2==]>'9+FRONB@LK6
M1B74-NU2VU8[7>:L?5<"JE'F,O8 JLHV**'+J5F70^USF:OI3:Y;QD-5V.8F
M9#PURWBH?2YS-;VYJ:)?X3:$Y*<G-[V??]>[W2:7N8+>Q#0>01VC0S@$*AP"
MM;SS1XL'U"Z 9@N@LK4Y"KM +V(7**A= ,T60&5K$Q9V@8+;!7/&WC0UY@,3
MC.4!/81AH,(PT.$-@[F*WMPZ[4< 56&;F3 ,='C#8*ZB-S/5?EPC^?8$J"K;
MO[42EL$;R#*8\_9%Y6D,""8*+*A*V["$:? Z3 /+RV@=+2M<V9H3VV5%I)VT
MS(EZTX',%D!E:T,4AL*[R(]@/5 _ 9HM@,K6)BRLA]=U!<'N%Y2J-_#D'?,S
M8@)SZVQ[+PR$9S804(;54X6_O"/2'1*8&VL+X^2WM&9G .5"/?4.'P5&9TA@
M;JPM#"'O/?,M.S]N+9L*?.,0Z8X)S WM"V)\\@R(ZHD=? [=1&GAQ&S-T[LW
M$XX]/SP$XW!09KOZL1"+K"RSI'ZY9>&*Y54 _WR=9>7W@^I)$\='D<S_!U!+
M P04    "  /@015FW5 J <#  #E"0  &0   'AL+W=O<FMS:&5E=',O<VAE
M970R."YX;6RM5FUOVC 0_BM65DVM1)OW !U$:H%JG32I*NWV8=H'DQS$:F)3
MVX'NW\]V4LI+RNC$%^*7>Y[S/7><W5LR_B0R (E>BIR*OI5).;^T;9%D4&!Q
MP>9 U<Z4\0)+->4S6\PYX-2 BMSV'">R"TRH%??,VAV/>ZR4.:%PQY$HBP+S
M/]>0LV7?<JW7A7LRRZ1>L./>',]@#/)Q?L?5S%ZQI*0 *@BCB,.T;UVYEZ-0
MVQN#'P268FV,="03QI[TY#;M6XX^$.202,V U6<! \AS3:2.\5QS6BN7&K@^
M?F6_,;&K6"98P(#E/TDJL[[5L5 *4USF\IXMOT(=CSE@PG)A?M&RMG4LE)1"
MLJ(&JQ,4A%9?_%+KL 9P@W< 7@WP#@7X-< _%!#4@.!00%@#3.AV%;L1;H@E
MCGN<+1'7UHI-#XSZ!JWT(E37R5ARM4L43L8#++(6TK]H]%R2!<Z!2M%"WS%_
M HDG.: Q)"4GDH!:QC1%]R D)XF$M,*=H_=(KAJL3X>*EN3B3.$>QT-T>G*&
M3A"AZ"%CI5#\HF=+%9@^GIW405Q707CO!/&MI!?(=UK(<SRO 3[8#Q]"HN"N
M@;L-\.'AWIO@H\.].YMP6R5SE5%OE5'/\/D?S*A.W3AC7)X_ "_0+5VHS!1Z
M#_VZFJ@DJ?_L[R;M*W=!LSO=QR[%'"?0MU2C$L 78,6?/[F1\Z4I$\<D&QZ3
M;'0DLHV<^:N<^?O83<Y,@A(]@+>T->6CHHH,E;X&%K'GAY'?[=F+=:4;S(+0
M[;8WS8:[9FX["OW.IMEH[_G_4YU@I4ZP5YVU%J+U:=*D(@C7H@@\W0HV%-GK
MY:.UM^O1]T)G2[4C>=Q0+5RI%OZSIEH[!57U ;ZI*!(96U+=A&4&:,"H8#E)
ML=X>2_6IN@2;5EWE1KTM&@LS;"C,;B=RM]+08!9T@S#:*LQ=,[?=;7>V"[/!
M+(K<Z"WWE7CVVA6I'T#J?IL1*E .4P5T+MJ*AU>/BFHBV=S<FA,FU1ULAIEZ
MAP'7!FI_RIA\G>B+>/6RB_\"4$L#!!0    (  ^!!%6?A2\XI0(  &T'   9
M    >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;*U56V_;(!C]*\BKIE9:ZVOL
MI$LLM8FJ==*DJI?U8=H#<;[$J!@\(''S[P?8M=*4IGO8BPWXG,,YF _&#1=/
ML@10Z+FB3$Z\4JGZW/=E44*%Y1FO@>DO2RXJK'17K'Q9"\ +2ZJH'P5!ZE>8
M,"\?V[$;D8_Y6E'"X$8@N:XJ++:70'DS\4+O9>"6K$IE!OQ\7.,5W(%ZJ&^$
M[OF]RH)4P"3A# E83KR+\'R:&;P%_"30R)TV,DGFG#^9SO5BX@7&$% HE%'
M^K6!*5!JA+2-/YVFUT]IB+OM%_4KFUUGF6,)4TX?R4*5$V_HH04L\9JJ6]Y\
M@R[/P.@5G$K[1$V+33(/%6NI>-61M8.*L/:-G[MUV"&$R3N$J"-$_TJ(.T)L
M@[;.;*P95C@?"]X@8=!:S33LVEBV3D.8^8MW2NBO1/-4?LTVP!07!"0ZGH'"
MA,H3=(H>[F;H^.@$'2'"T'W)UQ*SA1S[2L]IF'[1Z5^V^M$[^M_7[ S%P1<4
M!5'DH$\/TV=0:'IHZ>%KNJ^3]G&C/FYD]>(/XF[1C,B"<KD6@'Y=S*42>D/]
M=N5K!1.WH"FR<UGC B:>KB()8@->_OE3F 9?76G_D]BK['&?/3ZDGM_B1N\<
M!8)@ZOR3+3VU=%/]FSP,!\%P[&]V(SA0430<]:A7WI+>6W+0VZ.N]5/"3FO!
M"Y!.=ZW 8&?>P2B)]\R]!85!.GK'W* W-SAH[HHPHBML@5:<NVM@\&;:.(GV
M%\X!&L:!VUK:6TL/6KOG"E-=HGT1N]RE;R:.@F$VVK/G0*7#<.CVE_7^LL-[
MKMW%2%\WO<NMRV/FV'M!L&?Q U#KT-\Y#,U%] .+%6$245AJ6G"6Z8BB/=S;
MCN*U/1_G7.G3UC9+?1^", #]?<FY>NF8([>_8?._4$L#!!0    (  ^!!%50
M<$L Y0(   <)   9    >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;*U676_:
M,!3]*U9639TTFI O*(-(*VA:IVY"I=T>ICV8Y :L)C:S'6BE_?A=)R$"FK).
M@@=BQ_<<GW-]'7NX$?)!+0$T><PSKD;64NO5P+95O(2<J@NQ HXCJ9 YU=B5
M"UNM)-"D!.69[3I.:.>4<2L:EN^F,AJ*0F>,PU025>0YE4]7D(G-R.I:VQ>W
M;+'4YH4=#5=T 3/0]ZNIQ)[=L"0L!ZZ8X$1".K(^=@?COHDO [XSV*B=-C%.
MYD(\F,YU,K(<(P@RB+5AH/A8PQBRS!"AC-\UI]5,:8"[[2W[I]([>IE3!6.1
M_6")7HZLOD422&F1Z5NQ^0RUG\#PQ2)3Y3_95+$A!L>%TB*OP:@@9[QZTL<Z
M#SN KO\"P*T![FL!7@WP2J.5LM+6A&H:#:78$&FBD<TTRMR4:'3#N%G%F98X
MRA"GHPG,->F06;6(1*3D1O %N0.9DW+L? *:LDR]PZC[V82<G[TC9X1Q<K<4
MA:(\44-;HQ!#9\?UI%?5I.X+DWXI^ 7QG/?$=5RW!3X^#I] C/!N">_NPVVT
MW^3 ;7+@EGS>L1Q<<Z5E@?6IR<\;#"#7&G+UJ\U<Q>:WLYEM-U K&L/(PGVE
M0*[!BMZ^Z8;.AS:K)R+;,^XUQKUC[-$W_$K$5,HGADN^IED!VP+H:%, "2:F
M+0$5:UBRFL_$.O(NG3# I5SO6FL)ZU]Z0:\)VQ/M-Z+]HZ)GP)F0J))R1?Z0
MNCN#N)"05(5KQDB";K! PC8#1V?XWQ4\$=E>,H(F&<%)2S<XI?$3D>T9#QOC
MX=$JF$K&8[:B69O+"AKL%)[OF-]!??XS;$]9KU'6.ZKL!I0:E%N')$S%HN"M
M>ZCW;/).X'G^@<26J-#I^>T*^XW"_JL4IB#-EDD9IYA+OFB3V7^VASN^TSV4
MV185A)<',NV=8\I<$;Y2N6"XB3-($>=<]-"GK([=JJ/%JCRYYD+C.5@VEWA3
M 6D"<#P50F\[YC!L[C[17U!+ P04    "  /@015PM?]Y/L"  "N"0  &0
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MD^HR-<65>E !UP#5OV!,[BHZ0/-$2WX#4$L#!!0    (  ^!!%4-AQ(2;0,
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MN2$X(%R_H)ZO&).?#1V@./";_P]02P,$%     @ #X$$58JE+ #J @  1 D
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M8\S"9!J2XV)TWJTO&RT/H'-1/F3M_8)&3VHMREFT%2<G=3=2YRR^AEB 6BW
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M)N#SM1#Z:6!.[LJ3VMG_4$L#!!0    (  ^!!%5:#]*M<P,  (\*   9
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MM[]#&T]B^3+)M7N2;:L;>"2KM9%E"T8/2B::-_W9YF$'@#S]@*@%1(> X3.
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MY+<207("DC\AY"Q"Q#\X9A;L9@4600X)R.'!("],NT*0(P)R=#C(1N![<DQ
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M4')O<',O8V]R92YX;6Q02P$"% ,4    "  /@015F5R<(Q &  "<)P  $P
M            @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M  ^!!%5..5;UX@4  .H>   8              " @0T(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    "  /@015U;T6'T$'   ^'@  &
M            @($E#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#
M%     @ #X$$59D-SV=9 P  ^@P  !@              ("!G!4  'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (  ^!!%4#<N4#5@@  (0\
M   8              " @2L9  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q0
M2P$"% ,4    "  /@015V9<+W;(#  !^#0  &               @(&W(0
M>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ #X$$5;27"RG5
M"P  JF\  !@              ("!GR4  'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;%!+ 0(4 Q0    (  ^!!%7*/,4XMP<  %L@   8              "
M@:HQ  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  /@015
M\JNOWO((  !P%   &               @(&7.0  >&PO=V]R:W-H965T<R]S
M:&5E=#@N>&UL4$L! A0#%     @ #X$$59JJA0K>$   DRX  !@
M     ("!OT(  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (
M  ^!!%5@)=_5(0@  "H6   9              " @=-3  !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&UL4$L! A0#%     @ #X$$52[/:0CJ @  7@8  !D
M             ("!*UP  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"
M% ,4    "  /@015B,RQNK@#  !D"   &0              @(%,7P  >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (  ^!!%5(BV\&P <
M #83   9              " @3MC  !X;"]W;W)K<VAE971S+W-H965T,3,N
M>&UL4$L! A0#%     @ #X$$50"P[/XB"0  01H  !D              ("!
M,FL  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  /@015
MVHXV"&($  !'"@  &0              @(&+=   >&PO=V]R:W-H965T<R]S
M:&5E=#$U+GAM;%!+ 0(4 Q0    (  ^!!%5CVB"W<0X  -XJ   9
M      " @21Y  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%
M  @ #X$$56PD2T7@ @  * 8  !D              ("!S(<  'AL+W=O<FMS
M:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  /@0158OK&DJH$   '#0
M&0              @('CB@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+
M 0(4 Q0    (  ^!!%69-H96I (  *4%   9              " @<2/  !X
M;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ #X$$5>H[2$_F
M P  '0D  !D              ("!GY(  'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6Q02P$"% ,4    "  /@015Z;8;270%   1#@  &0
M@(&\E@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (  ^!
M!%4Y !Y4T@4  ! 0   9              " @6><  !X;"]W;W)K<VAE971S
M+W-H965T,C(N>&UL4$L! A0#%     @ #X$$598<UV,=!   S0D  !D
M         ("!<*(  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
M    "  /@015! L/[%("   Y!0  &0              @('$I@  >&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (  ^!!%4&+.@^Q 0  (8=
M   9              " @4VI  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL
M4$L! A0#%     @ #X$$551,7@=\ P  #0X  !D              ("!2*X
M 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  /@0151BDB
M:\8'  "61   &0              @('[L0  >&PO=V]R:W-H965T<R]S:&5E
M=#(W+GAM;%!+ 0(4 Q0    (  ^!!%6;=4"H!P,  .4)   9
M  " @?BY  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @
M#X$$59^%+SBE @  ;0<  !D              ("!-KT  'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6Q02P$"% ,4    "  /@0154'!+ .4"   '"0  &0
M            @($2P   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4
M Q0    (  ^!!%7"U_WD^P(  *X)   9              " @2[#  !X;"]W
M;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ #X$$50V'$A)M P
MN0L  !D              ("!8,8  'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6Q02P$"% ,4    "  /@01571FRL1@%  #\&P  &0              @($$
MR@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (  ^!!%6*
MI2P Z@(  $0)   9              " @5//  !X;"]W;W)K<VAE971S+W-H
M965T,S0N>&UL4$L! A0#%     @ #X$$5:F?E9_  P  ]@P  !D
M     ("!=-(  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
M"  /@015[=X]?I@#  #5$   &0              @(%KU@  >&PO=V]R:W-H
M965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (  ^!!%5%<1>GX 4  /@H   9
M              " @3K:  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L!
M A0#%     @ #X$$5?FCAT(+!   M14  !D              ("!4>   'AL
M+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  /@0156@_2K7,#
M  "/"@  &0              @(&3Y   >&PO=V]R:W-H965T<R]S:&5E=#,Y
M+GAM;%!+ 0(4 Q0    (  ^!!%4XW'MNF 4  !DF   9              "
M@3WH  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ #X$$
M55F^NFLW P  R!,   T              ( !#.X  'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    "  /@015EXJ[',     3 @  "P              @ %N\0
M7W)E;',O+G)E;'-02P$"% ,4    "  /@015 <0X?9@#   C&P  #P
M        @ %7\@  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ #X$$53QA
M]1J- 0  3Q@  !H              ( !'/8  'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ #X$$59C$(26B 0  IA@  !,
M     ( !X?<  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #  ,  '#0
&M/D

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>119</ContextCount>
  <ElementCount>234</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>35</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited</Role>
      <ShortName>Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2107103 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash</Role>
      <ShortName>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2115105 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2119106 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2126107 - Disclosure - Assets and Liabilities Measured at Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2131108 - Disclosure - Basic and Diluted Net Loss per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare</Role>
      <ShortName>Basic and Diluted Net Loss per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables</Role>
      <ShortName>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/Inventories</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2316304 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/Debt</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2320305 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/ShareBasedCompensation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2327306 - Disclosure - Assets and Liabilities Measured at Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2332307 - Disclosure - Basic and Diluted Net Loss per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables</Role>
      <ShortName>Basic and Diluted Net Loss per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails</Role>
      <ShortName>Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/DescriptionofBusiness</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails</Role>
      <ShortName>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails</Role>
      <ShortName>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash, Cash Equivalents, And Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash, Cash Equivalents, And Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/InventoriesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Debt - Summary of Long Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails</Role>
      <ShortName>Debt - Summary of Long Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Debt - Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails</Role>
      <ShortName>Debt - Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2421409 - Disclosure - Share-Based Compensation - Weighted-average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails</Role>
      <ShortName>Share-Based Compensation - Weighted-average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2422410 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Share-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - Share-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails</Role>
      <ShortName>Share-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Share-Based Compensation - RSUs and PBRSUs Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails</Role>
      <ShortName>Share-Based Compensation - RSUs and PBRSUs Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2425413 - Disclosure - Share-Based Compensation - Expense Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails</Role>
      <ShortName>Share-Based Compensation - Expense Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2428414 - Disclosure - Assets and Liabilities Measured at Fair Value - Components by Hierarchy Level (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value - Components by Hierarchy Level (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - Assets and Liabilities Measured at Fair Value - Significant Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value - Significant Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2430416 - Disclosure - Assets and Liabilities Measured at Fair Value - Contingent Consideration Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueContingentConsiderationRollForwardDetails</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value - Contingent Consideration Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="fold-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2433417 - Disclosure - Basic and Diluted Net Loss per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails</Role>
      <ShortName>Basic and Diluted Net Loss per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="fold-20220630.htm">fold-20220630.htm</File>
    <File>fold-06302022xex311.htm</File>
    <File>fold-06302022xex312.htm</File>
    <File>fold-06302022xex321.htm</File>
    <File>fold-20220630.xsd</File>
    <File>fold-20220630_cal.xml</File>
    <File>fold-20220630_def.xml</File>
    <File>fold-20220630_lab.xml</File>
    <File>fold-20220630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="615">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>57
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "fold-20220630.htm": {
   "axisCustom": 0,
   "axisStandard": 17,
   "contextCount": 119,
   "dts": {
    "calculationLink": {
     "local": [
      "fold-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "fold-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "fold-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "fold-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "fold-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "fold-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 359,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 1,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 6
   },
   "keyCustom": 14,
   "keyStandard": 220,
   "memberCustom": 8,
   "memberStandard": 25,
   "nsprefix": "fold",
   "nsuri": "http://www.amicustherapeutics.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.amicustherapeutics.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107103 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash",
     "role": "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash",
     "shortName": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Inventories",
     "role": "http://www.amicustherapeutics.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115105 - Disclosure - Debt",
     "role": "http://www.amicustherapeutics.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119106 - Disclosure - Share-Based Compensation",
     "role": "http://www.amicustherapeutics.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126107 - Disclosure - Assets and Liabilities Measured at Fair Value",
     "role": "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue",
     "shortName": "Assets and Liabilities Measured at Fair Value",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131108 - Disclosure - Basic and Diluted Net Loss per Common Share",
     "role": "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare",
     "shortName": "Basic and Diluted Net Loss per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)",
     "role": "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables",
     "shortName": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Inventories (Tables)",
     "role": "http://www.amicustherapeutics.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i11f13f2826434e75ba7e1100f8e58792_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets (Unaudited)",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited",
     "shortName": "Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i11f13f2826434e75ba7e1100f8e58792_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316304 - Disclosure - Debt (Tables)",
     "role": "http://www.amicustherapeutics.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320305 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://www.amicustherapeutics.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327306 - Disclosure - Assets and Liabilities Measured at Fair Value (Tables)",
     "role": "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables",
     "shortName": "Assets and Liabilities Measured at Fair Value (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332307 - Disclosure - Basic and Diluted Net Loss per Common Share (Tables)",
     "role": "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables",
     "shortName": "Basic and Diluted Net Loss per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i11f13f2826434e75ba7e1100f8e58792_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Description of Business (Details)",
     "role": "http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails",
     "shortName": "Description of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i11f13f2826434e75ba7e1100f8e58792_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ia1ae6aeddaf442cba31cc61b672cf523_D20220101-20220630",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i11f13f2826434e75ba7e1100f8e58792_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Additional Information (Details)",
     "role": "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails",
     "shortName": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtSecuritiesRealizedGainLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i11f13f2826434e75ba7e1100f8e58792_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Components (Details)",
     "role": "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails",
     "shortName": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Components (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i11f13f2826434e75ba7e1100f8e58792_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i11f13f2826434e75ba7e1100f8e58792_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash, Cash Equivalents, And Restricted Cash (Details)",
     "role": "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails",
     "shortName": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash, Cash Equivalents, And Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i11f13f2826434e75ba7e1100f8e58792_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i11f13f2826434e75ba7e1100f8e58792_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Inventories (Details)",
     "role": "http://www.amicustherapeutics.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i11f13f2826434e75ba7e1100f8e58792_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i11f13f2826434e75ba7e1100f8e58792_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i11f13f2826434e75ba7e1100f8e58792_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i11f13f2826434e75ba7e1100f8e58792_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Debt - Summary of Long Term Debt (Details)",
     "role": "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails",
     "shortName": "Debt - Summary of Long Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i7817625b346c448d9777f5897c0b43fb_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Debt - Interest Expense (Details)",
     "role": "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails",
     "shortName": "Debt - Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i7db5d4a26355471cb3592c15bd783d1c_D20220401-20220630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421409 - Disclosure - Share-Based Compensation - Weighted-average Assumptions (Details)",
     "role": "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails",
     "shortName": "Share-Based Compensation - Weighted-average Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i7db5d4a26355471cb3592c15bd783d1c_D20220401-20220630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ib23d91f5ea064297be63d22df3cfdee1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422410 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)",
     "role": "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails",
     "shortName": "Share-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ib23d91f5ea064297be63d22df3cfdee1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i4c027874ad0b4c14b107e9e7d4d2a4b3_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - Share-Based Compensation - Narrative (Details)",
     "role": "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
     "shortName": "Share-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i4c027874ad0b4c14b107e9e7d4d2a4b3_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i2ccbe1db3305487c82f9fcfe73e288b9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Share-Based Compensation - RSUs and PBRSUs Summary (Details)",
     "role": "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails",
     "shortName": "Share-Based Compensation - RSUs and PBRSUs Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i2ccbe1db3305487c82f9fcfe73e288b9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425413 - Disclosure - Share-Based Compensation - Expense Summary (Details)",
     "role": "http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails",
     "shortName": "Share-Based Compensation - Expense Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i11f13f2826434e75ba7e1100f8e58792_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428414 - Disclosure - Assets and Liabilities Measured at Fair Value - Components by Hierarchy Level (Details)",
     "role": "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails",
     "shortName": "Assets and Liabilities Measured at Fair Value - Components by Hierarchy Level (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i11f13f2826434e75ba7e1100f8e58792_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i11f13f2826434e75ba7e1100f8e58792_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - Assets and Liabilities Measured at Fair Value - Significant Unobservable Inputs (Details)",
     "role": "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails",
     "shortName": "Assets and Liabilities Measured at Fair Value - Significant Unobservable Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i0df4cd98b90b48bbac276b1d955f92ae_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i90601765a2f2418a9abfd28bd624e1fb_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430416 - Disclosure - Assets and Liabilities Measured at Fair Value - Contingent Consideration Roll Forward (Details)",
     "role": "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueContingentConsiderationRollForwardDetails",
     "shortName": "Assets and Liabilities Measured at Fair Value - Contingent Consideration Roll Forward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i90601765a2f2418a9abfd28bd624e1fb_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Operations (Unaudited)",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited",
     "shortName": "Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433417 - Disclosure - Basic and Diluted Net Loss per Common Share (Details)",
     "role": "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails",
     "shortName": "Basic and Diluted Net Loss per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited)",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
     "shortName": "Consolidated Statements of Comprehensive Loss (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i0bad18c6d78f464e948adc1f766b6749_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i15ca856684364a728cfb2cacad448766_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Unaudited)",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "i15ca856684364a728cfb2cacad448766_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of Business",
     "role": "http://www.amicustherapeutics.com/role/DescriptionofBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20220630.htm",
      "contextRef": "ic62d3deb269c41c2a701f2d91c3e5bf8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 35,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "fold_ATB200PompeProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to ATB-200 Pompe program.",
        "label": "ATB200 Pompe Program [Member]",
        "terseLabel": "ATB200 Pompe Program"
       }
      }
     },
     "localname": "ATB200PompeProgramMember",
     "nsuri": "http://www.amicustherapeutics.com/20220630",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_AmortizationDeferredFinancingCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Amortization Deferred Financing Costs",
        "terseLabel": "Amortization of deferred financing"
       }
      }
     },
     "localname": "AmortizationDeferredFinancingCosts",
     "nsuri": "http://www.amicustherapeutics.com/20220630",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_AssetImpairmentChargesAndOtherAssetWriteOffs": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Impairment Charges And Other Asset Write-Offs",
        "label": "Asset Impairment Charges And Other Asset Write-Offs",
        "verboseLabel": "Asset impairment charges and other asset write-offs"
       }
      }
     },
     "localname": "AssetImpairmentChargesAndOtherAssetWriteOffs",
     "nsuri": "http://www.amicustherapeutics.com/20220630",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_CallidusBiopharmaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Callidus Biopharma, Inc.",
        "label": "Callidus Biopharma Inc [Member]",
        "terseLabel": "Callidus Biopharma Inc"
       }
      }
     },
     "localname": "CallidusBiopharmaIncMember",
     "nsuri": "http://www.amicustherapeutics.com/20220630",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Also includes amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Cash, Cash Equivalents And Available-for-sale Debt Securities",
        "totalLabel": "Cost, cash balances and available-for-sale securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndAvailableforsaleDebtSecurities",
     "nsuri": "http://www.amicustherapeutics.com/20220630",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2": {
       "order": 1.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "label": "Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "terseLabel": "Gross unrealized gain, cash balances and available-for-sale securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.amicustherapeutics.com/20220630",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2": {
       "order": 2.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "label": "Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "negatedTerseLabel": "Gross unrealized loss, cash balances and available-for-sale securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.amicustherapeutics.com/20220630",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2": {
       "order": 3.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents cash and cash equivalents and marketable securities.",
        "label": "Cash, Cash Equivalents And Available-for-sale Debt Securities Fair Value Disclosure",
        "totalLabel": "Fair value, cash balances and available-for-sale securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure",
     "nsuri": "http://www.amicustherapeutics.com/20220630",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to clinical and regulatory contingent consideration milestones.",
        "label": "Contingent Consideration Liability Clinical And Regulatory Milestones [Member]",
        "terseLabel": "Clinical and regulatory milestones"
       }
      }
     },
     "localname": "ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember",
     "nsuri": "http://www.amicustherapeutics.com/20220630",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_ContingentConsiderationMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration, Measurement Input",
        "label": "Contingent Consideration, Measurement Input",
        "terseLabel": "Contingent consideration, measurement input"
       }
      }
     },
     "localname": "ContingentConsiderationMeasurementInput",
     "nsuri": "http://www.amicustherapeutics.com/20220630",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current",
        "label": "Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current",
        "terseLabel": "Corporate debt securities, gross unrealized gain"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent",
     "nsuri": "http://www.amicustherapeutics.com/20220630",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Before Tax, Current",
        "label": "Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Before Tax, Current",
        "negatedTerseLabel": "Corporate debt securities, gross unrealized loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent",
     "nsuri": "http://www.amicustherapeutics.com/20220630",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_ForeignCurrencyRemeasurementGainLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Remeasurement Gain (Loss), Before Tax",
        "label": "Foreign Currency Remeasurement Gain (Loss), Before Tax",
        "negatedLabel": "Foreign currency remeasurement loss"
       }
      }
     },
     "localname": "ForeignCurrencyRemeasurementGainLossBeforeTax",
     "nsuri": "http://www.amicustherapeutics.com/20220630",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_IncreaseDecreaseInNoncurrentOperatingLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of noncurrent liabilities that result from activities that generate operating income.",
        "label": "Increase (Decrease) In Noncurrent Operating Liabilities",
        "terseLabel": "Other non-current assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInNoncurrentOperatingLiabilities",
     "nsuri": "http://www.amicustherapeutics.com/20220630",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_MarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities",
        "label": "Marketable Securities [Member]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesMember",
     "nsuri": "http://www.amicustherapeutics.com/20220630",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_MeasurementInputProbabilityOfMilestoneAchievementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Probability Of Milestone Achievement [Member]",
        "label": "Measurement Input, Probability Of Milestone Achievement [Member]",
        "terseLabel": "Probability of achievement of milestones"
       }
      }
     },
     "localname": "MeasurementInputProbabilityOfMilestoneAchievementMember",
     "nsuri": "http://www.amicustherapeutics.com/20220630",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_ProbabilityWeightedDiscountedCashFlowMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to valuation technique of probability weighted discounted cash flow.",
        "label": "Probability Weighted Discounted Cash Flow [Member]",
        "terseLabel": "Probability weighted discounted cash flow"
       }
      }
     },
     "localname": "ProbabilityWeightedDiscountedCashFlowMember",
     "nsuri": "http://www.amicustherapeutics.com/20220630",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_SeniorSecuredTermLoanDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured Term Loan due 2026",
        "label": "Senior Secured Term Loan due 2026 [Member]",
        "terseLabel": "Senior Secured Term Loan due 2026"
       }
      }
     },
     "localname": "SeniorSecuredTermLoanDue2026Member",
     "nsuri": "http://www.amicustherapeutics.com/20220630",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the estimated dividend per share to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions Expected Dividend Per Share",
        "terseLabel": "Expected annual dividend per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare",
     "nsuri": "http://www.amicustherapeutics.com/20220630",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "fold_ShortTermCorporateDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Short Term Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "ShortTermCorporateDebtSecuritiesMember",
     "nsuri": "http://www.amicustherapeutics.com/20220630",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents Stock issued from exercise of warrants (in shares).",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "terseLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.amicustherapeutics.com/20220630",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "fold_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents Stock issued from exercise of warrants.",
        "label": "Stock Issued During Period, Value, Warrants Exercised",
        "terseLabel": "Warrants exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://www.amicustherapeutics.com/20220630",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r219",
      "r235",
      "r267",
      "r297",
      "r299",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r480",
      "r518",
      "r520",
      "r546",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails",
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r219",
      "r235",
      "r267",
      "r297",
      "r299",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r480",
      "r518",
      "r520",
      "r546",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails",
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r214",
      "r216",
      "r217",
      "r218",
      "r219",
      "r235",
      "r267",
      "r287",
      "r297",
      "r299",
      "r330",
      "r331",
      "r332",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r480",
      "r518",
      "r520",
      "r546",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails",
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r214",
      "r216",
      "r217",
      "r218",
      "r219",
      "r235",
      "r267",
      "r287",
      "r297",
      "r299",
      "r330",
      "r331",
      "r332",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r480",
      "r518",
      "r520",
      "r546",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails",
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r156",
      "r157",
      "r284",
      "r285",
      "r519",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r156",
      "r157",
      "r284",
      "r285",
      "r519",
      "r534",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r36",
      "r449"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r159",
      "r160"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r13",
      "r211"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation of property and equipment"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax",
        "verboseLabel": "Unrealized loss on available-for-sale securities"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r44",
      "r45",
      "r46",
      "r47",
      "r407"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.",
        "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax",
        "verboseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Accumulated other comprehensive (loss) gain:"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r342",
      "r343",
      "r344",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Vesting of restricted stock units, net of taxes"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r301",
      "r345",
      "r346"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r335"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total equity compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r27",
      "r161",
      "r186",
      "r188",
      "r189"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for doubtful accounts receivable"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r66",
      "r80",
      "r255",
      "r428"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r80",
      "r255",
      "r264",
      "r265",
      "r430"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and deferred financing"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of diluted earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r172",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-Backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r80",
      "r210"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Loss on impairment of assets"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited",
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r16",
      "r94",
      "r144",
      "r147",
      "r153",
      "r179",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r372",
      "r378",
      "r408",
      "r447",
      "r449",
      "r488",
      "r506"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r9",
      "r35",
      "r94",
      "r179",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r372",
      "r378",
      "r408",
      "r447",
      "r449"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r398"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Fair value of assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r170"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gain, available-for-sale securities"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross unrealized loss, available-for-sale securities"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r168",
      "r194"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": 1.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1": {
       "order": 1.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Cost, available-for-sale securities"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r165",
      "r169",
      "r194",
      "r492"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1": {
       "order": 3.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair value, available-for-sale debt securities",
        "verboseLabel": "Available-for-sale debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r167",
      "r194"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1": {
       "order": 1.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Corporate debt securities, fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r324",
      "r326",
      "r327",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r383",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r296",
      "r298",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r296",
      "r298",
      "r358",
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r79",
      "r368"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "verboseLabel": "Non-cash changes in the fair value of contingent consideration payable"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r364",
      "r365",
      "r367"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration payable"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails",
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r364",
      "r366"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Contingent consideration payable"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Capital expenditures unpaid at the end of period"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r12",
      "r82"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": 2.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1": {
       "order": 3.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": 2.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1": {
       "order": 2.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Fair value, cash balances"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r83",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents, Marketable Securities and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-Term Investments [Abstract]",
        "terseLabel": "Cash, Cash Equivalents, and Short-term Investments [Abstract]"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments [Text Block]",
        "terseLabel": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r76",
      "r82",
      "r88"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at the end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at the beginning of period",
        "totalLabel": "Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r76",
      "r417"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents, and restricted cash at the end of the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificate of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrants exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r288",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r41",
      "r493",
      "r512"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r98",
      "r99",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r21",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r21",
      "r449"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.01 par value, 500,000,000 shares authorized, 280,456,667 and 278,912,800 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income [Member]",
        "terseLabel": "Other Comprehensive Gain (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r50",
      "r52",
      "r53",
      "r60",
      "r496",
      "r514"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r132",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r90",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Contractual obligation"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Schedule of Liability Components of Long-Term Debt"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r288",
      "r295",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r63",
      "r481"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r92",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r249",
      "r256",
      "r257",
      "r259",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r93",
      "r96",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r262",
      "r263",
      "r264",
      "r265",
      "r431",
      "r489",
      "r490",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r19",
      "r260",
      "r490",
      "r505"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Principal"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r39",
      "r93",
      "r96",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r262",
      "r263",
      "r264",
      "r265",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r39",
      "r93",
      "r96",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r258",
      "r262",
      "r263",
      "r264",
      "r265",
      "r270",
      "r271",
      "r272",
      "r273",
      "r428",
      "r429",
      "r431",
      "r432",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Debt Instruments"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r245",
      "r428",
      "r432"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Less: debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "auth_ref": [
      "r168",
      "r194"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1": {
       "order": 2.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current",
        "totalLabel": "Corporate debt securities, cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r174",
      "r195",
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "terseLabel": "Fair value of available-for-sale debt securities in unrealized loss positions"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).",
        "label": "Debt Securities, Realized Gain (Loss)",
        "terseLabel": "Realized gain (loss) on debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.",
        "label": "Deferred Compensation Share-Based Arrangements, Liability, Current and Noncurrent",
        "terseLabel": "Deferred compensation plan liability"
       }
      }
     },
     "localname": "DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income after one year or beyond the normal operating cycle, if longer and noncurrent obligations not separately disclosed in the balance sheet (other liabilities, noncurrent).",
        "label": "Deferred Credits and Other Liabilities, Noncurrent",
        "terseLabel": "Deferred reimbursements"
       }
      }
     },
     "localname": "DeferredCreditsAndOtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r349",
      "r350"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r203"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "negatedLabel": "Less: deferred financing"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r80",
      "r142"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r303",
      "r304",
      "r336",
      "r337",
      "r339",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r61",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r116",
      "r118",
      "r120",
      "r121",
      "r122",
      "r126",
      "r127",
      "r395",
      "r396",
      "r497",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss attributable to common stockholders per common share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r61",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r118",
      "r120",
      "r121",
      "r122",
      "r126",
      "r127",
      "r395",
      "r396",
      "r497",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss attributable to common stockholders per common share\u00a0\u2014 diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Basic and Diluted Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation costs, period for recognition (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r54",
      "r55",
      "r56",
      "r98",
      "r99",
      "r100",
      "r103",
      "r112",
      "r114",
      "r129",
      "r183",
      "r269",
      "r274",
      "r342",
      "r343",
      "r344",
      "r354",
      "r355",
      "r394",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r446",
      "r523",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Financial assets and liabilities subject to fair value measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r398",
      "r399",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r398",
      "r399",
      "r400",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of Assets and Liabilities Subject to Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of Significant Unobservable Inputs Used in the Valuation of the Contingent Consideration Payable"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r247",
      "r262",
      "r263",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r399",
      "r453",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails",
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Assets and Liabilities Measured at Fair Value"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r247",
      "r262",
      "r263",
      "r288",
      "r289",
      "r294",
      "r295",
      "r399",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r247",
      "r262",
      "r263",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r399",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03",
        "verboseLabel": "Discount rate"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails",
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueContingentConsiderationRollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r403"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "Changes in fair value of contingent consideration payable",
        "negatedTerseLabel": "Changes in fair value during the period, included in the Consolidated Statements of Operations"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueContingentConsiderationRollForwardDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r402"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance, end of the period",
        "periodStartLabel": "Balance, beginning of the period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueContingentConsiderationRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r247",
      "r262",
      "r263",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r453",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails",
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r439",
      "r440"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Payment of finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r172",
      "r173",
      "r176",
      "r177",
      "r178",
      "r187",
      "r190",
      "r191",
      "r192",
      "r193",
      "r196",
      "r197",
      "r198",
      "r199",
      "r258",
      "r268",
      "r385",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Transactions"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r14",
      "r204",
      "r205",
      "r206",
      "r207",
      "r449",
      "r487"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r62",
      "r94",
      "r144",
      "r146",
      "r149",
      "r152",
      "r154",
      "r179",
      "r221",
      "r222",
      "r223",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r408"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r58",
      "r144",
      "r146",
      "r149",
      "r152",
      "r154",
      "r485",
      "r494",
      "r499",
      "r516"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r213",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r95",
      "r113",
      "r114",
      "r143",
      "r351",
      "r356",
      "r357",
      "r517"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued expenses, and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r208",
      "r209"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "In-process research\u00a0&amp; development"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r57",
      "r141",
      "r427",
      "r430",
      "r498"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "auth_ref": [
      "r68",
      "r254",
      "r264",
      "r265"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "terseLabel": "Contractual interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebtExcludingAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Components of Total Interest Expense"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r74",
      "r77",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid during the period for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryCostsForContractsOrProgramsPolicy": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the basis and manner that goods are added and removed from inventory for costs relating to long-term contracts or programs. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory and how cost is determined (such as FIFO, LIFO, average). Elements of costs in inventory may include retained costs representing the excess of manufacturing or production costs over the amounts charged to cost of sales or delivered or in-process units, initial tooling or other deferred startup costs.",
        "label": "Inventory Costs for Contracts or Programs, Policy [Policy Text Block]",
        "terseLabel": "Inventories and Cost of Goods Sold"
       }
      }
     },
     "localname": "InventoryCostsForContractsOrProgramsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r28",
      "r201"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r8",
      "r34",
      "r449"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.amicustherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r30",
      "r201"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/InventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r34",
      "r200"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "terseLabel": "Reserve for inventory"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r29",
      "r201"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r65",
      "r140"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r37",
      "r94",
      "r148",
      "r179",
      "r221",
      "r222",
      "r223",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r373",
      "r378",
      "r379",
      "r408",
      "r447",
      "r448"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r94",
      "r179",
      "r408",
      "r449",
      "r491",
      "r510"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r38",
      "r94",
      "r179",
      "r221",
      "r222",
      "r223",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r373",
      "r378",
      "r379",
      "r408",
      "r447",
      "r448",
      "r449"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Fair value of liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r19",
      "r246",
      "r261",
      "r262",
      "r263",
      "r490",
      "r507"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Long-term debt",
        "totalLabel": "Net carrying value of Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r39",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Investments in marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market",
        "verboseLabel": "Money market"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r76",
      "r78",
      "r81"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r48",
      "r51",
      "r56",
      "r59",
      "r81",
      "r94",
      "r102",
      "r107",
      "r108",
      "r109",
      "r110",
      "r113",
      "r114",
      "r119",
      "r144",
      "r146",
      "r149",
      "r152",
      "r154",
      "r179",
      "r221",
      "r222",
      "r223",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r396",
      "r408",
      "r495",
      "r513"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss attributable to common stockholders",
        "verboseLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r109",
      "r115",
      "r126",
      "r163",
      "r164",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r342",
      "r343",
      "r344",
      "r352",
      "r353",
      "r354",
      "r355",
      "r361",
      "r362",
      "r363",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r425",
      "r426",
      "r433",
      "r434",
      "r435",
      "r436",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r482",
      "r483",
      "r484",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Developments"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Ex-U.S."
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (expense) income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r144",
      "r146",
      "r149",
      "r152",
      "r154"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r438"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r438"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r437"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right-of-use assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r6",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r370",
      "r371",
      "r377"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized holding loss on available-for-sale securities",
        "verboseLabel": "Unrealized (loss) gain on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r370",
      "r371",
      "r377"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment (loss) gain",
        "verboseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r49",
      "r52",
      "r370",
      "r371",
      "r377"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other comprehensive (loss) gain"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive (loss) gain:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForTenantImprovements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.",
        "label": "Payments for Tenant Improvements",
        "terseLabel": "Tenant improvements paid through lease incentives"
       }
      }
     },
     "localname": "PaymentsForTenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Purchase of vested restricted stock units, net of taxes"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r166"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r69",
      "r70",
      "r166"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "terseLabel": "Sale and redemption of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r72",
      "r341"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from stock options exercised, net"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from warrants exercised"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r48",
      "r51",
      "r56",
      "r75",
      "r94",
      "r102",
      "r113",
      "r114",
      "r144",
      "r146",
      "r149",
      "r152",
      "r154",
      "r179",
      "r221",
      "r222",
      "r223",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r370",
      "r375",
      "r376",
      "r380",
      "r381",
      "r396",
      "r408",
      "r499"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r212",
      "r449",
      "r501",
      "r511"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property and equipment, less accumulated depreciation of $22,188 and $19,882 at June 30, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r212",
      "r535",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r12",
      "r82",
      "r88",
      "r486",
      "r508"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Unvested restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r23",
      "r274",
      "r449",
      "r509",
      "r527",
      "r532"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r98",
      "r99",
      "r100",
      "r103",
      "r112",
      "r114",
      "r183",
      "r342",
      "r343",
      "r344",
      "r354",
      "r355",
      "r394",
      "r523",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r138",
      "r139",
      "r145",
      "r150",
      "r151",
      "r155",
      "r156",
      "r158",
      "r283",
      "r284",
      "r481"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Net product sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited",
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r91",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potential Shares of Common Stock that were Excluded from the Computation as they were Anti-Dilutive Using the Treasury Stock Method"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Cash, Money Market Funds, and Marketable Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "terseLabel": "Schedule of Changes in Continent Consideration Payable"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of Cash, Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of the Numerator and Denominator Used in Computing Basic and Diluted Net Loss per Common Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Equity Compensation Expenses"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r11",
      "r31",
      "r32",
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventories for the Period"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r88",
      "r486",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r300",
      "r302",
      "r304",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r324",
      "r326",
      "r327",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r307",
      "r322",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Non-Vested RSU Activity under the Plan"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general, and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general, and administrative expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A senior loan takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for [must receive] repayment [prior] relative to junior and unsecured (general) creditors.",
        "label": "Senior Loans [Member]",
        "terseLabel": "Senior Loans"
       }
      }
     },
     "localname": "SeniorLoansMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Additional Disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Non-vested units (in shares)",
        "periodStartLabel": "Non-vested units (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number\u00a0of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Non-vested units (in dollars per share)",
        "periodStartLabel": "Non-vested units (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Non-vested units, weighted average remaining years"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Additional Disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options, exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options, exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Options, expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options, forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options, granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r340"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding (in shares)",
        "periodStartLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number\u00a0of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding (in dollars per share)",
        "periodStartLabel": "Options outstanding (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise\u00a0 Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r326"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, vested and unvested expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options, vested and unvested expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options, vested and unvested expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r324",
      "r326",
      "r327",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "terseLabel": "Non-vested units, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life of options (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life, options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life, options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life, options vested and unvested expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r89",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r43",
      "r54",
      "r55",
      "r56",
      "r98",
      "r99",
      "r100",
      "r103",
      "r112",
      "r114",
      "r129",
      "r183",
      "r269",
      "r274",
      "r342",
      "r343",
      "r344",
      "r354",
      "r355",
      "r394",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r446",
      "r523",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r129",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r42",
      "r250",
      "r269",
      "r270",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Equity component of the convertible notes (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r20",
      "r21",
      "r269",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted stock units, net of tax (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r20",
      "r21",
      "r269",
      "r274",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options, exercised (in shares)",
        "terseLabel": "Stock options exercised, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r43",
      "r269",
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Equity component of the convertible notes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r43",
      "r269",
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Stock options exercised, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r24",
      "r25",
      "r94",
      "r162",
      "r179",
      "r408",
      "r449"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r172",
      "r173",
      "r176",
      "r177",
      "r178",
      "r258",
      "r268",
      "r385",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "U.S. government agency bonds"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r130",
      "r131",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "verboseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r117",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r116",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=SL116692626-108610"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r548": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r549": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r550": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r551": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r552": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r553": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r554": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r555": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r556": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r557": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r558": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r559": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r560": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "8",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>58
<FILENAME>0001178879-22-000014-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178879-22-000014-xbrl.zip
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M(H.974&++.G=C40H[/MWP8?FX4Y0#^[;,K?SS].KO58OK]"*,C,UEE8O0@R
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M[Y>'Q1?#'$MC(D-"+S<JY90)N 'RB:L2I+D.Y_ "X"4?REC:&7&$;</ZQ48
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M+ JUK-(Z]=;K-*68$ TBI8AE3FM"K!/S'VBP6.9ZL3.YF,!8RA13Y0A-:2(
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M(=FC>KCC0B9#Y$XSZ[J9J5,C@,&K+PUGSLJY4F79-UGEY83<A'&8W T-%Z(
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M'V*"6Z/^(1H]=QL3$N,H_$UK1W">J:K*NJ:7"1_",L.9RL/2Q&WZ/F7X2;0
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M^-=:>MJHX[A#%)!Q@,A!3'X(63S6P5MDC30I9#&>\_W+*6^Y0:.2)JV2#NY
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MS[#G(I*L1L%D5C=L.>.ZVA410=6O\"\T<>J@Q3.77YWU7BT5-M&'SQ3=<TV
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M/=;G/!OFR1XG7C+$G9$(7%!(Q03_:)4&RBV56HX3J!2KRS O@&\>X)>0&U0
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M2S#0"WZ7AM]IHYU8"T%&AF24R0P (Y#*2)82./,^6I+/7R+:@!>)1RL ;BZ
MEV"S%P O#\!3=CP6)# J DIR8[EELD:62H8H=9(1G8YG:RH $U@DCJQ& /_
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MHE@S6G@_DLE62*\Y4WM<A_J34EUALWG8;-H5C[55U%F.,+4*@=:Y09A3B.J
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M*B+V(!+T"4L0UY1(XR($6O#?-/Q/ARX(Q:4)EB%,7-("'-'(*!>1C\!"U,R
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MWG[=__Z)';QZP=)_O[T[V8/\]_WGCKVCKS_M__,R'CR;A.SEELPG[[[M?_R
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M&*&!,9KP+Q0"&QQ23$J$$]R5 :L=)/M-%^07Y-] /H!5-D:;=H$'[KTAS/)
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M/YR3B<*V;XYMOURS@V#*="YO6DE)$4]I:PR)#AE7513+"F;:[#Q5G&V1X[%
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M(9QW!TD/1T'X'N]++._<](?7=N+=7S@]KX</!4YO@.&YX4DX3$MHAJ@%-*\
MFHN)&#]^WG_QQWOBJ3>"8H2]]P@VO0H9J2HDB!8&*X-)/E=/MBFI["T=!RJH
MLSU=NUL2MXXZA<=M$)+.%B')O:=.!>:\1-81@WC$#BGN*0("9T''Q"YZMO.4
M=\7UXSE+P,,5:-QI+YEXPY?3,/"]2;;Q3@>9V&TBP.$!H^U#5IDWSO&:=?9R
M89D! $]'H^"?32?[P\F[D-7I K-7@MGU(B'152(&[9#E/"(.NV3ZS2 =1<54
MQ%)&8'Z";9&J7*QW!8IN]910@:*;@:(5RYWD7$FO- )V)U*Z"HDTQ1@Q162T
M,:0<O*FXR::"H.Z1V>XN9>\P#,Q@TNF=I 2=V<4_K@UYDV/HV=%Q77(U';Z&
MKWJ?BEWOD6C8-U:CY=5P5*^YUPM+KE2)VP#J[K]83!)TQ \.]]YSXXGQ6B :
M8\HI%U+XJ>&HJKQDF B*F7_ 5>(*.#U(<+JQNC(7@%,!H:N!T-DR"+D0'87-
M PD9#>(61V0HQTB06%G&A#1)"ZWD%N%/9GX_3XSM!_C7]SX]_1_XT;YZX5F)
M%H71IB6&X%9D\A-_22I*SWU;B&B.U RA8YP;GD!KSE( 'F@P\+[)L/-\.,B!
MKZEN4J?)[6KZG3<3^" O\]DPK_:V>0&G3Z2 9IT.Q[TT.[^,4A$FH(2_?N[Y
MR7$KQ0LWUD/Z"Y[?8BRT83JY^)9;'-EOCJ-:'HW%GZFU&08<HR+ ]LH%5UP2
M960P)!A/K8L>/GC/^$Y[T_&H[<&I.0K(CH+YB$R$#OYB^I_-V7CGYZ5Q..D-
MT,JXKPY9/3!/_\>.X-9S6GNGH[H61YQ'=?>DYZ;CSN%Q&)G3, 7Q&W=K&0>=
M^\F%"W!;FC^3I60(_W%Y.C&C(YC>1CH(768<=P8HY_?YI[<#,_4]Z.0_UCMT
M23&0.Y<;A>:C'*=/,X^[BUDF3SH-%=F?GL CW 84HV6V<3 Z,H/>UQPI/U]&
M\,?NP/\^"N,49Y_^/(BS=35?5B]FX?>'T*9G_:'[>,>T9/^LI26O^@>'0$TH
MO.?#,_CO#[I_^,_C=Q]>]?;IRR]_G^S1/?J.__W;'KSGSW[X/W^>_?V7/[64
M5WM_O15P#7OWUTNZ]]M+NO_B'=D[>=7;^^LU@W>>O .B\_>'XX_OOKZ*>U^/
MSO:/W@?JN6-:HLI)EE+X)1=BY(A+ZRM5<6VDJWEC;S -?C<IE[K"(1I%N:""
M1T^T-;A2PEBL+?91[W0"<+W3A#FC:=AY^@+^'/5R19_D]7HV'<-R&8];HM(L
MD!7XA>^:M^99K"?GNV^^HG L0L:'Z7C2BV?U1[V!AV7R"U&W($#G[YWGH7PG
M 7SGIP2<.\]K=K+SCTYOW#&=H_[0FGZW<PJC!2U'/GB@90E5;0\ UQT/H-U'
M9YV&U'3BT.6J,C"RZ2@*L/1TTJ +_/Y3Z ]/\^_IA+8/_5[]76< %_4[)^G!
M:?YRD-K(C$)Z0#)OC9^DUG::AG6.36K7Z7 TB2":P^SO' W]-"7Z/DT?)]6D
M!\_IM?F@\HX0>Z/QI-L9CF ;.!D.AI,\ &?Y;:^,'9VUKX.KS:1^BSON0;-]
M!S;W,#X%5N";\>B8TZ2!I%^@+P9NC3&,D@VN'1H8%,"F]/#?4Z7+]N'=^NF]
MY+CU ?H9/O5@7C_W)L>YE6^?O'G2>34<^OS@%Z/I46?7 ]WHC2>C>KW^M//J
MQ2[,#K3O<^CWT[_IQI?3T? TP'+:FXWC[E$8N#.XX>4>W+ \B-  F+&3WB0U
M%_;,A;EJIJ>=KLX UFT''A6:!M0#5P]P,W+ICJ5NCB^F"_=:>-(0NN$(QF(\
M&0Y"F[*R&=7_'B\L2QCAWTS?P!\S1_Q&6UP]$9=H\CGZ0!IFQ/+=JTH6S%QZ
M0#(Y$<E_O9%V7W*D.S^9_G@(\@%R-:K7**QT8-Y',*ACV&]W_M&=RW5>@<-!
M_ZP1S 1 2=!!9EUOG%9M"R]9)$_#\+0?.H! :8%GX5N&@,_'0T" 3Z"MP:Z>
MU,PL #!6G4]FU#.PT3_I[,V:DJ4I.:4&D\46U!*>V@BRZT.F&65-7&=-] 8U
M2 X2XZW)_!CP+8%F6@XS#(0+,E*^?/(V?]'<\+\PVWYXDN_XW_Q%6C;_--"5
M;KT*3J;]22\MC62D2$.T /7CSM$(9C[4T R?]M-&F(NV9N\DK"1HWQB ,ZV\
MHS"$RT^/$TZ:; ?)3?\\'/7]D\[#1<=^VB3;_6^<=F88AI-S@+)WFM=5DIUS
M*$GGM]U=F*?=0P2_[,!$)3#X.!A^'B08V#U\1C'^>?>04DK2GMYQ/=#<^U,'
M*]LG 3;]:'X&L.A/DX"FF:YI!F#&YR%*9 7@>P!\X!1(3-JV^QT;QFD0D0.A
MACT5=OM)HO3K>_@3H$N=5\&.I@8@ Y0)72,1[,NS)?(LF1!:)]UA0S6 1,"L
MM=OXL\,7L(T#KM6=K&/S,UBT;X9!2X6T =C&87).&]Z$4U [+(!,LJ/.&Y&N
M3K\G;65&D#.7> LS"TT/G5U@2S_M_/[B[:O$)2:PQ.">QK3K\SMC9\] [Z!O
M25&:M2XME9J6S 4 GK2?.4FZ:#;HM7!-^^<\Y-EL??RK!QHUS-?RTY[]JWW:
M>?-:,QD@-0#&K8J?GKIG1A\!HT$.=Z>3X^&HT>&6GYV<*13_NK>[FW\CO_ZC
M194XG(X  OX#LPHJ?AJ -*I/.@>#/!)-'^:C##('8M^\N^%Q"X=I\V"]V#UG
M3/((_&OWPOZE[$4)AVI 24].A#K/U>(4Y?/=N],C>/!\A-/S#]QDF!?%K,GP
MP-.0ZD2%_ME#!I\YO, ^,&K .>_CP/=!P,,@)[CN15@.>:_NP?4Y2Y0]R]-2
MJR+ \ #Y/_5& $KM@GE^\._7+Q#1LU4#+_(!@"NS9YB.97X]4VS3UT,+??H4
M9CG2/8@U*"70>VC3Y'-J5J->@3::T"BVRS5-9V$,UV(,O:2399F9AM8Z.)\=
M((@YL8C+B-=.<A[WWB05B#H:9CG,ZR0IM<:Y,*[-C$L[Q'<I9<J+#P-EX-^3
M#%3GJ+4G\&VZ(M'7^0*&.TQ_B5%T >*!<(:ZD8U*.DYI(,Y2;2NX(1_GG]1*
M7BIUW&BJ#H8H356K,:=T:7,]<N'U:91F38#K4VJ HU%O<I:&*3^X?=($^'!_
MW/(G^/"DSD(QFM:EEI]T_CH.26=<) !P=;\_FX8L(_EE(3]F.$U >;8HJXM/
MK&_VX31'.P]69O0XF#ZTI&EF.#GM#\]"&K+<I68^07+3<*11*N)U#?%JM[/Y
M\,\633L#YZS.]86_!)=-,>+D8D[&]C3MB73/!&_94@3+I9:N00AU#8E6+F%-
M'O= )D]A3X:EV_O:FH*:)9(:/S8QS!=UTU8@Z1_AT0XP_?\,/R="WUUAK_4.
MG7?@94&-TQ2DV/" )%%G /'0M"-3[[Y+.\YT4#/:YJ;Z*^C5"'24_+X6CMJ]
MY@%;5>:K(>E7:;:GH(QE;N<#8$ OT^'_NOGT?>K"(AA_AAH<7YI12H0]WIVW
M\47=Q,N=2M*/SB/P\NO^T?M( E'""<24QXCS:)%1F")&.7$QDHJ3E#+YR7KU
M3- G^_U,A[+$_7,*:B/#"XP7-HA>8M*3VNH['64[9G\X'B>/8*.%U<:B- >=
MLV!&G49G?Q%<K4,QLO!$&\Z& [\.5,>]\03 !!X"LARGF?]GHC!'@?9]<*'[
M".V-V:H*&U#9::ZQTP!/"[!!C),GP2:+VWAJ@+7!W]"$OK'#9OAKFTZV[B]6
MLA^-4D&([*)[J K0,]/X73(]J\V1[;J$(3@9^FS^6%C0%J87AG5<^R3R/M[<
MEM.&M6LE[Z/NN/&GP.7I %K>P^:3TAO##A\3"*;;89..K<7K7)VL-M?67"RY
M5,T(GM_8BO(>W[A>@.?V(QHGW1GF$F  &.B3SN\SFTV[9;;FI=4-L]NQC5.P
M]6ADPKZZ9&;&*.@9S$#N<U8!!C Z-<?/M'TPC?"Z.G>6,Z=U@Y*%SPVG?=]J
M"<N];C9WUQS>&Z5<Q:-F):X$AJRX)A]]F(_>1)@/QUL2YK.U(17TQD,JWLP5
M.2!-PVE:XT>_#_L)+L9;$BB!]YZWM&CO\[N3U^3@!5SW%:X[A.]3/.6'?G_O
MZ]_]_0] B@Z//[P[?$W7:-'79[UW']YR:-.'U"9HR^>#WU[U#OYZ^W7_Y"V%
M^X\/?DLQH7_'@\,]NK_[/G"E"%<:$2P)XE@:I(CF"&,7@V5!,DE6 R68A\5M
M*BN=Y]RS='+0,.HB5MX+IMEJH,2;Z<E)LE4#3"Y,16<^%YUV,GX@=N+[C5EN
M?.!5\-I9*AE(+(Z6"D,-5]0*HP (9K'&-[4:8:/LC0_BRDH\JW\^WM7XQ^<]
M6(U4<<LI14[*E #6>*05#TAIJ2S#3L-R7)U0&R5WIG(5EL#JI=?:QPIS0HD3
M1I*XNAKO$^.Z8CQ>7EI)S!8#Q1XFW5S5C$Y'X=2,&M/A4I#SM(U1_'Y49K9U
MPKTCG\C]2EA,'8.2%*]D"VJ-0BV"G0(K<\EWVWJ$DPOQ]\:-E U)O9-6(\@&
MS5DZW$SU9J_J#<:P3%VCRPT[K^"R#L'HCWS9;M*0^B%]@$F:Z#_#43(!I,>\
M0?__DXRIHZ18]L\RV3[K^&'V/C3L.9MR&[JZVH;%W+T-3\QVHEEO:I<1C&P_
M3,)"9\:S <Q^P=IXVQLT5CB8:E/K/MWK3<XHQ#X0_]P%X]-Z/*E+;BSI!W4<
MQB#U+-'=5AM?NF$0DC$O;4G9WI=EI1--;]0_6Z'/WYRY<PCTXM[U4$3M_'WW
MN[";1?2')[LNHU);X 8YM'I\G+4<F[R=QF>'QG#P83JH+7$S 5I0?<Y9H.<\
MM['_UHZ'QAD[?\CN 'K=!SE+H55)O4T"68>E@Q#^[\S7NF+:@4>M6G;(D_HV
M>$#'S,7(+T>1+K]]$6 :B@3J8GWJ-L<FM2ZE339S71/LK/&P&^1'2T'/A17M
M_?'>51[;R!52/@3$J4@EH$R%,(]&:R4I(>01L9RE!?*0V<WWV4J]X[6[ZG2P
M8(MJN%'K2AY/[;CG>V;4"WF7AFVMC9F>W9K=:2-HMFGX1XJ"#OW>";Q\$EK(
MG8_]=_:_FX4) #@8L<'S;#($B%AH]^[ YS]K8C1^[!BR)T#/UU*&$"Q'5L /
M4)0#,M(JQ*/0RE9!.RH?$88TJZ?3+I_.XOIYN)@2&[H$..+:GN<(L>%XLLX^
M8C-(B]B13.UP56_4 5E:>$PZ-C "1C5 65U8NJ6V[S<#G'6L<QLR;,(TS&"N
M=/ED*A^E,)%Q:!"JWYL;OA- 31I1#SD-7>M"&+4A:J&IQCVK)&SZ6;D;'X<P
M:4*GZ@2/^>DYNUWRZ /(GO?\C+4IQO8HS,9G]HKZI2W7JKWPH)/-58^%V+J9
MFWTRAZIV"LYEKA=.SU(( /#!A8%K(/Q+WB?\_)T>F.<HPWKSUD'(*F(["NDN
MT)U2&1/?*,4S?W@]36GS&(5C&*M>'5H&MZ8PUW%2PU,DS2S(-3T^.R./AWT?
M1N/_SO42)V=WNGN\'8>#^!+D\R1-V>/;$AC0RLHQPRGL 80(B[CV&"DC.,(Z
M4L*#X-@^)EH)2R(MU=FB>+B[0&TKF\G^N6A3<[UDZDA1=UF[GMN!&NO0>,&V
MDR.CS$< FW;\:B 9CZ<GIVUD0HI CC$T3LI15E83K)[,J.OY.%\;CN;VJ5Q:
M*BNH1^G5%VT.]6O:>/*+@+4["R,[KT&MCWEQ<Q@O%C"J;\H:>AUUE8QPDVDV
M/M516K5WMCZCUT)P"AJ;C=0#C:O:G1UB:8R1<Z4D1<:,&V-MX[9><Y[7 2]F
M%E.PXK^?3V4[SA>%YRQ&X+2!&\V"&%]DQEPP+^?\1_+7]%;3/TL&]L]FW)@!
MYZ';,0<"Y"#7W@@V2WA8B@]ISD>"! 58MG6\W2Q'0'Y\>E<ZZIJ'I D/@$T5
M=LH+QB<%]>6@<AB7>>-O0NP:8UD6@*7U?Z=;=U.B\7LE'%>^KY7 Q[?1\_W/
M[[VVG!"FD'$PKEP8AS16$55$:DF,BX&N>=4"]X%;6/D5=_ K-H%Q27AE*D\,
M\6N'X>\3:EW5WI0K?><J)B\7*WW7!W[R\<PWR<_0;%5)4.:KL;[O80+\RHF3
M#%KC[)XYAJOZ9X E,%Z+<4SCSNET!,K2.#0N+P-PEB*:ZB!H0.H0TO'XR?$X
M':OKI\BIE6W<.'AF'4J4D-2&M1KL3Q9G9CR;F;J)M9Z;DPBV"L]B\\YIU%$*
MZ)XKI@LMG(?Z7=S?C+X.[FS\%C +"V, ?1R#5M1)46)'"<.AS3W03/W2(8WQ
M<AN3<I9/"?9B+\$X?/+)]/JINP@V)30V_44MKD7[VL.5#JU-0WMN8:Y,+ED;
MGS4Z\IND(T,;W@Z@Z7U8&;Z3E+C4UB/3:S;B)LYUZ65I&(%!GJ<JILO7W2Q+
MKW^SI/0^7[K]7W#[D\ZK>4]@[[1MZ.%L')KA6W)QSO,Q_&<ZG,R&.'EN<R"G
M'0T_IH-W(]".801'^;(V1 \^K3M3'Z;*[^@-3J?G1M$]'B?@=W>)IPM(F.6T
M$<+DL >^,DKBD.1Q.O! ]D(_G\ 8PQO&\:QA*_. Q4S[FT-,!L0R+(A8O?QF
M[ZH7&"R2Z;B6A=[,7)Z_;%9F8RQ:H#_U%\F.M?+EE23FNRZT$FRYFE@)7QQM
M>0>!DQ>L]N^$CJUP* ?DBC,OC+:!"^R5=4I8;705*LK(S8>:P1)-DUJK37_V
MQA^?@U+1FZ3?'A\3IGM_O"=4< V:$/+6<<1599"5H4)*8NJ$#5JX:G46E35$
M5<Q)ZSWG%*M*.<XK2:072GO\F)CPXGK*>W->3YVTH!X\Q5V***G#M%;V'U"/
MA^/Z$*%;'2E7C]0(1FI&1)>V0)>UC%4N6ZL3)^?QV>730>WAV7%]_B(])ALC
M5IZ7]CYK!A]G3M\F>JJ;:78:N6YR%Z2SC#'X)MX-GII/^R9/\.JYX9J8UF\]
MMYGIC8D>H_],33H_L7@F^-SQ7#_UE.+7DC?B:) I:/JX(9W9FK8PM'F;'D_=
M\=RIW9CJTDV-$; ]'=D$?H65<U:S8RF]G%DGO7QA8A</!2_.:7OPY8)93#ZV
M<R?Q]MGCN5O;]T%N&12]A$VH8CQPR3E61"OKL64R%7^.C*N[%]?Z3)#]D,U>
MPZ6YRJLFS=9LD<#J"KV:U;?!87!/+]/4.K=;4JHR 7THQ^C6&>CVJ!7?7UU+
M(OO?Y\\D(-JR,;A.J05+( SJ-; \N7,X!LBJDSG-7 /9][&XNG(2@!I)FN.8
MM05WS<T .L31/"&  [D<GB0S":ROF;Z?;";#S[7!.'F/YP=*6_6ZV^G%3K86
MY_#!<WK;I U<Z6'B@WZ6WB/WLS;%G]9)S3O)#UPK[P"'K5LX^+E3I.UP2E0Q
MS0;F?%(OB]-GT/:/Z_-MR=-N '?;#F9U'-J7PI-'24/OG:L5[:[;[)==!3,O
MM!G,1RD/DA].[21.^TNA3[=P0ENLLNS=MEDP-2^:1C6G.\9_SB;H<H>SJT?&
MR_</7_*#/]Y[+BD)+J+*4XMXT!@I&R-2@3+/L55<Q)VG^,EZ_9_.27TX^\EM
MAJC^GK!A-#G[O9^.E U\,@OGHYV//M2,[A^]KQA)AQ\=LEII4+((*%D&5RA$
M)0*HQ&DZ'Y'2U"Z6C*BSE?(PU:6EOH:VKWE[R=[5.D1KF#+AUK;]I3P;.5UF
M'5G:>;'P5TYP:?JN#4#ZU&3S:7V>R7X>TDZ0<OK. J7F6<<:$UY[4"2?Q:^W
MQZ5!@DX[U/N"CGL>QO&71R.V^X=[8N_HO=(ZG>602#/%$6R) MG(&:)5E*;"
M-E3$[3S-#I!F\28.\RVD-<2$R@3O302=PED#P. J8BM)712470=IW^89_U<O
M+F^L:0Y_ 94/F(D'$O3( #C-Y$$ZTZNE-+I")&K8327VR#J+D:!45Y2I8*39
M>1J39*2#(&NG;K.Z.LG9-,?C.A=A+5#])@R\E[,?)*[8?E<?21F.YI(8:Y:6
MOTA.HZ4J<@\TXN4PGZJK1\<U(;6GYT/BS _2* :M3[!V1S5I95+Z-D#!G-9W
M,AGU[+2V'Z1GYSMMLFVTD4@9Y5J]-261RGDBAH,Z"J?QU369_=H$;>E\6SX&
M-$U)/1<+73:9;!)DQTEH3P]]R0['[!#)ND9.:G@ZG=21I[,0G6YCA$D:RJGI
MC<:-&2N_+E'E;NW%/$Z9/VM=N_7%+IAHTE\U9-=)OL:-\[-M67+T?DC9VL-I
MW[@VFFMQG=5J3)M-MW&=UJDPLBGIG/.>K>*1SUNM!JD^I(6ZKMCUAX,CE/;0
MV1SG97*29C OVL_'89#RD7523- DN^CKR.<Z7G I\ DZF3/U+V1W,:-1/@=8
M!QYE9_Z@6;6I5M-I#FVJ4V5FO2^%6<-R?])Y'=O'Y5E,(C-O5/C22WP")OU#
MG1:F27DR'>2L\M/!S/<804_+D59#5R?*GQT:K!N1-.N%UN3%D@:I20"^U(?&
MC1Z7)6^F0*>AFF4=/._I_SV>^Z_7^CKO7&_<653*EW(8CGIITGP.*5L5_SDU
M6G#ZU^%<:;DG>5Q\37;*AV2A;3N:C,#C&9<ZO]NKZZ5F9A>^?EFVS:21[1HI
M5D+2>\F:[,,#%;\7\_#1<>]+&TY2 _&*+:2.PQV$E5.NN1Y#2#4>9ND%E],>
M@J"F"W/BYUE5@.4%!!/1Q# V8MC$'S:/6 3[)\E0TV8&7C?0S SSBVNJ!O>K
M&F6N6UITW3J3.O!ZUJSGN57C8HTYES]^..)[N^^5L:3RTJ"*I_.FT46DI4I.
M4QZ(QE7TR7==/:DNJ,EWODGF=J-$_ZS#5E^!EO=\F!QQ;O(7",_SQCSYZ TU
M!/0$JBJJ';/(>@X:7ZC@MZ DXB)47.%0!?.8#H T2Z;S9XUH#_UT<>LZ&>08
MN$5'R$*@Y(-S>]U)]LAS:RLLY>=>=WK/'!]M '[R;.?9 &HY*I5<KI>7?2%F
MMA-Z=63GH$[+T08GV#J9TFAV?B3QG]Z)G8Y2*$ PHR83T'A69N1)YV"40Z!+
M8N_K)O8>A85\2[67LSV_ZE,QLF0*&39FA5.@=">FSHTR(\CIE&W20)*C,P7O
MQDE(\WN45)1!;92NJW1,'D-)BCE+'\_P)"GSM>FIU@/J8U$6>M)F$AZNN*SG
M%I\Z0K>75-):B1LZ-QWE6/U4&Z]79RS-)2;R:[+>-YNF'&.].(M#FV-Z$P<<
M#?MEN[G>O-=[R4(BC\:FN&1+F ?-UWI>>WZCC95?"7:>N?5=0Z;';53U;)]*
M/")% <P.HB44S/7*:I/EPO/;59./UQ_W1BE"(9E(6X-->_+,YM.1N3MM91)X
MT?G/7&J+J;557R=26SC'V9XFR4NS_6QV+#Z?G"BK[]I[Z]PFL,QKSD&AF;EI
MDJ-1<G7*;/:"/=7. UO,4N!=>W/Z=S1.)1-2-$ZR'&8<:E-,+-1":,_1S%=G
MLC4NGLDU]:'=Y375[CS+W5@*A5EZ: Z!63T1G/K8YJZK3X V1M/O*,CEC,#J
M&0&R_6<$[CSF_T5O;(Z.1N&HJ1+=:+6'298>L;V#[7]^;TF@!&N&M(P1<9!M
MI+F62*C + ]*"RGNL[WC^^E_ABE4+9N>ZSCDG)@YX_'D.S:!C)%E7[S&ONCG
M@EFG#9A5U'*)")E??E0+$<OKKH;H\Y9=,^GM/I!T591K$9R.PR_M+[]".T_[
MYNR7WB!W(M_TZW(3SAGJ_+KZZSF0/L$UF$Y&\)]OW]Q\_21_]?/$KW_'Y1-!
MY(5?XR?D![\3],>>^JW&$O*$_.!CO_T=4[0T]GXU5E_JL3]G>:AE L0N2?W_
MM\-VY@3&IV/*O^ .R6+;/N]'+M5KE]+3+^GB<Q!C%3RS,&]ZMU+?JPF!Z\TJ
M';/?J_VB+Y?\HC.4?'RC\J;WY1)C\IW598W[>)0K0J.FV3'_[]=O#$4_Q/6]
M]0X'XJ=LGQA.X1%^_(]-K(B%\:GWQ;RSGDXZ^8AWI^W1O5HN24.XQ-A<JL./
M;>#(+2VJ>S<PUUI1&UE.]V[(R/7@V;D0 )Y_5+S.PVYXR*9'0W]/"<JCD8[1
M768!730(%ZV?C0T>[MSI]G>Y4?ROU2'<7/<7NSU*K]RF?E\AC(Q76 DE?+"2
M<QF<L4YX)0PSDI$896-(XQ>%D;$KQA.]_-(D%]IM4AL>FB^7BS%C]],6=_SN
MY$O_X,-+_.[#?O_OPR.^__7ME_T7?W[8_[K+_WZ1_O:]@]_^/-E_\0R>]7>O
MO0?>-?V;OJWV#O_L[=%_]P]>'+']PY=X_[>]]+Z/^6_ZFO_]VSN\]]N_C_=/
M_AGW>OCL7X<O)WMO\-G^X<=\8E##U(H0D"1*("X\0<I1BJC0HHJ*5)5Q@+ZR
M*SB^($SMQJ0H?7M%:2I@6,#PQL#04,I5Q14-%>::.E5A(H2W,7+NL2,9#$D+
MAJ2 X;:#(5X!0ZHKF&-KD)<N !CF C%*(QNQM%XJRYT!,&3=2JH"A@4,'S,8
M:J449<39*G"NE-:""QF%\9'9(-7YAU(+&&XO&)(9&'XX$OM_O%<A:..-0H9Y
MB3AG#JE43909(6#.->-1[CP5I O,L8!A </'#(8V:&6$B=$%STWTBE+)O11:
M81HBHPTS)(49WA,P9"M@B(TB6$J%B X8P%!8!&J 14)HR8T/S%1^YRGG7<'6
M<^ML*1C>DH/KSHRD+[^@2]I)OVM.I^<Z.L]%[_L,8\(86U%#B0B4.XD-H)J*
MAE!IL-,L%&O?O8*QLS5KGZR,=;12B'EF$->1(L.]1]ZR$*ESTBL.G(YUB;XB
MC-TF.UO!H<<NM5RR*F)E"0Z."U#!A-2$5Y4WADG&?3%+W3.I735+265EP$R"
MU)* .#8864<XDAX(9>3<N6BSU$HFMD5JBW#6PNE=Q7FT'H34<BFUHC"56B0+
M<B"PM18SR3T3SE4S"171&.(4"I4 S< HC;23!E&MI&.82^-4*LL@NY)>T4Y2
MI/.FI9-BH0QETMC(N !.1'S4ACGEM!/4%KW]ODGGJMX.<Q@4,")@N%0B'B5&
MVBJ++",X)KZD).CM6G>IXK<OG#\:P[05(::7$\;#X<3TU\_!W&'P4G/V@L&<
MI=37_3 SJA2S[:;&YZ'L#]@:3Y2KO%215SQHKHQW),JJLI7DNAA$[M/^L/]\
MS2#B)-9$<8&TM@9Q;SDR)FBD2( Y]R%YNG:>*@RJU8;MNAL0L_OA!2MX6_#V
MLG@;F&#*4QE32!7W6%/CO)#!4DZBDB7"ZK[A[:HI2PMK0;^J4+#*(2XY19IY
MA93UH$5SA3$%/BYEEQ-6\+;@;<';&\7;ZV:)+7B[97@[MTY^=70?\+:*E39>
M(J4(1YR&B%04'D509FB >:7$[CPE0G<YOR@-;0'< K@%<#=$<"OB526#IT)R
M:X,Q47$K3$4<D4R&8G"^9X#+5@#7$6IX9!A9'6C* *V0X9(@%QB+7EG@O@(
ME[.N(E=TUFXQX&9#]L\YQ<W=I"E_/4B5-(:CL^>INLFKX:@5AO'!Z/<ZJ^RX
MSE5^/Y?U-5)V_?%Y__/[X -HTSHY/@0L2VH8LD$'1 C6H' ;9NQZ;5J8"  J
MQX,PG%65PMIPT,\EPTQ3^Y@*=K?+*R5=32DUGS=%B7X;I@+(;Q92>3VLU+=+
M_5XJ/E?7+?E<5[7*-9K2N"0_SRBDHD Y15:N5])=RI9ZUA1 &HU3_[K-;\/I
MI',2)L<IP>3J.T?A4R]\3M57%ZO$IJ2Z=2K3L\X8&H).AI]20K:4HSCE8817
MYIK:&13F25KGU6WJ=&P)=S^E:MIFW/D<^OWT[\Q1=1SZ$:4*7*E1;;;*MN#(
MK-A,+U?C3L4^%AI>/Z,M-5/GX*POS&DX9[F#4[Y-&YK$O6UFYCQ"==;--I/J
M<MVPMEN]\2S/9BX;LOC=K"I.JF^3DC;G C>Y$-'LFO],4X7<MKKXO%1-^'):
M#](H%=H:-;7&4EFKWFBU 2G-62[JG<L0^:66SDM-+58W&<]J>AUE\1GGJF9M
MIMQ!WIWR[6_2:JMKP\/%!VU1K+LH]GT7PG=!3>?OH?+3Y^>-;J*!;<WAYOOY
M-*9KNAUH\#2F]*U-H7>0D>GI*<B:.ZZS2H]3(;"Y=/1.3]L+C^%'ORZ3UE[T
MJ3?.V:_3BFM65KIR73B[B[(W&IZ9?EZ0I^8L%W(ZI]CQ;9:H_3.,@QFYX]V!
M?P%"VQ_FLG.YP-LX/$I&L??U"/KP6NRE:UY\_+*W^]YHSRL<+9+,5HAS+!&P
M"H(J893V\ +/Y"J[<+'",@KB@C2<:FL\YSH&KC76//CJ$;&+=HUE 5E899EF
MC!\FLUCJLU_H\WS/"+60Y1UC7JKPPAN;RV=55^9EZ!N&,I[M2T >8#,9IWI@
M_6X#C@F]8+<U,XXWS-4L9M?-;F[> RB7WI3J(\"=,83QO-9[B[" IFG3;Y^8
MX'0X N@,HT^]5-MO.JYK)_K1]&BQ+ZE,6*X;:%S>?WV3O#M5XTNWQ%RL\8)Q
MJ/'X4^@,ABV+ $@-HT'.\IH><,[H(D#LC-$7/7:UN,/CVG2_"U; E.O,]R$5
M"DW$:C2IN7%=?B[12OBHI7)-AN#_]_]1E,A?89/>0!FZ>=)^F/D!@C]!8M+:
MO$K9.$(B89$J6G'&@Q06R ;HB#BJ()34]/WKRU6+:]7OJ>D?S$IAE&)QYQ:+
M>_$1VG/T>0]:N?_AW>>]=-K0"Z6KB*1D&G$I/3(P)<A7R@1K"9&4IY1H3RY*
MR=-4CNOT>ZW:<5ZUSA8Q,S[.YFNI=DG61^:U8V<U,^LZ ;ER91BUZ?T!;D89
M-),0#$]@-5M8M[&7\&RA*0F]:CS.J):?U7*#!,UV7IDV%1^%YYE9^V8%=T$I
M 5*:E;%4/CGU*2F1JV^>U45(>L[9<DV%5HUUJ7 42KB8U(Y4H@ NFS<WUU
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ML9Z.4]_@F; J>^-C^*IN[7BYA.BR)IV:W'1JU!M_!-#MY<=D*V8:F@:>QXU
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M7-N@4+P@#U9ZBT%A2X5]U:!0<6N-]B#=/'E(L/%(^PJC:+&2,.'&<%EB&(K
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ME[P7?'@K#EY\?%\%AX7E&#EA)>(:R+"*(B)5*1.E9@SV@XV5<;NRQ-RQ0[Y
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MXWJOX!XH1BDWI.T[YUU['"N=BW;L]D[J9_G.0;OAR3<-G6C2D&7TNE/YZSP
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M]F_U]F" ^B>=<WA.F"F-XTT.5;F0RM%YMIC!HYO9X/S'8]!V7IECK^GS'3I
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M1^P-G3]<(^G3K(<W?<3PVVN;#SE2<[?7.X]AY[P+8S?8*@=10:/1M3=S7!H
MC]@II[#26<=D)%*@&+W-H;D2P70*9*/%QC%!-(T;VXR9B7UR(GI@A=QKY4%!
MJ?F_I.9_#5>E\K\ 2)M2=I:1("E*5%/$<[Z0IC8B">M+,T9T<C(S),EG%[59
M/F![0U[P<L3*<X.)7G_L=%.LER<'JZC[/_/H8#CUY]W;7;8T#AZSDTZ21U&O
MF?-.(N.T0MQSA:S)-%(A81<HMHS);!RP9Q@'R^<_*X\%2N/@)8V#*<!5F@?S
M [5Q\T!0Y:+!$BD1#.)&)>0P]D@(2923VJ5<XYW0+;8DI:!*3W=Y-K"<]L$J
MG@V<U;OER<#;LPZ*B2_N*:V#)VVD4W(-K*!:*84"M3J3\UAD&==(4$:#XXZE
MD& C59/AN>71P1))=GETL-36P13@*JV#^8':N'5@HN#&)H\420RL RN0EM(B
MSJ+2&@<;,E\V(5NFS#I8WF>\ 4_WU"S;.Q16K^T"OS>G>P75W\=IOX0DPO+I
MH^2,1R6<59' @Y*.0BM#BT2U%U!ZR]S;Q6T=D['T+"@;>,+(.- .N \..:5
M,]::ZN02XR+GWII-JB<=YD_S+,TF8J4_O?2G+TYC?AK8E5FYJP%RX_JQH\QK
M(S7"UDD .160P3G6AC#XW2<F88RS?DR?K1^OK??\)4EKGE]<<!Z\N4\M+OB@
M;-\PO_T!3<[K[-PV<]5!NJ95!U]*[,EX)  ))BBO$$X*=!O"-++!YS(KW#L:
M32"<;&RK+3R7$I^E0K'^"L5Y+\S':A(+U"1NN!,+VL0;W4&6(#(+B+#Q6G34
M>^^T0(JK?/)N/-)64T0MD4(I+)@1&]N4;BU3KO$;.!3]%GN#$J0!Q//'X(]X
M79BTWZGDC^;A6YKC >J(X<M@8D/G/).>E\ZE%W0N#5;-^W:XJ?;<R1^5/J>%
M0>K>9/J6C)Q%B0V88Q8C;E- +H!-)D00V!'-HLTD26I3Z,D,KJ>=5\PH>N4Q
M;7E,N_9.IX<QL/1%S0_\QGU15!HE."B0S-B(.*86&1\!"[T*L X\9U04OBA2
MGM66OJ@Y^:(>+?+WN:A(Z:)Z%AJ,NZA2(,H;05#22B N3$"P*4AD0H!EX@,/
M/FULRRT]%Q=5J7ZLO_JQO"ZJAT'HI@9(Z<)Z#LB,N[ 48<I1HQ%-.+-J.X^T
MX1XI&P76CH=(Y<8V)5O/YI6:H\;Q!J*AAGIU4?K.]I<K#JIT2+U4B/_-&B@]
M3W-&PLG<X*1M$I9;1!S5B$NM$,PW1]I'$B4F5ED#QA?>9$HMD3N_/((LCR!7
MQKTT@FBE'VE^4#;A1_+),T(8PLY9Q%74R 7O$='&).^M99D$F>3"LNN'9&5,
MT^OXD>Z7[=)AM!BQGXAI"D%Q(0*">0_9?:R1-<H@QK3#P5& ^I1YPF@9TU0J
M%.OI,!H!H=)A-!>0&7<849H$\80@A:-!7$B!G!4""<J3HRH90?(!O=Z:5TK(
MW!Q&_^SG9;%=-"NOZ7K[O%AT\$FH_]C^-_RX;DS+=H_K;31XR#M"08J&'Q69
M*?0N4C7.>_UZNAQ\5&\'6*KOB"[0<*["3/!#TDR+:LF]2B?=]1AM5OHGL=+O
M]&T3A+L;?>>X#4_,2'\K?/!'KU_IQJ8=ADG!W*%A]%0O4Q57.L,4O>-!,9O*
MA>U5_L\CP(-[3)56W ;LN"?<$:RBB2KP0"UW;%;P^- Z:W8N8_P:NS_ 7)B.
M);7.,/2K@(W>?N[\Z/=_0&]KG?YAA,9=C\<H(_-LSI8519%F_)\OET<'X<Q1
M+O=VJJSVZ0BD_DNSNK\K:CM_-FMT5T#+Q=ZGSZS6^HP/&[73O?T_4W7_PU7U
MXCO /:.@7""J)$:<!4 !S'+5%2^3P%C$!!8&,U/<QI5A'=DB/*_>NQ.8YV)E
M9'%V0*8KMG)Q71W=#JNCGQ5)XWF1_THE%D$H'%($G *MB"<M),<I89L\YXK)
M&53BA:VS0=K[QTYW^%&^;KHV?-&!9\;VFUMENQ>PRB2+MG#)89\<K#+ND*7.
MH9#K)>)DF YA8[M_THVQDLV&WKABNW6SV:P:PA=/?%>'M53W,V#^%UB!T.$L
M)06&5?Z&1=6[[OUK[$*5!;_\D0.4P0:DKI"PMH^H$./*]&&K_ ;M; (HU7_$
MYF5EX\O7OWL;_UC9I?3KA0-]J]B,7#$'2P= W*PJ_-6$I@#:58YC&T"W"</0
M.W<-&),,T[#_Y\LS[(%F5@!YOG:@5,$=_4H![Y4XQ,__[@V_.\^JQ !,MRJ#
M5]_WCG1#(EBII^&3LA%0Z<=NJ]X&':57.0,4[>:+<Y-!<8DPJ7E;N&Y8=SB]
M>3O?JNS#11F8;?NRV'3:/7A$OK/0>^"V_'MNU&;EXJ3N3_+F%.+@=3?;4[XF
MV7JW E-\&ON5']FFN+YY<)J4_P*]JM5I#]6F8EB;E[E%UZ_(9WKY]P#]R-<7
M&M5FI6NSCGHYV/GR]\.M+A2U(X;-RI]/ZV&E:<]Z,*Z+]A/YDQC.FW$O3?<8
MW<I4(5)@HHU]4LC8^RQ=]?[E?M;)]Z%]OS?AJ[>VS36JI/KY.W>1*AL2\C;7
MN#;"(!MT0%0[;!*H*X+(C5L)>I\U! RJC90>)\84]RZ!"89MQ"I9RIU19J,2
M04,]@WGK=\'HW7X/LM6"-7N95]N(8@^+L6*'<S$N_ZDS^*-7_UF!U=P_ 66M
MG07_CFV1Q03L@ 20V;GHO;O7M_1KV)2_1LVA-W8*:(X9<X,%].#H@.59'*U?
M&Y^#$/ ,^UF&WEW_\J]0[YTU[>6[>KN SN*F?]UMN3B;,#Z+9@Z^_M=%/?1/
MWAG0A"7)KI9AV,+PQ8-OR5;AA1FSB ??,;T%5M*]7^,M\L3OF'[:4W_56(*W
ME.&KTEBV)?0B&BO8TYZZ/HT56TJ;F1[[0"C/(PYYGG#I*Q_[Z#$-34UUS@Y"
M/P:^LT[ZM^O^<WM0/FH&K_VZCLGU 5,Q&L-3IDI1C;+X9"=K51]!2RO^*MR^
MY6"%H?MU9,B*WV].YT:^/QP8TV]VR&[.#HK1N#E N&<YO0J&W<N4-"5O;;D'
M^[=Z&]3,SCD\(O0FF%1?8)1>86+*M7#_6ACZA\>6PAM(6Z_=FF7GA1_*%KZ$
MG>AC5@$JC!06%WGM7/5UC_^EWKM(@F,,"ZZ5US29Y%-4+%*MG2F.J0BAC"PH
M_O?#?\[!'-]M]\!V+RAU]\ ,[^Z?V/;P;.KFS.'-Q 6W/EP=[O\.[?A8/]K?
MO82VB5KCF!\>'/Z$]UY6][\UJ@>[[.C@J#%^X'VX7SNI?OKP\_#@SV:UL<MK
M.Z=T;^?DY*CQ ?JX^[-V4/UYV C-HU8M52=9P6$!>,%I0$F%A#C##AD1,6+&
M6.<9+(I\"*$V&2=+E")1IGV5:5\/AP4_#>GF%Q8\.]"-A106MEXV\[*5=S>N
M9Z5CAE\.YL9CAK4Q 2MJD9/:(AZD )C#$1%!E,;14LSYQC9A6Z:L,KK*-7'*
M$9MS%:$5,C ^#>*VYF%BTZG]7TMK@ L;I(H2*\.YC#9*JEV #1/40D'\RU7^
M>7"W+.9WI!Q0:17,:;N<Y$:WPCL7I$8B)($X%@PY80CR!D?A!'::Q(UMOJG)
M(Q.G%[<K/J#CKXTJO]X:^_/0Z 55][M@5.KO<P:D<?W=!Z6D"QP%L-UR\3*"
M#'4:V11EX$9+I>6@SL\CLY=?'I >IV0MG53/K'2_G?Z_ >?]("&I=,T_=MP>
M68=SA;3QP8HHM?%Y;WZU2=98;5*0P6/8\E) 7$F%G-,,,<^5Q2$FEO+FMZFF
M)+R7M3N7" U*]_QJ*OMWL:Y4]N>,=^/*/B<Z2J(8<CX3?%B?D'8&HRB<3T88
M)R(!O*-;O'36K[+>7([8VW76?QPD0)7N^O6U$&ZF^-9(*.V V??%20X_IR*E
M.G 492903Y@C$VA  18#84%QRO3&-A63]7CNLP)*=WSICE\+#?WC33YMKU3/
MYPQ#X^HYEEAHHRVRE+!<Q,8AS8Q'C$H<D])!%'4<Z!9YI'I>^N)+7WSIBW]J
M(/TR%GP;)A&/%9[*HS-S4L=J:/&/4^*Y (ATA'HB$X\".VE@)"5C\+%77BV<
M@KL,P7^U_70R!-]SJ0)V A'##>RGSB/+-$/.1A.=#E$)6U!S$RGG6Q1N#N)9
M'A&41P2+,T">!I1E!/\:H.2XU2&L9$)ZC9A+%'&1+')4*10I8V"2*J\%+B+X
MR;.I.=?V4&"U6+^?Y'UX*<%_? &YWEKR@;\<((SS@:O$$]4ZH5P, '%* [)&
M #X$6#38Q^"LV]BF6[PL(%?J(4_D W^BH3:=#_PIU0<>Q*%[>,!O]))5I_)]
M:909)P1GTENJ,L 8(1!W1"*KDD/.&>T3UX13EHTSLS5YZO+*)>3>#"-XLSG*
M^3?TB77C'>[E_.4-\62]"S? 5MPLZ#:W*O=QBL,S'DT"/B?$*$G 7Y&>^137
MCK\'Q:T@R2!FE<D5TS"RWH&2@;7#R7-KB-G8EF)K,NCRA@0\,Z<^DI;^O'W+
M7=FK7-3[)]><LJC8'6[(46'9A?HM^6MOP/0ZN?+GR3H^!Y6\9!U_-3I6>#:H
MS9Y9;5E PA>$'YPC0[U%F$>F'<.&$;&QW;_HS,0Y/KFWC.PJ0Y3F=$ME&M&S
M3J^8E'?%:J__B/^ZIM4LM+*1&X?[$+Z]Q;I>IWG>O_^6"2OWE3:CG!!Y9X!&
M?IYT;P_9CD&<N]&>(IN@L>]L\\)>]C;^>7=7AOUW; S'NS_HY'9!W3;MQ5/Y
M8X/"BAI8/B)(;BVUFD=+ E/1RDB=V%@IW:!XXNQ4Z:,P4ODP(,JN?+G%WX'&
M71D S]TA?2GFZ9D@$K2>CB]^VTOC()CAL?>6::=K%]\M(90RYI$(&'!.LPC;
M-]6(*,ND25AAS<9II%=IV?]RD6<R^ %E=4'+/B"#+ABRX2&]2KT]V!6S"(RH
M'G?TDB&'_*CN4# 99I;Y=G$>9 >%!>"?PC+-NL,>J!%V0-<^\MQ\4QR(5<'%
MGVFT1^5J_K39+TM_#7"\A0>0_%C^:RZV%*:+(#ZF<O[$QV0+M+RWWEBFGW;G
M>C5VKOS7K^H/G8VZ<WZA5F8U28/WBSI$U4Y1*.'#G4();WA4OM9_SC FCPY*
M>[B [S3Y@#WRC7(<K\1:F34N;TX,RVLU<+.P K_5L2D7U5P6U5,CAQ\=*J<&
MKIR7!_/9CD>_Q%ZT77]2%#X+\4=L=LZ*TF1#B_ UCL^?%RV\\F?KLW=_;0[>
M(^.:<4M=--SIJ+'BB>!$6 S.N^ORIGSF-,>ANRR&Z=ZTH2/P#<0Y-TX:1XW?
MX?^G/X]:NS]KC<\_H1W\L'$JJCLGC=K^Q].C3W\VH7WU\:/TO4^U5O53KLO]
ML778^$!K.Q^@G2?POM.+O4]54CWX<GK8^M8X:OV9.7@O)](7K0O!,\1YSAL2
M+"#+L$+8.,$3\UI0DTD%F3+S#7->^2CF$O[>&/R!H##I8J)4&NZC<8I$(1Q1
M1,4@@BO@CUS#'RGA;PGA#T]2&+)(>4 T*)(K+4ADI.#P6X1MS1!JI-K89IMD
M2OYV"7\E_+TA^).$><](")08+A+1WAOKK336&1TL>S3)10E_+PY_] ;^KCZP
MG#7N;,",>L2$TXAKZI#SWB+*I=8I4<6XR_D;FXKS$O]*_'O+^$<<ECXPQ9R+
M7 7O?*2)!>MB("0).E3_2*G^+2_^\1O\:YR2ZL5WZC"!K8P@%7,T.5<"V>0D
MTM9$%CR)*8B-;;/)Q2,9K%\/_N9TK+4*3M&OL0D?'F]6CF,[=FUSL_".VM"J
MM^N]?K<(9WR6@W1L:)[$O3!E>%></6$2&B/' 8QCX[#@7!MJF3+*$2>Y#03K
M6#H&EQT:+R<<@X(2;1*8PMB2A'CR IF4++*.,X(3X\J8C6V]B?6S-<-?(-"B
ME+]2LF=4>BA1GBBC4V#<*N(BU28J+(@/Q'%5^KR67[+'?5Y4"V:(3LAP8Q'W
M GY3%M0?02(QA%.;C3Z]*4K)7F/)#MQKYJ1)5E*N130Z&F4HM2)RXX0JW3G+
M+]GC[AQ'-#:<2A0DYR#/FB-K<41:&\R-B21%N[%-S293SR;I+D5[:45;"F-S
M/3BNB.!1:?@E)A,U,PPKC77IJ5A^T1[W5"3C6,Q*. M)(JZ$0Y9SA3QUV%NO
ML$\81)MN2O9LJITYBO8+,3^^F@NB2(*]SJ.9EJKSBH%9B^)Y7!??]3S&9UVV
MC'P01+270>G$)8^&:QL\24I*)Q4WI0=GR;>,VA\3'AR<8-.7B:#@@D"<&XI<
M$@(18D#CCRDDGP_WZ":7\V)G>S,4EB7$EA#[6"<Y$TP'JD"UXIP';*CU0:CH
M*"=)*U*ZTI8?8L==:8D$XQ452'L&6GET#%G,,#(*9I!@*I3PN0+NIF(E2W )
ML27$+A9BGT3X44+L4D'LB$_39Y^FC2E22P2R7%G$B8U(F\P;(AG5"E9QP')C
MF[--0N8<HE9"; FQ)<2.:[&2!"U5#*#;<.>BM4ES)ZPDGBBF8NE;7GZ(Y6,0
M&TUB0M&(./8.<<TURME?2%*FJ5(\V4S:S.@F-O.J[?KZ$'N7C?6&-^\.)?6O
M>/2F4%'=1W<WC0DN/ZE8JYY1$0.Q7,# *Z*MBI9$&ZCS*< 'WT6F?GL".>S"
M6:XF4K@+EBNU-5P1BR5FNRGAL%/O^6:GEXO,+0NY6NWK-0Q\!A&'-Q_\S0[I
M[B7<R_;V?S\YO()[KG:O:O3#%8@J RCX.4ZN5MNIG=8:_B? 1N.P\2>TTXOJ
MIX\-:%^CVJBRP_TJKNY[?-CXF*I7I[QZ\5TG(6R.X[<ZYS()2I$5V?-G'9&)
M)B(]'Z Y+.@8WF<P!=0V\"V5+'F>'-7<$IN2(R)GN:DP3L;VOM>+F<ZT'2K_
M6[>NWJSWZ[!VJM'F&0@5VZ_DF:D44W,OQ_O]+(@/M^=N^X.2 %%&*X,%S[%)
M3+#@K39":2&Y7C/ZN+PSVO;E?_<JJ=ZV;5^WS8J]G9+FR)1DQMG6R+2D/"T_
M\K04E_HFW%=/=?@RT]D.6>1&+CJIQVYF'+C<K%R<U/U)I=Z#?1Q>FQ_7&Q+9
MS4P:]Y2Q9G*)&"K_-W,N5&[(*5YC 53^__]/4T+_5?E\WLDD?F<@4P5O8"5O
MQ3]@NFWW-"\%4)5 FF (\^9WO3[@L]'ET3^!-=&_75*5$]LK_AY<<IDI BUL
MUKU>97CA<#$5K!.99G#K;4T]78JIWVV?G>?)S#SH>0[;E?\\L!B*B<Y@T'&9
MLKK@8,P+I)CKO#1&5P8(>ZP7SP[U;O3]YF7^%B9E^-<;FW.V3'-^,Y'G[9FF
M<FMBNWT)=6R@(+QOAQ'UX%H[V&M_B?Z\VP75'2ZH=3+]^N!/,/OJO?W<H3>L
MP['J^^_4@1$-RAJR/'K$C7&@PQF,7,(QDT%CJ]VX#L0"B\I+;DU,W"2;CW99
M$-1A3*(V;FT)==\/Z7,O"TK_N^K+\)-;A>EFK=VK,%T7;0D5=UG<W"Q X!>J
MT;7J-%"0^B>=WIUM$G9BVVQ.JP1;R/%@BRY4L.MWW&4'GEV[$JO!R6O,EI#D
M*92\BFX1Q1?"Q:H6P<4JU6*(8Q?4V-D>^T*,F:])0'>7-+/R8E6\EX^*K]"
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M6E+LT-V?];L;O*.[-MQXA[6QB*VMJ7;/LU4.BFK;<7J&T>,[2B^UI-@XM3A
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MTY9Z\-1L8TFV80 G\ QNV[K6-36WS; LL=7N]3HMMVOK[A+%7#7;V&VV,9N
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M;S#>2#S%@ V4"2P:)C6YPWE)\E-\W#V:H/ 7PPG6%M"S+" ?'4HD%5..AR'
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M9N8BQ\)_$1OU$Q&D+84^R$1:5G.L%:B74J"J^2EE8YN">3 O3ED/R7;UIFI
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M^-BZ4HD\+X&5RI:$[WI%#RTE#3UV&\5D*6 EBD-5*%GCM;RS6M:![<TT3ZL
MN1R7VIUFK=1VHZ'>;&.H)!TA\7R'MV!W2:"ET/''+*AT; 6*'\1L)+I%(D5$
MZ42-/'4,YB&?-. C/W95))]I#K:$-(K$X*ZYA]0B"MAP4ZE.4^M93VDJU;&:
M+=-ZB=9'[=[Z6Q\93=-ZVK!;F6S';*^S3]-6=;MM=1;JO;*^4BMAWNU\$Q?K
M4=&T>'M ?\)VE\NX\%9)A'XUG8#JWE/KZCVU"PV48)#M6)0WJ 4I0@MR_1@;
MS([%S<N5HA?-EWG!?=XYZWUQ6*C>SO5MYX:2',1M?=@HD$.J^/R'SERJ7-%<
M=@L[]XD%S"OU\5CK%-I-J[W$+'X<1XF/];\?J!6Z?\M_1))4C::VP*"Q6<)Q
M!#KUKODR%NERFZ<<?F1V/%6._02]&>^KEN(Z(^7/CH[OKU]WT0IWFAEU&RUC
M_UN'U!2W/Q1G-#K;Q"#<?";YUG3D_HWZJ=]7#B^CT9C/\_TZ!7;I0M%&N[,J
M(F.=I[SA0S(;O?:;*D;<&E_YQ$..D8F8C:=YN*).67X*Q6I;S+FL#VF)0]*M
MAME9E:W4ZLI3MOHRYJH#'^-<*/@941G<LQC,FQ:)*Z-(USK+9@^HL\W>'&](
M8;F))L!2RHD3ZPP9K%$^/B\=<N?H&_[;Z&A/-/9W)@>V/M][G8?=1L=\8EO;
MW>MP_K22HJTQM8M,.R(.YD3)$X&IZQ!='?'<VXCG/F@?ESQ.HC#DP3,NZ9NV
MP4VC8>FUHV2W#\GH-+3.%AN O2%'B9#\+R_Q7Z7-K;4;1F]59E([1C9\2$;#
MV";VYQO23H1O)%J3,5';RO?M<[O7T/4G!A)J5\C.'Z_9:YA6[0K9)@^+[^GN
M_G*:TI(&?%W^_L;+WS5@_M930?2V7P-?WY;ZMFSRMNC=AO;4R.CV;\O#B!%R
MI:8NK(+Y8@)98DL[47Y0KJA5/,)LF'PZF7]$G-I/_[3C'WZ:R?(O_7<8%W6(
M Z[:,6=?5>9->/R!!7=LFAS\4*T5\4-U9O:KOGB/  D>K>U_9\ FY$ -.4:$
M'SZBARQ&D2 HBDG,)GS@.P*!PL\:S2'D \(%#"II=U$\\8!V(WQ=&F"KZ@QY
M(HQ"->:(!X ?RM!VUM(Z9LXD18//AHVEX1/%BZ.1<C?T8<IW7+F#)<$82A"%
M [ )820.=*EX:4PV(H=1HA%,TH;I>/ZD <NL+']<=7?/KS49LACHC6 \$(X#
MID<3F1L)%R-REUV1NYSE F$?U@C[\L$(=_YD2+^<^"-<+ZP3SC?U<)VT 32+
MAFC?5QT_3S;*3TS,6+Y:E,O,O/K-0&Q<<Z#L<-!0,-LS9H'8P;X+F^P3I2)1
MG%3A:K=Q%YM*/M-!>::L.M/L&I009'2]V<XN<*-,IC$\$&9X+$^\E9,AF\BK
MR7-DF3MXG*N1Y]%M#*)47(!TDM,I33V)O,D=W!$%3@HFC5]ZG">+2/B^NT2_
M%5@S)2:0O!GJS=HWGU;:-_>I?7-3V2:]GH;(AT/NT#'EW.MI9-:@9X\0TRB<
M(N?U(E@L40FVJDZ2;.4^DA:MGB@#F'HT"&'6\-,7WHP5#VZK9_.N4\*4"A[H
M /YF[I$(-4F \D/)[M_O"+S2.TUOREZEV:'= @MGH3.+U47:M0#]RL"S,LPL
M9<!\T($<EB(/!:8?1*@2Y-A:,1\!LTWQ?P0%(+ 7&!5!P&+%9@&^[>W0@Z2$
M&_8MA]K:*D2<Q&>;@<_'0UX&# Z)Y)U9J/%-Y7>NH.!-4IL"(4 OQ>@$LT44
M%J6)\C=HEXGK$QL'D7(!/!IG$/C,]@-@WRBO483#87-4*OB8TWDB2\&IN:B;
M( RT9/+C&%&R8 DL#D%D)]AK6D+:C9"Y5]Z'$\D5]@CX/E#W AKTW7\=^(ZA
MM[FK,;-M6F97LUB7,XTS5[<=SX4/_NIT#]9%N"]NC\U!HPAI[_\W]5U_,B7A
M=L3&2,_*%4] <CJEK-Y]NYP/TGX?2$1JF)F2D, T?0],FG!ROQ5*=P0V"U@:
MFD5@D(+^C/];_@(IWT[] /0#PB?G,9A;8#7& Q9FF@F:<ND8=1&BTH"E(;P.
MIO*B, V=YJ,H#?I#* W; FE8\E0;>*.'[!;-^ G8V&"(@.4)=C:A[N%9TI?"
MU$&1)FX_*OFHL,!$P%Y ^8?_%POF&,,9,6F&Z*V63FR.AAD"$P)ETR$<2B\E
M%HF$) =%3C,9QE$Z&"H$3X]8E1RM:J"<^I2?(;=BN)!ABA?0Y?9$\9,D146B
M@8[V@-F1W/U&J0[*\T/X"1XTBV/47/ VOT;-8S&//V+)4/D81'=8R.ZD20+[
ML[=K?XRQ Q.M:"J2*X"-#[O0H/\J'&3>+0N0"!HE<U^@<Z+[3R@A,-0[P^HT
MK8J2XX>WV$J4!O))&>9)DHD1'_B]B]XU(%-XB5!]$^':'+"8U.B@(G(=*7+'
M*'7B6R$?X/>,U"4^F9(-*AN8JC8()N&O!!4H'8D5 *,*4I<\>"779*9O#R*X
MS2')+P:\S_&E.P1T)#Z5*U>8XT0IW@GE=[@P<,-BL)2!4&!': ,3SK_BW-$Q
M-((#$6B_T01&1>'&@;<YDT1Z2A$ +BY\*2X?Q%QL)^AA7YM*/T TR %I8",P
M(28,/8JXGYE1((Q[>6UA?%PN2-=<@2LV';Y)$9,X@&GA7L"0;D0" "2YCQ"Q
M$^3]TXS%T\"PE6.IHR8I^B[+[VXJ'T$%'H&M S.'J05)IG>N3$$->!,P?7S/
MP?_^CZ5K^H_*.6R:8D@S\(A&I/MY4A[QK!CMNC0:O@A4,U!^'91)]/0![@>2
M'@Y,RL<1;!*&9DAN?<SW\'H"'SR?\55 KHS.AG79%3D?PF#3[GY)A R_R$5^
M'\R!6]K7U\D*<>E$JJE<>DDQ6<7&ZYI-O>!_:#2BLQ1X1RCN>_C >P1CX@*+
M.<R:^"SY=N2^FMEMFKE;J4#[?F<:3:WTN52QJB&1*LXY,FA2!C#&0Q-F+A[9
MJ+C#C.98"7.0GR,I+0MUB,(96#99Q7P+OWA36>B0NS>5:9/NGU761;KP7"1J
MQIF>R0]ES*:YN@T?QHCNGD-MXQ;I>K-;=3PMBDAM4\/<SV#B3M*: &)GWP0I
ML  N6G&)@51&&1?)MJ0:@)2([1*K]%ZS'/4FW^%YI#+$C94>??)HVE&8)H)Y
M/<2ND-_!'"/9+T#X-.\C='$>1.M(UF;3K%*UO"=%T*SD"Q =&5ZIN;]UHBN"
M5+5$K\A434ATK64UC2V(=$V(2*U3ZM(AX[)HHK  FSF49"_.@%CBJE+8T NY
MWU@<RJAF/2SF/C+<)YE.QJUPPWR9BK*@#PF^_!'-A,9]UZO^['[=Y'YMO4Z(
M>N56RV4<W?JND$.GY'9X4Y;+N+1\/U\^RY>_DAUC551SC#DM'))\N\ /$C]!
M5E$P#XPSI< (@#N!HD$2/+/\)R6'D1A4Z#5E]TXY0M!4EE]BS+V 7"OO-%A!
MP3+RI3.I;,?<Y:-QIJ?>XXY8P+%>1M/6EU,/MYJQT"N)P3>["QD=9;1]+_$@
MD;W977JG%4Z0-[L)2"H+V5DMAE90OC6]K'P_3PZ)E$<R)C<IB?2V5<1$UB>)
MT'W6+C9'68DU*>4KJKP(J>ZG#GDH7=_O*]KDQSPB^F:TR<R8+06#GZ9)=LN*
MY'+#EVU0>8MF*1MO'"=[,POO",LQ#7UAE8/%:)2LVH7WIV194UY4Y'#N2L<B
MOI!_0P^4>*',2AB++*Q7?OAE[O9T LAY>*&(W\-!EZ6"=UJOS+86G1/^.^88
M)R5O13I))L#O\.\[RF:0[/U=IU13\_B!W\N!2_&6?)2EZ73OR6@Q,_V8B@V_
M*L7T]WVEBR_,[Z+<(\_?!/5$!LZ)&!9X'#$I..&<1+*7HI2=#Q8]G%!'!G61
MPY!'BTKN.E"$L)4QU7IDE4= ?BQ(9" =]2CY]DSN5Q(P*)@B$DDQFL^4,!W9
M/*:6P'!#H[@\A64[P7:>J"14#EO=XFEC3H+>V6(Z5W6[,'J*>T%\V %::XC2
M,9Y0)@6&UZ0J2_4^,APW0Q#9QVZ< K$@I\1$B.3'%<ZT/L/UG"$>TWQ1(1T,
M9K]BWB0P$3K#/#;64"HXYN.8Y_].)G [J[SB_K>(XL>3\/MTQ(%OCP/FB#*$
M&QFX/3PXN;HY4& "!_V;G_562_R-&4.#((5!@6Y XK' 8P?O:^K9//5(=I[=
M>Y'G/U]W2B9P:B? [:E0>(8;((6-_3%%+4OL0*2>@:6+)P '(G4=?R1*BN%_
M*VEU0*(BQ#3%KR.;,M9B/DA!0D7Q5&%C5/[P?8(]9=0L,^62+%\@,U;E"$7R
M'1]/*%*-TZ64M/SW->EMAW$!GQ$!0IE(G$ZHF 63&(MSC_FM#U.1(@=H +64
M$IF5B4BTE*J/<[/'B:F?I?AQZ>S(C&*Q*Q5-$B>1M+;J4]WM4Z7D Z'!SYH4
M%;4_#ZS/'Z(H,[\CXS9)>7V"6V*S(O^B$)@R12+WFI0O6W:*>75^)1!;+@NL
MCW/SQPEW+L8" YGC"/JW8*K<&88PM4&N_-"-9.XMCQ.>Z4"E*URK/!L^O!GU
M%O1/K*[P4O0-5G79UYBON+%<V$/*+:6*D%BXM5BB'(S\ 6PJ*",3Y9>CX. ]
M7A'@>4+WJ)H8 :Q,.-^P/%K8'!Q^7.L@.W!K"O<#5\B((P='DGJ>[_@5RS0J
M^SLRF5:1<_4U>V;*>7TC=N!&Y&X2?V2#CBW<;^C@J,G[>>1=BX?]NPR8^IUX
M6"^43-0"70P%@2^3=**X:KQ2$@N\VP]3"KC.>1M?:P7)Q@ C]F_3MIH F+&>
MC+6(Z@W!>*A0O.8T.\!I[HTMO )NL1/D7TO>W;X/%=?B..9C)FI)/3_(PSEP
M0I@_2C(8(2(0'*-RCI1.*Z IZ"$>@CAV\N==L.)%3A!"<P28S)4*8VX,%#Q5
ML]P5)V#^J&+;_<(FSE#]G7V#M2M8M":J?VLBV3R1B#)?I)+B'$188,@2 2"%
M2"!L"G\K-F$Y(88*@AY.E)04M@7/W@D</ HK4/!8#"'"#/GCY 2M/9W;<%-_
MH^L.DC(OM6<.J=UX5!+=!P2HG28P9D+9:863A@K:2Q[M^T^PKLZL*7D[/GL4
M20/$L!")*X*XW9R(YV@8'XCHMQG--X0+LS0F'"C>"_A8(&OC/?)%C<C]XXJ<
MT<JXU=PM@3$E5X',4UQ03$#%/&J!;)%D6="3&#:121A/"8^!0'^*F"*0=4"X
MS/94<F?DNQ/VE6<8&I2*FF7EL#!_4\V&MTJ\0%A@/_K)L(3:SA S3&+SS +[
M8>9Z"-)SZ(^%$*: 8N+#[%E<@?@3)%G81'X [XI",%7C:,J"R;11/)_#D1#5
M8MZ(P ;+7Q[5\GH7Y'69G\#II $RBBR<C-RO!-Y"SQ?8= *5YY;Z:\11R&[]
M&!C%X<'1Q7].CU6M=_ >\[Q(/I8Y509Y)#D/L9=&"5</V24FL<*91B,>RW]2
M!,@7_\QHK("S\056&R%/1($H/0%;A;DXSVP^]"2\3CP\!-8U&2I\[+M\Y#M$
M^G!.XA\U96[+R)R!K\K2!2L<#K,A@#3%]Y0G094.(1!@1"2$B<\TC$A[%K1%
M7IL\3:T^X:T**>8X*>I4(FN=.RR99%"TC1(L314B.K_X(X[54HED3E)K(FAB
M>D%]MIL]6R](T6&3XXEFG0WRU@5YBX.8BD?*X ?+%'S59_3\,RIE[4K0-;PV
M.3O<^U+#>PKPAJ"CHD\BB_PA[\D@RS.&(U34+!M2ID!*U$%F)UD.'NXJDC@(
M%4]4,!(^KBSP$W4W]!)R4\V"H4\R2$,<.8.Q2S*TV2I&&(HKB0CV#?'X",Y+
M^6\*B@XH0"32IIS%"0$HHU5&>,+S\\LAT\<I& 0.:3BQ?XM+SRMJ29,CZ&_X
M%N.EDVE3^9D@]J)0*F)XBR>E)8TBEP>T>)N#3G;+"VLS^[$HX94>EX;4-27:
M65+8I 7ZN)^4LWNP/4H:SD' DRX0#B*<1 $E)OJA)4*L#&D^H+IZ:@*T"':*
M% I-Y3('6!9R(U=B,P4QU_\:A4I<;9LW8SEEE3"P'B!2V3G.+6%%*!0ZJC2!
M8^,"7DWHVYGC].&BRS7?T&W5_N8 RE_@6L5X/K035T5U:G%,'\5N7$I3<FUH
M$\B0=AEMXBPSK/.E*S_ F]#$]E^ZQ=V]4[T'W75OY<:*"SUB0>"[8-^JN]:T
M+?=*"F9+%F\V6>JSH1G$J\D'1#=L#"(C'4O<X9+8>&>T2WU$%W:'DPPV:T$E
MKW"1C9G[A 2S%F]Y9[6>..ZB-)WB%4UE08>"G011;2C*NZR1<!FL\UW'JGXH
MH"G*N!3;[0$CL?U]$((@0:\R_'U2<EL_5E#XNTW9UI!6]KF$(GHF^I:Y"B@)
M'YD?*_]A =AY-(CV8U8G]CC0_OXBT:[*;'@ .NJW_> U<JZ"U5C+LAKMJ2RA
MK) 5K*"!4.@OPV7@J1A1>4>(1SX.>*%PECA<M\(Y@>J1W 666#Y2 7K[5NCX
MG#3E.]^%VPV6F NF ;&,[H^)\DN4""57W6H"<$:^F*- ,2PP41)$AL\"<WGH
M1)#1@B7]7VDQAP</K/G@?1/47E=XKI/Y-S06C9YO&#P!UL8 F\@(:U(@V)?O
M0PY@)QOQEH@8R#TCU3+:'%J^J4B.Y4P84V@%OQD*_1+Z&.GP16.@2QZ&R32X
M9:'/MDR7@DZ$5Z%D=<Z2(W*U!]9P>(#_/'C?H(_O(Z&,#RX*Z,E24 =]$J6F
M 7EX;[8#D"3J4GP\IRTX?YD1UE3.YIBB2/.1_2X\6'-TE\6UEY $5:"($L]%
M!X-H&34SAT9)+@T&V$]J(GH/6%:S$"1C'E?F+:RP:776=N8N03=.WHU@?B<(
M*FGV8]6>JK.?R>6DX22>XO?R3WR1+[P^$AT-Y6AIMK1$= TIKO V$/(''+%*
M'Q:TD_E79/_/N=-]8RWF/P7L6W0] E+^E?PYV[WZH'?].PVFJ$[IU!>3C01X
M'A#Q.9P4%>KG9AVG9F:NR#IA<PQB=FF'!Y^N?T6&0!ET;"9U2T3V8;1!$-GH
M@,)YD6=-7K8%B"S[G@6]W?HC[)TZBL(HZX C_(>XQ3:80(7Z>G)U0YST([-C
MS!]*J+'#H33$CBHRHI^1@+2P2FH'\'T>CPK/Y^+G&@H0R7W2@FIN<CWY 95#
MZAMFJ\#9+#5YE3IR+-U:2>9Q'_FN.N%<=J;#O5)&[&]*/\(4_(1L8V1])/JP
M)=\>Y PNWP.YVSK8Q43#W?8J'R%R,;J?^D5HZS(*_+P[XW6I'_&_4W=0\2=O
M)TI8[EN_=_+UT99H;MX:53:E8<$4=)<,!:CH18E8E'[>QZ4$3U8.^Y1UK.KC
M2>X=:A12C-"^1:F"D)H8\8Q=2@ A9HIL0YS IW[_4C3M$;_/6Y,)G+%%+\JB
M,@D:3E2J_I5CTIT_(B <6FZ2I *S6P+C,,J:DG!(V.0,G6$CT?H*0XN+N^^P
MDH861 G5PGLRRC@@K?>>Y\2;7*G1"B5PT8Z5V7%Y:EE8CD;.$41+.J7X)25>
M (U$+O:=#ZGUD(S.D:8J]!.0$FF6/5O=IK^SFUA-9(T2M&H3)_9M<7P@EN"9
M6#80Q:!C=$=:L$THNI5QX?2*7M(T]]BG"*Z('5(;V CS644K8X%6FI<:9/%,
M1E!Y+(E",D?27'HZ?NRDHX1*P!#3;%B!U!,4B(W2Z!O:!)+:0".XMGS!"@C=
M5$9,61Q/\4O<)_X -0A"BD4_;LQM0TA8D,., JXB.5BD;HIF\TT$(T\%N!]-
M$"/%KH]]LW,LXJ1,N6*5XA>2NG(J%L6SXJ;NL?_J,;X5RV;E851I89\E3Y1N
MP"/0YM*G[<-5*ZA+WF.\^XE(:BR]HY25,2Z+KN)\*G<BZX!+KG>]J5RG(]AI
M\@"4A=T"@7A0.-Q'L,O3_TL6LSF6$*L1]H!4SHI'^J(OX!4Q KQ8'X'J!4_5
M6NJO!: QK!E^1_:GV*ACT"/)A#$T 0.^O^2T8ESWBF,OY\J9Q*#ZIZ'SFD&P
M+P,R5>9Z-S^%<M?8G'DOC0-C;XR#+5D"IS<G9XK15'[[TC^_.;WIWYS^YT3I
MGQ_C!Y^S?Q^?7A]]OKC^<G5RK?1_OOARHYSUKWX]N5&N3J]_?9V7$!'=90T[
M=HW/2N^ 00.M"/C>$.@(/QDU2,M(Z%I2!1#<NDL&7/[TM*&<PL52NOV&<O ;
M>H^ ]^%EH='@@R#[]W&NLH*H(%U'-&%7KN#M!YD9L%"(*"O+CT5I *2;Q=(6
MH.+3$%5UN!]D=4B!+@NURCN#JD[^,>Y)YG:F^A7QD\1'C7(90;;DO>X<[-TE
M,YO*T<7YS=7%YVNZ8)=7%T<GQWBG7N<-ZN=.,^IZ(/X4UH]"_O.L1@94_M]$
MJB;HY_?H1[\U*-@H3*/"XI35-7"!*/<PP]XOS#]9X))D5?<.=^F*'9:]N5=I
MP.6;#*9J[4/^7OP3']+:;OFCPK*Y+AI G63IVGU1SZWU#+/BB#[$!P[*/SMX
M3\U<T)CQ.>$[EXRF)!UC3^FDU/7[$A1I!(</X&6$' "W] +3/R4&;?%](=7E
M]XTB\D6E/_BS<D/QXM9*&S_/9B4]O-AT8;X]-I/J;^9F@T>2]_!E$]JF*IT0
MWQ"$TECV/)$!Y[0@D);1@T$YQ_2S)!%XK9))%_UUI5W>$,$FA%X/IIDU[H?4
MPWLB$HUD'2L0C%TV342YI]3WQ7B%!>-A.C45L]HCOWS$%9(A%\CL"GB89-83
MFVQL*GY"I2:C5*279M&+%+/59+YIE69F@>J?1:AX9=!1/HZQHJE!X48,;&;G
MXG*';@7ZE :,SK?8C8),]M= >I"C'I=CE"3E98K['#\59U^(]"27Z/*HI5V
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MM?/&K]UW5H,W=Z9'WBKY>"?[5QB:PU^8<@UQ!"/V3YA_5X90?OY$_(13V G
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M75E_^_N7@]FC3[CLIHOYCX_Y]^SQ(YRG19[./_SX^/V[7\ ]_OM/WWWWM_\
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M,/\PI4APO3PBY.<O:794DW?_6"SRY^EL-DD82V+9 O>"ELPD@HO%$Z%<*@H
MHH^M([!-Z!J3G], ',U%T0PD9T^/P6O)%5DMX1,H*PBB4EN0VOB"3F .K#$0
M[B)L_7"$O15+V[D$-90_0=EBGDZ\$^2\^$*&J%1#I$J4$'E&\,X6#"ZP8EUK
M5^ Z0C81M7DXHMZ=V<WD?CY[$UE,"E.!0A$7J$P!6332@;%61F%X8'; 1/)
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M3V7,V:S?54TWT>*7)S)85JO19YR>]P;DY9R@>S0GD_*-7SD;X\(G42>A=''
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MT9"KW_SX\):D/H!^NEU1=^.>&TBHS?V)=XN3*T*NNTAV@H7%: ."L3:"RM*
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M-D[20L'1Y:%&):U)10 &J4D?64 0)@-:E:5C&HMJ77"UP>']F$Y;F4[KT6R
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MR.N!CJ9:&,(NQS']ZO!?.,%I&!/0O7Q$$J\Y\'H9T2G6V2E8B;XD+>MID1A
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MD%2?UHF\6!2T:)O@ZP7 Y"HYIPHPFS-#$9RSK3MG+X=L6PGW+;%F$7?;:6\
MT_ <VJE<>G/A.M[3"/\R8 ?*Q:\$=#NY^2$TOHA4@ZEKZQS3Q=58?DT;.0&T
M>41P.9*OE- SA<0+V;J_T0YPZXZT_LY1:Q4M#4FIUY//Q^3?5 F(T^0@9VA5
M<0FR\JQ"\^ ,*\ Y"239($-HW:_E%CA;C+^U5^0BRJRIA0&B^#=!DV?98QVS
M2_6D12V&4=PB1"XB8'"Z&(:2J<&29M?A/#6"W$<+0ZP@HTF8I%$87[0?Z)?0
MXH)-@@99"J<EE*5"GBZ9?%RX2) 4NN;M]19 >>+F<P/]#!"L^C -DUG!:17+
M>YQ^&24:\MMR ]I9/4HVN_E7IU-KF;$,9$ZW',>6K.T6!.EV3+L#+'1-QV2,
M*RH(#K(>4E1<.XBNYC4R)^/2HV&F=4_PW6?J7;;[KA-U%:4.0-"7W=$1[4X$
M[5V@;>KW;OYZDL;'&?,?H_FGEV%6*TKK?VJ[H"]A7)&?VA!8#$%.GD08"3E9
ME>!%$!!4L4$[U$JUCN;>'^WF#;WML:3;BHH'\",^OO]7]P6GDZ,^N3O]W)VD
M=JM$]PZ11(6S]]7R.36.3LYT%^]1&@4\U8GMA "OLH9Z YWBB:5H6V>L[@'S
M"=-Q:*4.L$CVMOB+D/[$? V:$2@R"QH<*@*D:S]A8S(4\L]242EST3H!< N<
M)\RK5DH:P&_YK9O@M]_"]$^<_WH\R6>HA&%"EJ1!:*:(U4S6>V:)V@Q3D%F0
M"=+Z)O";D3QAUC10S0 I][-U$5]AG%]CLPU!(I,!?&U'KZPL$&W,X)V4@6MM
MI6F]Q=T*Z G3IYVB%O;;W^Y)F?>CP\FHC%*8S#].NC@C8=?HTDE(<?C#,DN]
M?AOG95:7RY4C,\H+R1+]&Z540N;(I4"#626IZ4U+'YE9"LCV"X#JW_=VW@=,
MGR:C_S[&2U4JM/V68HL"G6KM%.,"7-$!F$4EZYV[4J@=K NZ;4S;J$OFV>K
MF8?D;"$K1]1^O,Z \,BC<2@+MHZ>/XBZY)WB;XN*YE44W= MKZOXP0)PE[)9
M_=)#NVJ.RAD/W 1RV3P6"+8@Y*0--]*GE-U=F\0J+_Q!JV%U-&0=05L!GJ2_
MN!(F*F6A),Y!H7#@%*LUM"5E3Y99+JV=JR''\Y#*3P=;*W>&,+M2I'JV>>RE
M_SX>S487S4:BR]FB@,QJLQ$=$WB,-*#BDT_:J1!;'Y9< .4AY]';4&7!?K^.
MR@8\!W<95OURBF=M6)<!.%"^_$YPVTF"-U'E$O187P];(8Q(FGN=)?"B$JBH
M$:(,!>KL22F8H-U0[LB&B7)'#GH[/%E%_ WY<6* DHTQRL>S%Z/N\Z<P/0JO
M)^DT)L88$BS!P(E8V^AI!3Y[ 4EK-%HSGF5<SB]8^([-NP*-M=&U%^4 V=D%
M7L:+;^?MXW/D,0N#8'EMF9A\!A\P0&&Y**Z+:9_@N!/4#X/D6@B[I1H'R)XM
M %CAG?6^6@+@0*;)G>"V8YHT5NIRE%E3(X-4-]T%5,N@#1H#*(T %9*"D)V%
M%)5G(@EN8^OT_98H<X>1LFW&K**(YN;*'0'7E_17H]1WQMO'P^-Q?=:WWT9C
MG,V[R7FV+XN837()BD0%2G$'T5H-Z*T4M>V$M6DYRZ8%G,T;08UUO$1 <T %
M#7DJYO9C9%II5M!Q<#%&0BDRV7<Z@K,F([>66]&Z\>7C/U$\B.4T@$*';-^P
MW(&C)<#^.&3<4N/KG02]A[JV?LA8Y:BYS+7[,$T\Q8H&EX*F*2AB4=D(XP?K
MF?#0#QEOCEJK:&E#AXS/3B\F=*6>9 4L4M2+9!-X+F@C9RIPE82P?K!3Z@_O
M#.E*BESA#.DJ6AC G+J:S3[W4W1AG.Q+FATQT7@+U^ S+Q"9]CR50$!;'T%?
MA.6'R72UW+:%TA:62K8ET_D1[+N1#601+4:U'?.GC?:6H,0:HA]@*[H%H1+*
M*<L13)0.E D<:+$-$%62GFDN'&_=>7;3I+C#;MDT)U:1^ :X4-OT=<>3^7Z8
M7URSH8(SM"H&Y3PA]):,-5<7R91#REDQW_IZ]KM1;=Y(::7#.ZBQI@):ET=>
MA?=NVL73(-7;<AZ1VDN?1F1*U4^=->10QG >%4BK:,ID)L%Y(\#+'++7,8AT
MI01Z0?#PG@ >/#\V)OTAN@30Y]Z62SUC3_I)693&<@9>AT*@LH08BP6>LDDV
MR42F?.-UY$8@/XS8J^?_UU;7=0[IM<^H7NHX?"*)</&3_KQ42/TYVU/*+P-W
M(+-V1:C;L74;*/GJ =4-:&B(P\\KPO:(222R]NI!25 J.S+YE *&.CH?)*-?
M/T9"W6$G;Y]/JRBF=89U[\,+P=B[VBN=]N3#:3@ZR\GI)%D-(@EGZ\Z;"SCG
M:.>MM[GGQ&6R92F[9]$;MG!7RY!ZZ5H+=8#(W/5-M^<ZQRP9?1I4\(3*2T%;
M+NV[%I/./J$7MG74]F8D/PR:KKG"KM/(M*?1J7NP#*Z!3)=%F+9CH[30VYU4
M6$/H U@C"_$IF70IP0 7J6_QH>LE\A&*)H=?R4R:;-U7=+-DN,.^V"075I%U
M:TOBDDO_!XX./\TQGX6 L.]B]>NX^^MT'U16U%LI/1A>V[[4*S2"YAX*1ZQM
MK4RY>OW@ N-BA9=NWMYHHZ9N S)N:&O,IO.#_6I4G9RD$$%8[NC5!BVQW-76
MVY(3B*B5PF0B+A5RI:=>FOCTW<6D_^Z%/RR(;ETU7.>"79L+9Y1< L8J]L$R
MK-A&J&(-X5]5WQJ2:[C 7X5#>Y>PBE8494J]:=H+B#)F")%IE]$XP9?R&+:M
MP 5;=WO]K2*PQGK[C21U='SF@:KDE+.,UA+#:%=(Y,Y&B1ZTIK&$)(122\6N
M[]#<=R_=W,Z[EMB[%C)KO)/^%KY> F)TBH8)>C.3"E2V"@(O'I@G<\*G$%.T
M+91W^:4/4'GWEMG"F3=0JZ^Z[:<P(1MN?$P&W.\X?]/-9F1VU,ZPI[<6KM'*
M:Y7'-VW5=>]Q76G%E;G$R*7W&KEBOKC LW1&6I&LDIP=K/*B-8/MD_DHU[>,
MON!%.[E?OI[TZ_V52%SOFSR>]P;<V_)+F$[(KIN]PVD/XLUYFXW(D@XJ<["B
M=O_'>AUT20BV6"6R-+;XYM=E-\*^;HB U/-Z0B3!JJ3S^QES%(DE2Q/4BMK1
M,26(1.):CB)ME%F9YCW&;@2RA7CT-CAU-9:POE(&"%1_!^K EB 1N0#/$PTO
MHJ2OR%U6/&EKL/@<6A^\^0[ YIG10"FWJ7DEB0X0*SR+7>Q]H=WC$'\_KM)X
M6WI6S]X>SV=S6M.KEWPV<N-4M$G*>KV]J 2WX )R2$D8Z\@B8[EUAF)5C$]T
M^1A4E5ND7F]9'#B>F1%9 4::9\HR!\X&^BI%K3%G[UWKV/5* #=/NF'U?4]R
MK:ZLS3'KU#2]AKGV^"LB2@92.)IUY(Z 2Q)!&Z=C;:(?TH:XM0CBTV17$X4-
MT6UC'&:SM^6/OF9A_G:Z7]'_\K5>(#+#=]-1PO-?SDY_.^,T*4)TD3O(A) \
MZ5C 9U, '9=*1?*I+#9FV;V /M'M<WBE#L#$-26W=U3S50>&9RU*\D"^/(G-
ML C1U_M9L7"O=(I9MKZEJ GP)\K4S2M]@"/W[],GS,?C6N^WWG!.$G/1H=.$
M&ISVA9RG+"#ROER0T4;AG$;9^I!1VQ%LJGGM3C!XB\K?E;:T:P[\Q;>;'W!2
MT,*=3"X(DD>VH)S+0,99!,M]\+RXQ,M2R8G-K>>W#6=;A03;)&G;%;\9688H
MG;\1V>_AZ+RH;@E\0QW"N /;=BH:=X8,2Y%T34UN@W$R)\:<YJ!]QGHTET'@
M9"CI:&J!&-E+IK6CMAVFW5$N^6")MHH"!R#8+T>?Q]TWQ/?S+OWY]O/)M1)]
M!MSQDF+DI49&\.12DB"P@/2.&:<#*[+U[<0+P>R*\W1?O75#"'V !-H^SN;3
M4:IQK KM(TEYMO_^XUE-1"[!U K"0E^!8I@@*"[!8I9)1Y5%;!UZO!70(V-%
M.^$/TWGU"T[G([(.;[P:KVBN0NUCI52JL2791SDU"*Y$%*'(DMM?'GTKI$?&
MCI8*&""X]_XXSFCP8?KM?:AN2$_ADSI()[F06D(RGM")OG%5-) <,L-2#-B\
M?<9",#_<LT:*&H)!%W#JE'E;+AVM/#L L03"@=RKN]%MQ\%JI,ZK)!E&%P/L
M2TL@%1ZSLDR#MB>7C6OPGEN2K0TQ2U&B;VVV;(LM=SA)6R/+*BH8@"3OIJ,O
M88[OQB%=[A*#V6<K1(&8T=&^:2TX7Y-B)LG@F+0VMH[#WXQD\Z9*:YUUS06^
MT+M94%1]^N/Z3PPS_.??_C]02P,$%     @ #X$$5>ADT'X)KP  !$(' !4
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MB;GG<PZI%!(BCA@D# O(61(D@2!!D%HM.&P>/36Y>]^N!M@I6X<J,ZGJ1\#
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M&N#)R@+E-;4F-.<?[:3OBF^+F;#^&._ P+)=6PA?:A-!EP;0X4''>G:O:[D
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MAA5 (%8(;13,BG23L6$H*H<>(C1NT  '#?+UIET;GK8F^LW@1-N,&$,1/M+
M\>4A4Z_NO-E756JNGEW'#C8=THX==1&^U?NM9?^/UC)GJM^'Q=/B;_7$$<>
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M6"SN"_+8OE\H363 @@!Z"*40Q1&#. QB*.*4AH$(?9X8K9Z<;&5JGVJ#$]1
M08O4XO3X43)/?ZS.*!KXTSW$3I_LBD=ILC@A[X*N\?,FZIP^QW,G*IO@AN"G
MQBQ7"1'/$7;RN/G1F\<[*WX._]9![[,77QPFGE=977T@^]8)TGSSG<V77/"W
M"KIVT9;-J_5!OB&%[N12^5>UA[:)OI.^QZ.41##%M<R&(<2!/L<94XH"&2'I
MD9ZQY(X@3DVCN\&5'Q>5^J[T FE;GD '7':"4?24L0)_B$* E>%-E5O](7;,
M!Z3^-I^;2S5S\'5+'?BMK#]/=<.7HO97GMMG_RJJA_[)N9R]089K%5=]+X;V
M*3NO1->\;JFB[?[O]KVZ:66D7DIH7J61@C]==X;[B'M7 *\5EN^8X!.Q^ZY;
MZCE&':X;W>AC_8\?5H=-5W70*2$I$FKBS0F/($JD#U.)(R@92SR)0R9]NS0"
MUA F-\;4 K_*"; JB<YO0"ZJ_M6&>G2-YU'$?2HACOT$:H= _<W#$"<I)S[F
M+,#A*H7<53MG.R_<P-VS7@->]\RHG6(XX@[Z%4Q_&?_#)KE"8U]GK=[A4-J;
M95=#I3V <8?"W@3M#77]G]1O*+O+E=:+LM)I$?*RSLO5#*>J[6XZXYD,2,PE
M0Q#).("(4@%3+Z$P(7[B<11@%ED=R#5M>&K#EJX!4Q!6+=6$*&MM4!I9&V&G
MBL;4FVGA$(0.K( KR*#%?%,G'KP!:]Q;>=G="9HM58YDS+C94<7+EHQ=R;*^
M?P"?^Y-JO\AT6I?ZLGITK"N1OET44F354ETS2WT6Q<0GD"8B52XX(1!3G,"(
MQ,H!ER%CTBI6\6)$4Y.VORK,^J-3D_5B#;\Y'0:6>5:5C6^N_KDBWP?R!HUZ
MTH%SZ+I_!M_1TYW0& ,::]8A&8U!-V!C4KMXUCJ);='HCF$CN88V'(_A*1KA
MF8[C:$.?E1]I]>!^:OW758FJ+ZL*576:T$ D6*  0<8Y5Q*,4TA"'D,N0\1\
MSE(:6:W$'VYF<KJZKM=U^_14+ A[J ^\KC'W2L)ZA&$S:;R<MX'U[E+*K(7L
M-"..U.E((Z-*SFE#=W7DS-67;O$=..M2OGSN_'2DXN9F9R9)P]#''H,(<^74
M(99 2CP!N?"$"&(FI&>54L\AMJG)T%;&E >]PE2O%C5FB-WZLGJI2>_.]-U[
MN[QK;3?=1NVP$7?;#IW<*_7"X-9)OF-U@D?:9'-&OO/=M<N176E;S1FEQ_?3
MW#71,S="5K+Y0L<G?I#=)?!/HBX&\&I15N5>:M?REI;U$IQR)Y7W&*8QC*/8
MATA&$J8>C;3X,^2')$P#*W?R,CB3T_MZWX!N[QMTMA:^KH#;YERXK-/,9'V\
MKAAQEZ=G+]CG<G!"GJN,#Y>!&3<OA!/B]K)'N'EJ/XG]6&3?5"L?Y^KUU,]=
MA8$F@8]3I9I>HDO\8B1@JC-3BY0G,8Y2E*#81CH/-S,U26Q1@C5,.^4[PJ69
MHEW.T,!*M4?.^;AC:V4Z38(CQ3G2R*A*<MK0784X<[73'9/Z=)'RYKZI[ZV.
MDFK^7F6TFPMUYM-0^%X4PD!R 9&7$DA3SX,$I5Z:RBB(?.%@M\0,S=1TI#T^
MR928+^JIL]X3>1#J%VOP(%]4UIE&+^JQBW9%W/?#%7=$VNQX&W.:F.5-WQBD
M@G6U%6)'[+#;((98IK %8D>;X?:'Y4/['/7J;'B_%E(4A>!M.HC\OG;T9E&,
M$&$X@L3# 43,1S!-)(5Q&GO8]R.4))[YH:^S[4U-.KN(]6?)6]1 KF#;G'(Z
M3_=I51R Q(%U;XN_%5JPA@MJO&XIM#DRYI3*D0Z/[;Z2.NEL)C,&LIPU)V?)
M7 WM"CS@62%8-7\&I*J*C"Z;S.+5 A!]ENQIH6?YBP*T\6$+J1AH(RHV99+!
M'P^9WL\JQ.;E)U7M/PB=*+=Q)0KQI%&IFY]J[7)V1LVXATZ?5CO_F!'/K1G;
MM'V"S?RVGO6A.*]74<G\(\GX7?Z*/&7J7>HDF)WAF$@1!"F,F) 0^;Z$.$P#
MY6NGGO!)*&5L=2[@?).3&Q#6B,&3@@RS'+ &M&51I_-DFWG(;BD<>CC8L*?1
MUAMZ#=Z;K5-Z#NLR&=/CJA33^0;'K;YD3,!>P27S.WMFM=]/IK\)]M'_<)OS
M[5]TKIQ1/R18^@1RBIB:\M='9*6O2R('% =)E&(V:T:CSQ4I*C-%N@B3S9>V
MBVRXCZZI;<%T;0NQP=I48^I$3M87M",[%?=9GK>^P-/I QH#=&T<$,348 )Y
ME%"(8N%!0G5E&8QE@B-!I4!MU[[)#4\YC=RQ*UR3ZM;681N_0[&/):$\A=Q+
M]+>:J%ED'=L<AFE*"45<I+-JH=1E8IVYP32-CBP?%G_D>MALCJOGY6*><=($
MT:H_FMQH;8TA\':^^,-R3>^R;C;S6$;KO(&=F<,U@[8BFYM+=$?N_+)[A\."
M&"Z8=54]XR(LXY;:<$';7ET.)P_MYUB]RPC-YO7T_=52S1/S:AW/($E$./,]
M&'I8'RL)**0!\:$4-,0AI31A5ALEQYN:VLRMA0?F&\1_L1/'$[2:*9\;L@:6
MM0Y(I6XM:4/$?9QGPY$4G6AH5)TY;_"NB!C<T3?.8L&$X*5.0G'X2+N(XS3U
M*8(1]3E$1-<:DQA#GZ<)IJ''?)_;A5R<:7%J>K$"W*2'*4_D?[ -RSA'O6F$
MAD-"!P_6Z'+9;(:V<-?) !RF #"FQED(Q[GV1H[F,#1_/[##],:+RQ@V9[N:
M3<^93!*$J9= 3%,!42HI) %!,!0H#@..@SBQJAMTI)VI*<QV0</M(H2]SZL>
MX]AP;G8Y<T//NK8J"ZY.DPY86O 0#^XK#&ZU<JU"@X=,/5%O\.#E%]2*H.<3
M6=/=1-:M0NG#X(*K*94^UZ\G5%\6^E<?-F4\=U)8?Q*/39K-3H8,7<'5GW&/
M):D@$221'T.$(Q^2,$4P#F5*XI"IB9+=&:W)F#8U_5MGYR=M=OYBA5R'IJWS
MELPS*6[6KM>WFHYZ3669MS^(EAF]M:U_U:/(Q"0ZR*;*Q"0 3VA<<)F?ZJ^;
M=^Q-Y]72OU97;6@Z4&!B317HIM[19#FN,C&I_G=99F(:AHU?9V(:=A\+49P>
MPGZ.QGM1W>5L\2C>+<IR1E-&PB3A,$BQA(AC#Z910"&/99K@D!$A$YM]J:VG
M3VV?26=6F2M<>]%@K#,/>5C,%9F6NT8[I :$>5$8P@3%'D0T0C"EB$/*(BD\
M3_U!K [K]"=U!!]F1>HEA&&.4\X#15CJJ>EOP )(8S^$ ?>"6":^%\<ZI:=A
M!(,]7>M,G4-'(K@@BU!&8\(B2"F-%%DXAB1@3/TG]H.0>Z$G+&NY]7Z_QJFG
M-M9G:^9[]B9K8/=/L]0  R\TM)_ [0Y='TEQZ@B=M1=VD E'CM#VLT?U10Z:
MM>L.'+ZHWXC<*?ESES\M*UV6LBWUZN,D1C%.%4$D4%/QP(-4$ &]5"1Q@'@2
M(*/#!^>;FMJPTJV#5$,%&FO/\KLG&#;[Z-WP-K "]*7,^L,_SX8C%3C1T*B2
M<-[@77TPN*-GC/IE*?7?9;FXJ\1C.?/]T)<>U4'L.K P2A)($">0!E+X84IQ
MS*E5)+LC8%,3HJWB&>7Y@XC#]IJ97%VC+P86-V<U3+1QH+;.H2*Z)MQ5*+XK
M6.,&[#LF<R^LW_7SKZ+DMX^+95[-0AK)U&<$IGY$( HC#M-44"AD1 -=O,0C
MR8@RWJ#Z030<B"WQ8-OB4=^@]U96(K*NX=U_;]I-GX\R"-CWY(\Q MR QK+)
MB/\VT=-0_A;3CR3[VS0ZUOR=A_<-_CF8G._ELYX<U-F ):*<>H)#R?4ID9A'
M,"6Q@,R/ TQ8C&)AY9.?;7%J0GTT*R9];B>S/5(OG^?=3%"=LCFP6%Y*9(]X
M(4-RG$4.G6MOY!@B0_/WHXE,;^R1WN3 $8S;G-]^(]E<+PK+15&JW^H2(!M-
MO&5L^;BL,]W]4BS*\K>\$&2>_5/]2++\I;Y)?"'?9R0.N/(N,8S#(("(!Y%.
M.*4<3\]7?_<]$D:I<5Z4 8%.3>)JK&"Y!@ON%=KV]!LEZE*F?!H=>$%6UD-E
M"=3V6R\_#/X2G!;.*77MT'I[\"@<4):"V_U^U-9V7%CEDFX,!LT+LC$9_%*_
M((W50)D]D;ZW2#,SD7=@I/PTDW@7[++,C-!!)]/3#-G^>'EM1F!Q*R'.&.WU
M36Q19\JH:XSQID+-7<[T 2[^<EF]7U3_EZAT3HU92B*!DA3!) I"->/Q$:02
M^U#()(I2X=$TM-K@-&UX:EY!B[NI3-@"5TZ"SK#C)'>!87<83H0&('GP\;GA
MMXL9K$ #NJR @@V>156GY7%Y(-V.*F=GSPV;'?F8N1T9^R?*+>_O)UY_(SJJ
ML];23SHDL^P$:<XD8C)@+(4R3#R(1"P@EGX,9122""<\2IC5J=!3C4U-I%98
M[<3G))UF@N.*I(%%9@6SR7=1 ^T&R[M3%1,^'"G)R:9&50\3HW<5P^B>OI68
M=?C7.NG,.]UI.C%A$U9$9(@\X5-(<"0AHDA $H3J1\8P9YZD EOE"3S9VM1T
MH@U#7*,%*[@]P[=.4VTF(<X('%A#+N"N1UUE TZ<%5,^U=;(%90-S-XOFVQR
M4S\I>4NRHLYU?5N6HA:K3MJ+-I*,?\@_Z4F<SD^K+GB_4/.V]L>7I,S*=53"
MC$N4>EQ*Z(4^4QZ*\"$1,8=I@.,X%10'V.HLN5-T4Y.J-G^LFAF0VKIZZ.XD
MR 'EDOY=L$K'3TM%!/BFF0"/F_ ^2V_(;5^;:=_5>G!@K=1VK8H'W&ZZKV,<
M6%D'E("N[:NOZEH(:A,'B@T;A'U'JNP6VZ@J/@BMNZH_3",79 AX>?X$XLO=
M$XA-]9.[O*R*>OF[_% ]B.++ \G;LXGVAQ#+&6;J_V2 89+$%**(JP&&1PPR
M'P=12B.&4BL'=U+636V44N\4;$_Z+_-,IUC\XWCF@&=!;,]!38I\FQP 4\$\
MH4'101J MEQ2AR)0<P0J1=(F24#?/  NB_A,\25PF0M@,K:-GPY@,J8?\0VF
M";)G8=_M/<+5#N+;1?&9S,5FCU"?=ORX:&H-SSR&))9^ )&/8XBDAR"1(8,Q
MH2%+&8NP93G?'B"F-E*_W<P1%_)0" _7V_V=$/0L[\8"U<><GUK;+ ?Q7GUH
M-M8.W3,##XG[(19;_:)MN.D&66@SP,H.AV5^+V#157'?/A#&+>E[ 4E[A7PO
M>58_(6VT_=6JT&2[1"UB+Q!(A# ,$@Y10B5,L8^@'R6(QR&7C%G%=1]L96I2
MV'J1:Y0]%_\/,VJF6Q?S-+ PV5-D+3HG*7"D*H?;&%4V3IJYJPNG+[;[\+G(
M9K?*B^/:DWL[)_?*+4I%H@N#^2356W])#'$213#F$:.^CS )C#[VO2=/[0-?
M@P,:G=E7O4_7Z2_Y(A(&_GH-[3?^9(_:>N S51[DG^\7WWY6]S1?J/K+YL/<
M?](H'^-1 U8?X/$+>N<RT_&/'XO%MXP+_O+Y-S75NLOOZK28>CF65=FWIMHR
M\U.&><AA+)F:K,1Q  E+(^@G8401)0%"5@5XS)NV^FQ'RH)6GS9X:K'KU:!L
MA5O7PFR!6^=2,NT+L\%[&(8'U@1-;AWY_;%#[@N-7%'\$UB#![?G:>Z3D,F2
M,7?9FDP;'CN5DR4A!_(\V3[!31*HUUG)])G33Z02OXI'*HI9',=1%"$*91J%
M$*4)A6E$&.3J1RR1AU)BM=YROLFI>1PKA*!0$"]+ 76 7S-9<LO:P'*TEQ+J
M!JPYU(#!UP;R@,FACO,S4)*H PU>-5G4<0+.)8TZ<6?/E".;PQ_UFK.> A7B
M0>1E]DUL\MGMKI1TUE#XWY=EI0$J8?P@]3$PC\72$RB!7&?L1+HV,J8^A8*+
M$(G$8\BG=NDH!T!I\TF.D]3RMYU%WT7NXL#GD!UM)H]7[KRAIWP?7MW='#BR
M=V ]>6/'#2!2C8YNCNN-P+.K%"0#(!PW(<EP%.^E)QFPJ9Y#11WPM(Y_TD.1
MTBDU.LV"A"8^)QRJB3.&".E:17&:PIACCV,6ARP*K#).'6MI:M[GSMY>#=M2
MEH^2:BBN+J@:6B)KC#=@$YP)-C@=ZM\Y*ERIV-%VQM6B<^;N*<K9&WKD$]EU
M4-6TF#;AD,\?Y*_97,V)%[FX90^9^%9?U<ZL>,000HD/DY0@Y2.F&*:>GT#J
MI1Z.DT#$H5%(^B4@IJ8F'=BUG&SPZA\?5W;89/KHVSVGQ6<LTL>?"G>[X(,$
M:S- QX[S,V2'GXEY1HT1^F.D;!F#]8M=!HP+"3V9W:+OL\?+7'&A]5M9*2Y]
M5N_*FKL>\WKF2KE$B#$"8ZP#U1+&(!:!^C$FU"=2$(:8S=[/B;:FMMFS!;5'
MZ9%3M)KYK([(&GATV.9IJX[&#=";.FI,5HAO!B^J84"7N]J;1UL:N_[F.9,/
MU. \>TL_'='><CWB?1'L(<_^L5P5BHBB@.*(Q) IAQ6BU%,B$G&F_I8B(G@2
M,0_93'N/-30U/W6-$]P^/14+Y:?6Q^?6J'N&=1WEV4Q57+ WL*1<3IRU>)QC
MQ9%R'&UF5-DX9^RN9IR]?M ]E;>+0F3W^2N=K29GSU\*DI?SYL3 _E([BE 4
M$H8AE4(I3.!1-57V/1@G+)215,Y+E RRIV*#<GI[*BUZP%KXH-K@!V1MP"!;
M*5;]ZW0K9:@^&WJ=L)/FL#E==M('6_7MRDS0L7-KKV7CK(V^V=*G)\;=;+%"
M.,7-ECX4]]QLZ=54SS%D9U^G7T)6Y8@*%DD/"I_5==L%Q#1)8,)33C@-N8>,
M,C([134U=_9(^F67>^]..M-PB!B[BP8>%,QVUL\GR*4.$^0.PK4KV7>":5RA
M=TGCGK0[?;C]29 W>:5/EM1#1O5)/"T*'22JLT8MRUD<L%AR+B"-0YTR(XXA
M0<JK)Q)%F&'?E]RH5-.YAJ8FN0W6UG.KP!HM:.":'QPYR>YIP73)V< :V)<N
MJW,F)EST.G9R\L&CG4(Q,:][*,7H^AX;YO4N_-WC$\D*[2Z^>B#%O=!IA&K'
ML_[7OREM$A^D+&=!B$,6,@)]%/L0)7X",?,E3 @C'O&]  >QV:S?NNWIS>5K
M?"!;PP>LP5^OH2WJ^6(=@0/^T#; A3+"8H?6JE\,ML>'XGKH.7C-X 8W:('7
MM0J:27ES20T>?AB09(N][Z'('FG#VR7I=GO<?8@[N;%M]<#Q=K/[V+FUA=WK
M ?VF_ILGEN\733+SO)JEC+,XIA+&7J+/$'M2>8E1"&6,9.*%:<"I50[/@ZU,
MS4]LWOU\D<,68*\8R\.$FDVG+Z9I8+WNJ(.:&V\@NIODGF3 T:3U<!NC3D)/
MFKD[J3Q]L9L5O\TD=7O*.A-I$*>>+Z#4Z<,10C%,?2^!8<11*C$.HU!8;@49
M-CU!G_!L.J7+5NJ.=@)*I!)D+B&C$D%$O%#),4,PI3QB"4Y)K#KA@I55%UTP
M;@3\P173<3JCW\JH"XJOO_@YW&KF.7X&6K \VNQ5UR3/D7%NV?'L_2-G &[S
M"MYR7N>X(O/-<8#REI9U)L%9Z#$O$LK=9$1('72 (/:9<CQ90N)8!HA3J\HV
M@Z*=FC)NP'9.NXR5A=>H>\UD<S*=-K#6.LB2N\Z#>[COP=>5V0X#O$;IGFOG
MKS7"^F/DH[6AW5E^6:M&KS,2O?DN"I:5>LA\OVS.OM X%4GD04'"$"+N>\J[
MEA[$J11"L-BCD55XK7.$4QMQUO(C-DC!BRP'I3:K_&G<L6>_0\<9;R[JIA]H
MC.G8>0,:2Z<SJASMA(F,)/OX?JC1XRB]KD>,XPWU'"663T_SNF$RUUFTWLX7
M?]SE:B[[V !;N::88Q9B&D"LRVDB&7J0!%X( \$D96F(?&F5'M>PW:DI>A<V
MX!U/<B&;A'U2V0&RC2&6$F_8&X;"[9[CH>6X2V^=HT]C!AW0P[CL=D2YDDS#
M5L<50CLJ]N3-\O:!7-ORC(J^7112K*H3?ZRK=>]4<6AU5GPL,B9FOM[/"T4"
M$1&>4C^$($V\&(:^B!(1$<H3H["P:QDP-1E=^TRRL4-Y5=HMYHOYG!2EKI_>
MN,BN/637[X4C!_J*O3T!_[HT=; [-.B:' T1!\H:K<@ -1LC^N #]>-8+KIK
M^-/RX ?J'&L'?R@<?:L*/16"94VA7*'&[AIMSF\?=7SE/YM0+QPA%OF"0I)&
M%"(O#6"*6 PC'V$<)5X2AE;;#B:-3FW(ZF*N QQ)!ZQM%2 #SKD?>)%/*$QB
MCB#"G$"*$S7K0@BG7 8R]B*[H +7K(\34# V[V9#NFLN!]^VWL#5N3%;P#6?
MMR9\]BBD9$Z0L\))!DV.7"C)G(3]PD@6]_8(>]?5Z3(U).65^EN9J;OJ1ZYJ
MYSZ_4C=FC,Q5DY_$O3Z1LRB>UZF!RC8=%I$X#CVJHYZDIZ-N,*0DEC"22<A]
MAO7&@''6.">0IC9NK$#7WUJQAMTO>YR;3CLM<=?IBH$%<&,/V#)H78C\&:P[
M2L=X;XS:I#8K^^29<]-C%I'WH_?<2"'YG[0>EO5TL;.\JI<*JK:&;;4 [,C'
MQC;=S[:Z?_,5_ME1 +]3_D]&]KMI:;R0?Z?,;)T%</OD'H/IZ2J&Q\^TZAP&
MZS.M[=&V&>$1IDS-ME+?(Q"%)($T#=6/@K%$!D&<8#'+Q;U^WA?#H=4E0"-Q
M2!MQV(,YI,073PM==&0WQO4&W.\F%#!/LN>^>PU&W]%[Z^K!LV_-,@=H V_
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M]?F1S.<OEV66B[*<Q;'O>S3PH BPA$A&!.* !Y!$.$@]A@,<([M#7%O/G]J
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MP 3[&*(TC=5,GH60>I*$820]+*S6)@?$.K6AI(MT:[+;P]L=LHO-1HN)=-S
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M+<90%*B9;Q)!#W,"D1<12-0OH!<PY*<LC4.*;>:_O1D;+:5XYH0W,Y7LR\;
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MS3/J4Y$5^=XG"^8P76LZ:YE$APT^">J<6@7Z*P<;4\'&UE5_MM?7YMZ ;?/
MRC[7J3L'[02GJ3^'07J%U*&#4GXX]>BP3?8,/CR>M\9C1 C$!!32(Q!Q/X6I
MK^O1A5X81D1&MH&"/TS*H$,I@D2-V')'\>*L0#]$'J NR/^^R@)T^$3_(.OR
MHZ4#FDH"(/N4/X,E^?E8B">2\;8VQ6W.Z]/TS3&2U=S*3P,:R8##, EU)DI*
M(4'8AQY+A5Z\]PD*;(3$H,VI*4H+>57^ILF7M:B3;#0Y5"I >M3 -&'?3&@<
M<SJPXJSH;.'6;#8I2QK$ TQ[+0ARI#8F+8XJ.Q84[.J/S:W]BWK>Y4K3ZGH>
MOZFWISVFH6L'ZIGY3*8)B8.(P-#SU(0WDO]O>U_;([>MI?E]?X6 !782H)D5
M)4JB9H %.K:3-=:QO;9S+P;Y4.!KMS;54D^INN.>7[\DI:I2O:E(%:56%CN8
M&]O=$GG.0_'A(7E>,""1VO]*GC&$H"0PRQ>EN"-KP;^YE?GL[=AJWN3-O#GJ
M?L1-K*CK?PVXCF;BK:3N%3_[$;>C'C\ 3AC\M1/V)NB(&[R]!..@DJ!6T'BL
M#MK?W^2%0JW4/U4SU.[%D4*V+GC)_T-MW 17-*@)D>D)7^D?=3VL[NY6A@O4
M/F]5E'7!3'SN@J<1#D,J )&Z*CB*,,@3$0$2DYQG)!98$J_16V-I,C<+;2MF
M4&SD#)Z;R/EGHZ,Q,I[*]A^B55=O;9[[3H1F]OU8;CO_#E_%V+M:BZ OVYBO
M?^R^H'>=#T?_^&;?A7;W&6Z!:1(X3!@"-O;@3A4--IH>\PH,&WNXG&/$1A=H
MX"5Z8P2T*=NWD1LZC%MGO-B8!O4B(3B*(YF"E$NDW0LI(#2D($=<9DD(1>[H
M?V/9\>R6Q([<VN5_;Z]@R(P+*=3FC>_"QAPOXVV'Q/)Z?@2@Q[ZP/\"XV6#4
M]9,279CD$<U9T59VCQ?YCFCYNMJW[7;:RWY',(ZN_UW?'\9AAX4F=I7#*(^D
M1$3[1&NGP4P@@ EB@,:IR#$,<4IC%](ZV]/<6$JGX&#M'&G"CW3LI;FB?VQR
M&#^HJ65T<".G\UC;L9$7!$>FGXV,.A%!@U'PQRA5U"Z"X8E=SO<S*9U<5/>0
M/RZ_,/"D@MT+_K04;1#7D4UF+H8VAIDRLAI;3JT_#\W/#NH3II!&&"42,,TM
M2-<(IS0/ 48"I33)(AQ)I^,'K^+-C9HVVNF%O5/64/VK5<GQU,#O6%H>!;S:
M"(V]O^\,3L\>WNC7V<EO5 PZ.HY:?W*< ?"U!_<KW+0;ZU& /=HMC]/+P.0"
M1._2UVTL! LEC1FD(%$/ T2Y!#B)$Y!((<,H19!DPJTLRE[[+G-]FK(EK7B.
MM+L/FAUK#@9B9-)KY1HA1.2DQKZ"[_?:GC:R_I1:1V'S)Q]RFZ)<%(MWY;I8
MO_Q2+,7J#5F+NVKULHA9R")&) A#'@.4IC'(49B#!(824H;#)*$V%M>9]N=F
M,C4B!D;&8".DW7P]AV#_C/6 R]A[-"=(K"?N!<5/3-U:L)_NJN?_KMYL9JWZ
MRVZRGFMODNEZ09G-A+WTV+@I>\Q)Q8*G)(W2E *1PE ?U B "<M!2E"*48Y0
MEC@=U#CU/K?IODTP0]H$,ZPYKJF;[#+53OP !-2<].CTFLVO'7-JN@V3Y3H_
M%OACVP%NB7V,^-/G\ME#;>)$/DW?L\SBLP?+T!0^^XU,G;G8_.>;ZO6VY)_5
ME_E1?:MOJP=2E L>B5A&8:JHD6. 8,1 SF0&8IZ'.<Q(*K.)RDZ=%W)N-&HD
M#;2HP1^-A(Z)@D8924^^)B./S]@7? Y#,V$VW\O8O7K.WAX1Y^6 <07(_O+O
M6O0U\,KQX7%9O0CQ5:R>"R9.2_BQ:AWCC!BU2<'3_;V^!_U8K?]=K+\(5MV5
MVA>SR0_\2[5J?Z2?@XLD%HD0"((HU?>881H!0D(!F.!1++)$D-RI]M*TXL]M
M8?A=%VEI!=:V]<Z+C>F;Z1M]1:JT"&2U"E8[/8R1_2+(RM7&GOACL;R(G>TG
M,/85QZEKC1V7F/#FUI^UO>W06JJ?KM7@KX.=HC=MHGKSG724]7@__"ICY.O2
M>5KAI[W)?I6!.;H>?QTIW%9,X^&S>EG\_G5!$BDEH;JTBE0[F3@A &=2@@2'
M6$99* 6SBIW>-3F[E>6GKS_9K0T=6/KY>IBR(W/H[Q_??WOW-OCZ[?;;NZ_7
M\]VQCCT'K>W##06U_]BQ3Z>I21CA6/3-+#WQFRL.%.AEUV+:7WU"7YD>G(-\
M$=H4-AYYI8E[?B++;V+U !=QQ+,P1@*0-(H!RO(0T)CJ(A%I'&4PE1ETKX<T
MK0YSXX:C4]W51O* [40/EH44-T'5^E"(G=X#SBXF_F@<CC;F^RE,:'U>&T#3
M0>)$L:0M&D$'CD#CX?FHY77&TN=)S,0:3']0\SI#=/(<YY5$&;;T=@J^;JO!
M:J_U9:6+OV[3UE!!4<K5\AAR[0 :20J(A!) D0N441Z&F5,N#[MNY[; =:1V
MS AD";/=^N(?O)&7A([ -UV/V)W0HR0(<L/)$]U:=CHI0[H!<4AJCF\/C-);
MFO$4_/0>O\T@LHA3R2G+$) <"H"P"$$NXAQ0F8@(LU!PZ>1%8=?MW'BH277?
MI";;/]YM$PTYAN/986]'3OX1?>W3TG<7,'6/P'."R%?\G5VGTT;?.0%Q%'OG
M]O8P7OIU5=7UYU4EB_5"QEG."%64$T&N2R@+0$04 9'R* IE%"54N*3.[;3M
MQ# 3I+HUHND*D4HV-S+I F;'& -A&)D6&@0^]R/@//5/Z.II?G=;GG02GU#I
M<*:>>F38=-1AG<7:W(C?EKS)J'HG2EUQ:$'"C'.!8I#B* &(8 ER*-3T#"44
M$B5<YDYI\7OZFIM!T!'5A,2RKK!N\[</8;OY[ FWD>?W(61OK"!SGO 68'@B
M@+Z>)B4$"Y4/"<+F%?>XBK8:Q\N[[^Q>FW/:-V:1*)4205,@>*AV$$D$09Y@
M!!)"4DXSE(78JL+@N0[F1@T;&8.-D(&6TCZTXB2(_43@ YJQC7XW5)RB*_I4
M'Q1><;+!R>(K^M3I!ECT/C<T*.J+N"OT^4*Y-M\=C?-4HH@ $B8Y0!+G0*WU
M"* XBUB<RSA$CE%1^QW,;?*V,4 [(1TG[TD0+T_>:Z$9>?(ZHC(@-.JTZE?$
M1ATT.'%PU&EUCJ.CSCSW.LDR.T$+!W<A[2V)^+PJF%A$,LV8KE+ $<QTI&0(
M,$\XX"E)(I2J70'#B\;?\>N:K-8.U_GC2^\RJPYU&&^"M3KLQ6%IUU!>+9=D
MU238,;%8CFZB4WT2*$$H93$"<1I#@!!/ <XR"&(*TRRG>9HD>?M)O"OYW_R#
MV&CP_S^'<Y^#W;9UA@,\X<GWM9X:>W&#1YX:&P0" \%\<IHZCME,,IC:2CVO
M<!F_0^$[.ZEK]Q/;1$WQEEUN\]H44OBF-EJM_+><&R=FLMQ=S6Z+L"]81"03
M"051C%* (,\ P3@#61(E.84TRU(\2?KPZ_28V_9L)VS'E<$UN]<K?1(C+XK3
M#?3\%\FV-%8'C+9JS5K!L5M"3W]-XY3.>MUA?>UU]$HM_A[KJI^A\K;.>A)G
MX+4AJ>_U_[00SV39WC-\O:]6:^U$^=X$$!FI=GD2"8%AE&0QP"SE.F&++KD1
M"@ IB7 (49C'T.DZT5V&N:UW6OR;0/\WZ&AQ$_Q&5G^*IN3?K@+ZC;E6^Z*4
M4H:3W@SH]QSO(@<,F^4=Y;B#,?;=Y9EQT( ;'8!6(NAH,5)ZWRM@]'7K.4""
M:6]#AT-T=$MZ15/#>/.+>!;ED]A4K]5,_,]B??_FJ5Y7#V+U[CM;/IG*#74M
MU/_S;^3[ D5I&.>( R(3"9!,(" 9EX 3'/(4T5P*)Q?- 3+,C3=U9O+'5<6?
MV#JHU< Y;A&&C((=#8Z,[<@TV$J_J^ZMY0_^4@H$&PVT]V:K0[!10A?Y]D>!
M5T#HB0*'2# I!5X!T2$%7M/4%96R=64.P=\JRZ:\:T+'F\1:;W3H^:HN=/&'
MYN_K0EE!.R-H07A")!$49%D4 91B94]*B$%$8L*A(D?.G )GKA-G;L3X;N?"
M7I5ZQUQ)M2G6Z0"WP@=EM5:[X,'I_ZX</\MCDLE&9>S3#I/VO-$D:%1I<X#<
MM!D"=;*0C3YZN#H:=8Q_SU6^KX;69R7PX<),7RW\:N!.5A2_OM6A_D"WG*M^
MZC?JKY]6WZJ_R@43 J8R3T$68JB/MG- 4X0 S3B+HS#G>6Q5FJ*GC]FQ9N/_
MTLJI)J3^5[4*M*RNOD''@-JZ!UT%TS0>0FX(#? 3.HO!%:Y"QVU.["UT5JEC
MAZ'SCPXSMCX]BA71OK]M\,[NN@+"G,02Y2"3(@6(IUCM*J,0X# FDB>I M*I
M.-_9GN8VV;>";F+[7$./SV-J9]MX06KD^;X#:2/D*-<F%Z'P9&:<[V=2"^*B
MNH?&P>47W-?]-Y4R([:?+$)IPE@6 A(+HK93H?H;2D( )8VRG,>80:M#^:.6
MYS;MC7#!([D3ENFVCK&ZO) /1F#L\VVCO,\9?%;;00OU?DN3+<\G%>@NRJ<?
M&+84ZXJDN]LZ4XYHP63.LSR4@!(9 X0E 21%"4CB,$U(R CD5N[W/7W,;1YV
MRX4U15IW-YANZ_ I0.U6X"MA&OO(H(/0AZJ\:^Z>#K%J:Z5Y7(Q[4/&T#)_J
M8=(%N$?%PZ6W[]%A!+#-]?&^?'Q:UQ_$LUC&;34L&D>4HS@!-&+:P9I@@#.&
M .%1@F7$DCQR"K7MZ6MNA&!D^V__%:;AO\5N!- '**.AB&0>@2S3X4PTH8IC
M$=4!S#B*\C2-2>16D\T3I--4:-O420Z4^>B8O*0/53MZ]834R#2[2YMT$S2"
MW@1&U" >H:R;!2:>2+:OITG)UD+E0]*U>65HGH.RKI8%-]Y5G]7?V,O.Q04G
M2&:Q3$"&(04H(P)0'D4@$B&&L:2<8*<[I;[.YD:_>[*Z9C;HP=2.*GPA-?K^
MJ2/F3= (&OS1_CF.)Y %,MX2'?1T-7&F@\M*'Z<ZL'AGX)9MZS>IKU]VWIE?
MQ%*G2=)YT.LCY\R.ZQRF.0Q%"$%(1*ZV=V&F[ _(="0EC_)$(BG<MG?7R3,W
MZCGG">ZX#;QRD"RWC--!/_;VLC\]VTB.C9[P\[41O5*::3>M?J [VN!Z:G9X
M>LJ_B-+_EVKUMGJB:_FTO&5FSU)_$4P4S^8\1W)!<(8B &-( ((2 \(X YE(
M82)XSGGL%&=EU^W<B'(KM:D;PUNY ](*KBL.M9*[YZFT& 0[AO0/[<A$N!$N
MV$EW$^Q#_68E>+$./E2U1P<<-Z \9JNTZ'3R;)7V0)S*5NGP]C":TB[@I1K.
MEW]6JS_?EY]7%1-U_5&L/\DOHA:K9U$O.,LC0=(,8(HSG<H; 1Q1"N*,4AA'
M<4*ETTVZ19]S(R@M*2A*\-C(ZL9"-AC;49!GY$;FGZVT-X&6-RC*H)7X)M .
M[I4,-E+[(Q\'B#PQCTV/D]*. P2'G./RJAOAU*OUXK>B+!Z>'C8GV'DF29@D
M@,2I!(BC!. \P0#EJ9 LA2*A5K1RU/+<R*,5SHXTCG'JIX:KM!^9 %JY/)XV
MG]6V;RZKESKS6/UK-X>/VYMDIIY58S,?SS\P-"9!;7GT_N:3_*4HE5%1D.7G
MJC;ALUOWCXCG(DLS!O(\@6J=3P7(8Q@!G,*,8$Q@+HA;Y,'E3N<V5[<RZ]5I
M*W6P$=O&Q63X -@9 ;YA'?LXYGI$!X0 V$/DS='?HLN)W?GM03AVVG=X=ZAK
M_KL'L;HKRKM?5]5?ZWM]1$/*ET5.(209(B BVAA 6:Y8*,J R'7J72HCR(2;
M>_[)?N9&/*T#^D;6H!$V:*5U==(_#6T_OW@$;&1*&8C5 '?]7B2N<-D_W>[$
M;ON]RAV[[O<_/CP[?U6:$*'/9/5I97B'FQORSV)E3F<7B9111# '2"C;!"4\
M!)C$$0C##,9,A FD3D>D%GW.C1P:D8-:RWP3/))5\&S*8?G(J6@S!+9WW5Z!
M'?W*VV#ZM<%4":S#?1J1VV)C2N@FA-%O<G]+B#PF^;_4X^3)_BTA.)7TW_;5
M*X]#OY"_?E.-KY3=<W!2EQ+"$"0<D(3I@F*1VB"1#*I=4AR'H4QPFCOYTESN
M<FYLI 0-'C:2#CP*/8^OXTFH%]2F.PC5V&WEG>(8]"(^OD]!SW?X.H>@%P$X
M>P9Z^4TWDI'5DI])R7/[3(JEOLZ1U4KG>]'.V;L@Z!-%%!?*[A%$Y@S *%*F
M$61JFT0A DDD. I92M,LMBDMYE,H)Z*:H":9\8!];CQ@F<Y]1<E27Z@U]7O(
M1CV@] -:P:"^G(Y@O!'M)[[7&J>QK;"3B<D"I55P>SP^)D9DI]KIRK"O,'2\
M8B:*POB7S&X(]Z0;T2P0CZHY,WPZ(\MCM5JW&3_T/]NII[8H0JUYI*Y%\VLS
M/=5D7 =R.UMU=E3]CFCV^7_="Y/\M'YB]P%Y,&[_A:XU:'K3+ZL)K>:NVA<I
MNE8S_;'I>-7\0OU8/:;:*!A9!GP+X4^=_*E+M32O[U6C8MF<53Z0EX"*X$D[
MD:E-EEIT2L%,LR9;E):N(R_O9%]=Z2JKJ^8U\UA5K75&FKV'UE7SN^UQ:+TY
M<*M_"KYIU4_+0:NV\P,XU739-;_IN5:#I4"C#T6M,VSHAI6&A>I'";D=*T.,
MI@2<_HOH3$+]PX==HL8=.9X/,+6V4\:8"XTEHULVYDF8QJ$Q4;SV-8D1,P8Z
M&S-GE+:'1HQ*L5KM)X;=5;OO^&S6FXK2+V^>5GHV*V$_*@B;?RPR!"7'*0(Y
M$1"@7#" L<P 3^,T32!*!7(*+O,DU]SV;1NU]@M /ZIG@N5&#]<(53\#:+?G
M>X5A&=GZV8[(7I[PK@-S5ZN;8*N7,ID:90Q)[W3S&2SK%6QO ;9^I)HX*-<K
ME,>!O'Z;'QQ_9FX%G\CR$UT6=XTI+-.4<(YS@&+M.BA# 7">90#F-!4,T93D
MW#'P[+B7N?%L1\B@VDKI''IV D[;<_@K01K]Y'V'SZ?+^ R)+#NOO[^0LA-]
M3!U+=E[-$T%D/0]/7)MF:TG>UO730Y/,_TM1__G+2HCW:D>G/K;U%[4?6G"<
M\3"4,8A8'@(4,0YR"6. A"0YRC)"(R?Z&%WBN5&1EC&02DBU)VRD'! P/_XX
MV_':K$9O9([T4$2F<SC6T?LF,-^$5CW8Z!Y\Z?LFIJL5XSI.KUT5QEK>OT?]
M%U?XO55Z<>[XROPTG7(QNS#9.$MHQA ',I(,H!1)0&.!02RY#*4R6@EQNM?M
M[6UNZX3.?MZ>^&TV"?I\_3=!M-SF>'9')P/3K9Q$W8[YO6$Y,FN?O(\8JY2*
M%2B^<ZZ<[.MULJ[TJ7TV[TKO2\-H91,YW,85?ZN^D>^ZQ,!]M=2%!7ZI5J>)
M<4'5#IWF/ =1SI1UB](0D(@IZS:A$0G3)($I793BSK1J3SQ#Y;&:1WDSCXZD
M&F].?58-W2M9]462+E>CV&BU*Q%E7.*"I[+0QV-EXTVQ)M]="Z8,'D,[_AIU
M2*:AME:%&UT+)>C(?G/:!-TM^OX([UH4/7'A8#$FI<EKP3IDT*O;&T:N'6M$
M5Z[2LUWWJ'BGJ02R8"A"221CD J8 )0S!@@F$&".(XKBA%.<V?C!V'8X-Q^7
M;[J//:/-U'3KR/W?_BN.8/9O;5%1-UZ\"+\=__D$=62>.T3R FK.)&8+A2>R
MNMC=I*1DJ_PA^5B_YQZ*]&U%-']]?7F@U7*12"(0@SF0G$4 Q6$(<I1# $/.
M.88B9(G5)O"HY;EM^%KA@D8Z^_"B?;CZ9_]5((P\S2WU=PH9.JGKH""A_98F
M"PLZJ4 W$.CT T/C_WXIEN+CDXEQC])$JKFE-D!4%^M(<@2P$"$(\YS&%*4X
MR1R#_G:-SVWJM=%K6L"@D= UNJ\#W.49> T<(T]"!R0&Q.X=JWQ%P%ZGL8FC
M]([5. [-._',X%O\30VN?>>O-A=%$NFD'1@#D<1$6]L$X##$(,690!&5+,E"
MQ_O\OO[F-G7?'%89=+[4[T77^GK?%V;C7_1OX3ITW?:?@=H2%W\. +V]3>T*
M8*/Z":< J]>&<<DW]=HGV3D)NOU>U(LXC7$<)AC@A.J07LB!^G@H(!&F.!4I
MH8E5];W>7N;'&TLE<Z5+'3V+O2M<O<7L_ON3\71?WY,RV'_I#ZV78]*1TR-@
MQS)7XSHZMXP-J3,!]4+FB79.]S$IV?2J>4@Q_0\//!.LRCLU:Q\T9^GV&UY)
M:(9$'($\XYE.I"H 3I5E@A*<8Z%L%O5C%UXYU<G<:,44SUEOBN?<!%K.041Q
M$E'+H[TK<1K[.&^OOI =1.YG>CT8^#K'.]7%M&=W/4H>G=?U/3L@:';?.MF&
MJ>A+![(4MXP]/3R9:XE?5U5=_UZN!%D6_ZG^28KR9QW-(KZ1[ZW3\T+R..(R
M1(!E60H0HA 0CD*0"TBIS"',6&K#%-XEFQN]O*E6CY4)J>/:>-_%?]T$=UJ;
MX&FK3G"G]'$(O/0ZH/U$]:K#-#*['6RJ;CHQLTHUH'53/]MI%QCU@IU^@5;P
M)FA4U%>[V\"2UQI,AU#:UQK4B>)I7V-PW>(WQQB WB!.KQU.%\DY!DY[X9RC
M=##,./]8E;]OSK.D$(F$F79P(FJOGR<28)0R$(8TXX*+*(=.+I6=MN>V5K[[
M#G[_Z:MEY=U36-E9VP,1&'D94E*I/T<XTCNAKB=[NMORI&;T"94.K>=3CPR;
MC)]6=Z0L_M,L5'MEI&Y+_KE) &#^V<GRN<W\N:OZSE,!14@2D*0Q HAA#@B4
M$9"(4D19PHATVEI[D6IN!-!52JVS7;7,B517L?U,N#O=!F<7]C/.=A0T^>B-
M3%Y3#9PS^7D%VA-M^I%I4L+U"N,A5?MMW%_9Y:BU*D(B(YR%(1 IB@$B- ,X
M$QQ  C..(A*CS"F LJ>ON1%RI^QR='V!X,C)3/,$T\C,=[Y <#11@>!H%-NN
MKZ=7+Q <]=M^-J\,HXDOVZ )G?A'\=-!_I\%SQ'/(,= \%#MUL*( BHH!@QE
M4% !4T*=?#LN=3@WPMC):U)AN7'&173MB,,G9B.S1P>N-YL48H=Y_/RQARTP
MGBCD8G>3\HBM\H=D8OW>X.3MCRMQ+\JZ>%9\Q:H'T:Z22&!]PY(!B3E15)+'
M "MR 2P))8Y0S#*W',EG>YH;AS2^!GOBFE/8X ==8M$],_L9?.W(Q MJ([/(
M/E2-D*/XAEV PE^V]3/]3)UCO5_=$YG5+[PP<8J8)J[C?:D(S-RUU&9F?;LG
MY:<F/\"OJHEU_;[\+%9%Q1<ZE11C"0(LICE B0A!GN80L#0C<4XC&B=R\2Q6
MM!H]5XRCZ"Z3L:O >'/2R*>6=5U=PE24<"6NR4;=C@?G.)(CTZJ']#&-\D%'
M^ZXGW:=--ID& E/;TX P@S0R X?MM;/)N(K]]T@J,W PO.66&=K_M9ML$Z3X
MN\Y+\.7K[ZW9EHF(<*S6)YCC"* LI8 D$((PB[,8Y\HPEDYF<6]O<S.-?R][
MLS<,W6Z?PMEUKWTE>M-MM(V@@9$T^$')6O\X@JULA8OW??:IOEYID]VC]OD=
M=M]+[@&2K2_&+T7-R/+?!5F]*_E;G2DO1A%/<Q0#*72J:P+5SCJ/.4BS*$1I
MGJ;<+GRBKY.Y,<<FU7$C:* E#92HP5OK3(:]D/:SA2^@QMY'#\'(*:CR$@B#
M@BO/-CI9D.4EM;K!EA>?'68T_+:ML;#SX=JX0Z8)E)S01)D,N=K72@8!A5*"
ME-&()!&7$;9R5K;H:V[3_KTQ&)J=A]I>G*Q$X68U] %M9S-X@F]D,MA)N><_
MZLWYTP$-3W9"7T^36@D6*A_:"#:O#"..=V15%N5=O2E^^+98/BE39!'C,%',
MP $AD5!& F* YCD$J<PPCU)!18I<2.-,/W,C#%U,;ZE=H,E:&67TJ9D!ZTK7
MN]B63VWSQIARJ9N?:YT:3P&3*RGZMX W&GHIL'INE.P8QP/V([/-1L)=O=2;
MH)72']5<@,$3S9SK95**N:#J(;U<>GQH(=2U&F,=&=ZDAE5SZ]UWMGS2Z5]^
MK2K^5[%<+I1A$L5"&R=2ZD@JG0T"IQ@DRDR17%"L_N=6"O5RIW,CG?<E>%Q5
M3-2Z\E>M;$)VWU()>7A41*(=.*K'WD2(PP? CD)\PSHRG^S$#1IYFS*I/VQE
M#C9"GR?B ?52[3'R5C'5HLN):Z;:@W!<-=7AW8&7B60I/DEST/)1?3^?Y+<5
M*6MBRO*]K1Y(42Y0CD42"@QX&D8 85VFF:0($&4/<1+G#!,G'Z;+7<Z-C[3$
MVDVY.2K\HQ'2T9W< FC+FS>O\(U]9^:&G/M]EC48OFZB+G<X[1V2-0!'MS_V
M;T[LI]!>(OW#7&W<EOS=]T?!3'Y<_:-/3^M:T:+FP#9?&V$9Q(P3D$28 A2A
M&. LR4"84,1D$D7*=)BDHHVCX'.CN>W]<WNII+T/GS8W3*+51>_]](]>P9/!
M];L8V9-AQ-&>OR?#]EOYQ^Y;>=?Y1/2/U5,[$&Z\92-\K8%[;5\&5['_'KX,
M P?#FR_#T/Z'K8F_UVJA?5>OBP>R%O4B$EA2&$*0"*I,:R0S0!-* 99J.4LQ
MA9(0EY5KO_FYK2^_-P4GMO*Y+1L'T-F1^W! 1J;@0RQN@L_5LF OP1_MGZ.4
MMSD-AR=B.VA\4OHYK=@A29QY:J"G_DGW_Q-%<189QW&:$@)BPIG:0"<Q(!!"
M '%*J=H]YPPYI6>T[GEN!&""XYZ;X#@=#A10HG[/G%.^6B-O1Q*CX#FV;\*Y
M\*"]&H4[T3VZ_;NBY2L,P+K?:<,"7.$X"A-P;F!@W@KMHWDB)D$'T7P4:[7_
M)]\_5RMC-G7N^KY5GXFI:[W):) A0F@F$<@(5#9+"*5B,\P %HG$49KD!".W
MJ !/DKG,SFF<_AO?;K87CO.#ODW]T>1V^U?'A!2>!M".%%]A4$:FS%-Q9&UP
M5!-)UMR)**O,I/5JE0MN#RZ^&_W&R4[A%W-?^2D\235MA@J_4![EJ/#<_#!*
MO^7_YZGUYOI6W7)>Z/[(\C,I^/OR#7DLUF1I=KWT<&/\1:BEIB[6XJM8/1=,
M-([Z7P2K[DK3BEE[%C!,H+)04P"YKA#.TP@0HKA>Y(Q**2B$J54)D:D$GIO!
M:T[7@5'&+ ,;;=R(?_1AMEL1YC1X(R\5MY_?O[E8A%$G^& KH<MHRDHO++KH
M]TXG?\O"5,![6B]&%W?2A60J\ ]7F,GZO3)!4EO.6@NJ2U?^7E:T5OWJU:Y)
MMZ([+EFQ+$A3@US[:ZZ*\D[-JZ+>%*%[:8B(1S+*<@(!BQ$'*((AR#F$(*8\
M4EL.BB4BBT>CS]<U6:WM5IU19'5AJT.)QR.NGYL#E9N BKNBU#YLIGCOO0@>
M^R-))QQD&BID:)B"4%(,D,P(R$F"093D3%D;D) D; ?Y7<G_5D.\D7>" 18E
MG]_0VAD2KSY8(UL/W1Q@'16#OY2.05?)-D-8L*_F3;#5,S"*WFQ+T;XTS8Z0
M0&R,H?"=>LRKC*^3M&P,F,^F.QNELZM+3F^"@Z!(8Z'K55$H<J#6]AC0/(H
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M^B=*TUN^.)!EQ%_M=9?JX/-*]?:D%&KJMJS>W.MPENV%F'E"S;'B<2F^Z0W
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M#SI/-AZ/[TNVTF=#;T7S9^/#H_CDW7=VK\7\0M;BG92"K1<A#7.!6 Q$%D<
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MUT'T]0)->YCL#<"C V%_+0\CY;="BI6N.";5GT5Y]Z:J==7:#$*8,%TRGJ4
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M+/J<VY9I([(YMN0[H9NSXI[HEL&@V[&#9RA'9HL]%#OR;F*$@C\:D3WN:QP
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MT5('T+M?:-=7]$1H%D+T%BB205!(Z]9Y+8$L.R]<TCKVK>=6;DO;R'/)CP;
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M<F"T^SN/Q&HBIM&$ $%RI3F28<ZM3WX?HF=<3ZT5)FY:G&8:Z+_=Z95EN_]
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MPX)AU-^!LW-&^<6MOJ"U+%+0;BAT;:3E) 3C#' NF$_DQ2%OC=UK!(R+OY%
M</-4>6^-= "G_07WC>UY>C/#^97K&Q@P11X+1%7+3SW/X).VP QRR5%9ZUK?
MPQV"CW'!?0"L;MK*L77< <XO7?]OZ:+S^T!:9J9KO2L13:&%%@4"0T>QKRW&
M\&(+:^TYW4O,R.9T=)PLAE!:!^C[KF3O$^RK;_.)C8ZU*QXX'3>]GRVXDFF'
MXBQ3])&M:UX@=CC5XV:M^W /CJS[QXSVR['85V+N6@I:DY;_N:"88CJ;KK^^
MI=AB(JRSR0@-VM2<?J@=WC36-I3."PPU)=3\$&=XMCJW_XV1VFJA# 2;I[:2
MWDY7?_RRS/FBR'HC$*F2C))B\*+"YFX' ^21!"(DY\PXY4+KFS.#,S7RKO.$
M5M'!D.EE#=TZ'[LMD+"+6:EWH_@DFVP4\4LJJEXH(VL2G$)0Q: O2FO?_&K(
M<-R,>Y3:PZH9'R1C7RD89 M^,?T\37E>C] VOSS)DBF6G8:84(.*/D+P20*%
M;2F&Y ,O-VK/[NMO<@QRQSTW'6E==(J&QWJ(>B6!<5%RT?ST](%G'.78=%L>
M^S@OY2H4PV.=0KEIMRIJV6/B$%GP/(?(2_.Y4R.?E^Z[F,]KZUZ?KE=KG->;
MF&\7L]DOBV7]X21YAX65 BG5D9[2D#,8& .=BQ7(7!3->YT-P\FC/DG=!<W-
M H9VP.@E2F@CA=].-RGJX(*0A5P^CJPVH<JUAR;WM3F+<JX(Q-RZ05=S)AYI
M/JHA,H=;+'O 9.]U\FE3O?9NC<MU%ZOE5_K@>O5R?E95]^MRL5I-9%86C4=R
M3KFJ8Q$".,\YZ.B5-4SF 29JMV?CD>:>^ETQAT*EA[VE>L8O*12BZ.>TMEPZ
MXV7#]NKJ_86?O^1EG)(<)I9%S^I>GJVN%=B1.-0&P7KE?+V[;IO7]>Q.Y2/-
M& V(]6$5W47?K4/%3G(N>;HF3_=R44^\-LS99 &9X36CG.F5UF B1B6M"]$U
M1WM[-AYIHJA?TW\H5)[$>OGYRZ?I<O,[WX10LN R(8=LZM!%P6@G1!G 9K2E
M&".+[Z86Y'XVQIUZ^P37RZ%0>1+KY7:$I7.22BN$%&P=!E@\.)$EH+!%,T]A
ME^[FB/N@0-S\<ZT<"28'!N(_S_M8*_^95[1LG\W3Y8GEHKYU6S844,E4Z]]T
MDAY4*;3KTCX,:(.5SA<5NLOR;LO;H[Y8/V;>=Q#P]!"M'[P+;V*[6C=Z+@!5
M%+FMO@"3A?;@)"VX&!UXK24FZZP(K1M:-6?B45^T'W.9' :')[ >KAB$BYNU
MS\YNUEYD0=XLIS%7QZ"<.P8F",FU8,!T)@DYDI"WF4-P)EEID&%N/9_B^%P^
MZOOXG1PX#@&H?YPE-^$^L.)2(@?<!=J992&QH -K4U#%EZ";7WTZ$FM/YN!R
M$(2/LR!W@MOC.>J\]^K0G0=8#PI(B1 $VCH**"82$"/]>5202DS"!U-8^WFD
MQV/OR1R-=K$F1X+=8]@=OR>:"^ZWDXZ.P8<ZCETQ1EK47$%@D8/GJ%0RHIC8
M>@CY<3E\,L>XCV)=#@>^I[ T[SCR>]BEB"9BUA84+X:$A!Y\#B0I[E0=8HU"
ML=X6YXX\/IECY4>Q/(<$X%-8H'><,3[L6UADUG.2BHSD\XM0P&6'($66T7@1
M66[>;_3(/#Z9<^Q'L4"'!.!C6*"-8O'$K&#&.HB>URG8G'3(F(-DDLLJ*$G1
M^1-._3R&H_(NEN,(</N'.5Q_4&)98N)!%:A7 $!%CN"40>#"VBQBT4KV5N-U
M&,?C;J./^#SDB$![ AODE?/8A\5BE$@E>4B13"N9*%YO39.11<-1QI12.'ID
MV8:U<3?(1[S0AH#.$UA1SU*:UA<X^Z;;;PK#(@23VH.3NGHG04 0+D!*RA8F
MDM9VD!XI0S&TU>JQ_UP] \*DES43OB^,L+/?_#;7MIF;*:/SC6A.<58;R8A)
M"3EHCB0871-,WD3P.5HR*SIE:6O/[&ZZ#>W/YN,^N6\(\E8=BHZ$N">P*'=V
MI.^3')\(VNN5L@IX5N0"B%P 2V 0L7C!@XPR#W*CK0ON'_=!?[]+>"1\/H&5
M?;_G?K^(BL\NF8 0I*[-VQ@C7ZEP\+H$],PBY[UMMWNP^;@/__M=JT,CKI=%
MV29W_)(D,9VOIG'3-6X28S1.9P4FLIHM3G5TH[)@'0\Q493B1,<W]JXS\[B/
M[P=>8*.CYPDLH^][!<\^?%AN;NC>$)1UKA0>"@1O)"A+[CUZR8$D9DB-P0M]
M]#$M0S'[N _I^UV&QT'?TUVF5_R$^P3%0@I1>G(&E%>@:NV\4R0M1J^,8C)K
MV=LMC;V9?=R']X]NF39&WV-MS_L;+FM)T>?<O"GOK6\^2BO>A_GIHP&OY@8Q
M4+"C?+&@!'EIP6ERVDB@!5$KIUNW%'@J TLS+UYE6Z DD>I(+0$^% 0=;$R,
ML^1%\VM"_QQ8NB-FAQM8NHOZ.W"<KL\QC)I'YTN!['RF[81)<+R.TV*6JVB8
M"=AZV3_)@:4[@>#!@:6[:*0#..TON >&% I=2B!J(6GDH(HWM+"#!&:R,E))
MJ>71>S4_\H&E.\'J& -+=]%Q!SB_?_9E0N<R2@N%U?Q6K+7M16?(B1FN3"@L
MM+Y2\8\TL'0GG&P]L'07I76 OK<4'"ZG-5#<L/+[?+I>O7WW^SDS'J,MQCG(
MNMZI\,E#(!XHIHVB=N,T,;>N37Z0H,X/G(^-PG;*ZP")>V<^7GT;@)21&RTB
M&)$=*,RUQS):H#>C1!94[.>NRZNG-CKW$$?UR+KO .V7&TA>?I[&?$]Z9S'_
M?);/J[RNWB_6.+OZ\QK&_K98_U=>O\UQ\6$^_9]S2W">#)PXSIB-,H.5H8#B
M*=0*KPS<"Z^#*2&EUK7M1V&L<V^D,5KO\SVZ@<Y37D]G-T]_62S/WZJ?XR0=
M'W0R":RJXX6UU>!)E>"M2%E9I55HW;CNN!QV[FD]TA5V.)@>Z\D+N:4K).?W
MI_KBW>G)"2[;3T9\Z"%'.8_9FLL^CF;0(P]."C ^6%"6PE1RV]AF8JWR2A4F
M6_>K?2I',X(%+V408%TFT653((B@(*#D2=5N(+)YNXM_'LWLB-GACF9V47\'
MWM'UC"W7)J-R)+A-W9R4%E"D!(71V[8XR57K<K G>32S$P@>/)K912,=P&F0
M1!B30NJL(V0D&2I=*U%DUF"D5L)R*5,^^OW11WXTLQ.LCG$TLXN..\#YP_G5
M8JSWB2(,M"G7,B\.(8@ZT%,I'D-PJ%N?)1Z>'']<1S0[X66GY/@NRNL B0T"
MXN0RQMH0*V>R""H( ZAB 2T4R=0'#+SU(/1_)L=;N I'UOUC1OO/_WTZ77]]
M.:>5?[K1RNL:O;__B//SM.9ETN;J>"HIN0A:2<A1!E"I<,"@-;! =D9&+4L_
MW?'WXK#SG:$Q?ELMG^'!](^QU,ZGX7 ?#6,B@ WUH)LG!BA1TXY;0W;#HE'=
MS'[=E;E'NL".@/#C+\8]X/9X9E#L+9[K4P(F,AEO<DSU!G*=!) B.!$<>)]M
MBD:4HA[/EG>=MT=Z<O64UN(!8-M[*7[.R[#H?E,\NYYU*1E5K.>I-MH1WH"R
MGB*"9!Q$Y-HQ7HS2W<P_VY&W1]IOXBDMPP/ ]K@G1']7,N?-_Z\()RAI32P"
M,LHZJS$)0&$29*N2=$SG<OSY$NW8>Z2]*9[28CP,<D]\/=YTWHOF1J92@'M&
M'@,I$IPA#SZA*$XBJE*ZR54.$BOVUZ#B*:W%0^#VV)O6;R^<&^VL-D[]"S(F
MO^!TN6D9<%71-D@G(DI(2B,Y%TR 8\B >90YL60L/_KXE^.*X)'&G8\FR3H8
M'/\QLK#?%=^$4Y!>%"JPPA=06!N >"M!9(K8)7*OW./)"6W/]Y//W0ZW<#HT
M CNA^!\N[_M]\04O@]*Q%I^[6C*$D8(2D:%HADZ69*7LIB-C:^8?Z0[^#V4)
MAL3S/U3N^?NB(ZLII<F*'$"A:U3$P2,)46)6'"6WO+3NX-(-\T\^>_T$3,&0
M>'[2,<&5T;??EYHAV;!D$;A5"92SFWMT'A"S=$DQ5.;H4]&/POF3SYD_ 1,P
M&)*?]/K?(9IB@8(F%CTP3(YLIA(0F"K@BJ1_:,:U;7U#L >^GWR._@FL_8%0
M_.3S^P_W+A8VY,T=(1.SI'BI;"X/%8C&)F7JC0G_>)* A\_WZ\_%[SU?WPY>
M3WH/WGV6$RE<&ADB<V"]SG5*&P4P47@2HTIDPT+T[O&<L>TA@*>:J6^X9(ZV
MS(?&;R^+/WQ?>&%WA=_=@O_2HR'3+ECVSH+S.H"*5I+'Q30)SDOIN1!IF%FZ
MHW#[5-/N R_K_I'Y6'L5U=$9\U4>JDO1W5]_E/Y$6W#61V>BXD2B-4$;A T1
MJC\+:+VMEP>4CT8;F5JW*'DJG8F,8L5X92"7LFDH*\$GX\$SSQ5WR'7[2N9_
M=B;:$;/#=2;:1?T=.%DOYV2R\CM2\H:Y5_47*K^U?8GR(1;/+$1DQ(IR H*G
MS1)]*=KJZ%EL'>\\0,Y3Z5JT$T 6PVBK7^"=-QY)T@IO3 0AA0%%+@]XYS@P
MS;/VGCA41X)>#UV%FJE].SCMH8,. /66=$($?'PV3R_RYSQ;?*H\G7M<YUUG
MT#(4C/NS:4+*BP0!:8N@]QAFQ!Q$:UAM05:7X-H'!+<[ #752 <@>Y=G]*,/
MO^8Y.?TS8NQ9.IG.I]4#J6/@SGE;G3,GLR]1RUKM5&=9:>8 (]G[I&5"F[D1
ML;DKN N!XT;^PP%O."WU ,$&)Q>H1 GU0KA3M.BX-K1G. 0;E4F"I.!*-Z?*
MKYY:*ZI#_+\CZ[X#M#^;;3Z3TX,)E4F(C@4G. B_*3-UQ)_V!30C9KWS@C5O
M7KD=98_TS&1/O-QLLMI>>?WG-)^M5GE=NY"_FF*8SJ;K:=UIL*8U$JZ_E;CL
MD<_<]JL;YS+WXJA1'O/RV^_*X6<>G4:F(/[_Y5U;<UNWKG[?_P4SO%]>SDR<
MIOMDIHTS<3I]]) @F6AJ2]F2G%W_^PW*ENTXEJT+EQ:3OK12;*^%RP<0( $P
MQDS R0(\&@O.L."<S@5#Z_M9GZ/G4%_WU+,_DAQ/Z)?^.O=:RJ1+A*RYK.6S
M"IS*U5ZTHO@EHTNMR\&?)6A<S]8,%X]]5CLE_#2N:A6W['4 L]L+QG%;3W%W
M#.>54@K%9*QI32$H:4U+;*WJ8X(5+;FUI77(<A3G=2/V5T^*_73Z(>/5?$[)
M&?W"N]ETOOY*P<%DL5+%O;'IXF)VFI'=DEP4KY&R0 $Y,YLR!BR\=9K2GHN.
MW>0N"-SH)L=1=P>920L)U+]?8>%CQL_3R7^N\F.A2,S*<&>A=LN!"HR!CU9#
M$MXSHY3-NO5![%$8&S>;[]HLVH*B TNYWSLYN5I08KE8O,+_7$T6J^J<Q<GU
M@V^U9HWD0"JD3XL)H>!6$G<!6,DA\NP C8NDG* @2#0@E4J:,69%^\E$[<@?
MM^9Y,-2/I>"?)L*NNR*S:=T[C-?_/Z$'S?'S]6_US.2 ZJ=F[QXG+M]1)L<(
MV44*2ML0P#F!]1YG"2$+^BI$(=%'E*+U><X/$;*?*UJ(F%,>++<<E%A="L8I
MD@N<4F*54 Z7RQQ*?,<!^BYX&RQ WTFY'40;=XR?7-]]_-9_K.HF(B\VBU+
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M_P-02P$"% ,4    "  /@015=S5'EUT(   ?*P  %P              @ $
M    9F]L9"TP-C,P,C R,GAE>#,Q,2YH=&U02P$"% ,4    "  /@015 (-K
MZDT(  !H*P  %P              @ &2"   9F]L9"TP-C,P,C R,GAE>#,Q
M,BYH=&U02P$"% ,4    "  /@015>>WL,[(%  !9(0  %P
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H9"TR,#(R,#8S,%]P<F4N>&UL4$L%!@     )  D 60(  '</ P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
